PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC				Behar, E; Chao, NJ; Hiraki, DD; Krishnaswamy, S; Brown, BW; Zehnder, JL; Grumet, FC			Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; CARDIAC TRANSPLANTATION; LYMPHOCYTES-T; REJECTION; CLONING; MARROW; GENE	Background. Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e,, other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is a minor alloantigen. Methods. We directly sequenced samples of complementary DNA (cDNA) encoding CD31 molecules from 21 unrelated normal subjects. Sequence-specific primers were then designed to amplify alleles by the polymerase chain reaction, thereby permitting CD31 typing of genomic DNA from additional normal subjects. To assess the relevance of CD31 matching to bone marrow transplantation, we performed CD31 typing of 46 recipients of bone marrow (32 without GVHD and 14 with severe [grade III or IV] acute GVHD) and their HLA-identical sibling donors. The immunoreactivity of CD31 phenotypes with anti-CD31 monoclonal antibodies was compared by flow cytometry. Results. Direct sequencing of cDNA for CD31 from the 21 normal subjects identified a single polymorphism, (C) under bar TG-->(G) under bar TG (Leu-->Val), at codon 125; we designated the resulting alleles CD31.L and CD31.V, respectively. The CD31 genotypes of these and 142 other unrelated subjects were of the expected frequencies. Among the transplant recipients, 71 percent of those with acute GVHD had CD31 genotypes that were not identical to the donor's genotype, as compared with 22 percent of the recipients without GVHD (P = 0.004). The binding of anti-CD31 monoclonal antibodies as measured by fluorescence-activated cell sorting correlated with the CD31 types of homozygous cell lines. Conclusions. The adhesion molecule CD31 is polymorphic. When donor and recipient genotypes are not identical, the risk of GVHD increases. Prospective CD31 typing may reduce the risk of acute GVHD. (C) 1996, Massachusetts Medical Society.	STANFORD UNIV,CTR BLOOD,DEPT PATHOL,PALO ALTO,CA 94304; STANFORD UNIV,DEPT HLTH RES & POLICY,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University; Stanford University; Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033811] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33811] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armitage P., 1994, STAT METHODS MED RES, V3; BEHAR E, 1994, TISSUE ANTIGENS, V44, P332, DOI 10.1111/j.1399-0039.1994.tb02406.x; BRASILE L, 1985, TRANSPLANTATION, V40, P672, DOI 10.1097/00007890-198512000-00020; CERILLI J, 1987, TRANSPL P, V19, P4468; CHAO NJ, 1993, NEW ENGL J MED, V329, P1225, DOI 10.1056/NEJM199310213291703; DAVENPORT C, 1995, J IMMUNOL, V154, P2568; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; FLEISCHHAUER K, 1990, NEW ENGL J MED, V323, P1818, DOI 10.1056/NEJM199012273232607; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GUMINA RJ, 1993, THROMB HAEMOSTASIS, V69, P923; HANSEN JA, 1994, CLIN TRANSPLANTS 199, P193; HARTL DL, 1987, PRIMER PROPULATION G, P23; KALIL J, 1989, TRANSPLANT P, V21, P711; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KITAJIMA T, 1994, IMMUNOL LETT, V40, P207, DOI 10.1016/0165-2478(93)00017-8; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; MARIJT WAF, 1993, BLOOD, V82, P3778; METZELAAR MJ, 1991, THROMB HAEMOSTASIS, V66, P700; MILSTEIN CP, 1974, NATURE, V248, P160, DOI 10.1038/248160a0; MORAES JR, 1989, TRANSPLANTATION, V48, P951, DOI 10.1097/00007890-198912000-00010; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PIERSON GR, 1987, UCLA S MOL CELLULAR, V53, P307; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; STASTNY P, 1981, TRANSPLANTATION CLIN, P132; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VINCI G, 1994, TRANSPLANTATION, V58, P361, DOI 10.1097/00007890-199408150-00019; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; ZEHNDER JL, 1995, BLOOD, V85, P1282, DOI 10.1182/blood.V85.5.1282.bloodjournal8551282; 1991, LANCET, V337, P649	39	121	128	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					286	291		10.1056/NEJM199602013340502	http://dx.doi.org/10.1056/NEJM199602013340502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532023				2022-12-01	WOS:A1996TV69500002
J	Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC				Newcomb, RA; Storer, BE; Longnecker, MP; Mittendorf, R; Greenberg, ER; Willett, WC			Pregnancy termination in relation to risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FULL TERM PREGNANCY; REPRODUCTIVE FACTORS; SPONTANEOUS-ABORTION; WOMEN; PROGESTERONE; INCREASE	Objective. - To evaluate the association between pregnancy terminations and of breast cancer. Design and Setting. - Population-based case-control study in Wisconsin, Massachusetts, Maine, and New Hampshire. Study Participants. - Cases were women younger than 75 years with a new diagnosis of breast cancer (n=6888), identified from statewide tumor registries. Controls younger than 65 years (n=9529) were randomly selected from lists of licensed drivers, or for older subjects, from lists of Medicare beneficiaries. Exposures and Outcomes. - Breast cancer risk in relation to spontaneous or induced abortions. Results.- After adjustment for parity, age at first birth, and other risk factors, pregnancy termination (induced or spontaneous) was associated with a relative risk (RR) of breast cancer of 1.12 (95% confidence interval [CI], 1.04 to 1.21), compared with the risk among women who had never had a termination, Induced terminations were associated with a RR of 1.23 (95% CI, 1.00 to 1.51), which was somewhat greater than the risk associated with spontaneous terminations (RR, 1.21, 95% CI, 1.02 to 1.20). The association with induced abortions was stronger for those performed before legalization of abortion in 1973 (RR, 1.35; 95% CI, 1.01 to 1.80) than after this time (RR, 1.12; 95% CI, 0.84 to 1.49), suggesting a bias in reporting this sensitive procedure. Conclusions. - A weak positive association was observed between abortion-whether induced or spontaneous - and risk of breast cancer. The increase in risk of breast cancer was somewhat greater among women with a history of induced terminations. However, this association may be due to reporting bias and was not significantly different than the slight risk for spontaneous terminations.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA; UNIV CHICAGO, CHICAGO LYING IN HOSP, DEPT OBSTET & GYNECOL, CHICAGO, IL USA; DARTMOUTH HITCHCOCK MED SCH, NORRIS COTTON CANC CTR, HANOVER, NH USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Fred Hutchinson Cancer Center; University of California System; University of California Los Angeles; University of Chicago; Dartmouth College; Norris Cotton Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Newcomb, RA (corresponding author), UNIV WISCONSIN, CTR COMPREHENS CANC, MED SCI CTR, ROOM 4780, 1300 UNIV AVE, MADISON, WI 53706 USA.			Longnecker, Matthew/0000-0001-6073-5322	NCI NIH HHS [CA 47305, CA 47147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047147, R01CA047305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; ANDERSON BA, 1994, DEMOGRAPHY, V31, P115, DOI 10.2307/2061911; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; CALLE EE, 1995, CANCER CAUSE CONTROL, V6, P460, DOI 10.1007/BF00052187; CUMMINGS P, 1994, BRIT MED J, V308, P1672, DOI 10.1136/bmj.308.6945.1672; CUNNINGHAM DS, 1993, J REPROD MED, V38, P301; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; HADJIMICHAEL OC, 1986, BRIT J CANCER, V53, P281, DOI 10.1038/bjc.1986.46; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; HELMRICH SP, 1983, AM J EPIDEMIOL, V117, P35, DOI 10.1093/oxfordjournals.aje.a113513; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Koonin L M, 1993, MMWR CDC Surveill Summ, V42, P29; KRIEGER N, 1989, BREAST CANCER RES TR, V13, P205, DOI 10.1007/BF02106571; KVALE G, 1987, AM J EPIDEMIOL, V126, P831, DOI 10.1093/oxfordjournals.aje.a114720; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1987, INT J EPIDEMIOL, V16, P347, DOI 10.1093/ije/16.3.347; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; LONGNECKER MP, 1992, EPIDEMIOLOGY, V3, P535, DOI 10.1097/00001648-199211000-00014; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MICHELS KB, 1995, CANCER CAUSE CONTROL, V6, P75, DOI 10.1007/BF00051683; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; Rebar RW, 1994, MATERNAL FETAL MED P, P144; ROSENBERG L, 1988, AM J EPIDEMIOL, V127, P981, DOI 10.1093/oxfordjournals.aje.a114901; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SELLERS TA, 1993, CANCER CAUSE CONTROL, V4, P21, DOI 10.1007/BF00051710; TALAMINI R, 1985, AM J EPIDEMIOL, V4, P70; VESSEY MP, 1982, BRIT J CANCER, V45, P327, DOI 10.1038/bjc.1982.58; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WITT BR, 1990, FERTIL STERIL, V53, P1029; 1977, MANUAL INT CLASSIFIC	43	46	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					283	287						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544267				2022-12-01	WOS:A1996TP96500023
J	Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ				Diaz, JJ; Dodon, MD; SchaererUthurralt, N; Simonin, D; Kindbeiter, K; Gazzolo, L; Madjar, JJ			Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein	NATURE			English	Article							REX-RESPONSE ELEMENT; RNA-BINDING PROTEIN; VIRAL MESSENGER-RNA; HTLV-I REX; GENE-EXPRESSION; INFECTED-CELLS; TYPE-1; SEQUENCE; PRODUCT; DNA	HERPES simplex virus type 1 (HSV-1) Us11 protein, a true late gene product packaged within the virion, is delivered into cells after infection, exhibits a nucleocytoplasmic localization at early times, and later accumulates in the nucleoli(1-5). This RNA-binding basic phosphoprotein, capable of oligomerization, is supposed to be involved in post-transcriptional regulation of gene expression after HSV-1 infection(6,7). Expression of human T-cell leukaemia/lymphoma virus type-I (HTLV-I) and of human immunodeficiency virus type 1 (HIV-1) is post-transcriptionally regulated by Rex and Rev, respectively(8). These proteins are required for the cytoplasmic expression of unspliced gag-pol and singly spliced env transcripts(9,10). Here we show that HSV-1 Us11 protein is able to bind Rex- and Rev-responsive elements and to transactivate envelope retroviral glycoprotein expression.			Diaz, JJ (corresponding author), UNIV LYON 1,CNRS UMR30,FAC MED,RUE GUILLAUME PARADIN,F-69372 LYON 08,FRANCE.		DIAZ, Jean-Jacques/AAT-3846-2021; Duc-Dodon, Madeleine/I-6580-2016; DIAZ, Jean-Jacques/H-3018-2014	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319				BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIAZ JJ, 1993, J GEN VIROL, V74, P397, DOI 10.1099/0022-1317-74-3-397; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; INOUE J, 1991, ONCOGENE, V6, P1753; JOHNSON PA, 1986, J GEN VIROL, V67, P871, DOI 10.1099/0022-1317-67-5-871; MACLEAN CA, 1987, J GEN VIROL, V68, P1921, DOI 10.1099/0022-1317-68-7-1921; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MASSE T, 1990, MOL GEN GENET, V220, P377, DOI 10.1007/BF00391742; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALKER TJ, 1992, J VIROL, V66, P5879, DOI 10.1128/JVI.66.10.5879-5889.1992; PUVIONDUTILLEUL F, 1987, EUR J CELL BIOL, V43, P487; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; RIXON FJ, 1984, NUCLEIC ACIDS RES, V12, P2473, DOI 10.1093/nar/12.5.2473; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROLLER RJ, 1992, J VIROL, V66, P3624, DOI 10.1128/JVI.66.6.3624-3632.1992; ROLLER RJ, 1991, J VIROL, V65, P5873, DOI 10.1128/JVI.65.11.5873-5879.1991; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TANAKA Y, 1991, J IMMUNOL, V147, P354	30	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					273	277		10.1038/379273a0	http://dx.doi.org/10.1038/379273a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538795				2022-12-01	WOS:A1996TQ16900051
J	Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R				Huang, YY; Kandel, ER; Varshavsky, L; Brandon, EP; Qi, M; Idzerda, RL; McKnight, GS; Bourtchouladze, R			A genetic test of the effects of mutations in PKA on mossy fiber LTP and its relation to spatial and contextual learning	CELL			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; HIPPOCAMPAL-FORMATION; ANATOMICAL DATA; MUTANT MICE; MEMORY; RAT; ORGANIZATION; LOCALIZATION; ENHANCEMENT	Using a genetic approach, we assessed the effects of mutations in protein kinase A (PKA) on long-term potentiation (LTP) in the messy fiber pathway and its relationship to spatial and contextual learning. Ablation by gene targeting of the C beta(1) or the RI beta isoform of PKA produces a selective defect in messy fiber LTP, providing genetic evidence for the role of these isoforms in the messy fiber pathway. Despite the elimination of messy fiber LTP, the behavioral responses to novelty, spatial learning, and conditioning to context are unaffected. Thus, contrary to current theories about hippocampal function, messy fiber LTP does not appear to be required for spatial or contextual learning. In the absence of messy fiber LTP, adequate spatial and contextual information might reach the CA1 region via other pathways from the entorhinal cortex.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	Columbia University; University of Washington; University of Washington Seattle	Huang, YY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BACH ME, 1995, CELL, V81, P905; BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BERGER TW, 1991, LONG TERM POTENTIATI, P327; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CRUSIO WE, 1989, BEHAV BRAIN RES, V32, P81, DOI 10.1016/S0166-4328(89)80075-0; DOUGLAS RJ, 1969, J COMP PHYSIOL PSYCH, V69, P473, DOI 10.1037/h0028163; DOUGLAS RJ, 1990, SPONTANEOUS ALTERNAT, P73; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLM IE, 1991, J COMP NEUROL, V308, P409, DOI 10.1002/cne.903080308; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Huang Y Y, 1994, Learn Mem, V1, P74; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; HUANG YY, 1994, LEARN MEMORY, V79, P69; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JARRARD LE, 1976, J COMP PHYSIOL PSYCH, V90, P1035, DOI 10.1037/h0078659; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; JONES B, 1972, EXP NEUROL, V36, P362, DOI 10.1016/0014-4886(72)90030-1; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1989, NEUROSCIENCE, V9, P3040; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHWEGLER H, 1988, BEHAV GENET, V18, P153, DOI 10.1007/BF01067837; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SPENCER WA, 1962, PHYSL HIPPOCAMPE, P71; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SWANSON LW, 1982, NEUROSCI RES PROG B, V20, P613; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; YECKEL MF, 1995, HIPPOCAMPUS, V5, P108, DOI 10.1002/hipo.450050204; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	52	219	222	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1211	1222		10.1016/0092-8674(95)90146-9	http://dx.doi.org/10.1016/0092-8674(95)90146-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548807	Bronze			2022-12-01	WOS:A1995TM76200016
J	Woyka, J				Woyka, J			Hospice at home	BRITISH MEDICAL JOURNAL			English	Article											Woyka, J (corresponding author), HARROW HLTH CARE CTR,HARROW HA1 4LF,MIDDX,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1687	1688		10.1136/bmj.311.7021.1687	http://dx.doi.org/10.1136/bmj.311.7021.1687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541758	Green Published			2022-12-01	WOS:A1995TL94200018
J	AYALA, FJ				AYALA, FJ			THE MYTH OF EVE - MOLECULAR-BIOLOGY AND HUMAN ORIGINS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; II NUCLEOTIDE-SEQUENCES; HUMAN MITOCHONDRIAL-DNA; HUMAN-EVOLUTION; ALLELIC GENEALOGY; MHC POLYMORPHISM; SEVERE MALARIA; ANTIGEN; LOCI; SUBSTITUTION	It has been proposed that modern humans descended from a single woman, the ''mitochondrial Eve'' who lived in Africa 100,000 to 200,000 years ago. The human immune system DRB1 genes are extremely polymorphic, with gene lineages that coalesce into an ancestor who lived around 60 million years ago, a time before the divergence of the apes from the Old World monkeys. The theory of gene coalescence suggests that, throughout the last 60 million years, human ancestral populations had an effective size of 100,000 individuals or greater. Molecular evolution data favor the African origin of modern humans, but the weight of the evidence is against a population bottleneck before their emergence. The mitochondrial Eve hypothesis emanates from a confusion between gene genealogies and individual genealogies.			AYALA, FJ (corresponding author), UNIV CALIF IRVINE, IRVINE, CA 92717 USA.							ARDEN B, 1982, P NATL ACAD SCI-BIOL, V79, P2342, DOI 10.1073/pnas.79.7.2342; AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; AYALA FJ, IN PRESS MOL PHYLOGE; BERGSTROM T, 1995, IMMUNOL REV, V143, P13, DOI 10.1111/j.1600-065X.1995.tb00668.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BONTROP RE, 1994, IMMUNOGENETICS, V39, P81; BONTROP RE, 1995, IMMUNOL REV, V143, P33, DOI 10.1111/j.1600-065X.1995.tb00669.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; Clark G. A., 1992, MIDDLE PALEOLITHIC A, P183; CLARK GA, 1989, AM ANTHROPOL, V91, P962, DOI 10.1525/aa.1989.91.4.02a00090; CLARK GA, 1994, RECHERCHE, V25, P316; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; FAN WM, 1989, HUM IMMUNOL, V26, P107, DOI 10.1016/0198-8859(89)90096-7; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; GIBBONS A, 1995, SCIENCE, V267, P1272, DOI 10.1126/science.7871421; GOLDSTEIN DB, 1995, P NATL ACAD SCI USA, V92, P6723, DOI 10.1073/pnas.92.15.6723; GRIFFITHS RC, 1980, THEOR POPUL BIOL, V17, P37, DOI 10.1016/0040-5809(80)90013-1; GYLLENSTEN UB, 1989, P NATL ACAD SCI USA, V86, P9986, DOI 10.1073/pnas.86.24.9986; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; HAMMER MF, 1995, NATURE, V378, P376, DOI 10.1038/378376a0; HEDRICK PW, 1994, AM NAT, V143, P945, DOI 10.1086/285643; HILL AVS, 1992, NATURE, V355, P403, DOI 10.1038/355403a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0; JONES S, 1992, CAMBRIDGE ENCY HUMAN, P246; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; Kimura M., 1983, NEUTRAL THEORY MOL E; Kingman J.F.C., 1982, J APPL PROB A, V19A, P27, DOI [10.2307/3213548, DOI 10.2307/3213548]; Kingman J.F.C., 1982, STOCHASTIC PROCESS A, V13, P235, DOI [DOI 10.1016/0304-4149(82)90011-4, 10.1016/0304-4149(82)90011-4]; KLEIN J, 1994, PHILOS T R SOC B, V346, P351, DOI 10.1098/rstb.1994.0152; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; Klein J., 1986, NATURAL HIST MAJOR H; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; Li Wen-Hsiung, 1993, P253; Lowenstein J.M., 1986, Pacific Discovery, V39, P38; MARSH SGE, 1993, IMMUNOGENETICS, V37, P79; MARSH SGE, 1991, IMMUNOGENETICS, V33, P321, DOI 10.1007/BF00216691; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MCDEVITT H, 1995, IMMUNOL REV, V143, P113, DOI 10.1111/j.1600-065X.1995.tb00672.x; Menozzi Cavalli-Sforza P, 1994, HIST GEOGRAPHY HUMAN; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; NEI M, 1987, MOL EVOLUTIONARY GEN, P395; OHUIGIN C, 1993, IMMUNOGENETICS, V38, P165; PARES JM, 1995, SCIENCE, V269, P830, DOI 10.1126/science.7638599; POTTS WK, 1995, IMMUNOL REV, V143, P181, DOI 10.1111/j.1600-065X.1995.tb00675.x; ROGERS AR, 1995, HUM BIOL, V67, P1; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SATTA Y, 1993, P NATL ACAD SCI USA, V90, P7480, DOI 10.1073/pnas.90.16.7480; SATTA Y, 1991, MOL EVOLUTION MAJOR, P51; SCHWAIGER FW, 1995, IMMUNOL REV, V143, P199, DOI 10.1111/j.1600-065X.1995.tb00676.x; SNEATH P H, 1973, P573; Spuhler James N., 1993, P262; STONEKING M, 1990, GENETICS, V124, P717; STRINGER CB, 1992, PHILOS T ROY SOC B, V337, P217, DOI 10.1098/rstb.1992.0099; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; STRINGER CB, 1990, SCI AM, V263, P98, DOI 10.1038/scientificamerican1290-98; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; Swofford David L., 1990, P411; TAJIMA F, 1983, GENETICS, V105, P437; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1985, GENETICS, V110, P325; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WADDLE DM, 1994, NATURE, V368, P452, DOI 10.1038/368452a0; WADDLE DM, 1992, CONTINUITY REPLACEME, P83; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WHITFIELD LS, 1995, NATURE, V378, P379, DOI 10.1038/378379a0; WILLS C, 1995, EVOLUTION, V49, P593, DOI 10.1111/j.1558-5646.1995.tb02296.x; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOLPOFF MH, 1988, SCIENCE, V241, P772, DOI 10.1126/science.3136545; 1992, B WORLD HEALTH ORGAN, V70, P801	88	144	150	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 22	1995	270	5244					1930	1936		10.1126/science.270.5244.1930	http://dx.doi.org/10.1126/science.270.5244.1930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533083				2022-12-01	WOS:A1995TL42000025
J	TANG, JL; MORRIS, JK; WALD, NJ; HOLE, D; SHIPLEY, M; TUNSTALLPEDOE, H				TANG, JL; MORRIS, JK; WALD, NJ; HOLE, D; SHIPLEY, M; TUNSTALLPEDOE, H			MORTALITY IN RELATION TO TAR YIELD OF CIGARETTES - A PROSPECTIVE-STUDY OF 4 COHORTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER RISK; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SMOKERS; HEALTH	Objective--To investigate relation between tar yield of manufactured cigarettes and mortality from smoking related diseases. Design--Prospective epidemiological study of four cohorts of men studied between 1967 and 1982. Setting--Combined data from British United Provident Association (BUPA) study (London), Whitehall study (London), Paisley-Renfrew study (Scotland), and United Kingdom heart disease prevention project (England and Wales). Subjects--Of the 56 255 men aged over 35 who were included in the studies, 2742 deaths occurred among 12 400 smokers. Average follow up was 13 years. Main outcome measures--Relative mortality from smoking related diseases according to tar yields of cigarettes smoked. Results--Age adjusted mortality from smoking related diseases in smokers of filter cigarettes was 9% lower (95% confidence interval 1% to 17%) than in smokers of plain cigarettes (P=0.017). Mortality from smoking related diseases consistently decreased with decreasing tar yield. Relative mortality in cigarette smokers for a 15 mg decrease in tar yield per cigarette was 0.75 (0.52 to 1.09) for lung cancer, 0.77 (0.61 to 0.97) for coronary heart disease, 0.86 (0.50 to 1.50) for stroke, 0.78 (0.40 to 1.48) for chronic obstructive lung disease, 0.78 (0.65 to 0.93) for these smoking related diseases combined, and 0.77 (0.65 to 0.90) for all smoking related diseases. Conclusion--About a quarter of deaths from lung cancer, coronary heart disease, and possibly other smoking related diseases would have been avoided by lowering tar yield from 30 mg per cigarette to 15 mg. Reducing cigarette tar yields in Britain has had a modest effect in reducing smoking related mortality.	ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6QB, ENGLAND; RUCHILL HOSP, GREATER GLASGOW HLTH BOARD, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of London; Queen Mary University London; University of Glasgow; University of Dundee			Tang, Jin-Ling/AAJ-4090-2021; Wald, Nicholas/AAY-8924-2021; Tang, JL/G-1759-2013; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				[Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; CASTELLI WP, 1981, LANCET, V2, P109, DOI 10.1016/S0140-6736(81)90297-X; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; HAMMOND EC, 1976, ENVIRON RES, V12, P263, DOI 10.1016/0013-9351(76)90036-0; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HIGENBOTTAM T, 1982, J EPIDEMIOL COMMUN H, V36, P113, DOI 10.1136/jech.36.2.113; KAUFMAN DW, 1989, AM J EPIDEMIOL, V129, P703, DOI 10.1093/oxfordjournals.aje.a115185; KOZLOWSKI LT, 1989, AM J PUBLIC HEALTH, V79, P198, DOI 10.2105/AJPH.79.2.198; LUBIN JH, 1984, INT J CANCER, V33, P569, DOI 10.1002/ijc.2910330504; NEGRI E, 1993, BRIT MED J, V306, P1567, DOI 10.1136/bmj.306.6892.1567; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; PEACH H, 1986, THORAX, V41, P203, DOI 10.1136/thx.41.3.203; PETITTI DB, 1985, J CHRON DIS, V38, P581, DOI 10.1016/0021-9681(85)90047-5; PETITTI DB, 1985, PREV MED, V14, P217, DOI 10.1016/0091-7435(85)90037-4; REID DD, 1974, LANCET, V1, P469; ROSE G, 1980, BRIT MED J, V1, P745; STELLMAN SD, 1989, PREV MED, V18, P518, DOI 10.1016/0091-7435(89)90010-8; STELLMAN SD, 1986, IARC SCI PUBL, V74, P237; Tang J, 1992, J SMOKING RELATED DI, V3, P203; VUTUC C, 1983, J NATL CANCER I, V71, P435; WALD N, 1980, LANCET, V2, P813; WALD N, 1991, UK SMOKING STATISTIC; Wald N, 1989, NICOTINE SMOKING LOW; WALD NJ, 1985, LANCET, V2, P1111; WALD NJ, 1976, BRIT MED J, V1, P434, DOI 10.1136/bmj.1.6007.434-a; WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605	27	52	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 9	1995	311	7019					1530	1533		10.1136/bmj.311.7019.1530	http://dx.doi.org/10.1136/bmj.311.7019.1530			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520394	Green Published			2022-12-01	WOS:A1995TK21400021
J	HIRSCH, JA; ALONSO, JM; REID, RC				HIRSCH, JA; ALONSO, JM; REID, RC			VISUALLY EVOKED CALCIUM ACTION-POTENTIALS IN CAT STRIATE CORTEX	NATURE			English	Article							PYRAMIDAL CELLS; DENDRITES; NEURONS; INVITRO; INVIVO	EARLY intracellular studies of cerebral cortical neurons indicated that synaptic input evokes dendritic action potentials that convey information towards the soma(1). Subsequent work in vitro established that neocortical neurons produce dendritic Ca2+ action potentials(2-5). To determine whether natural stimuli elicit Ca2+ spikes, we combined the techniques of whole-cell recording(6,7), pharmacology(8) and quantitative receptive field mapping(9). Our findings show that visual stimulation routinely evoked Ca2+ spikes in distinct functional(10) and anatomical(11) classes of cells in different layers of the cat striate cortex(12). Hence regenerative Ca2+ potentials appear to play a role in both the initial and later stages of cortical sensory processing.			HIRSCH, JA (corresponding author), ROCKEFELLER UNIV,NEUROBIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Hirsch, Judith/E-9006-2013					AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; AMITAI Y, 1993, CEREB CORTEX, V3, P26, DOI 10.1093/cercor/3.1.26; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; DENO RL, 1944, CEREB CORTEX, P291; FERSTER D, 1992, J NEUROSCI, V14, P1262; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH JA, 1995, J PHYSIOL-LONDON, V483, P183, DOI 10.1113/jphysiol.1995.sp020577; Hirsch Judith A., 1994, Society for Neuroscience Abstracts, V20, P1476; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; LLINAS R, 1971, J NEUROPHYSIOL, V34, P532, DOI 10.1152/jn.1971.34.4.532; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; POCKBERGER H, 1991, BRAIN RES, V539, P181, DOI 10.1016/0006-8993(91)91619-C; PURPURA D, 1963, J NEUROPHYSIOL, V27, P117; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; REGEHR WG, 1992, J NEUROSCI, V12, P4202; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; REUVENI I, 1993, J NEUROSCI, V13, P4609; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; STAFSTROM CE, 1985, J NEUROPHYSIOL, V53, P153, DOI 10.1152/jn.1985.53.1.153; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	30	59	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					612	616		10.1038/378612a0	http://dx.doi.org/10.1038/378612a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524394				2022-12-01	WOS:A1995TJ22100076
J	RAMEH, LE; CHEN, CS; CANTLEY, LC				RAMEH, LE; CHEN, CS; CANTLEY, LC			PHOSPHATIDYLINOSITOL (3,4,5)P-3 INTERACTS WITH SH2 DOMAINS AND MODULATES PI-3-KINASE ASSOCIATION WITH TYROSINE-PHOSPHORYLATED PROTEINS	CELL			English	Article							GROWTH-FACTOR STIMULATION; KINASE-ACTIVITY; INSULIN STIMULATION; SIGNAL TRANSDUCTION; CATALYTIC SUBUNIT; INTACT-CELLS; RAT-LIVER; RECEPTOR; POLYPHOSPHOINOSITIDES; TRANSFORMATION	Src homology 2 (SH2) domains on the regulatory subunit of phosphoinositide 3-kinase (PI 3-kinase) mediate its binding to specific tyrosine-phosphorylated proteins in stimulated cells. Using a pharmacological and genetic approach, we show that the amount of PI 3-kinase associated with tyrosine-phosphorylated proteins inversely correlates with the amount of PI 3-kinase lipid products present in the cell. An explanation for this observation is provided by our finding that phosphatidylinositol (3,4,5)trisphosphate (PtdIns [3,4,5]P-3) binds directly and selectively to the SH2 domains of the 85 kDa subunit of PI 3-kinase and thereby blocks binding to tyrosine-phosphorylated proteins. The SH2 domain of pp60(c-src) also specifically bound PtdIns (3,4,5)P-3, and the binding was competed by a phosphopeptide specific for the Src SH2 domain. These results indicate that production of PtdIns (3,4,5)P-3 at the membrane disrupts the binding of PI 3-kinase to phosphoproteins. This lipid may also recruit other SH2-containing proteins to the membrane to initiate downstream signaling.	BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA	Harvard University; Beth Israel Deaconess Medical Center; University of Kentucky	RAMEH, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM036624, R37GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41890, GM36624, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTLEY LC, 1991, CELL, V65; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; END P, 1993, J BIOL CHEM, V268, P10066; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1991, ONCOGENE, V6, P407; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sambrook J., 1989, MOL CLONING LAB MANU; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	284	318	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					821	830		10.1016/0092-8674(95)90195-7	http://dx.doi.org/10.1016/0092-8674(95)90195-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521499	Bronze			2022-12-01	WOS:A1995TH94800019
J	HISATAKE, K; ROEDER, RG; HORIKOSHI, M				HISATAKE, K; ROEDER, RG; HORIKOSHI, M			FUNCTIONAL DISSECTION OF TFIIB DOMAINS REQUIRED FOR TFIIB-TFIID-PROMOTER COMPLEX-FORMATION AND BASAL TRANSCRIPTION ACTIVITY	NATURE			English	Article							RNA POLYMERASE-II; PREINITIATION COMPLEX; TATA FACTOR; FACTOR ATF; INITIATION; MUTATIONS; SUBUNIT	THE protein TFIIB is a general transcription initiation factor1 that interacts with a promoter complex (D.DNA) containing the TATA-binding subunit (TFIIDtau, or TBP) of TFIID to facilitate subsequent interaction with RNA polymerase II (ref. 2) through the associated TFIIF (ref. 3). The potential bridging function2,4 of TFIIB raises the possibility of two structural domains and emphasizes the importance of TFIIB structure-function studies for a further understanding of preinitiation complex assembly and function1. Here we show that human TFIIB (refs 5,6) is comprised of functionally distinct N- and C-terminal domains. The C-terminal domain, containing the direct repeats and associated bask regions, is necessary and sufficient for interaction with the D.DNA complex. By contrast, the N-terminal domain that is dispensable for formation of the TFIIDtau-TFIIB-promoter (D.B.DNA) complex is required for subsequent events leading to basal transcription initiation. On the basis of these results, we discuss structural and functional similarities between TFIIB and TFIIDtau, which have similar structural organization and motifs5.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Rockefeller University; University of Tokyo				Hisatake, Koji/0000-0002-5795-3115				ALLFREDO L, 1992, CELL, V71, P211; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P6639, DOI 10.1093/nar/19.23.6639; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WERNER M, 1992, MOL CELL BIOL, V12, P1087, DOI 10.1128/MCB.12.3.1087; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754	27	72	72	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					744	747		10.1038/363744a0	http://dx.doi.org/10.1038/363744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515820				2022-12-01	WOS:A1993LJ33900063
J	MURAKAMI, M; HIBI, M; NAKAGAWA, N; NAKAGAWA, T; YASUKAWA, K; YAMANISHI, K; TAGA, T; KISHIMOTO, T				MURAKAMI, M; HIBI, M; NAKAGAWA, N; NAKAGAWA, T; YASUKAWA, K; YAMANISHI, K; TAGA, T; KISHIMOTO, T			IL-6-INDUCED HOMODIMERIZATION OF GP-130 AND ASSOCIATED ACTIVATION OF A TYROSINE KINASE	SCIENCE			English	Article							SIGNAL TRANSDUCER; VACCINIA VIRUS; STIMULATING FACTOR; FACTOR RECEPTOR; INTERLEUKIN-6; GP130; CELLS; GLYCOPROTEIN; EXPRESSION; CYTOKINES	The biological functions of interleukin-6 (IL-6) are mediated through a signal-transducing component of the IL-6 receptor, gp130, which is associated with the ligand-occupied IL-6 receptor (IL-6R) protein. Binding of IL-6 to IL-6R induced disulfide-linked homodimerization of gp130. Tyrosine kinase activity was associated with dimerized but not monomeric gp130 protein. Substitution of serine for proline residues 656 and 658 in the cytoplasmic motif abolished tyrosine kinase activation and cellular responses but not homodimerization of gp130. The IL-6-induced gp130 homodimer appears to be similar in function to the heterodimer formed between the leukemia inhibitory factor (LIF) receptor (LIFR) and gp130 in response to the LIF or ciliary neurotrophic factor (CNTF). Thus, a general first step in IL-6-related cytokine signaling may be the dimerization of signal-transducing molecules and activation of associated tyrosine kinases.	TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA 553,JAPAN	Tosoh Corporation; Osaka University; Osaka University	MURAKAMI, M (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUBER R, 1980, KLIN WOCHENSCHR, V58, P1217, DOI 10.1007/BF01478928; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MICHAELSEN TE, 1977, J BIOL CHEM, V252, P883; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, UNPUB; SUGIMOTO M, 1985, MICROBIOL IMMUNOL, V29, P421, DOI 10.1111/j.1348-0421.1985.tb00843.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Westermark B, 1989, Prog Growth Factor Res, V1, P253, DOI 10.1016/0955-2235(89)90014-8; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YASUDA A, 1990, J VIROL, V64, P2788, DOI 10.1128/JVI.64.6.2788-2795.1990; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261	34	667	683	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1808	1810		10.1126/science.8511589	http://dx.doi.org/10.1126/science.8511589			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511589				2022-12-01	WOS:A1993LH20500051
J	SHAPIRO, L; KAISER, D; LOSICK, R				SHAPIRO, L; KAISER, D; LOSICK, R			DEVELOPMENT AND BEHAVIOR IN BACTERIA	CELL			English	Review									HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	SHAPIRO, L (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S	6	14	14	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					835	836		10.1016/0092-8674(93)90264-Q	http://dx.doi.org/10.1016/0092-8674(93)90264-Q			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500176	Bronze			2022-12-01	WOS:A1993LF06100002
J	MARX, PA; COMPANS, RW; GETTIE, A; STAAS, JK; GILLEY, RM; MULLIGAN, MJ; YAMSHCHIKOV, GV; CHEN, DX; ELDRIDGE, JH				MARX, PA; COMPANS, RW; GETTIE, A; STAAS, JK; GILLEY, RM; MULLIGAN, MJ; YAMSHCHIKOV, GV; CHEN, DX; ELDRIDGE, JH			PROTECTION AGAINST VAGINAL SIV TRANSMISSION WITH MICROENCAPSULATED VACCINE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; HUMAN CERVICOVAGINAL SECRETIONS; SECRETORY IMMUNE-RESPONSES; FEMALE GENITAL-TRACT; BIODEGRADABLE MICROSPHERES; IMMUNOGLOBULIN-A; CONFERS PROTECTION; ORAL IMMUNIZATION; RHESUS MACAQUES; DELIVERY SYSTEM	Although protection in animal models against intravenous challenges with simian immunodeficiency virus (SIV) has been reported, no previous vaccines have protected against a heterosexual route of infection. In this study, five of six macaques were protected against vaginal challenge when immunized with formalin-treated SIV in biodegradable microspheres by the intramuscular plus oral or plus intratracheal route. Oral immunization alone did not protect. After a second vaginal challenge, three of four intramuscularly primed and mucosally boosted macaques remained protected. The data suggest that protection against human immunodeficiency virus vaginal transmission could be provided by microsphere-based booster vaccines when used to immunize women who are systemically primed.	SO RES INST, DIV CONTROLLED RELEASE, BIRMINGHAM, AL 35255 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; NEW MEXICO STATE UNIV, DEPT BIOL, HOLLOMAN AFB, NM 88330 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA	Emory University; New Mexico State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	MARX, PA (corresponding author), NEW MEXICO STATE UNIV, NEW MEXICO REG PRIMATE RES LAB, HOLLOMAN AFB, NM 88330 USA.		Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NIAID NIH HHS [AI28147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI028147, U19AI028147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; CURTISS R, 1989, CURR TOP MICROBIOL, V146, P35; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; ELDRIDGE JH, 1989, CURR TOP MICROBIOL, V146, P59; ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978, DOI 10.1128/IAI.59.9.2978-2986.1991; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V; ELDRIDGE JH, 1992, RES IMMUNOL, V143, P557, DOI 10.1016/0923-2494(92)80069-W; ELDRIDGE JH, IN PRESS RETROVIRUSE; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOLARZ MN, 1975, RHESUS MONKEY ANATOM, P251; HEREMANS JF, 1974, ANTIGENS, V2, P365; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; HOLMES KK, 1990, WEEKLY EPIDEMIOL REC, V6, P33; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; JACKSON S, 1990, INFECT IMMUN, V58, P1932, DOI 10.1128/IAI.58.6.1932-1936.1990; JALANTI R, 1977, INT ARCH ALLER A IMM, V53, P402, DOI 10.1159/000231778; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; MARX PA, UNPUB; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; McGhee J R, 1990, Infect Dis Clin North Am, V4, P315; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MICHALEK SM, 1989, CURR TOP MICROBIOL, V146, P51; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MOLDOVEANU Z, 1989, CURR TOP MICROBIOL, V146, P91; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Ogra P L, 1976, Dev Biol Stand, V33, P19; OGRA PL, 1973, J IMMUNOL, V110, P1307; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; OHAGAN DT, 1989, VACCINE, V7, P213, DOI 10.1016/0264-410X(89)90231-4; OHAGAN DT, 1991, VACCINE, V9, P768, DOI 10.1016/0264-410X(91)90295-H; OHAGAN DT, 1989, VACCINE, V7, P421, DOI 10.1016/0264-410X(89)90156-4; PARR MB, 1985, J REPROD FERTIL, V74, P361, DOI 10.1530/jrf.0.0740361; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PREVEC L, 1990, J INFECT DIS, V161, P27, DOI 10.1093/infdis/161.1.27; PREVEC L, 1991, J ACQ IMMUN DEF SYND, V4, P568; QUINN TC, 1990, AIDS, V4, P709, DOI 10.1097/00002030-199008000-00001; SCHODEL F, 1990, J IMMUNOL, V145, P4317; Schumacher, 1980, IMMUNOLOGICAL ASPECT, P93; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990; THAPAR MA, 1990, IMMUNOLOGY, V70, P121; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; WALDMAN RH, 1972, CLIN EXP IMMUNOL, V10, P427; WILKIE BN, 1972, J REPROD FERTIL, V31, P359, DOI 10.1530/jrf.0.0310359; WIRA CR, 1987, J IMMUNOL, V138, P4159; YANG SL, 1983, FERTIL STERIL, V39, P359; 1992, MORBID MORTAL WEEKLY, V41, P899; 1991, MORBID MORTAL WEEKLY, V40, P358	58	260	273	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1323	1327		10.1126/science.8493576	http://dx.doi.org/10.1126/science.8493576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493576				2022-12-01	WOS:A1993LE02500043
J	PATTERSON, BK; TILL, M; OTTO, P; GOOLSBY, C; FURTADO, MR; MCBRIDE, LJ; WOLINSKY, SM				PATTERSON, BK; TILL, M; OTTO, P; GOOLSBY, C; FURTADO, MR; MCBRIDE, LJ; WOLINSKY, SM			DETECTION OF HIV-1 DNA AND MESSENGER-RNA IN INDIVIDUAL CELLS BY PCR-DRIVEN INSITU HYBRIDIZATION AND FLOW-CYTOMETRY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERIPHERAL-BLOOD; T-CELL; LYMPHOCYTES; AMPLIFICATION; RESERVOIR; INFECTION	Human immunodeficiency virus type-1 (HIV-1) DNA and messenger RNA sequences in both cell lines and blood obtained directly from HIV-1-infected patients were amplified by polymerase chain reaction and hybridized to fluorescein-labeled probes in situ, and the individually labeled cells were analyzed by flow cytometry. After flow cytometric analysis, heterogeneous cell populations were reproducibly resolved into HIV-1-positive and -negative distributions. Fluorescence microscopy showed that the cellular morphology was preserved and intracellular localization of amplified product DNA was maintained. Retention of nonspecific probe was not observed. Analysis of proviral DNA and viral messenger RNA in cells in the blood of HIV-1-infected patients showed that the HIV-1 genome persists in a large reservoir of latently infected cells. With the use of this technique it is now possible to detect single-copy DNA or low-abundance messenger RNA rapidly and reproducibly in a minor subpopulation of cells in suspension at single-cell resolution and to sort those cells for further characterization.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; APPL BIOSYST INC,DEPT DNA ANAL,FOSTER CITY,CA 94404; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University; Thermo Fisher Scientific; Applied Biosystems; Northwestern University			Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Furtado, Manohar/0000-0001-6016-1357	NIAID NIH HHS [AI-32535] Funding Source: Medline; NICHD NIH HHS [HD-26619-01] Funding Source: Medline; PHS HHS [P01-25569] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI032535] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMADORI A, 1992, J IMMUNOL, V148, P2709; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BAUMAN JGJ, 1988, CYTOMETRY, V9, P517, DOI 10.1002/cyto.990090602; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; DUDIN G, 1987, HUM GENET, V76, P290; EMBLETON MJ, 1992, NUCLEIC ACIDS RES, V20, P3831, DOI 10.1093/nar/20.15.3831; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MACDONELL K, 1990, AM J MED, V89, P708; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PATTERSON B, UNPUB; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TIMM EA, 1992, BIOTECHNIQUES, V12, P363; VANDEKKEN H, 1990, CYTOMETRY, V11, P153, DOI 10.1002/cyto.990110118; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	236	276	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					976	979		10.1126/science.8493534	http://dx.doi.org/10.1126/science.8493534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493534				2022-12-01	WOS:A1993LB79100041
J	Connolly, DL; Shanahan, CM; Weissberg, PL				Connolly, DL; Shanahan, CM; Weissberg, PL			Water channels in health and disease	LANCET			English	Editorial Material											Connolly, DL (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE,ENGLAND.			Shanahan, Catherine/0000-0002-8352-8171				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; MARPLES D, 1995, J CLIN INVEST, V95, P838; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIELS A, IN PRESS NATURE GENE; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907	13	13	15	2	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					210	212		10.1016/S0140-6736(96)90399-2	http://dx.doi.org/10.1016/S0140-6736(96)90399-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551876				2022-12-01	WOS:A1996TT06900005
J	Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC				Berger, JM; Gamblin, SJ; Harrison, SC; Wang, JC			Structure and mechanism of DNA topoisomerase II	NATURE			English	Article							GYRASE-B-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; PURIFICATION; COMPLEXES; HOMOLOGY; SEQUENCE; FRAGMENT	The crystal structure of a large fragment of yeast type II DNA topoisomerase reveals a heart-shaped dimeric protein with a large central hole. It provides a molecular model of the enzyme as an ATP-modulated clamp with two sets of jaws at opposite ends, connected by multiple joints. An enzyme with bound DNA can admit a second DNA duplex through one set of jaws, transport it through the cleaved first duplex, and expel it through the other set of jaws.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute				Gamblin, Steve/0000-0001-5331-639X				ADACHI T, 1984, NUCLEIC ACIDS RES, V12, P6389, DOI 10.1093/nar/12.16.6389; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Caron Paul R., 1994, V29B, P271; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COWTAN KA, 1994, CCP4 DENSITY MODIFIC; Gellert M, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P391; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; Huang W M, 1994, Adv Pharmacol, V29A, P201; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MURZIN AG, 1994, CURR OPIN STRUC BIOL, V4, P441, DOI 10.1016/S0959-440X(94)90114-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; THOMAS W, 1991, GENETICS, V128, P703; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	43	707	730	2	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					225	232		10.1038/379225a0	http://dx.doi.org/10.1038/379225a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538787				2022-12-01	WOS:A1996TQ16900037
J	CAMERON, AM; STEINER, JP; ROSKAMS, AJ; ALI, SM; RONNETT, GV; SNYDER, SH				CAMERON, AM; STEINER, JP; ROSKAMS, AJ; ALI, SM; RONNETT, GV; SNYDER, SH			CALCINEURIN ASSOCIATED WITH THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR-FKBP12 COMPLEX MODULATES CA2+ FLUX	CELL			English	Article							RECONSTITUTED LIPID VESICLES; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; TRISPHOSPHATE RECEPTOR; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; KINASE-C	The immunosuppressant drug FK506 binds to the immunophilin protein FKBP12 and inhibits its prolyl isomerase activity. Immunosuppresive actions, however, are mediated via an FK506-FKBP12 inhibition of the Ca2+-activated phosphatase calcineurin. Physiologic cellular roles for FKBP12 have remained unclear. FKBP12 is physically associated with the RyR and IP(3)R Ca2+ channels in the absence of FK506, with added FK506 disrupting these complexes, Dissociation of FKBP12 results in alteration of channel Ca2+ conductance in both cases. We now report that calcineurin is physiologically associated with the IP(3)R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin, Calcineurin anchored to the IP(3)R via FKBP12 regulates the phosphorylation status of the receptor, resulting in a dynamic Ca2+-sensitive regulation of IP3-mediated Ca2+ flux.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	CAMERON, AM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, F30MH010325, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline; NIMH NIH HHS [MH 10325-03, MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IKEDA Y, 1994, J AM CHEM SOC, V116, P4143, DOI 10.1021/ja00088a086; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SHARP AH, 1993, J NEUROSCI, V13, P3051; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WALSH CT, 1992, J BIOL CHEM, V267, P13115; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1990, J BIOL CHEM, V265, P21419	56	445	453	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					463	472		10.1016/0092-8674(95)90124-8	http://dx.doi.org/10.1016/0092-8674(95)90124-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521476	Bronze			2022-12-01	WOS:A1995TC97700016
J	MIZUUCHI, M; BAKER, TA; MIZUUCHI, K				MIZUUCHI, M; BAKER, TA; MIZUUCHI, K			ASSEMBLY OF PHAGE-MU TRANSPOSOSOMES - COOPERATIVE TRANSITIONS ASSISTED BY PROTEIN AND DNA SCAFFOLDS	CELL			English	Article							STRAND TRANSFER-REACTION; BACTERIOPHAGE-MU; B-PROTEIN; TRANSPOSITIONAL ENHANCER; INVITRO TRANSPOSITION; TN7 TRANSPOSITION; ESCHERICHIA-COLI; RIBONUCLEASE-H; TARGET DNA; A-PROTEIN	Transposition of phage Mu takes place within higher order protein-DNA complexes called transpososomes. These complexes contain the two Mu genome ends synapsed by a tetramer of Mu transposase (MuA). Transpososome assembly is tightly controlled by multi pie protein and DNA sequence cofactors. We find that assembly can occur through two distinct pathways. One previously described pathway depends on an enhancer-like sequence element, the internal activation sequence (IAS). The second pathway depends on a MuB protein-target DNA complex. For both pathways, all four MuA monomers in the tetramer need to interact with an assembly-assisting element, either the IAS or MuB. However, once assembled, not all MuA monomers within the transpososome need to interact with MuB to capture MuB-bound target DNA. The multiple layers of control likely are used in vivo to ensure efficient rounds of DNA replication when needed, while minimizing unwanted transposition products.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	MIZUUCHI, M (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.				NIGMS NIH HHS [GM499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUKOLJ G, 1991, NUCLEIC ACIDS RES, V19, P5949, DOI 10.1093/nar/19.21.5949; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; WU ZG, 1992, J BIOL CHEM, V267, P9552; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZOU A, 1991, J BIOL CHEM, V266, P20476	48	39	40	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					375	385		10.1016/0092-8674(95)90115-9	http://dx.doi.org/10.1016/0092-8674(95)90115-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521467	Bronze			2022-12-01	WOS:A1995TC97700007
J	IRVINE, HD; LAMONT, DW; HOLE, DJ; GILLIS, CR				IRVINE, HD; LAMONT, DW; HOLE, DJ; GILLIS, CR			ASBESTOS AND LUNG-CANCER IN GLASGOW AND THE WEST OF SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; HEALTH; MESOTHELIOMA; EXPOSURE	Objective-To quantify the relation between lung cancer and exposure to asbestos in men in west Scotland and to estimate the proportion of lung cancer which may be attributed to exposure to asbestos. Design-An ecological correlation study of the incidence of lung cancer in men and past asbestos exposure. The unit of analysis was the postcode sector. Correction was made for past cigarette smoking, air pollution, and deprivation. Setting-The region covered by the west of Scotland cancer registry, containing 2.72 million people and including Glasgow and the lower reaches of the River Clyde, where shipbuilding was once a major industry. Subjects-All men diagnosed with lung cancer between 1975 and 1984 whose residence at the time of registration was within the west of Scotland. Main outcome measure-The population attributable risk for asbestos related lung cancer. Results-An estimated 5.7% (95% confidence interval 2.3 to 9.11%) of all lung cancers in men registered in the west of Scotland during the period 1975-84 were asbestos related, amounting to 1081 cases. Conclusions-A considerable proportion of cases of lung cancer in men in Glasgow and the west of Scotland from 1975 to 1984 were asbestos related. Most of these may not have been considered for compensation by the Department of Social Security. Given the very small annual number of recorded cases of asbestosis this condition is probably not a prerequisite for the development of asbestos related lung cancer. A heightened awareness of the increasing incidence of asbestos related neoplasms and their more thorough investigation are recommended.			IRVINE, HD (corresponding author), RUCHILL HOSP, GREATER GLASGOW HLTH BOARD, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, SCOTLAND.							[Anonymous], 1965, ANN NY ACAD SCI, V132, P745; BRIDBORD K, 1981, BANBURY REPORT, V9, P701; Carstairs V., 1991, DEPRIVATION HLTH SCO; DANIEL FB, 1983, ENVIRON HEALTH PERSP, V53, P163, DOI 10.2307/3429629; DOLL R, 1989, IARC SCI PUBL, V90, P511; DOLL R, 1981, CAUSES CANC, P1238; DORWARD AJ, 1981, BRIT J DIS CHEST, V75, P397, DOI 10.1016/0007-0971(81)90027-9; ENTERLINE PE, 1981, BANBURY REPORT, V9, P19; FRASER RG, 1989, DIAGNOSIS DISEASES C, V2; FULTON M, 1988, EUR J CLIN NUTR, V42, P797; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1990, J SOC OCCUP MED, V40, P5; Hammond E C, 1979, Ann N Y Acad Sci, V330, P473, DOI 10.1111/j.1749-6632.1979.tb18749.x; HIGGINSON J, 1980, PREV MED, V9, P180, DOI 10.1016/0091-7435(80)90073-0; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HUGHES JM, 1991, BRIT J IND MED, V48, P229; KIPEN HM, 1987, BRIT J IND MED, V44, P96; MANCUSO TF, 1963, ARCH ENVIRON HEALTH, V6, P210, DOI 10.1080/00039896.1963.10663384; MARTISCHNIG KM, 1977, BRIT MED J, V1, P746, DOI 10.1136/bmj.1.6063.746; MUIR C, 1987, IARC SCI PUBLICATION, V88; MURRAY R, 1990, BRIT J IND MED, V47, P361; Parkes W.R., 1982, OCCUPATIONAL LUNG DI; PETO J, 1981, BANBURY REPORT, V9, P51; Peto J., 1985, ASBESTOS EFFECTS HLT; ROGGLI VL, 1986, BRIT J IND MED, V43, P18; SEATON A, 1988, CROFTON DOUGLASS RES; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; SELIKOFF IJ, 1964, JAMA-J AM MED ASSOC, V188, P22; SLUISCREMER GK, 1980, CHEST, V78, P380, DOI 10.1378/chest.78.2_Supplement.380; STJERNSWARD J, 1988, LUNG CANCER, V4, P11; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; WARNOCK ML, 1986, CHEST, V89, P20, DOI 10.1378/chest.89.1.20; 1989, SOCIAL SECURITY STAT; 1951, 1951 CENSUS SCOTLAND; 1991, HLTH SAFETY STATISTI, V99, P72; 1976, NATIONAL SURVEY AIR, V5; 1988, WORLD HLTH STATISTIC, V41, P115	37	37	37	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1993	306	6891					1503	1506		10.1136/bmj.306.6891.1503	http://dx.doi.org/10.1136/bmj.306.6891.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518676	Green Published, Bronze			2022-12-01	WOS:A1993LF94000022
J	ASHTONRICKARDT, PG; VANKAER, L; SCHUMACHER, TNM; PLOEGH, HL; TONEGAWA, S				ASHTONRICKARDT, PG; VANKAER, L; SCHUMACHER, TNM; PLOEGH, HL; TONEGAWA, S			PEPTIDE CONTRIBUTES TO THE SPECIFICITY OF POSITIVE SELECTION OF CD8+ T-CELLS IN THE THYMUS	CELL			English	Article							RECEPTOR TRANSGENIC MICE; CLASS-I MOLECULES; ANTIGEN PRESENTATION; SELF-PEPTIDES; MHC MOLECULES; LYMPHOCYTES-T; H-2 ANTIGENS; TOLERANCE; EPITHELIUM; EXPRESSION	Mice deficient in the gene encoding the peptide transporter associated with antigen processing (TAP1) have drastically reduced levels of surface expression of MHC class I molecules and few CD8+ T cells. Addition of class I binding peptides to cultured fetal thymi from TAP1 mutant mice invariably allowed the rescue of class I expression, while only some of these peptides promoted the positive selection of CD8+ T cells, which were polyclonal and specific for the peptide-MHC complex. A nonselecting peptide was converted to a mixture of selecting peptides when the residues involved in the interaction with TCRs were altered. A mixture of self-peptides derived from C57BL/6 thymi induced positive selection of CD8+ T cells at concentrations that gave relatively low class I surface expression. The implication of these observations is that self-peptides determine, in part, the repertoire of specificities exhibited by CD8+ T cells.	MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	ASHTONRICKARDT, PG (corresponding author), MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Van Kaer, Luc/H-1033-2015; Schumacher, Ton/Y-2432-2019	Van Kaer, Luc/0000-0001-5275-2309; Schumacher, Ton/0000-0003-0517-8804				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FARR AG, 1986, ANAT REC, V216, P85, DOI 10.1002/ar.1092160115; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JENKINSON EJ, 1981, J EXP MED, V153, P280, DOI 10.1084/jem.153.2.280; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANBLEEK GM, 1990, NATURE, V348, P213; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	32	269	274	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1041	1049		10.1016/0092-8674(93)90281-T	http://dx.doi.org/10.1016/0092-8674(93)90281-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500174	Bronze			2022-12-01	WOS:A1993LF06100019
J	COHEN, FE				COHEN, FE			THE PARALLEL BETA-HELIX OF PECTATE LYASE-C - SOMETHING TO SNEEZE AT	SCIENCE			English	Editorial Material							PROTEIN-STRUCTURE		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	COHEN, FE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.							BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; COHEN FE, 1980, NATURE, V285, P378, DOI 10.1038/285378a0; COLLOCH N, 1991, J MOL BIOL, V221, P603, DOI 10.1016/0022-2836(91)80075-6; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; STERNBERG MJE, 1977, J MOL BIOL, V110, P209; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	17	26	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1444	1445		10.1126/science.8502989	http://dx.doi.org/10.1126/science.8502989			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502989				2022-12-01	WOS:A1993LF05800024
J	BRADY, RL; DODSON, EJ; DODSON, GG; LANGE, G; DAVIS, SJ; WILLIAMS, AF; BARCLAY, AN				BRADY, RL; DODSON, EJ; DODSON, GG; LANGE, G; DAVIS, SJ; WILLIAMS, AF; BARCLAY, AN			CRYSTAL-STRUCTURE OF DOMAIN-3 AND DOMAIN-4 OF RAT CD4 - RELATION TO THE NH2-TERMINAL DOMAINS	SCIENCE			English	Article							CLASS-II MHC; ANTIGEN; BINDING; RETROVIRUS; RECEPTOR; MOLECULE; FRAGMENT; CELLS	The CD4 antigen is a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigens and is also a receptor for the human immunodeficiency virus. The extracellular portion of CD4 is predicted to fold into four immunoglobulin-like domains. The crystal structure of the third and fourth domains of rat CD4 was solved at 2.8 angstrom resolution and shows that both domains have immunoglobulin folds. Domain 3, however, lacks the disulfide between the beta sheets; this results in an expansion of the domain. There is a difference of 30 degrees in the orientation between domains 3 and 4 when compared with domains 1 and 2. The two CD4 fragment structures provide a basis from which models of the overall receptor can be proposed. These models suggest an extended structure comprising two rigid portions joined by a short and possibly flexible linker region.	UNIV OXFORD SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	BRADY, RL (corresponding author), UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND.							BARCLAY AN, 1992, LEUCOCYTE ANTIGENS F, P4; BRADY RL, UNPUB; BRUNGER AT, 1990, X PLOR MANUAL; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; FINCH JT, COMMUNICATION; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	28	140	143	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					979	983		10.1126/science.8493535	http://dx.doi.org/10.1126/science.8493535			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493535				2022-12-01	WOS:A1993LB79100042
J	PETTICREW, M; MCKEE, M; JONES, J				PETTICREW, M; MCKEE, M; JONES, J			CORONARY-ARTERY SURGERY - ARE WOMEN DISCRIMINATED AGAINST	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BYPASS-SURGERY; HEART-DISEASE; MORTALITY; SEX; REVASCULARIZATION; TRANSPLANTATION; MANAGEMENT; ACCURACY; DELAY; BIAS	Objective-To determine whether the sex differences in access to cardiac surgery observed in the United States exist in the United Kingdom. Design-Retrospective analysis of routinely collected data. Setting-South West Thames and North West Thames regional health authorities. Subjects-8564 patients discharged from hospital with a principal diagnosis of coronary heart disease in 1987-8 in South West Thames region and 15 243 discharges in North West Thames region in 1990-1. Main outcome measures-Performance of angiography or coronary artery bypass surgery. Results-In all age groups and among patients with a principal diagnosis of either angina or chronic ischaemia men were significantly more likely than women to undergo revascularisation in both regions. Using multiple logistic regression to control for potential clinical and demographic confounders, the male to female odds ratio for revascularisation among all cases was 1.59 (95% confidence interval 1.25 to 2.03) in South West Thames region and 1.47 (1.32 to 1.63) in North West Thames region. Conclusion-There appears to be a systematic difference in the treatment received by men and women in the United Kingdom. The reasons for this are uncertain.			PETTICREW, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, HLTH SERV RES UNIT, LONDON WC1E 7HT, ENGLAND.		Petticrew, Mark/AAY-6274-2021; McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BROGAN D, 1988, NEW ENGL J MED, V319, P55; BROOK RH, 1988, LANCET, V1, P750; CHIRIKOS TN, 1984, WOMEN HEALTH, V9, P55, DOI 10.1300/J013v09n01_05; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DOUGLAS JS, 1981, CIRCULATION, V64, P11; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; FOSTER DA, 1992, NEW ENGL J MED, V326, P570; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KASSEBAUM DG, 1992, NEW ENGL J MED, V326, P571; KENNEDY JW, 1982, CIRCULATION, V66, P16; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND C M, 1988, Archives of Internal Medicine, V148, P1305, DOI 10.1001/archinte.148.6.1305; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; MACKINTOSH AF, 1986, J ROY COLL PHYS LOND, V20, P220; MARBER M, 1991, BRIT MED J, V302, P1189, DOI 10.1136/bmj.302.6786.1189; MCGEE HM, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283-a; MUKHERJEE AK, 1991, PUBLIC HEALTH, V105, P69, DOI 10.1016/S0033-3506(05)80319-1; OLDRIDGE MB, 1980, AM HEART J, V338, P1366; Payer Lynn, 1989, MED CULTURE; POSES RM, 1992, NEW ENGL J MED, V326, P570; REES JL, 1982, BRIT MED J, V284, P1856, DOI 10.1136/bmj.284.6332.1856; SELLAR C, 1990, J EPIDEMIOL COMMUN H, V44, P313, DOI 10.1136/jech.44.4.313; SHELDON WC, 1975, PROG CARDIOVASC DIS, V18, P237, DOI 10.1016/0033-0620(75)90013-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; 1990, EGRET EPIDEMIOLOGICA; 1988, HLTH UNINSURED; SPSSX DATA ANAL SYST	32	108	109	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	1993	306	6886					1164	1166		10.1136/bmj.306.6886.1164	http://dx.doi.org/10.1136/bmj.306.6886.1164			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499817	Green Published, Bronze			2022-12-01	WOS:A1993LA68500020
J	PHILIPP, R; POND, K; REES, G				PHILIPP, R; POND, K; REES, G			LITTER AND MEDICAL WASTE ON BATHING BEACHES IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									FARNBOROUGH COLL TECHNOL,DEPT SCI & ENVIRONM TECHNOL,FARNBOROUGH,ENGLAND; FARNBOROUGH COLL TECHNOL,NORWICH UNION COASTWATCH,FARNBOROUGH,ENGLAND		PHILIPP, R (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,WHO,COLLABORATING CTR ENVIRONM HLTH PROMOT & ECOL,BRISTOL BS8 2PR,ENGLAND.			Pond, Katherine/0000-0001-7907-5272				GODLEE F, 1991, BRIT MED J, V303, P1124, DOI 10.1136/bmj.303.6810.1124; WALKER A, 1992, BRIT MED J, V304, P242, DOI 10.1136/bmj.304.6821.242; 1991, ASSESSMENT STATE POL, P34; 1987, PUBLIC HLTH IMPLICAT, P25; 1990, 4TH HOUS COMM ENV CO, V1	5	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1042	1042		10.1136/bmj.306.6884.1042	http://dx.doi.org/10.1136/bmj.306.6884.1042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490500	Green Published, Bronze			2022-12-01	WOS:A1993KY44800022
J	BOOY, R; HODGSON, S; GRIFFITHS, H; CHAPEL, HM; MOXON, ER				BOOY, R; HODGSON, S; GRIFFITHS, H; CHAPEL, HM; MOXON, ER			ANTIBODY PERSISTENCE AFTER ACCELERATED IMMUNIZATION AGAINST HAEMOPHILUS-INFLUENZAE TYPE-B	BRITISH MEDICAL JOURNAL			English	Article							CONJUGATE VACCINE		UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT IMMUNOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	BOOY, R (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.		Booy, Robert/D-4188-2011					BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1992, LANCET, V340, P847, DOI 10.1016/0140-6736(92)92719-V; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; MADORE DV, 1990, PEDIATRICS, V85, P331; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P520, DOI 10.1136/adc.64.4.520	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					971	972		10.1136/bmj.306.6883.971	http://dx.doi.org/10.1136/bmj.306.6883.971			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490473	Bronze, Green Published			2022-12-01	WOS:A1993KX43600018
J	Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H				Bachman, JG; Alcser, KH; Doukas, DJ; Lichtenstein, RL; Corning, AD; Brody, H			Attitudes of Michigan physicians and the public toward legalizing physician-assisted suicide and voluntary euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIE	Background. There has been a continuing public debate about assisted suicide and the proper role, if any, of physicians in this practice. Legislative bans and various forms of legalization have been proposed. Methods. We mailed questionnaires to three stratified random samples of Michigan physicians in specialties likely to involve the care of terminally ill patients: 500 in the spring of 1994, 500 in the summer of 1994, and 600 in the spring of 1995. Similar questionnaires were mailed to stratified random samples of Michigan adults: 449 in the spring of 1994 and 899 in the summer of 1994. Several different questionnaire forms were used, all of which included questions about whether physician-assisted suicide should be banned in Michigan or legalized under certain conditions. Results. Usable questionnaires were returned by 1119 of 1518 physicians eligible for the study (74 percent), and 998 of 1307 eligible adults in the sample of the general public (76 percent). Asked to choose between legalization of physician-assisted suicide and an explicit ban, 56 percent of physicians and 66 percent of the public supported legalization, 37 percent of physicians and 26 percent of the public preferred a ban, and 8 percent of each group were uncertain, When the physicians were given a wider range of choices, 40 percent preferred legalization, 37 percent preferred ''no law'' (i.e., no government regulation), 17 percent favored prohibition, and 5 percent were uncertain. If physician-assisted suicide were legal, 35 percent of physicians said they might participate if requested - 22 percent would participate in either assisted suicide or voluntary euthanasia, and 13 percent would participate only in assisted suicide. Support for physician-assisted suicide was lowest among the strongly religious. Conclusions. Most Michigan physicians prefer either the legalization of physician-assisted suicide or no law at all; fewer than one fifth prefer a complete ban on the practice, Given a choice between legalization and a ban, two thirds of the Michigan public prefer legalization and one quarter prefer a ban. (C) 1996, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; MICHIGAN STATE UNIV, CTR ETH & HUMANITIES LIFE SCI, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT PHILOSOPHY, E LANSING, MI 48824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University; Michigan State University	Bachman, JG (corresponding author), UNIV MICHIGAN, INST SOCIAL RES, SURVEY RES CTR, ANN ARBOR, MI 48106 USA.		Brody, Howard/GQA-6310-2022; Doukas, David/ABB-9276-2021					ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; BACHMAN JG, 1994, NEW ENGL J MED, V331, P812, DOI 10.1056/NEJM199409223311215; BATTIN MP, 1995, ACAD MED, V70, P583; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Dillman DA, 1978, MAIL TELEPHONE SURVE; FINLAY B, 1985, SOCIOL SOC RES, V69, P548; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; MCCARRICK P M, 1992, Kennedy Institute of Ethics Journal, V2, P79; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Nunnally J.C., 1994, PSYCHOMETRIC THEORY; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; Schuman H., 1981, QUESTIONS ANSWERS AT; SCHWARZ N, 1992, CONTEXT AFFECTS SOCI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; VOGT WP, 1993, DICT STATISTICS METH; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOOD FW, 1990, AM PROFILE OPINIONS; 1994, DEATH IS SOUGHT ASSI; 1991, J AM GERIATR SOC, V39, P826; 1994, FINAL REPORT MICHIGA	29	201	201	3	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					303	309		10.1056/NEJM199602013340506	http://dx.doi.org/10.1056/NEJM199602013340506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532027				2022-12-01	WOS:A1996TV69500006
J	Lukowitz, W; Mayer, U; Jurgens, G				Lukowitz, W; Mayer, U; Jurgens, G			Cytokinesis in the Arabidopsis embryo involves the syntaxin-related KNOLLE gene product	CELL			English	Article							VESICULAR TRANSPORT; THALIANA; EXPRESSION; DROSOPHILA; EPIMORPHIN; PROTEINS; CLONING; FAMILY; GENOME; LIGHT	The embryo of the flowering plant Arabidopsis develops by a regular pattern of cell divisions and cell shape changes. Mutations in the KNOLLE (KN) gene affect the rate and plane of cell divisions as well as cell morphology, resulting in mutant seedlings with a disturbed radial organization of tissue layers. At the cellular level, mutant embryos are characterized by incomplete cross walls and enlarged cells with polyploid nuclei, The KN gene was isolated by positional cloning. The predicted KN protein has similarity to syntaxins, a protein family involved in vesicular trafficking. During embryogenesis, KN transcripts are detected in patches of single cells or small cell groups. Our results suggest a function for KN in cytokinesis.	UNIV MUNICH, LEHRSTUHL GENET, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich								AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ASADA T, 1994, J CELL SCI, V107, P2249; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cas R., 1987, PLANT MOL BIOL MAN A, DOI [DOI 10.1007/978-94-017-5294-7_, 10.1007/978-94-009-3167-1]; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; GEBHARDT C, 1989, THEOR APPL GENET, V78, P65, DOI 10.1007/BF00299755; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Goodbody K. C., 1994, V139, P221; GUNNING BES, 1982, CYTOSKELETON PLANT G, P230; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRIS SD, 1994, GENETICS, V136, P517; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HEPLER PK, 1990, PROTOPLASMA, V157, P182, DOI 10.1007/BF01322651; HEPLER PK, 1967, J ULTRA MOL STRUCT R, V19, P498, DOI 10.1016/S0022-5320(67)80076-5; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIME G, 1992, DEVELOPMENT, V114, P165; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; INOUE A, 1992, J BIOL CHEM, V267, P10613; JANTTI J, 1994, J CELL SCI, V107, P3623; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Kimura M., 1983, NEUTRAL THEORY MOL E; KONING AJ, 1991, PLANT CELL, V3, P657, DOI 10.1105/tpc.3.7.657; KOOMNEEF M, 1983, ARABID INFO SERV, V20, P89; Lambert AM, 1993, CURR OPIN CELL BIOL, V5, P116, DOI 10.1016/S0955-0674(05)80016-X; LEHNER CF, 1992, J CELL SCI, V103, P1021; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LIU CM, 1995, DEV GENET, V16, P321, DOI 10.1002/dvg.1020160405; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAHEWSHWARI P, 1950, INTRO EMBRYOLOGY ANG; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Matallana E., 1992, Methods in Arabidopsis research., P144; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MCINTOSH K, 1995, INT J PLANT SCI, V156, P1, DOI 10.1086/297222; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OWEN HA, 1995, PROTOPLASMA, V185, P7, DOI 10.1007/BF01272749; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; ROPER W, 1977, PROTOPLASMA, V93, P89, DOI 10.1007/BF01276284; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SIMANIS V, 1995, SEMIN CELL BIOL, V6, P79, DOI 10.1016/1043-4682(95)90004-7; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Swofford D., 1998, PAUP PHYLOGENETIC AN; TIMBERLAKE W E, 1986, P343; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Wick SM, 1991, CURR OPIN CELL BIOL, V3, P253, DOI 10.1016/0955-0674(91)90149-S	69	397	422	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					61	71		10.1016/S0092-8674(00)80993-9	http://dx.doi.org/10.1016/S0092-8674(00)80993-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548827	Bronze			2022-12-01	WOS:A1996TQ17000009
J	Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T				Matsumoto, M; Nakagawa, T; Inoue, T; Nagata, E; Tanaka, K; Takano, H; Minowa, O; Kuno, J; Sakakibara, S; Yamada, M; Yoneshima, H; Miyawaki, A; Fukuuchi, Y; Furuichi, T; Okano, H; Mikoshiba, K; Noda, T			Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; MOUSE CEREBELLUM; P400 PROTEIN; PURIFICATION; EXPRESSION; CURRENTS; INVITRO; SLICES	THE inositol 1,4,5-trisphosphate (InsP(3)) receptor acts as an InsP(3)-gated Ca2+ release channel in a variety of cell types(1,2). Type 1 InsP(3) receptor (IP(3)R1) is the major neuronal member of the IP(3)R family in the central nervous system(3,4), predominantly enriched in cerebellar Purkinje cells but also concentrated in neurons in the hippocampal CA1 region, caudate-putamen, and cerebral cortex(5,6). Here we report that most IP(3)R1-deficient mice generated by gene targeting die in utero, and born animals have severe ataxia and tonic or tonic-clonic seizures and die by the weaning period. An electroencephalogram showed that they suffer from epilepsy, indicating that IP(3)R1 is essential for proper brain function. However, observation by light microscope of the haematoxylin-eosin staining of the brain and peripheral tissues of IP(3)R1-deficient mice showed no abnormality, and the unique electrophysiological properties of the cerebellar Purkinje cells of IP(3)R1-deficient mice were not severely impaired.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; INST CANC RES,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN; KEIO UNIV,SCH MED,DEPT NEUROL,SHINJUKU KU,TOKYO 160,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; EXPLORATORY RES ADV TECHNOL,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo; Keio University; RIKEN			Okano, Hideyuki/I-7584-2019; Inoue, Takafumi/AAM-9533-2020; Noda, Tetsuo/B-1667-2016; Miyawaki, Atsushi/K-3569-2014; Furuichi, Teiichi/B-5086-2014; Minowa, Osamu/AAM-1238-2020; Yamada, Maki/U-5251-2019; Mikoshiba, Katsuhiko/N-7943-2015; Yamada, Maki/A-1573-2015	Inoue, Takafumi/0000-0002-2728-0060; Miyawaki, Atsushi/0000-0002-2329-3235; Furuichi, Teiichi/0000-0002-9676-1888; Sakakibara, Shin-ichi/0000-0001-8983-2249; Yamada, Maki/0000-0002-1956-6069; Nakagawa, Toshiyuki/0000-0001-8415-4119				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREPEL F, 1986, J PHYSIOL-LONDON, V372, P1; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Lyon MF, 1989, GENETIC VARIANTS STR; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAGATA E, 1994, NEUROSCIENCE, V61, P983, DOI 10.1016/0306-4522(94)90418-9; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKANISHI S, 1991, J NEUROSCI, V11, P2075; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAMAMOTOHINO M, 1995, NEUROREPORT, V6, P273, DOI 10.1097/00001756-199501000-00012	24	340	347	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					168	171		10.1038/379168a0	http://dx.doi.org/10.1038/379168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538767				2022-12-01	WOS:A1996TP36000059
J	Long, JA; Moan, EI; Medford, JI; Barton, MK				Long, JA; Moan, EI; Medford, JI; Barton, MK			A member of the KNOTTED class of homeodomain proteins encoded by the STM gene of Arabidopsis	NATURE			English	Article							MAIZE HOMEOBOX GENE; THALIANA; MUTATION; CELLS; SITE	THE KNOTTED class of plant genes encodes homeodomain proteins(1,2). These genes have been found in all plant species where they have been sought(3-5) and, where examined, show expression patterns that suggest they play an important role in shoot meristem function(5-7). Until now, all mutant phenotypes associated with these genes have been due to gain-of-function mutations(4,5,8,9), making it difficult to deduce their wild-type function. Here we present evidence that the Arabidopsis SHOOT-MERISTEMLESS (STM) gene, required for shoot apical meristem formation during embryogenesis, encodes a class I KNOTTED-like protein. We also describe the expression pattern of this gene in the wild-type plant. To our knowledge, STM is the first gene shown to mark a specific pattern element in the developing plant embryo both phenotypically and molecularly.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,MOLEC & CELLULAR BIOL PROGRAM,MADISON,WI 53706; PENN STATE UNIV,DEPT BIOL,COLLEGE PARK,PA 16802	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; BARTON MK, 1993, DEVELOPMENT, V119, P823; BECRAFT PW, 1994, GENETICS, V136, P295; Bowman J., 1994, ARABIDOPSIS ATLAS MO, P133; BURKE TJ, 1988, MOL GEN GENET, V213, P435, DOI 10.1007/BF00339613; FREELING M, 1985, GENETICS, V111, P617; JACKSON D, 1994, DEVELOPMENT, V120, P405; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KUIPER MTR, 1988, J BIOL CHEM, V263, P2848; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MCCONNELL JR, 1995, DEV GENET, V16, P358, DOI 10.1002/dvg.1020160409; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MULLER KJ, 1995, NATURE, V374, P727, DOI 10.1038/374727a0; SINHA N, 1993, GENE DEV, V7, P878; SMITH LG, 1992, DEVELOPMENT, V116, P21; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	20	1162	1244	9	183	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					66	69		10.1038/379066a0	http://dx.doi.org/10.1038/379066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538741				2022-12-01	WOS:A1996TN21600055
J	Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA				Blangy, A; Lane, HA; dHerin, P; Harper, M; Kress, M; Nigg, EA			Phosphorylation by p34(cdc2) regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo	CELL			English	Article							CELL-FREE-EXTRACTS; MITOTIC SPINDLE; MICROTUBULE DYNAMICS; ASPERGILLUS-NIDULANS; P34CDC2 KINASE; PROTEIN-KINASE; FISSION YEAST; GENE; CYCLE; IDENTIFICATION	We have isolated a human homolog of Xenopus Eg5, a kinesin-related motor protein implicated in the assembly and dynamics of the mitotic spindle. We report that microinjection of antibodies against human Eg5 (HsEg5) blocks centrosome migration and causes HeLa cells to arrest in mitosis with monoastral microtubule arrays. Furthermore, an evolutionarily conserved cdc2 phosphorylation site (Thr-927) in HsEg5 is phosphorylated specifically during mitosis in HeLa cells and by p34(cdc2)/cyclin B in vitro. Mutation of Thr-927 to nonphosphorylatable residues prevents HsEg5 from binding to centrosomes, indicating that phosphorylation controls the association of th is motor with the spindle apparatus. These results indicate that HsEg5 is required for establishing a bipolar spindle and that p34(cdc2) protein kinase directly regulates its localization.	CNRS, INST RECH CANC, F-94801 VILLEJUIF, FRANCE; UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva	Blangy, A (corresponding author), SWISS INST EXPTL CANC RES, 155 CHEM BOVERESSES, CH-1066 EPALINGES, SWITZERLAND.			nigg, erich/0000-0003-4835-5719; BLANGY, Anne/0000-0001-7043-0784				AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Hunt T, 1991, Semin Cell Biol, V2, P213; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; Karsenti E, 1991, Semin Cell Biol, V2, P251; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUDJOU M, 1991, J CELL BIOL, V115, P129, DOI 10.1083/jcb.115.1.129; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NISLOW C, 1990, J CELL BIOL, V111, P511, DOI 10.1083/jcb.111.2.511; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; THOMAS D, 1990, GENET ANAL-BIOMOL E, V7, P87, DOI 10.1016/0735-0651(90)90033-C; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; TIHY F, 1992, GENOMICS, V13, P1371, DOI 10.1016/0888-7543(92)90075-4; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	69	744	794	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1159	1169		10.1016/0092-8674(95)90142-6	http://dx.doi.org/10.1016/0092-8674(95)90142-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548803	Bronze			2022-12-01	WOS:A1995TM76200012
J	Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW				Li, ZY; Otevrel, T; Gao, YJ; Cheng, HL; Seed, B; Stamato, TD; Taccioli, GE; Alt, FW			The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination	CELL			English	Article							HAMSTER OVARY CELL; PRE-B CELLS; CYCLE-DEPENDENT REPAIR; RAY-SENSITIVE MUTANTS; LIGHT CHAIN GENES; IONIZING-RADIATION; SCID MUTATION; MOUSE THYMOCYTES; MICE; REARRANGEMENT	The XR-1 Chinese hamster ovary cell line is impaired in DNA double-strand break repair (DSBR) and in ability to support V(D)J recombination of transiently introduced substrates. We now show that XR-1 cells support recombination-activating gene 1- and 2-mediated initiation of V(D)J recombination within chromosomally integrated substrate, but are highly impaired in ability to complete the process by forming coding and recognition sequence joins. On this basis, we isolated a human cDNA sequence, termed XRCC4, whose expression confers normal V(D)J recombination ability and significant restoration of DSBR activity to XR-1, clearly demonstrating that this gene product is involved in both processes. The XRCC4 gene maps to the previously identified locus on human chromosome 5, is deleted in XR-1 cells, and encodes a ubiquitously expressed product unrelated to any described protein.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; LANKENAU MED RES CTR,WYNNEWOOD,PA 19096	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Lankenau Medical Center; Lankenau Institute for Medical Research	Li, ZY (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115, USA.				NCI NIH HHS [CA58301] Funding Source: Medline; NIAID NIH HHS [AI20047, AI35714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714, R01AI020047, R37AI020047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, NATURE, V296, P325, DOI 10.1038/296325a0; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; FAIRMAN MP, 1992, NUCLEIC ACIDS RES, V20, P4145, DOI 10.1093/nar/20.16.4145; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FINIE NJ, 1995, P NATL ACAD SCI USA, V92, P320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1995, PHILOS T ROY SOC B, V347, P43, DOI 10.1098/rstb.1995.0007; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GLIMCHER LH, 1982, NATURE, V298, P283, DOI 10.1038/298283a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; JONES NJ, 1988, MUTAT RES, V193, P139, DOI 10.1016/0167-8817(88)90044-2; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANSFORD R, 1995, IN PRESS MOL IMMUNOL; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; MALYAPA RS, 1994, RADIAT RES, V140, P321; MALYNN BA, 1995, INT IMMUNOL, V7, P1637, DOI 10.1093/intimm/7.10.1637; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MILLER RD, 1995, P NATL ACAD SCI US, V92; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OTEVREL T, 1995, GENOMICS, V27, P211, DOI 10.1006/geno.1995.1029; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SELIG S, 1995, P NATL ACAD SCI USA, V92, P3702, DOI 10.1073/pnas.92.9.3702; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; STAMATO TD, 1987, MUTAT RES, V183, P61, DOI 10.1016/0167-8817(87)90046-0; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; YANCOPOULOS GD, 1990, P NATL ACAD SCI USA, V87, P5759, DOI 10.1073/pnas.87.15.5759; YANCOPOULOS GD, 1990, MOL CELL BIOL, V10, P1697, DOI 10.1128/MCB.10.4.1697; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	79	377	386	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1079	1089		10.1016/0092-8674(95)90135-3	http://dx.doi.org/10.1016/0092-8674(95)90135-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548796	Bronze			2022-12-01	WOS:A1995TM76200005
J	Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P				Gough, A; Faint, J; Salmon, M; Bacon, P; Emery, P			HLA-DR4 and career prospects in rheumatology: Is there a link?	BRITISH MEDICAL JOURNAL			English	Article							ARTHRITIS	Objective-To determine whether HLA type is associated with career progress in rheumatology. Design-Comparison of HLA type after HLA analysis of samples of venous blood. Setting-Department of Rheumatology Research, University of Birmingham. Subjects-All (37) staff in the department. Results-All the senior academics and most staff with a PhD expressed HLA-DR4. The prevalence of expression in each of these groups was significantly greater than that found in the controls. None of the junior doctors or secretaries expressed DR4. Conclusion-The junior doctors in the department have poor career prospects as HLA-DR4 seems to be associated with academic achievement.	UNIV BIRMINGHAM,DEPT RHEUMATOL RES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham			emery, paul/B-3560-2013		Arthritis Research UK [18475] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		BIDWELL JL, 1986, MOL IMMUNOL, V23, P1111, DOI 10.1016/0161-5890(86)90009-X; EMERY P, 1992, BRIT MED J, V305, P1387, DOI 10.1136/bmj.305.6866.1387; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1665	1666		10.1136/bmj.311.7021.1665	http://dx.doi.org/10.1136/bmj.311.7021.1665			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541751	Green Published			2022-12-01	WOS:A1995TL94200010
J	SEEDS, NW; WILLIAMS, BL; BICKFORD, PC				SEEDS, NW; WILLIAMS, BL; BICKFORD, PC			TISSUE-PLASMINOGEN ACTIVATOR INDUCTION IN PURKINJE NEURONS AFTER CEREBELLAR MOTOR LEARNING	SCIENCE			English	Article							IMPAIRED ACQUISITION; NEURITE OUTGROWTH; SENSORY NEURONS; LOCOMOTOR TASKS; RATS; DEGRADATION; BINDING; MEMORY; CELLS	The cerebellar cortex is implicated in the learning of complex motor skills. This learning may require synaptic remodeling of Purkinje cell inputs. An extracellular serine protease, tissue plasminogen activator (tPA), is involved in remodeling various nonneural tissues and is associated with developing and regenerating neurons. in situ hybridization showed that expression of tPA messenger RNA was increased in the Purkinje neurons of rats within an hour of their being trained for a complex motor task. Antibody to tPA also showed the induction of tPA protein associated with cerebellar Purkinje cells. Thus, the induction of tPA during motor learning may play a role in activity-dependent synaptic plasticity.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR MED SCI TRAINING,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,VET ADM MED CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEEDS, NW (corresponding author), UNIV COLORADO,HLTH SCI CTR,PROGRAM NEUROSCI,DENVER,CO 80262, USA.		Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004418] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04418] Funding Source: Medline; NIGMS NIH HHS [T32-GM 08497] Funding Source: Medline; NINDS NIH HHS [NS-09818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ANDERSON B, 1992, BEHAV NEUROSCI, V106, P509; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BICKFORD P, 1992, NEUROBIOL AGING, V13, P475, DOI 10.1016/0197-4580(92)90075-9; BICKFORD P, 1993, BRAIN RES, V620, P133, DOI 10.1016/0006-8993(93)90279-V; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FRIEDMAN GC, 1994, DEV BRAIN RES, V81, P41, DOI 10.1016/0165-3806(94)90066-3; GILBERT PFC, 1974, BRAIN RES, V70, P1, DOI 10.1016/0006-8993(74)90208-X; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P147; ITO M, 1977, CEREBELLUM NEURAL CO; KALDERON N, 1979, P NATL ACAD SCI USA, V76, P5992, DOI 10.1073/pnas.76.11.5992; Kleim J. A., 1994, Society for Neuroscience Abstracts, V20, P1435; KRYSTOSEK A, 1978, FED PROC, V37, P1702; KRYSTOSEK A, 1991, SCIENCE, V213, P1532; LALONDE R, 1990, BRAIN RES REV, V15, P325, DOI 10.1016/0165-0173(90)90006-A; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARS WM, 1993, AM J PATHOL, V143, P949; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; MOONEN G, 1983, NATURE, V298, P753; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Seeds N W, 1990, Adv Exp Med Biol, V265, P169; SEEDS NW, UNPUB; SEEDS NW, 1992, NERVE GROWTH CONE, P219; SIMMONS, 1990, J HISTOTECHN, V12, P169; SOREQ H, 1983, DEV BRAIN RES, V11, P149, DOI 10.1016/0165-3806(83)90212-2; VERRALL S, 1989, J CELL BIOL, V109, P265, DOI 10.1083/jcb.109.1.265; VERRALL S, 1989, THESIS U COLORADO HL; WATSON M, 1984, BRAIN RES, V296, P129, DOI 10.1016/0006-8993(84)90518-3	36	255	261	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1992	1994		10.1126/science.270.5244.1992	http://dx.doi.org/10.1126/science.270.5244.1992			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533091				2022-12-01	WOS:A1995TL42000042
J	STEHNOBITTEL, L; PEREZTERZIC, C; CLAPHAM, DE				STEHNOBITTEL, L; PEREZTERZIC, C; CLAPHAM, DE			DIFFUSION ACROSS THE NUCLEAR-ENVELOPE INHIBITED BY DEPLETION OF THE NUCLEAR CA2+ STORE	SCIENCE			English	Article							PORE COMPLEX; MEMBRANE; PROTEINS	Intact, isolated nuclei and a nuclear membrane (ghost) preparation were used to study regulation of the movement of small molecules across the Xenopus laevis oocyte nuclear membrane. In contrast to models of the nuclear pore complex, which assume passive bidirectional diffusion of molecules less than 70 kilodaltons, diffusion of intermediate-sized molecules was regulated by the nuclear envelope calcium stores. After depletion of nuclear store calcium by inositol 1,4,5-trisphosphate or calcium chelators, fluorescent molecules conjugated to 10-kilodalton dextran were unable to enter the nucleus. Dye exclusion after calcium store depletion was not dependent on the nuclear matrix because it occurred in nuclear ghosts lacking nucleoplasm. Smaller molecules and ions (500-dalton Lucifer yellow and manganese) diffused freely into the core of the nuclear ghosts and intact nuclei even after calcium store depletion. Thus, depletion of the nuclear calcium store blocks diffusion of intermediate-sized molecules.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Stehno-Bittel, Lisa/0000-0002-8879-6124	PHS HHS [41303] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V113, P259; DAVIS L I, 1992, Current Opinion in Cell Biology, V4, P424, DOI 10.1016/0955-0674(92)90007-Y; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIN C, 1994, CELL CALCIUM, V16, P247, DOI 10.1016/0143-4160(94)90088-4; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6868; PAINE PL, 1992, BIOTECHNIQUES, V13, P238; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; SCHLENSTEDT G, 1992, J CELL BIOL, V123, P785; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; Stewart M, 1992, Semin Cell Biol, V3, P267, DOI 10.1016/1043-4682(92)90028-T	24	171	173	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1835	1838		10.1126/science.270.5243.1835	http://dx.doi.org/10.1126/science.270.5243.1835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525380				2022-12-01	WOS:A1995TK47600050
J	WILKINSON, JQ; LANAHAN, MB; YEN, HC; GIOVANNONI, JJ; KLEE, HJ				WILKINSON, JQ; LANAHAN, MB; YEN, HC; GIOVANNONI, JJ; KLEE, HJ			AN ETHYLENE-INDUCIBLE COMPONENT OF SIGNAL-TRANSDUCTION ENCODED BY NEVER-RIPE	SCIENCE			English	Article							EXPRESSION; ARABIDOPSIS; FAMILY	The ripening-impaired tomato mutant Never-ripe (Nr) is insensitive to the plant hormone ethylene. The gene that cosegregates with the Nr locus encodes a protein with homology to the Arabidopsis ethylene receptor ETR1 but is lacking the response regulator domain found in ETR1 and related prokaryotic two-component signal transducers. A single amino acid change in the sensor domain confers ethylene insensitivity when expressed in transgenic tomato plants. Modulation of NR gene expression during fruit ripening controls response to the hormone ethylene.	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; MONSANTO CO,CHESTERFIELD,MO 63198; CIBA GEIGY CORP,RES TRIANGLE PK,NC 27709; TEXAS A&M UNIV,DEPT HORT SCI,COLLEGE STN,TX 77843	State University System of Florida; University of Florida; Monsanto; Texas A&M University System; Texas A&M University College Station			Klee, Harry/A-7912-2008					Abeles F.B., 2012, ETHYLENE PLANT BIOL; BRADFORD KJ, 1994, PLANT PHYSIOL, V105, P1029, DOI 10.1104/pp.105.4.1029; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chang C. Y., COMMUNICATION; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kader A. A., 1976, In 'Second Tomato Quality Workshop' [see FSTA (1977) 9 12J1812]., P57; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RUSSELL DA, 1991, MOL GEN GENET, V229, P219, DOI 10.1007/BF00272159; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; WILKINSON JD, UNPUB; WILKINSON JQ, 1995, PLANT MOL BIOL, V27, P1097, DOI 10.1007/BF00020883; Yang S.F, 1987, PLANT SENESCENCE ITS, P156; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	22	498	535	6	91	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1807	1809		10.1126/science.270.5243.1807	http://dx.doi.org/10.1126/science.270.5243.1807			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525371				2022-12-01	WOS:A1995TK47600041
J	CHEN, CC; DAVID, AS; NUNNERLEY, H; MICHELL, M; DAWSON, JL; BERRY, H; DOBBS, J; FAHY, T				CHEN, CC; DAVID, AS; NUNNERLEY, H; MICHELL, M; DAWSON, JL; BERRY, H; DOBBS, J; FAHY, T			ADVERSE LIFE EVENTS AND BREAST-CANCER - CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL RESPONSE; PSYCHOSOCIAL STRESS; COPING STRATEGIES; DIAGNOSIS; WOMEN; RISK	Objective--To investigate the strength of association between past life events and the development of breast cancer. Design--Case-control study. A standardised life events interview and rating was administered before a definitive diagnosis. Setting--Breast Cancer Screening Assessment Unit and surgical outpatient clinics at King's College Hospital, London. Subjects--119 consecutive women aged 20-70 who were referred for biopsy of a suspicious breast lesion. Main outcome measures--Odds ratio of the risk of developing breast cancer after life events in the preceding five years after adjustment for confounders. Results--41 women were diagnosed as having malignant disease while the remainder had benign conditions. Severe Life events increased the risk of breast cancer. The crude odds ratio was 3.2 (95% confidence interval 1.35 to 7.6). After adjustment for age and the menopause and other potential confounders this rose to 11.6 (3.1 to 43.7). Multiple logistic regression analysis showed that all severe events and coping with the stress of adverse events by confronting them and focusing on the problems significantly predicted a diagnosis of breast cancer. Non-severe life events and long term difficulties had no significant association. Conclusion--These findings suggest an aetiological association between life stress and breast cancer.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PSYCHOL MED,LONDON SE5 8AZ,ENGLAND; UNIV LONDON KINGS COLL HOSP,BREST SCREENING ASSESSMENT TEAM,LONDON SE5 9RS,ENGLAND; MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London	CHEN, CC (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PSYCHIAT,138 SHEN HI RD,TAINAN 70428,TAIWAN.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X				BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; Brown G., 1978, SOCIAL ORIGINS DEPRE; Brown GW, 1989, LIFE EVENTS ILLNESS; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHEN C, IN PRESS J PSYCHOSOM; CHEN CC, 1984, THESIS U LONDON LOND, P75; COOPER CL, 1992, PSYCHOL MED, V22, P447, DOI 10.1017/S0033291700030397; COOPER CL, 1993, PSYCHOL MED, V23, P653, DOI 10.1017/S0033291700025435; Eysenck H. J., 1964, EYSENCK PERSONALITY; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; FORSEN A, 1991, PSYCHOTHER PSYCHOSOM, V55, P176, DOI 10.1159/000288427; GEYER S, 1991, J PSYCHOSOM RES, V35, P355, DOI 10.1016/0022-3999(91)90090-B; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; GOODKIN K, 1992, J PSYCHOSOM RES, V36, P635, DOI 10.1016/0022-3999(92)90053-5; GREER S, 1975, J PSYCHOSOM RES, V19, P147, DOI 10.1016/0022-3999(75)90062-8; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; JASMIN C, 1990, ANN ONCOL, V1, P22, DOI 10.1093/oxfordjournals.annonc.a057666; Lewis CE, 1994, PSYCHOIMMUNOLOGY CAN; MUSLIN HL, 1966, ANN NY ACAD SCI, V125, P802, DOI 10.1111/j.1749-6632.1966.tb45429.x; PETTINGALE KW, 1988, J PSYCHOSOM RES, V32, P255, DOI 10.1016/0022-3999(88)90066-9; RAMIREZ AJ, 1990, LANCET, V335, P1408, DOI 10.1016/0140-6736(90)91294-K; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; SCHONFIELD J, 1975, J PSYCHOSOM RES, V19, P229, DOI 10.1016/0022-3999(75)90018-5; Tobin D. L., 1984, USERS MANUAL COPING	25	125	129	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1527	1530		10.1136/bmj.311.7019.1527	http://dx.doi.org/10.1136/bmj.311.7019.1527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK214	8520393	Green Published			2022-12-01	WOS:A1995TK21400020
J	WHITNEY, JA; GOMEZ, M; SHEFF, D; KREIS, TE; MELLMAN, I				WHITNEY, JA; GOMEZ, M; SHEFF, D; KREIS, TE; MELLMAN, I			CYTOPLASMIC COAT PROTEINS INVOLVED IN ENDOSOME FUNCTION	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; BREFELDIN-A; MDCK CELLS; GUANINE-NUCLEOTIDE; TRANSPORT; LYSOSOMES	Endosomes are intermediates for a complex series of sorting and transport events that occur during receptor-mediated endocytosis. These involve the recognition of targeting determinants on the cytoplasmic domains of many membrane proteins as well as the formation of specific transport vesicles. Accordingly, endosome function is likely to be governed by the regulated assembly of cytoplasmic coat complexes. We have found that, in vitro, endosomes recruit a characteristic set of cytoplasmic proteins in a GTP gamma S-stimulated and brefeldin A-sensitive fashion. Among these are members of the COP-I and ARF families of coat proteins. In addition, endosomes were also found to assemble distinct, clathrin-like coats. Since microinjection of antibodies to beta-COP inhibits the entry of enveloped viruses via the endocytic pathway, it is apparent that the recruitment of COP-I or COP-I-related proteins plays an important role in the function of endosomes in intact cells.	UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	WHITNEY, JA (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Sheff, David/A-1269-2007; Mellman, Ira/ABG-5896-2020					AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; KILLISCH I, 1992, J CELL SCI, V103, P211; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1995, IN PRESS ANN REV DEV; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWA.J, 1991, CELL, V67, P601; LOWE M, 1995, IN PRESS J BIOL CHEM; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHEFF D, 1995, IN PRESS J BIOL CHEM; SODEIK B, 1994, J VIROL, V68, P1103, DOI 10.1128/JVI.68.2.1103-1114.1994; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	41	264	267	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					703	713						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521487				2022-12-01	WOS:A1995TH94800007
J	QUINN, M; ALLEN, E				QUINN, M; ALLEN, E			CHANGES IN INCIDENCE OF AND MORTALITY FROM BREAST-CANCER IN ENGLAND AND WALES SINCE INTRODUCTION OF SCREENING	BRITISH MEDICAL JOURNAL			English	Article							TRIAL; MAMMOGRAPHY; HEALTH; PROGRAM; UPDATE; STAGE; WOMEN	Objective-To assess the impact of the NHS breast screening programme on the incidence of and mortality from breast cancer. Design-Comparison of age specific incidence and mortality before and after the introduction of screening in the late 1980s. Setting-England and Wales. Subjects-Women aged over 30 years. Results-In 1992 the age standardised incidence of breast cancer was 40% higher than in 1979. After the introduction of screening in 1988 recorded incidence rates rose steeply in the screened age group (50-64 year olds) but not in others. In 1992 the rates levelled off at about 25% higher than in 1987. Total mortality hom breast cancer has increased steadily since the 1950s; the rates increased earlier in the younger age groups. By the mid-1980s rates had begun to fall in the younger age groups; but total mortality was still among the highest in the world. Age standardised mortality in the 55-69 age group changed little during the first three years of screening but then fell steeply and in 1994 was 12% lower than in 1987. Conclusion-Since the introduction of screening there have been pronounced increases in recorded incidence in the screened age group. Cancer registries have an essential role in assessing screening programmes and cancer services. The steep decrease in mortality in 55-69 year olds which began three years after screening started is unlikely to be due to screening. The widespread adoption of treatment with tamoxifen during this period may be important. With the reduction in mortality already observed and the expected additional benefits from screening, the Health of the Nation target should be achieved.			QUINN, M (corresponding author), OFF POPULAT CENSUSES & SURVEYS,NATL CANC REGISTRAT BUR,ST CATHERINES HOUSE,LONDON WC2B 6JP,ENGLAND.		Allen, Liz/B-2625-2012; Allen, Liz/AAK-3137-2020	Allen, Liz/0000-0002-9298-3168; Allen, Liz/0000-0002-9298-3168				ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; ANDERSON TJ, 1991, BRIT J CANCER, V64, P108, DOI 10.1038/bjc.1991.251; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1995, POLICY FRAMEWORK COM; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BAUM M, 1991, BRIT J CANCER, V64, P205, DOI 10.1038/bjc.1991.276; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BERAL V, IN PRESS 2ND P INT S; Berrino F, 1995, IARC SCI PUBLICATION, V132; BREWSTER D, 1994, ACCURACY 1990 CANCER; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; COLEMAN MP, 1993, IARC SCI PUBLICATION, V121; CRISP WJ, 1993, BRIT J SURG, V80, P863, DOI 10.1002/bjs.1800800718; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELLIOTT P, 1992, LANCET, V339, P854, DOI 10.1016/0140-6736(92)90290-J; ELLIOTT P, 1992, J EPIDEMIOL COMMUN H, V46, P345, DOI 10.1136/jech.46.4.345; EVANS DGR, 1994, BRIT MED J, V308, P183, DOI 10.1136/bmj.308.6922.183; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; LAW J, 1995, 4TH P INT C BREAST C; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; MCPHERSON K, 1994, BRIT MED J, V309, P1003, DOI 10.1136/bmj.309.6960.1003; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MOODY C, 1994, J ROY SOC MED, V87, P259; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PATNICK J, 1993, NHS BREAST SCREENING; PATNICK J, 1994, NHS BREAST SCREENING; ROBERTSON FM, 1990, SURG GYNECOL OBSTET, V171, P55; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SEDDON D, 1994, ACCURACY POPULATION; Shapiro S, 1988, PERIODIC SCREENING B; SIKORA K, 1994, BRIT MED J, V308, P188, DOI 10.1136/bmj.308.6922.188; SILVA ID, 1995, BRIT J CANCER, V72, P485, DOI 10.1038/bjc.1995.360; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; VERBEEK ALM, 1984, LANCET, V1, P1222; WILSON JMG, 1968, WHO34 PUBL HLTH PAP; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224; 1995, UPDATES; 1985, MORTALITY STATIS DH2; 1994, CANCER S E ENGLAND 1; 1983, LANCET, V1, P257; 1995, OUTCOME OBJECTIVES; 1994, CANCER SURVIVAL 1981; 1994, KEY POPULATION VI VS; 1991, EVIDENCE EXPERIENCE; 1983, CANCER STATISTIC MB1; 1994, BREAST CANCER B STIM; 1995, CANCER REGISTRY REPO, V3; 1994, SERIES MBI, V22; 1993, MED RES SERVICES; 1993, BREAST, V2, P13; 1992, USERS VIEWS REPORT S; 1986, BREAST CANCER SCREEN; 1994, TRENDS CANCER SURVIV; 1992, LANCET, V339, P71; 1995, MORTALITY STATIS DH2; 1986, BRIT MED J, V293, P946; 1993, HLTH NATION KEY AREA	64	151	151	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1391	1395		10.1136/bmj.311.7017.1391	http://dx.doi.org/10.1136/bmj.311.7017.1391			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520272	Green Published			2022-12-01	WOS:A1995TG90200016
J	KORETZ, RL; ABBEY, H; COLEMAN, E; GITNICK, G				KORETZ, RL; ABBEY, H; COLEMAN, E; GITNICK, G			NON-A, NON-B POSTTRANSFUSION HEPATITIS - LOOKING BACK IN THE 2ND DECADE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-C; BLOOD TRANSFUSION; ALANINE AMINOTRANSFERASE; FATIGUE	RECOMBINANT INTERFERON-ALFA; CONTROLLED TRIAL; POSTTRANSFUSION HEPATITIS; DOUBLE-BLIND; DISEASE	Objective: To determine the long-term course of non-A, non-B post-transfusion hepatitis. Design: Follow-up in 1989 to 1992 of patients prospectively identified as having contracted non-A, non-B post-transfusion hepatitis between 1972 and 1980. Setting: A university hospital. Patients: Patients who were prospectively followed from receipt of blood products and in whom otherwise unexplained abnormalities in their serum alanine aminotransferase levels developed without serologic evidence of exposure to hepatitis A or B. Measurements: The presence or absence of clinical evidence of liver failure or symptoms of chronic hepatitis. Results: Of 90 patients identified in the 1970s, 80 were recontacted and evaluated between 1989 and 1992. Based on the current status of these 80 patients and on the last known status of the remaining patients, the following observations were made: 1) Although about 40% had some symptoms during the early phase of the disease, none subsequently experienced significant clinical problems related to hepatic inflammation; 2) eight patients (seven with chronic hepatitis) developed hepatic failure; and 3) life-table analysis showed that the probabilities of developing clinical evidence of cirrhosis after 16 years of disease in the entire cohort, in the subgroup who developed chronic hepatitis, in the patients who had hepatitis C, and in those with chronic hepatitis C were 18%, 21%, 17%, and 20%, respectively. Conclusions: For most of the study patients, non-A, non-B post-transfusion hepatitis was a biochemical and histologic disease that had not yet caused hepatic symptoms. If hepatic failure does occur, it is usually seen only after 10 or more years of disease. Before that time, many infected persons die due to other disease processes.	UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles								AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; BERMAN M, 1979, ANN INTERN MED, V91, P1, DOI 10.7326/0003-4819-91-1-1; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; FEINMAN SV, 1988, GASTROENTEROLOGY, V95, P464, DOI 10.1016/0016-5085(88)90505-7; GREENSTEIN AJ, 1975, NEW ENGL J MED, V293, P685, DOI 10.1056/NEJM197510022931403; KNODELL RG, 1975, GASTROENTEROLOGY, V69, P1278; KORETZ RL, 1976, GASTROENTEROLOGY, V71, P797; KORETZ RL, 1990, HEPATOLOGY, V12, P880; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; KORETZ RL, 1980, GASTROENTEROLOGY, V79, P893; PARFREY PS, 1985, KIDNEY INT, V28, P959, DOI 10.1038/ki.1985.224; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; [No title captured]; 1988, LANCET, V2, P1465	17	220	221	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					110	115		10.7326/0003-4819-119-2-199307150-00003	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512159				2022-12-01	WOS:A1993LU90200003
J	MARINGHINI, A; CIAMBRA, M; BACCELLIERE, P; RAIMONDO, M; ORLANDO, A; TINE, F; GRASSO, R; RANDAZZO, MA; BARRESI, L; GULLO, D; MUSICO, M; PAGLIARO, L				MARINGHINI, A; CIAMBRA, M; BACCELLIERE, P; RAIMONDO, M; ORLANDO, A; TINE, F; GRASSO, R; RANDAZZO, MA; BARRESI, L; GULLO, D; MUSICO, M; PAGLIARO, L			BILIARY SLUDGE AND GALLSTONES IN PREGNANCY - INCIDENCE, RISK-FACTORS, AND NATURAL-HISTORY	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLELITHIASIS; PREGNANCY; BILIARY TRACT DISEASES; GALLBLADDER DISEASES; ULTRASONOGRAPHY	NATIONAL COOPERATIVE GALLSTONE; GALLBLADDER-DISEASE; ACUTE-PANCREATITIS; CHOLELITHIASIS; PREVALENCE; TIME; NUCLEATION; ESTROGEN; ORIGIN; ECHOES	Objective: To evaluate the incidence and symptoms of and risk factors for biliary sludge and gallstones during pregnancy and to assess the natural history of these conditions in the first year after delivery. Design: Cohort study. Patients: A total of 272 pregnant women recruited in the first trimester. Measurements: Biliary sludge and gallstones were diagnosed using ultrasonography, both during pregnancy and after delivery. Predictors of the presence or disappearance of sludge and stones were examined. Main Results: Overall, from the first trimester of pregnancy until the immediate postpartum period, 67 women were newly diagnosed with biliary sludge, and 6 women were newly diagnosed with gallstones. The respective incidence rates were 31% (95% CI, 25% to 37%) and 2% (95% CI, 0.2% to 4%). During pregnancy, 28% of women experienced biliary pain, which was associated only with presence of stones. After delivery, 92 women had sludge and 23 had stones. Sludge disappeared in 61 % of these women (CI, 50% to 73%) after a mean follow-up of 5 months, and stones disappeared in 28% of women (CI, 10% to 46%) after 9.7 months of follow-up. Conclusions: Biliary sludge occurred frequently during pregnancy but was generally asymptomatic and often disappeared spontaneously after delivery. Gallstones were much less frequent and were more likely to be associated with biliary pain.	UNIV PALERMO, I-90134 PALERMO, ITALY	University of Palermo			Barresi, Luca/B-4622-2013; Maringhini, Alberto/GRX-4152-2022	Barresi, Luca/0000-0002-3788-145X; Raimondo, Massimo/0000-0002-3750-1541; Maringhini, Alberto/0000-0002-0995-7701				AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; ANGELICO M, 1988, HEPATOLOGY, V8, P907; BARBARA L, 1988, HEPATOLOGY, V8, P1256; BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; BARBARA L, 1988, Journal of Hepatology, V7, pS6; BARTOLI E, 1984, GASTROINTEST RADIOL, V9, P35, DOI 10.1007/BF01887798; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; Bockus HL, 1935, PA MED J, V39, P482; BRAVERMAN DZ, 1988, J CLIN GASTROENTEROL, V10, P642, DOI 10.1097/00004836-198812000-00014; CAPOCACCIA L, 1984, AM J EPIDEMIOL, V119, P796; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; Chandrcharoensin-Wilde C, 1988, Birth Defects Orig Artic Ser, V23, P263; COLTON T, 1976, STATISTICS MED; CONRAD MR, 1979, AM J ROENTGENOL, V132, P967, DOI 10.2214/ajr.132.6.967; COOPERBERG PL, 1980, NEW ENGL J MED, V302, P1277, DOI 10.1056/NEJM198006053022303; DWORKEN HJ, 1960, GASTROENTEROLOGY, V38, P76; EVERSON GT, 1982, GASTROENTEROLOGY, V82, P711; FILLY RA, 1980, J CLIN ULTRASOUND, V8, P193, DOI 10.1002/jcu.1870080302; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GLANCY JJ, 1980, J CLIN ULTRASOUND, V8, P27, DOI 10.1002/jcu.1870080107; GLENN F, 1968, SURG GYNECOL OBSTETR, V127, P1067; GOLDSTEIN A, 1981, J CLIN ULTRASOUND, V9, P365, DOI 10.1002/jcu.1870090704; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HOLAN KR, 1979, GASTROENTEROLOGY, V77, P611; HOPPESEYLER G, 1905, NORTHNAGELS ENCY PRA; JAFFE CC, 1979, RADIOLOGY, V131, P469, DOI 10.1148/131.2.469; JORGENSEN T, 1989, GUT, V30, P433; Kennedy R., 1880, LANCET, V2, P456; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEE SP, 1988, GASTROENTEROLOGY, V95, P1161, DOI 10.1016/0016-5085(88)90219-3; LYNN J, 1973, ANN SURG, V178, P514, DOI 10.1097/00000658-197310000-00014; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARAM ES, 1990, ARCH INTERN MED, V150, P1833, DOI 10.1001/archinte.150.9.1833; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARINGHINI A, 1988, GASTROENTEROLOGY, V95, P1160, DOI 10.1016/0016-5085(88)90218-1; Mauer KR, 1989, GASTROENTEROLOGY, V96, P487; PASSMORE R, 1986, HUMAN NUTRITION DIET, P516; ROBERTSON HE, 1944, INT ABSTR SURG, V78, P193; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SAMPLINER RE, 1970, NEW ENGL J MED, V283, P1358, DOI 10.1056/NEJM197012172832502; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; SCRAGG RKR, 1984, BRIT MED J, V288, P1795, DOI 10.1136/bmj.288.6433.1795; SEDAGHAT A, 1980, NEW ENGL J MED, V302, P1274, DOI 10.1056/NEJM198006053022302; SHERMAN BM, 1975, J CLIN INVEST, V55, P699, DOI 10.1172/JCI107979; SIMEONE JF, 1980, RADIOLOGY, V137, P181, DOI 10.1148/radiology.137.1.7422843; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SMALL DM, 1980, NEW ENGL J MED, V302, P1305, DOI 10.1056/NEJM198006053022309; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; THISTLE JL, 1984, ANN INTERN MED, V101, P171, DOI 10.7326/0003-4819-101-2-171; VANDERLINDEN W, 1961, ACTA CHIR SCAND    S, V269, P1; WYSOWSKI DK, 1986, AM J EPIDEMIOL, V123, P532, DOI 10.1093/oxfordjournals.aje.a114268	53	133	139	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					116	120		10.7326/0003-4819-119-2-199307150-00004	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512160				2022-12-01	WOS:A1993LU90200004
J	RANDOLPH, AG; WASHINGTON, AE; PROBER, CG				RANDOLPH, AG; WASHINGTON, AE; PROBER, CG			CESAREAN DELIVERY FOR WOMEN PRESENTING WITH GENITAL HERPES LESIONS - EFFICACY, RISKS, AND COSTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SIMPLEX VIRUS-INFECTION; NEONATAL HERPES; DECISION-ANALYSIS; PREGNANT-WOMEN; INFANTS; MORBIDITY; ACYCLOVIR; CULTURES; TIME	Objective.-To assess the effect of cesarean delivery on neonatal and maternal morbidity and mortality and their associated costs for two populations of women presenting with genital herpes lesions at delivery: those with and those without a history of genital herpes. Data Sources.-MEDLINE (search for herpes simplex virus and neonatal, cesarean, and mortality) and recognized experts. Data Extraction.-The quality of the overall data used for baseline values was graded using a predetermined scale. Results.-The practice of cesarean delivery for women with a history of genital herpes lesions that recur at delivery results in more than 1580 excess cesarean deliveries performed for every poor neonatal outcome prevented, a cost per neonatal herpes case averted of $2.5 million and a cost per quality-adjusted life-year gained of $203 000. For these women, lowering the efficacy of cesarean delivery or the herpes simplex virus vertical transmission rate could result in maternal deaths outnumbering neonatal deaths prevented. In contrast, cesarean delivery for women with no history of genital herpes simplex virus who have lesions at delivery has low maternal costs per neonatal benefit and saves money. Conclusions.-Women who present with their first clinical episode of genital herpes at delivery should have a cesarean section performed. However, the current practice of cesarean delivery for women with a history of genital herpes lesions that recur at delivery results in high maternal morbidity and mortality at substantial financial expense, underscoring the urgency of examining alternative management strategies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GYNECOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,MEDTEP RES CTR MINOR POPULAT,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	RANDOLPH, AG (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.			Randolph, Adrienne/0000-0002-3084-3071	AHRQ HHS [HS07373-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARNOLD CB, 1988, STAT B METROP INSUR, V69, P18; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BALDWIN S, 1989, TERATOLOGY, V39, P1, DOI 10.1002/tera.1420390102; BASHORE RA, 1990, AM J OBSTET GYNECOL, V162, P1428, DOI 10.1016/0002-9378(90)90902-J; BINKIN NJ, 1989, MED DECIS MAKING, V9, P225, DOI 10.1177/0272989X8900900401; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; Bujko M, 1989, Clin Exp Obstet Gynecol, V16, P6; CATALANO PM, 1991, AM J OBSTET GYNECOL, V164, P1303, DOI 10.1016/0002-9378(91)90704-U; CHANG TW, 1977, NEW ENGL J MED, V296, P573; CHANG TW, 1977, JAMA-J AM MED ASSOC, V296, P573; CHUANG TY, 1983, MAYO CLIN PROC, V58, P436; CHUANG TY, 1988, AM J PREV MED, V4, P47, DOI 10.1016/S0749-3797(18)31219-4; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; GIBBS RS, 1988, OBSTET GYNECOL, V71, P779; LAYDE PM, 1979, JAMA-J AM MED ASSOC, V241, P2290, DOI 10.1001/jama.241.21.2290; LIBMAN MD, 1991, REV INFECT DIS, V13, P1093; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; NAHMIAS AJ, 1983, INFECT DIS, P636; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PETITTI DB, 1982, OBSTET GYNECOL, V59, P6; Prober C G, 1989, Curr Clin Top Infect Dis, V10, P1; SHANKARAN S, 1988, PEDIATRICS, V81, P372; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAYPEDERSEN B, 1990, LANCET, V336, P756, DOI 10.1016/0140-6736(90)92255-G; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; 1986, HOSPITAL FACT BOOK C; 1987, BLESSED EVENTS BOTTO, P18; 1981, NIH822067 DEP HLTH H; 1991, STATISTICAL ABSTRACT	37	89	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					77	82		10.1001/jama.270.1.77	http://dx.doi.org/10.1001/jama.270.1.77			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510301				2022-12-01	WOS:A1993LK36600028
J	MOODIE, SA; WILLUMSEN, BM; WEBER, MJ; WOLFMAN, A				MOODIE, SA; WILLUMSEN, BM; WEBER, MJ; WOLFMAN, A			COMPLEXES OF RAS.GTP WITH RAF-1 AND MITOGEN-ACTIVATED PROTEIN-KINASE KINASE	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CASCADE; RAS	The guanosine triphosphate (GTP)-binding protein Ras functions in regulating growth and differentiation; however, little is known about the protein interactions that bring about its biological activity. Wild-type Ras or mutant forms of Ras were covalently attached to an insoluble matrix and then used to examine the interaction of signaling proteins with Ras. Forms of Ras activated either by mutation (Gly12Val) or by binding of the GTP analog, guanylyl-imidodiphosphate (GMP-PNP) interacted specifically with Raf-1 whereas an effector domain mutant, Ile36Ala, failed to interact with Raf-1. Mitogen-activated protein kinase (MAP kinase) activity was only associated with activated forms of Ras. The specific interaction of activated Ras with active MAP kinase kinase (MAPK) was confirmed by direct assays. Thus the forming of complexes containing MAPKK activity and Raf-1 protein are dependent upon the activity of Ras.	UNIV COPENHAGER,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia	MOODIE, SA (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44106, USA.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999	NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39076, CA 40042] Funding Source: Medline; NIGMS NIH HHS [GM 41220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ANDERSON NG, 1992, CELL SIGNAL, V4, P239, DOI 10.1016/0898-6568(92)90063-E; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIBATTISTE D, 1993, ONCOGENE, V8, P637; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, UNPUB; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SMITH MR, 1986, NATURE, V320, P5400; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	37	912	954	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1658	1661		10.1126/science.8503013	http://dx.doi.org/10.1126/science.8503013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503013				2022-12-01	WOS:A1993LG17600033
J	BREO, DL				BREO, DL			THE UNITED-STATES RACE TO CURE AIDS - AT 4 ON A SCALE OF 10, SAYS FAUCI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		FAUCI, 1993, NEW ENGLAND J M 0204; FAUCI, 1993, NATURE          0325	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2898	2900		10.1001/jama.269.22.2898	http://dx.doi.org/10.1001/jama.269.22.2898			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497096				2022-12-01	WOS:A1993LE93600030
J	CHARDIN, P; CAMONIS, JH; GALE, NW; VANAELST, L; SCHLESSINGER, J; WIGLER, MH; BARSAGI, D				CHARDIN, P; CAMONIS, JH; GALE, NW; VANAELST, L; SCHLESSINGER, J; WIGLER, MH; BARSAGI, D			HUMAN SOS1 - A GUANINE-NUCLEOTIDE EXCHANGE FACTOR FOR RAS THAT BINDS TO GRB2	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; CDC25 GENE; MUTATION; GROWTH; CELLS; REQUIREMENT; CLONING; P21RAS; SYSTEM	A human complementary DNA was isolated that encodes a widely expressed protein, hSos1, that is closely related to Sos, the product of the Drosophila son of sevenless gene. The hSos1 protein contains a region of significant sequence similarity to CDC25, a guanine nucleotide exchange factor for Ras from yeast. A fragment of hSos1 encoding the CDC25-related domain complemented loss of CDC25 function in yeast. This hSos1 domain specifically stimulated guanine nucleotide exchange on mammalian Ras proteins in vitro. Mammalian cells overexpressing full-length hSos1 had increased guanine nucleotide exchange activity. Thus hSos1 is a guanine nucleotide exchange factor for Ras. The hSos1 interacted with growth factor receptor-bound protein 2 (GRB2) in vivo and in vitro. This interaction was mediated by the carboxyl-terminal domain of hSos1 and the Src homology 3 (SH3) domains of GRB2. These results suggest that the coupling of receptor tyrosine kinases to Ras signaling is mediated by a molecular complex consisting of GRB2 and hSos1.	COLD SPRING HARBOR LAB,1 BUNGTOWN RD,BOX 100,COLD SPRING HARBOR,NY 11724; CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Cold Spring Harbor Laboratory; Centre National de la Recherche Scientifique (CNRS); New York University				Wigler, Michael/0000-0003-4396-1971; Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R56CA055360, R01CA055360, P01CA046370, R37CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360, CA46370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pringle JR, 1981, SACCHAROMYCES CEREVI; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STEIN MJ, 1993, UNPUB; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WIGLER M, UNPUB; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; [No title captured]	45	727	757	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1338	1343		10.1126/science.8493579	http://dx.doi.org/10.1126/science.8493579			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493579				2022-12-01	WOS:A1993LE02500047
J	ESCARY, JL; PERREAU, J; DUMENIL, D; EZINE, S; BRULET, P				ESCARY, JL; PERREAU, J; DUMENIL, D; EZINE, S; BRULET, P			LEUKEMIA INHIBITORY FACTOR IS NECESSARY FOR MAINTENANCE OF HEMATOPOIETIC STEM-CELLS AND THYMOCYTE STIMULATION	NATURE			English	Article							PRIMORDIAL GERM-CELLS; MURINE; DIFFERENTIATION; SURVIVAL; INVITRO	LEUKAEMIA inhibitory factor (LIF) has a variety of effects on different cell types in vitro1, inhibiting the differentiation of embryonic stem cells2,3 and promoting the survival and/or proliferation of primitive haematopoietic precursors4,5 and primordial germ cells6,7. Here we show that LIF-deficient mice derived by gene targeting techniques have dramatically decreased numbers of stem cells in spleen and bone marrow. Injection of spleen and marrow cells from these mice promotes long-term survival of lethally irradiated wild-type animals, however, showing that the LIF- stem cells remain pluripotent. The numbers of committed progenitors are also reduced in the spleen but not the bone marrow, suggesting that stem cells interact differently with the splenic and medullary microenvironment. Heterozygous animals are intermediate in phenotype, implying that LIF has a dosage effect, and defects in stem cell number can be compensated by exogenous LIF. LIF thus appears to be required for the survival of the normal pool of stem cells, but not their terminal differentiation.	INST PASTEUR,UNITE EMBRYOL MOLEC,CNRS,URA 1148,F-75724 PARIS 15,FRANCE; INST GUSTAVE ROUSSY,INSERM,U362,F-94800 VILLEJUIF,FRANCE; CHU NECKER,INSERM,U345,F-75015 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								CONQUET F, 1992, P NATL ACAD SCI USA, V89, P8195, DOI 10.1073/pnas.89.17.8195; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; DEFELICI M, 1991, DEV BIOL, V147, P281, DOI 10.1016/S0012-1606(05)80025-9; FLETCHER FA, 1991, J EXP MED, V174, P837, DOI 10.1084/jem.174.4.837; GEARING DP, 1988, NUCLEIC ACIDS RES, V16, P9857, DOI 10.1093/nar/16.20.9857; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; KOLA I, 1990, GROWTH FACTORS, V2, P325; LE PT, 1990, J IMMUNOL, V145, P3310; LEARY AG, 1990, BLOOD, V75, P1960; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1990, BLOOD, V76, P50; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; RATJEN PD, 1990, CELL, V62, P1105; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; STAHL J, 1990, J BIOL CHEM, V265, P8833; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WORTON RG, 1969, J CELL PHYSIOL, V74, P171, DOI 10.1002/jcp.1040740209	24	337	350	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					361	364		10.1038/363361a0	http://dx.doi.org/10.1038/363361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497320				2022-12-01	WOS:A1993LD91700057
J	PASSADOR, L; COOK, JM; GAMBELLO, MJ; RUST, L; IGLEWSKI, BH				PASSADOR, L; COOK, JM; GAMBELLO, MJ; RUST, L; IGLEWSKI, BH			EXPRESSION OF PSEUDOMONAS-AERUGINOSA VIRULENCE GENES REQUIRES CELL-TO-CELL COMMUNICATION	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ELASTASE; AUTOINDUCER; PROTEIN; IDENTIFICATION; INACTIVATION; INHIBITION; LUCIFERASE; TOXIN	Pseudomonas aeruginosa is an opportunistic human pathogen that causes a variety of infections in immunocompromised hosts and individuals with cystic fibrosis. Expression of elastase, one of the virulence factors produced by this organism, requires the transcriptional activator LasR. Experiments with gene fusions show that gene lasI is essential for high expression of elastase. The lasI gene is involved in the synthesis of a diffusible molecule termed Pseudomonas autoinducer (PAI). PAI provides P. aeruginosa with a means of cell-to-cell communication that is required for the expression of virulence genes and may provide a target for therapeutic approaches.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14620 USA	University of Rochester					NIAID NIH HHS [AI33713, T32AI07362] Funding Source: Medline; NIGMS NIH HHS [T32GM07356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007362, R01AI033713, R37AI033713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEPPU T, 1992, GENE, V115, P159, DOI 10.1016/0378-1119(92)90554-3; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; COOK JPD, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORING G, 1981, ZBL BAKT-INT J MED M, V249, P89, DOI 10.1016/S0174-3031(81)80045-5; EBERHARD A, 1972, J BACTERIOL, V109, P1101, DOI 10.1128/JB.109.3.1101-1105.1972; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; GAMBELLO MJ, 1993, INFECT IMMUN, V61, P1180, DOI 10.1128/IAI.61.4.1180-1184.1993; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; GAMBELLO MJ, 1991, THESIS U ROCHESTER; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HECK LW, 1990, J IMMUNOL, V144, P2253; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Miller JH., 1972, EXPT MOL GENETICS; MORIHARA K, 1979, INFECT IMMUN, V24, P188, DOI 10.1128/IAI.24.1.188-193.1979; MORIHARA K, 1985, BACTERIAL ENZYMES VI, P49; PASSADOR L, UNPUB; RALLING G, 1985, MOL GEN GENET, V201, P379, DOI 10.1007/BF00331327; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOCK J, 1990, J BACTERIOL, V172, P3974; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; SINAI A, UNPUB; Smith T. F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TODER DS, 1991, MOL MICROBIOL, V5, P2003, DOI 10.1111/j.1365-2958.1991.tb00822.x; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; 1984, FOCUS, V6, P4	32	679	726	5	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1993	260	5111					1127	1130		10.1126/science.8493556	http://dx.doi.org/10.1126/science.8493556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493556				2022-12-01	WOS:A1993LC94200030
J	LIN, WC; DESIDERIO, S				LIN, WC; DESIDERIO, S			REGULATION OF V(D)J RECOMBINATION ACTIVATOR PROTEIN RAG-2 BY PHOSPHORYLATION	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; SIGNAL SEQUENCES; RECEPTOR GENES; B-CELLS; KINASE; DEFECT; EXPRESSION; MUTATION	Antigen receptor genes are assembled by site-specific DNA rearrangement. The recombination activator genes RAG-1 and RAG-2 are essential for this process, termed V(D)J rearrangement. The activity and stability of the RAG-2 protein have now been shown to be regulated by phosphorylation. In fibroblasts RAG-2 was phosphorylated predominantly at two serine residues, one of which affected RAG-2 activity in vivo. The threonine at residue 490 was phosphorylated by p34cdcs kinase in vitro; phosphorylation at this site in vivo was associated with rapid degradation of RAG-2. Instability was transferred to chimeric proteins by a 90-residue portion of RAG-2. Mutation of the p34cdc2 phosphorylation site of the tumor suppressor protein p53 conferred a similar phenotype, suggesting that this association between phosphorylation and degradation is a general mechanism.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	LIN, WC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CARTER P, 1987, METHOD ENZYMOL, V154, P382; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; ERICKSON A, 1992, J BIOL CHEM, V265, P19728; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOBAYASHI Y, 1991, J IMMUNOL, V147, P3201; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBER MR, 1987, GENES DEV, V751; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lin W. A., UNPUB; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MELCHERS F, 1989, COLD SH Q B, V54, P183; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORIHARA K, 1968, BIOCHEM BIOPH RES CO, V30, P625, DOI 10.1016/0006-291X(68)90558-5; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	45	194	196	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					953	959		10.1126/science.8493533	http://dx.doi.org/10.1126/science.8493533			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493533				2022-12-01	WOS:A1993LB79100035
J	PARVIN, JD; SHARP, PA				PARVIN, JD; SHARP, PA			DNA TOPOLOGY AND A MINIMAL SET OF BASAL FACTORS FOR TRANSCRIPTION BY RNA POLYMERASE-II	CELL			English	Article							MAJOR LATE PROMOTER; SIMIAN VIRUS 40; PREINITIATION COMPLEX; TATA BOX; ACCURATE TRANSCRIPTION; FUNCTIONAL-PROPERTIES; INITIATION; GENE; PURIFICATION; CHROMATIN	Immunoglobulin heavy chain (IgH) gene transcription in vitro can be reconstituted with a minimal reaction containing only TATA-binding protein (TBP), TFIIB, and RNA polymerase II (pol II) when the template is negatively supercoiled. Transcription from linear DNA templates containing either the IgH or the adenovirus major late promoters (MLPs) requires in addition TFIIF, TFIIE, TFIIH, and a fraction containing TFIIA and TFIIJ. Promoters vary in their activities in the minimal reaction. Initiation at the adenovirus MLP site was not observed in this reaction, even with templates containing negative superhelical density. When only TBP, TFIIB, and pol II were present in the reaction, the more negatively supercoiled the IgH template DNA was, the more active the transcription. It is suggested that the free energy of supercoiling promotes the formation of an open complex for initiation of transcription by the minimal set of transcription factors.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	PARVIN, JD (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14051, P01-CA42063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTCHAN P, 1973, P NATL ACAD SCI USA, V70, P3077, DOI 10.1073/pnas.70.11.3077; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRADKIN LG, 1985, P NATL ACAD SCI USA, V82, P7979, DOI 10.1073/pnas.82.23.7979; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARLAND RM, 1983, NATURE, V302, P38, DOI 10.1038/302038a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUCHNIK AN, 1982, EMBO J, V1, P1353, DOI 10.1002/j.1460-2075.1982.tb01322.x; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; OHBA R, 1992, BIOCHEM BIOPH RES CO, V186, P963, DOI 10.1016/0006-291X(92)90840-H; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1992, CELL, V68, P1153; PETERSON MG, 1991, NATURE, V354, P369; PROBST E, 1979, J MOL BIOL, V135, P709, DOI 10.1016/0022-2836(79)90173-6; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WANG JC, 1977, NUCLEIC ACIDS RES, V4, P1225, DOI 10.1093/nar/4.5.1225; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716	49	331	336	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					533	540		10.1016/0092-8674(93)90140-L	http://dx.doi.org/10.1016/0092-8674(93)90140-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490964				2022-12-01	WOS:A1993LA74300014
J	MORRISS, R; SHARPE, M; SHARPLEY, AL; COWEN, PJ; HAWTON, K; MORRIS, J				MORRISS, R; SHARPE, M; SHARPLEY, AL; COWEN, PJ; HAWTON, K; MORRIS, J			ABNORMALITIES OF SLEEP IN PATIENTS WITH THE CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							FIBROSITIS SYNDROME; DEPRESSION; INTENSITY; EXERCISE; ANXIETY	Objective-To determine whether patients with the chronic fatigue syndrome have abnormalities of sleep which may contribute to daytime fatigue. Design-A case-control study of the sleep of patients with the chronic fatigue syndrome and that of healthy volunteers. Setting-An infectious disease outpatient clinic and subjects' homes. Subjects-12 patients who met research criteria for the chronic fatigue syndrome but not for major depressive disorder and 12 healthy controls matched for age, sex, and weight. Main outcome measures-Subjective reports of sleep from patients' diaries and measurement of sleep patterns by polysomnography. Subjects' anxiety, depression, and functional impairment were assessed by interview. Results-Patients with the chronic fatigue syndrome spent more time in bed than controls (544 min v 465 min, p < 0.001) but slept less efficiently (90% v 96%, p < 0.05) and spent more time awake after initially going to sleep (31.9 min v 16.6 min, p < 0.05). Seven patients with the chronic fatigue syndrome had a sleep disorder (four had difficulty maintaining sleep, one had difficulty getting to sleep, one had difficulty in both initiating and maintaining sleep, and one had hypersomnia) compared with none of the controls (p = 0.003). Those with sleep disorders showed greater functional impairment than the remaining five patients (score on general health survey 50.4% v 70.4%, p < 0.05), but their psychiatric scores were not significantly different. Conclusions-Most patients with the chronic fatigue syndrome had sleep disorders, which are likely to contribute to daytime fatigue. Sleep disorders may be important in the aetiology of the syndrome.	LITTLEMORE HOSP,MRC,CLIN PHARMACOL UNIT,OXFORD OX4 4XN,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND; UNIV HOSP S MANCHESTER,DEPT MED STAT,MANCHESTER M20 8LR,LANCS,ENGLAND	University of Oxford; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				Sharpley, Ann L/0000-0002-0623-1067; sharpe, michael/0000-0002-6474-9980; Morriss, Richard/0000-0003-2910-4121				ABBEY SE, 1990, CAN J PSYCHIAT, V35, P625, DOI 10.1177/070674379003500714; ARRIAGA F, 1990, BIOL PSYCHIAT, V27, P649, DOI 10.1016/0006-3223(90)90533-8; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; GARDNER MJ, 1989, STATISTICS CONFIDENC, P9; GOLDENBERG DL, 1987, JAMA-J AM MED ASSOC, V257, P2782, DOI 10.1001/jama.257.20.2782; Horne J.A., 1991, SLEEP SLEEPINESS PER, P169; KENDELL RE, 1991, LANCET, V337, P160; KRUPP LB, 1991, J CLIN PSYCHIAT, V52, P403; KUPFER DJ, 1992, BRIT J PSYCHIAT, V161, P309, DOI 10.1192/bjp.161.3.309; Mackie R.R., 1977, VIGILANCE THEORY OPE; MCMURRAY RG, 1984, AVIAT SPACE ENVIR MD, V55, P1031; MOLDOFSKY H, 1989, Journal of Rheumatology, V16, P150; MOLDOFSKY H, 1975, PSYCHOSOM MED, V37, P341, DOI 10.1097/00006842-197507000-00008; MYLES WS, 1985, MED SCI SPORT EXER, V17, P580; NEYTA N, 1990, HUM PSYCHOPHARMACOL, V6, P173; REYNOLDS CF, 1987, SLEEP, V10, P199, DOI 10.1093/sleep/10.3.199; REYNOLDS CF, 1983, PSYCHIAT RES, V8, P81, DOI 10.1016/0165-1781(83)90094-X; SASKIN P, 1986, PSYCHOSOM MED, V48, P319, DOI 10.1097/00006842-198605000-00002; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; SHARPLEY AL, 1988, SLEEP, V11, P273, DOI 10.1093/sleep/11.3.273; Spitzer R.L., 1990, STRUCTURED CLIN INTE; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WHELTON CL, 1988, SLEEP RES, V17, P309; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1987, DIAGNOSTIC STATISTIC	26	87	89	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1161	1164		10.1136/bmj.306.6886.1161	http://dx.doi.org/10.1136/bmj.306.6886.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LA685	8499816	Bronze, Green Published			2022-12-01	WOS:A1993LA68500019
J	Turek, FW				Turek, FW			Melatonin hype hard to swallow	NATURE			English	Editorial Material							ENTRAINMENT; RHYTHMS; SLEEP				Turek, FW (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							Aschoff J., 1982, VERTEBRATE CIRCADIAN, P129; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; EBIHARA S, 1986, SCIENCE, V231, P491, DOI 10.1126/science.3941912; GASTON S, 1968, SCIENCE, V160, P1125, DOI 10.1126/science.160.3832.1125; HOFFMAN RA, 1965, SCIENCE, V148, P1609, DOI 10.1126/science.148.3677.1609; JAMES SP, 1987, NEUROPSYCHOPHARMACOL, V1, P41, DOI 10.1016/0893-133X(87)90008-X; MADDOX J, 1995, NATURE, V378, P435, DOI 10.1038/378435a0; Pierpaoli W, 1995, MELATONIN MIRACLE; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R., 1995, MELATONIN; SACK RL, 1991, J BIOL RHYTHM, V6, P249, DOI 10.1177/074873049100600305; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; TUREK FW, 1976, SCIENCE, V194, P1441, DOI 10.1126/science.1006311; VANCOEVORDEN A, 1991, AM J PHYSIOL, V260, pE651, DOI 10.1152/ajpendo.1991.260.4.E651	14	40	41	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					295	296		10.1038/379295a0	http://dx.doi.org/10.1038/379295a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552179				2022-12-01	WOS:A1996TR32300027
J	Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW				Gwee, KA; Graham, JC; McKendrick, MW; Collins, SM; Marshall, JS; Walters, SJ; Read, NW			Psychometric scores and persistence of irritable bowel after infectious diarrhoea	LANCET			English	Article							LIFE EVENTS; COMMUNITY; SYMPTOMS; ANXIETY; RAT	Background Although previous studies have shown that psychological disturbances are frequently associated with the irritable bowel syndrome (IBS), the relation was not necessarily cause and effect. The development of chronic bowel symptoms resembling IBS after an episode of acute gastroenteritis has allowed us to examine prospectively the role of psychological factors. Methods 75 patients with acute gastroenteritis completed a series of psychometric tests soon after admission to hospital. Of these, 22 had persistent symptoms compatible with IBS after the acute illness, and in 20 of these the symptoms were still present at six months. Findings At the time of their initial illness, patients who subsequently developed IBS symptoms had higher scores for anxiety, depression, somatisation, and neurotic trait than those who returned to normal bowel function. The psychometric scores had not changed when remeasured three months after the acute illness. Lactose malabsorption was not an important factor. Interpretation These results support the hypothesis that psychological factors are important in IBS.	UNIV SHEFFIELD, NO GEN HOSP, GI MOTIL UNIT, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT INFECT DIS & MED, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; MCMASTER UNIV, INTESTINAL DIS RES UNIT, HAMILTON, ON, CANADA; UNIV SHEFFIELD, SHEFFIELD CTR HLTH & RELATED RES, SHEFFIELD, S YORKSHIRE, ENGLAND	Northern General Hospital; University of Sheffield; University of Sheffield; McMaster University; University of Sheffield				Marshall, Jean S./0000-0002-5642-1379; Walters, Stephen/0000-0001-9000-8126				[Anonymous], 1992, GASTROENTEROL INT; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHAUDHARY NA, 1962, Q J MED, V31, P307; COLLINS SM, 1992, ANN NY ACAD SCI, V664, P415, DOI 10.1111/j.1749-6632.1992.tb39780.x; COLLINS SM, 1989, STRESS DIGESTIVE MOT, P151; CRAIG TKJ, 1984, J PSYCHOSOM RES, V28, P411, DOI 10.1016/0022-3999(84)90073-4; CREED F, 1981, LANCET, V1, P1381; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; Eysenck HJ, 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; KHAN I, 1994, GASTROENTEROLOGY, V106, pA523; MACDONALD AJ, 1980, BRIT J PSYCHIAT, V136, P276, DOI 10.1192/bjp.136.3.276; MCHUGH KJ, 1993, GASTROENTEROLOGY, V104, pA1051; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; METZ G, 1975, LANCET, V1, P1155; PALMER RL, 1974, POSTGRAD MED J, V50, P416, DOI 10.1136/pgmj.50.585.416; Rubio C A, 1992, In Vivo, V6, P81; SAUNDERS PR, 1993, GASTROENTEROLOGY, V104, pA1061; STEWART GT, 1950, BMJ-BRIT MED J, V1, P405, DOI 10.1136/bmj.1.4650.405; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165, DOI 10.1093/oxfordjournals.aje.a116483; TALLEY NJ, 1991, EUR J GASTROEN HEPAT, V3, P71; VALLANCE BA, 1994, GASTROENTEROLOGY, V106, pA582; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	417	427	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					150	153		10.1016/S0140-6736(96)90341-4	http://dx.doi.org/10.1016/S0140-6736(96)90341-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544549				2022-12-01	WOS:A1996TQ24400010
J	Buhl, EH; Otis, TS; Mody, I				Buhl, EH; Otis, TS; Mody, I			Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model	SCIENCE			English	Article							PAIRED-PULSE DEPRESSION; DENTATE GRANULE CELLS; FIBER SYNAPTIC REORGANIZATION; RAT HIPPOCAMPAL SLICES; A-RECEPTOR COMPLEX; FASCIA-DENTATA; MOSSY FIBERS; PATCH-CLAMP; GYRUS; NEURONS	In the kindling model of temporal robe epilepsy, several physiological indicators of inhibition by gamma-aminobutyric acid (GABA) in the hippocampal dentate gyrus are consistent with an augmented, rather than a diminished, inhibition. In brain slices obtained from epileptic (kindled) rats, the excitatory drive onto inhibitory interneurons was increased and was paralleled by a reduction in the presynaptic autoinhibition of GABA release. This augmented inhibition was sensitive to zinc most likely after a molecular reorganization of GABA(A) receptor subunits. Consequently, during seizures, inhibition by GABA may be diminished by the zinc released from aberrantly sprouted messy fiber terminals of granule cells, which are found in many experimental models of epilepsy and in human temporal robe epilepsy.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL RNRC 3131,LOS ANGELES,CA 90095; UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; UNIV WISCONSIN,SCH MED,CTR MED SCI,DEPT NEUROPHYSIOL,MADISON,WI 53706	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; University of Wisconsin System; University of Wisconsin Madison					NINDS NIH HHS [NS 12151, NS 30549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030549, R01NS030549, P50NS012151, P01NS012151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; AVOLI M, 1991, EPILEPSY RES, V10, P33, DOI 10.1016/0920-1211(91)90092-T; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CLARK M, 1994, MOL BRAIN RES, V26, P309, DOI 10.1016/0169-328X(94)90104-X; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Frederickson C. J., 1994, Biological Signals, V3, P127; FREDERICKSON CJ, COMMUNICATION; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HARRISON NL, 1994, NEUROPHARMACOLOGY, V33, P935, DOI 10.1016/0028-3908(94)90152-X; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; ISOKAWA M, 1991, EPILEPSY RES, V9, P242, DOI 10.1016/0920-1211(91)90058-N; ISOKAWA M, 1993, J NEUROSCI, V13, P1511, DOI 10.1523/jneurosci.13-04-01511.1993; KAMPHUIS W, 1994, NEUROSCI LETT, V174, P5, DOI 10.1016/0304-3940(94)90105-8; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KOHR G, 1993, J NEUROSCI, V13, P3612; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KRAUS JE, 1994, J NEUROSCI, V14, P4196; LAMBERT NA, 1994, J NEUROPHYSIOL, V72, P121, DOI 10.1152/jn.1994.72.1.121; LEGENDRE P, 1991, MOL PHARMACOL, V39, P267; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; MOTT DD, 1993, J NEUROPHYSIOL, V69, P674, DOI 10.1152/jn.1993.69.3.674; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; OLIVER MW, 1985, EXP BRAIN RES, V57, P443; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; Ribak C E, 1991, Hippocampus, V1, P355, DOI 10.1002/hipo.450010403; SAXENA NC, 1994, J NEUROSCI, V14, P7077; Schwartzkroin PA, 1993, EPILEPSY MODELS MECH; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SOLLESZ I, 1995, NEURON, V14, P1273; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SUTULA TP, 1991, EPILEPSY RES, V10, P62, DOI 10.1016/0920-1211(91)90096-X; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TITULAER MNG, 1995, J NEUROCHEM, V64, P2615; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; URNO K, 1994, HIPPOCAMPUS, V4, P583; VALDES F, 1982, P NATL ACAD SCI-BIOL, V79, P193, DOI 10.1073/pnas.79.1.193; WANG YX, 1990, PFLUG ARCH EUR J PHY, V415, P582, DOI 10.1007/BF02583509; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WHITE G, 1995, NEUROREPORT, V6, P461, DOI 10.1097/00001756-199502000-00014	66	329	333	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					369	373		10.1126/science.271.5247.369	http://dx.doi.org/10.1126/science.271.5247.369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553076				2022-12-01	WOS:A1996TQ52800047
J	Dodds, AW; Ren, XD; Willis, AC; Law, SKA				Dodds, AW; Ren, XD; Willis, AC; Law, SKA			The reaction mechanism of the internal thioester in the human complement component C4	NATURE			English	Article							STRUCTURAL BASIS; NUCLEOPHILIC MODIFICATION; 4TH COMPONENT; 3RD COMPONENT; BINDING; C-3; SEQUENCE; SITE; C3B; IDENTIFICATION	A KEY step in the elimination of pathogens from the body is the covalent binding of complement proteins C3 and C4 to their surfaces(1-5). Proteolytic activation of these proteins results in a conformational change(6,7), and an internal thioester(8-10) is exposed which reacts with amino or hydroxyl groups on the target surface to form amide or ester bonds, or is hydrolysed(11-15). We report here that the binding of the human C4A isotype involves a direct reaction between amino-nucleophiles and the thioester. A two-step mechanism is used by the C4B isotype. The histidine at position 1,106 (aspartic acid in C4A) first attacks the thioester to form an acyl-imidazole intermediate. The released thiol then acts as a base to catalyse the transfer of the acyl group to amino- and hydroxyl-nucleophiles, including water.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford			Law, Alex/A-2212-2011	Dodds, Alister William/0000-0003-3396-1257				BELT KT, 1984, CELL, V36, P907; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CAMPBELL RD, 1981, BIOCHEM J, V199, P359, DOI 10.1042/bj1990359; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CHU CT, 1994, LAB INVEST, V71, P792; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DODDS AW, 1988, COMPLEMENT INFLAMMAT, V5, P89, DOI 10.1159/000463039; DODDS AW, 1986, IMMUNOGENETICS, V24, P279, DOI 10.1007/BF00395532; DODDS AW, 1990, BIOCHEM J, V265, P494; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; HOSTETTER MK, 1982, NATURE, V298, P72, DOI 10.1038/298072b0; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SK, 1979, J IMMUNOL, V123, P1388; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LAW SKA, 1995, FOCUS SERIES; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; NG YC, 1993, COMPLEMENT HLTH DISE, P199; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; REN XD, 1995, FEBS LETT, V368, P87, DOI 10.1016/0014-5793(95)00606-A; REN XD, 1993, IMMUNOGENETICS, V37, P120, DOI 10.1007/BF00216835; SCHWEIZER M, 1987, EUR J BIOCHEM, V164, P375, DOI 10.1111/j.1432-1033.1987.tb11068.x; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; THOMAS ML, 1983, BIOCHEMISTRY-US, V22, P942, DOI 10.1021/bi00273a036; WEITZMAN JB, 1993, COMPLEMENT HLTH DISE, P269; YU CY, 1986, EMBO J, V5, P2873, DOI 10.1002/j.1460-2075.1986.tb04582.x	30	149	155	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					177	179		10.1038/379177a0	http://dx.doi.org/10.1038/379177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538770				2022-12-01	WOS:A1996TP36000062
J	Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N				Penny, GD; Kay, GF; Sheardown, SA; Rastan, S; Brockdorff, N			Requirement for Xist in X chromosome inactivation	NATURE			English	Article							STEM-CELLS; CONTROLLING ELEMENTS; MOUSE DEVELOPMENT; GENE; EXPRESSION; EMBRYOS; TRANSLOCATION; LOCATION; POSITION; CONTAINS	The Xist gene has been proposed as a candidate for the X inactivation centre the master regulatory switch locus that controls X chromosome inactivation. So far this hypothesis has been supported solely by indirect evidence. Here we describe gene targeting of Xist, and provide evidence for its absolute requirement in the process of X chromosome inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,COMPARAT MED SECT,MRC,CLIN SCI CTR,LONDON W12 0NN,ENGLAND	Imperial College London			Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BALL TC, 1995, BLOOD, V85, P3086, DOI 10.1182/blood.V85.11.3086.bloodjournal85113086; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, MAMM GENOME, V1, P152, DOI 10.1007/BF00351061; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1970, GENET RES, V15, P183, DOI 10.1017/S0016672300001518; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CATTANACH BM, 1967, GENETICS, V57, P331; DUTRILLAUX B, 1974, ANN GENET-PARIS, V17, P207; GREEN MC, 1989, GENETIC VARIANTS STR, P282; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Nagy A., 1993, Gene targeting: a practical approach., P147; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; PAMIERI SL, 1994, DEV BIOL, V166, P259; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUSSELL LB, 1970, GENETICS, V64, P281; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Singer-Sam J, 1992, PCR Methods Appl, V1, P160; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P10469, DOI 10.1073/pnas.89.21.10469; TADA T, 1993, DEVELOPMENT, V119, P813; TAKAGI N, 1984, DEV BIOL, V103, P425, DOI 10.1016/0012-1606(84)90330-0; TAKAGI N, 1990, DEVELOPMENT, V109, P189; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; ZINN AR, 1991, GENOMICS, V11, P1097, DOI 10.1016/0888-7543(91)90037-F	46	975	1004	1	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					131	137		10.1038/379131a0	http://dx.doi.org/10.1038/379131a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538762				2022-12-01	WOS:A1996TP36000048
J	KritzSilverstein, D; BarrettConnor, E				KritzSilverstein, D; BarrettConnor, E			Long-term postmenopausal hormone use, obesity, and fat distribution in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BODY-FAT; REPLACEMENT THERAPY; ADIPOSE-TISSUE; RISK-FACTORS; MENOPAUSE; POPULATION; ASSOCIATION; GOTHENBURG; HISTORY	Objective.-To determine whether long-term postmenopausal hormone replacement is associated with measures of obesity and body composition in elderly women. Design.-A 15-year prospective and cross-sectional cohort study. Setting.-Rancho Bernardo, a geographically defined community in Southern California. Participants.-A total of 671 women aged 65 to 94 years, who were initially enrolled in the Rancho Bernardo Study between 1972 and 1974 and participated in a 1988 to 1991 follow-up clinic visit. These women had never used hormone replacement therapy (n=194), used hormones intermittently (n=331), or used hormones continuously (n=146) for the 15 years between baseline and follow-up. Main Outcome Measures.-Height and weight were obtained at both clinic visits; differences in body mass index (BMI) between baseline and follow-up were computed. At follow-up, waist and hip circumferences and bioelectric impedance were measured. Results.-Age-adjusted comparisons indicated intermittent and continuous hormone users had significantly lower mean BMIs at baseline than women who had never used hormone replacement therapy. After adjustment for potentially confounding covariates, there were no significant differences between estrogen users and nonusers in BMI at follow-up, change in weight or BMI between baseline and follow-up, or waist-hip ratio or fat mass at follow-up. Conclusion.-Hormone replacement therapy, whether used intermittently or continuously for 15 or more years, is not associated with the weight gain and central obesity that is commonly observed in postmenopausal women.	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,DIV EPIDEMIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					AHRQ HHS [HS06726] Funding Source: Medline; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1980, AM J EPIDEMIOL, V111, P705, DOI 10.1093/oxfordjournals.aje.a112948; GOODMAN MT, 1990, AM J EPIDEMIOL, V131, P815, DOI 10.1093/oxfordjournals.aje.a115572; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HART DM, 1978, FRONT HORM RES, V5, P174; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2; KAYE SA, 1990, INT J OBESITY, V14, P583; KULLER L, 1990, SERONO S; KULLER LH, 1994, EXP GERONTOL, V29, P495, DOI 10.1016/0531-5565(94)90030-2; KUSHNER RF, 1992, J AM COLL NUTR, V11, P199; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; LUKASKI HC, 1985, AM J CLIN NUTR, V41, P810, DOI 10.1093/ajcn/41.4.810; LUNDGREN H, 1989, INT J OBESITY, V13, P413; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOTELOVITZ M, 1982, CURR THER RES CLIN E, V31, P746; NOTELOVITZ M, 1975, S AFR MED J, V49, P2251; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; TONKELAAR I, 1990, INT J OBESITY, V14, P753; Tonkelaar I D, 1989, Int J Obes, V13, P817; UTIAN WH, 1978, MATURITAS, V1, P3, DOI 10.1016/0378-5122(78)90003-8; WING RR, 1991, ARCH INTERN MED, V151, P97, DOI 10.1001/archinte.151.1.97; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250; 1995, JAMA-J AM MED ASSOC, V273, P199	26	86	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					46	49						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531286				2022-12-01	WOS:A1996TM23800021
J	CARROLL, JM; ROMERO, MR; WATT, FM				CARROLL, JM; ROMERO, MR; WATT, FM			SUPRABASAL INTEGRIN EXPRESSION IN THE EPIDERMIS OF TRANSGENIC MICE RESULTS IN DEVELOPMENTAL DEFECTS AND A PHENOTYPE RESEMBLING PSORIASIS	CELL			English	Article							TGF-ALPHA; TERMINAL DIFFERENTIATION; GROWTH-FACTOR; SKIN; CELLS; MOUSE; DISEASE; OVEREXPRESSION; CARCINOGENESIS; HYPERPLASIA	Integrin expression is normally confined to the basal layer of the epidermis, but when epidermal homeostasis is perturbed, the receptors are also expressed by suprabasal, differentiating keratinocytes. We have used the involucrin promoter to express functional human integrin subunits alpha(2), alpha(5), and beta(1) in the suprabasal epidermal layers of transgenic mice. In mice expressing alpha(5) or beta(1) alone or alpha(2) beta(1) or alpha(5) beta(1) heterodimers, there were hair and whisker abnormalities and a failure of eyelid fusion. In addition, mice expressing beta(1) alone or in combination with an or as exhibited epidermal hyperproliferation, perturbed keratinocyte differentiation, and skin inflammation, all of which are features of a common human skin disease, psoriasis.	IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DJIAN P, 1993, MOL BIOL EVOL, V10, P1136; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; FINDLATER GS, 1993, J ANAT, V183, P121; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOTTLIEB JL, 1995, NATURE MED, V1, P442; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HERTLE MD, 1995, J INVEST DERMATOL, V104, P260, DOI 10.1111/1523-1747.ep12612801; HEYDEN A, 1994, EPITHELIAL CELL BIOL, V3, P96; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HYNES RO, 1988, J CELL BIOL, V109, P409; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KRUEGER GG, 1994, J INVEST DERMATOL, V102, pS14, DOI 10.1111/1523-1747.ep12386079; KRUEGER GG, 1984, J AM ACAD DERMATOL, V11, P937, DOI 10.1016/S0190-9622(84)80018-3; KRUEGER JG, 1994, PSORIASIS, P18; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MENDRICK DL, 1993, LAB INVEST, V69, P690; MILLER DR, 1987, CANCER RES, V47, P1935; MORRIS RJ, 1994, KERATINOCYTE METHODS, P25; NASIR A, 1994, J CLIN INVEST, V94, P892, DOI 10.1172/JCI117411; PAUKKONEN K, 1995, ARCH DERMATOL RES, V287, P166; ROOP DR, 1984, J BIOL CHEM, V259, P8037; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHWARTZBERG PL, 1991, CELL, V85, P1165; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUNDBERG JP, 1993, IMMUNOL INVEST, V22, P389, DOI 10.3109/08820139309063417; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167-5699(95)80132-4; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1994, KERATINOCYTE HDB, P153; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P9710, DOI 10.1073/pnas.91.21.9710; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P12780, DOI 10.1073/pnas.91.26.12780; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	50	264	279	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					957	968		10.1016/0092-8674(95)90211-2	http://dx.doi.org/10.1016/0092-8674(95)90211-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521519	Bronze			2022-12-01	WOS:A1995TK74500014
J	HUANG, YZ; BAKER, RT; FISCHERVIZE, JA				HUANG, YZ; BAKER, RT; FISCHERVIZE, JA			CONTROL OF CELL FATE BY A DEUBIQUITINATING ENZYME ENCODED BY THE FAT FACETS GENE	SCIENCE			English	Article							CARBOXYL-TERMINAL HYDROLASE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; DROSOPHILA; CLONING; EXPRESSION	Ubiquitin is a highly conserved polypeptide found in all eukaryotes. The major function of ubiquitin is to target proteins for complete or partial degradation by a multisubunit protein complex called the proteasome. Here, the Drosophila fat facets gene, which is required for the appropriate determination of particular cells in the fly eye, was shown to encode a ubiquitin-specific protease (Ubp), an enzyme that cleaves ubiquitin from ubiquitin-protein conjugates. The Fat facets protein (FAF) acts as a regulatory Ubp that prevents degradation of its substrate by the proteasome. Flies bearing fat facets gene mutations were used to show that a Ubp is cell type- and substrate-specific and a regulator of cell fate decisions in a multicellular organism.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,GENET GRP,CANBERRA,ACT 2601,AUSTRALIA	University of Texas System; University of Texas Austin; Australian National University; John Curtin School of Medical Research								BAKER RR, UNPUB; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FISCHERVIZE JA, UNPUB; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; OH CE, 1994, J NEUROSCI, V14, P3166; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAMBROOK G, 1989, MOL CLONING LABORATO; SAVILLE KJ, 1993, P NATL ACAD SCI USA, V90, P8842, DOI 10.1073/pnas.90.19.8842; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THUMMEL CS, 1988, GENE, V74, P543; Thummel CS, 1992, DROS INF SERV, V71, P150; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, pCH22; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	30	236	249	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1828	1831		10.1126/science.270.5243.1828	http://dx.doi.org/10.1126/science.270.5243.1828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525378				2022-12-01	WOS:A1995TK47600048
J	TREIER, M; BOHMANN, D; MLODZIK, M				TREIER, M; BOHMANN, D; MLODZIK, M			JUN COOPERATES WITH THE ETS DOMAIN PROTEIN POINTED TO INDUCE PHOTORECEPTOR R7 FATE IN THE DROSOPHILA EYE	CELL			English	Article							RECEPTOR TYROSINE KINASE; C-JUN; TRANSCRIPTION FACTORS; SEVENLESS; ACTIVATION; CELLS; GENE; RAS; PHOSPHORYLATION; FOS	R7 photoreceptor fate in the Drosophila eye is induced by the activation of the Sevenless receptor tyrosine kinase and the RAS/MAP kinase signal transduction pathway. We show that expression of a constitutively activated JUN isoform in ommatidial precursor cells is sufficient to induce R7 fate independent of upstream signals normally required for photoreceptor determination. We present evidence that JUN interacts with the ETS domain protein Pointed to promote R7 formation. This interaction is cooperative when both proteins are targeted to the same promoter and is antagonized by another ETS domain protein, YAN, a negative regulator of R7 development, furthermore, phyllopod, a putative transcriptional target of RAS pathway activation during R7 induction, behaves as a suppressor of activated JUN. Taken together, these data suggest that JUN and Pointed act on common target genes to promote neuronal differentiation in the Drosophila eye, and that phyllopod might be such a common target.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Treier, Mathias/AAD-6388-2021					BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEGEMANN G, 1995, DEVELOPMENT, V121, P225; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MLODZIK M, 1992, MECH DEVELOP, V37, P37, DOI 10.1016/0925-4773(92)90013-A; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	39	104	104	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					753	760		10.1016/0092-8674(95)90188-4	http://dx.doi.org/10.1016/0092-8674(95)90188-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521492	Bronze			2022-12-01	WOS:A1995TH94800012
J	GIAID, A; YANAGISAWA, M; LANGLEBEN, D; MICHEL, RP; LEVY, R; SHENNIB, H; KIMURA, S; MASAKI, T; DUGUID, WP; STEWART, DJ				GIAID, A; YANAGISAWA, M; LANGLEBEN, D; MICHEL, RP; LEVY, R; SHENNIB, H; KIMURA, S; MASAKI, T; DUGUID, WP; STEWART, DJ			EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; RELAXING FACTOR; MESSENGER-RNA; C-FOS; POTENT; VASOCONSTRICTOR; MITOGENESIS; FIBROBLASTS; SCLERODERMA; RELEASE	Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin-1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1-like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1-like immunoreactivity. There was a strong correlation between the intensity of endothelin-1-like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75230 USA; MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT SURG, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT PATHOL, MONTREAL H3A 2T5, QUEBEC, CANADA; KYOTO UNIV, KYOTO 606, JAPAN; CHIBA UNIV, FAC MED, CHIBA, JAPAN; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75230 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University; McGill University; McGill University; Kyoto University; Chiba University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Langleben, David/AAJ-9152-2020	Kimura, Sadao/0000-0001-6768-7474				CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; Dubin D, 1989, J VASC MED BIOL, V1, P150; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; KANSE SM, 1991, J CARDIOVASC PHARM, V17, pS113, DOI 10.1097/00005344-199100177-00029; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOMURO I, 1989, FEBS LETT, V244, P509; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MICHEL RP, 1991, J APPL PHYSIOL, V71, P601, DOI 10.1152/jappl.1991.71.2.601; MONCADA S, 1978, PHARMACOL REV, V30, P293; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; SCHARFFETTER K, 1988, EUR J CLIN INVEST, V18, P9, DOI 10.1111/j.1365-2362.1988.tb01158.x; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SNEDECOR GW, 1980, STATISTICAL METHODS, P135; STELZNER TJ, 1992, AM J PHYSIOL, V262, pL614, DOI 10.1152/ajplung.1992.262.5.L614; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WAGENVOORT CA, 1981, HISTOPATHOLOGY, V5, P595, DOI 10.1111/j.1365-2559.1981.tb01826.x; WOOD P, 1958, BRIT HEART J, V20, P557; YAMANE K, 1991, ARTHRITIS RHEUM, V34, P243, DOI 10.1002/art.1780340220; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	36	1419	1484	4	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1732	1739		10.1056/NEJM199306173282402	http://dx.doi.org/10.1056/NEJM199306173282402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8497283				2022-12-01	WOS:A1993LG03800002
J	JOHNSON, CL; RIFKIND, BM; SEMPOS, CT; CARROLL, MD; BACHORIK, PS; BRIEFEL, RR; GORDON, DJ; BURT, VL; BROWN, CD; LIPPEL, K; CLEEMAN, JI				JOHNSON, CL; RIFKIND, BM; SEMPOS, CT; CARROLL, MD; BACHORIK, PS; BRIEFEL, RR; GORDON, DJ; BURT, VL; BROWN, CD; LIPPEL, K; CLEEMAN, JI			DECLINING SERUM TOTAL CHOLESTEROL LEVELS AMONG UNITED-STATES ADULTS - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; LIPID RESEARCH CLINICS; MINNESOTA-HEART-SURVEY; EDUCATION-PROGRAM; DISEASE; TRENDS; MORTALITY; PLASMA; RISK	Objective.-To examine the secular trend in serum total cholesterol levels of the US adult population. Design.-Nationally representative cross-sectional surveys with both an in-person interview and a medical examination that included the measurement of blood lipid levels. Setting/Participants.-Between 6000 and 13 000 adults aged 20 through 74 years examined in each of four separate national surveys during 1960 through 1962, 1971 through 1974, 1976 through 1980, and 1988 through 1991. Results.-Mean serum total cholesterol levels in US adults aged 20 through 74 years have consistently declined over the time period 1960 through 1991. More than half of the decline occurred during the time period 1976 through 1991. This decline occurred across the entire distribution of serum cholesterol levels and in all age-sex groups. High-density lipoprotein cholesterol and very low-density lipoprotein cholesterol levels have not changed, suggesting that the decline in total cholesterol levels is due to a decline in low-density lipoprotein cholesterol levels. Conclusions.-These results document a continuing and substantial decline in serum cholesterol levels among US adults. They suggest that public health programs, designed to reduce cholesterol levels, are proving successful. The observed downward trend in serum cholesterol levels has coincided with a continuing decline in coronary heart disease mortality. These observations suggest that the Healthy People 2000 goal of reducing the mean serum cholesterol level of US adults to no more than 200 mg/dL (5.17 mmol/L) is attainable.	NHLBI,NATL CHOLESTEROL EDUC PROGRAM,BLDG 31,ROOM 4A-05,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ABELL LL, 1952, J BIOL CHEM, V195, P357; ABRAHAM S, 1978, VITAL HLTH STAT 11, V205; AHMED S, 1979, CLIN CHEM, V25, P880; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BACHORIK PS, 1979, CLIN CHIM ACTA, V96, P145, DOI 10.1016/0009-8981(79)90064-0; BACHORIK PS, 1984, CLIN CHEM, V30, P839; BRIEFEL RR, 1986, PREV MED, V15, P352; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; CARROLL MD, 1990, VITAL HLTH STATIS 11, V240; CARROLL MD, 1993, VITAL HLTH STATIS 11, V242; CLEEMAN JI, 1989, CLIN LAB MED, V9, P7, DOI 10.1016/S0272-2712(18)30638-3; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; ELLERBE P, 1990, CLIN CHEM, V36, P370; EZZATI T, 1992, IN PRESS 1992 P SURV; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRANK E, 1992, JAMA-J AM MED ASSOC, V268, P1566, DOI 10.1001/jama.268.12.1566; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULWOOD R, 1987, JAMA-J AM MED ASSOC, V257, P937; FULWOOD R, 1986, VITAL HLTH STAT 11, V236; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HAINLINE A, 1986, CLIN CHEM, V32, P611; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIPPEL K, 1978, CLIN CHEM, V24, P1477; MILLER H, 1969, VITAL HLTH STAT 6, V6; MOORE FE, 1967, VITAL HLTH STAT 11, V22; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; PIETINEN P, 1987, AM HEART J, V113, P620, DOI 10.1016/0002-8703(87)90643-0; RIZEK RL, 1980, CURRENT FOOD CONSUMP; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; WOTEKI CE, 1990, J NUTR, V120, P1440, DOI 10.1093/jn/120.suppl_11.1440; WRIGHT J, 1992, NUTRITION MONITERING; 1975, HANES STUDY FINAL RE; 1982, DHEW NIH75628 PUBL; 1990, NUTRITION YOUR HLTH; 1965, VITAL HLTH STAT 1, V4; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1991, HLTH PEOPLE 2000 NAT; 1988, ARCH INTERN MED, V148, P36; 1988, PHS8950210 US DEP HL; 1985, VITAL HLTH STAT 1, V19; 1974, USDHEW HSM11073371 P; 1989, PHS891255 US DEP AGR; 1987, AM J CLIN NUTR, V45, P1060; 1984, JAMA-J AM MED ASSOC, V251, P351; 1981, VITAL HLTH STAT 1, V15; 1991, CIRCULATION, V83, P2154; 1993, JAMA-J AM MED ASSOC, V269, P3015; 1973, VITAL HLTH STAT 1 A, V10	52	415	428	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3002	3008		10.1001/jama.269.23.3002	http://dx.doi.org/10.1001/jama.269.23.3002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501842				2022-12-01	WOS:A1993LF94100029
J	GRAINGER, DJ; KIRSCHENLOHR, HL; METCALFE, JC; WEISSBERG, PL; WADE, DP; LAWN, RM				GRAINGER, DJ; KIRSCHENLOHR, HL; METCALFE, JC; WEISSBERG, PL; WADE, DP; LAWN, RM			PROLIFERATION OF HUMAN SMOOTH-MUSCLE CELLS PROMOTED BY LIPOPROTEIN(A)	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PLASMINOGEN ACTIVATION; APOLIPOPROTEIN(A); ATHEROSCLEROSIS; FACTOR-BETA-1; QUANTITATION; INHIBITION; EXPRESSION; BINDING; FIBRIN	Elevated blood concentrations of lipoprotein(a) [Lp(a)] and its constituent, apolipoprotein(a) [apo(a)], constitute a major risk factor for atherosclerosis, but their physiological activities remain obscure. Lp(a) and purified apo(a) stimulated the growth of human smooth muscle cells in culture. This effect resulted from inhibition of plasminogen activation, and consequently the activation by plasmin of latent transforming growth factor-beta, which is an inhibitor of smooth muscle cell growth. Because smooth muscle proliferation is one of the hallmarks of atherosclerotic lesions, these results point to a plausible mechanism for the atherogenic activity of Lp(a).	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,SCH CLIN MED,CAMBRIDGE CB2 2QQ,ENGLAND	Stanford University; University of Cambridge; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATTEGAY EJ, 1990, CELL, V102, P1217; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COLLETTA AA, 1990, BR J CANCER RES, V82, P132; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRAINGER DJ, 1992, BIOCHEM J, V283, P403, DOI 10.1042/bj2830403; GRAINGER DJ, UNPUB; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; KNIGHT BL, 1991, ATHEROSCLEROSIS, V87, P227, DOI 10.1016/0021-9150(91)90025-X; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NIENDORF AM, 1988, VIRCHOWS ARCH A, V417, P105; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	32	354	372	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1655	1658		10.1126/science.8503012	http://dx.doi.org/10.1126/science.8503012			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503012				2022-12-01	WOS:A1993LG17600032
J	KNOWLTON, N; WEIGT, LA; SOLORZANO, LA; MILLS, DK; BERMINGHAM, E				KNOWLTON, N; WEIGT, LA; SOLORZANO, LA; MILLS, DK; BERMINGHAM, E			DIVERGENCE IN PROTEINS, MITOCHONDRIAL-DNA, AND REPRODUCTIVE COMPATIBILITY ACROSS THE ISTHMUS OF PANAMA	SCIENCE			English	Article							EASTERN PACIFIC; 2 SIDES; GENETICS; NEOGENE	It is widely believed that gene flow connected many shallow water populations of the Caribbean and eastern Pacific until the Panama seaway closed 3.0 to 3.5 million years ago. Measurements of biochemical and reproductive divergence for seven closely related, transisthmian pairs of snapping shrimps (Alpheus) indicate, however, that isolation was staggered rather than simultaneous. The four least divergent pairs provide the best estimate for rates of molecular divergence and speciation. Ecological, genetic, and geological data suggest that gene flow was disrupted for the remaining three pairs by environmental change several million years before the land barrier was complete.			KNOWLTON, N (corresponding author), SMITHSONIAN TROP RES INST, UNIT 0948, APO AA, MIAMI, FL 34002 USA.		Mills, DeEtta/G-8532-2015	Mills, DeEtta/0000-0002-9977-7834				BERMINGHAM E, 1993, P NATL ACAD SCI USA, V90, P2734, DOI 10.1073/pnas.90.7.2734; Burton R.S., 1982, ESTUARINE COMP, P537, DOI [10.1016/b978-0-12-404070-0.50038-7., DOI 10.1016/B978-0-12-404070-0.50038-7]; Chace F.A. Jr., 1972, Smithsonian Contributions to Zoology, VNo. 98, P1; CHAKRABORTY R, 1977, EVOLUTION, V31, P347, DOI 10.1111/j.1558-5646.1977.tb01017.x; COATES AG, 1992, GEOL SOC AM BULL, V104, P814, DOI 10.1130/0016-7606(1992)104<0814:COTIOP>2.3.CO;2; Collins L.S., 1992, PALEONTOLOGICAL SOC, V6, P67; COLLINS T, 1992, PALEONTOL SOC SPEC P, V6, P68; COYNE JA, 1989, EVOLUTION, V43, P362, DOI [10.1111/j.1558-5646.1989.tb04233.x, 10.2307/2409213]; DUQUECARO H, 1990, PALAEOGEOGR PALAEOCL, V77, P203, DOI 10.1016/0031-0182(90)90178-A; Gillespie J.H., 1991, CAUSES MOL EVOLUTION; GLYNN P W, 1972, Bulletin of the Biological Society of Washington, V2, P13; GROSBERG RK, 1982, ECOLOGY, V63, P894, DOI 10.2307/1937228; HASSON PF, 1986, MICROPALEONTOLOGY, V32, P32, DOI 10.2307/1485698; HOLTHUIS L B, 1980, Zoologische Mededelingen (Leiden), V55, P47; JACKSON JBC, 1993, SCIENCE, V260, P1624, DOI 10.1126/science.260.5114.1624; JONES DS, 1985, GREAT AM BIOTIC INTE, P325; Jordan DS, 1908, AM NAT, V42, P73, DOI 10.1086/278905; KEIGWIN L, 1982, SCIENCE, V217, P350, DOI 10.1126/science.217.4557.350; Keller G., 1989, J S AM EARTH SCI, V2, P73, DOI DOI 10.1016/0895-9811(89)90028-X; Kim W, 1988, SMITHSONIAN CONTRIBU, V454, P1, DOI DOI 10.5479/SI.00810282.454; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KNOWLTON N, 1982, BEHAV ECOL SOCIOBIOL, V10, P289, DOI 10.1007/BF00302819; KNOWLTON N, 1985, B MAR SCI, V37, P893; Knowlton Nancy, 1992, Proceedings of the San Diego Society of Natural History, V18, P1; LESSIOS HA, 1984, EVOLUTION, V38, P1144, DOI 10.1111/j.1558-5646.1984.tb00382.x; LESSIOS HA, 1979, NATURE, V280, P599, DOI 10.1038/280599a0; LESSIOS HA, 1990, AM NAT, V135, P1, DOI 10.1086/285028; LESSIOS HA, 1981, EVOLUTION, V35, P618, DOI 10.1111/j.1558-5646.1981.tb04924.x; LESSIOS HA, 1990, EVOLUTION, V44, P933, DOI 10.1111/j.1558-5646.1990.tb03815.x; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; MAYR E, 1954, EVOLUTION, V8, P1, DOI 10.2307/2405661; Mayr E, 1963, ANIMAL SPECIES EVOLU; MCCOMMAS SA, 1982, MAR BIOL, V68, P169, DOI 10.1007/BF00397603; Murphy Robert W., 1990, P45; NEI M, 1975, EVOLUTION, V29, P1, DOI [10.1111/j.1558-5646.1975.tb00807.x, 10.2307/2407137]; NEI M, 1978, GENETICS, V89, P583; Nolan B.A., 1970, FORMA FUNCT, V2, P289; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; RUBINOFF RW, 1971, EVOLUTION, V25, P88, DOI 10.1111/j.1558-5646.1971.tb01861.x; SAITO T, 1976, GEOLOGY, V4, P305, DOI 10.1130/0091-7613(1976)4<305:GSOCDI>2.0.CO;2; Swofford D., 1998, PAUP PHYLOGENETIC AN; SWOFFORD DL, 1981, J HERED, V72, P281, DOI 10.1093/oxfordjournals.jhered.a109497; VAWTER AT, 1980, EVOLUTION, V34, P705, DOI 10.1111/j.1558-5646.1980.tb04009.x; Vermeij G.J., 1978, BIOGEOGRAPHY ADAPTAT, V3, P245, DOI 10.1017/S0094837300005352; WEINBERG JR, 1989, MAR BIOL, V103, P143, DOI 10.1007/BF00543341	45	449	457	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1629	1632		10.1126/science.8503007	http://dx.doi.org/10.1126/science.8503007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503007				2022-12-01	WOS:A1993LG17600023
J	REES, WA; KELLER, RW; VESENKA, JP; YANG, GL; BUSTAMANTE, C				REES, WA; KELLER, RW; VESENKA, JP; YANG, GL; BUSTAMANTE, C			EVIDENCE OF DNA BENDING IN TRANSCRIPTION COMPLEXES IMAGED BY SCANNING FORCE MICROSCOPY	SCIENCE			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; INITIATION; ELONGATION; FILMS	Complexes of Escherichia coli RNA polymerase with DNA containing the lambda P(L) promoter have been deposited on mica and imaged in air with a scanning force microscope. The topographic images reveal the gross spatial relations of the polymerase relative to the DNA template. The DNA appears bent in open promoter complexes containing RNA polymerase bound to the promoter and appears more severely bent in elongation complexes in which RNA polymerase has synthesized a 15-nucleotide transcript. This difference could be related to the conformational changes that accompany the maturation of open promoter complexes into elongation complexes and suggests that formation of the elongation complex involves a considerable modification of the spatial relations between the polymerase and the DNA template.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R37GM015792, R01GM015792, R01GM029158, R01GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-32543, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA H, 1992, NATURE, V358, P171, DOI 10.1038/358171a0; ARNDT K, 1990, J MOL BIOL, V211, P79; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; BUSTAMANTE C, IN PRESS CURR OPIN S; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; EDSALL JT, 1953, PROTEINS           B, V1, P549; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HANSMA HG, 1992, SCIENCE, V256, P1180, DOI 10.1126/science.256.5060.1180; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HIRSH J, 1976, J MOL BIOL, V108, P471, DOI 10.1016/S0022-2836(76)80131-3; KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUHNKE G, 1987, EMBO J, V6, P507, DOI 10.1002/j.1460-2075.1987.tb04782.x; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINDSAY SM, 1992, SPIE P, V1639, P127; MEISENBERGER O, 1980, FEBS LETT, V112, P117; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NOVAK RL, 1968, J BIOL CHEM, V243, P6068; REES WA, UNPUB; RHODES G, 1974, J BIOL CHEM, V249, P6675; SCHAFER R, 1973, EUR J BIOCHEM, V33, P207, DOI 10.1111/j.1432-1033.1973.tb02671.x; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THUNDAT T, 1992, ULTRAMICROSCOPY, V42, P1101, DOI 10.1016/0304-3991(92)90409-D; TICHELAAR W, 1983, EUR J BIOCHEM, V135, P263, DOI 10.1111/j.1432-1033.1983.tb07647.x; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YANG J, 1992, FEBS LETT, V301, P173, DOI 10.1016/0014-5793(92)81241-D	38	205	210	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1646	1649		10.1126/science.8503010	http://dx.doi.org/10.1126/science.8503010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503010				2022-12-01	WOS:A1993LG17600029
J	Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH				Liese, JG; Jendrossek, V; Jansson, A; Petropoulou, T; Kloos, S; Gahr, M; Belohradsky, BH			Chronic granulomatous disease in adults	LANCET			English	Article							HUMAN-NEUTROPHILS; INFECTION; PHAGOCYTE; VARIANT	Background Chronic granulomatous disease (CGD), an inherited disorder of granulocyte function caused by failure of intracellular superoxide production, normally presents in the first years of life with severe recurrent bacterial and fungal infections. Methods From the files of two children's hospitals we identified 11 CGD patients who were remarkable for an unusually late diagnosis, at 13-43 years of age. Their clinical and laboratory features were examined. Findings The first clinical manifestation occurred at a median age of 3.6 years but CGD was not diagnosed until a median age of 22 years. Pneumonias and abscesses caused by Staphylococcus aureus and Aspergillus species were the most frequent infections. Granulomas, often leading to chronic complications, occurred in 7 of the patients. With 1.1 severe infections in 100 patient months, the 11 patients had a lower frequency of severe infections than patients with classic CGD; however, such infections could be equally life-threatening. 8 of the patients had X-linked CGD with small but detectable quantities of cytochrome b(558), normally absent in X-linked CGD; and 3 had autosomal-recessive CGD. 9 patients had residual production of reactive oxygen metabolites, a feature that could explain the low incidence of infections. Interpretation CGD in adults may be more common than previously assumed. In view of the possibility of timely treatment, infection prophylaxis, and genetic counselling for affected families, CGD should be excluded in any patient with unexplained infections or granulomas.	UNIV GOTTINGEN,KINDERKLIN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	Liese, JG (corresponding author), UNIV MUNICH,KINDERKLIN,LINDWURMSTR 4,D-80337 MUNICH,GERMANY.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; CAZZOLA M, 1985, HAEMATOLOGICA, V76, P1581; CHUSID MJ, 1975, JAMA-J AM MED ASSOC, V233, P1295, DOI 10.1001/jama.233.12.1295; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; CURNUTTE JT, 1986, ADV HUM GENET, V19, P229; DILWORTH JA, 1977, AM J MED, V63, P233, DOI 10.1016/0002-9343(77)90237-6; FINN A, 1990, ARCH DIS CHILD, V65, P942, DOI 10.1136/adc.65.9.942; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; JENDROSSEK V, 1993, BLOOD, V81, P211; JOHNSTON RB, 1977, PEDIATR CLIN N AM, V24, P365; LANDING BH, 1957, PEDIATRICS, V20, P431; LUTTER R, 1984, J BIOL CHEM, V259, P9603; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; MOUY R, 1991, NEW ENGL J MED, V325, P1516; MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6; NAKAMURA M, 1987, BLOOD, V69, P1404; NERURKAR LS, 1987, SOUTHERN MED J, V80, P1296, DOI 10.1097/00007611-198710000-00022; NEWBURGER PE, 1980, BLOOD, V55, P85; NEWBURGER PE, 1986, BLOOD, V68, P914; PREISIG E, 1971, EUR J CLIN INVEST, V1, P409, DOI 10.1111/j.1365-2362.1971.tb00550.x; ROOS D, 1992, J LEUKOCYTE BIOL, V51, P164, DOI 10.1002/jlb.51.2.164; SCHAPIRO BL, 1991, NEW ENGL J MED, V325, P1786, DOI 10.1056/NEJM199112193252506; SMITH RM, 1991, BLOOD, V77, P673; STYRT B, 1984, PEDIATR INFECT DIS J, V3, P556, DOI 10.1097/00006454-198411000-00015; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; 1991, NEW ENGL J MED, V324, P509	26	106	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					220	223		10.1016/S0140-6736(96)90403-1	http://dx.doi.org/10.1016/S0140-6736(96)90403-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551880				2022-12-01	WOS:A1996TT06900009
J	Graur, D; Duret, L; Gouy, M				Graur, D; Duret, L; Gouy, M			Phylogenetic position of the order Lagomorpha (rabbits, hares and allies)	NATURE			English	Article							RODENTIA	EVER since they have been classified as ruminants in the Old Testament (Leviticus 11:6, Deuteronomy 14:7) and equated with hyraxes in the vulgate Latin translation, rabbits and their relatives (order Lagomorpha) have frequently experienced radical changes in taxonomic rank By using 91 orthologous protein sequences, we have attempted to answer the classical question ''What, if anything, is a rabbit?''(1). Here we show that Lagomorpha is significantly more closely related to Primates and Scandentia (tree shrews) than it is to rodents. This newly determined phylogenetic position invalidates the superordinal taxon Glires (Lagomorpha + Rodentia), and indicates that the morphological 'synapomorphies' previously used to cluster rodents and lagomorphs into Glires(2,3), may actually represent symplesiomorphies or homoplasies that are of no phylogenetic value. This raises the possibility that the ancestral eutherian morphotype may have possessed many rodent-like morphological characters.	UNIV LYON 1,LAB BIOMETRIE GENET & BIOL POPULAT,CNRS,URA 2055,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Graur, D (corresponding author), TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT ZOOL,IL-69978 RAMAT AVIV,ISRAEL.			Duret, Laurent/0000-0003-2836-3463				BAILEY WJ, 1992, SCIENCE, V256, P86, DOI 10.1126/science.1301735; CASANE D, 1994, GENETICS, V138, P471; DEJONG WW, 1993, MAMMAL PHYLOGENY : PLACENTALS, P5; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; EASTEAL S, 1990, GENETICS, V124, P165; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GEORGE DG, 1994, NUCLEIC ACIDS RES, V22, P3569; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; Kimura M., 1983, NEUTRAL THEORY MOL E; KISHINO H, 1990, J MOL EVOL, V30, P151; LI WH, 1989, MOL BIOL EVOL, V6, P424; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; Luckett W. P., 1993, Journal of Mammalian Evolution, V1, P127, DOI 10.1007/BF01041591; McKenna MC, 1975, PHYLOGENY PRIMATES, P2146, DOI [10.1007/978-1-4684-2166-8_2, DOI 10.1007/978-1-4684-2166-8_2]; MIGNOTTE F, 1990, EUR J BIOCHEM, V194, P561, DOI 10.1111/j.1432-1033.1990.tb15653.x; MILINKOVITCH MC, 1995, TRENDS ECOL EVOL, V10, P328, DOI 10.1016/S0169-5347(00)89120-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1988, PHYLOGENY CLASSIFICA, V2, P31; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WOOD AE, 1957, EVOLUTION, V11, P417, DOI 10.2307/2406062	25	221	227	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					333	335		10.1038/379333a0	http://dx.doi.org/10.1038/379333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552186				2022-12-01	WOS:A1996TR32300055
J	Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM				Kashina, AS; Baskin, RJ; Cole, DG; Wedaman, KP; Saxton, WM; Scholey, JM			A bipolar kinesin	NATURE			English	Article							ELECTRON-MICROSCOPY; MITOTIC SPINDLE; FISSION YEAST; IN-VITRO; PROTEIN; MOTOR; MICROTUBULES; GENE; ORGANIZATION; ANTIBODY	CHROMOSOME Segregation during mitosis depends on the action of the mitotic spindle, a self-organizing, bipolar protein machine which uses microtubules (MTs) and their associated motors(1,2). Members of the BimC subfamily of kinesin-related MT-motor proteins are believed to be essential for the formation and functioning of a normal bipolar spindle(3-14). Here we report that KRP(130), a homotetrameric BimC-related kinesin purified from Drosophila melanogaster embryos(13), has an ultrastructure. It consists of four kinesin-related polypeptides assembled into a bipolar aggregate with motor domains at opposite ends, analogous to a miniature myosin filament(15). Such a bipolar 'minifilament' could crosslink spindle MTs and slide them relative to one another. We do not know of any other MT motors that have a bipolar structure.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	Kashina, AS (corresponding author), UNIV CALIF DAVIS,SECT MOLEC & CELLULAR BIOL,DAVIS,CA 95616, USA.				NIGMS NIH HHS [R01 GM046295-09, R01 GM046295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1987, J CELL SCI, V87, P105; ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; COLE DG, 1994, J BIOL CHEM, V269, P22913; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOGAN CJ, 1993, P NATL ACAD SCI USA, V90, P6611, DOI 10.1073/pnas.90.14.6611; HOULISTON E, 1994, DEV BIOL, V164, P147, DOI 10.1006/dbio.1994.1187; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; KOONCE MP, 1987, NATURE, V328, P737, DOI 10.1038/328737a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; MITCHISON TJ, 1992, PHILOS T ROY SOC B, V336, P99, DOI 10.1098/rstb.1992.0049; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SANDERS WS, 1992, CELL, V70, P451; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; TSUPRUN VL, 1991, DOKL AKAD NAUK SSSR+, V320, P1270; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VEMOS I, 1995, TRENDS CELL BIOL, V5, P297; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	28	289	300	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					270	272		10.1038/379270a0	http://dx.doi.org/10.1038/379270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538794	Green Accepted			2022-12-01	WOS:A1996TQ16900050
J	Barr, S				Barr, S			The 1990 Florida dental investigation: Is the case really closed?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRANSMISSION	In 1994, a magazine article, a newspaper article, and a segment of the television newsmagazine 60 Minutes presented information that cast doubt on the Centers for Disease Control and Prevention's conclusion that a dentist in Florida had infected six of his patients with the human immunodeficiency virus (HIV). These reports were based on previously unavailable documentary evidence, which suggested that the infected patients had unreported or undetected risk factors for HIV infection and that the molecular analyses used to determine that the dentist and his patients had the same strains of HIV had potentially serious flaws. A recent article in this journal sought to dismiss the relevance of this information in the eyes of the scientific community. That report, however, failed to respond directly to many key pieces of evidence, and it offered no rebuttal beyond personal invective and a reassertion of previously published material. Although scientists and clinicians should not rely solely on media reports when drawing conclusions about this complex and controversial case, they deserve a chance to consider and reflect on this material in a meaningful way.										BARR S, 1994, LEARS MAGAZINE   APR, P68; BARR S, 1994, NY TIMES        0416; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; CRANDALL KA, 1995, J VIROL, V69, P2351, DOI 10.1128/JVI.69.4.2351-2356.1995; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; SMITH TF, 1992, SCIENCE, V256, P1155, DOI 10.1126/science.256.5060.1155	11	8	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					250	254		10.7326/0003-4819-124-2-199601150-00009	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534001				2022-12-01	WOS:A1996TQ01600009
J	Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S				Hannigan, GE; LeungHagesteijn, C; FitzGibbon, L; Coppolino, MG; Radeva, G; Filmus, J; Bell, JC; Dedhar, S			Regulation of cell adhesion and anchorage-dependent growth by a new beta(1)-integrin-linked protein kinase	NATURE			English	Article							EXPRESSION; DIFFERENTIATION; INTEGRINS; SEQUENCE	THE interaction of cells with the extracellular matrix regulates cell shape, motility, growth, survival, differentiation and gene expression, through integrin-mediated signal transduction(1-3). We used a two-hybrid screen to isolate genes encoding proteins that interact with the beta(1)-integrin cytoplasmic domain. The most frequently isolated complementary DNA encoded a new, 59K serine/threonine protein kinase, containing four ankyrin-like repeats. We report here that this integrin-linked kinase (ILK) phosphorylated a beta(1)-integrin cytoplasmic domain peptide in vitro and coimmunoprecipitated with beta(1) in lysates of mammalian cells. Endogenous ILK kinase activity was reduced in response to fibronectin. Overexpression of p59(ILK) disrupted epithelial cell architecture and inhibited adhesion to integrin substrates, while inducing anchorage-independent growth. We propose that ILK is a receptor-proximal protein kinase regulating integrin-mediated signal transduction.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CANC BIOL RES PROGRAM, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1N 6N5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa			Hannigan, Greg/A-5092-2009	Dedhar, Shoukat/0000-0003-4355-1657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILMUS J, 1994, ONCOGENE, V9, P3627; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	29	932	1015	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					91	96		10.1038/379091a0	http://dx.doi.org/10.1038/379091a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538749				2022-12-01	WOS:A1996TN21600063
J	Doyle, G				Doyle, G			A new breed of parasuicide patient	BRITISH MEDICAL JOURNAL			English	Note											Doyle, G (corresponding author), ST LUKES HOSP,DEPT YOUNG PEOPLES,MIDDLESBROUGH TS4 3AF,CLEVELAND,ENGLAND.							1994, INT STATISTICAL CLAS	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1696	1696		10.1136/bmj.311.7021.1696	http://dx.doi.org/10.1136/bmj.311.7021.1696			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541763	Green Published			2022-12-01	WOS:A1995TL94200024
J	Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA				Sivolapenko, GB; Douli, V; Pectasides, D; Skarlos, D; Sirmalis, G; Hussain, R; Cook, J; CourtenayLuck, NS; Merkouri, E; Konstantinides, K; Epenetos, AA			Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody	LANCET			English	Article							MONOCLONAL-ANTIBODIES; TUMOR-LOCALIZATION; NEOPLASMS; THERAPY; ANALOG	Specific tumour imaging with radiolabelled monoclonal antibodies has been extensively investigated. Although some success has been reported, there are many limitations due to the slow kinetics, poor extravasation, catabolism by the reticuloendothelial system, and nonspecific uptake of macromolecules such as antibodies. We have tried to overcome some of the problems associated with monoclonal antibodies while retaining their specificity by using an antibody-derived synthetic peptide. A synthetic pentadecapeptide (alpha M2) derived from the third heavy-chain complementarity-determining region (CDR-3H) of a tumour-associated monoclonal antibody was produced and shown to retain its specificity against the pan-carcinoma cell-surface antigen, polymorphic epithelial mucin, detected by the parent antibody. The peptide was radiolabelled with technetium-99m and injected intravenously to image malignant lesions in 26 women with primary, recurrent, or metastatic breast cancer. Visualisation of breast tumours and their metastases was obtained shortly after administration of alpha M2, and was optimum by 3 h. Overall, 57 (77%) of 74 sites were visualised. Successful imaging was achieved in 14 of 15 primary tumour sites and all of eight local recurrences. Five of six metastases in the opposite breast, eight of 15 metastatic axillary lymph nodes, and all of six metastatic supraclavicular lymph nodes were imaged. Metastatic sites in the lungs, mediastinum, chest wall, and liver were poorly visualised because of background cardiac blood pool, alpha M2 detected small lesions (<2 cm) as efficiently as larger ones. The peptide was rapidly (3 h) cleared from the circulation. No acute or chronic adverse reactions due to the alpha M2 were observed. Specific tumour targeting with the radiolabelled anticancer peptide alpha M2 offers new opportunities for breast cancer imaging and possibly therapy.	SAMARITAN HOSP,ANTISOMA LTD,LONDON,ENGLAND; ENCEPHALOS RES & THERAPEUT INST,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN ONCOL,ICRF,ONCOL UNIT,LONDON W12 0NN,ENGLAND; METAXA CANC HOSP,PIRAES,GREECE; AGII ANARGIRI CANC HOSP,ATHENS,GREECE; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London				Sivolapenko, Gregory/0000-0003-2388-362X				BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BOVEN E, 1991, EUR J CANCER, V27, P1430, DOI 10.1016/0277-5379(91)90025-9; BUCHSBAUM DJ, 1985, INT J NUCL MED BIOL, V12, P79, DOI 10.1016/0047-0740(85)90160-3; COURTENAYLUCK NS, 1986, CANCER RES, V46, P6489; EPENETOS AA, 1986, CANCER RES, V46, P3183; EPENETOS AA, 1989, BRIT J CANCER, V59, P152, DOI 10.1038/bjc.1989.32; ESTEBAN JM, 1987, INT J CANCER, V39, P50, DOI 10.1002/ijc.2910390110; HALPERN SE, 1990, J NUCL MED, V31, P1436; HIRD V, 1991, BRIT J CANCER, V64, P911, DOI 10.1038/bjc.1991.425; HUSSAIN R, IN PRESS PEPTIDES; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KALOFONOS HP, 1988, CANCER RES, V48, P1977; KRENNING EP, 1989, LANCET, V1, P242; SCHATTEN C, 1991, LANCET, V337, P395, DOI 10.1016/0140-6736(91)91169-U; SCHROFF RW, 1985, CANCER RES, V45, P879; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; VIRGOLINI I, 1994, NEW ENGL J MED, V331, P1116, DOI 10.1056/NEJM199410273311703	17	49	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1662	1666		10.1016/S0140-6736(95)92839-1	http://dx.doi.org/10.1016/S0140-6736(95)92839-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551823				2022-12-01	WOS:A1995TL42300009
J	ZHENG, YX; WONG, ML; ALBERTS, B; MITCHISON, T				ZHENG, YX; WONG, ML; ALBERTS, B; MITCHISON, T			NUCLEATION OF MICROTUBULE ASSEMBLY BY A GAMMA-TUBULIN-CONTAINING RING COMPLEX	NATURE			English	Article							ASPERGILLUS-NIDULANS; ORGANIZING CENTERS; CENTROSOME; MITOSIS; PROTEIN; CHROMOSOMES; COMPONENT; INVITRO; BINDING	The highly conserved protein gamma-tubulin is required for microtubule nucleation in vivo. When viewed in the electron microscope, a highly purified gamma-tubulin complex from Xenopus consisting of at least seven different proteins is seen to have an open ring structure. This complex acts as an active microtubule-nucleating unit which can cap the minus ends of microtubules in vitro.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	ZHENG, YX (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BRYAN J, 1971, P NATL ACAD SCI USA, V68, P1762, DOI 10.1073/pnas.68.8.1762; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS P, 1980, J CELL BIOL, V84, P668, DOI 10.1083/jcb.84.3.668; HORIO T, 1991, J CELL SCI, V99, P693; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; MALDELKOW E, 1995, TRENDS CELL BIOL, V5, P262; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; VASSILEV A, 1995, J CELL SCI, V108, P1083; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; WILSON EB, 1925, CELL DEV HEREDITY, P1232; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	36	693	703	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	1995	378	6557					578	583		10.1038/378578a0	http://dx.doi.org/10.1038/378578a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524390				2022-12-01	WOS:A1995TJ22100066
J	ZHOU, MM; RAVICHANDRAN, KS; OLEJNICZAK, ET; PETROS, AM; MEADOWS, RP; SATTLER, M; HARLAN, JE; WADE, WS; BURAKOFF, SJ; FESIK, SW				ZHOU, MM; RAVICHANDRAN, KS; OLEJNICZAK, ET; PETROS, AM; MEADOWS, RP; SATTLER, M; HARLAN, JE; WADE, WS; BURAKOFF, SJ; FESIK, SW			STRUCTURE AND LIGAND RECOGNITION OF THE PHOSPHOTYROSINE BINDING DOMAIN OF SHC	NATURE			English	Article							HIGH-AFFINITY; SIGNAL-TRANSDUCTION; PHOSPHOLIPID-VESICLES; DISTANCE GEOMETRY; PROTEINS; RECEPTOR; ASSOCIATION; ACTIVATION; PEPTIDE	The nuclear magnetic resonance structure of the phosphotyrosine binding (PTB) domain of Shc complexed to a phosphopeptide reveals an alternative means of recognizing tryosine-phosphorylated proteins. Unlike in SH2 domains, the phosphopeptide forms an antiparallel beta-strand with a beta-sheet of the protein, interacts with a hydrophobic pocket through the (pY-5) residue, and adopts a beta-turn. The PTB domain is structurally similar to pleckstrin homology domains (a alpha-sandwich capped by an alpha-helix) and binds to acidic phospholipids, suggesting a possible role in membrane localization.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Abbott Laboratories; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Sattler, Michael/C-1169-2010; Sattler, Michael/A-2407-2012	Sattler, Michael/0000-0002-1594-0527				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DIKIC I, 1985, J BIOL CHEM, V270, P15125; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FLOWER DR, 1993, FEBS LETT, V333, P99, DOI 10.1016/0014-5793(93)80382-5; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1993, J BIOL CHEM, V269, P1599; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TORTORELLA D, 1994, ANAL BIOCHEM, V217, P176, DOI 10.1006/abio.1994.1106; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	50	321	339	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					584	592		10.1038/378584a0	http://dx.doi.org/10.1038/378584a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524391				2022-12-01	WOS:A1995TJ22100067
J	HAN, TS; VANLEER, EM; SEIDELL, JC; LEAN, MEJ				HAN, TS; VANLEER, EM; SEIDELL, JC; LEAN, MEJ			WAIST CIRCUMFERENCE ACTION LEVELS IN THE IDENTIFICATION OF CARDIOVASCULAR RISK-FACTORS - PREVALENCE STUDY IN A RANDOM SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL DETERMINATION; FAT DISTRIBUTION; WEIGHT-LOSS; MEN; OBESITY; DISEASE; DIET	Objective-To determine the frequency of cardiovascular risk factors in people categorised by previously defined ''action levels'' of waist circumference. Design-Prevalence study in a random population sample. Setting-Netherlands. Subjects- 2183 men and 2698 women aged 20-59 years selected at random from the civil registry of Amsterdam and Maastricht. Main outcome measures-Waist circumference. waist to hip ratio, body mass index (weight (kg)/height (m(2))), total plasma cholesterol concentration, high density lipoprotein cholesterol concentration, blood pressure, age, and lifestyle. Results-A waist circumference exceeding 94 cm in men and 80 cm in women correctly identified subjects with body mass index of greater than or equal to 25 and waist to hip ratios greater than or equal to 0.95 in men and greater than or equal to 0 80 in women with a sensitivity and specificity of greater than or equal to 96%. Men and women with at least one cardiovascular risk factor (total cholesterol greater than or equal to 6 5 mmol/l, high density lipoprotein cholesterol greater than or equal to 0.9 mmol/l, systolic blood pressure greater than or equal to 160 mm Hg, diastolic blood pressure greater than or equal to 95 mm Hg) were identified with sensitivities of 57% and 67% and specificities of 72% and 62% respectively. Compared with those with waist measurements below action levels, age and lifestyle adjusted odds ratios for having at least one risk factor were 2.2 (95% confidence interval 1.8 to 2.8) in men with a waist measurement of 94-102 cm and 1.6 (1.3 to 2.1) in women with a waist measurement of 80-88 cm, In men and women with larger waist measurements these age- and lifestyle adjusted odds ratios were 4.6 (3.5 to 6.0) and 2.6 (2.0 to 3.2) respectively, Conclusions-Larger waist circumference identifies people at increased cardiovascular risks.	UNIV GLASGOW,ROYAL INFIRM,DEPT HUMAN NUTR,GLASGOW G31 2ER,LANARK,SCOTLAND; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,BILTHOVEN,NETHERLANDS	Royal Infirmary of Edinburgh; University of Glasgow; Netherlands National Institute for Public Health & the Environment			seidell, jacob c/N-7427-2013; seidell, jacob/AAF-5362-2019	seidell, jacob/0000-0002-9262-9062; Han, Thang/0000-0003-2570-0938				Belsley D. A., 2005, REGRESSION DIAGNOSTI; CHAN JM, 1994, DIABETES CARE, V9, P961; DENTONKELAAR I, 1995, BREAST CANCER RES TR, V34, P55, DOI 10.1007/BF00666491; EDWARDS KL, 1994, ARTERIOSCLER THROMB, V14, P1940, DOI 10.1161/01.ATV.14.12.1940; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; ROSS R, 1992, J APPL PHYSIOL, V72, P787, DOI 10.1152/jappl.1992.72.2.787; ROSS R, 1993, AM J CLIN NUTR, V67, P470; SEIDELL JC, 1988, EUR J CLIN NUTR, V42, P805; SEIDELL JC, 1992, INT J OBESITY, V16, P17; SEIDELL JC, 1995, PROGR OBESITY RES, P303; SONNICHSEN AC, 1992, METABOLISM, V41, P1035, DOI 10.1016/0026-0495(92)90134-V; STURMANS F, 1984, EPIDEMIOLOGY THEORIE; SWINSCOW TDV, 1983, STATISTICS SQUARE ON; VERSCHUREN WMM, 1993, NETH J CARDIOL, V6, P205; WING RR, 1995, INT J OBESITY, V19, P67; WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086; 1989, EURICPNUT125 WHO NUT; 1988, WORLD HLTH STAT Q, V41, P115; [No title captured]	26	603	658	0	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1401	1405		10.1136/bmj.311.7017.1401	http://dx.doi.org/10.1136/bmj.311.7017.1401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520275	Green Published			2022-12-01	WOS:A1995TG90200021
J	LANGENBACH, R; MORHAM, SG; TIANO, HF; LOFTIN, CD; GHANAYEM, BI; CHULADA, PC; MAHLER, JF; LEE, CA; GOULDING, EH; KLUCKMAN, KD; KIM, HS; SMITHIES, O				LANGENBACH, R; MORHAM, SG; TIANO, HF; LOFTIN, CD; GHANAYEM, BI; CHULADA, PC; MAHLER, JF; LEE, CA; GOULDING, EH; KLUCKMAN, KD; KIM, HS; SMITHIES, O			PROSTAGLANDIN-SYNTHASE-1 GENE DISRUPTION IN MICE REDUCES ARACHIDONIC ACID-INDUCED INFLAMMATION AND INDOMETHACIN-INDUCED GASTRIC-ULCERATION	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IMMEDIATE-EARLY GENE; ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; G/H SYNTHASE; COMPLEMENTARY-DNA; CDNA CLONING; COLON CANCER; ASPIRIN USE; CYCLOOXYGENASE	Cyclooxygenases 1 and 2 (COX-1 and COX-2) are key enzymes in prostaglandin biosynthesis and the target enzymes for the widely used nonsteroidal anti-inflammatory drugs. To study the physiological roles of the individual isoforms, we have disrupted the mouse Ptgs1 gene encoding COX-1. Homozygous Ptgs1 mutant mice survive well, have no gastric pathology, and show less indomethacin-induced gastric ulceration than wild-type mice, even though their gastric prostaglandin E(2) levels are about 1% of wild type. The homozygous mutant mice have reduced platelet aggregation and a decreased inflammatory response to arachidonic acid, but not to tetradecanoyl phorbol acetate. Ptgs1 homozygous mutant females mated to homozygous mutant males produce few live offspring. COX-1-deficient mice provide a useful model to distinguish the physiological roles of COX-1 and COX-2.	NIEHS, BIOCHEM RISK ANAL LAB, RES TRIANGLE PK, NC 27709 USA; NIEHS, EXPTL PATHOL LAB, RES TRIANGLE PK, NC 27709 USA; NIEHS, REPROD & DEV TOXICOL LAB, RES TRIANGLE PK, NC 27709 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	LANGENBACH, R (corresponding author), NIEHS, EXPTL CARCINOGENESIS & MUTAGENESIS LAB, RES TRIANGLE PK, NC 27709 USA.				NHLBI NIH HHS [HL49227] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK WS, 1990, ARCH TOXICOL, V64, P210, DOI 10.1007/BF02010727; BLACK H E, 1986, Toxicologic Pathology, V14, P83; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, METHOD ENZYMOL, V187, P469; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ETTARH RR, 1993, SCAND J GASTROENTERO, V28, P795, DOI 10.3109/00365529309104012; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; Ghanayem BI, 1987, GASTROENTEROLOGY, V92, P106, DOI 10.1016/0016-5085(87)90845-6; HEATH CW, 1994, CANCER-AM CANCER SOC, V74, P2885, DOI 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; KARGMAN SL, 1995, CANCER RES, V55, P2556; KELLY RW, 1994, ENDOCR REV, V15, P684, DOI 10.1210/er.15.5.684; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEVI S, 1994, BRIT J RHEUMATOL, V33, P605; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARNETT LJ, 1992, CANCER RES, V52, P5575; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MORHAM SG, 1995, CELL, V83; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P181, DOI 10.1016/0021-9150(87)90245-0; PRICE AH, 1990, DRUGS, V40, P1, DOI 10.2165/00003495-199000405-00003; RAINSFORD KD, 1993, AGENT ACTION SUPPL, V44, P59; RAINSFORD KD, 1987, J PHARM PHARMACOL, V39, P669; RAO CV, 1995, CANCER RES, V55, P1464; ROBERT A, 1975, GASTROENTEROLOGY, V69, P1045; ROBERT A, 1979, GASTROENTEROLOGY, V77, P761, DOI 10.1016/0016-5085(79)90235-x; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SAMET JM, 1995, J BIOL CHEM, V270, P8044, DOI 10.1074/jbc.270.14.8044; SEIBERT K, 1994, RECEPTOR, V4, P17; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Simon Lee S., 1994, Current Opinion in Rheumatology, V6, P238, DOI 10.1097/00002281-199405000-00002; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; SMITH WL, 1990, STROKE, V21, P24; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; THORBURN GD, 1992, EARLY HUM DEV, V29, P63, DOI 10.1016/0378-3782(92)90059-P; THORBURN GD, 1991, REPROD FERT DEVELOP, V3, P277, DOI 10.1071/RD9910277; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Vane J R, 1992, J Physiol Pharmacol, V43, P195; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WATANABE S, 1994, J LIPID MEDIAT CELL, V10, P283; WEN PZ, 1993, GENOMICS, V15, P458, DOI 10.1006/geno.1993.1091; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOKOYAMA M, 1985, AM J PATHOL, V119, P367; ZAHRADNIK HP, 1992, EICOSANOIDS, V5, pS56	82	948	976	3	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					483	492		10.1016/0092-8674(95)90126-4	http://dx.doi.org/10.1016/0092-8674(95)90126-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521478	Bronze, Green Submitted			2022-12-01	WOS:A1995TC97700018
J	ROA, BB; GARCIA, CA; SUTER, U; KULPA, DA; WISE, CA; MUELLER, J; WELCHER, AA; SNIPES, GJ; SHOOTER, EM; PATEL, PI; LUPSKI, JR				ROA, BB; GARCIA, CA; SUTER, U; KULPA, DA; WISE, CA; MUELLER, J; WELCHER, AA; SNIPES, GJ; SHOOTER, EM; PATEL, PI; LUPSKI, JR			CHARCOT-MARIE-TOOTH DISEASE TYPE-1A - ASSOCIATION WITH A SPONTANEOUS POINT MUTATION IN THE PMP22 GENE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERKALEMIC PERIODIC PARALYSIS	Background. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy. CMT type 1A is associated with a 1.5-megabase (Mb) DNA duplication in region p11.2-p12 of chromosome 17 in most patients. An increased dosage of a gene within the duplicated segment appears to cause the disease. The PMP22 gene, which encodes a myelin protein, has been mapped within the duplication and proposed as a candidate gene for CMT type 1A. Methods. We analyzed DNA samples from a cohort of 32 unrelated patients with CMT type 1 who did not have the 1.5-Mb tandem duplication in 17p11.2-p12 for mutations within the PMP22 coding region. Molecular techniques included the polymerase chain reaction (PCR), heteroduplex analysis to detect point mutations, and direct nucleotide-sequence determination of amplified PCR products. Results. A 10-year-old boy was identified with a point mutation in PMP22, which resulted in the substitution of cysteine for serine in a putative transmembrane domain of PMP22. Analysis of family members revealed that the PMP22 point mutation arose spontaneously and segregated with the CMT type 1 phenotype in an autosomal dominant pattern. The patients with the PMP22 point mutation had clinical and electrophysiologic phenotypes that were similar to those of patients with the 1.5-Mb duplication. Conclusions. The PMP22 gene has a causative role in CMT type 1. Either a point mutation in PMP22 or a duplication of the region including the PMP22 gene can result in the disease phenotype.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT NEUROL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305; SWISS FED INST TECHNOL,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Louisiana State University System; Louisiana State University System; Stanford University; Stanford University; Swiss Federal Institutes of Technology Domain; ETH Zurich			Kulpa, Deanna/ABE-2035-2020; Kulpa, Deanna A/O-5016-2019; Suter, Ueli/A-1624-2010; Patel, Pragna/H-9129-2017	Kulpa, Deanna A/0000-0002-0411-7295; Wise, Carol/0000-0002-6790-2194; Patel, Pragna/0000-0003-3584-1072				BELLONE E, 1992, J MED GENET, V29, P492; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; Charcot JM, 1886, REV MED-PARIS, V6, P97; DYCK PJ, 1992, PERIPHERAL NEUROPATH, V2, P1094; HALLAM PJ, 1992, ANN NEUROL, V31, P570, DOI 10.1002/ana.410310518; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; KAKU DA, IN PRESS NEUROLOGY; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LUPSKI JR, 1993, AM J MED GENET, V45, P92, DOI 10.1002/ajmg.1320450122; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1992, CLIN RES, V40, P645; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1992, BRAIN PATHOL, V2, P337, DOI 10.1111/j.1750-3639.1992.tb00710.x; LUPSKI JR, 1991, CURRENT NEUROLOGY, V11, P1; MACMILLAN JC, 1992, J MED GENET, V29, P12, DOI 10.1136/jmg.29.1.12; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P769; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P211; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, IN PRESS PHENOTYPIC; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SKRE H, 1974, CLIN GENET, V6, P98; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; Tooth HH, 1886, PERONEAL TYPE PROGRE; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5	44	309	321	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					96	101		10.1056/NEJM199307083290205	http://dx.doi.org/10.1056/NEJM199307083290205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510709				2022-12-01	WOS:A1993LL19600005
J	ROBERTS, SGE; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR				ROBERTS, SGE; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR			INTERACTION BETWEEN AN ACIDIC ACTIVATOR AND TRANSCRIPTION FACTOR-TFIIB IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION	NATURE			English	Article							BINDING; MECHANISM; MEDIATOR; INVITRO; DOMAIN; VP16	HOW eukaryotic promoter-specific activator proteins (activators) stimulate transcription is a central question. We have previously shown that an acidic activator can directly interact with the general transcription factor TFIIB and increase its stable assembly into a preinitiation complex1,2. We have proposed that this increase in TFIIB assembly is at least part of the mechanism by which an acidic activator functions1,2. A prediction of this hypothesis is that a TFIIB mutant unable to interact with an acidic activator could not support activated transcription, and here we present experiments that verify this prediction. In conjunction with previous studies, our results argue that interaction between an acidic activator and TFIIB is necessary for transcriptional activation.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	ROBERTS, SGE (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365; Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x	18	209	212	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					741	744		10.1038/363741a0	http://dx.doi.org/10.1038/363741a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515819				2022-12-01	WOS:A1993LJ33900062
J	MCLACHLAN, EM; JANIG, W; DEVOR, M; MICHAELIS, M				MCLACHLAN, EM; JANIG, W; DEVOR, M; MICHAELIS, M			PERIPHERAL-NERVE INJURY TRIGGERS NORADRENERGIC SPROUTING WITHIN DORSAL-ROOT GANGLIA	NATURE			English	Article							SENSORY NEURONS; RAT; NORADRENALINE; MODES; CAT	IN humans, trauma to a peripheral nerve may be followed by chronic pain syndromes which are only relieved by blockade of the effects of sympathetic impulse traffic1-4. It is presumed that, after the lesion, noradrenaline released by activity of sympathetic postganglionic axons excites primary afferent neurons by activating alpha-adrenoceptors2,5, generating signals that enter the 'pain pathways' of the central nervous system. The site of coupling is unclear. In some patients local anaesthesia of the relevant peripheral nerve6 does not alleviate pain, implying that ectopic impulses arise either within the central nervous system, or in proximal parts of the primary afferent neurons. In experimentally lesioned rats, activity can originate within the dorsal root ganglia7,8. Here we report that, after sciatic nerve ligation, noradrenergic perivascular axons in rats sprout into dorsal root ganglia and form basket-like structures around large-diameter axotomized sensory neurons; sympathetic stimulation can activate such neurons repetitively. These unusual connections provide a possible origin for abnormal discharge following peripheral nerve damage. Further, in contrast to the sprouting of intact nerve terminals into nearby denervated effector tissues in skin9,10, muscle11, sympathetic ganglia12 and sweat glands13, the axons sprout into a target which has not been-partially denervated.	CHRISTIAN ALBRECHTS UNIV KIEL,INST PHYSIOL,W-2300 KIEL 1,GERMANY; HEBREW UNIV JERUSALEM,INST ORAL HLTH RES,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL	University of Kiel; Hebrew University of Jerusalem	MCLACHLAN, EM (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA.		McLachlan, Elspeth M/A-1844-2013	McLachlan, Elspeth M/0000-0003-0755-8747				AKASU T, 1985, J PHYSIOL-LONDON, V361, P165, DOI 10.1113/jphysiol.1985.sp015639; BONICA JJ, 1990, MANAGEMENT PAIN, V2, P220; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CRUTCHER KA, 1982, BRAIN RES BULL, V9, P501, DOI 10.1016/0361-9230(82)90158-7; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DEVOR M, 1990, J NEUROPHYSIOL, V64, P1733, DOI 10.1152/jn.1990.64.6.1733; DEVOR M, 1979, J COMP NEUROL, V185, P211, DOI 10.1002/cne.901850113; DIAMOND J, 1992, J NEUROSCI, V12, P1454; FUKUDA A, 1987, J PHYSIOL-LONDON, V393, P213, DOI 10.1113/jphysiol.1987.sp016820; GOLDSTEIN RS, 1988, NEUROSCI LETT, V94, P58, DOI 10.1016/0304-3940(88)90270-4; JANIG W, 1984, J COMP NEUROL, V225, P302, DOI 10.1002/cne.902250213; JANIG W, 1992, REFLEX SYMPATHETIC D; Janig W, 1990, PAIN SYMPATHETIC NER, P17; JOBLING P, 1992, J PHYSIOL-LONDON, V454, P107, DOI 10.1113/jphysiol.1992.sp019256; KENNEDY WR, 1984, ANN NEUROL, V15, P73, DOI 10.1002/ana.410150114; KOLSTON J, 1991, NEUROSCI LETT, V130, P187, DOI 10.1016/0304-3940(91)90393-8; KUMMER W, 1990, CELL TISSUE RES, V261, P595, DOI 10.1007/BF00313540; MAEHLEN J, 1981, J PHYSIOL-LONDON, V319, P555, DOI 10.1113/jphysiol.1981.sp013926; MORRIS JL, 1989, INT J DEV NEUROSCI, V7, P521, DOI 10.1016/0736-5748(89)90011-7; ROTSHENKER S, 1988, TRENDS NEUROSCI, V11, P363, DOI 10.1016/0166-2236(88)90059-8; SCHMALBRUCH H, 1987, ANAT REC, V219, P323, DOI 10.1002/ar.1092190314; SHIR Y, 1991, PAIN, V45, P309, DOI 10.1016/0304-3959(91)90056-4; SMALL JR, 1990, J NEUROL SCI, V100, P98, DOI 10.1016/0022-510X(90)90019-J; Sunderland S., 1978, NERVES NERVE INJURIE; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WALL PD, 1983, PAIN, V17, P321, DOI 10.1016/0304-3959(83)90164-1; WILLIS WJD, 1992, HYPERALGESIA ALLODYN; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; YOSHIMURA M, 1987, BRAIN RES, V414, P138, DOI 10.1016/0006-8993(87)91334-5; [No title captured]	30	581	608	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					543	546		10.1038/363543a0	http://dx.doi.org/10.1038/363543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505981				2022-12-01	WOS:A1993LF93900050
J	FINNEY, RE; BISHOP, JM				FINNEY, RE; BISHOP, JM			PREDISPOSITION TO NEOPLASTIC TRANSFORMATION CAUSED BY GENE REPLACEMENT OF H-RAS1	SCIENCE			English	Article							BLADDER-CARCINOMA ONCOGENE; EMBRYONIC STEM-CELLS; HA-RAS ONCOGENE; MALIGNANT ACTIVATION; POINT MUTATIONS; LUNG-CARCINOMA; EXPRESSION; HARVEY; CARCINOGENESIS; TUMORIGENICITY	Homologous recombination was used to introduce a nominally transforming mutation into an endogenous H-ras1 gene in Rat1 fibroblasts. Although both the mutant and the remaining normal allele were expressed equally, the heterozygous cells were not neoplastically transformed. Instead, spontaneously transformed cells arose from the heterozygotes at a low frequency, and the majority of these cells had amplified the mutant allele. Thus, the activated H-ras1 allele was not by itself dominant over the normal allele but predisposed cells to transformation by independent events, such as amplification of the mutant allele.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FINNEY, RE (corresponding author), UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,BOX 0552,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA 44338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CUNHA GR, 1991, DEVELOPMENT, V111, P145; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; FINNEY RE, UNPUB; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; Luria SE, 1943, GENETICS, V28, P491; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90278-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PICARD D, 1985, EMBO J, V4, P2831, DOI 10.1002/j.1460-2075.1985.tb04011.x; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; Sambrook J., 1989, MOL CLONING LAB MANU; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	32	119	123	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1524	1527		10.1126/science.8502998	http://dx.doi.org/10.1126/science.8502998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502998				2022-12-01	WOS:A1993LF05800043
J	NICCHITTA, CV; BLOBEL, G				NICCHITTA, CV; BLOBEL, G			LUMENAL PROTEINS OF THE MAMMALIAN ENDOPLASMIC-RETICULUM ARE REQUIRED TO COMPLETE PROTEIN TRANSLOCATION	CELL			English	Article							DISULFIDE-ISOMERASE; SECRETORY PROTEINS; ROUGH MICROSOMES; DOCKING PROTEIN; DOG PANCREAS; BINDING-PROTEIN; ALPHA-FACTOR; MEMBRANES; YEAST; ATP	The role of the lumenal contents (reticuloplasm) of the endoplasmic reticulum (ER) in protein translocation was determined by in vitro analysis. Depletion of the reticuloplasm from mammalian rough microsomes revealed two distinct stages of the translocation reaction. The first stage, translocation up to and including signal peptide cleavage, was insensitive to the loss of the reticuloplasm, whereas the second stage, net transfer of the nascent chain into the ER lumen, was reticuloplasm dependent. In reticuloplasm-depleted membranes, signal-cleaved and glycosylated translocation intermediates were observed to transit free from the translocation channel to the cis, or cytoplasmic, side of the membrane. This translocation defect was complemented by reconstitution of lumenal proteins into depleted membranes. We propose that lumenal proteins are necessary for unidirectional protein translocation in mammalian ER.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANG D, 1991, J BIOL CHEM, V266, P24233; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FEYNMAN RP, 1963, FEYNMAN LECTURES PHY; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KOCH GLE, 1987, J CELL SCI, V87, P491; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STADDON JM, 1992, J BIOL CHEM, V267, P25239; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931; ZIMMERMAN DL, 1990, J BIOL CHEM, V265, P4048	52	161	161	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					989	998		10.1016/0092-8674(93)90276-V	http://dx.doi.org/10.1016/0092-8674(93)90276-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500184	Bronze			2022-12-01	WOS:A1993LF06100014
J	VONAHSEN, U; NOLLER, HF				VONAHSEN, U; NOLLER, HF			FOOTPRINTING THE SITES OF INTERACTION OF ANTIBIOTICS WITH CATALYTIC GROUP-I INTRON RNA	SCIENCE			English	Article							16S RIBOSOMAL-RNA; BINDING-SITE; TETRAHYMENA RIBOZYME; CHEMICAL PROBES; SEQUENCE; STREPTOMYCIN; NUCLEOTIDES; SUBSTRATE	Aminoglycoside inhibitors of translation have been shown previously to inhibit in vitro self-splicing by group I introns. Chemical probing of the phage T4-derived sunY intron shows that neomycin, streptomycin, and elated antibiotics protected the N-7 position of G96, a universally conserved guanine in the binding site for the guanosine cofactor in the splicing reaction. The antibiotics also disrupted structural contacts that have been proposed to bring the 5' cleavage site of the intron into proximity to the catalytic core. In contrast, the strictly competitive inhibitors deoxyguanosine and arginine protected only the N-7 position of G96. Parallels between these results and previously observed protection of 16S ribosomal RNA by aminoglycosides raise the possibility that group I intron splicing and transfer RNA selection by ribosomes involve similar RNA structural motifs.			VONAHSEN, U (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NIGMS NIH HHS [GM17129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; DAVIES J, IN PRESS RNA WORLD; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; STERN S, 1988, METHOD ENZYMOL, V164, P481; VONAHSEN U, 1990, NATURE, V346, P801; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; VONAHSEN U, UNPUB; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; XU MQ, 1989, GENE, V82, P77; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	30	97	102	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1993	260	5113					1500	1503		10.1126/science.8502993	http://dx.doi.org/10.1126/science.8502993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502993				2022-12-01	WOS:A1993LF05800035
J	VONITZSTEIN, M; WU, WY; KOK, GB; PEGG, MS; DYASON, JC; JIN, B; PHAN, TV; SMYTHE, ML; WHITE, HF; OLIVER, SW; COLMAN, PM; VARGHESE, JN; RYAN, DM; WOODS, JM; BETHELL, RC; HOTHAM, VJ; CAMERON, JM; PENN, CR				VONITZSTEIN, M; WU, WY; KOK, GB; PEGG, MS; DYASON, JC; JIN, B; PHAN, TV; SMYTHE, ML; WHITE, HF; OLIVER, SW; COLMAN, PM; VARGHESE, JN; RYAN, DM; WOODS, JM; BETHELL, RC; HOTHAM, VJ; CAMERON, JM; PENN, CR			RATIONAL DESIGN OF POTENT SIALIDASE-BASED INHIBITORS OF INFLUENZA-VIRUS REPLICATION	NATURE			English	Article							2-DEOXY-2,3-DEHYDRO-N-ACETYLNEURAMINIC ACID; BINDING-SITES; NEURAMINIDASE; RESOLUTION; HEMAGGLUTININ; GLYCOPROTEIN; ASSAY	Two potent inhibitors based on the crystal structure of influenza virus sialidase have been designed. These compounds are effective inhibitors not only of the enzyme, but also of the virus In cell culture and in animal models. The results provide an example of the power of rational, computer-assisted drug design, as well as indicating significant progress in the development of a new therapeutic or prophylactic treatment for influenza infection.	CSIRO,DIV BIOMOLEC ENGN,PARKVILLE,VIC 3052,AUSTRALIA; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	Commonwealth Scientific & Industrial Research Organisation (CSIRO); GlaxoSmithKline	VONITZSTEIN, M (corresponding author), MONASH UNIV,VICTORIAN COLL PHARM,DEPT PHARMACEUT CHEM,381 ROYAL PARADE,PARKVILLE,VIC 3052,AUSTRALIA.		Phan, Tien/GRN-9075-2022; von Itzstein, Mark/E-4823-2010; Varghese, Joseph N/A-8191-2012; Dyason, Jeffrey C/L-5534-2014	Smythe, Mark/0000-0001-7840-1021				BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; BURNET FM, 1948, AUST J EXP BIOL MED, V26, P381, DOI 10.1038/icb.1948.39; CARROLL SM, 1982, ARCH VIROL, V71, P273, DOI 10.1007/BF01314879; CHONG AKJ, 1992, EUR J BIOCHEM, V207, P335, DOI 10.1111/j.1432-1033.1992.tb17055.x; CHONG AKJ, 1991, BIOCHEM INT, V24, P165; CHONG AKJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P65, DOI 10.1016/0167-4838(91)90526-6; COLMAN PM, 1983, NATURE, V303, P41, DOI 10.1038/303041a0; COLMAN PM, 1985, CURR TOP MICROBIOL I, V114, P117; COLMAN PM, 1989, INFLUENZA VIRUSES, P175; DIMMOCK NJ, 1971, J GEN VIROL, V13, P481, DOI 10.1099/0022-1317-13-3-481; Drzeniek R, 1972, Curr Top Microbiol Immunol, V59, P35; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOTTSCHALK A, 1957, BIOCHIM BIOPHYS ACTA, V23, P645, DOI 10.1016/0006-3002(57)90389-X; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V17, P865, DOI 10.1128/AAC.17.5.865; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hirst GK, 1942, J EXP MED, V76, P195, DOI 10.1084/jem.76.2.195; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; KLENK E, 1955, H-S Z PHYSIOL CHEM, V301, P235, DOI 10.1515/bchm2.1955.301.1-2.235; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; LANGMUIR AD, 1985, NEW ENGL J MED, V313, P1027, DOI 10.1056/NEJM198510173131618; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; NOHLE U, 1982, EUR J BIOCHEM, V126, P543, DOI 10.1111/j.1432-1033.1982.tb06815.x; PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1; Palese P., 1977, CHEMOPROPHYLAXIS VIR, P189; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; POTIER M, 1990, BIOCHEM J, V267, P197, DOI 10.1042/bj2670197; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHAUER R, 1983, STRUCTURAL CARBOHYDR, P83; STOFF JC, 1992, EUR J PHARMACOL, V213, P439; TINTELNOT M, 1989, J COMPUT AID MOL DES, V3, P67, DOI 10.1007/BF01590996; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1991, J MOL BIOL, V221, P473, DOI 10.1016/0022-2836(91)80068-6; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VONITZSTEIN M, IN PRESS CARBOHYDR R; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	41	1523	1626	9	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					418	423		10.1038/363418a0	http://dx.doi.org/10.1038/363418a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502295				2022-12-01	WOS:A1993LE93800048
J	MATTHEWS, DJ; WELLS, JA				MATTHEWS, DJ; WELLS, JA			SUBSTRATE PHAGE - SELECTION OF PROTEASE SUBSTRATES BY MONOVALENT PHAGE DISPLAY	SCIENCE			English	Article							SITE-SPECIFIC PROTEOLYSIS; HUMAN GROWTH-HORMONE; ESCHERICHIA-COLI; ASSISTED CATALYSIS; SERINE PROTEASES; SUBTILISIN BPN'; PROTEINS; MECHANISM; SECRETION; SEQUENCE	A method is described here for identifying good protease substrates among approximately 10(7) possible sequences. A library of fusion proteins was constructed containing an amino-terminal domain used to bind to an affinity support, followed by a randomized protease substrate sequence and the carboxyl-terminal domain of M13 gene III. Each fusion protein was displayed as a single copy on filamentous phagemid particles (substrate phage). Phage were then bound to an affinity support and treated with the protease of interest. Phage with good protease substrates were released, whereas phage with substrates that resisted proteolysis remained bound. After several rounds of binding, proteolysis, and phagemid propagation, sensitive and resistant substrate sequences were identified for two different proteases, a variant of subtilisin and factor X(a). The technique may also be useful for studying the sequence specificity of a variety of posttranslational modifications.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; CARTER P, 1990, ACS SYM SER, V427, P181; CARTER P, 1989, PROTEINS, V6, P240, DOI 10.1002/prot.340060306; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ESTELL DA, 1986, SCIENCE, V233, P659, DOI 10.1126/science.233.4764.659; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FUH G, 1990, J BIOL CHEM, V265, P3111; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS DC, UNPUB; MITSUI Y, 1979, J MOL BIOL, V131, P697, DOI 10.1016/0022-2836(79)90198-0; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	29	292	347	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1993	260	5111					1113	1117		10.1126/science.8493554	http://dx.doi.org/10.1126/science.8493554			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493554				2022-12-01	WOS:A1993LC94200026
J	VARLEY, P; GRONENBORN, AM; CHRISTENSEN, H; WINGFIELD, PT; PAIN, RH; CLORE, GM				VARLEY, P; GRONENBORN, AM; CHRISTENSEN, H; WINGFIELD, PT; PAIN, RH; CLORE, GM			KINETICS OF FOLDING OF THE ALL BETA-SHEET PROTEIN INTERLEUKIN-1-BETA	SCIENCE			English	Article							NMR-SPECTROSCOPY; SECONDARY STRUCTURE; INTERMEDIATE; RESOLUTION; RESONANCE; ASSIGNMENT; FRAMEWORK; STABILITY; H-1	The folding of the all-beta sheet protein, interleukin-1beta, was studied with nuclear magnetic resonance (NMR) spectroscopy, circular dichroism, and fluorescence. Ninety percent of the beta structure present in the native protein, as monitored by far-ultraviolet circular dichroism, was attained within 25 milliseconds, correlating with the first kinetic phase determined by tryptophan and 1-anilinonaphthalene-8-sulfonate fluorescence. In contrast, formation of stable native secondary structure, as measured by quenched-flow deuterium-hydrogen exchange experiments, began after only 1 second. Results from the NMR experiments indicated the formation of at least two intermediates with half-lives of 0.7 to 1.5 and 15 to 25 seconds. The final stabilization of the secondary structure, however, occurs on a time scale much greater than 25 seconds. These results differ from previous results on mixed alpha helix-beta sheet proteins in which both the alpha helices and beta sheets were stabilized very rapidly (less than 10 to 20 milliseconds).	NIDDKD,CHEM PHYS LAB,BLDG 5,ROOM 132,BETHESDA,MD 20892; UNIV NEWCASTLE UPON TYNE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND; NIH,PROT EXPRESS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Newcastle University - UK; National Institutes of Health (NIH) - USA			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Wingfield, Paul/0000-0002-9515-4752; Gronenborn, Angela M/0000-0001-9072-3525				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; FINKELSTEIN AV, 1991, PROTEINS, V9, P23, DOI 10.1002/prot.340090104; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, UNPUB; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103	24	164	165	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1110	1113		10.1126/science.8493553	http://dx.doi.org/10.1126/science.8493553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493553				2022-12-01	WOS:A1993LC94200025
J	MOXHAM, CM; HOD, Y; MALBON, CC				MOXHAM, CM; HOD, Y; MALBON, CC			INDUCTION OF G-ALPHA(I2)-SPECIFIC ANTISENSE RNA INVIVO INHIBITS NEONATAL GROWTH	SCIENCE			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HUMAN PITUITARY-TUMORS; ADENYLYL CYCLASE; TRANSGENIC MICE; MESSENGER-RNA; HORMONE GENE; G-PROTEINS; EXPRESSION; GI2	Guanosine triphosphate-binding regulatory proteins (G proteins) are key elements in transmembrane signaling and have been implicated as regulators of more complex biological processes such as differentiation and development. The G protein Galpha(i2) is capable of mediating the inhibitory control of adenylylcyclase and regulates stem cell differentiation to primitive endoderm. Here an antisense RNA to Galpha(i2) was expressed in a hybrid RNA construct whose expression was both tissue-specific and induced at birth. Transgenic mice in which the antisense construct was expressed displayed a lack of normal development in targeted organs that correlated with the absence of Galpha(i2). The loss of Galpha(i2) expression in adipose tissue of the transgenic mice was correlated with a rise in basal levels of adenosine 3',5'-monophosphate (cAMP) and the loss of receptor-mediated inhibition of adenylylcyclase. These data expand our understanding of G protein function in vivo and demonstrate the necessity for Galpha(i2) in the development of liver and fat.	SUNY, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; SUNY Maritime College	MOXHAM, CM (corresponding author), SUNY, HLTH SCI CTR, DEPT MOLEC PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020					BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; BEALE EG, 1985, J BIOL CHEM, V260, P748; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CLEMENTI E, 1990, ONCOGENE, V5, P1059; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HOD Y, 1988, J BIOL CHEM, V263, P7747; HOGAN B, 1986, MANIPULATING MOUSE E, P174; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MOXHAM CM, IN PRESS DEV GENET; MOXHAM CM, UNPUB; RICHARDS W, UNPUB; RUIZ J P G, 1978, Proceedings of the National Academy of Sciences of the United States of America, V75, P4189, DOI 10.1073/pnas.75.9.4189; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	24	125	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					991	995		10.1126/science.8493537	http://dx.doi.org/10.1126/science.8493537			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493537				2022-12-01	WOS:A1993LB79100046
J	YIP, J				YIP, J			RISK-FACTORS FOR DEVELOPMENT OF MICROALBUMINURIA IN INSULIN-DEPENDENT DIABETIC-PATIENTS - A COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; INCIPIENT NEPHROPATHY; METABOLIC CONTROL; SMOKING	Objective-To investigate the risk factors for the development of persistent microalbuminuria in insulin dependent diabetic patients. Design-Four year follow up of a cohort of diabetic patients. Setting-Outpatient departments of teaching and district general hospitals in England. Subjects-148 non-microalbuminuric, non-hypertensive insulin dependent diabetic patients. Main outcome measures-Urinary albumin excretion rate and arterial blood pressure. Results-137 patients completed four year follow up, of whom 11 developed persistent microalbuminuria (albumin excretion rate greater-than-or-equal-to 30 mug/min on at least two consecutive occasions), giving a cumulative frequency of 8%. 103 remained normoalbuminuric and 23 exhibited intermittent microalbuminuria. At baseline the persistent microalbuminuric group had had significantly raised blood pressure (mean 137.9 (SD 14.9)/82.3 (7.6) v 123.5 (13.2)/72.8 (9.1) mm Hg), glycated haemoglobin concentration 10.4% (2.0%) v 8-9% (2.0%), and albumin excretion rate (median (interquartile range) 17.5 (13.0-22.3) v 4.8 (3.7-6.7) mug/min) (p < 0.05 for all) compared with the normoalbuminuric group. Blood pressure and glycated haemoglobin remained significantly higher in the persistent microalbuminuric group throughout the study (p < 0.05). Multiple regression analysis showed initial albumin excretion rate, blood pressure, and smoking to be significant determinants of persistent microalbuminuria (p < 0.02). Conclusion-In insulin dependent diabetic patients with poor glucose control, which may initially increase albumin excretion rate, an early rise of arterial pressure and smoking are implicated in the development of persistent microalbuminuria.			YIP, J (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,LONDON SE1 9RT,ENGLAND.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI 10.1007/BF00290267; ARMITAGE P, 1987, STATISTICAL METHODS, P408; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CHAVERS BM, 1989, NEW ENGL J MED, V320, P966, DOI 10.1056/NEJM198904133201503; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; GATLING W, 1985, DIABETIC MED, V2, P451, DOI 10.1111/j.1464-5491.1985.tb00681.x; Jarrett R J, 1979, Diabetes Care, V2, P175, DOI 10.2337/diacare.2.2.175; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1986, UREMIA INVEST, V9, P85; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P500; REID DD, 1976, LANCET, V2, P979; RUDBERG S, 1992, KIDNEY INT, V41, P822, DOI 10.1038/ki.1992.126; VIBERTI GC, 1982, LANCET, V1, P1430; VIGSTRUP J, 1985, ACTA OPHTHALMOL, V63, P530; WISEMAN MJ, 1984, DIABETOLOGIA, V26, P402; 1985, SAS USERS GUIDE STAT; 1984, NEW ENGL J MED, V6, P2365; 1992, DIABETES CARE, V4, P495	24	168	168	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1235	1239						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499853				2022-12-01	WOS:A1993LB80400015
J	VANWIJNGAARDEN, WJ; DUNCAN, ID				VANWIJNGAARDEN, WJ; DUNCAN, ID			RATIONALE FOR STOPPING CERVICAL SCREENING IN WOMEN OVER 50	BRITISH MEDICAL JOURNAL			English	Article							CANCER	Objective-To investigate whether the currently recommended age at which to stop cervical screening (64) can be lowered and what criteria should be used for safely doing so. Design-Retrospective case analysis study. Setting-Dundee and Angus districts of Scotland. Subjects-Women diagnosed as having cervical intraepithelial neoplasia and microinvasive or invasive cancer of the cervix in 1989 and 1990 (798 cases). Main outcome measure-History of cervical cytology results according to age (age groups of five years) and screening interval (three years and five years). Results-Cervical intraepithelial neoplasia was most common in women under 45 (711 cases in women of 45 and under v 38 cases in those of 46 and over). Cervical intraepithelial neoplasia occurring de novo was not seen in women over 50 who had been screened every three years. Microinvasive or invasive cancer of the cervix was diagnosed in 26 women over 50. None of these women had participated adequately in the cervical screening programme. Conclusion-Cervical intraepithelial neoplasia typically occurs in younger women. All women over 50 with an adequate history of negative results on smear testing every three years may be safely discharged from further screening if these findings are confirmed in other populations.			VANWIJNGAARDEN, WJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND.							DUGUID HLD, 1985, LANCET, V2, P1053; DUNCAN I, 1992, GUIDELINES CLIN PRAC; FLETCHER A, 1990, LANCET, V335, P97, DOI 10.1016/0140-6736(90)90552-G; 1986, BMJ, V293, P659; 1987, REPORT INTERCOLLEGIA; 1987, REPORT CERVICAL CYTO; 1990, CANCER CERVIX UTERI; 1988, DHSSHC881HCFP882 DEP; 1985, CERVICAL CYTOLOGY SC	9	70	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					967	971		10.1136/bmj.306.6883.967	http://dx.doi.org/10.1136/bmj.306.6883.967			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490472	Bronze, Green Published			2022-12-01	WOS:A1993KX43600017
J	Nightingale, SL				Nightingale, SL			Progress in international harmonization of drug approval requirements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, JAMA-J AM MED ASSOC, V270, P302	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-01	WOS:A1996TP96500007
J	Horton, R				Horton, R			The infected metropolis	LANCET			English	Editorial Material																		[Anonymous], 1995, WORLD URBANIZATION P; Barrera R, 1995, Bull Pan Am Health Organ, V29, P193; Bellow S., 1995, IT ALL ADDS UP; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; Karlen A., 1995, PLAGUES PROGR SOCIAL; ROHTER L, 1995, NY TIMES INT    0923, P5; STEERE AC, 1995, INFECTIOUS DISEASES IN AN AGE OF CHANGE, P1; 1995, LANCET, V346, P809	8	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					134	135		10.1016/S0140-6736(96)90333-5	http://dx.doi.org/10.1016/S0140-6736(96)90333-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544541	Bronze			2022-12-01	WOS:A1996TQ24400002
J	Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH				Reimold, AM; Grusby, MJ; Kosaras, B; Fries, JWU; Mori, R; Maniwa, S; Clauss, IM; Collins, T; Sidman, RL; Glimcher, MJ; Glimcher, LH			Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice	NATURE			English	Article							AMP RESPONSE ELEMENT; NF-KAPPA-B; CYCLIC-AMP; E-SELECTIN; BINDING PROTEIN; C-FOS; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION	ACTIVATING transcription factor-2 (ATF-2) is a basic region leucine zipper protein whose DNA target sequence is the widely distributed cAMP response element (CRE). We report here that mice carrying a germline mutation in ATF-2 demonstrated unique actions of ATF-2 not duplicated by other ATF/CREB family members. Mutant mice had decreased postnatal viability and growth, with a defect in endochondral ossification at epiphyseal plates similar to human hypochondroplasia. The animals had ataxic gait, hyperactivity and decreased hearing. In the brain, there were reduced numbers of cerebellar Purkinje cells, atrophic vestibular sense organs and enlarged ventricles. Unlike CREB alpha/delta-deficient mice whose main defect is in longterm potentiation, the widespread abnormalities in ATF-2 mutant mice demonstrate its absolute requirement for skeletal and central nervous system development, and for maximal induction of select genes with CRE sites, such as E-selectin.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,DIV NEUROGENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,VASC RES DIV,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ORTHOPAED SURG,LAB STUDY SKELETAL DISORDERS & REHABIL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Reimold, AM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Fries, Jochen/AAM-5999-2020	Fries, Jochen/0000-0003-2054-6345				BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FRIES JWU, 1993, AM J PATHOL, V143, P725; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hayat M.A., 1989, PRINCIPLES TECHNIQUE, DOI DOI 10.1007/978-1-349-09857-6; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEMERRER M, 1994, NAT GENET, V6, P318; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MATSUURA S, 1990, BIOCHEM BIOPH RES CO, V168, P993, DOI 10.1016/0006-291X(90)91127-E; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	29	236	246	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					262	265		10.1038/379262a0	http://dx.doi.org/10.1038/379262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538792				2022-12-01	WOS:A1996TQ16900048
J	Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ				Mande, SC; Mehra, V; Bloom, BR; Hol, WGJ			Structure of the heat shock protein chaperonin-10 of Mycobacterium leprae	SCIENCE			English	Article							GROES; BINDING; MODELS; CYCLE	Members of the chaperonin-10 (cpn10) protein family, also called heat shock protein 10 and in Escherichia coli GroES, play an important role in ensuring the proper folding of many proteins. The crystal structure of the Mycobacterium leprae cpn10 (MI-cpn10) oligomer has been elucidated at a resolution of 3.5 angstroms. The architecture of the MI-cpn10 heptamer resembles a dome with an oculus in its roof. The inner surface of the dome is hydrophilic and highly charged. A flexible region, known to interact with cpn60, extends from the lower rim of the dome. With the structure of a cpn10 heptamer now revealed and the structure of the E. coli GroEL previously known, models of cpn10:cpn60 and GroEL:GroES complexes are proposed.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,BIOMOLEC STRUCT CTR,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL & IMMUNOL,SEATTLE,WA 98195; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Mande, Shekhar/C-2136-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023545, R01AI023545] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23545, AI07118] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BOOM BR, 1992, SCIENCE, V257, P105; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, X PLOR USER MANUAL; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; COWTAN K, 1994, NEWSLETTER PROTEIN C, V31, P34; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FOSSATI G, 1995, J BIOL CHEM, V270, P26159, DOI 10.1074/jbc.270.44.26159; HARRIS JR, 1995, J STRUCT BIOL, V115, P68, DOI 10.1006/jsbi.1995.1031; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HUGHES AL, 1993, MOL BIOL EVOL, V10, P1343; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM J, UNPUB; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MAYERHARTL MK, 1995, SCIENCE, V269, P836; MEHRA V, 1992, J EXP MED, V175, P275, DOI 10.1084/jem.175.1.275; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURRAY CJL, 1994, GLOBAL COMP ASSESSME, P54; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	40	127	129	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					203	207		10.1126/science.271.5246.203	http://dx.doi.org/10.1126/science.271.5246.203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539620				2022-12-01	WOS:A1996TP36400042
J	Shakhnovich, E; Abkevich, V; Ptitsyn, O				Shakhnovich, E; Abkevich, V; Ptitsyn, O			Conserved residues and the mechanism of protein folding	NATURE			English	Article							CHYMOTRYPSIN INHIBITOR-2; 3-DIMENSIONAL STRUCTURE; TRANSITION; SEQUENCES	EXPERIMENTAL(1-6) and simulation(7) studies show that small monomeric proteins fold in one kinetic step, which entails overcoming the free-energy barrier between the unfolded and the native protein through a transition state(8,9). Two models of transition state formation have been proposed: a 'nonspecific' one in which it depends on the formation of a sufficient number of native-like contacts regardless of what amino acids are involved(10-12) and a 'specific' one, in which it depends on formation of a specific subset of the native structure (a folding nucleus)(8,13,14). The latter requires that some amino acids form most of their contacts in the transition state, whereas others only do so on reaching the native conformation. If so, mutations affecting the stability of the transition state nucleus should have a greater effect on the folding kinetics than mutations elsewhere, and the residues involved should be evolutionarily conserved. Lattice-model simulations and experiments(8,13-16) suggest that such mutations exist. Here we present a method for determining the folding nucleus of a protein with known structure with two-state folding kinetics. This method is based on the alignment of many sequences designed to fold into the native conformation of a protein to identify the positions where amino acids are most conserved in designed sequences. The method is applied to chymotrypsin inhibitor 2 (CI2), a protein whose transition state has been previously studied by protein engineering(14-16). The involvement of residues in folding nucleus of CI2 is clearly correlated with their conservation in design, and the residues forming the nucleus are highly conserved in 23 natural sequences homologous to CI2.	RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,RUSSIA; NCI,MOLEC STRUCT SECT,LMMB,BETHESDA,MD	Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shakhnovich, E (corresponding author), HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138, USA.							ABKEVICH VI, 1994, J CHEM PHYS, V101, P6052, DOI 10.1063/1.467320; ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P7243, DOI 10.1021/bi00147a006; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; GUO Z, 1995, BIOPOLYMERS, V35, P137; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; HAO MH, 1995, J CHEM PHYS, V102, P1334, DOI 10.1063/1.468920; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KOLINSKI A, 1993, J CHEM PHYS, V98, P7420, DOI 10.1063/1.464706; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MYAZAWA S, 1985, MACROMOLECULES, V18, P534; OLTSEN DE, 1994, P NATL ACAD SCI USA, V91, P10422; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1993, PROTEIN ENG, V6, P793, DOI 10.1093/protein/6.8.793; SHAKHNOVICH EI, 1993, P NATL ACAD SCI USA, V90, P7195, DOI 10.1073/pnas.90.15.7195; SHAKHNOVICH EI, 1994, PHYS REV LETT, V72, P3907, DOI 10.1103/PhysRevLett.72.3907; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; [No title captured]	31	310	314	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					96	98		10.1038/379096a0	http://dx.doi.org/10.1038/379096a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538750				2022-12-01	WOS:A1996TN21600064
J	SRIVASTAVA, D; CSERJESI, P; OLSON, EN				SRIVASTAVA, D; CSERJESI, P; OLSON, EN			A SUBCLASS OF BHLH PROTEINS REQUIRED FOR CARDIAC MORPHOGENESIS	SCIENCE			English	Article							LOOP-HELIX PROTEINS; MUSCLE TRANSCRIPTION; GENE-EXPRESSION; HEART; MYOCYTES	Skeletal muscle development is controlled by a family of muscle-specific basic helix-loop-helix (bHLH) transcription factors. Two bHLH genes, dHAND and eHAND, have now been isolated that are expressed in the bilateral heart primordia and subsequently throughout the primitive tubular heart and its derivatives during chick and mouse embryogenesis. Incubation of stage 8 chick embryos with dHAND and eHAND antisense oligonucleotides revealed that either oligonucleotide alone had no effect on embryonic development, whereas together they arrested development at the looping heart tube stage. Thus, dHAND and eHAND may play redundant roles in the regulation of the morphogenetic events of vertebrate heart development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTH J, 1994, BIOTECHNIQUES, V17, P324; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EVANS SM, 1993, DEV BIOL, V159, P485, DOI 10.1006/dbio.1993.1258; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KIRBY ML, 1990, CIRCULATION, V83, P332; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAYNE RM, 1995, CIRCULATION, V91, P494, DOI 10.1161/01.CIR.91.2.494; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RUDNICKI MA, 1985, BIOESSAYS, V17, P203; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHOENWOLF GC, 1989, LABORATORY STUDIES C; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SRIVASTAVA DK, UNPUB, P42502; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V142, P363; YOSH WJ, 1995, CELL, V82, P689; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	43	437	447	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1995	1999		10.1126/science.270.5244.1995	http://dx.doi.org/10.1126/science.270.5244.1995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533092				2022-12-01	WOS:A1995TL42000043
J	SCHALLER, GE; BLEECKER, AB				SCHALLER, GE; BLEECKER, AB			ETHYLENE-BINDING SITES GENERATED IN YEAST EXPRESSING THE ARABIDOPSIS ETR1 GENE	SCIENCE			English	Article							THALIANA	Mutations in the ETR1 gene of Arabidopsis thaliana confer insensitivity to ethylene, which indicates a role for the gene product in ethylene signal transduction. Saturable binding sites for [C-14]ethylene were detected in transgenic yeast expressing the ETR1 protein, whereas control yeast lacking ETR1 showed no detectable ethylene binding. Yeast expressing a mutant form of ETR1 (etr1-1) also showed no detectable ethylene binding, which provides an explanation for the ethylene-insensitive phenotype observed in plants carrying this mutation. Expression of truncated forms of ETR1 in yeast provided evidence that the amino-terminal hydrophobic domain of the protein is the site of ethylene binding. It was concluded from these results that ETR1 acts as an ethylene receptor in Arabidopsis.	UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								Abeles F.B., 2012, ETHYLENE PLANT BIOL; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; COLLMAN JP, 1967, PRINCIPLES APPLICATI; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SANDERS IO, 1991, ANN BOT-LONDON, V68, P97, DOI 10.1093/oxfordjournals.aob.a088242; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SISLER EC, 1979, PLANT PHYSIOL, V64, P538, DOI 10.1104/pp.64.4.538; SISLER EC, 1990, PLANT GROWTH REGUL, V9, P157, DOI 10.1007/BF00027443; SISLER EC, 1991, PLANT HORMONE ETHYLE, P81; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	19	443	487	5	50	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1809	1811		10.1126/science.270.5243.1809	http://dx.doi.org/10.1126/science.270.5243.1809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525372				2022-12-01	WOS:A1995TK47600042
J	TSUKIYAMA, T; WU, C				TSUKIYAMA, T; WU, C			PURIFICATION AND PROPERTIES OF AN ATP-DEPENDENT NUCLEOSOME REMODELING FACTOR	CELL			English	Article							HEAT-SHOCK GENES; HYPERSENSITIVE SITES; DROSOPHILA EMBRYOS; HISTONE OCTAMER; DNASE-I; CHROMATIN; TRANSCRIPTION; PROTEIN; INVITRO; RESOLUTION	We report the purification of an ATP-dependent nucleosome remodeling factor (NURF) from Drosophila embryo extracts. NURF is composed of at least four polypeptides that act in concert with the GAGA transcription factor to alter chromatin structure at the hsp70 promoter. The energy requirement is attributed to an ATPase activity that is stimulated by nucleosomes but not by free DNA or histones, suggesting that NURF acts directly on a nucleosome to perturb its structure. This finding and the physical properties of NURF contrast sharply with the multisubunit SW12/SNF2 complex, which has also been shown to alter nucleosomes in an ATP-dependent manner. The results suggest that two distinct systems may be involved in remodeling chromatin for transcription.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COSTLOW N, 1984, MOL CELL BIOL, V4, P1853, DOI 10.1128/MCB.4.9.1853; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KORNBERG RD, 1995, ANN REV CELL BIOL, V7, P371; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; NEUBAUER B, 1989, METHOD ENZYMOL, V170, P630; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; van Holde K.E., 1989, CHROMATIN; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301	45	508	518	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1011	1020		10.1016/0092-8674(95)90216-3	http://dx.doi.org/10.1016/0092-8674(95)90216-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521501	Bronze			2022-12-01	WOS:A1995TK74500019
J	MACKIE, MA; DAVIDSON, J				MACKIE, MA; DAVIDSON, J			PRESCRIBING OF QUININE AND CRAMP INDUCING DRUGS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							MUSCLE		GLASGOW ROYAL INFIRM,DEPT CLIN PHARMACOL,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow	MACKIE, MA (corresponding author), GLASGOW ROYAL INFIRM,DEPT MED PRESCRIBING,GLASGOW G4 0SF,LANARK,SCOTLAND.							BATEMAN DN, 1986, ADVERSE DRUG REACT, V4, P215; EATON JM, 1989, POSTGRAD MED, V86, P227; MANSONHING M, 1995, BMJ-BRIT MED J, V310, P13, DOI 10.1136/bmj.310.6971.13; MCGEE SR, 1990, ARCH INTERN MED, V150, P511, DOI 10.1001/archinte.150.3.511	4	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1541	1541		10.1136/bmj.311.7019.1541	http://dx.doi.org/10.1136/bmj.311.7019.1541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520397	Green Published			2022-12-01	WOS:A1995TK21400025
J	FENTON, B; GLOVER, DM				FENTON, B; GLOVER, DM			A CONSERVED MITOTIC KINASE ACTIVE AT LATE ANAPHASE TELOPHASE IN SYNCYTIAL DROSOPHILA EMBRYOS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; POLO	MUTATIONS in the Drosophila gene polo cause abnormal mitotic and meiotic divisions1,2. This gene encodes a 577-amino-acid protein that has an N-terminal putative kinase domain and a 300-residue C-terminal domain2. In budding yeast, a homologous kinase is encoded by CDC5 (ref. 3), a gene required for nuclear division late in the mitotic cycle4 and during meiosis5. Murine homologues have also been described6,7. Here we show that the polo gene product immunoprecipitated from extracts of single Drosophila embryos can phosphorylate casein in vitro, and that the kinase activity peaks cyclically at late anaphase/telophase. This contrasts with the cyclical activity of cyclin B-associated p34cdc2 kinase, which is maximal upon entry into mitosis during the rapid cycles of mitosis in the syncytium.	UNIV DUNDEE, INST MED SCI,DEPT ANAT & PHYSIOL, CANC RES CAMPAIGN,CELL CYCLE GENET GRP, DUNDEE DD1 4HN, SCOTLAND	University of Dundee				Glover, David/0000-0003-0956-0103				BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLAY F, IN PRESS P NATN ACAD; FOE VE, 1983, J CELL SCI, V61, P31; FRASCH M, 1986, J CELL SCI, V82, P155; GONZALEZ C, 1993, CELL CYCLE PRACTICAL; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; KITADA K, IN PRESS MOL CELL BI; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; SCHILD D, 1980, GENETICS, V96, P859; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; SUNKEL CE, 1988, J CELL SCI, V89, P25; WHITFIELD WGF, 1988, J CELL SCI, V89, P467; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	17	115	121	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					637	640		10.1038/363637a0	http://dx.doi.org/10.1038/363637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510757				2022-12-01	WOS:A1993LH13900059
J	GARDOSI, J; MONGELLI, M				GARDOSI, J; MONGELLI, M			RISK ASSESSMENT ADJUSTED FOR GESTATIONAL-AGE IN MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							LAST MENSTRUAL PERIOD; ULTRASOUND; PREGNANCY	Objective-To investigate the relation between errors in calculation of gestational age and assessment of risk of Down's syndrome and to analyse the implications for screening programmes. Design-Retrospective analysis of dating of gestational age by menstrual history v ultrasound scan. Computer program with maternal age and concentrations of alpha fetoprotein and free beta human chorionic gonadotrophin to calculate risk for a range of expected dates of delivery. Computer simulated prospective application of new screening programme. Setting-Teaching hospitals in Nottingham. Subjects-31561 women with singleton pregnancies with gestational age based on routine ultrasound scan. Computer simulation of 20000 women in three age ranges (up to 37; up to 40; all). Main outcome measures-Distribution of error between gestational age based on ultrasound scan v menstrual history. Proportion of women in the population who require precise dating of pregnancy; proportion of women who require amniocentesis. Results-With gestational age derived from ultrasound scan as reference the 95% confidence interval for gestational age by menstrual history was -27 to +9 days. A screening programme for Down's syndrome for women up to age 40 would yield a low risk (<1:250) for this range of days in 86.0% of cases. The 14.0% of women remaining would have one or more high risk values in their report and would thus require an ultrasound scan for precise dating of the pregnancy; 30% of these-that is, 3.7% of the screened population-would be identified as high risk and require consideration for amniocentesis. Conclusions-Screening programmes for Down's syndrome require the facility for precise dating of pregnancy to improve the accuracy of risk assessment. This can be achieved without introducing additional scans for early dating in the whole population but by selecting only those cases (about 14%) when an error in dates is likely to affect the risk of Down's syndrome.			GARDOSI, J (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CUCKLE H, 1992, BRIT MED J, V305, P1504, DOI 10.1136/bmj.305.6867.1504; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; GEIRSSON RT, 1991, ULTRASOUND OBST GYN, V1, P212, DOI 10.1046/j.1469-0705.1991.01030212.x; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1992, ANN CLIN BIOCHEM, V29, P390, DOI 10.1177/000456329202900403; Neumann J. von, 1951, NBS APPL MATH SER, V12, P36; REYNOLDS TM, 1992, AM J OBSTET GYNECOL, V166, P872, DOI 10.1016/0002-9378(92)91353-C; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALDENSTROM U, 1990, OBSTET GYNECOL, V76, P336; WICHMANN BA, 1982, APPLIED STATISTICS, V31, P188; 1988, STATISTICAL PACKAGE	18	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1509	1511		10.1136/bmj.306.6891.1509	http://dx.doi.org/10.1136/bmj.306.6891.1509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518678	Bronze, Green Published			2022-12-01	WOS:A1993LF94000024
J	DANISHEFSKY, SJ; MCCLURE, KF; RANDOLPH, JT; RUGGERI, RB				DANISHEFSKY, SJ; MCCLURE, KF; RANDOLPH, JT; RUGGERI, RB			A STRATEGY FOR THE SOLID-PHASE SYNTHESIS OF OLIGOSACCHARIDES	SCIENCE			English	Article							GLYCALS; CORROBORATION; REARRANGEMENT	Repeating glycosidic linkages of oligosaccharides can be synthesized by solid-phase methods. Glycals were attached to a polystyrene copolymer with a silyl ether bond and were activated to function as glycosyl donors with 3,3-dimethyldioxirane. Glycosidation was performed by reactions with a solution-based acceptor (itself a glycal). Excess ar-ceptor and promoter were removed by rinsing after each coupling, and the desired oligosaccharides were then easily obtained from the polymer by the addition of tetra-n-butylammonium fluoride. By this method, glycosidations are stereospecific and interior deletions are avoided.			DANISHEFSKY, SJ (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NHLBI NIH HHS [HL 25848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM W, 1987, J ORG CHEM, V52, P2800, DOI 10.1021/jo00389a029; BOLITT V, 1990, J ORG CHEM, V55, P5812, DOI 10.1021/jo00310a006; CARUTHERS MH, 1982, GENETIC ENG, V4, pCH1; CHAN TH, 1985, J CHEM SOC CHEM COMM, P909, DOI 10.1039/c39850000909; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8329, DOI 10.1021/ja00047a077; DANISHEFSKY SJ, 1992, J AM CHEM SOC, V114, P8331, DOI 10.1021/ja00047a078; DOUGLAS SP, 1991, J AM CHEM SOC, V113, P5095, DOI 10.1021/ja00013a075; FARRALL MJ, 1976, J ORG CHEM, V41, P3877, DOI 10.1021/jo00886a023; FRECHET JM, 1972, CARBOHYD RES, V22, P399, DOI 10.1016/S0008-6215(00)81291-4; FRECHET JMJ, 1980, POLYM SUPPORTED REAC, pCH8; FRIESEN RW, 1989, J AM CHEM SOC, V111, P6656, DOI 10.1021/ja00199a027; GRIFFITH DA, 1990, J AM CHEM SOC, V112, P5811, DOI 10.1021/ja00171a021; GUTHRIE RD, 1971, J CHEM SOC C, P2690, DOI 10.1039/j39710002690; GUTHRIE RD, 1973, J CHEM SOC PERK T 1, P2414, DOI 10.1039/p19730002414; HALCOMB RL, 1991, J AM CHEM SOC, V113, P5080, DOI 10.1021/ja00013a065; HALCOMB RL, 1989, J AM CHEM SOC, V111, P6661, DOI 10.1021/ja00199a028; LEMIEUX RU, 1965, CAN J CHEMISTRY, V43, P2190, DOI 10.1139/v65-296; MCDONALD FE, 1992, J ORG CHEM, V57, P7001, DOI 10.1021/jo00052a001; MERRIFIELD RB, 1988, ANAL BIOCHEM, V174, P399, DOI 10.1016/0003-2697(88)90039-5; MURRAY RW, 1985, J ORG CHEM, V50, P2847, DOI 10.1021/jo00216a007; RAMESH S, 1990, J ORG CHEM, V55, P5, DOI 10.1021/jo00288a003; SINAY P, 1991, PURE APPL CHEM, V63, P519, DOI 10.1351/pac199163040519; SUZUKI K, 1990, J AM CHEM SOC, V112, P8895, DOI 10.1021/ja00180a037; THIEM J, 1978, SYNTHESIS-STUTTGART, P696; VEENEMAN GH, 1987, TETRAHEDRON LETT, V28, P6695, DOI 10.1016/S0040-4039(00)96948-X	25	298	308	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1307	1309		10.1126/science.8493573	http://dx.doi.org/10.1126/science.8493573			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493573				2022-12-01	WOS:A1993LE02500037
J	Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC				Bouhnik, Y; Lemann, M; Mary, JY; Scemama, G; Tai, R; Matuchansky, C; Modigliani, R; Rambaud, JC			Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; EXPERIENCE; PREGNANCY; TOXICITY	Background Crohn's ulcerative gastrointestinal disease is presently managed through a variety of medical interventions, including-according to severity of illness-anti-inflammatory, immunosuppressive, and corticosteroid agents; and with remedial surgery to correct anatomical abnormalities caused by disease processes. The immunosuppressant azathioprine (or its metabolite, 6-mercaptopurine) is considered an efficient maintenance therapy for Crohn's, but there is always concern about bone-marrow suppression, liver damage, and other adverse effects. For how long persons with this disease should be given these drugs has not been determined. Methods Patients who were treated with azathioprine or 6-mercaptopurine for more than 6 months, and who were in prolonged clinical remission (>6 months without steroids) were followed. The time-to-relapse was analysed in those on treatment, in those who stopped treatment for reasons other than a relapse, and in the whole sample, taking into account that they could be treated with the drugs or not, as a function of time. The influence of concomitant variables on time-to-relapse rate was examined using the Cox proportional hazard model. Findings In the 157 patients who continued to take the therapy, cumulative probabilities of relapse al 1 and 5 years were 11% and 32% respectively. Female gender, younger age, and a time for achieving remission more than 6 months were associated with a higher risk of relapse. In 42 patients who stopped therapy, probabilities of relapse at 1 and 5 years were 38% and 75%, respectively. Male gender, younger age and duration of remisson less than 4 years were associated with a higher risk of relapse. After 4 years of remission on these drugs, the risk of relapse appeared to be similar, whether the therapy was maintained or stopped. Interpretation Taking into account the potential risks of long-term immunosuppressive therapy, the usefulness of maintaining azathioprine or 6-mercaptopurine in patients who have been in remission for more than 4 years is questionable.	HOP ST LOUIS,SERV GASTROENTEROL,F-75010 PARIS,FRANCE; HOP ST LAZARE,SERV GASTROENTEROL,F-75475 PARIS,FRANCE; UNIV PARIS 07,INSERM,U263,CTR BIOINFORMAT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; ALTMAN DG, 1994, STAT MED, V13, P201; BYAR DP, 1988, CANCER CLIN TRIALS, P382; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; COTTONE M, 1994, GASTROENTEROLOGY, V106, P643, DOI 10.1016/0016-5085(94)90697-1; EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GAUDIER FL, 1988, SURG GYNECOL OBSTET, V167, P533; HARVEY RF, 1980, LANCET, V1, P514; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KORELITZ BI, 1993, AM J GASTROENTEROL, V88, P1198; LARVOL L, 1994, NEW ENGL J MED, V331, P883, DOI 10.1056/NEJM199409293311321; LEB DE, 1971, ARCH INTERN MED, V128, P441, DOI 10.1001/archinte.128.3.441; LEMANN M, 1990, GASTROEN CLIN BIOL, V14, P548; LENNARDJONES JE, 1981, DIGEST DIS SCI, V77, P364; LILLEYMAN JS, 1994, LANCET, V343, P1188, DOI 10.1016/S0140-6736(94)92400-7; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; NYMAN M, 1985, SCAND J GASTROENTERO, V20, P1197, DOI 10.3109/00365528509089276; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; ODONOGHUE DP, 1978, LANCET, V2, P944; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; REIMERS TJ, 1978, SCIENCE, V201, P65, DOI 10.1126/science.663638; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; TUCHMANNDUPLESS.H, 1966, CR SOC BIOL, V166, P501	27	405	412	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					215	219		10.1016/S0140-6736(96)90402-X	http://dx.doi.org/10.1016/S0140-6736(96)90402-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551879				2022-12-01	WOS:A1996TT06900008
J	Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB				Lambright, DG; Sondek, J; Bohm, A; Skiba, NP; Hamm, HE; Sigler, PB			The 2.0 angstrom crystal structure of a heterotrimeric G protein	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; BETA-GAMMA; SIGNAL TRANSDUCTION; LIPID MODIFICATIONS; AMINO TERMINUS; GTP-BINDING; PHOSPHODIESTERASE; IDENTIFICATION	The structure of a heterotrimeric G protein reveals the mechanism of the nucleotide-dependent engagement of the alpha and beta gamma subunits that regulates their interaction with receptor and effector molecules. The interaction involves two distinct interfaces and dramatically alters the conformation of the alpha but not of the beta gamma subunits. The location of the known sites for post-translational modification and receptor coupling suggest a plausible orientation with respect to the membrane surface and an activated heptahelical receptor.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60680	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1993, X PLOR VERSION 3 1 M; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	56	1005	1027	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					311	319		10.1038/379311a0	http://dx.doi.org/10.1038/379311a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552184				2022-12-01	WOS:A1996TR32300049
J	Vescovi, EG; Soncini, FC; Groisman, EA				Vescovi, EG; Soncini, FC; Groisman, EA			Mg2+ as an extracellular signal: Environmental regulation of Salmonella virulence	CELL			English	Article							ESCHERICHIA-COLI; MAGNESIUM-METABOLISM; EPITHELIAL-CELLS; TYPHIMURIUM; EXPRESSION; TRANSPORT; PROTEINS; BACTERIA; GENE; MACROPHAGES	Ions are not traditionally thought to act as first messengers in signal transduction cascades. However, while searching for genes regulated by the PhoP/PhoQ virulence regulatory system of Salmonella typhimurium, we recovered two loci whose expression is controlled by the concentration of Mg2+. To determine whether Mg2+ is the signal modulating the whole PhoP/ phoQ system, we evaluated the gene expression pattern of six PhoP-activated genes. Growth in physiological concentrations of divalent cations repressed transcription of PhoP-activated genes and rendered wild-type Salmonella phenotypically PhoP(-). Mg2+ changed the conformation of the periplasmic domain of phoQ, identifying this protein as a Mg2+ sensor. A mutation in the sensing domain of phoQ altered the set point for Mg2+ and rendered Salmonella avirulent.			Vescovi, EG (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.			Garcia Vescovi, Eleonora/0000-0002-4431-8606; Soncini, Fernando/0000-0002-8925-7763	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029554] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN; Brown Edward M., 1994, P15; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Davis R., 1980, ADV BACTERIAL GENETI; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FOSTER JW, 1990, J BACTERIOL, V172, P771, DOI 10.1128/jb.172.2.771-778.1990; GARCIADELPORTILLO F, 1992, MOL MICROBIOL, V6, P3289, DOI 10.1111/j.1365-2958.1992.tb02197.x; GROISMAN EA, 1992, J BACTERIOL, V174, P486, DOI 10.1128/jb.174.2.486-491.1992; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; HEBERT SC, 1995, CURR OPIN CELL BIOL, V7, P484, DOI 10.1016/0955-0674(95)80004-2; KIER LD, 1979, J BACTERIOL, V138, P155, DOI 10.1128/JB.138.1.155-161.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller, 1972, EXPT MOL GENETICS; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; NORRIS V, 1991, MOL MICROBIOL, V5, P775, DOI 10.1111/j.1365-2958.1991.tb00748.x; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; RATHMAN M, 1995, 95TH GEN M WASH; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; ROOF SK, 1994, J AM COLL NUTR, V13, P424; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SILVER S, 1971, J BIOL CHEM, V246, P569; SMITH DL, 1993, MINER ELECTROL METAB, V19, P266; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VESCOVI EG, 1994, RES MICROBIOL, V145, P473, DOI 10.1016/0923-2508(94)90096-5; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x	47	627	640	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					165	174		10.1016/S0092-8674(00)81003-X	http://dx.doi.org/10.1016/S0092-8674(00)81003-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548821	Bronze			2022-12-01	WOS:A1996TQ17000019
J	Billups, B; Attwell, D				Billups, B; Attwell, D			Modulation of non-vesicular glutamate release by pH	NATURE			English	Article							RAT-BRAIN; GLIAL-CELLS; TRANSPORTER; ASPARTATE; SALAMANDER; ISCHEMIA; RETINA; HIPPOCAMPUS; EXPRESSION; MEMBRANE	GLUTAMATE uptake into glial cells helps to keep the brain extracellular glutamate concentration, [glu](0), below levels that kill neurons. Uptake is powered(1-4) by the transmembrane gradients of Na+, K+ and pH. When the extracellular [K+] rises in brain ischaemia, uptake reverses, releasing glutamate into the extracellular space(5,6). Here we show, by monitoring glutamate transport electrically and detecting released glutamate with ion channels in neurons placed outside glial cells, that a raised [Hf] inhibits both forward and reversed glutamate uptake. No electroneutral reversed uptake was detected, contradicting the idea(7) that forward and reversed uptake differ fundamentally. Suppression of reversed uptake by the low pH occurring in ischaemia(8,9) will slow the Ca2+-independent release of glutamate(10) which can raise [glu], to a neurotoxic level(11,12), and will thus protect the brain during a transient loss of blood supply.			Billups, B (corresponding author), UCL, DEPT PHYSIOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Attwell, David/ABE-6750-2020	Billups, Brian/0000-0001-5378-2809	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Attwell David, 1994, Current Opinion in Neurobiology, V4, P353, DOI 10.1016/0959-4388(94)90096-5; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; ELIASOF S, 1993, J NEUROSCI, V13, P402; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; IKEDA M, 1989, NEUROSCI LETT, V96, P202, DOI 10.1016/0304-3940(89)90058-X; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; LORD RSA, 1990, AUST NZ J OPHTHALMOL, V18, P299, DOI 10.1111/j.1442-9071.1990.tb00624.x; MADL JE, 1993, J NEUROSCI, V13, P4429; MOBBS P, 1988, BRAIN RES, V460, P235, DOI 10.1016/0006-8993(88)90368-X; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NADEAU SE, 1994, J FAM PRACTICE, V38, P495; NELSON PJ, 1983, BIOCHEMISTRY-US, V22, P5459, DOI 10.1021/bi00292a030; NEWMAN EA, 1984, J NEUROPHYSIOL, V51, P164, DOI 10.1152/jn.1984.51.1.164; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SCHWARTZ EA, 1993, NEURON, V10, P1141, DOI 10.1016/0896-6273(93)90062-V; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; YAMADA KA, 1993, J NEUROSCI, V13, P3904	30	128	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 11	1996	379	6561					171	174		10.1038/379171a0	http://dx.doi.org/10.1038/379171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538768				2022-12-01	WOS:A1996TP36000060
J	Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB				Pier, GB; Grout, M; Zaidi, TS; Olsen, JC; Johnson, LG; Yankaskas, JR; Goldberg, JB			Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; AERUGINOSA STRAIN PAO; PSEUDOMONAS-AERUGINOSA; DEFECTIVE-MUTANTS; EPITHELIAL-CELLS; LIPOPOLYSACCHARIDE; SURFACE; LOCALIZATION; POLYSACCHARIDE	Cystic fibrosis (CF) patients are hypersusceptible to chronic Pseudomonas aeruginosa lung infections. Cultured human airway epithelial cells expressing the Delta F508 allele of the cystic fibrosis transmembrane conductance regulator (CFTR) were defective in uptake of P. aeruginosa compared with cells expressing the wild-type allele. Pseudomonas aeruginosa lipopolysaccharide (LPS)-core oligosaccharide was identified as the bacterial ligand for epithelial cell ingestion; exogenous oligosaccharide inhibited bacterial ingestion in a neonatal mouse model, resulting In Increased amounts of bacteria in the lungs. CFTR may contribute to a host-defense mechanism that is important for clearance of P. aeruginosa from the respiratory tract.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill	Pier, GB (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331	NHLBI NIH HHS [HL42384, R01 HL058398] Funding Source: Medline; NIAID NIH HHS [AI22806, AI35674] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058398, P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035674, R01AI022806] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARONSON M, 1988, INFECT IMMUN, V56, P1615, DOI 10.1128/IAI.56.6.1615-1617.1988; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; CERVIN MA, 1994, MICROB PATHOGENESIS, V17, P291, DOI 10.1006/mpat.1994.1075; COYNE MJ, 1994, J BACTERIOL, V176, P3500, DOI 10.1128/JB.176.12.3500-3507.1994; DALAL E, 1994, INFECT IMMUN, V62, P5505, DOI 10.1128/IAI.62.12.5505-5510.1994; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EVANS DJ, 1994, MOL MICROBIOL, V13, P427, DOI 10.1111/j.1365-2958.1994.tb00437.x; FLEISZIG SMJ, 1995, INFECT IMMUN, V63, P4072, DOI 10.1128/IAI.63.10.4072-4077.1995; GOLDBERG JB, 1992, P NATL ACAD SCI USA, V89, P10716, DOI 10.1073/pnas.89.22.10716; GROUT M, UNPUB; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JARRELL K, 1977, MICROBIOS, V19, P103; JEFFERY PK, 1988, SCANNING MICROSCOPY, V2, P553; KOVAL SF, 1977, J GEN MICROBIOL, V98, P387, DOI 10.1099/00221287-98-2-387; KROPINSKI AM, 1979, CAN J MICROBIOL, V25, P390, DOI 10.1139/m79-060; LAM J, 1980, INFECT IMMUN, V28, P546; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; OHMAN DE, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P28; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ORIKASA S, 1977, INVEST UROL, V15, P185; PENKETH A, 1983, AM REV RESPIR DIS, V127, P605, DOI 10.1164/arrd.1983.127.5.605; PIER GB, 1978, INFECT IMMUN, V22, P908, DOI 10.1128/IAI.22.3.908-918.1978; PIER GB, 1986, J CLIN MICROBIOL, V24, P189, DOI 10.1128/JCM.24.2.189-196.1986; PLOTKOWSKI MC, 1992, J MED MICROBIOL, V36, P104, DOI 10.1099/00222615-36-2-104; ROWE PSN, 1983, EUR J BIOCHEM, V132, P329, DOI 10.1111/j.1432-1033.1983.tb07366.x; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWAN ET, 1995, MOL MICROBIOL, V15, P267, DOI 10.1111/j.1365-2958.1995.tb02241.x; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; ZAR H, 1995, J PEDIATR-US, V126, P230, DOI 10.1016/S0022-3476(95)70549-X	34	322	334	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					64	67		10.1126/science.271.5245.64	http://dx.doi.org/10.1126/science.271.5245.64			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539601	Green Submitted, Green Accepted			2022-12-01	WOS:A1996TP02200043
J	Thanos, D; Maniatis, T				Thanos, D; Maniatis, T			Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome	CELL			English	Article							FACTOR-BINDING-SITES; NF-KAPPA-B; REGULATORY ELEMENTS; INTERFERON GENE; ACTIVATION; PROMOTER; IRF-1; TRANSCRIPTION; DOMAINS; CELLS	We present evidence that transcriptional activation of the human interferon-beta (IFN beta) gene requires the assembly of a higher order transcription enhancer complex (enhanceosome). This multicomponent complex includes at least three distinct transcription factors and the high mobility group protein HMG I(Y). Both the in vitro assembly and in vivo transcriptional activity of this complex require a precise helical relationship between individual transcription factor-binding sites. In addition, HMG I(Y), which binds specifically to three sites within the enhancer, promotes cooperative binding of transcription factors in vitro and is required for transcriptional synergy between these factors in vivo. Thus, HMG I(Y) plays an essential role in the assembly and function of the IFN beta gene enhanceosome.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Thanos, Dimitris/AAE-5720-2019; Li, Yapeng/N-1042-2017	Li, Yapeng/0000-0002-5042-6881	NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CORBIN V, 1990, GENETICS, V124, P637; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GONZALEZCRESPO S, 1994, SCIENCE, V264, P255, DOI 10.1126/science.8146656; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKINIGHT SL, 1982, TRANSCRIPTIONAL REGU; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MEACOCK S, 1994, J BIOL CHEM, V269, P31756; Miller JH., 1972, EXPT MOL GENETICS; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; ONDEK B, 1988, NATURE, V333, P42; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PTASHNE M, 1992, GENETIC SWITCH GENE; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; SZYMANSKI K, 1995, EMBO J, V10, P2229; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THANOS D, 1993, COLD SPRING HARB SYM, V58, P733; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266	53	845	852	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1091	1100		10.1016/0092-8674(95)90136-1	http://dx.doi.org/10.1016/0092-8674(95)90136-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548797	Bronze			2022-12-01	WOS:A1995TM76200006
J	LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C				LOUKERIS, TG; LIVADARAS, I; ARCA, B; ZABALOU, S; SAVAKIS, C			GENE-TRANSFER INTO THE MEDFLY, CERATITIS-CAPITATA, WITH A DROSOPHILA-HYDEI TRANSPOSABLE ELEMENT	SCIENCE			English	Article							MEDITERRANEAN FRUIT-FLY; TRANSFORMATION; GENOME	Exogenous functional DNA was introduced into the germline chromosomes of the Mediterranean fruit fly (medfly) Ceratitis capitata with a germline transformation system based on the transposable element Mines from Drosophila hydei. Transformants were identified as phenotypic revertants of a white-eyed mutation carried by the recipient strain. Clusters of transformants were detected among the progeny of 390 individuals screened for germline transformation. Five independent and phenotypically active integration events were identified, in each of which a single copy of the transposon was inserted into a different site of the medfly genome. Molecular analysis indicates that they represent transposase-mediated insertions of the transposon into medfly chromosomes.	FDN RES & TECHNOL HELLAS,INST MOLEC BIOL & BIOTECHNOL,GR-71110 CRETE,GREECE; UNIV CRETE,SCH MED,DIV BASIC MED SCI,CRETE,GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete			Savakis, Babis/D-3633-2009; Arca, Bruno/C-8383-2012	Arca, Bruno/0000-0002-4029-0984				ARCA B, UNPUB; BLACKMAN RK, 1989, EMBO J, V8, P211, DOI 10.1002/j.1460-2075.1989.tb03366.x; CAREY JR, 1991, SCIENCE, V253, P1369, DOI 10.1126/science.1896848; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; KNIPLING EF, 1959, SCIENCE, V130, P902, DOI 10.1126/science.130.3380.902; LIDHOLM DA, 1993, GENETICS, V134, P859; LIVADARAS I, UNPUB; LOUIS C, 1987, FRUITFLIES, P47; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, UNPUB; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MINTZAS AC, 1983, DEV BIOL, V95, P492, DOI 10.1016/0012-1606(83)90051-9; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; Robertson H.M., 1993, Insect Molecular Biology, V2, P125, DOI 10.1111/j.1365-2583.1993.tb00132.x; ROBERTSON HM, 1995, ANNU REV ENTOMOL, V40, P333, DOI 10.1146/annurev.en.40.010195.002001; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZWIEBEL LJ, 1995, SCIENCE, V270, P2005, DOI 10.1126/science.270.5244.2005	22	241	269	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2002	2005		10.1126/science.270.5244.2002	http://dx.doi.org/10.1126/science.270.5244.2002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533094				2022-12-01	WOS:A1995TL42000045
J	COCCHI, F; DEVICO, AL; GARZINODEMO, A; ARYA, SK; GALLO, RC; LUSSO, P				COCCHI, F; DEVICO, AL; GARZINODEMO, A; ARYA, SK; GALLO, RC; LUSSO, P			IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS	SCIENCE			English	Article							VIRUS-REPLICATION; FUNCTIONAL EXPRESSION; PROGENITOR CELLS; BINDING-PROTEIN; LINE PF-382; INFECTION; MIGRATION; RECEPTORS; MONOCYTE; INVITRO	Evidence suggests that CD8(+) T lymphocytes are involved in the control of human immunodeficiency virus (HIV) infection in vivo, either by cytolytic mechanisms or by the release of HIV-suppressive factors (HIV-SF). The chemokines RANTES, MIP-1 alpha, and MIP-1 beta were identified as the major HIV-SF produced-by CD8(+) T cells. Two active proteins purified from the culture supernatant of an immortalized CD8(+) T cell clone revealed sequence identity with human RANTES and MIP-1 alpha. RANTES, MIP-1 alpha, and MIP-1 beta were released by both immortalized and primary CD8(+) T cells. HIV-SF activity produced by these cells was completely blocked by a combination of neutralizing antibodies against RANTES, MIP-1 alpha, and MIP-1 beta. Recombinant human RANTES, MIP-1 alpha, and MIP-1 beta induced a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). These data may have relevance for the prevention and therapy of AIDS.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; ADV BIOSCI LABS,KENSINGTON,MD 20852	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Garzino-Demo, Alfredo/0000-0002-4095-6950				ABIMIKU AG, 1995, NAT MED, V1, P321, DOI 10.1038/nm0495-321; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BELLONE G, 1987, LEUKEMIA, V1, P603; BERTINI R, 1995, AIDS RES HUM RETROV, V11, P155, DOI 10.1089/aid.1995.11.155; Bolognesi D P, 1993, Semin Immunol, V5, P203, DOI 10.1006/smim.1993.1024; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BROXMEYER HE, 1990, BLOOD, V76, P1110; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CASTRO BA, 1991, CELL IMMUNOL, V132, P246, DOI 10.1016/0008-8749(91)90023-5; COCCHI F, UNPUB; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; DEROSSI A, 1986, P NATL ACAD SCI USA, V83, P4297, DOI 10.1073/pnas.83.12.4297; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GARZINODEMO A, UNPUB; GIRARD M, 1995, J VIROL, V69, P6239, DOI 10.1128/JVI.69.10.6239-6248.1995; HEENEY JL, 1994, J EXP MED, V180, P769, DOI 10.1084/jem.180.2.769; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANAGI M, 1988, J IMMUNOL, V119, P470; KUNA P, 1992, J IMMUNOL, V149, P636; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; LUSSO P, 1994, P NATL ACAD SCI USA, V91, P3872, DOI 10.1073/pnas.91.9.3872; LUSSO P, 1990, J VIROL, V64, P6134; LUSSO P, 1988, J EXP MED, V166, P1659; LUSSO P, UNPUB; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PEGORARO L, 1985, JNCI-J NATL CANCER I, V75, P285; PUTKONEN P, 1994, J MED PRIMATOL, V23, P89, DOI 10.1111/j.1600-0684.1994.tb00107.x; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WANG JM, 1993, J IMMUNOL, V150, P3022; WHITTON JL, 1990, VIROLOGY, P369; WOLFE SD, 1989, FASEB J, V3, P2565; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570	48	2551	2711	0	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1811	1815		10.1126/science.270.5243.1811	http://dx.doi.org/10.1126/science.270.5243.1811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525373	Green Submitted			2022-12-01	WOS:A1995TK47600043
J	WERNER, MH; CLORE, GM; FISHER, CL; FISHER, RJ; TRINH, L; SHILOACH, J; GRONENBORN, AM				WERNER, MH; CLORE, GM; FISHER, CL; FISHER, RJ; TRINH, L; SHILOACH, J; GRONENBORN, AM			THE SOLUTION STRUCTURE OF THE HUMAN ETS1-DNA COMPLEX REVEALS A NOVEL MODE OF BINDING AND TRUE SIDE-CHAIN INTERCALATION	CELL			English	Article							SERUM RESPONSE ELEMENT; CO-CRYSTAL STRUCTURE; TATA-BOX COMPLEX; TRANSCRIPTION FACTORS; DNA COMPLEX; PROTEIN; MOTIF; RESOLUTION; SUGGESTS; PROGRAM	The solution structure of a 24.4 kDa specific complex of the DNA-binding domain (DBD) of the human ETS1 (hETS1) oncoprotein with a 17-mer DNA has been solved by NMR. The interaction of the hETS1 DBD with DNA reveals a surprising twist on the general features of helix-turn-helix (HTH)-DNA interactions, Major groove recognition involves the C-terminal two thirds of the HTH recognition helix, while minor groove recognition occurs via true intercalation of the side chain of Trp-28, which extends from the minor to the major groove. This results in a sharp kink of similar to 60 degrees and a widening of the minor groove over one-half turn of the DNA. The orientation of the HTH element of the hETS1 DBD with respect to the major groove is significantly rotated relative to other HTH proteins. These observations establish the ETS family of DNA-binding proteins as a distinct family of HTH proteins.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21701; NIDDKD,CELLULAR & DEV BIOL LAB,BIOTECHNOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	WERNER, MH (corresponding author), NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892, USA.		Clore, G Marius/L-2546-2018; Fisher, Robert/B-1431-2009; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A.T, 1993, XPLOR VERSION 31 SYS; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLORE GM, 1994, PROTEIN SCI, V3, P372; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1985, PROG NMR SPECTROSC, V17, P1; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEIERSTANGER BH, 1995, ANNU REV BIOPH BIOM, V24, P463, DOI 10.1146/annurev.bb.24.060195.002335; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P252; MAVROTHALASSITI.G, 1994, ONCOGENE, V9, P425; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P129; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; TIMMS MJ, 1994, MOL REPROD DEV, V39, P208; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	45	114	118	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					761	771		10.1016/0092-8674(95)90189-2	http://dx.doi.org/10.1016/0092-8674(95)90189-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521493	Bronze			2022-12-01	WOS:A1995TH94800013
J	LUBAN, J; BOSSOLT, KL; FRANKE, EK; KALPANA, GV; GOFF, SP				LUBAN, J; BOSSOLT, KL; FRANKE, EK; KALPANA, GV; GOFF, SP			HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GAG PROTEIN BINDS TO CYCLOPHILIN-A AND CYCLOPHILIN-B	CELL			English	Article							MURINE LEUKEMIA VIRUSES; CYCLOSPORINE-A; HOMOLOG NINAA; BALB-C; HIV-1; GENE; MYRISTYLATION; IMMUNOPHILIN; INFECTIVITY; ACTIVATION	Retroviral Gag protein is capable of directing the assembly of virion particles independent of other retroviral elements and plays an important role early in the infection of a cell. Using the GAL4 two hybrid system, we screened a cDNA expression library and identified two host proteins, cyclophilins (CyPs) A and B, which interact specifically with the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein Pr55gag. Glutathione S-transferase-CyP fusion proteins bind tightly to Pr55gag in vitro, as well as to the HIV-1 capsid protein p24. Cyclosporin A efficiently disrupts the Gag-CyPA interaction and less efficiently disrupts the Gag-CyPB interaction. The Gag-CyP interaction may be important for the HIV-1 life cycle and may be relevant to the pathology caused by this immunosuppressive virus.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University	LUBAN, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.			Kalpana, Ganjam/0000-0003-4111-0604; Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000988, U01AI024845] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 00988, AI 24845] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER D M, 1991, P182; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HEITMAN J, 1992, NEW BIOL, V4, P448; HOPKINS N, 1977, J VIROL, V21, P309, DOI 10.1128/JVI.21.1.309-318.1977; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HSU HW, 1985, VIROLOGY, V142, P211, DOI 10.1016/0042-6822(85)90435-0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KAUFMANN R, 1992, J ACQ IMMUN DEF SYND, V15, P760; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KRAUSSLICH HG, 1993, VIROLOGY, V192, P605, DOI 10.1006/viro.1993.1077; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1991, J VIROL, V65, P3203, DOI 10.1128/JVI.65.6.3203-3212.1991; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUBAN J, 1993, IN PRESS J VIROL; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWARTZ O, 1992, AIDS RES HUM RETROV, V8, P545, DOI 10.1089/aid.1992.8.545; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAMNES M A, 1992, Trends in Cell Biology, V2, P272, DOI 10.1016/0962-8924(92)90200-7; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; STRATHERN J N, 1991, P319; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WAINBERG MA, 1988, BLOOD, V72, P1904; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; Weiss R, 1984, RNA TUMOR VIRUSES; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	65	683	724	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1067	1078		10.1016/0092-8674(93)90637-6	http://dx.doi.org/10.1016/0092-8674(93)90637-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513493				2022-12-01	WOS:A1993LH54800004
J	CUMBERLEDGE, S; KRASNOW, MA				CUMBERLEDGE, S; KRASNOW, MA			INTERCELLULAR SIGNALING IN DROSOPHILA SEGMENT FORMATION RECONSTRUCTED INVITRO	NATURE			English	Article							POLARITY GENE ARMADILLO; WINGLESS; EXPRESSION; EMBRYOS; EMBRYOGENESIS; REQUIREMENTS; EPIDERMIS; PROTEIN	GENETIC studies show that intercellular signalling is involved in key steps in Drosophila melanogaster development, but it has not previously been possible to investigate these processes in simplified in vitro systems. Analysis of engrailed (en) and wingless (wg) and other segment polarity genes suggests that two or more intercellular signalling processes may be involved in intrasegmental patterning1-3. Expression of en and wg begins about three hours after egg laying, in adjacent rows of cells in the posterior half of each segmental primordium4-7. In wg- embryos and in conditional mutants in which wg function is inactivated during a critical period between three and five hours after egg laying, early en expression begins normally but then disappears within several hours4,8-10. The wg gene encodes a protein highly similar to the product of the mouse Wnt-1 proto-oncogene, a secreted glycoprotein11,12; wg protein is proposed to function as an extracellular signal, maintaining en expression and activating other molecular and morphogenetic processes in nearby cells4,8,9,13. Several lines of evidence support the model, including the secretion of wg protein in the embryo7,14, genetic mosaic experiments15-17 and cell lineage studies18. We tested this model using purified embryonic cells isolated by whole animal cell sorting19, and validated three key predictions: (1) when en-expressing cells from early embryos are grown alone in culture, they rapidly and selectively lose en expression; (2) purified wg-expressing cells provide a locally active signal that prevents this loss; (3) heterologous cells engineered to express wg also show signalling activity, indicating that wg protein alone, or in conjunction with more generally expressed factors, is the signal.			CUMBERLEDGE, S (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRASNOW MA, 1991, SCIENCE, V251, P81, DOI 10.1126/science.1898782; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7	21	45	46	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					549	552		10.1038/363549a0	http://dx.doi.org/10.1038/363549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505983				2022-12-01	WOS:A1993LF93900052
J	KRISHNAN, SN; FREI, E; SWAIN, GP; WYMAN, RJ				KRISHNAN, SN; FREI, E; SWAIN, GP; WYMAN, RJ			PASSOVER - A GENE REQUIRED FOR SYNAPTIC CONNECTIVITY IN THE GIANT FIBER SYSTEM OF DROSOPHILA	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; FASCICLIN-II; MELANOGASTER; PROTEIN; LOCUS; ADHESION; SEQUENCES; MUTATIONS; MEMBRANE	Passover (Pas) flies fail to jump in response to a light-off stimulus. The mutation disrupts specific synapses of the giant fibers (GFs), command neurons for this response. Pas was cloned from a P element-induced allele. The cDNA encodes a putative membrane protein of 361 amino acids. Null, hypomorphic, and dominant alleles were sequenced. In the adult central nervous system, and in the pupa during GF synapse formation, Pas is consistently expressed in the GF and in a large thoracic cell in the location of its postsynaptic targets. Pas establishes a new gene family. The Drosophila ogre protein, required for postembryonic neuroblast development, is 47% identical; the C. elegans Unc-7 protein, which when mutated alters the connectivity of a few neurons, is 33% identical.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39813] Funding Source: Medline; NINDS NIH HHS [NS-07314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIRD DH, 1990, GENETICS, V126, P1045; BAIRD DH, 1988, THESIS YALE U NEW HA; BARID DH, 1993, IN PRESS J NEUROBIOL, V24; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GOODMAN CS, 1992, NERVE GROWTH CONE, P283; Gorczyca M., 1984, Journal of Neurogenetics, V1, P289, DOI 10.3109/01677068409107093; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cellbio.7.1.505; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KING DG, 1980, J NEUROCYTOL, V9, P753, DOI 10.1007/BF01205017; KOTO M, 1981, BRAIN RES, V221, P213, DOI 10.1016/0006-8993(81)90772-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIPSHITZ HD, 1985, DEV BIOL, V108, P56, DOI 10.1016/0012-1606(85)90009-0; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOSE A, 1992, CELL, V70, P537; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; Power ME, 1943, J MORPHOL, V72, P517, DOI 10.1002/jmor.1050720306; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER LE, 1990, J BIOL CHEM, V265, P6890; SINGH NR, 1989, NEUROBIOLOGY SENSORY, P203; STARICH TA, 1993, GENETICS, V133, P527; SWAIN GP, 1990, BRAIN RES, V535, P147, DOI 10.1016/0006-8993(90)91833-3; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; THOMAS JB, 1984, J NEUROSCI, V4, P530; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATANABE T, 1990, GENETICS, V126, P1033; WATARSTON R, 1992, NAT GENET, V152, P172; WYMAN RJ, 1983, COLD SPRING HARB SYM, V48, P641, DOI 10.1101/SQB.1983.048.01.068	45	84	85	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					967	977		10.1016/0092-8674(93)90274-T	http://dx.doi.org/10.1016/0092-8674(93)90274-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500183	Bronze			2022-12-01	WOS:A1993LF06100012
J	HAMERSCASTERMAN, C; ATARHOUCH, T; MUYLDERMANS, S; ROBINSON, G; HAMERS, C; SONGA, EB; BENDAHMAN, N; HAMERS, R				HAMERSCASTERMAN, C; ATARHOUCH, T; MUYLDERMANS, S; ROBINSON, G; HAMERS, C; SONGA, EB; BENDAHMAN, N; HAMERS, R			NATURALLY-OCCURRING ANTIBODIES DEVOID OF LIGHT-CHAINS	NATURE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; VARIANT SURFACE GLYCOPROTEIN; ESCHERICHIA-COLI; SEGMENTAL FLEXIBILITY; TRYPANOSOMA-BRUCEI; BINDING-PROTEIN; GENERATION; DIFFERENTIATION; REPERTOIRE; MOLECULES	RANDOM association of VL and VH repertoires contributes considerably to antibody diversity1. The diversity and the affinity are then increased by hypermutation in B cells located in germinal centres2. Except in the case of 'heavy chain' disease3, naturally occurring heavy-chain antibodies have not been described, although antigen binding has been demonstrated for separated heavy chains4 or cloned VH domains5. Here we investigate the presence of considerable amounts of IgG-like material of M(r) 100K in the serum of the camel (Camelus dromedarius)6. These molecules are composed of heavy-chain dimers and are devoid of light chains, but nevertheless have an extensive antigen-binding repertoire, a finding that calls into question the role of light chains in the camel. Camel heavy-chain IgGs lack CH1, which in one IgG class might be structurally replaced by an extended hinge. Heavy-chain IgGs are a feature of all camelids. These findings open new perspectives in the engineering of antibodies.	VRIJE UNIV BRUSSELS, INST MOLEC BIOL, PAARDENST 65, B-1640 RHODE ST GENESE, BELGIUM; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	Vrije Universiteit Brussel; Trinity College Dublin			Muyldermans, Serge V/C-6418-2016; Abrams, William R/A-5782-2008; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575				BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DUNNICK W, 1980, NUCLEIC ACIDS RES, V8, P1475, DOI 10.1093/nar/8.7.1475; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; FLEISCHMAN JB, 1962, ARCH BIOCHEM BIOPHYS, P174; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JACKSON T, 1992, MOL IMMUNOL, V29, P667, DOI 10.1016/0161-5890(92)90204-B; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KLEIN J, 1990, IMMUNOLOGY; KOBAT EA, 1987, SEQUENCES PROTEINS I, P511; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; ROHOLT O, 1964, P NATL ACAD SCI USA, V51, P173, DOI 10.1073/pnas.51.2.173; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY L, 1989, P NATL ACAD SCI USA, V86, P5728, DOI 10.1073/pnas.86.15.5728; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SELIGMANN M, 1979, IMMUNOL REV, V48, P145, DOI 10.1111/j.1600-065X.1979.tb00302.x; SONGA EB, 1988, ANN SOC BELG MED TR, V68, P233; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; UNGAR-WARON H, 1987, Israel Journal of Veterinary Medicine, V43, P198; UTSUMI S, 1964, BIOCHEMISTRY-US, V3, P1329, DOI 10.1021/bi00897a024; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0	26	1979	2761	40	399	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					446	448		10.1038/363446a0	http://dx.doi.org/10.1038/363446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502296				2022-12-01	WOS:A1993LE93800057
J	NAZARETH, I; KING, M				NAZARETH, I; KING, M			DECISION-MAKING BY GENERAL-PRACTITIONERS IN DIAGNOSIS AND MANAGEMENT OF LOWER URINARY-TRACT SYMPTOMS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL JUDGMENT	Objective-To identify factors influencing decision making by general practitio Setting-Two suburban London general practices. Subjects-Women presenting to their family doctor with lower urinary tract symptoms. Design-After each consultation the doctor completed a questionnaire on presenting symptoms; clinical examination; investigations undertaken; presence of psychological, social, and menstrual problems; patients' requests for antibiotics; antibiotic prescribing; knowledge of the patient; attitude towards the consultation; and any other factors assisting in diagnosis and management. Finally, doctors predicted the presence or absence of clinically important bacteriuria. Each woman completed a demographic questionnaire, the 12 item general health questionnaire, and the modified menstrual distress questionnaire, after which each provided a clean catch midstream urine sample. Case notes were examined for information on previous reports of results of urine analysis. Results-When the general practitioners did not know the patients well they were 4.5 times more likely to assume that there was a clinically important infection. When they knew the patient well, they were four times more likely to make a correct prediction of the test result and 12 times less likely to prescribe antibiotics. Doctors were five times more likely to predict the test result correctly in patients from social classes 1 and 2 and were six times more likely to prescribe antibiotics for the older women in the sample. Conclusions-In women presenting with urinary tract symptoms, these family practitioners seemed to take no particular regard of physicial, psychological, or menstrual factors in making their assessments. They were most accurate in their prediction of the result of urine analysis and least likely to prescribe antibiotics when they had a good general knowledge of the patient. Which came first, the diagnosis or prescribing, is difficult to say and probably differed in individual cases. Doctors tended to be more conservative in their management of older women and those whom they knew less well.	ROYAL FREE HOSP, SCH MED, DEPT ACAD PSYCHIAT, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	NAZARETH, I (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				Altman DG, 1991, PRACTICAL STATISTICS; ANDERSON JE, 1981, CAN FAM PHYSICIAN, V27, P1909; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BROOKE JB, 1984, MED INFORM, V9, P45, DOI 10.3109/14639238409010937; BROOKS D, 1978, BACTERIOLOGICAL EXAM, P39; CLARE AW, 1979, EMOTION REPRODUCTI A, V20, P177; DOBBS FF, 1987, J ROY COLL GEN PRACT, V37, P100; GAYMANS R, 1976, LANCET, V2, P674; Goldberg DP., 1972, DETECTION PSYCHIATRI; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; MOND NC, 1965, LANCET, V1, P514; MOOS RH, 1969, AM J OBSTET GYNECOL, V103, P390, DOI 10.1016/0002-9378(69)90499-2; MOOS RH, 1968, PSYCHOSOM MED, V30, P853, DOI 10.1097/00006842-196811000-00006; ODOWD TC, 1984, BRIT MED J, V288, P1347, DOI 10.1136/bmj.288.6427.1347; Raynes N V, 1980, J R Coll Gen Pract, V30, P166; 1982, LANCET, V2, P694; 1986, MORBIDITY STATISTICS, P159	19	37	38	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1103	1106		10.1136/bmj.306.6885.1103	http://dx.doi.org/10.1136/bmj.306.6885.1103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495157	Bronze, Green Published			2022-12-01	WOS:A1993KZ56500024
J	Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA				Peters, RK; Kjos, SL; Xiang, A; Buchanan, TA			Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; PIMA-INDIANS; FOLLOW-UP; PARITY; CELL	Background Pregnancy is associated with marked insulin resistance that seems to have little, if any, impact on the long-term risk of non-insulin-dependent diabetes mellitus (NIDDM) in the general population. The aim of this study was to test whether pregnancy would alter the risk of NIDDM among women with a high prevalence of pancreatic beta-cell dysfunction, as indicated by a history of gestational diabetes mellitus. Methods The cohort consisted of 666 Latino women with gestational diabetes attending a high-risk family planning clinic. They were followed up for up to 7.5 years, during which lime they were weighed and underwent an oral glucose-tolerance test annually. The effect of an additional pregnancy, and of other risk factors for diabetes, was examined. Findings 87 (13%) of the women completed an additional pregnancy. 80 of those women did not have NIDDM immediately after the additional pregnancy and their subsequent annual incidence rate of NIDDM was 30.9% (95% CI 12.7-49.1), more than 2.5 times the annual incidence rate of NIDDM in the cohort overall (11.9%; 95% CI 10.0-13.8). Proportional hazards regression analysis using the presence or absence of an additional pregnancy as a time-dependent variable confirmed that an additional pregnancy increased the rate ratio of NIDDM to 3.34(95% CI 1.80-6.19), compared with women without an additional pregnancy after adjustment for other potential diabetes risk factors during the index pregnancy (antepartum oral glucose tolerance, highest fasting glucose, gestational age at diagnosis of gestational diabetes) and during follow-up (postpartum body mass index [BMI], and glucose tolerance, weight change, breast feeding, and months of contraceptive use). Weight gain also was independently associated with an increased risk of NIDDM; the rate ratio was 1.95 (95% CI 1.63-2.33) for each 10 lb (4.5 kg) gained during follow-up after adjustment for the additional pregnancy and the other potential risk factors. Interpretation The study showed that a single pregnancy, independent of the well-known effect of weight gain, accelerated the development of NIDDM in a group of women with a high prevalence of pancreatic beta-cell dysfunction. This finding implies that episodes of insulin resistance may contribute to the decline in beta-cell function that leads to NIDDM in many high-risk individuals.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT OBSTET & GYNECOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-43] Funding Source: Medline; NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BLEICHER SJ, 1964, NEW ENGL J MED, V271, P866, DOI 10.1056/NEJM196410222711702; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; CATALANO PM, 1991, AM J OBSTET GYNECOL, V165, P1667, DOI 10.1016/0002-9378(91)90012-G; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COX DR, 1972, J R STAT SOC B, V34, P187; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DONG ZG, 1993, AUST NZ J OBSTET GYN, V33, P350, DOI 10.1111/j.1479-828X.1993.tb02107.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GAUDIER FL, 1992, OBSTET GYNECOL, V80, P755; GRANT PT, 1986, AUST NZ J OBSTET GYN, V26, P17, DOI 10.1111/j.1479-828X.1986.tb01521.x; HANSON RL, 1995, DIABETES, V43, P261; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, AM J MED, V93, P13, DOI 10.1016/0002-9343(92)90674-Z; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; PYKE DA, 1956, LANCET, V270, P818; RYAN EA, 1985, DIABETES, V34, P380, DOI 10.2337/diabetes.34.4.380; RYAN EA, 1995, DIABETES, V44, P506, DOI 10.2337/diabetes.44.5.506; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SPELLACY WN, 1963, NEW ENGL J MED, V268, P988, DOI 10.1056/NEJM196305022681805; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P221; 1979, DIABETES, V29, P1039	27	201	207	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					227	230		10.1016/S0140-6736(96)90405-5	http://dx.doi.org/10.1016/S0140-6736(96)90405-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551882				2022-12-01	WOS:A1996TT06900011
J	Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L				Brocke, S; Gijbels, K; Allegretta, M; Ferber, I; Piercy, C; Blankenstein, T; Martin, R; Utz, U; Karin, N; Mitchell, D; Veromaa, T; Waisman, A; Gaur, A; Conlon, P; Ling, N; Fairchild, PJ; Wraith, DC; OGarra, A; Fathman, CG; Steinman, L			Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein	NATURE			English	Article							T-CELL RECEPTOR; TUMOR NECROSIS FACTOR; MULTIPLE-SCLEROSIS	FOLLOWING induction of experimental encephalomyelitis with a T-cell clone, L10C1, that is specific for the myelin basic protein epitope p87-99, the inflammatory infiltrate in the central nervous system contains a diverse collection of T cells with heterogeneous receptors. We show here that when clone L10C1 is tolerized in vivo with an analogue of p87-99, established paralysis is reversed, inflammatory infiltrates regress, and the heterogeneous T-cell infiltrate disappears from the brain, with only the T-cell clones that incited disease remaining in the original lesions. We found that antibody raised against interleukin-4 reversed the tolerance induced by the altered peptide ligand. Treatment,vith this altered peptide ligand selectively silences pathogenic T cells and actively signals for the efflux of other T cells recruited to the site of disease as a result of the production of interleukin-4 and the reduction of tumour-necrosis factor-alpha in the lesion.	STANFORD UNIV,MED CTR,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; NEUROCRINE BIOSCI,LA JOLLA,CA 92121; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB1 1QP,ENGLAND; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94305	Stanford University; Stanford University; Stanford University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Weizmann Institute of Science; Neurocrine Biosciences; University of Cambridge; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Waisman, Ari/C-7383-2015	Waisman, Ari/0000-0003-4304-8234; Steinman, Lawrence/0000-0002-2437-2250; O'Garra, Anne/0000-0001-9845-6134; Wraith, David/0000-0003-2147-5614	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GOLD DP, 1992, J IMMUNOL, V148, P1712; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; SELMAJ KW, 1990, J IMMUNOL, V144, P129; STEINMAN L, 1994, BEHRING I MITT, V94, P148; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGT AB, 1994, J IMMUNOL, V153, P1665; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	21	361	379	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					343	346		10.1038/379343a0	http://dx.doi.org/10.1038/379343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552189				2022-12-01	WOS:A1996TR32300058
J	Palevsky, PM; Bhagrath, R; Greenberg, A				Palevsky, PM; Bhagrath, R; Greenberg, A			Hypernatremia in hospitalized patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypernatremia; hospitalization; sodium; fluid therapy; water-electrolyte balance	HYPONATREMIA; DEHYDRATION	Objective: To determine the incidence, clinical characteristics, and outcome for general medical-surgical hospital patients with hypernatremia. Design: A prospective cohort study. Setting: A 942-bed urban university hospital. Patients: All patients who developed a serum sodium concentration of 150 mmol/L or greater during a 3-month observation period. Measurements: Daily fluid balance, mental status, and serum and urine electrolytes and osmolality. Results: 103 patients were identified. Eighteen patients were hypernatremic on hospital admission, and 85 developed hypernatremia during hospitalization. Patients who developed hypernatremia during hospitalization were younger than patients who developed hypernatremia before hospital admission (mean age +/- SD, 58.9 +/- 19.2 years compared with 76.6 +/- 16.6 years; P < 0.01) but did not differ in age from the patients of the general hospitalized population. Eighty-nine percent of patients who developed hypernatremia during hospitalization had urine concentrating defects, primarily as the result of the use of diuretics or of solute diuresis, whereas only 50% of patients who were hypernatremic on admission could be shown to have concentrating defects (P < 0.01). Fifty-five percent of all hypernatremic patients had increased insensible water losses, and 35% had increased enteral water losses. Eighty-six percent of patients with hospital-acquired hypernatremia lacked free access to water, 74% had enteral water intake of less than 1 L/d, and 94% received less than 1 L of intravenous electrolyte-free water per day during the development of hypernatremia. No supplemental electrolyte-free water was prescribed during the first 24 hours of hypernatremia in 49% of patients. The duration of hypernatremia was shorter in patients who were hypernatremic on admission (median duration, 3 days) than in patients with hospital-acquired hypernatremia (median duration, 5 days; P < 0.05). Mortality was 41% for all patients, but hypernatremia was judged to have contributed to mortality in only 16% of patients. Conclusions: Although the development of hypernatremia before hospital admission occurs primarily in geriatric patients, hospital-acquired hypernatremia was more common in our cohort and had an age distribution similar to that of the general hospitalized population. Hospital-acquired hypernatremia was primarily iatrogenic, resulting from inadequate and inappropriate prescription of fluids to patients with predictably increased water losses and impaired thirst or restricted free water intake or both. Treatment of hypernatremia is often inadequate or delayed. Efforts to manage hypernatremia better and altogether avoid hospital-acquired hypernatremia should focus on both physician education and the development of hospital systems to prevent errors in fluid prescription.	VET AFFAIRS MED CTR, MED SERV, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Palevsky, PM (corresponding author), UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, A919 SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400; Greenberg, Arthur/0000-0002-2838-8401				ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; BECK LH, 1987, ANN INTERN MED, V107, P768, DOI 10.7326/0003-4819-107-5-768; BRENNAN J, 1990, J CRIT ILLNESS, V5, P330; DAGGETT P, 1979, BRIT MED J, V1, P1177, DOI 10.1136/bmj.1.6172.1177; FITZSIMONS JT, 1976, KIDNEY INT, V10, P3, DOI 10.1038/ki.1976.74; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; HIMMELSTEIN DU, 1983, J AM GERIATR SOC, V31, P466, DOI 10.1111/j.1532-5415.1983.tb05118.x; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LONG CA, 1991, POSTGRAD MED J, V67, P643, DOI 10.1136/pgmj.67.789.643; MACDONALD NJ, 1989, BRIT MED J, V299, P1426, DOI 10.1136/bmj.299.6713.1426; MAHOWALD JM, 1981, J AM GERIATR SOC, V29, P177, DOI 10.1111/j.1532-5415.1981.tb01761.x; PALEVSKY PM, 1992, CURRENT THERAPY NEPH; Plum F, 1966, DIAGNOSIS STUPOR COM, V1st; SNYDER NA, 1987, ANN INTERN MED, V107, P309, DOI 10.7326/0003-4819-107-2-309; TIERNEY WM, 1986, J GEN INTERN MED, V1, P380, DOI 10.1007/BF02596422	16	212	227	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					197	+		10.7326/0003-4819-124-2-199601150-00002	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533994				2022-12-01	WOS:A1996TQ01600002
J	Celentano, DD; Nelson, KE; Suprasert, S; Eiumtrakul, S; Tulvatana, S; Kuntolbutra, S; Akarasewi, P; Matanasarawoot, A; Wright, NH; Sirisopana, N; Theetranont, C				Celentano, DD; Nelson, KE; Suprasert, S; Eiumtrakul, S; Tulvatana, S; Kuntolbutra, S; Akarasewi, P; Matanasarawoot, A; Wright, NH; Sirisopana, N; Theetranont, C			Risk factors for HIV-1 seroconversion among young men in northern Thailand	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; INFECTION; AIDS; AFRICA; FEMALE; PROSTITUTES; TYPE-1; SPREAD; UGANDA	Objective.-To identify behavioral and sociodemographic risk factors for incident human immunodeficiency virus-1 (HIV-1) infection among healthy young men in northern Thailand. Design.-Men inducted into military service in northern Thailand in May and November 1991 were followed at 6-month intervals until discharge 2 years later. Trained nonmilitary interviewers identified risk factors for HIV-1 infection through interviews with the men. Setting.-Thirteen military bases in northern Thailand. Participants.-A total of 1932 seronegative men, aged 19 to 23 years (average age, 21 years) at enrollment, conscripted into the Royal Thai Army and Air Force from six upper-northern Thai provinces. Main Outcome Measures.-Human immunodeficiency virus-1 seroincidence as determined through enzyme-linked immunosorbent assay and verified by Western blot, and univariate and multivariate analyses of risk factors related to H1V-1 incidence. Results.-A total of 85 men seroconverted to HIV-1 over the period of observation, giving an incidence rate of 2.43 per 100 person-years. Factors strongly associated with HIV-1 seroconversion were frequency of visits to female commercial sex workers (CSWs), sex with men, and incident sexually transmitted diseases (STDs). High frequency of condom use showed a significant (P<.001) protective effect for HIV-1 incidence among men with a history of recent sex with female CSWs in univariate analysis, but a multivariate model demonstrated no difference in HIV-1 seroconversion rates by consistency of condom use. Multivariate analysis incorporating condom use showed that having sex with men (adjusted relative risk [RR], 2.59; 95% confidence interval [CI], 1.08 to 6.25), having sex with CSWs (adjusted RR ranged from 2.54 [95% CI, 1.81 to 3.58] to 2.74 [95% CI, 1.56 to 4.81]), and incident STDs (adjusted RR, 2.38 [95% CI, 1.31 to 4.32]) to be predictors of incident HIV-1 infection. Substance use was not associated with HIV-1 seroconversion rates in multivariate analysis. Conclusion.-The HIV-1 incidence in this cohort of young men appears to be primarily attributable to having sex with female CSWs. Condom use provided some protection, although nor in multivariate analysis; however, condom use has previously been shown likely to be useful in preventing HIV-1 transmission. Thus, programs to increase effective condom use in brothels are essential. Efforts to extend condom use to non-CSW partners are especially needed. More effective prevention and treatment of STDs may also be necessary to decrease HIV-1 infection in this population.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CHIANG MAI UNIV,DEPT FAMILY MED,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,OFF PRESIDENT,CHIANG MAI 50000,THAILAND; MINIST PUBL HLTH,ROYAL THAI AF,CHIANG MAI,THAILAND; MINIST PUBL HLTH,ROYAL THAI ARMY,CHIANG MAI,THAILAND; ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ; ARMED FORCES RES INST MED SCI,BANGKOK 10400,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	Celentano, DD (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,624 N BROADWAY,BALTIMORE,MD 21205, USA.							AKARASEWI P, 1991, 9TH NAT THAI SEM EP; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BEYRER C, 1995, AIDS, V9, P171, DOI 10.1097/00002030-199509020-00009; BROWN T, 1994, AIDS, V8, pS131; CAMERON DW, 1989, LANCET, V2, P403; CARAEL M, 1988, AIDS, V2, P201; CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270; CELENTANO DD, 1994, AIDS, V8, P533, DOI 10.1097/00002030-199404000-00018; CELENTANO DD, 1993, AIDS, V7, P1647, DOI 10.1097/00002030-199312000-00016; CONANT M, 1986, JAMA-J AM MED ASSOC, V255, P1706, DOI 10.1001/jama.1986.03370130062013; CONANT MA, 1984, SEX TRANSM DIS, V11, P94, DOI 10.1097/00007435-198404000-00009; CORWIN JA, 1991, 7TH INT C AIDS FLOR; DESJARLAIS D, 1991, 8TH INT C AIDS FLOR; ESTEBANEZ P, 1989, 5 INT C AIDS MONTR; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HARRISON L, 1990, 6TH INT C AIDS SAN F; HOOYKAAS C, 1989, 5 INT C AIDS MONTR; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HUNTER DJ, 1993, EPIDEMIOLOGY, V4, P63, DOI 10.1097/00001648-199301000-00012; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; KUNANUSONT C, 1991, 7TH INT C AIDS FLOR; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LINDAN C, 1991, AIDS, V5, P993, DOI 10.1097/00002030-199108000-00011; MCKEGANEY NP, 1994, AIDS, V8, P1215, DOI 10.1097/00002030-199409000-00002; MEYER H, 1990, AM MED NEWS     0727; MOODIE R, 1993, AIDS, V7, P1543, DOI 10.1097/00002030-199312000-00001; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; NOPKESORN T, 1993, 9TH INT C AIDS 4 STD; NZILA N, 1990, 6TH INT C AIDS SAN F; PADIAN NS, 1987, REV INFECT DIS, V9, P947; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO; PICKERING H, 1992, SOC SCI MED, V34, P75, DOI 10.1016/0277-9536(92)90069-3; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P2094, DOI 10.1001/jama.254.15.2094; RODRIGUES LC, 1993, JAMA-J AM MED ASSOC, V269, P870; RODRIGUES LC, 1992, BRIT MED J, V305, P364, DOI 10.1136/bmj.305.6849.364-a; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; SAWANPANYALERT P, 1994, AIDS, V8, P825, DOI 10.1097/00002030-199406000-00016; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; SITTITRAI W, 1994, AIDS, V8, pS143; SWADDIWUDHIPONG W, 1990, SE ASIAN J TROP MED, V2, P447; THANPRASERTSUK S, 1991, 7TH INT C AIDS FLOR; THOMAS MR, 1990, 6TH INT C AIDS SAN F; UNGCHUSAK K, 1991, 7 INT C AIDS FLOR; UNGPHAKORN J, 1994, AIDS S2, V8, pS133; VANICHSENI S, 1990, 6TH INT C AIDS SAN F; VANLANDINGHAM MJ, 1992, 1992 ANN M POP ASS A; WANGROONGSARB Y, 1985, SE ASIAN J TROP MED, V16, P717; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WENIGER BG, 1994, AIDS, V8, P1007, DOI 10.1097/00002030-199407000-00020; YU XF, 1995, J VIROL, V69, P4649, DOI 10.1128/JVI.69.8.4649-4655.1995; 1990, PRESENTATION FINDING	60	57	58	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					122	127		10.1001/jama.275.2.122	http://dx.doi.org/10.1001/jama.275.2.122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN280	8531307				2022-12-01	WOS:A1996TN28000028
J	Moss, M; Bucher, B; Moore, FA; Moore, EE; Parsons, PE				Moss, M; Bucher, B; Moore, FA; Moore, EE; Parsons, PE			The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APACHE-II; TRAUMA; PROGNOSIS; MORTALITY; SYSTEM	Objective.-To determine the effect of a history of chronic alcohol abuse on the incidence of acute respiratory distress syndrome (ARDS) and in-hospital mortality. Design.-Prospective cohort study. Patients.-A total of 351 medical and surgical intensive care unit patients with one of seven at-risk diagnoses for the development of ARDS. Main Outcome Measures.-The development of ARDS and in-hospital mortality. Results.-Of the 351 patients enrolled in the study, the incidence of ARDS in patients with a history of alcohol abuse was significantly higher than in patients without a history of alcohol abuse (43% vs 22%) (P<.001; relative risk [RR], 1.98; 95% confidence interval [Cl], 1.32 to 2.85), in patients with sepsis, ARDS developed in 52% of the patients with a prior history of alcohol abuse compared with only 20% in patients without a history of alcohol abuse (P<.001; RR, 2.59; 95% Cl, 1.29 to 5.12). Fifty-one percent (52/102) of the patients who developed ARDS died compared with only 14% (36/249) of patients who did not develop ARDS (P<.001). In the subset of patients who developed ARDS, the in-hospital mortality rate was 65% in patients with a prior history of alcohol abuse. This mortality rate was significantly higher (P=.003) than the mortality rate in patients without a history of alcohol abuse (36%). Conclusions.-A prior history of chronic alcohol abuse significantly increases the risk of developing ARDS in critically ill patients with an identified at-risk diagnosis. Our results may be useful in the earlier and more accurate identification of patients at high risk for developing ARDS.	DENVER GEN HOSP,DEPT MED,DENVER,CO 80204; DENVER GEN HOSP,DEPT SURG,DENVER,CO 80204; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT BIOSTAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DENVER,CO 80262	Denver Health Medical Center; Denver Health Medical Center; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [K08 HL01849, HL40784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001849, P50HL040784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLA AK, 1993, ADV EXP MED BIOL, V335, P165; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Capps JA, 1923, J AMER MED ASSOC, V80, P0750, DOI 10.1001/jama.1923.02640380014005; Doyle R. L., 1995, Journal of Investigative Medicine, V43, p143A; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; HALLENGREN B, 1978, ACTA MED SCAND, V204, P43; HANLEY ME, 1994, SEMIN RESP CRIT CARE, V15, P260; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; HUDSON LD, 1994, SEM RESP CRIT CARE M, V15, P254, DOI 10.1055/s-2007-1006371; HUDSON LD, 1982, CLIN CHEST MED, V3, P195; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KELSEY JL, 1986, METHODS OBSERVATIONA, P285; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MATUSCHAK GM, 1987, J CRIT CARE, V2, P162, DOI 10.1016/0883-9441(87)90003-7; MATUSCHAK GM, 1990, AM REV RESPIR DIS, V141, P1296, DOI 10.1164/ajrccm/141.5_Pt_1.1296; MCANENA OJ, 1992, J TRAUMA, V33, P504, DOI 10.1097/00005373-199210000-00003; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MOORE EE, 1981, J TRAUMA, V21, P439; MOSS M, 1995, CRIT CARE MED, V23, P1629, DOI 10.1097/00003246-199510000-00006; MOSS M, 1994, AM J RESP CRIT CARE, V149, pA417; PARSONS PE, 1992, AM REV RESPIR DIS, V146, P694, DOI 10.1164/ajrccm/146.3.694; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; RINALDO JE, 1986, CHEST, V90, P470, DOI 10.1378/chest.90.4.470; 1985, NATIONAL I ALCOHOL A	26	318	321	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					50	54		10.1001/jama.275.1.50	http://dx.doi.org/10.1001/jama.275.1.50			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM238	8531287				2022-12-01	WOS:A1996TM23800022
J	CORREABORDES, J; NURSE, P				CORREABORDES, J; NURSE, P			P25(RUM1) ORDERS S-PHASE AND MITOSIS BY ACTING AS AN INHIBITOR OF THE P34(CDC2) MITOTIC KINASE	CELL			English	Article							P34CDC2 PROTEIN-KINASE; FISSION YEAST; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ENCODES; CDC13; CDC2+	p25(rum1) from the fission yeast S. pombe is shown to act as a specific in vitro inhibitor of the p34(cdc2)/p56(cdc13) mitotic kinase. It is also shown that early G1 cells contain p25(rum1), which associates with and inhibits the mitotic kinase, and maintains p56(cdc13) miotic B cyclin at a low level, ensuring that these cells do not undergo a premature lethal entry into mitosis. A high level of p25(rum1) in G2 cells inhibits the p34(cdc2)/p56(cdc13) kinase that removes the block preventing a further S phase and leads to repeated rounds of DNA replication. Thus, the cyclin-dependent kinase inhibitor p25(rum1), acting on the p34(cdc2) mitotic kinase, plays an important role in ensuring the correct sequence of S phase and mitosis during the cell cycle.			CORREABORDES, J (corresponding author), IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Correa-Bordes, Jaime/H-5545-2015	Correa-Bordes, Jaime/0000-0002-1961-4761				ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASI G, 1995, MOL CELL BIOL, V15, P2028; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; FISHER DL, 1996, IN PRESS EMBO J; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OBARAISHIHARA T, 1994, EMBO J, V13, P1863, DOI 10.1002/j.1460-2075.1994.tb06455.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4	45	175	177	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1001	1009		10.1016/0092-8674(95)90215-5	http://dx.doi.org/10.1016/0092-8674(95)90215-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521500	Bronze			2022-12-01	WOS:A1995TK74500018
J	SMEDLEY, SR; EISNER, T				SMEDLEY, SR; EISNER, T			SODIUM UPTAKE BY PUDDLING IN A MOTH	SCIENCE			English	Article							BUTTERFLIES	Male Lepidoptera commonly visit stands of water to drink, a behavior known as puddling. Males of the notodontid moth Gluphisia septentrionis routinely puddle for hours, imbibing hundreds of gut-loads and voiding the fluid as repetitive anal jets. Cationic analyses showed puddling to lead to systemic sodium gain, a potential benefit to Gluphisia, whose larval food plant is low in sodium. Male Gluphisia are specialized for puddling, possessing a wide oral slit and a highly expanded enteric surface. The acquired sodium is transferred to the female at mating, for eventual incorporation into the eggs. Sodium acquisition may be the primary function of puddling in Lepidoptera.			SMEDLEY, SR (corresponding author), CORNELL UNIV, NEUROBIOL & BEHAV SECT, SEELEY G MUDD HALL, ITHACA, NY 14853 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI002908] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 02908] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER P H, 1982, Journal of the Lepidopterists' Society, V36, P161; ADLER PH, 1982, CAN J ZOOL, V60, P322, DOI 10.1139/z82-043; ARMS K, 1974, SCIENCE, V185, P372, DOI 10.1126/science.185.4148.372; BOTKIN DB, 1973, P NATL ACAD SCI USA, V70, P2745, DOI 10.1073/pnas.70.10.2745; Denton D., 1984, HUNGER SALT ANTHR PH, V1st; Harvey W.R., 1980, P105; JONES RL, 1985, MINERAL LICKS; KRIZEK G O, 1989, Journal of Research on the Lepidoptera, V27, P143; LABARBERA M, 1982, AM SCI, V70, P54; LIKENS GE, 1970, YALE U SCH FORESTRY, V79; Mattson W.J., 1987, P105; McDowell L.R., 1992, MINERALS ANIMAL HUMA; MENEELY GR, 1976, NUTR REV, V34, P225; MILLER JS, 1991, B AM MUS NAT HIST, P1; PHILLIPS JE, 1986, ADV INSECT PHYSIOL, V19, P329; PIVNICK KA, 1987, PHYSIOL ENTOMOL, V12, P461, DOI 10.1111/j.1365-3032.1987.tb00773.x; PLETSCHER DH, 1982, THESIS YALE U NEW HA; POULTON EB, 1917, P ENTOMOL SOC LONDON, V65, P77; REINTHAL WJ, 1963, J LEPID SOC, V17, P35; SMEDLEY SR, 1993, THESIS CORNELL U ITH; 1988, ICAP 61 OPERATORS MA	21	84	98	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1816	1818		10.1126/science.270.5243.1816	http://dx.doi.org/10.1126/science.270.5243.1816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525374				2022-12-01	WOS:A1995TK47600044
J	AITCHISON, TC; SIREL, JM; WATT, DC; MACKIE, RM				AITCHISON, TC; SIREL, JM; WATT, DC; MACKIE, RM			PROGNOSTIC TREES TO AID PROGNOSIS IN PATIENTS WITH CUTANEOUS MALIGNANT-MELANOMA	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL	Objectives-To design user friendly guides to prognosis for patients who have had invasive primary cutaneous malignant melanomas surgically excised. Design--Adaptation of the classification tree method was used to derive prognostic trees for four different subgroups of malignant melanoma patients in whom known and possible prognostic variables interacted in different ways. Setting-Scotland. Subjects-Statistical modelling for prognostic trees was based on 1978 patients whose primary malignant melanoma was first diagnosed in 1979-86 for whom five year follow up and all relevant clinical pathological data were available, The resultant model was validated with 300 patients first diagnosed in 1987 for whom the same information was available. Main outcome measures--Actual and predicted rate of survival after diagnosis of primary cutaneous malignant melanoma. Results--The four subgroups of patients were men and women with ulcerated and non-ulcerated cutaneous primary melanomas. Validation of the model showed excellent agreement between actual status of patients in the relevant subgroups and their status as predicted by the model. Conclusions--The prognostic trees are simple to use and give more accurate prognosis for individual patients than is currently available from tumour thickness alone.	UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow; University of Glasgow								BALCH CM, 1992, CUTANEOUS MELANOMA, P165; Brieman L, 1984, CLASSIFICATION REGRE; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; EVERITT BS, 1989, STATISTICAL METHODS, P83; MACKIE RM, 1995, BRIT J CANCER, V71, P173, DOI 10.1038/bjc.1995.35; RIGEL DS, 1991, DERMATOL CLIN, V9, P631; VOSSAERT KA, 1992, J AM ACAD DERMATOL, V26, P429, DOI 10.1016/0190-9622(92)70068-Q	7	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1536	1539		10.1136/bmj.311.7019.1536	http://dx.doi.org/10.1136/bmj.311.7019.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520396	Green Published			2022-12-01	WOS:A1995TK21400023
J	HARRISON, MJ; VANBUUREN, ML				HARRISON, MJ; VANBUUREN, ML			A PHOSPHATE TRANSPORTER FROM THE MYCORRHIZAL FUNGUS GLOMUS VERSIFORME	NATURE			English	Article							DIRECT LINEAR PLOT; SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE MUTATION; INORGANIC-PHOSPHATE; NUCLEOTIDE-SEQUENCE; PHOSPHORUS UPTAKE; PLANTS; ROOTS; PARAMETERS; HYPHAE	VESICULAR-arbuscular (A) mycorrhizal fungi form symbiotic associations with the roots of most terrestrial plants, including many agriculturally important crop species(1-3). The fungi colonize the cortex of the root to obtain carbon from their plant host, while assisting the plant with the uptake of phosphate and other mineral nutrients from the soil(2-5). This association is beneficial to the plant, because phosphate is essential for plant growth and development, especially during growth under nutrient-limiting conditions(2,6-8). Molecular genetic studies of these fungi and their interaction with plants have been limited owing to the obligate symbiotic nature of the VA fungi, so the molecular mechanisms underlying fungal-mediated uptake and translocation of phosphate from the soil to the plant remain unknown. Here we begin to investigate this process by identifying a complementary DNA that encodes a transmembrane phosphate transporter (GvPT) from Glomus versiforme, a VA mycorrhizal fungus. The function of the protein encoded by GvPT was confirmed by complementation of a yeast phosphate transport mutant. Expression of GvPT was localized to the external hyphae of G. versiforme during mycorrhizal associations, these being the initial site of phosphate uptake from the soil.			HARRISON, MJ (corresponding author), SAMUEL ROBERTS NOBLE FDN INC,DIV PLANT BIOL,2510 SAM NOBLE PKWY,ARDMORE,OK 73401, USA.							AMMERER G, 1983, METHOD ENZYMOL, V101, P192; Beever R. E., 1980, Advances in Botanical Research, V8, P127, DOI 10.1016/S0065-2296(08)60034-8; BERHE A, 1995, EUR J BIOCHEM, V227, P566, DOI 10.1111/j.1432-1033.1995.tb20426.x; Bethlenfalvay Gabor J., 1992, V54, P1; BRADY JF, 1989, COMPUT METH PROG BIO, V28, P271, DOI 10.1016/0169-2607(89)90160-0; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; ECKENRODE VK, 1985, J MOL EVOL, V21, P259, DOI 10.1007/BF02102358; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Harley J.L., 1983, MYCORRHIZAL SYMBIOSI; HARRISON MJ, 1994, PLANT J, V6, P9, DOI 10.1046/j.1365-313X.1994.6010009.x; JAKOBSEN I, 1992, NEW PHYTOL, V120, P371, DOI 10.1111/j.1469-8137.1992.tb01077.x; JEFFRIES P, 1987, CRC CR REV BIOTECHN, V5, P319, DOI 10.3109/07388558709079476; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; MANN BJ, 1989, GENE, V83, P281, DOI 10.1016/0378-1119(89)90114-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; PEARSON JN, 1993, NEW PHYTOL, V124, P489, DOI 10.1111/j.1469-8137.1993.tb03840.x; PEARSON JN, 1993, NEW PHYTOL, V124, P481, DOI 10.1111/j.1469-8137.1993.tb03839.x; PFLEGER FL, 1994, APS S SERIES; SANDERS FE, 1971, NATURE, V233, P278, DOI 10.1038/233278c0; SIMON L, 1992, APPL ENVIRON MICROB, V58, P291, DOI 10.1128/AEM.58.1.291-295.1992; SMITH SE, 1990, NEW PHYTOL, V114, P1, DOI 10.1111/j.1469-8137.1990.tb00370.x; SMITH SE, 1988, ANNU REV PLANT PHYS, V39, P221, DOI 10.1146/annurev.arplant.39.1.221; SMITH SSE, 1980, BIOL REV, V55, P475, DOI 10.1111/j.1469-185X.1980.tb00701.x; THOMSON BD, 1990, NEW PHYTOL, V116, P647, DOI 10.1111/j.1469-8137.1990.tb00550.x; TOHE A, 1974, J BACTERIOL, V120, P608, DOI 10.1128/JB.120.2.608-617.1974; UEDA Y, 1975, MOL GEN GENET, V136, P255, DOI 10.1007/BF00334020; VERSAW WK, 1995, GENE, V153, P135, DOI 10.1016/0378-1119(94)00814-9; [No title captured]	30	378	410	3	97	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					626	629		10.1038/378626a0	http://dx.doi.org/10.1038/378626a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524398				2022-12-01	WOS:A1995TJ22100080
J	GLISE, B; BOURBON, H; NOSELLI, S				GLISE, B; BOURBON, H; NOSELLI, S			HEMIPTEROUS ENCODES A NOVEL DROSOPHILA MAP KINASE KINASE, REQUIRED FOR EPITHELIAL-CELL SHEET MOVEMENT	CELL			English	Article							LARVAL CUTICLE; ZYGOTIC LOCI; X-CHROMOSOME; PROTEIN; MELANOGASTER; PATTERN; MORPHOGENESIS; PURIFICATION; PHENOTYPES; LIBRARIES	During Drosophila embryogenesis, a cell sheet movement, dorsal closure, allows establishment of the dorsal epidermis. In this morphogenetic process, lateral epithelia undergo a dramatic movement toward the dorsal midline. In the mutant hemipterous (hep), spreading of the epithelia is blocked; in genetically sensitized hep embryos, cell sheet movement can be arrested at any time, indicating hep requirement in maintaining this morphogenetic activity. Further, hep is required for expression in the dorsal epithelium edges of another dorsal closure gene, puckered, The HEP protein is homologous to the Jun kinase kinase (JNKK) group of mitogen-activated protein kinase kinases (MAPKKs), These data suggest that hep functions in a novel Drosophila MAPK pathway, controlling puckered expression and morphogenetic activity of the dorsal epidermis.			GLISE, B (corresponding author), CNRS,CTR DEV BIOL,UNITE MIXTE RECH 9925,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE.			Noselli, stephane/0000-0002-7296-324X; Glise, Bruno/0000-0001-9135-8822				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ARIAS AM, 1993, DEV DROSOPHILA MELAN, V1, P517; ASHBUMER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHOU TB, 1992, GENETICS, V131, P643; COSTA M, 1993, DEV DROSOPHILA; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAS MS, 1992, PEDIATR NEUROSURG, V18, P229, DOI 10.1159/000120670; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FEHON RG, 1994, DEVELOPMENT, V120, P545; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LEPTIN M, 1994, CURR BIOL, V4, P709, DOI 10.1016/S0960-9822(00)00156-1; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; NOSELLI S, 1992, MOL CELL BIOL, V12, P724, DOI 10.1128/MCB.12.2.724; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; RAMAIN P, 1993, DEVELOPMENT, V149, P1277; RAY RP, 1991, DEVELOPMENT, V113, P35; RING JM, 1993, DEVELOPMENT S, V119, P251; SAMBROOK S, 1989, MOL CLONING LABORATO; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TERRACOL R, 1994, GENETICS, V138, P165; Thummel CS, 1992, DROS INF SERV, V71, P150; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VALLE D, 1992, INSECT BIOCHEM MOLEC, V23, P457; Wieschaus E., 1986, P199; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WINICK J, 1993, DEVELOPMENT, V119, P1055; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	56	283	289	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					451	461		10.1016/0092-8674(95)90123-X	http://dx.doi.org/10.1016/0092-8674(95)90123-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521475	Bronze			2022-12-01	WOS:A1995TC97700015
J	TENG, BB; BURANT, CF; DAVIDSON, NO				TENG, BB; BURANT, CF; DAVIDSON, NO			MOLECULAR-CLONING OF AN APOLIPOPROTEIN-B MESSENGER-RNA EDITING PROTEIN	SCIENCE			English	Article							SMALL-INTESTINE; CHANNELS; BINDING; TISSUE; SITE; RAT	Mammalian apolipoprotein B (apo B) exists in two forms, each the product of a single gene. The shorter form, apo B48, arises by posttranscriptional RNA editing whereby cytidine deamination produces a UAA termination codon. A full-length complementary DNA clone encoding an apo B messenger RNA editing protein (REPR) was isolated from rat small intestine. The 229-residue protein contains consensus phosphorylation sites and leucine zipper domains. HepG2 cell extracts acquire editing activity when mixed with REPR from oocyte extracts. REPR is essential for apo B messenger RNA editing, and the isolation and characterization of REPR may lead to the identification of other eukaryotic RNA editing proteins.	UNIV CHICAGO,DEPT MED,MC 4076,CHICAGO,IL 60637	University of Chicago			Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, K04HL002166, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO-4 HL-02166, HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; PEASE RJ, 1990, J BIOL CHEM, V265, P553; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SUMIKAWA K, 1984, EMBO J, V3, P2291, DOI 10.1002/j.1460-2075.1984.tb02128.x; TENG B, UNPUB; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; WU JH, 1990, J BIOL CHEM, V265, P12312	29	501	522	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1816	1819		10.1126/science.8511591	http://dx.doi.org/10.1126/science.8511591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511591				2022-12-01	WOS:A1993LH20500054
J	SAHA, S; BRICKMAN, JM; LEHMING, N; PTASHNE, M				SAHA, S; BRICKMAN, JM; LEHMING, N; PTASHNE, M			NEW EUKARYOTIC TRANSCRIPTIONAL REPRESSORS	NATURE			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; YEAST; ACTIVATORS; DROSOPHILA; PROTEIN; INVITRO; DORSAL; INITIATION; SEQUENCES	TRANSCRIPTIONAL activating sequences have been described1 that are encoded by parts of the genome of Escherichia coli. These acidic peptides, fused to a DNA-binding fragment of the yeast transcriptional activator GAL4, activate transcription of a gene in a wide array of eukaryotes, provided that gene bears GAL4-binding sites nearby2-4. Here we describe an E. coli-encoded sequence that, when attached to the same DNA-binding fragment (GAL4(1-147)), converts that fragment into a repressor. Thus, as assayed in yeast or in vitro in yeast extracts, this molecule represses transcription when bound upstream of a variety of different activators. Two additional repressing regions that work when tethered upstream, a multiple mutant derivative of the original isolate and a synthetic peptide are, like the original isolate, highly basic. At least one activator can be inhibited by the mutant but not by the parental repressing region. These and other findings suggest that these repressing regions interact with and inhibit the activity of activating regions bound nearby on DNA.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University				Brickman, Joshua/0000-0003-1580-7491				DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KAMENS J, 1991, NEW BIOL, V3, P1005; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1992, GENETIC SWITCH GENE; RAY RP, 1991, DEVELOPMENT, V113, P35; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; van Holde K.E., 1989, CHROMATIN; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	23	86	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					648	652		10.1038/363648a0	http://dx.doi.org/10.1038/363648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510759				2022-12-01	WOS:A1993LH13900062
J	PETER, M; GARTNER, A; HORECKA, J; AMMERER, G; HERSKOWITZ, I				PETER, M; GARTNER, A; HORECKA, J; AMMERER, G; HERSKOWITZ, I			FAR1 LINKS THE SIGNAL-TRANSDUCTION PATHWAY TO THE CELL-CYCLE MACHINERY IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; POSITIVE FEEDBACK; MATING-PHEROMONE; GENE; START; STE12; DIVISION; ARREST; CLN2	Alpha factor induces arrest of yeast a cells in G1 and transcription of genes involved in mating. Prior work indicates that FUS3, a member of the MAP kinase family, and FAR1, whose molecular activity is unknown, contribute to cell cycle arrest by inhibiting G1 cyclins. Here we show that FAR1 is a substrate for FUS3 and that this phosphorylation regulates association of FAR1 with CDC28-CLN2 kinase. We show also that FAR1 is phosphorylated in vitro by the CDC28-CLN2 complex and in vivo in a CDC28-dependent manner. Mutational analysis of FAR1 reveals a correlation between its ability to associate with CDC28-CLN2 and to arrest the cell cycle. These results suggest that FAR1 protein is the link between the signaling pathway and the cell cycle machinery.	UNIV VIENNA,LUDWIG BOLTZMANN FORSCH STELLE,INST BIOCHEM & MOLEK ZELLBIOL,A-1030 VIENNA,AUSTRIA; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143	Ludwig Boltzmann Institute; University of Vienna; University of Oregon; University of Oregon; University of California System; University of California San Francisco	PETER, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,PROGRAM GENET,SAN FRANCISCO,CA 94143, USA.			Gartner, Anton/0000-0003-4639-9902	NIGMS NIH HHS [GM31286, GM30027] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031286, R01GM030027] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOL MOL; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIZUELA L, 1987, EMBO J, V6, P3707; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CHANG F, 1991, THESIS U CALIFORNIA; CLAERKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, CELL, V258, P478; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Ducommun B, 1991, Semin Cell Biol, V2, P233; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; FUJIMURA H, 1990, CURR GENET, V18, P395, DOI 10.1007/BF00309907; FUJIMURA H, 1991, CURR GENET, V2, P205; FUTCHER BA, 1991, SEMIN CELL BIOL, V2, P205; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GU Y, 1992, EMBO J, V11, P3996; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARLOW E, 1988, ANTIBODIES LABORATOR; HICKS JB, 1976, GENETICS, V83, P245; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cb.07.110191.003411; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NEIMAN AM, 1990, CELL REGUL, V1, P391, DOI 10.1091/mbc.1.5.391; OGAS J, 1992, THESIS U CALIFORNIA; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1980, GENETICS, V95, P561; Reed SI, 1991, CURR OPIN GENET DEV, V1, P391, DOI 10.1016/S0959-437X(05)80305-3; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUBIN G, 1975, METHOD CELL BIOL, P45; Sambrook J., 1989, MOL CLONING LAB MANU; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; Sherman F., 1982, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprague George F. Jr., 1992, Current Biology, V2, P587, DOI 10.1016/0960-9822(92)90159-8; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VALDIVIESO HM, 1993, MOL CELL BIOL, V13, P1013; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P100; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	74	309	311	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					747	760		10.1016/0092-8674(93)90254-N	http://dx.doi.org/10.1016/0092-8674(93)90254-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500168				2022-12-01	WOS:A1993LD83000013
J	BUDAY, L; DOWNWARD, J				BUDAY, L; DOWNWARD, J			EPIDERMAL GROWTH-FACTOR REGULATES P21(RAS) THROUGH THE FORMATION OF A COMPLEX OF RECEPTOR, GRB2 ADAPTER PROTEIN, AND SOS NUCLEOTIDE EXCHANGE FACTOR	CELL			English	Article							AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASE; RAS PROTEINS; P21RAS; ONCOGENE; STIMULATION; ACTIVATION; GDP; SIMILARITY	Antisera against murine Son of sevenless (Sos) recognize a protein of M(r) 155,000 in rat-1 fibroblasts with specific guanine nucleotide exchange activity toward p21c-Ha-ras. Epidermal growth factor (EGF) receptor coimmunoprecipitates with Sos from EGF-stimulated, but not quiescent, cells. The SH2 and SH3 domain-containing ''adapter'' protein Grb2 is also found in Sos immunoprecipitates in an EGF-inducible manner. In vitro reconstitution shows that Grb2 is required for the binding of activated EGF receptor to Sos. A phosphopeptide corresponding to tyrosine 1068 of the EGF receptor blocks both the assembly of the complex and EGF stimulation of nucleotide exchange on p21ras in a permeabilized cell system. These results suggest that EGF-induced activation of nucleotide exchange on p21ras proceeds through the recruitment of cytosolic Sos to a complex with EGF receptor and Grb2 at the plasma membrane.			BUDAY, L (corresponding author), IMPERIAL CANC RES FUND, SIGNAL TRANSDUCT LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Downward, Julian/0000-0002-2331-4729				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN S, 1982, J BIOL CHEM, V257, P1523; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GATES RE, 1985, BIOCHEMISTRY-US, V24, P5209, DOI 10.1021/bi00340a038; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAVES JD, 1991, J IMMUNOL, V146, P3709; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HARLOW E, 1988, ANTIBODIES LABORATOR; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUROYA K, 1992, ONCOGENE, V7, P277; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TORTI M, 1992, J BIOL CHEM, V267, P8293; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	1061	1089	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					611	620		10.1016/0092-8674(93)90146-H	http://dx.doi.org/10.1016/0092-8674(93)90146-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490966				2022-12-01	WOS:A1993LA74300020
J	MADAN, I				MADAN, I			PREEMPLOYMENT CHEST RADIOGRAPHY FOR HEALTH-SERVICE STAFF - WHO NEEDS IT	BRITISH MEDICAL JOURNAL			English	Article							TUBERCULOSIS				MADAN, I (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT OCCUPAT HLTH,LONDON SE1 7EH,ENGLAND.			madan, ira/0000-0003-2200-7329				COCKCROFT A, 1990, BRIT MED J, V300, P1723; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; 1990, BMJ, V300, P995; 1992, THORAX, V47, P770	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1041	1042		10.1136/bmj.306.6884.1041	http://dx.doi.org/10.1136/bmj.306.6884.1041			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490499	Green Published, Bronze			2022-12-01	WOS:A1993KY44800021
J	CARDOZO, L				CARDOZO, L			IS ROUTINE INDUCTION OF LABOR AT TERM EVER JUSTIFIED	BRITISH MEDICAL JOURNAL			English	Article							PROLONGED PREGNANCY	Balancing the risks of prolonged gestation against those of induced labour is difficult. Risks to the fetus increase slightly after 42 weeks' gestation but women having labour induced are more likely to have instrumental deliveries or babies with low Apgar scores. Since many women are now expressing a preference for minimal interference in childbirth the most acceptable management of post-term pregnancy seems to be increased fetal surveillance. Each case needs to be considered individually and it is important that the woman is involved in the decision to induce.			CARDOZO, L (corresponding author), UNIV LONDON KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND.							AUGENSEN K, 1987, BRIT MED J, V294, P1192, DOI 10.1136/bmj.294.6581.1192; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P683, DOI 10.3109/00016348909006139; BOYD ME, 1988, AM J OBSTET GYNECOL, V158, P334, DOI 10.1016/0002-9378(88)90150-0; CARDOZO L, 1986, BMJ-BRIT MED J, V293, P1059, DOI 10.1136/bmj.293.6554.1059; CHAPPATTE O, 1992, LANCET, V339, P122; GIBB DMF, 1982, BRIT J OBSTET GYNAEC, V89, P292, DOI 10.1111/j.1471-0528.1982.tb04698.x; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; KELLEHER C, IN PRESS J OBSTET GY; MCCOLGIN SW, 1990, OBSTET GYNECOL, V76, P678; PEARCE JM, 1991, OBSTET GYNECOL, V77, P204, DOI 10.1097/00006250-199102000-00008; SAUNDERS N, 1991, LANCET, V338, P1190, DOI 10.1016/0140-6736(91)92044-3	11	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					840	841		10.1136/bmj.306.6881.840	http://dx.doi.org/10.1136/bmj.306.6881.840			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490378	Green Published, Bronze			2022-12-01	WOS:A1993KV34800025
J	Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ				Goulmy, E; Schipper, R; Pool, J; Blokland, E; Falkenburg, JHF; Vossen, J; Gratwohl, A; Vogelsang, GB; vanHouwelingen, HC; vanRood, JJ			Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE DISTRIBUTION; LYMPHOCYTES; TOLERANCE; LEUKEMIA; CELLS	Background. Graft-versus-host disease (GVHD) can be a major complication of allogeneic bone marrow transplantation even when the donor and recipient are siblings and share identical major histocompatibility antigens. The explanation may be a mismatch of minor histocompatibility antigens. We previously characterized five minor histocompatibility antigens, HA-1, 2, 3, 4, and 5, that are recognized by T cells in association with the major histocompatibility antigens HLA-A1 and A2. Methods. We collected peripheral-blood leukocytes from 148 bone marrow recipients and their sibling donors, who were genotypically HLA identical. Fifty pairs were positive for HLA-A1, 117 were positive for HLA-A2, and 19 were positive for both. The pairs were typed with cytotoxic-T-cell clones specific for minor histocompatibility antigens HA-1, 2, 3, 4, and 5. Results. Mismatches of HA-3 were equally distributed among recipients in whom GVHD developed and those in whom it did not. By contrast, a mismatch of only HA-1 was significantly correlated with GVHD of grade II or higher (odds ratio, infinity; P = 0.02) in adults. One or more mismatches of HA-1, 2, 4, and 5 were also significantly associated with GVHD (odds ratio, infinity; P = 0.006) in adults. These associations were not observed in children. Conclusions. A mismatch of minor histocompatibility antigen HA-1 can cause GVHD in adult recipients of allogeneic bone marrow from HLA-identical donors. Prospective HA-1 typing may improve donor selection and identify recipients who are at high risk for GVHD. (C) 1996, Massachusetts Medical Society.	UNIV LEIDEN HOSP,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT PEDIAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT MED STAT,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,EUROPDONOR FDN,2300 RC LEIDEN,NETHERLANDS; KANTONSSPITAL,DIV HEMATOL,DEPT RES,CH-4031 BASEL,SWITZERLAND; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Kantonsspital Aarau AG (KSA); University of Basel; Johns Hopkins University; Johns Hopkins Medicine	Goulmy, E (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHEMATOL & BLOOD BANK,2300 RC LEIDEN,NETHERLANDS.		van houwelingen, hans c/C-1872-2008	van houwelingen, hans c/0000-0002-0494-4637				ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BEATTY PG, 1990, GRAFT VERSUS HOST DI, V12, P415; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BRESOW NE, 1980, IARC SCI PUBLICATION, V32; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1992, INT IMMUNOL, V4, P53, DOI 10.1093/intimm/4.1.53; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; ELKINS WL, 1987, BONE MARROW TRANSPL, V1, P397; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, 1982, HLA TYPING METHODOLO, V2, P105; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; NIEDERWIESER D, 1993, BLOOD, V81, P2200; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VANLOCHEM E, IN PRESS TRANSPLANT; VOSSEN JM, 1990, GRAFT VERSUS HOST DI, V12, P403; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1989, BONE MARROW TRANSPL, V4, P221	28	445	458	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					281	285		10.1056/NEJM199602013340501	http://dx.doi.org/10.1056/NEJM199602013340501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532022				2022-12-01	WOS:A1996TV69500001
J	OBrien, CP; McLellan, AT				OBrien, CP; McLellan, AT			Myths about the treatment of addiction	LANCET			English	Article							ALCOHOL DEPENDENCE; HYPERTENSION; NALTREXONE				OBrien, CP (corresponding author), UNIV PENN,VA MED CTR,DEPT PSYCHIAT,3900 CHESTNUT ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005186] Funding Source: NIH RePORTER; NIDA NIH HHS [P50-DA-05186] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALTERMAN AI, 1991, J NERV MENT DIS, V179, P401, DOI 10.1097/00005053-199107000-00003; Armor D. J., 1976, ALCOHOLISM TREATMENT; Ball J. C., 1991, EFFECTIVENESS METHAD; CLARK LT, 1991, AM HEART J, V121, P664, DOI 10.1016/0002-8703(91)90443-L; DEKKER FW, 1993, EUR RESPIR J, V6, P886; DELEON G, 1994, 841286 NAT I DRUG AB; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; GERSTEIN DR, 1979, AM J DRUG ALCOHOL AB, V6, P1, DOI 10.3109/00952997909007029; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GERSTEIN DR, 1994, ADP94628 CAL DEP ALC; GORLIN R, 1991, AM HEART J, V121, P658, DOI 10.1016/0002-8703(91)90442-K; GRABER AL, 1992, DIABETES CARE, V15, P1477, DOI 10.2337/diacare.15.11.1477; Harrison W. H., 1993, INTERNAL MED; HAVASSY BE, 1995, ADDICTION, V90, P699, DOI 10.1046/j.1360-0443.1995.90569911.x; Herman W. H., 1985, DIABETIC RENAL DISOR; HIGGINS ST, 1994, ARCH GEN PSYCHIAT, V51, P568; HOROWITZ RI, 1990, LANCET, V336, P542; Hubbard RL, 1989, DRUG ABUSE TREATMENT; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; Mattick RP, 1996, LANCET, V347, P97, DOI 10.1016/S0140-6736(96)90215-9; MCLELLAN AT, 1980, DRUG ALCOHOL DEPEN, V5, P189, DOI 10.1016/0376-8716(80)90179-9; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Miller WR, 1986, TREATING ADDICTIVE B; Moos R, 1990, ALCOHOLISM TREATMENT; OBRIEN CP, 1986, PHILADELPHIA MED, V82, P442; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; SCHAUB AF, 1993, CLIN EXP HYPERTENS, V15, P1121, DOI 10.3109/10641969309037099; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SIMPSON DD, 1980, ARCH GEN PSYCHIAT, V37, P896; SINNOCK P, 1955, HOSPITALIZATION DIAB; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1989, PUBLIC USE DATATAPE; 1989, PREVENTION TREATMENT	34	342	348	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					237	240		10.1016/S0140-6736(96)90409-2	http://dx.doi.org/10.1016/S0140-6736(96)90409-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551886	hybrid			2022-12-01	WOS:A1996TT06900015
J	Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD				Barnes, PF; ElHajj, H; PrestonMartin, S; Cave, MD; Jones, BE; Otaya, M; Pogoda, J; Eisenach, KD			Transmission of tuberculosis among the urban homeless	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; COMPLEX; ELEMENT; IS6110; TOOL	Objective. - To determine the relative frequencies of primary and reactivation tuberculosis in the urban homeless. Design. - Prospective evaluation of homeless tuberculosis patients. Setting. - Central Los Angeles, Calif. Patients. - Thirty-four homeless patients with culture-proven tuberculosis. Interventions. - IS61 10-based restriction fragment length polymorphism (RFLP) analysis was performed on Mycobacterium tuberculosis isolates. If results were inconclusive, pTBN12-based RFLP analysis was performed. Main Outcome Measure. - Clustering of M tuberculosis isolates. A cluster consisted of two or more isolates with indistinguishable RFLP patterns. Results. - Twenty-four of 34 homeless patients had clustered isolates in six clusters. Conclusions. - The minimum percentage of cases due to primary tuberculosis in the homeless was estimated to be 53%, compared with the traditional estimate of 10% in the general population. The results suggest that primary tuberculosis caused the majority of tuberculosis cases in this population of the urban homeless in central Los Angeles.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV ARKANSAS MED SCI HOSP,DEPT PATHOL,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT ANAT,LITTLE ROCK,AR 72205; MCLELLAN MEM VET HOSP,MED RES SERV,LITTLE ROCK,AR; STATOLOGY,TAHOE PARADISE,CA	University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Barnes, PF (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED,DIV INFECT DIS,HMR 904,2025 ZONAL AVE,LOS ANGELES,CA 90033, USA.				NIAID NIH HHS [AI35222, AI35265] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035222, R01AI035265] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BERMUDEZ LE, 1991, J INFECT DIS, V163, P1286, DOI 10.1093/infdis/163.6.1286; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; COUSINS DV, 1993, VET MICROBIOL, V37, P1, DOI 10.1016/0378-1135(93)90178-A; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; KLIMAS NG, 1991, AM J MED, V90, P163, DOI 10.1016/0002-9343(91)80155-F; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; MCMURRAY DN, 1992, J NUTR, V122, P738, DOI 10.1093/jn/122.suppl_3.738; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROSSI PH, 1987, SCIENCE, V235, P1336, DOI 10.1126/science.2950592; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1992, MMWR-MORBID MORTAL W, V41, P13; 1990, MMWR-MORBID MORTAL W, V39, P9	17	120	123	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					305	307		10.1001/jama.275.4.305	http://dx.doi.org/10.1001/jama.275.4.305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544271				2022-12-01	WOS:A1996TP96500027
J	Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG				Ferguson, SSG; Downey, WE; Colapietro, AM; Barak, LS; Menard, L; Caron, MG			Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization	SCIENCE			English	Article							ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; DESENSITIZATION; RHODOPSIN; KINASE; MECHANISM; PATHWAYS; BINDING	beta-Arrestins are proteins that bind phosphorylated heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) and contribute to the desensitization of GPCRs by uncoupling the signal transduction process. Resensitization of GPCR responsiveness involves agonist-mediated receptor sequestration. Overexpression of beta-arrestins in human embryonic kidney cells rescued the sequestration of beta(2)-adrenergic receptor (beta(2)AR) mutants defective in their ability to sequester, an effect enhanced by simultaneous overexpression of beta-adrenergic receptor kinase 1, Wild-type beta(2)AR sequestration was inhibited by the overexpression of two beta-arrestin mutants. These findings suggest that beta-arrestins play an integral role in GPCR internalization and thus serve a dual role in the regulation of GPCR function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337	28	796	812	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					363	366		10.1126/science.271.5247.363	http://dx.doi.org/10.1126/science.271.5247.363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553074				2022-12-01	WOS:A1996TQ52800045
J	Yeh, SR; Fricke, RA; Edwards, DH				Yeh, SR; Fricke, RA; Edwards, DH			The effect of social experience on serotonergic modulation of the escape circuit of crayfish	SCIENCE			English	Article							BEHAVIOR; RECEPTORS; AGGRESSION; OCTOPAMINE; LOBSTERS	The neuromodulator serotonin has widespread effects in the nervous systems of many animals, often influencing aggression;and dominance status. In crayfish, the effect of serotonin on the neural circuit for tailflip escape behavior was found to depend on the animal's social experience. Serotonin reversibly enhanced the response to sensory stimuli of the lateral giant (LG) tailflip command neuron in socially dominant crayfish, reversibly inhibited it in subordinate animals, and persistently enhanced it in socially isolated crayfish, Serotonin receptor agonists had opposing effects: A vertebrate serotonin type 1 receptor agonist inhibited the LG neurons in dominant and subordinate crayfish and had no effect in isolates, whereas a vertebrate serotonin type 2 receptor agonist enhanced the LG neurons' responses in all three types of crayfish. The LG neurons appear to have at ]east two populations of serotonin receptors that differ in efficacy in dominant, subordinate, and socially isolate crayfish.	GEORGIA STATE UNIV,DEPT BIOL,ATLANTA,GA 30302; EMORY UNIV,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322	University System of Georgia; Georgia State University; Emory University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026457] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS26457] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOVBJERG RV, 1953, PHYSIOL ZOOL, V26, P173, DOI 10.1086/physzool.26.2.30154514; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; COCCARO EF, 1992, INT CLIN PSYCHOPHARM, V7, P3, DOI 10.1097/00004850-199200710-00001; EDWARDS DH, 1991, J NEUROSCI, V11, P2117; GLANZMAN DL, 1983, J NEUROSCI, V3, P2263; GLENNON RA, 1987, J MED CHEM, V30, P1, DOI 10.1021/jm00384a001; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; KRASNE FB, 1969, J EXP BIOL, V50, P29; KRAVITZ EA, 1988, SCIENCE, V241, P1775, DOI 10.1126/science.2902685; LEONARD BE, 1992, INT CLIN PSYCHOPHARM, V7, P13, DOI 10.1097/00004850-199200710-00002; LINNOILA VMI, 1992, J CLIN PSYCHIAT, V53, P46; LIVINGSTONE MS, 1980, SCIENCE, V208, P76, DOI 10.1126/science.208.4439.76; REAL D, 1990, BRAIN RES, V521, P203, DOI 10.1016/0006-8993(90)91544-Q; STEKLIS HD, 1986, AM J PRIMATOL, V11, P133, DOI 10.1002/ajp.1350110206; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; VU ET, 1993, J NEUROSCI, V13, P4379; WINBERG S, 1992, J COMP PHYSIOL A, V170, P93; Wine J.J., 1982, P241; YEH SC, UNPUB; ZHANG B, 1994, J EXP BIOL, V190, P55; ZUCKER RS, 1972, J NEUROPHYSIOL, V35, P599, DOI 10.1152/jn.1972.35.5.599	21	217	218	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					366	369		10.1126/science.271.5247.366	http://dx.doi.org/10.1126/science.271.5247.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553075	Green Submitted			2022-12-01	WOS:A1996TQ52800046
J	Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA				Finger, EB; Puri, KD; Alon, R; Lawrence, MB; vonAndrian, UH; Springer, TA			Adhesion through L-selectin requires a threshold hydrodynamic shear	NATURE			English	Article							NODE HOMING RECEPTOR; HUMAN NEUTROPHILS; LECAM-1; IDENTIFICATION; LEUKOCYTES; SURFACE; GMP-140; MAC-1; RATES; FLOW	SELECTINS are cell adhesion molecules that bind carbohydrate ligands and promote interaction between leukocytes and the vessel wall in vascular shear flow(1,2). Selectin-ligand bonds have high mechanical strength, allowing initial tethering to the vessel wall through one or few bonds, and have fast on and off rates, permitting rolling in response to hydrodynamic drag(3). The L-selectin molecule on leukocytes binds to peripheral node addressin on high endothelial venules of lymph nodes to mediate leukocyte rolling(4,5) and binds to a ligand on neutrophils to mediate rolling of leukocytes over one another(6). Here we describe a surprising mechanism for regulation of these interactions, both in vitro and in vivo. Shear above a critical threshold is required to promote and maintain rolling interactions through L-selectin, but not through E-selectin, P-selectin or VCAM-1. The shear threshold requirement for L-selectin may be physiologically important in low shear to prevent inappropriate aggregation of leukocytes and interaction with the vessel wall.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV VIRGINIA,DEPT BIOMED ENGN,CHARLOTTESVILLE,VA 22903	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Virginia			ALON, RONEN/GRX-6987-2022; von Andrian, Ulrich H/A-5775-2008; Finger, Erik/AFP-0406-2022	Finger, Erik/0000-0003-3899-6985; Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J IMMUNOL, V154, P5356; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROCHON YP, 1994, J IMMUNOL, V152, P1385; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SPRINGER TA, 1995, TRAFFIC SIGNALS ROLL; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	29	392	403	2	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					266	269		10.1038/379266a0	http://dx.doi.org/10.1038/379266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538793				2022-12-01	WOS:A1996TQ16900049
J	Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB				Sherin, JE; Shiromani, PJ; McCarley, RW; Saper, CB			Activation of ventrolateral preoptic neurons during sleep	SCIENCE			English	Article							FOS-LIKE IMMUNOREACTIVITY; RAT-BRAIN; C-FOS; BASAL FOREBRAIN; POSTERIOR HYPOTHALAMUS; WAKING DISCHARGE; UNIT-ACTIVITY; CAT; AREA; MICROINJECTION	The rostral hypothalamus and adjacent basal forebrain participate in the generation of sleep, but the neuronal circuitry involved in this process remains poorly characterized. Immunocytochemistry was used to identify the FOS protein, an immediate-early gene product, in a group of ventrolateral preoptic neurons that is specifically activated during deep. The retrograde tracer cholera toxin B, in combination with FOS immunocytochemistry, was used to show that sleep-activated ventrolateral preoptic neurons innervate the tuberomammillary nucleus, a posterior hypothalamic cell group thought to participate in the modulation of arousal. This monosynaptic pathway in the hypothalamus may play a key role in determining sleep-wake states.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, BROCKTON VET ADM HOSP, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University of Chicago			McCarley, Robert W/N-5562-2014; Saper, Clifford/L-3815-2019; Shenton, Martha/V-8780-2019	McCarley, Robert W/0000-0001-5705-7495; 	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030140, R01NS022835] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10709] Funding Source: Medline; NINDS NIH HHS [NS30140, NS22835] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM MN, IN PRESS AM J PHYSL; BENTIVOGLIO M, 1993, SLEEP RES, V22, P475; BOBERLY AA, 1985, BRAIN MECHANISMS SLE, P35; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P327; DETARI L, 1984, ELECTROEN CLIN NEURO, V58, P362, DOI 10.1016/0013-4694(84)90062-2; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; ELMQUIST JK, 1993, ENDOCRINOLOGY, V133, P3054, DOI 10.1210/en.133.6.3054; ERICSON H, 1991, J COMP NEUROL, V305, P462, DOI 10.1002/cne.903050309; FINDLAY ALR, 1969, J PHYSIOL-LONDON, V201, P237, DOI 10.1113/jphysiol.1969.sp008753; GARCIAARRARAS JE, 1983, J NEUROPHYSIOL, V49, P528, DOI 10.1152/jn.1983.49.2.528; GRASSIZUCCONI G, 1994, J PHYSIOLOGY-PARIS, V88, P91, DOI 10.1016/0928-4257(94)90096-5; GRASSIZUCCONI G, 1993, SLEEP RES, V22, P478; GRITTI I, 1994, J COMP NEUROL, V339, P251, DOI 10.1002/cne.903390206; HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006; KAADA BR, 1951, ACTA PHYSL SCAND, V24, P200; KAITIN KI, 1984, EXP NEUROL, V83, P347, DOI 10.1016/0014-4886(84)90103-1; KONONEN J, 1990, NEUROSCI LETT, V120, P105, DOI 10.1016/0304-3940(90)90179-D; KOYAMA Y, 1994, BRAIN RES BULL, V33, P367, DOI 10.1016/0361-9230(94)90278-X; KRILOWICZ BL, 1994, BRAIN RES, V668, P30, DOI 10.1016/0006-8993(94)90507-X; LIN JS, 1988, NEUROPHARMACOLOGY, V27, P111, DOI 10.1016/0028-3908(88)90159-1; LIN JS, 1989, BRAIN RES, V479, P225, DOI 10.1016/0006-8993(89)91623-5; LUCAS EA, 1975, EXP NEUROL, V46, P368, DOI 10.1016/0014-4886(75)90142-9; MALLICK BN, 1983, EXP NEUROL, V81, P586, DOI 10.1016/0014-4886(83)90328-X; MATSUMURA H, 1994, P NATL ACAD SCI USA, V91, P11998, DOI 10.1073/pnas.91.25.11998; Mauthner L, 1890, WIEN MED WSCHR, V40, P961; MCGINTY D, 1994, BRAIN RES, V667, P273, DOI 10.1016/0006-8993(94)91506-7; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; MENDELSON WB, 1989, NEUROPSYCHOPHARMACOL, V2, P61, DOI 10.1016/0893-133X(89)90008-0; MONTI JM, 1993, LIFE SCI, V53, P1331, DOI 10.1016/0024-3205(93)90592-Q; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285, DOI 10.1152/jn.1946.9.4.285; NITZ DN, 1995, SLEEP RES, V24, P12; OGAWA Y, 1988, BRAIN RES BULL, V20, P897, DOI 10.1016/0361-9230(88)90108-6; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; POMPEIANO M, 1994, J SLEEP RES, V3, P80, DOI 10.1111/j.1365-2869.1994.tb00111.x; ROBERTS WW, 1969, EXP NEUROL, V25, P282, DOI 10.1016/0014-4886(69)90051-X; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SALLANON M, 1989, NEUROSCIENCE, V32, P669, DOI 10.1016/0306-4522(89)90289-3; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SENBA E, 1985, J NEUROSCI, V5, P3393; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERIN JE, 1993, SOC NEUR ABSTR, V19, P31; SHERIN JE, UNPUB; SHIROMANI PJ, 1995, MOL BRAIN RES, V29, P163, DOI 10.1016/0169-328X(94)00242-7; Snedecor GW., 1989, STAT METHODS, P177; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERMAN MB, 1962, EXP NEUROL, V6, P91, DOI 10.1016/0014-4886(62)90080-8; Sterman MB, 1985, BRAIN MECHANISMS SLE, P277; SWETT CP, 1968, ARCH ITAL BIOL, V106, P283; SZYMUSIAK R, 1989, BRAIN RES BULL, V23, P111, DOI 10.1016/0361-9230(89)90169-X; SZYMUSIAK R, 1989, BRAIN RES, V498, P355, DOI 10.1016/0006-8993(89)91116-5; SZYMUSIAK R, 1986, BRAIN RES, V370, P82, DOI 10.1016/0006-8993(86)91107-8; SZYMUSIAK R, 1986, EXP NEUROL, V94, P598, DOI 10.1016/0014-4886(86)90240-2; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; VANHULZEN ZJM, 1980, PHYSIOL BEHAV, V25, P807, DOI 10.1016/0031-9384(80)90298-X; VANNIMERCIER G, 1984, CR ACAD SCI III-VIE, V298, P195; WATANABE T, 1983, NEUROSCI LETT, V39, P249, DOI 10.1016/0304-3940(83)90308-7; WILCOX BJ, 1982, NEUROSCI LETT, V29, P105, DOI 10.1016/0304-3940(82)90337-8; YANG OZ, 1994, SOC NEUR ABSTR, V20, P346	59	720	754	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					216	219		10.1126/science.271.5246.216	http://dx.doi.org/10.1126/science.271.5246.216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539624				2022-12-01	WOS:A1996TP36400046
J	Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH				Sobol, RW; Horton, JK; Kuhn, R; Gu, H; Singhal, RK; Prasad, R; Rajewsky, K; Wilson, SH			Requirement of mammalian DNA polymerase-beta in base-excision repair	NATURE			English	Article							CELLS; AGENTS	SYNTHESIS Of DNA by DNA polymerase-beta is distributive on single-stranded DNA templates, but short DNA gaps with a 5' PO4 in the gap are filled processively to completion(1,2). In vitro studies have suggested a role of beta-polymerase in different types of DNA repair(3-9). However, the significance of these studies to the in vivo role of beta-polymerase has remained unclear. Because genetic studies are essential for determining the physiological role of a gene, we established embryonic fibroblast cell lines homozygous for a deletion mutation in the gene encoding DNA polymerase-beta. Extracts from these cell lines were found to be defective in uracil-initiated base-excision repair. The beta-polymerase-deleted cells are normal in viability and growth characteristics, although they exhibit increased sensitivity to monofunctional DNA-alkylating agents, but not to other DNA-damaging agents. Both the deficiency in base-excision repair and hypersensitivity to DNA-alkylating agents are rescued following stable transfection with a wild-type beta-polymerase minitransgene. These studies demonstrate that beta-polymerase functions specifically in base-excision repair in vivo.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne	Sobol, RW (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,CELL BIOL LAB,GALVESTON,TX 77555, USA.		Kühn, Ralf/U-1278-2017; Wilson, Samuel H/E-6644-2019; Sobol, Robert W./E-4125-2013	Kühn, Ralf/0000-0003-1694-9803; Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563; Rajewsky, Klaus/0000-0002-6633-6370				BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; KOMBERG A, 1991, DNA REPLICATION; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P211; KRIEGLER M, 1995, CURRENT PROTOCOLS MO; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; PRASAD R, 1994, J BIOL CHEM, V269, P18096; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P49; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	17	748	770	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					183	186		10.1038/379183a0	http://dx.doi.org/10.1038/379183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538772				2022-12-01	WOS:A1996TP36000064
J	Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM				Chittajallu, R; Vignes, M; Dev, KK; Barnes, JM; Collingridge, GL; Henley, JM			Regulation of glutamate release by presynaptic kainate receptors in the hippocampus	NATURE			English	Article							NEURONS; RAT; AMPA; 2,3-BENZODIAZEPINE; DESENSITIZATION; CYCLOTHIAZIDE; TRANSMISSION; ACTIVATION; ANTAGONIST; CHANNELS	MOST reported actions of kainate are mediated by AMPA (alpha-amino-3-hydroxy-5-methyl 3-isosazolepropionate) receptors(1,2). Here we report that, unlike AMPA which stimulates, kainate elicits a dose-dependent decrease in L-glutamate release from rat hippocampal synaptosomes and also depresses glutamatergic synaptic transmission. Brief exposure to kainate inhibited Ca2+-dependent [H-3]L-glutamate release by up to 80%. Inhibition was reversed by kainate antagonists but not by the AMPA-selective noncompetitive antagonist 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3- benzodiazepine (GYKI 52466)(3-7). A corresponding reversible kainate-evoked depression of NMDA (N-methyl-D-aspartate) receptor-mediated excitatory postsynaptic currents (e.p.s.cs) was observed when AMPA receptors were blocked by GYKI 52466. The synaptic depression was preceded by a brief period of enhanced release and a small inward current was also observed. The effects of kainate were unaffected by metabotropic glutamate (mGlu), GABA(A), GABA(B), glycine and adenosine receptor antagonists. These results indicate that glutamate release can be modulated directly by kainate autoreceptors.	UNIV BRISTOL,SCH MED SCI,DEPT ANAT,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Bristol; University of Birmingham			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Vignes, Michel/AAA-7693-2019; Chittajallu, Ramesh/AAX-3749-2020; Henley, Jeremy M/A-2776-2009	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966; Chittajallu, Ramesh/0000-0002-9794-0052; Henley, Jeremy/0000-0003-3589-8335; Dev, Kumlesh/0000-0003-4274-9119	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGRAWAL SG, 1986, BRIT J PHARMACOL, V87, P345, DOI 10.1111/j.1476-5381.1986.tb10823.x; BAHN S, 1994, J NEUROSCI, V14, P5525; BARNES JM, 1994, BRIT J PHARMACOL, V113, P339, DOI 10.1111/j.1476-5381.1994.tb16902.x; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; COLLINGRIDGE G, 1994, NMDA RECEPTOR; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; JOHANSEN TH, 1993, EUR J PHARM-MOLEC PH, V246, P195, DOI 10.1016/0922-4106(93)90031-4; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; MARTIN D, 1991, J NEUROCHEM, V56, P1647, DOI 10.1111/j.1471-4159.1991.tb02063.x; NISTRI A, 1991, J PHYSIOL-LONDON, V435, P465, DOI 10.1113/jphysiol.1991.sp018519; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; RUANO D, 1995, J NEURON, V14, P1009; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TAMAWA I, 1990, AMINO ACIDS CHEM BIO, P538; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZEMAN S, 1992, BRIT J PHARMACOL, V106, P367, DOI 10.1111/j.1476-5381.1992.tb14342.x; ZHOU M, 1995, J NEUROCHEM, V64, P1556; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	338	342	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					78	81		10.1038/379078a0	http://dx.doi.org/10.1038/379078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538745				2022-12-01	WOS:A1996TN21600059
J	NAGELE, R; FREEMAN, T; MCMORROW, L; LEE, HY				NAGELE, R; FREEMAN, T; MCMORROW, L; LEE, HY			PRECISE SPATIAL POSITIONING OF CHROMOSOMES DURING PROMETAPHASE - EVIDENCE FOR CHROMOSOMAL ORDER	SCIENCE			English	Article							INSITU HYBRIDIZATION; CELL-CYCLE; INTERPHASE NUCLEUS; CONFOCAL MICROSCOPY; TUMOR-CELLS; CENTROMERES; DOMAINS; METAPHASE; TELOMERES; MOVEMENT	The relative locations of several chromosomes within wheel-shaped prometaphase chromosome rosettes of human fibroblasts and HeLa cells were determined with fluorescence hybridization. Homologs were consistently positioned on opposite sides of the rosette, which suggests that chromosomes are separated into two haploid sets, each derived from one parent. The relative locations of chromosomes on the rosette were mapped by dual hybridizations. The data suggest that the chromosome orders within the two haploid sets are antiparallel. This chromosome arrangement in human cells appears to be both independent of cell type- and species-specific and may influence chromosome topology throughout the cell cycle.	THOMAS JEFFERSON UNIV,DEPT LAB SCI,PHILADELPHIA,PA 19107; RUTGERS STATE UNIV,DEPT BIOL,CAMDEN,NJ 08102	Jefferson University; Rutgers State University Camden; Rutgers State University New Brunswick	NAGELE, R (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT BIOL MOLEC,STRATFORD,NJ 08084, USA.			Freeman, Theresa/0000-0002-5959-5884				BARTHOLDI MF, 1991, J CELL SCI, V99, P255; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FREEMAN T, UNPUB; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAAF T, 1989, HUM GENET, V81, P137, DOI 10.1007/BF00293889; HAAF T, 1991, EXP CELL RES, V182, P325; HADLACZKY G, 1986, EXP CELL RES, V167, P1, DOI 10.1016/0014-4827(86)90199-0; HILLIKER AJ, 1989, EXP CELL RES, V185, P297, DOI 10.1016/0014-4827(89)90301-7; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HULSPAS R, 1992, CELL BIOL INT REP, V16, P739, DOI 10.1016/S0309-1651(05)80018-9; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; JORDAN MA, 1992, J CELL SCI, V102, P401; LANDEGENT J, 1988, P NATL ACAD SCI USA, V85, P9138; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MANUELIDIS L, 1985, ANN NY ACAD SCI, V450, P205, DOI 10.1111/j.1749-6632.1985.tb21494.x; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; POPP S, 1990, EXP CELL RES, V189, P1, DOI 10.1016/0014-4827(90)90249-A; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; VANDEKKEN H, 1990, CYTOMETRY, V11, P570, DOI 10.1002/cyto.990110503; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068	24	126	129	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1831	1835		10.1126/science.270.5243.1831	http://dx.doi.org/10.1126/science.270.5243.1831			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525379				2022-12-01	WOS:A1995TK47600049
J	PATAPOUTIAN, A; WOLD, BJ; WAGNER, RA				PATAPOUTIAN, A; WOLD, BJ; WAGNER, RA			EVIDENCE FOR DEVELOPMENTALLY PROGRAMMED TRANSDIFFERENTIATION IN MOUSE ESOPHAGEAL MUSCLE	SCIENCE			English	Article							MYOD	Transdifferentiation is a relatively rare phenomenon in which cells of one differentiated type and function switch to a second discrete identity. In vertebrate embryos, smooth muscle and skeletal muscle are distinct tissues that arise from separate compartments of the mesoderm. The musculature of the mouse esophagus was found to undergo a conversion from smooth muscle in the fetus to skeletal muscle during early postnatal development. The switch from smooth to skeletal muscle features the transitory appearance of individual cells expressing a mixed phenotype, which suggests that this conversion is a result of programmed transdifferentiation.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIAMS NIH HHS [AR40708] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DJ, 1989, TRENDS GENET, V5, P175; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BROCKES JP, 1994, TRENDS GENET, V10, P169, DOI 10.1016/0168-9525(94)90094-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; COLES HSR, 1993, DEVELOPMENT, V118, P777; DUBOND JL, 1993, DIFFERENTIATION, V55, P1; HITCHCOCK PF, 1992, TRENDS NEUROSCI, V15, P103, DOI 10.1016/0166-2236(92)90020-9; LANDIS SC, 1990, TRENDS NEUROSCI, V8, P344; MINER JH, 1992, DEVELOPMENT, V114, P853; Okada T.S, 1991, TRANSDIFFERENTIATION; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; Prosser C. L., 1973, Comparative animal physiology,, P719; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VOLPE P, 1993, DEV BIOL, V159, P441, DOI 10.1006/dbio.1993.1254; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	17	131	136	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1818	1821		10.1126/science.270.5243.1818	http://dx.doi.org/10.1126/science.270.5243.1818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525375				2022-12-01	WOS:A1995TK47600045
J	WALL, MA; COLEMAN, DE; LEE, E; INIGUEZLLUHI, JA; POSNER, BA; GILMAN, AG; SPRANG, SR				WALL, MA; COLEMAN, DE; LEE, E; INIGUEZLLUHI, JA; POSNER, BA; GILMAN, AG; SPRANG, SR			THE STRUCTURE OF THE G-PROTEIN HETEROTRIMER G(I-ALPHA-1)BETA(1)GAMMA(2)	CELL			English	Article							BETA-GAMMA; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURES; SUBUNITS; ALPHA; IDENTIFICATION; MECHANISM; RECEPTORS	The crystallographic structure of the G protein heterotrimer G(i alpha 1)(GDP)beta 1(1 gamma 2) (at 2.3 Angstrom) reveals two nonoverlapping regions of contact between alpha and beta, an extended interface between beta and nearly all of gamma, and limited interaction of alpha with gamma. The major alpha/beta interface covers switch II of alpha, and GTP-induced rearrangement of switch II causes subunit dissociation during signaling. Alterations in GDP binding in the heterotrimer (compared with alpha-GDP) explain stabilization of the inactive conformation of alpha by beta gamma. Repeated WD motifs in beta form a circularized sevenfold beta propeller. The conserved cores of these motifs are a scaffold for display of their more variable linkers on the exterior face of each propeller blade.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WALL, MA (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIAHIGUERA I, 1996, IN PRESS J BIOL CHEM; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HEPLER JR, 1995, IN PRESS J BIOL CHEM; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1993, O VERSION 5 9; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1994, ENZYMOL, V237, P146; LESK AM, 1986, PROTEIN ENG, V1, P77, DOI 10.1093/protein/1.1.77; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; XIA ZX, 1992, J BIOL CHEM, V267, P22289; 1994, ACTA CRYSTALLOGR, V50, P760	58	973	991	2	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1047	1058		10.1016/0092-8674(95)90220-1	http://dx.doi.org/10.1016/0092-8674(95)90220-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521505	Bronze			2022-12-01	WOS:A1995TK74500023
J	STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H				STEWARTBROWN, S; SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H			THE EFFECTS OF FUNDHOLDING IN GENERAL-PRACTICE ON PRESCRIBING HABITS 3 YEARS AFTER INTRODUCTION OF THE SCHEME	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objective--To observe changes in prescribing practice that occurred after the introduction of fundholding in first wave practices and to contrast these with changes occurring in similar non-fundholding practices. Design--Prospective observational study. Setting--Oxford region fundholding study. Subjects--Eight first wave fundholding practices and five practices that were not interested in fundholding in 1990-1, which were similar in terms of practice size, training status, locality, and urban rural mix. Three of the fundholding and none of the non-fundholding practices were dispensing practices. Main outcome measures--Changes in prescribing practice as measured by net cost per prescribing unit, cost per item, number of items prescribed, and substitution rates for generic drugs three years after the introduction of fundholding. Data for fundholding practices were analysed separately according to whether they were dispensing or non-dispensing practices. Results--Prescribing costs rose by a third or more in all types of practice. The patterns of change observed in this cohort after one year of fundholding were reversed. No evidence existed that fundholding had controlled prescribing costs among non-dispensing fundholders; costs among dispensing fundholders rose least, but the differences were small compared with the overall increase in costs. Conclusions--Early reports of the effectiveness of fundholding in curbing prescribing costs have not been confirmed in this longer term study.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE UNIT,OXFORD OX3 7LF,ENGLAND; KINGS FUND CTR,LONDON W1M 0AN,ENGLAND	University of Oxford	STEWARTBROWN, S (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; CHEW R, 1992, COMPENDIUM HLTH STAT; COULTER A, IN PRESS EUROPEAN J; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; 1993, EFFECTIVE HLTH CARE, V5	7	67	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1543	1547		10.1136/bmj.311.7019.1543	http://dx.doi.org/10.1136/bmj.311.7019.1543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520399	Green Published			2022-12-01	WOS:A1995TK21400027
J	DAI, JW; SHEETZ, MP				DAI, JW; SHEETZ, MP			AXON MEMBRANE FLOWS FROM THE GROWTH CONE TO THE CELL BODY	CELL			English	Article							PLASMA-MEMBRANE; LIPID FLOW; MOVEMENTS; TRANSPORT; GLYCOPROTEINS; ENDOCYTOSIS; LOCOMOTION; PROTEINS; NEURONS; FORCE	During the growth of axons, the surface area of the neuron increases dramatically. Membrane addition as well as exchange could contribute to rapid membrane dynamics or flow. Using diffusing latex beads to monitor membrane flow, we find that axonal membrane flows rapidly (7 mu m/min) from growth cone to cell body during axon growth and that flow is inhibited by brefeldin A. To power this flow, there is a membrane tension gradient from growth cone to cell body that could draw the membrane over the axon at that rate. Further, when an artificial flow is induced to the center of the axon by use of laser tweezers, the primary source of the membrane is from the growth cone. We suggest that during neuron growth, there is excess membrane added at the growth cone in chick dorsal root ganglia (DRGs) that undergoes endocytosis at the cell body, thereby creating a flow that can rapidly alter the content of the axon membrane.			DAI, JW (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BERK DA, 1992, BIOPHYS J, V61, P9, DOI 10.1016/S0006-3495(92)81811-8; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; BRETSCHER MS, 1984, SCIENCE, V224, P681, DOI 10.1126/science.6719108; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; DAI J, 1995, IN PRESS COLD SPRING, V60; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GRIFFIN JW, 1981, J CELL BIOL, V88, P205, DOI 10.1083/jcb.88.1.205; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HOCHMUTH RM, 1995, IN PRESS BIOPHYS J; ISHIHARA A, 1993, BIOPHYS J, V65, P1754, DOI 10.1016/S0006-3495(93)81231-1; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LEE GM, 1991, P NATL ACAD SCI USA, V88, P6274, DOI 10.1073/pnas.88.14.6274; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MARTENSON C, 1993, NATURE, V366, P66, DOI 10.1038/366066a0; OKABE S, 1993, J CELL BIOL, V120, P1177, DOI 10.1083/jcb.120.5.1177; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; PFENNINGER KH, 1981, J CELL BIOL, V89, P547, DOI 10.1083/jcb.89.3.547; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SCHNAPP BJ, 1988, CELL MOTIL CYTOSKEL, V10, P47, DOI 10.1002/cm.970100109; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SHEETZ MP, 1990, CELL, V61, P231, DOI 10.1016/0092-8674(90)90804-N; SMITH RS, 1994, J NEUROCHEM, V62, P1698; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; WAUGH RE, 1987, BIOPHYS J, V52, P391, DOI 10.1016/S0006-3495(87)83227-7	34	96	98	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					693	701						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521486				2022-12-01	WOS:A1995TH94800006
J	ANTONINI, A; STRYKER, MP				ANTONINI, A; STRYKER, MP			RAPID REMODELING OF AXONAL ARBORS IN THE VISUAL-CORTEX	SCIENCE			English	Article							BRIEF MONOCULAR DEPRIVATION; UNILATERAL EYE CLOSURE; KITTEN STRIATE CORTEX; SENSITIVE PERIOD; DEPRIVED CATS; REVERSAL; INNERVATION; BICUCULLINE; AMBLYOPIA; RECOVERY	If vision in one eye is blurred or occluded during a critical period in postnatal development, neurons in the visual cortex lose their responses to stimulation through that eye within a few days. Anatomical changes in the nerve terminals that provide input to the visual cortex have previously been observed only after weeks of deprivation, suggesting that synapses become physiologically ineffective before the branches on which they sit are withdrawn. Reconstruction of single geniculocortical axonal arbors in the cat after either brief or prolonged monocular occlusion revealed striking axonal rearrangements in both instances. Rapid withdrawal of the branches of deprived-eye arbors suggests that axonal branches bearing synapses respond quickly to changing patterns of neuronal activity.			ANTONINI, A (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,WM KECK FDN CTR INTEGRAT NEUROSCI,BOX 0444,SAN FRANCISCO,CA 94143, USA.		Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807; Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R01EY002874, R37EY002874, T32EY007120] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY002874, EY02874, IT32 EY07120-01, T32 EY007120] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, IN PRESS J NEUROSCI; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BURCHFIEL JL, 1981, BRAIN RES, V206, P479, DOI 10.1016/0006-8993(81)90551-5; DUFFY FH, 1976, NATURE, V260, P256, DOI 10.1038/260256a0; FERSTER D, 1978, J COMP NEUROL, V182, P923, DOI 10.1002/cne.901820510; FRIEDLANDER MJ, 1989, J PHYSIOL-LONDON, V416, P183, DOI 10.1113/jphysiol.1989.sp017756; FRIEDLANDER MJ, 1991, J NEUROSCI, V11, P3268; GAREY LJ, 1974, BRAIN RES, V66, P165, DOI 10.1016/0006-8993(74)90086-9; GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5; HENDRY SHC, 1988, J NEUROSCI, V8, P1225; HENDRY SHC, 1990, J NEUROSCI, V10, P2438; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; Hubel D H, 1976, Cold Spring Harb Symp Quant Biol, V40, P581; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; JONES EG, 1990, J EXP BIOL, V153, P155; MALACH R, 1984, J NEUROPHYSIOL, V51, P538, DOI 10.1152/jn.1984.51.3.538; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MITZDORF U, 1980, J PHYSIOL-LONDON, V304, P203, DOI 10.1113/jphysiol.1980.sp013320; MOVSHON JA, 1977, J NEUROPHYSIOL, V40, P1255, DOI 10.1152/jn.1977.40.6.1255; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; NEUROTRACE AP, 1988, SOC NEUR ABSTR, V14, P550; OLSON CR, 1978, J NEUROPHYSIOL, V41, P65, DOI 10.1152/jn.1978.41.1.65; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; ROSEN KM, 1992, P NATL ACAD SCI USA, V89, P5437, DOI 10.1073/pnas.89.12.5437; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHERMAN SM, 1972, J NEUROPHYSIOL, V35, P532, DOI 10.1152/jn.1972.35.4.532; SPEAR PD, 1980, J NEUROPHYSIOL, V43, P559, DOI 10.1152/jn.1980.43.3.559; TIEMAN SB, 1984, J COMP NEUROL, V222, P166, DOI 10.1002/cne.902220203; VANSLUYTERS RC, 1978, J PHYSIOL-LONDON, V284, P1; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WORLEY PF, 1990, COLD SPRING HARB SYM, V55, P213, DOI 10.1101/SQB.1990.055.01.023	33	392	398	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1819	1821		10.1126/science.8511592	http://dx.doi.org/10.1126/science.8511592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511592				2022-12-01	WOS:A1993LH20500055
J	BREKKE, OH; MICHAELSEN, TE; SANDIN, R; SANDLIE, I				BREKKE, OH; MICHAELSEN, TE; SANDIN, R; SANDLIE, I			ACTIVATION OF COMPLEMENT BY AN IGG MOLECULE WITHOUT A GENETIC HINGE	NATURE			English	Article							SEGMENTAL FLEXIBILITY; 3-DIMENSIONAL STRUCTURE; IMMUNOGLOBULIN-G; CHIMERIC HUMAN; C1Q BINDING; ANTIBODIES; EXPRESSION; REGION; SITE	THE hinge region links the two Fab arms to the Fc portion of the IgG molecule. It mediates flexibility to the molecule and serves as a connecting structure between the two heavy chains. In addition it provides space between the Fab and Fc parts. All three properties have been proposed to be important for the ability of IgG to initiate complement activation leading to complement-mediated cell lysis (CML)1. Here we report the construction of a hinge-deleted mouse-human chimaeric IgG3 molecule with specificity for the hapten NIP (3-iodo-4-hydroxy-5-nitrophenacetyl), HM-1. HM-1 lacks the genetic hinge, but has an introduced cysteine between Ala 231 (EU numbering) and Pro 232 in the lower hinge encoded by the C(H)2 exon. The introduced cysteine forms a disulphide bond between the two heavy chains of the molecule. In CML, HM-1 shows a greater activity than IgG3 wild type. This is the first time an IgG molecule without a genetic hinge has been found to be active in CML. We conclude that the hinge functioning as a spacer is not a prerequisite for complement activation. Rather, its major role seems to be to connect the heavy chains to each other in the amino-terminal part of C(H)2. Because HM-1 is expected to have low Fab-Fc flexibility, this molecular feature is probably of no importance for complement activation.	UNIV OSLO,DEPT BIOL,POB 1050,N-0316 BLINDERN,NORWAY; NATL INST PUBL HLTH,N-0462 OSLO,NORWAY	University of Oslo				Michaelsen, Terje Einar/0000-0001-8877-8519				AASE A, IN PRESS J IMMUNOL; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DEUTSCH HF, 1971, J IMMUNOL, V107, P929; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; ITO W, 1985, BIOCHEMISTRY-US, V24, P6467, DOI 10.1021/bi00344a024; KLEIN M, 1981, P NATL ACAD SCI-BIOL, V78, P524, DOI 10.1073/pnas.78.1.524; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MICHAELSEN TE, 1990, SCAND J IMMUNOL, V32, P517, DOI 10.1111/j.1365-3083.1990.tb03192.x; MICHAELSEN TE, 1976, SCAND J IMMUNOL, V5, P1123; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Nezlin R, 1990, Adv Immunol, V48, P1, DOI 10.1016/S0065-2776(08)60750-6; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RAJAN SS, 1983, MOL IMMUNOL, V20, P787, DOI 10.1016/0161-5890(83)90057-3; SANDLIE I, 1989, EUR J IMMUNOL, V19, P1599, DOI 10.1002/eji.1830190912; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SEEGAN GW, 1979, P NATL ACAD SCI USA, V76, P907, DOI 10.1073/pnas.76.2.907; SILVERTON EW, 1977, P NATL ACAD SCI USA, V74, P5140, DOI 10.1073/pnas.74.11.5140; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162	25	35	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					628	630		10.1038/363628a0	http://dx.doi.org/10.1038/363628a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510754				2022-12-01	WOS:A1993LH13900056
J	CROZAT, A; AMAN, P; MANDAHL, N; RON, D				CROZAT, A; AMAN, P; MANDAHL, N; RON, D			FUSION OF CHOP TO A NOVEL RNA-BINDING PROTEIN IN HUMAN MYXOID LIPOSARCOMA	NATURE			English	Article							SINGLE GENE; EXPRESSION; SEQUENCE; DOMAIN; CELLS	HUMAN myxoid liposarcomas contain a characteristic chromosomal translocation, t(12;16)(q13;p11)1,2, that is associated with a structural rearrangement of the gene encoding CHOP 3, a growth arrest and DNA-damage inducible member of the C/EBP family of transcription factors4,5 residing on 12q13.1 6. Using a CHOP-specific complementary probe and antiserum we report here the presence of an abnormal CHOP transcript and protein in these tumours. Cloning of the translocation-associated CHOP gene product revealed a fusion between CHOP and a gene provisionally named TLS (translocated in liposarcoma). TLS is a novel nuclear RNA-binding protein with extensive sequence similarity to EWS7, the product of a gene commonly translocated in Ewing's sarcoma. In TLS-CHOP the RNA-binding domain of TLS is replaced by the DNA-binding and leucine zipper dimerization domain of CHOP. Targeting of a conserved effector domain of RNA-binding proteins to DNA may play a role in tumour formation.	NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN	New York University; New York University; Lund University; Skane University Hospital	CROZAT, A (corresponding author), NYU MED CTR,DEPT MED,NEW YORK,NY 10016, USA.			Aman, Pierre/0000-0002-1482-8875; Crozat, Anne/0000-0002-2539-8479; Ron, David/0000-0002-3014-5636				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P271; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, IN PRESS MOL CELL BI; CRETIN C, 1990, PLANT MOL BIOL, V15, P783, DOI 10.1007/BF00016128; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SREEKANTIAIAH S, 1992, CANCER, V69, P2484; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P291, DOI 10.1016/0165-4608(86)90011-7	18	737	758	3	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					640	644		10.1038/363640a0	http://dx.doi.org/10.1038/363640a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510758				2022-12-01	WOS:A1993LH13900060
J	IONOV, Y; PEINADO, MA; MALKHOSYAN, S; SHIBATA, D; PERUCHO, M				IONOV, Y; PEINADO, MA; MALKHOSYAN, S; SHIBATA, D; PERUCHO, M			UBIQUITOUS SOMATIC MUTATIONS IN SIMPLE REPEATED SEQUENCES REVEAL A NEW MECHANISM FOR COLONIC CARCINOGENESIS	NATURE			English	Article							ARBITRARY PRIMERS; CHAIN-REACTION; DNA; POLYMORPHISMS; MUTAGENESIS; INVITRO; CANCER	SPONTANEOUS errors in DNA replication have been suggested to play a significant role in neoplastic transformation and to explain the chromosomal alterations seen in cancer cells1. A defective replication factor could increase the mutation rate in clonal variants arising during tumour progression, but despite intensive efforts, increases in tumour cell mutation rates have not been unambiguously shown2. Here we use an unbiased genomic fingerprinting technique3 to show that 12 per cent of colorectal carcinomas carry somatic deletions in poly(dA . dT) sequences and other simple repeats. We estimate that cells from these tumours can carry more than 100,000 such mutations. Only tumours with affected poly(dA . dT) sequences carry mutations in the other simple repeats examined, and such mutations can be found in all neoplastic regions of multiple tumours from the same patient, including adenomas. Tumours with these mutations show distinctive genotypic and phenotypic features. We conclude that these mutations reflect a previously undescribed form of carcinogenesis in the colon (predisposition to which may be inherited) mediated by a mutation in a DNA replication factor resulting in reduced fidelity for replication or repair (a 'mutator mutation').	CALIF INST BIOL RES,11099 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033	University of Southern California			Peinado, Miguel A./A-5591-2008	Peinado, Miguel A./0000-0002-4090-793X; Perucho, Manuel/0000-0002-2169-2662				ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS CC, 1991, CANCER RES, V51, pS5023; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KAHN S, 1987, ANTICANCER RES, V7, P639; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOEB LA, 1974, CANCER RES, V34, P2311; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PEINADO MA, 1993, INT J ONCOL, V2, P123; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SHIBATA D, IN PRESS J NATN CANC; SHIBATA D, 1992, AM J PATHOL, V141, P1; SINNETT D, 1990, GENOMICS, V7, P331, DOI 10.1016/0888-7543(90)90166-R; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUGARBAKER P, 1985, CANCER PRINCIPLES PR, P814; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	23	2346	2413	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					558	561		10.1038/363558a0	http://dx.doi.org/10.1038/363558a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505985				2022-12-01	WOS:A1993LF93900055
J	PAGEL, M				PAGEL, M			HONEST SIGNALING AMONG GAMETES	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; A-FACTOR; ALPHA-FACTOR; YEAST; COURTSHIP; SELECTION; INDUCTION; PARTNERS; GENE	THE gametes of many lower eukaryotic organisms emit pheromones that attract gametes of the opposite mating type or sex1-4. Gametes move or grow in the direction of the highest pheromone concentration, suggesting that the strength of the pheromonal signal is used to infer proximity, or that the strongest signal is most likely to be noticed. Here I offer a new explanation of pheromonal signalling and chemotaxis in gametes. I show that pheromonal signals can be interpreted as sexually selected traits that honestly advertise variation in quality among gametes, given that signals are costly to produce and that gametes compete; by 'quality' I refer to some aspect of a gamete's fitness. A gamete's preference for a mating partner, then, is predicted to vary with the quality of a prospective partner as inferred from the strength of its signal. This view can explain characteristics of the signalling and mate selection behaviours of gametes that are not predicted by models of mate choice based on proximity or 'passive attraction' to the strongest signal5. These include repeated partner exchanges2, escalated exchanges of mating pheromones6-9, and rejection of gametes that signal at low levels8,9.			PAGEL, M (corresponding author), UNIV LONDON, QUEEN MARY & WESTFIELD COLL, SCH MATH SCI, LONDON E1 4NS, ENGLAND.							ACHSTETTER T, 1989, MOL CELL BIOL, V9, P4507, DOI 10.1128/MCB.9.10.4507; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSSON M, 1986, EVOLUTION, V40, P804, DOI 10.1111/j.1558-5646.1986.tb00540.x; CRANDALL M, 1977, RECEPTORS RECOGNITIO, P45; CRANDALL M, 1978, S SOC EXPT BIOL CELL, P105; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; MACHLIS L, 1973, PLANT PHYSIOL, V52, P527, DOI 10.1104/pp.52.6.527; MASCARENHAS JP, 1978, RECEPTORS RECOGNIT B, P169; Maynard Smith J., 1982, pi; Miller R.L., 1985, P275; MUSGRAVE A, 1987, TRENDS BIOCHEM SCI, V12, P470, DOI 10.1016/0968-0004(87)90232-5; Parker G.A., 1982, P173; Pomiankowski A.N., 1988, Oxford Surveys in Evolutionary Biology, V5, P136; POMMERVILLE J, 1977, EXP CELL RES, V109, P43, DOI 10.1016/0014-4827(77)90042-8; STRAZDIS JR, 1983, NATURE, V305, P543, DOI 10.1038/305543a0; WIESE L, 1978, S SOC EXPT BIOL CELL, P83; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	23	30	31	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					539	541		10.1038/363539a0	http://dx.doi.org/10.1038/363539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505979				2022-12-01	WOS:A1993LF93900048
J	BRAUN, MM; COTE, TR; RABKIN, CS				BRAUN, MM; COTE, TR; RABKIN, CS			TRENDS IN DEATH WITH TUBERCULOSIS DURING THE AIDS ERA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; INFECTION; EPIDEMIC; MORTALITY; IMPACT	Objective.-To describe and analyze recent changes in tuberculosis mortality in the United States during the acquired immunodeficiency syndrome (AIDS) epidemic. Design.-We used National Center for Health Statistics multiple-cause mortality data and analyzed deaths with tuberculosis (1980 through 1990) and/or AIDS (1987 through 1990) as an underlying or associated cause. We also categorized the 50 states and the District of Columbia into high (five states), medium (23 states), and low (23 states) AIDS incidence groups and then compared the groups' rates of death with tuberculosis during the period 1980 through 1990. Study Population.-Residents of the United States who died in the period 1980 through 1990. Main Outcome Measures.-Death certificates indicating AIDS and/or tuberculosis. Results.-A bimodal age distribution of persons dying with tuberculosis has emerged concurrent with the AIDS epidemic. A new peak spanning the ages 20 to 49 years accompanies the preexisting peak in the elderly. In 1990, 54.2% (729/1344) of the deaths with tuberculosis in persons 20 to 49 years of age occurred in persons who also had AIDS listed on their death certificates. During the period 1987 through 1990, there was an increasing trend in the proportion of AIDS deaths that also had tuberculosis: 2.3% (353/15 075) in 1987, 2.5% (460/18 649) in 1988, 3.0% (738/24 607) in 1989, and 3.0% (836/27 975) in 1990 (P<.001). Of AIDS deaths in 1990, 1.6% (253/15 565) of whites died with tuberculosis, compared with 4.7% (400/8533) of blacks (P<.001) and 4.7% (172/3666) of Hispanics (P<.001). In the high AIDS incidence states, the rate of death with tuberculosis in persons aged 20 to 49 years rose from 0.61 to 2.82 per 100 000 population in the period 1982 through 1990, an increase of 362%. For this age group in the states with medium and low AIDS incidence, the rates of death with tuberculosis during this period rose 52% and 47% (from 0.44 to 0.67 and from 0.19 to 0.28 per 100 000 population), respectively. The increases in the rate of death with tuberculosis within all three groups and the differences among the groups were all highly statistically significant (P<.001). Conclusion.-The AIDS epidemic has significantly increased the number and rate of tuberculosis deaths in younger adults through 1990, although in this study discrimination of deaths due to tuberculosis from deaths with tuberculosis was not possible. Vigorous efforts to prevent and treat tuberculosis and AIDS are indicated to reverse the trends we have described.	NCI,ENVIRONM EPIDEMIOL BRANCH,ENVIRONM STUDIES SECT,BETHESDA,MD 20892; NCI,VIRAL STUDIES SECT,BETHESDA,MD 20892; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								[Anonymous], 1992, MMWR Recomm Rep, V41, P51; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; CASTRO KG, 1992, MMWR MORB MORTAL WKL, V41, P6; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732	24	64	67	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2865	2868		10.1001/jama.269.22.2865	http://dx.doi.org/10.1001/jama.269.22.2865			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497090				2022-12-01	WOS:A1993LE93600022
J	SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP				SOUTHALL, DP; CRONIN, BC; HARTMANN, H; HARRISONSEWELL, C; SAMUELS, MP			INVASIVE PROCEDURES IN CHILDREN RECEIVING INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							PAIN				SOUTHALL, DP (corresponding author), N STAFFORDSHIRE HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; HARPIN VA, 1983, ARCH DIS CHILD, V58, P226, DOI 10.1136/adc.58.3.226; McGrath PJ., 1987, PAIN CHILDREN ADOLES; TOHILL J, 1990, LANCET, V336, P569, DOI 10.1016/0140-6736(90)92127-4	5	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1512	1513		10.1136/bmj.306.6891.1512-a	http://dx.doi.org/10.1136/bmj.306.6891.1512-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518680	Green Published, Bronze			2022-12-01	WOS:A1993LF94000026
J	GRUER, L; CAMERON, J; ELLIOTT, L				GRUER, L; CAMERON, J; ELLIOTT, L			BUILDING A CITY WIDE SERVICE FOR EXCHANGING NEEDLES AND SYRINGES	BRITISH MEDICAL JOURNAL			English	Article							DRUG-ABUSERS; INFECTION	How best can injecting drug misusers obtain clean injecting equipment in a city where drug injecting is widespread? An exchange service for needles and syringes throughout Glasgow has been established in health centres and clinics in the evening. Over the past four years seven new exchanges have been opened and over 2700 injecting drug misusers have attended. Attendances rose from under 1000 in 1988 to 28000 in 1992. The exchanges also provide a wide range of other health and social services. Public hostility to the exchanges has abated. During the same period equipment sharing in the city diminished and the observed prevalence of HIV among injecting drug misusers stabilised at around 1%.			GRUER, L (corresponding author), RUCHILL HOSP,CTR HIV & ADDICT RESOURCE,GLASGOW G20 9NB,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				[Anonymous], 1988, AIDS DRUG MISUSE 1; BARDSLEY J, 1990, CAN J PUBLIC HEALTH, V81, P39; DONOGHOE MC, 1991, DRUGLINK, V1, P8; ELLIOTT L, IN PRESS ADDICTION; FOLLETT EAC, 1986, LANCET, V1, P446; FRISCHER M, 1992, INT J STD AIDS, V3, P288, DOI 10.1177/095646249200300412; FRISCHER M, 1991, INT J EPIDEMIOL, V20, P21; FRISCHER M, 1992, ANSWER AIDS NEWS S, V13, P1; GRUER LD, 1991, INT J STD AIDS, V2, P356, DOI 10.1177/095646249100200509; Hart G, 1989, AIDS Care, V1, P125, DOI 10.1080/09540128908260247; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HAW S, 1991, ANSWER AIDS NEWS S, V31, P1; MCKEGANEY N, 1992, BMJ-BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; SCOTT RN, 1992, BRIT MED J, V304, P1630, DOI 10.1136/bmj.304.6842.1630; SMITSON GB, 1988, BMJ, V286, P1717; Stimson GV, 1988, INJECTING EQUIPMENT; 1992, 1991 92 GREAT GLASGL	18	33	33	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1394	1397		10.1136/bmj.306.6889.1394	http://dx.doi.org/10.1136/bmj.306.6889.1394			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518609	Green Published, Bronze			2022-12-01	WOS:A1993LD82900026
J	NICHOLSON, KG				NICHOLSON, KG			IMMUNIZATION AGAINST INFLUENZA AMONG PEOPLE AGED OVER 65 LIVING AT HOME IN LEICESTERSHIRE DURING WINTER 1991-2	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; REDUCTION; DEATHS; IMMUNIZATION; PNEUMONIA; MORTALITY	Objectives-To assess the size of the elderly population for whom influenza vaccine is indicated and how many are vaccinated. Design-Cohort questionnaire study. Setting-Leicestershire general practices. Subjects-800 elderly subjects selected at random from the Leicestershire family health services authority list who were not living in residential care, 565 of whom returned a questionnaire. Main outcome measures-Patient profile, vaccine offers, vaccination status, and reasons for not accepting vaccine. Results-170 of 334 (51%) people aged 65-74 years and 106 of 205 (52%) aged greater-than-or-equal-to 75 years had one or more medical indications for influenza vaccine. 195 people were offered vaccine, 49 of whom had no risk factor. 152 offers were made opportunistically during visits to the practice and only six were made in writing or by telephone. Overall 113 of 266 patients with known medical indications were immunised. Vaccine was accepted by 148 of 189 (78%) offered it, and, as judged by acceptance in sequential years, influenza vaccine was well tolerated. The main reasons for not being vaccinated were misconception about risk status and inadequate advice from doctors. Conclusions-The prevalence of medical indications for vaccine is not large enough to justify a policy of universal immunisation. Most patients offered vaccine accept it and tolerate it well. Improved targeting and education is needed to increase immunisation of people at risk.			NICHOLSON, KG (corresponding author), DEPT MICROBIOL,MED SCI BLDG,POB 138,LEICESTER LE1 9HN,ENGLAND.							ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; Ashley J., 1991, Population Trends, P16; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; CURWEN M, 1990, BRIT MED J, V300, P896; FEERY BJ, 1979, J INFECT DIS, V139, P237, DOI 10.1093/infdis/139.2.237; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HOWELLS CHL, 1975, LANCET, V1, P381; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; NGUYENVANTAM JS, 1992, EPIDEMIOL INFECT, V108, P537, DOI 10.1017/S0950268800050032; NICHOLSON KG, 1987, VACCINE, V5, P302, DOI 10.1016/0264-410X(87)90156-3; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; SERFLING RE, 1967, AM J EPIDEMIOL, V86, P433, DOI 10.1093/oxfordjournals.aje.a120753; Serie C, 1977, Dev Biol Stand, V39, P317; WISELKA MJ, 1992, LANCET, V339, P367; 1990, IMMUNISATION INFECTI	16	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					974	976		10.1136/bmj.306.6883.974	http://dx.doi.org/10.1136/bmj.306.6883.974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490478	Bronze, Green Published			2022-12-01	WOS:A1993KX43600023
J	Shaper, AG				Shaper, AG			Reflections on the seven countries study	LANCET			English	Editorial Material											Shaper, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							BLACKBURN H, 1995, TRAIL HEART ATTACKS, P148; Kromhout D., 1994, 7 COUNTRIES STUDY SC, P219; TOSHIMA H, 1994, LESSONS SCI 7 COUNTR, P243	3	7	7	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					208	208		10.1016/S0140-6736(96)90396-7	http://dx.doi.org/10.1016/S0140-6736(96)90396-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551873				2022-12-01	WOS:A1996TT06900002
J	Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA				Parrington, J; Swann, K; Shevchenko, VI; Sesay, AK; Lai, FA			Calcium oscillations in mammalian eggs triggered by a soluble sperm protein	NATURE			English	Article							SEA-URCHIN EGGS; FERTILIZATION; ACTIVATION; OOCYTES; FUSION	AT fertilization in mammals, the sperm induces a characteristic series of Ca2+ oscillations in the egg which serve as the essential trigger for egg activation and early development of the embryo(1-3). It is not known how the sperm initiates this fundamental process, however(4-6), nor has any pathway linking sperm-egg membrane-receptor binding with intracellular Ca2+ release been demonstrated(7-11). Microinjection of sperm extracts into mammalian eggs elicits Ca2+ oscillations identical to those occurring at fertilization(12-14), which suggests that sperm may introduce a Ca2+ oscillation-inducing factor into the egg on gamete membrane fusion(12,15-18). Here we identify a soluble sperm protein that exhibits Ca2+ oscillation-inducing ('oscillogen') activity in eggs, Sperm oscillogen exists as an oligomer with a subunit of M(r) 33K and a specific intracellular localization at the equatorial segment of the sperm head. Cloning of the 33K oscillogen complementary DNA indicates similarity with a hexose phosphate isomerase found in prokaryotes. This sperm-derived oscillogen, termed oscillin, may represent the physiological trigger for development in mammals.	NATL INST MED RES, MRC, LONDON NW7 1AA, ENGLAND; ST GEORGE HOSP, SCH MED, MRC, EXPTL EMBRYOL & TERATOL UNIT, LONDON SW17 0RE, ENGLAND; UCL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND	MRC National Institute for Medical Research; St Georges University London; University of London; University College London			Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Lai, Tony/0000-0003-2852-8547; Swann, Karl/0000-0002-4355-1449				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berrie CP, 1996, BIOCHEM J, V313, P369, DOI 10.1042/bj3130369; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DALE B, 1985, EXPERIENTIA, V41, P1068, DOI 10.1007/BF01952148; DOZORTSEV D, 1995, HUM REPROD, V10, P403, DOI 10.1093/oxfordjournals.humrep.a135952; Foltz KR, 1993, ZYGOTE, V1, P276, DOI 10.1017/S0967199400001593; HARLOW E, 1988, ANTIBODIES LABORATOR; HOMA ST, 1994, HUM REPROD, V9, P2356, DOI 10.1093/oxfordjournals.humrep.a138452; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; NUCCITELLI R, 1991, CURR TOP DEV BIOL, V25, P1; OHLENDIECK K, 1995, TRENDS BIOCHEM SCI, V20, P29, DOI 10.1016/S0968-0004(00)88947-1; Shen SS, 1992, CURR OPIN GENET DEV, V2, P642, DOI 10.1016/S0959-437X(05)80185-6; STICE SL, 1990, MOL REPROD DEV, V25, P272, DOI 10.1002/mrd.1080250309; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; Swann K, 1993, ZYGOTE, V1, P273, DOI 10.1017/S0967199400001581; TESARIK J, 1994, HUM REPROD, V9, P511, DOI 10.1093/oxfordjournals.humrep.a138537; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Yanagimachi R., 1988, P135	26	339	345	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					364	368		10.1038/379364a0	http://dx.doi.org/10.1038/379364a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552195				2022-12-01	WOS:A1996TR32300064
J	LeDuc, JW				LeDuc, JW			World Health Organization strategy for emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LeDuc, JW (corresponding author), WHO,DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], 1995, WKLY EPIDEMIOL REC, V5, P35; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; Lederberg J., 1992, EMERGING INFECT MICR; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; OBRIEN TF, 1995, EMERG INFECT DIS, V1, P66, DOI 10.3201/eid0102.950209; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; 1994, B WORLD HEALTH ORGAN, V72, P845; 1995, WHOCDSBVI952 PUBL; 1995, REPORT NATIONAL SCI	12	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					318	320		10.1001/jama.275.4.318	http://dx.doi.org/10.1001/jama.275.4.318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544274				2022-12-01	WOS:A1996TP96500030
J	AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN				AlChalabi, A; Enayat, ZE; Bakker, MC; Sham, PC; Ball, DM; Shaw, CE; Lloyd, CM; Powell, JF; Leigh, PN			Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease	LANCET			English	Article							SPORADIC ALZHEIMERS-DISEASE	Background Variants of the apolipoprotein E (APOE) gene influence the age of onset of Alzheimer's disease. APOE may influence the presentation of other neurological diseases. We investigated the relationship between the allelic variants of apolipoprotein E and clinical presentation in motor neuron disease. Methods 123 patients with motor neuron disease and 121 controls were studied. Diagnosis, location of onset and date of onset were recorded prospectively. Genotyping was performed blind to clinical information. Findings Possession of at least one epsilon 4 allele was significantly more common in patients with bulbar onset motor neuron disease (14/33, 42%) than in limb onset patients (20/90, 22%) and controls (26/121, 21%) (chi(2)=4.93, p=0.026 and chi(2)=5.91, p=0.015, respectively). Interpretation These results suggest that the apolipoprotein E epsilon 4 allele may influence the pattern of motor neuron loss in motor neuron disease and that it may affect neuronal function in ways unrelated to the deposition of beta-amyloid or accumulation of neurofibrillary tangles.	INST PSYCHIAT,DEPT CLIN NEUROSCI,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,KINGS MND CARE & RES CTR,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHOL,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London			Al-Chalabi, Ammar/E-5361-2010; Leigh, Peter/AAD-5638-2019; Powell, John F/G-4412-2011	Al-Chalabi, Ammar/0000-0002-4924-7712; Powell, John F/0000-0001-6124-439X				ABRAHAMS S, 1995, J NEUROL SCI, V129, P54, DOI 10.1016/0022-510X(95)00063-8; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NORRIS F, 1993, J NEUROL SCI, V118, P48, DOI 10.1016/0022-510X(93)90245-T; REBECK GW, 1993, NEURON, V11, P575; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHNEIDER JA, 1995, ANN NEUROL, V38, P131, DOI 10.1002/ana.410380122; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WHENHAM PR, 1991, LANCET, V337, P1158	10	83	84	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					159	160		10.1016/S0140-6736(96)90343-8	http://dx.doi.org/10.1016/S0140-6736(96)90343-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544551				2022-12-01	WOS:A1996TQ24400012
J	Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L				Bednarek, SY; Ravazzola, M; Hosobuchi, M; Amherdt, M; Perrelet, A; Schekman, R; Orci, L			COPI- and COPII-coated vesicles bud directly from the endoplasmic reticulum in yeast	CELL			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; TRANSPORT VESICLES; GOLGI-COMPLEX; GUANINE-NUCLEOTIDE; PROTEIN-TRANSPORT; BETA-COP; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; MEMBRANE-PROTEIN	The cytosolic yeast proteins Sec13p-Sec31p, Sec23p-Sec24p, and the small GTP-binding protein Sar1p generate protein transport vesicles by forming the membrane coat termed COPII. We demonstrate by thin section and immunoelectron microscopy that purified COPII components form transport vesicles directly from the outer membrane of isolated yeast nuclei. Another set of yeast cytosolic proteins, coatomer and Arf1p (COPI), also form coated buds and vesicles from the nuclear envelope. Formation of COPI-coated, but not COPII-coated, buds and vesicles on the nuclear envelope is inhibited by the fungal metabolite brefeldin A. The two vesicle populations are distinct. However, both vesicle types are devoid of endoplasmic reticulum (ER) resident proteins, and each contains targeting proteins necessary for docking at the Golgi complex. Our data suggest that COPI and COPII mediate separate vesicular transport pathways from the ER.	UNIV GENEVA, SCH MED, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	Bednarek, SY (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DOERING TL, 1996, IN PRESS EMBO J; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; OPRINS A, 1994, J CELL BIOL, V124, P725; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, P NATL ACAD SCI USA, V90, P11089, DOI 10.1073/pnas.90.23.11089; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SEGAARD M, 1994, CELL, V8, P937; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	60	234	242	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1183	1196		10.1016/0092-8674(95)90144-2	http://dx.doi.org/10.1016/0092-8674(95)90144-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548805	Bronze			2022-12-01	WOS:A1995TM76200014
J	GRAUSCHOPF, U; WINTHER, JR; KORBER, P; ZANDER, T; DALLINGER, P; BARDWELL, JCA				GRAUSCHOPF, U; WINTHER, JR; KORBER, P; ZANDER, T; DALLINGER, P; BARDWELL, JCA			WHY IS DSBA SUCH AN OXIDIZING DISULFIDE CATALYST	CELL			English	Article							BOND FORMATION INVIVO; ESCHERICHIA-COLI; ISOMERASE DSBA; REDOX PROPERTIES; ACTIVE-SITE; IN-VIVO; THIOREDOXIN	DsbA, a member of the thioredoxin family of disulfide oxidoreductases, acts in catalyzing disulfide bond formation by donating its disulfide to newly translocated proteins. We have found that the two central residues within the active site Cys-30-Pro-31-His-32-Cys-33 motif are critical in determining the exceptional oxidizing power of DsbA. Mutations that change these two residues can alter the equilibrium oxidation potential of DsbA by more than 1000-fold. A quantitative explanation for the very high redox potential of DsbA was found by measuring the pK(a) of a single residue, Cys-30. The pK(a) of Cys-80 varied dramatically from mutant to mutant and could accurately predict the oxidizing power of each DsbA mutant protein.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY	University of Regensburg			Winther, Jakob R./K-4451-2014; Korber, Philipp/AAN-7633-2021	Winther, Jakob R./0000-0001-6995-9154; Korber, Philipp/0000-0001-7526-6549				BARDWELL J, 1994, PHOSPHATE IN MICROORGANISMS, P270; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; FREEDMAN RB, 1994, CURR BIOL, V4, P933, DOI 10.1016/S0960-9822(00)00210-4; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GUILHOT C, 1995, IN PRESS P NATL ACAD; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; WUNDERLICH M, 1994, THESIS U REGENSBURG; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	33	277	290	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					947	955		10.1016/0092-8674(95)90210-4	http://dx.doi.org/10.1016/0092-8674(95)90210-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521518	Bronze			2022-12-01	WOS:A1995TK74500013
J	YUSEFZADEH, F; UCHIDA, KI; ROBERTS, D				YUSEFZADEH, F; UCHIDA, KI; ROBERTS, D			SHOCK-EXCITED OH MASER EMISSION OUTLINING THE GALACTIC-CENTER SUPERNOVA REMNANT G359.1-0.05	SCIENCE			English	Article							MOLECULAR CLOUDS; SHELL	A search using the Very Large Array was performed for 1720-megahertz OH maser line emission from a number of nonthermal radio continuum sources in the galactic center region. The 1720-megahertz transition has recently been noted for its potential as a tracer of shock activity. The most striking result was the detection of extended 1720-megahertz OH maser emission, as well as a number of compact OH maser features, along the interface between a large-scale continuum shell (G359.1-0.5) and its surrounding ring of high-velocity molecular gas. The morphological correlation among the neutral gas, the nonthermal shell, and the maser features provides strong support for the hypothesis that the 1720-megahertz maser line of OH arises from gas shocked by the impact of the expanding supernova remnant into the molecular material. However, the radial velocities of the molecular cloud surrounding G359.1-0.5 are more negative than that of the OH maser spots by more than 50 kilometers per second. Here it is suggested that only the low-radial-velocity component of the carbon monoxide material at the limb of the remnant satisfies the physical conditions required for collisional pumping of the OH 1720-megahertz line behind the expanding shock front.	MAX PLANCK INST RADIOASTRON,D-53121 BONN,GERMANY; UNIV ILLINOIS,DEPT ASTRON,CHAMPAIGN,IL 61801	Max Planck Society; University of Illinois System; University of Illinois Urbana-Champaign	YUSEFZADEH, F (corresponding author), NORTHWESTERN UNIV,DEPT PHYS & ASTRON,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.							BALLY J, 1988, ASTROPHYS J, V324, P223, DOI 10.1086/165891; ELITZUR M, 1976, ASTROPHYS J, V203, P124, DOI 10.1086/154054; FRAIL DA, 1994, ASTROPHYS J, V424, pL111, DOI 10.1086/187287; GRAY AD, 1991, NATURE, V353, P237, DOI 10.1038/353237a0; HOLLENBACH D, 1989, ASTROPHYS J, V342, P306, DOI 10.1086/167595; LISZT HS, 1985, ASTROPHYS J, V293, pL65, DOI 10.1086/184492; TURNER BE, 1982, ASTROPHYS J, V255, pL33, DOI 10.1086/183764; UCHIDA K, 1992, ASTRON J, V104, P1533, DOI 10.1086/116337; UCHIDA KI, 1992, ASTROPHYS J, V398, P128, DOI 10.1086/171842; WARDLE M, 1991, MON NOT R ASTRON SOC, V251, P119, DOI 10.1093/mnras/251.1.119; YUSEFZADEH F, 1984, NATURE, V310, P557, DOI 10.1038/310557a0	11	52	52	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1801	1804		10.1126/science.270.5243.1801	http://dx.doi.org/10.1126/science.270.5243.1801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525369				2022-12-01	WOS:A1995TK47600039
J	KISSINGER, CR; PARGE, HE; KNIGHTON, DR; LEWIS, CT; PELLETIER, LA; TEMPCZYK, A; KALISH, VJ; TUCKER, KD; SHOWALTER, RE; MOOMAW, EW; GASTINEL, LN; HABUKA, N; CHEN, XH; MALDONADO, F; BARKER, JE; BACQUET, R; VILLAFRANCA, JE				KISSINGER, CR; PARGE, HE; KNIGHTON, DR; LEWIS, CT; PELLETIER, LA; TEMPCZYK, A; KALISH, VJ; TUCKER, KD; SHOWALTER, RE; MOOMAW, EW; GASTINEL, LN; HABUKA, N; CHEN, XH; MALDONADO, F; BARKER, JE; BACQUET, R; VILLAFRANCA, JE			CRYSTAL-STRUCTURES OF HUMAN CALCINEURIN AND THE HUMAN FKBP12-FK506-CALCINEURIN COMPLEX	NATURE			English	Article							FKBP-FK506	CALCINEURIN (CaN) is a calcium- and calmodulin-dependent protein serine/threonine phosphatase which is critical for several important cellular processes, including T-cell activation(1). CaN is the target of the immunosuppressive drugs cyclosporin A and FK506, which inhibit CaN after forming complexes with cytoplasmic binding proteins (cyclophilin and FKBP12, respectively)(2). We report here the crystal structures of full-length human CaN at 2.1 Angstrom resolution and of the complex of human CaN with FKBP12-FK506 at 3.5 Angstrom resolution. In the native CaN structure, an autoinhibitory element binds at the Zn/Fe-containing active site. The metal-site geometry and active-site water structure suggest a catalytic mechanism involving nucleophilic attack on the substrate phosphate by a metal-activated water molecule. In the FKBP12-FK506-CaN complex, the auto-inhibitory element is displaced from the active site. The site of binding of FKBP12-FK506 appears to be shared by other non-competitive inhibitors of calcine-urin, including a natural anchoring protein.	AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	Pfizer				Moomaw, Ellen/0000-0002-2341-1676				BABU YS, 1988, J MOL BIOL, V203, P191; BRUNGER AT, 1993, X PLOR VERSION 3 1 M; BURROUGHS SE, 1994, BIOCHEMISTRY-US, V33, P10428, DOI 10.1021/bi00200a026; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUERINI D, 1992, J BIOL CHEM, V267, P22542; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWIS C, 1995, FASEB J, V9, pA1346; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1990, FASEB J, V4, pA2237; Qin K. -F., 1995, FASEB J, V9, pA1347; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, P1; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040	29	673	702	4	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					641	644		10.1038/378641a0	http://dx.doi.org/10.1038/378641a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524402				2022-12-01	WOS:A1995TJ22100085
J	FRISCH, M; FRIIS, S; KJAER, SK; MELBYE, M				FRISCH, M; FRIIS, S; KJAER, SK; MELBYE, M			FALLING INCIDENCE OF PENIS CANCER IN AN UNCIRCUMCISED POPULATION (DENMARK 1943-90)	BRITISH MEDICAL JOURNAL			English	Article									DANISH CANC SOC,RES CTR,DIV CANC EPIDEMIOL,COPENHAGEN,DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Kjaer, Susanne/0000-0002-8347-1398; melbye, mads/0000-0001-8264-6785				GORDON A, 1993, BRIT MED J, V306, P1, DOI 10.1136/bmj.306.6869.1; Nomura A, 1982, CANCER EPIDEMIOL, P624; Remondino PC, 1891, HIST CIRCUMCISION; Wolbarst AL, 1932, LANCET, V1, P150; 1943, STATISTISK ARBOG, P32; 1991, STATISTISK ARBOG, P73	6	92	93	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1471	1471		10.1136/bmj.311.7018.1471	http://dx.doi.org/10.1136/bmj.311.7018.1471			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520335	Green Published			2022-12-01	WOS:A1995TJ04400024
J	ISOM, LL; RAGSDALE, DS; DEJONGH, KS; WESTENBROEK, RE; REBER, BFX; SCHEUER, T; CATTERALL, WA				ISOM, LL; RAGSDALE, DS; DEJONGH, KS; WESTENBROEK, RE; REBER, BFX; SCHEUER, T; CATTERALL, WA			STRUCTURE AND FUNCTION OF THE BETA-2 SUBUNIT OF BRAIN SODIUM-CHANNELS, A TRANSMEMBRANE GLYCOPROTEIN WITH A CAM MOTIF	CELL			English	Article							AMINO-ACID SEQUENCE; RAT-BRAIN; SKELETAL-MUSCLE; ALPHA-SUBUNIT; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; NA+ CHANNELS; EXPRESSION; PROTEIN; NEURONS	Voltage-gated sodium channels in brain neurons are complexes of a pore-forming alpha subunit with smaller beta 1 and beta 2 subunits, cDNA cloning and sequencing showed that the beta 2 subunit is a 186 residue glycoprotein with an extracellular NH2-terminal domain containing an immunoglobulin-like fold with similarity to the neural cell adhesion molecule (CAM) contactin, a single transmembrane segment, and a small intracellular domain, Coexpression of beta 2 with alpha subunits in Xenopus oocytes increases functional expression, modulates gating, and causes up to a 4-fold increase in the capacitance of the oocyte, which results from an increase in the surface area of the plasma membrane microvilli. beta 2 subunits are unique among the auxiliary subunits of ion channels in combining channel modulation with a CAM motif and the ability to expand the cell membrane surface area. They may be important regulators of sodium channel expression and localization in neurons.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Isom, Lori/0000-0002-9479-6729	NCRR NIH HHS [M01 RR00042] Funding Source: Medline; NINDS NIH HHS [NS 25704] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DUGANDZIJANOVAKOVIC S, 1995, J NEUROSCI, V15, P492; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B., 1992, IONIC CHANNELS EXCIT; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JUNG M, 1993, GLIA, V9, P163, DOI 10.1002/glia.440090302; KELLY GM, 1991, METHOD CELL BIOL, V36, P389; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINSON SR, 1986, ANN NY ACAD SCI, V479, P162, DOI 10.1111/j.1749-6632.1986.tb15568.x; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; QU Y, 1995, IN PRESS J BIOL CHEM; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; REBER BFX, 1987, J BIOL CHEM, V262, P11369; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; VAUGHAN L, 1994, PERSPECT DEV NEUROBI, V2, P43; WESTENBROEK RE, 1992, J NEUROSCI, V12, P2259, DOI 10.1523/jneurosci.12-06-02259.1992; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOLLNER DA, 1988, NEURON, V1, P727, DOI 10.1016/0896-6273(88)90171-7; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D; ZINSCH AH, 1992, J CELL BIOL, V119, P203	44	385	395	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					433	442		10.1016/0092-8674(95)90121-3	http://dx.doi.org/10.1016/0092-8674(95)90121-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521473	Bronze			2022-12-01	WOS:A1995TC97700013
J	BRILLEDWARDS, P; GINSBERG, JS; JOHNSTON, M; HIRSH, J				BRILLEDWARDS, P; GINSBERG, JS; JOHNSTON, M; HIRSH, J			ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPARIN; PARTIAL THROMBOPLASTIN TIME; THROMBOEMBOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; ANTICOAGULANTS	PARTIAL THROMBOPLASTIN TIME; MOLECULAR-WEIGHT HEPARIN; CONTINUOUS INTRAVENOUS HEPARIN; PROXIMAL-VEIN THROMBOSIS; VENOUS THROMBOSIS; SUBCUTANEOUS HEPARIN; INITIAL TREATMENT; STANDARD HEPARIN; INVITRO; SAMPLE	Objective: To compare two methods of determining a therapeutic range of activated partial thromboplastin time (aPTT) results. Design: Cohort studies. Setting: Referral teaching hospital. Patients: Inpatients who received unfractionated heparin intravenously for venous thromboembolic disease. Measurements: A therapeutic range determined by aPTT ratios of 1.5 to 2.5 times the control value as compared with a therapeutic range determined by protamine titration heparin levels of 0.2 to 0.4 U/mL. Results: For all aPTT reagents studied, a ratio of 1.5 times the control value is much less than a minimum protamine titration heparin level of 0.2 U/mL. Various manufacturers' aPTT reagents and reagent lots from the same manufacturer show considerable variation in response to heparin and therefore have different therapeutic ranges. Conclusions: A different dose of heparin would be required to produce an aPTT ratio of 1.5 times the control value, depending on the reagent used. Establishing a therapeutic range for aPTT results using protamine titration heparin levels of 0.2 to 0.4 U/mL as a reference standard is practical and compensates for the variable response of aPTT reagents to heparin.	HAMILTON CIVIC HOSP, RES CTR, HAMILTON, ON, CANADA	McMaster University	BRILLEDWARDS, P (corresponding author), MCMASTER UNIV, MED CTR, 1200 MAIN ST W, HSC-3W12, HAMILTON L8N 3Z5, ONTARIO, CANADA.		ginsberg, jeffrey s/ABC-1065-2020					ANSELL J, 1991, AM J CLIN PATHOL, V95, P222, DOI 10.1093/ajcp/95.2.222; BAIN B, 1980, AM J CLIN PATHOL, V74, P668; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BRANDT JT, 1981, AM J CLIN PATHOL, V76, P530; CHIU HM, 1977, BLOOD, V49, P171; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; GAWOSKI JM, 1987, ARCH PATHOL LAB MED, V111, P785; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; LENTZ SR, 1992, MANUAL MED THERAPEUT, P323; MOSER KM, 1991, HARRISONS PRINCIPLES, P1090; POLLER L, 1989, AM J CLIN PATHOL, V92, P124, DOI 10.1093/ajcp/92.1.124; POLLER L, 1989, RES CLIN LAB, V19, P363; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; REFN I, 1954, SCAND J CLIN LAB INV, V6, P284, DOI 10.3109/00365515409134865; SCIALLA SJ, 1985, AM J CLIN PATHOL, V84, P351, DOI 10.1093/ajcp/84.3.351; SHOJANIA AM, 1988, AM J CLIN PATHOL, V89, P19, DOI 10.1093/ajcp/89.1.19; SPECTOR I, 1967, JAMA-J AM MED ASSOC, V201, P75; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANDENBESSELAAR AMHP, 1990, THROMB HAEMOSTASIS, V63, P16; WESSLER S, 1955, CIRCULATION, V12, P553, DOI 10.1161/01.CIR.12.4.553; ZANKE B, 1990, AM J CLIN PATHOL, V93, P684, DOI 10.1093/ajcp/93.5.684; ZUCKER S, 1969, J LAB CLIN MED, V73, P320; [No title captured]	28	264	267	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					104	109		10.7326/0003-4819-119-2-199307150-00002	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8512158				2022-12-01	WOS:A1993LU90200002
J	JONIDES, J; SMITH, EE; KOEPPE, RA; AWH, E; MINOSHIMA, S; MINTUN, MA				JONIDES, J; SMITH, EE; KOEPPE, RA; AWH, E; MINOSHIMA, S; MINTUN, MA			SPATIAL WORKING-MEMORY IN HUMANS AS REVEALED BY PET	NATURE			English	Article							PREFRONTAL CORTEX; IMAGERY	THE concept of working memory is central to theories of human cognition because working memory is essential to such human skills as language comprehension and deductive reasoning1-4. Working memory is thought to be composed of two parts, a set of buffers that temporarily store information in either a phonological or visuospatial form, and a central executive responsible for various computations such as mental arithmetic5,6. Although most data on working memory come from behavioural studies of normal and brain-injured humans7, there is evidence about its physiological basis from invasive studies of monkeys8-10. Here we report positron emission tomography (PET) studies of regional cerebral blood flow in normal humans that reveal activation in right-hemisphere prefrontal, occipital, parietal and premotor cortices accompanying spatial working memory processes. These results begin to uncover the circuitry of a working memory system in humans.	UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; PRESBYTERIAN UNIV HOSP, DIV NUCL MED, PITTSBURGH, PA 15213 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	JONIDES, J (corresponding author), UNIV MICHIGAN, DEPT PSYCHOL, ANN ARBOR, MI 48109 USA.			Awh, Edward/0000-0002-5211-5278; Minoshima, Satoshi/0000-0002-0043-3047				BADDELEY A, 1988, J MEM LANG, V27, P586, DOI 10.1016/0749-596X(88)90028-9; Baddeley A.D., 1986, WORKING MEMORY; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; CHAFEE M, 1989, SOC NEUR ABSTR, V15, P786; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; FARAH MJ, 1988, PSYCHOL REV, V95, P307, DOI 10.1037/0033-295X.95.3.307; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOLDENBERG G, 1987, NEUROPSYCHOLOGIA, V25, P473, DOI 10.1016/0028-3932(87)90072-8; Goldmanrakic PS., 1987, HDB PHYSL NERVOUS SY, P373; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Holding D.H., 1985, PSYCHOL CHESS SKILL; KOSSLYN SM, IN PRESS J COGN NEUR; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; MINOSHIMA S, 1993, J NUCL MED, V34, P322; PASSINGHAM RE, 1985, BEHAV NEUROSCI, V99, P3, DOI 10.1037/0735-7044.99.1.3; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Tesak J, 2005, NEUROPSYCHOLOGICAL I	21	914	925	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					623	625		10.1038/363623a0	http://dx.doi.org/10.1038/363623a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510752	Green Published			2022-12-01	WOS:A1993LH13900054
J	SMITH, RG; CHENG, K; SCHOEN, WR; PONG, SS; HICKEY, G; JACKS, T; BUTLER, B; CHAN, WWS; CHAUNG, LYP; JUDITH, F; TAYLOR, J; WYVRATT, MJ; FISHER, MH				SMITH, RG; CHENG, K; SCHOEN, WR; PONG, SS; HICKEY, G; JACKS, T; BUTLER, B; CHAN, WWS; CHAUNG, LYP; JUDITH, F; TAYLOR, J; WYVRATT, MJ; FISHER, MH			A NONPEPTIDYL GROWTH-HORMONE SECRETAGOGUE	SCIENCE			English	Article							PITUITARY-CELLS; INVIVO ACTIVITY; GH RELEASE; HIS-D-TRP-ALA-TRP-D-PHE-LYS-NH2; DISCOVERY; INVITRO; ACTS; MEN	A nonpeptidyl secretagogue for growth hormone of the structure 3-amino-3-methyl-N-(2,3,4,5-tetrahydro-2-oxo-1-{[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methy1}-1H-1-benzazepin-3(R)-yl)-butanamide (L-692,429) has been identified. L-692,429 synergizes with the natural growth hormone secretagogue growth hormone-releasing hormone and acts through an alternative signal transduction pathway. The mechanism of action of L-692,429 and studies with peptidyl and nonpeptidyl antagonists suggest that this molecule is a mimic of the growth hormone-releasing hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6). L-692,429 is an example of a nonpeptidyl specific secretagogue for growth hormone.	MERCK RES LABS, DEPT BASIC MED CHEM, RAHWAY, NJ 07065 USA	Merck & Company	SMITH, RG (corresponding author), MERCK RES LABS, DEPT BASIC ANIM SCI RES, RAHWAY, NJ 07065 USA.							BLAKE AD, 1991, J ENDOCRINOL, V129, P11, DOI 10.1677/joe.0.1290011; BOWERS CY, 1990, J CLIN ENDOCR METAB, V70, P975, DOI 10.1210/jcem-70-4-975; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BRIXEN K, 1990, J BONE MINER RES, V5, P609; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; CHENG K, UNPUB; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HICKEY G, UNPUB; HOMBURG R, 1990, CLIN ENDOCRINOL, V32, P781, DOI 10.1111/j.1365-2265.1990.tb00925.x; HORBER FF, 1990, J CLIN INVEST, V86, P265, DOI 10.1172/JCI114694; HORWELL D C, 1988, Drugs of the Future, V13, P1061; MOMANY FA, 1984, ENDOCRINOLOGY, V114, P1531, DOI 10.1210/endo-114-5-1531; MORGAN BA, 1989, ANNU REP MED CHEM, V24, P243; MURPHY WJ, 1992, P NATL ACAD SCI USA, V89, P4481, DOI 10.1073/pnas.89.10.4481; NEILL JD, 1983, ENDOCRINOLOGY, V112, P1135, DOI 10.1210/endo-112-3-1135; OPNG SS, 1992, 74TH P M END SOC BET, P255; PONG SS, 1991, 73RD P ANN M END SOC, P88; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SCHOEN WR, UNPUB; SHIBASAKI T, 1984, J CLIN ENDOCR METAB, V58, P212, DOI 10.1210/jcem-58-1-212	24	317	355	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1640	1643		10.1126/science.8503009	http://dx.doi.org/10.1126/science.8503009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LG176	8503009				2022-12-01	WOS:A1993LG17600027
J	LAMME, VAF; VANDIJK, BW; SPEKREIJSE, H				LAMME, VAF; VANDIJK, BW; SPEKREIJSE, H			CONTOUR FROM MOTION PROCESSING OCCURS IN PRIMARY VISUAL-CORTEX	NATURE			English	Article							EVOKED-POTENTIALS; STRIATE CORTEX; CAT; CELLS; CONNECTIONS; ORIENTATION; SELECTIVITY; MECHANISMS; NEURONS	RELATIVE motion is one of the most salient cues for segmentation of a visual scene into separate objects. This is illustrated by the vivid contours that are perceived when random dot patterns move in different directions1,2. Once motion is hatted in such displays the segmentation contours disappear. This makes random dot patterns ideal for the study of contour from motion processing in isolation. Contour from motion processing obviously relies on direction-selective neurons, which are found in many visual cortical areas3-5. It is, however, largely unknown at what level of processing their signals interact to serve the global process of motion-based image segmentation. To answer this quesion, we recorded visually evoked potentials, both in man and in awake monkey, to a stimulus specifically designed to signal the presence of neuronal activity related to contour from motion processing. We report here that response components specific to contour from motion were elicited only when the stimulus yielded a contour percept. In awake monkey, the sources of these components were located within the supra- and infra-granular layers of primary visual cortex. We conclude that V1 is involved in image segmentation processing.	NETHERLANDS OPHTHALM RES INST,POB 12141,1100 AC AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,MED PHYS LAB,1105 AZ AMSTERDAM,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam								ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; BLASDEL GG, 1985, J NEUROSCI, V5, P3350; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; DAGNELIE G, 1989, VISUAL NEUROSCI, V3, P509, DOI 10.1017/S0952523800009858; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; HILDRETH EC, 1987, ANNU REV NEUROSCI, V10, P477, DOI 10.1146/annurev.ne.10.030187.002401; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KRAUT MA, 1985, ELECTROEN CLIN NEURO, V62, P300, DOI 10.1016/0168-5597(85)90007-3; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, IN PRESS VISUAL NEUR; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; MNAKAYAMA K, 1985, VISION RES, V25, P427; NICHOLSON C, 1975, J NEUROPHYSIOL, V38, P356, DOI 10.1152/jn.1975.38.2.356; NOTHDURFT HC, 1985, VISION RES, V25, P99, DOI 10.1016/0042-6989(85)90084-7; ORBAN GA, 1987, J NEUROPHYSIOL, V57, P1792, DOI 10.1152/jn.1987.57.6.1792; SCHIMMEL H, 1967, SCIENCE, V157, P92, DOI 10.1126/science.157.3784.92; SPORNS O, 1991, P NATL ACAD SCI USA, V88, P129, DOI 10.1073/pnas.88.1.129; Van Essen D. C., 1985, CEREBRAL CORTEX, V3	19	74	74	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					541	543		10.1038/363541a0	http://dx.doi.org/10.1038/363541a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505980				2022-12-01	WOS:A1993LF93900049
J	ANDERSON, R				ANDERSON, R			AIDS - TRENDS, PREDICTIONS, CONTROVERSY	NATURE			English	Editorial Material											ANDERSON, R (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ADES AE, 1989, J EPIDEMIOL COMMUN H, V43, P53, DOI 10.1136/jech.43.1.53; ANDERSON R M, 1991; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; CHIN J, 1992, WORLD HLTH STAT Q, V45, P22; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HYMAN JM, 1988, MATH BIOSCI, V90, P415, DOI 10.1016/0025-5564(88)90078-8; NORMAN C, 1985, SCIENCE, V230, P1020, DOI 10.1126/science.2997927; IN PRESS COMM DIS RE; 1993, MORBID WKLY REP, V41, P1; 1993, COMMUNICAB DIS REP, V3, pR1; 1993, WHOEC36 COLL CTR AID, P1	13	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					393	394		10.1038/363393a0	http://dx.doi.org/10.1038/363393a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502292	Bronze			2022-12-01	WOS:A1993LE93800025
J	HIGGINS, MW; ENRIGHT, PL; KRONMAL, RA; SCHENKER, MB; ANTONCULVER, H; LYLES, M				HIGGINS, MW; ENRIGHT, PL; KRONMAL, RA; SCHENKER, MB; ANTONCULVER, H; LYLES, M			SMOKING AND LUNG-FUNCTION IN ELDERLY MEN AND WOMEN - THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FORCED EXPIRATORY VOLUME; PULMONARY-FUNCTION; ADULT-POPULATION; ONE 2ND; MORTALITY; DISEASE; RISK; PREDICTORS; TECUMSEH; CANCER	Objective.-To investigate relationships between cigarette smoking and pulmonary function in elderly men and women. Design.-Cross-sectional analysis of baseline data from a prospective, population-based study of risk factors, preclinical, and overt cardiovascular and pulmonary disease. Setting.-Defined communities in Forsyth County, North Carolina; Pittsburgh, Pa; Sacramento County, California; and Washington County, Maryland. Population.-A total of 5201 noninstitutionalized men and women 65 years of age and older. Main Outcome Measures.-Pulmonary function; means of forced expiratory volume in 1 second (FEV1) and forced vital capacity and prevalence of low FEV1 levels. Results.-Prevalence of cigarette smoking was 10% to 20% and higher in women than men and in blacks than whites. Forced vital capacity and FEV1 levels were related positively to height and white race and negatively to age and waist girth. Age- and height-adjusted FEV1 means were 23% and 18% lower in male and female current smokers, respectively, than in never smokers but not reduced in never smokers currently living with a smoker. Smokers who quit before age 40 years had FEV1 levels similar to never smokers, but FEV1 levels were lower by 7% and 14% in smokers who quit at ages 40 to 60 years and older than 60 years, respectively. Lung function was related inversely to pack-years of cigarette use. Prevalence rates of impaired lung function were highest in current smokers and lowest in never smokers. Regression coefficients for the smoking variables were smaller in persons without cardiovascular or respiratory conditions than in the total cohort. Conclusions.-Cigarette smoking is associated with reduced pulmonary function in elderly men and women. However, smokers who quit, even after age 60 years, have better pulmonary function than continuing smokers.	UNIV ARIZONA,CTR RESP SCI,TUCSON,AZ 85721; CARDIOVAS HLTH STUDY COORDINATING CTR,SEATTLE,WA; UNIV CALIF IRVINE,CALIF COLL MED,IRVINE,CA 92717; UNIV CALIF DAVIS,DIV OCCUPAT & ENVIRONM MED,DAVIS,CA 95616; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT GERIATR MED,WINSTON SALEM,NC 27103	University of Arizona; University of California System; University of California Irvine; University of California System; University of California Davis; Wake Forest University; Wake Forest Baptist Medical Center	HIGGINS, MW (corresponding author), NHLBI,FED BLDG,ROOM 2C08,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA.				PHS HHS [N01-87086, N01-87079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECKLAKE M, 1991, AM REV RESPIR DIS, V144, P1202; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286, DOI 10.1164/ajrccm/137.2.286; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125, DOI 10.1164/ajrccm/147.1.125; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GARDNER RM, 1987, AM REV RESPIR DIS, V136, P1285; HIGGINS MW, 1982, AM REV RESPIR DIS, V125, P144; HIGGINS MW, 1970, ARCH ENVIRON HEALTH, V21, P418, DOI 10.1080/00039896.1970.10667260; HIGGINS MW, 1984, AM REV RESPIR DIS, V130, P380; KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; MILLER A, 1988, CHEST, V94, P1187, DOI 10.1378/chest.94.6.1187; NELSON SB, 1990, CHEST, V97, P288, DOI 10.1378/chest.97.2.288; NOMURA A, 1991, AM REV RESPIR DIS, V144, P307, DOI 10.1164/ajrccm/144.2.307; NORUSIS MJ, 1990, SPSS PCT STATISTICS; TELL GS, IN PRESS ANN EPIDEMI; WARE JH, 1990, AM J EPIDEMIOL, V132, P685, DOI 10.1093/oxfordjournals.aje.a115710; 1989, 898411 DEP HLTH HUM; 1992, PREVENTION PROFILE H; 1992, MMWR MORB MORTAL WKL, V41, P354; [No title captured]; 1984, PHS8450205 DEP HLTH	24	85	87	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2741	2748		10.1001/jama.269.21.2741	http://dx.doi.org/10.1001/jama.269.21.2741			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492399				2022-12-01	WOS:A1993LD67100023
J	COHEN, J				COHEN, J			FLYING DUTCHMAN - GOUDSMIT,JAAP	SCIENCE			English	Item About an Individual																		COHEN J, 1993, SCIENCE, V260, P1260, DOI 10.1126/science.8493566; COHEN J, 1993, SCIENCE, V260, P1259, DOI 10.1126/science.8493565	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1263	1263		10.1126/science.8493569	http://dx.doi.org/10.1126/science.8493569			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493569				2022-12-01	WOS:A1993LE02500026
J	LATIF, F; TORY, K; GNARRA, J; YAO, M; DUH, FM; ORCUTT, ML; STACKHOUSE, T; KUZMIN, I; MODI, W; GEIL, L; SCHMIDT, L; ZHOU, FW; LI, H; WEI, MH; CHEN, F; GLENN, G; CHOYKE, P; WALTHER, MM; WENG, YK; DUAN, DSR; DEAN, M; GLAVAC, D; RICHARDS, FM; CROSSEY, PA; FERGUSONSMITH, MA; LEPASLIER, D; CHUMAKOV, I; COHEN, D; CHINAULT, AC; MAHER, ER; LINEHAN, WM; ZBAR, B; LERMAN, MI				LATIF, F; TORY, K; GNARRA, J; YAO, M; DUH, FM; ORCUTT, ML; STACKHOUSE, T; KUZMIN, I; MODI, W; GEIL, L; SCHMIDT, L; ZHOU, FW; LI, H; WEI, MH; CHEN, F; GLENN, G; CHOYKE, P; WALTHER, MM; WENG, YK; DUAN, DSR; DEAN, M; GLAVAC, D; RICHARDS, FM; CROSSEY, PA; FERGUSONSMITH, MA; LEPASLIER, D; CHUMAKOV, I; COHEN, D; CHINAULT, AC; MAHER, ER; LINEHAN, WM; ZBAR, B; LERMAN, MI			IDENTIFICATION OF THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE	SCIENCE			English	Article							RENAL-CELL CARCINOMA; POINT MUTATIONS; CANCER; CHROMOSOME-5Q21; REGION; FAP	A gene discovered by positional cloning has been identified as the von Hippel-Lindau (VHL) disease tumor suppressor gene. A restriction fragment encompassing the gene showed rearrangements in 28 of 221 VHL kindreds. Eighteen of these rearrangements were due to deletions in the candidate gene, including three large nonoverlapping deletions. Intragenic mutations were detected in cell lines derived from VHL patients and from sporadic renal cell carcinomas. The VHL gene is evolutionarily conserved and encodes two widely expressed transcripts of approximately 6 and 6.5 kilobases. The partial sequence of the inferred gene product shows no homology to other proteins, except for an acidic repeat domain found in the procyclic surface membrane glycoprotein of Trypanosoma brucei.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702; NCI,SURG BRANCH,BETHESDA,MD 20892; NCI,CANC DIAG BRANCH,BETHESDA,MD 20892; NCI,DEPT RADIOL,CTR CLIN,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; MAHER, EAMONN R/A-9507-2008	Dean, Michael C/0000-0003-2234-0631; MAHER, EAMONN R/0000-0002-6226-6918; Le Paslier, Denis/0000-0003-4335-9956; Gnarra, James/0000-0002-6369-3110				CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSSEY PA, IN PRESS HUM MOL GEN; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LATIF F, 1993, CANCER RES, V53, P861; Latif F., 1992, American Journal of Human Genetics, V51, pA63; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MAHER ER, 1990, J MED GENET, V27, P311, DOI 10.1136/jmg.27.5.311; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, GENOMICS, V8, P957; MAHER ER, UNPUB; MCKUSICK VA, 1883, MENDELIAN INHERITANC, P534; MOWATT MR, 1989, MOL CELL BIOL, V9, P1332, DOI 10.1128/MCB.9.3.1332; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P244; RICHARDS FM, 1993, J MED GENET, V30, P104, DOI 10.1136/jmg.30.2.104; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TRAFATTER JA, 1993, CELL, V72, P791; VANCE JM, 1992, AM J HUM GENET S, V51, P203; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; White R, 1992, CURR OPIN GENET DEV, V2, P53, DOI 10.1016/S0959-437X(05)80321-1; YAO M, IN PRESS HUM GENET	37	2243	2354	3	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1317	1320		10.1126/science.8493574	http://dx.doi.org/10.1126/science.8493574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493574				2022-12-01	WOS:A1993LE02500041
J	MERSON, MH				MERSON, MH			SLOWING THE SPREAD OF HIV - AGENDA FOR THE 1990S	SCIENCE			English	Article											MERSON, MH (corresponding author), WHO,GLOBAL PROGRAM AIDS,CH-1211 GENEVA 27,SWITZERLAND.							ESPARZA J, 1992, RETROVIRUSES HUMAN A, P217; VIRAVAIDYA M, 1991, EC IMPACT AIDS THAIL; IN PRESS EFFECTIVE A; 1993, WHOGPACNPEVA931 GLOB; 1993, UNPUB POTENTIAL VACC; 1993, GPADIR932 WHO GLOB P; 1991, WHO TECH REP SER, V810	7	97	106	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1266	1268		10.1126/science.8493570	http://dx.doi.org/10.1126/science.8493570			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493570				2022-12-01	WOS:A1993LE02500030
J	WANG, HW; WYSOCKI, CJ; GOLD, GH				WANG, HW; WYSOCKI, CJ; GOLD, GH			INDUCTION OF OLFACTORY RECEPTOR SENSITIVITY IN MICE	SCIENCE			English	Article							ANDROSTENONE; ABILITY; MOUSE	Repeated exposure to olfactory ligands (odorants) increased peripheral olfactory sensitivity in mice. For two unrelated ligands, androstenone and isovaleric acid, induction of olfactory sensitivity was odorant-specific and occurred only in inbred strains that initially had low sensitivity to the exposure odorant. These data demonstrate stimulus-induced plasticity in a sensory receptor cell, suggesting a form of stimulus-controlled gene expression. Induction with two unrelated odorants implies that olfactory induction is a general phenomenon that may occur in a large fraction of the human population.			WANG, HW (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.							AMOORE JE, 1991, GENETICS PERCEPTION, V3, pCH23; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; GETCHELL TV, 1987, NEUROBIOLOGY TASTE S, pCH5; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; KENT PF, 1992, J NEUROPHYSIOL, V68, P1804, DOI 10.1152/jn.1992.68.5.1804; Labows J.N., 1984, PERFUMER FLAVOURIST, V9, P21; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; OTTOSON D, 1956, ACTA PHYSIOL SCAND, V35, P7; SHIRLEY SG, 1987, BIOCHEM J, V245, P175, DOI 10.1042/bj2450175; TROITSKAYA V T, 1987, Neirofiziologiya, V19, P133; Wang Hai-Wei, 1992, Chemical Senses, V17, P714; WHISSELBUECHY D, 1976, NATURE, V242, P271; WYSOCKI CJ, 1989, P NATL ACAD SCI USA, V86, P7976, DOI 10.1073/pnas.86.20.7976; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; WYSOCKI CJ, 1989, CHEM SENSES NUTRITIO; WYSOCKI CJ, UNPUB	19	150	154	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					998	1000		10.1126/science.8493539	http://dx.doi.org/10.1126/science.8493539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493539				2022-12-01	WOS:A1993LB79100048
J	RONA, RJ; GULLIFORD, MC; CHINN, S				RONA, RJ; GULLIFORD, MC; CHINN, S			EFFECTS OF PREMATURITY AND INTRAUTERINE GROWTH ON RESPIRATORY HEALTH AND LUNG-FUNCTION IN CHILDHOOD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; DISTRESS SYNDROME; CHILDREN; STANDARDS; PREGNANCY; SYMPTOMS; HISTORY; TRICEPS; MOTHERS; ASTHMA	Objective-To determine whether birth weight and gestational age are associated with respiratory illness and lung function in children aged 5-11 years. Design-Cross sectional analysis of parent reported birth weight, gestational age, and respiratory symptoms; parental smoking and social conditions; forced vital capacity (FVC), forced expiratory volume in one second (FEV1), forced expiratory rates between 25% and 75% and 75% and 85% (FEF25-75 and FEF75-85), and height. Setting-Primary schools in England and Scotland in 1990. Subjects-5573 children aged 5-11 (63.3% of eligible children) had respiratory symptoms analysed and 2036 children (67.1% of eligible children) had lung function measured. Main outcome measures-Symptoms of asthma, bronchitis, occasional and frequent wheeze, cough first thing in the morning, and cough at any other time and lung function. Results-Birth weight adjusted for gestational age was significantly associated with all lung function measurements, except FEF25-75. The association remained for FVC (b=0.475, 95% confidence interval 0.181 to 0.769) and FEV1 (b=0.502, 0.204 to 0.800) after adjustment for gestational age, parental smoking, and social factors. FEF75-85 was the only lung function related to gestational age. Respiratory symptoms, especially wheeze most days (adjusted odds ratio 0.9, 0.84 to 0.97) were significantly associated with prematurity. Every extra week of gestation reduced the risk of severe wheeze by about 10%. Conclusions-Lung function is affected mainly by intrauterine environment while respiratory illness, especially wheezing, in childhood is related to prematurity.			RONA, RJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT PUBL HLTH MED, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND.		Gulliford, Martin C/I-8606-2018; Rona, Roberto J/C-2348-2011	Gulliford, Martin C/0000-0003-1898-9075; Rona, Roberto/0000-0003-3739-5571				ALHO OP, 1990, INT J PEDIATR OTORHI, V19, P129, DOI 10.1016/0165-5876(90)90218-G; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERTRAND JM, 1985, NEW ENGL J MED, V312, P742, DOI 10.1056/NEJM198503213121202; BLAND JM, 1990, J R STAT SOC C-APPL, V39, P229; CHAN KN, 1988, ARCH DIS CHILD, V63, P905, DOI 10.1136/adc.63.8.905; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; CHINN S, 1992, EUR J CLIN NUTR, V46, P489; COLE TJ, 1988, J R STAT SOC A STAT, V151, P385, DOI 10.2307/2982992; GALDESSEBALDT M, 1989, PEDIATR PULM, V7, P259, DOI 10.1002/ppul.1950070412; GREENBERGER PA, 1985, NEW ENGL J MED, V312, P897, DOI 10.1056/NEJM198504043121406; GREENOUGH A, 1990, J PERINAT MED, V18, P489, DOI 10.1515/jpme.1990.18.6.489; GREENOUGH A, 1992, REVERSIBLE OBSTRUCTI, V6, P31; MANSELL AL, 1987, J PEDIATR-US, V110, P111, DOI 10.1016/S0022-3476(87)80301-3; Osborn A.F., 1984, SOCIAL LIFE BRITAINS; RONA RJ, 1977, ANN HUM BIOL, V4, P501, DOI 10.1080/03014467700002511; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SEIDMAN DS, 1987, BRIT J OBSTET GYNAEC, V94, P731, DOI 10.1111/j.1471-0528.1987.tb03717.x; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; TANNER JM, 1975, ARCH DIS CHILD, V50, P142, DOI 10.1136/adc.50.2.142; TILLEY BC, 1985, AM J EPIDEMIOL, V121, P269, DOI 10.1093/oxfordjournals.aje.a113997	23	208	215	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	1993	306	6881					817	820		10.1136/bmj.306.6881.817	http://dx.doi.org/10.1136/bmj.306.6881.817			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490372	Green Published, Bronze			2022-12-01	WOS:A1993KV34800018
J	Struthers, MD; Cheng, RP; Imperiali, B				Struthers, MD; Cheng, RP; Imperiali, B			Design of a monomeric 23-residue polypeptide with defined tertiary structure	SCIENCE			English	Article							ZINC-FINGER PEPTIDE; 4-HELIX BUNDLE; CRYSTAL-STRUCTURE; METAL-BINDING; PROTEIN ZFY; SPECTROSCOPY; DOMAIN; MOTIFS; PROBE	Small proteins or protein domains generally require disulfide bridges or metal sites for their stabilization. Here it is shown that the beta beta alpha architecture of zinc fingers can be reproduced in a 23-residue polypeptide in the absence of metal ions. The sequence was obtained through an iterative design process. A key feature of the final design is the incorporation of a type II' beta turn to aid in beta-hairpin formation. Nuclear magnetic resonance analysis reveals that the alpha helix and beta hairpin are held together by a defined hydrophobic core. The availability of this structural template has implications for the development of functional polypeptides.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA	California Institute of Technology				Imperiali, Barbara/0000-0002-5749-7869				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; EIS PS, 1993, BIOCHEMISTRY-US, V32, P7981, DOI 10.1021/bi00082a020; Fasman GD, 1989, PREDICTION PROTEIN S, P193; FEZOUI Y, 1994, P NATL ACAD SCI USA, V91, P3675, DOI 10.1073/pnas.91.9.3675; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GOODSELL DS, 1993, TRENDS BIOCHEM SCI, V18, P65, DOI 10.1016/0968-0004(93)90153-E; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; IMPERIALI B, 1992, J AM CHEM SOC, V114, P3182, DOI 10.1021/ja00035a002; KURODA Y, 1995, PROTEIN ENG, V8, P97, DOI 10.1093/protein/8.2.97; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIEBERMAN M, 1991, J AM CHEM SOC, V113, P1470, DOI 10.1021/ja00004a090; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; QUINN TP, 1994, P NATL ACAD SCI USA, V91, P8747, DOI 10.1073/pnas.91.19.8747; RALEIGH DP, 1995, J AM CHEM SOC, V117, P7558, DOI 10.1021/ja00133a035; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SMITH DDS, 1995, PROTEIN ENG, V8, P13, DOI 10.1093/protein/8.1.13; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRUTHERS MS, UNPUB; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P5660, DOI 10.1021/bi00476a002; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; WETLAUFER DB, 1990, TRENDS BIOCHEM SCI, V15, P414, DOI 10.1016/0968-0004(90)90275-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAN YB, 1994, PROTEIN SCI, V3, P1069, DOI 10.1002/pro.5560030709	38	278	284	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					342	345		10.1126/science.271.5247.342	http://dx.doi.org/10.1126/science.271.5247.342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553067				2022-12-01	WOS:A1996TQ52800038
J	Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A				Spinozzi, F; Agea, E; Bistoni, O; Forenza, N; Monaco, A; Bassotti, G; Nicoletti, I; Riccardi, C; Grignani, F; Bertotto, A			Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN IGE SYNTHESIS; INTERLEUKIN-4; LYMPHOCYTES; RECEPTOR; APOPTOSIS; COMPLEX	Objective: To test the hypothesis that allergen-specific, steroid-sensitive gamma delta T lymphocytes are increased in bronchoalveolar lavage fluid of patients with asthma. Design: Case series. Setting: The outpatient allergy services at the University of Perugia, Perugia, Italy. Patients: 12 untreated atopic patients (6 children and 6 adults) with mildly symptomatic chronic asthma were studied. Bronchoalveolar ravage fluid from 10 healthy nonsmoking volunteers and age-matched children with cystic fibrosis (n = 5) or anatomic malformation of the airways (n = 4) served as control samples. Intervention: Three patients received treatment with deflazacort, 60 mg twice daily, for 1 week. Measurements: CD3(+), CD4(+), and CD8(+) T cells from patients and controls were examined by two-color flow cytometry for coexpression of V delta 1 and V delta 2 isoforms of the gamma delta T-cell receptor. In vitro pulmonary gamma delta T-cell proliferation in response to a specific allergen, the apoptotic death of these cells after incubation with 10(-7) M dexamethasone, and bronchoalveolar lavage fluid T-lymphocyte composition before and after 1 week of deflazacort therapy were evaluated in 3 Dermatophagoides pteronyssinus-sensitive patients. Results: The proportion of gamma delta T lymphocytes, primarily CD4(+) or CD4(-) CD8(-) cells, was higher in asthmatic patients than in controls (P < 0.05 by one-way analysis of variance). Most lung gamma delta CD4(+) lymphocytes expressed the gamma delta T-cell receptor V delta 1 chain. These cells proliferated in response to allergen stimulation, underwent steroid-induced apoptosis in vitro, and disappeared after systemic steroid treatment. Conclusions: Allergen-specific, steroid-sensitive gamma delta T cells may be one of the cellular components involved in the airway inflammation that characterizes allergic bronchial asthma.					bistoni, onelia/G-8234-2011; Riccardi, Carlo/N-4610-2014	Riccardi, Carlo/0000-0001-9257-3997				BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DELPRETE G, 1992, ALLERGY, V47, P450; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FAJAC I, 1992, CLIN EXP IMMUNOL, V87, P127; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MIGLIORATI G, 1993, BLOOD, V81, P1352; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OKUDA M, 1992, ALLERGY, V47, P255, DOI 10.1111/j.1398-9995.1992.tb00659.x; PAWANKAR R, 1995, J ALLERGY CLIN IMMUN, V95, P190; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053	23	67	69	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					223	227		10.7326/0003-4819-124-2-199601150-00005	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8533997				2022-12-01	WOS:A1996TQ01600005
J	Panter, KR; Hannah, ME				Panter, KR; Hannah, ME			Umbilical cord prolapse: So far so good?	LANCET			English	Editorial Material											Panter, KR (corresponding author), UNIV TORONTO,WOMENS COLL HOSP,DEPT OBSTET & GYNAECOL,TORONTO,ON,CANADA.							FENTON AN, 1951, AM J OBSTET GYNECOL, V62, P52, DOI 10.1016/0002-9378(51)91090-3; FERRARA TB, 1989, AM J OBSTET GYNECOL, V161, P1114; Goldthorp W O, 1967, Br J Clin Pract, V21, P21; KOONINGS PP, 1990, J REPROD MED, V35, P690; Kurzrock J, 1932, AM J OBSTET GYNECOL, V23, P403, DOI 10.1016/S0002-9378(32)90832-1; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; MACFARLANE AJ, 1990, 3 4 MORE STUDY TRIPL, P218; MESLEH T, 1993, J OBSTET GYNECOL, V13, P24; MURPHY DJ, 1995, BRIT J OBSTET GYNAEC, V102, P826, DOI 10.1111/j.1471-0528.1995.tb10850.x; YLAOUTINEN A, 1985, ACTA OBSTET GYN SCAN, V64, P567	10	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					74	74		10.1016/S0140-6736(96)90207-X	http://dx.doi.org/10.1016/S0140-6736(96)90207-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538343				2022-12-01	WOS:A1996TP28100006
J	Quon, KC; Marczynski, GT; Shapiro, L				Quon, KC; Marczynski, GT; Shapiro, L			Cell cycle control by an essential bacterial two-component signal transduction protein	CELL			English	Article							GRAM-NEGATIVE BACTERIA; CAULOBACTER-CRESCENTUS; BACILLUS-SUBTILIS; DNA-REPLICATION; GENE-EXPRESSION; DIVISION; MUTAGENESIS; PROMOTER; DIFFERENTIATION; IDENTIFICATION	Dividing cells must coordinate cell cycle events to ensure genetic stability. Here we identify an essential two-component signal transduction protein that controls multiple events in the Caulobacter cell cycle, including cell division, stalk synthesis, and cell cycle-specific transcription. This protein, CtrA, is homologous to response regulator transcription factors and controls transcription from a group of cell cycle-regulated promoters critical for DNA replication, DNA methylation, and flagellar biogenesis. CtrA activity in the cell cycle is controlled both transcriptionally and by phosphorylation. As purified CtrA binds an essential DNA sequence motif found within its target promoters, we propose that CtrA acts in a phosphorelay signal transduction system to control bacterial cell cycle events directly at the transcriptional level.			Quon, KC (corresponding author), STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM5 1426, GM 32506/512OMZ] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEY MRK, 1991, GENETICS, V129, P333; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; ELY B, 1991, METHOD ENZYMOL, V204, P372; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FISHER JA, 1988, J BACTERIOL, V170, P4706, DOI 10.1128/jb.170.10.4706-4713.1988; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOBER JW, 1992, MOL BIOL CELL, V3, P913, DOI 10.1091/mbc.3.8.913; GOBER JW, 1995, MICROBIOL REV, V59, P31, DOI 10.1128/MMBR.59.1.31-47.1995; GUENZI E, 1994, MOL MICROBIOL, V12, P505, DOI 10.1111/j.1365-2958.1994.tb01038.x; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; IRETON K, 1992, P NATL ACAD SCI USA, V89, P8808, DOI 10.1073/pnas.89.18.8808; IRETON K, 1994, EMBO J, V13, P1566, DOI 10.1002/j.1460-2075.1994.tb06419.x; JENAL U, 1994, J MOL BIOL, V243, P227, DOI 10.1006/jmbi.1994.1650; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOKJOHN TA, 1987, J BACTERIOL, V169, P1499, DOI 10.1128/jb.169.4.1499-1508.1987; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; KUTSUKAKE K, 1994, MOL GEN GENET, V243, P605, DOI 10.1007/BF00279569; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; Miller JH., 1972, EXPT MOL GENETICS; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEWTON A, 1989, P NATL ACAD SCI USA, V86, P6651, DOI 10.1073/pnas.86.17.6651; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; OSLEY MA, 1977, P NATL ACAD SCI USA, V74, P124, DOI 10.1073/pnas.74.1.124; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAMAKRISHNAN G, 1994, J BACTERIOL, V176, P7587, DOI 10.1128/JB.176.24.7587-7600.1994; RAMPERSAUD A, 1994, J BIOL CHEM, V269, P12559; RIZZO MF, 1993, J BACTERIOL, V175, P6970, DOI 10.1128/jb.175.21.6970-6981.1993; RUDOLPH J, 1995, EMBO J, V14, P667, DOI 10.1002/j.1460-2075.1995.tb07045.x; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT JM, 1966, J CELL BIOL, V28, P423, DOI 10.1083/jcb.28.3.423; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STEPHENS CM, 1995, J BACTERIOL, V177, P1662, DOI 10.1128/jb.177.7.1662-1669.1995; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VANWAY SM, 1993, J BACTERIOL, V175, P367, DOI 10.1128/JB.175.2.367-376.1993; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZHUANG WY, 1992, J BACTERIOL, V177, P34; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	59	383	387	0	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					83	93		10.1016/S0092-8674(00)80995-2	http://dx.doi.org/10.1016/S0092-8674(00)80995-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548829	Bronze			2022-12-01	WOS:A1996TQ17000011
J	Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR				Turton, MD; OShea, D; Gunn, I; Beak, SA; Edwards, CMB; Meeran, K; Choi, SJ; Taylor, GM; Heath, MM; Lambert, PD; Wilding, JPH; Smith, DM; Ghatei, MA; Herbert, J; Bloom, SR			A role for glucagon-like peptide-1 in the central regulation of feeding	NATURE			English	Article							NEUROPEPTIDE-Y CONTENT; C-FOS; RATS; EXPRESSION; INSULIN; HYPOTHALAMUS; BEHAVIOR; SATIETY; BRAIN; CELLS	THE sequence of glucagon-like peptide-(1) (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role(1). We have shown that GLP-1 and its specific receptors are present in the hypothalamus(2,3). No physiological role for central GLP-1 has been established. We report here that intracerebroventricular (ICV) GLP-1 powerfully inhibits feeding in fasted rats, ICV injection of the specific GLP-1-receptor antagonist, exendin (9-39)(4), blocked the inhibitory effect of GLP-1 on food intake. Exendin (9-39) alone had no influence on fast-induced feeding but more than doubled food intake in satiated rats, and augmented the feeding response to the appetite stimulant, neuropeptide Y. Induction of c-fos is a marker of neuronal activation(5). Following ICV GLP-1 injection, c-fos appeared exclusively in the paraventricular nucleus of the hypothalamus and central nucleus of the amygdala, and this was inhibited by prior administration of exendin (9-39). Both of these regions of the brain are of primary importance in the regulation of feeding(6). These findings suggest that central GLP-1 is a new physiological mediator of satiety.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,ENDOCRINE UNIT,LONDON W12 0NN,ENGLAND; UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	Imperial College London; University of Cambridge			Wilding, John/ABB-6443-2020; Wilding, John PH/A-7106-2008	Wilding, John/0000-0003-2839-8404; Wilding, John PH/0000-0003-2839-8404; O'Shea, Donal/0000-0002-1408-5274; Smith, David/0000-0001-6831-280X				ANTIN J, 1975, J COMP PHYSIOL PSYCH, V89, P784, DOI 10.1037/h0077040; ARNOLD FJL, 1992, NEUROSCIENCE, V51, P377, DOI 10.1016/0306-4522(92)90322-S; BILLINGTON CJ, 1983, AM J PHYSIOL, V245, pR920, DOI 10.1152/ajpregu.1983.245.6.R920; BLUNDELL JE, 1985, BRAIN RES BULL, V15, P371, DOI 10.1016/0361-9230(85)90004-8; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOW HL, 1984, EUR J PHARMACOL, V102, P297, DOI 10.1016/0014-2999(84)90261-9; CLARK JT, 1985, ENDOCRINOLOGY, V117, P2435, DOI 10.1210/endo-117-6-2435; GOKE R, 1993, J BIOL CHEM, V268, P19650; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KANSE SM, 1988, FEBS LETT, V241, P209, DOI 10.1016/0014-5793(88)81063-9; KREYMANN B, 1989, BRAIN RES, V502, P325, DOI 10.1016/0006-8993(89)90628-8; KULKARNI RN, 1995, REGUL PEPTIDES, V57, P201; LAMBERT PD, 1993, ENDOCRINOLOGY, V133, P29, DOI 10.1210/en.133.1.29; LAMBERT PD, 1995, BRAIN RES, V670, P59, DOI 10.1016/0006-8993(94)01224-6; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAI A, 1993, AM J PHYSIOL, V265, pG118, DOI 10.1152/ajpgi.1993.265.1.G118; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; VEALE PR, 1994, EUR J PHARMACOL, V262, P133, DOI 10.1016/0014-2999(94)90036-1; WANG ZL, 1995, J CLIN INVEST, V95, P417, DOI 10.1172/JCI117671; WILDING JPH, 1993, NEUROENDOCRINOLOGY, V57, P581, DOI 10.1159/000126410; WILDING JPH, 1992, J ENDOCRINOL, V132, P299, DOI 10.1677/joe.0.1320299	24	1474	1581	1	126	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					69	72		10.1038/379069a0	http://dx.doi.org/10.1038/379069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538742				2022-12-01	WOS:A1996TN21600056
J	Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H				Hiramatsu, R; Akagi, K; Matsuoka, M; Sakumi, K; Nakamura, H; Kingsbury, L; David, C; Hardy, RR; Yamamura, K; Sakano, H			The 3' enhancer region determines the B/T specificity and pro-B pre-B specificity of immunoglobulin V-kappa-J(kappa) joining	CELL			English	Article							CHAIN INTRON ENHANCER; V(D)J RECOMBINATION; GENE REARRANGEMENT; CONSTANT REGION; LOCUS CONTAINS; ETS ONCOGENE; BONE-MARROW; CELL; HEAVY; EXPRESSION	Using transgenic substrates, we found that the immunoglobulin kappa gene 3' enhancer (E3') acts as a negative regulator in V-kappa-J(kappa) joining. Although the E3' was originally identified as a transcriptional enhancer, it acts in a suppressive manner for recombinational regulation. Base substitution analysis has shown that the PU.1-binding site within the E3' regulates the B/T specificity of V-kappa-J(kappa) joining. In a substrate with a mutated PU.1-binding site (GAGGAA to TCTTCG), V-kappa-J(kappa) joining occurred not only in B cells, but also in T cells. The E3' region is also responsible for determining the pro-B/pre-B specificity of V-kappa-J(kappa) joining. When the E3' region was deleted, kappa gene rearrangement actively occurred at the early pro-B stage of B cell development: nongermline (N) nucleotides were common at recombination junctions.	KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, DEPT DEV GENET, KUMAMOTO 862, JAPAN; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	Kumamoto University; Mayo Clinic; Fox Chase Cancer Center; University of Tokyo	Hiramatsu, R (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV IMMUNOL, BERKELEY, CA 94720 USA.		Sakumi, Kunihiko/G-4808-2011	Matsuoka, Masao/0000-0002-0473-754X				AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOODHARDT M, 1987, P NATL ACAD SCI USA, V84, P4229, DOI 10.1073/pnas.84.12.4229; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEINRICH G, 1984, J EXP MED, V159, P417, DOI 10.1084/jem.159.2.417; HROMAS R, 1993, BLOOD, V82, P2998; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HSIEH CL, 1992, J BIOL CHEM, V22, P15963; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KUNG JT, 1981, J IMMUNOL, V127, P873; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LAUSTER R, 1993, EMBO J, V12, P4615, DOI 10.1002/j.1460-2075.1993.tb06150.x; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MATTHIAS P, 1993, MOL CELL BIOL, V13, P1547, DOI 10.1128/MCB.13.3.1547; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; ROSS IL, 1994, ONCOGENE, V9, P121; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; WATRIN F, 1994, TRANSGENESIS TARGETE, P1; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	53	55	55	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1113	1123		10.1016/0092-8674(95)90138-8	http://dx.doi.org/10.1016/0092-8674(95)90138-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548799	Bronze			2022-12-01	WOS:A1995TM76200008
J	GIBBARD, S; LEVY, EH; LUNINE, JI				GIBBARD, S; LEVY, EH; LUNINE, JI			GENERATION OF LIGHTNING IN JUPITER WATER CLOUD	NATURE			English	Article							MOIST CONVECTION; ICE; VOYAGER-1	LIGHTING is a familiar feature of storms on the Earth, and has also been seen on Jupiter(1-3) and inferred indirectly to occur on Venus and Neptune(4,5). On Jupiter, lightning mag. be important as a source of energy to drive chemical reactions in the atmosphere, perhaps determining the abundances of molecules such as CO, HCN and C2H2 (ref. 6). Lightning may be generated in Jupiter's water clouds by a mechanism similar to that which operates in terrestrial thunderstorms(7-9). Here we investigate the development of lightning by modelling the thunderstorm separation of electrical charge on precipitating ice particles at varying depths in Jupiter's atmosphere, We find that lightning can indeed be generated in the jovian water clouds, and that-in agreement with estimates from the analysis of Voyager images(10)-it is most likely to occur at the 3- or 4-bar pressure level, Our model also predicts that a condensed-water abundance in the range of at least 1-2 g m(-3) is required for lightning to occur in jovian thunderstorms-a prediction that may be tested when the Galileo probe arrives at Jupiter on 7 December 1995.			GIBBARD, S (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.							BORTUCKI WJ, 1986, J GEOPHYS RES, V91, P9893; BORUCKI WJ, 1992, ICARUS, V96, P1, DOI 10.1016/0019-1035(92)90002-O; CARANTI JM, 1985, J GEOPHYS RES-ATMOS, V90, P6041, DOI 10.1029/JD090iD04p06041; COOK AF, 1979, NATURE, V280, P794, DOI 10.1038/280794a0; GROSS GW, 1982, J GEOPHYS RES-OCEANS, V87, P7170, DOI 10.1029/JC087iC09p07170; ILLINGWORTH AJ, 1988, J GEOPHYS RES, V90, P6026; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; KEITH WD, 1989, J GEOPHYS RES-ATMOS, V94, P13103, DOI 10.1029/JD094iD11p13103; LEVIN Z, 1983, ICARUS, V56, P80, DOI 10.1016/0019-1035(83)90129-X; LUNINE JL, 1987, ICARUS, V60, P566; NORVILLE K, 1991, J GEOPHYS RES-ATMOS, V96, P7463, DOI 10.1029/90JD02577; PODOLAK M, 1988, ICARUS, V75, P566, DOI 10.1016/0019-1035(88)90165-0; RINNERT K, 1985, J GEOPHYS RES-ATMOS, V90, P6225, DOI 10.1029/JD090iD04p06225; RUSSELL CT, 1993, ANNU REV EARTH PL SC, V21, P43, DOI 10.1146/annurev.ea.21.050193.000355; SCARF FL, 1979, SCIENCE, V204, P991, DOI 10.1126/science.204.4396.991; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; STOKER CR, 1986, ICARUS, V67, P106, DOI 10.1016/0019-1035(86)90179-X; TAKAHASHI T, 1975, J ATMOS SCI, V32, P123, DOI 10.1175/1520-0469(1975)032<0123:ECLCIW>2.0.CO;2; Uwan M.A., 1987, LIGHTNING DISCHARGE; WEAST R, 1967, CRC HDB CHEM PHYSICS; YAIR H, 1995, ICARUS, V115, P421; YAIR H, 1995, ICARUS, V114, P278; YANAI M, 1973, J ATMOS SCI, V30, P611, DOI 10.1175/1520-0469(1973)030<0611:DOBPOT>2.0.CO;2	23	27	27	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					592	595		10.1038/378592a0	http://dx.doi.org/10.1038/378592a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524392				2022-12-01	WOS:A1995TJ22100068
J	TRICHOPOULOU, A; KOURISBLAZOS, A; WAHLQVIST, ML; GNARDELLIS, C; LAGIOU, P; POLYCHRONOPOULOS, E; VASSILAKOU, T; LIPWORTH, L; TRICHOPOULOS, D				TRICHOPOULOU, A; KOURISBLAZOS, A; WAHLQVIST, ML; GNARDELLIS, C; LAGIOU, P; POLYCHRONOPOULOS, E; VASSILAKOU, T; LIPWORTH, L; TRICHOPOULOS, D			DIET AND OVERALL SURVIVAL IN ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; COLORECTAL-CANCER; MORTALITY	Objective-To assess the influence of a specific dietary pattern on overall survival. Design-Cohort study. Setting-Three rural Greek villages, the data from which were collected as part of an international cross cultural study of food habits in later life. Subjects-182 elderly residents of the three villages. Main outcome measure-Overall mortality. Results-Diet was assessed with a validated extensive semiquantitative questionnaire on food intake. A one unit increase in diet score, devised a priori on the basis of eight component characteristics of the traditional common diet in the Mediterranean region, was associated with a significant 17% reduction in overall mortality (95% confidence interval 1% to 31%). Conclusion-A diet meeting currently understood health criteria does predict survival among people.	NATL SCH PUBL HLTH, NATL CTR NUTR, GR-11521 ATHENS, GREECE; MONASH MED CTR, DEPT MED, CLAYTON, VIC 3168, AUSTRALIA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, HARVARD CTR CANC PREVENT, BOSTON, MA 02115 USA	National & Kapodistrian University of Athens; Monash University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			TRICHOPOULOU, ANTONIA/ABF-8727-2021; Wahlqvist, Mark Lawrence/E-8800-2010; Vassilakou, Tonia/R-6967-2017	TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Vassilakou, Tonia/0000-0002-9993-1897; GNARDELLIS, CHARALAMPOS/0000-0001-8862-7868; Polychronopoulos, Evangelos/0000-0001-7061-4081				BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; DALES LG, 1978, INT J EPIDEMIOL, V7, P373, DOI 10.1093/ije/7.4.373; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; GNARDELLIS C, 1995, EPIDEMIOLOGY, V6, P74, DOI 10.1097/00001648-199501000-00015; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; Helsing E., 1989, EUR J CLIN NUTR, V43, P1; HJERMANN I, 1981, LANCET, V2, P1303; KATSOUYANNI K, 1991, AM J EPIDEMIOL, V133, P24, DOI 10.1093/oxfordjournals.aje.a115798; KATSOUYANNI K, 1991, DIETARY VARIABILITY, P1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1982, LANCET, V2, P518; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; TRICHOPOULOS D, 1990, RECENT PROGR RES NUT; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; Trichopoulou A, 1994, J Cardiovasc Risk, V1, P9, DOI 10.1097/00043798-199406000-00003; TRICHOPOULOU A, 1993, EUR J CLIN NUTR, V47, pS76; TRICHOPOULOU A, 1993, EUR J CLIN NUTR, V47, P549; TRICHOPOULOU A, 1992, COMPOSITION GREEK FO; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT W, 1991, NEW ENGL J MED, V324, P121, DOI 10.1056/NEJM199101103240209; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; [No title captured]; [No title captured]	29	906	919	3	71	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	1995	311	7018					1457	1460		10.1136/bmj.311.7018.1457	http://dx.doi.org/10.1136/bmj.311.7018.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520331	Green Published			2022-12-01	WOS:A1995TJ04400019
J	KIM, B; LITTLE, JW				KIM, B; LITTLE, JW			LEXA AND LAMBDA-CI-REPRESSORS AS ENZYMES - SPECIFIC CLEAVAGE IN AN INTERMOLECULAR REACTION	CELL			English	Article							RECA-MEDIATED CLEAVAGE; T7 EXPRESSION SYSTEM; GROUP-I INTRON; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; DEPENDENT CLEAVAGE; CBP2 PROTEIN; MUTAGENESIS; PHOSPHORYLATION; AUTODIGESTION	During the SOS response, LexA repressor is inactivated. by specific cleavage. Although cleavage requires RecA protein in vivo, RecA acts indirectly as a coprotease by stimulating an inherent self-cleavage activity of LexA. In lambda lysogens, cleavage of lambda CI repressor in a similar but far slower reaction results in prophage induction. We describe an intermolecular cleavage reaction in which the C-terminal fragment of LexA acted as an enzyme to cleave other molecules of LexA. The C-terminal fragment of lambda repressor cleaved the LexA substrates about as efficiently as did the LexA enzyme, suggesting that the slow rate of CI self-cleavage results from a weak interaction between its cleavage site and the active site.	UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA	University of Arizona	KIM, B (corresponding author), UNIV ARIZONA, DEPT BIOCHEM, TUCSON, AZ 85721 USA.							Ausubel F.M., 1994, CURRENT PROTOCOLS MO; Blair WS, 1991, CURR OPIN CELL BIOL, V3, P1039, DOI 10.1016/0955-0674(91)90126-J; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CECH TR, 1992, J BIOL CHEM, V267, P17479; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EGUCHI Y, 1988, J MOL BIOL, V202, P565, DOI 10.1016/0022-2836(88)90286-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HORII T, 1981, CELL, V27, P515, DOI 10.1016/0092-8674(81)90393-7; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Johnson A D, 1980, Methods Enzymol, V65, P839; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KIM B, 1993, THESIS U ARIZONA TUC; LEY H, 1984, BRL FOCUS, V6, P5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; ROBERTS JW, 1983, LAMBDA, V2, P123; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; SAUER RT, 1982, J BIOL CHEM, V257, P4458; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; SMITH MH, 1991, P NATL ACAD SCI USA, V88, P7356, DOI 10.1073/pnas.88.16.7356; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	42	72	73	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1165	1173		10.1016/0092-8674(93)90645-7	http://dx.doi.org/10.1016/0092-8674(93)90645-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513500				2022-12-01	WOS:A1993LH54800012
J	VANVACTOR, D; SINK, H; FAMBROUGH, D; TSOO, R; GOODMAN, CS				VANVACTOR, D; SINK, H; FAMBROUGH, D; TSOO, R; GOODMAN, CS			GENES THAT CONTROL NEUROMUSCULAR SPECIFICITY IN DROSOPHILA	CELL			English	Article							SELECT APPROPRIATE PATHWAYS; PATTERNED NEURITE OUTGROWTH; JAPANESE MEDAKA FISH; GROWTH CONES; CHICK-EMBRYO; PRIMARY MOTONEURONS; LUMBOSACRAL LEVEL; PROXIMAL TISSUES; SENSORY NEURONS; NERVOUS-SYSTEM	In each abdominal hemisegment of the Drosophila embryo, an array of 30 muscle fibers is innervated by about 34 motoneurons in a highly stereotyped and cell-specific fashion. To begin to elucidate the molecular basis of neural specificity in this system, we conducted a genetic screen for mutations affecting neuromuscular connectivity. We focus on 5 genes required for specific aspects of pathway (beaten path, stranded, and short stop) and target (walkabout and clueless) recognition. The different classes of mutant phenotypes suggest that neural specificity is controlled by a hierarchy of molecular mechanisms: motoneurons are guided toward the correct region of mesoderm, in many cases navigating a series of choice points along the way; they then display an affinity for a particular domain of neighboring muscles; and finally, they recognize their specific muscle target from within this domain.			VANVACTOR, D (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Van Vactor, Jr., David L./0000-0001-8156-9482				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1990, DEVELOPMENT, V110, P791; BENTLEY D, 1992, NERVE GROWTH CONE, P265; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BROADIE KS, 1993, J NEUROSCI, V13, P167; BROADIE KS, 1993, J NEUROSCI, V13, P144; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CASH S, 1992, J NEUROSCI, V12, P2051; CHANG S, 1992, DEVELOPMENT, V114, P815; CHIBA A, 1993, J NEUROSCI, V13, P714; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; DAVIES JA, 1990, NEURON, V2, P11; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GATCHALIAN CL, 1992, NEURON, V9, P105, DOI 10.1016/0896-6273(92)90225-3; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KESHISHIAN H, 1993, IN PRESS J NEUROBIOL; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1993, IN PRESS COLD SPRING, V57; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKAMOTO H, 1991, DEV BIOL, V146, P62, DOI 10.1016/0012-1606(91)90446-A; OKAMOTO H, 1991, DEV BIOL, V146, P49, DOI 10.1016/0012-1606(91)90445-9; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PIKE SH, 1990, J NEUROSCI, V10, P44; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TEAR G, 1993, IN PRESS PERSPECT DE; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; WESTERFIELD M, 1990, NEURON, V4, P867, DOI 10.1016/0896-6273(90)90139-7; WESTERFIELD M, 1988, TRENDS NEUROSCI, V11, P18, DOI 10.1016/0166-2236(88)90044-6; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WIESCHAUS E, 1984, W ROUX ARCH DEV BIOL, V193, P283	63	376	376	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1137	1153		10.1016/0092-8674(93)90643-5	http://dx.doi.org/10.1016/0092-8674(93)90643-5			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513498				2022-12-01	WOS:A1993LH54800010
J	YODER, MD; KEEN, NT; JURNAK, F				YODER, MD; KEEN, NT; JURNAK, F			NEW DOMAIN MOTIF - THE STRUCTURE OF PECTATE LYASE-C, A SECRETED PLANT VIRULENCE FACTOR	SCIENCE			English	Article							ERWINIA-CHRYSANTHEMI EC16; SOFT-ROT ERWINIAS; ESCHERICHIA-COLI; MOLECULAR-CLONING; GENES; PATHOGENESIS; EXPRESSION; RESOLUTION; REFINEMENT; ENZYMES	Pectate lyases are secreted by pathogens and initiate soft-rot diseases in plants by cleaving polygalacturonate, a major component of the plant cell wall. The three-dimensional structure of pectate lyase C from Erwinia chrysanthemi has been solved and refined to a resolution of 2.2 angstroms. The enzyme folds into a unique motif of parallel beta strands coiled into a large helix. Within the core, the amino acids form linear stacks and include a novel asparagine ladder. The sequence similarities that pectate lyases share with pectin lyases, pollen and style proteins, and tubulins suggest that the parallel beta helix motif may occur in a broad spectrum of proteins.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								BARRAS F, 1987, MOL GEN GENET, V209, P319, DOI 10.1007/BF00329660; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BUDELIER KA, 1990, MOL GEN GENET, V224, P183, DOI 10.1007/BF00271551; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CONDEMINE G, 1992, MOL MICROBIOL, V6, P3199, DOI 10.1111/j.1365-2958.1992.tb01775.x; CRAWFORD MS, 1987, ARCH BIOCHEM BIOPHYS, V258, P196, DOI 10.1016/0003-9861(87)90336-5; EVANS CH, 1990, BIOCH ELEMENTS, V8, P11; FARRELL K, UNPUB; GYSLER C, 1990, GENE, V89, P101, DOI 10.1016/0378-1119(90)90211-9; He S. Y., 1993, Biotechnology in plant disease control., P39; HE SY, 1990, J BACTERIOL, V172, P4988, DOI 10.1128/jb.172.9.4988-4995.1990; HE SY, 1991, P NATL ACAD SCI USA, V88, P1079, DOI 10.1073/pnas.88.3.1079; HE SY, 1991, J BACTERIOL, V173, P4310, DOI 10.1128/JB.173.14.4310-4317.1991; HINTON JCD, 1989, MOL MICROBIOL, V3, P1785, DOI 10.1111/j.1365-2958.1989.tb00164.x; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN NT, 1986, J BACTERIOL, V168, P595, DOI 10.1128/jb.168.2.595-606.1986; KEEN NT, 1984, J BACTERIOL, V159, P825, DOI 10.1128/JB.159.3.825-831.1984; KOTOUJANSKY A, 1987, ANNU REV PHYTOPATHOL, V25, P405, DOI 10.1146/annurev.py.25.090187.002201; KUSTERVANSOMERE.M, 1991, THESIS; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MANDELKOW EM, 1989, GUANINE NUCLEOTIDE B, V165, P385; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; PEROMBELON MCM, 1980, ANNU REV PHYTOPATHOL, V18, P361, DOI 10.1146/annurev.py.18.090180.002045; PRESTON JF, 1992, J BACTERIOL, V174, P2039, DOI 10.1128/jb.174.6.2039-2042.1992; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROGERS HJ, 1992, PLANT MOL BIOL, V20, P493, DOI 10.1007/BF00040608; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651; YODER MD, 1990, J BIOL CHEM, V265, P11429	39	383	400	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1503	1507		10.1126/science.8502994	http://dx.doi.org/10.1126/science.8502994			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502994				2022-12-01	WOS:A1993LF05800036
J	CHELAZZI, L; MILLER, EK; DUNCAN, J; DESIMONE, R				CHELAZZI, L; MILLER, EK; DUNCAN, J; DESIMONE, R			A NEURAL BASIS FOR VISUAL-SEARCH IN INFERIOR TEMPORAL CORTEX	NATURE			English	Article							SUPERIOR COLLICULUS; SINGLE UNITS; ATTENTION; FEATURES; NEURONS; MONKEY	WE often search for a face in a crowd or for a particular object in a cluttered environment. In this type of visual search, memory interacts with attention: the mediating neural mechanisms should include a stored representation of the object and a means for selecting that object from among others in the scene1-4. Here we test whether neurons in inferior temporal cortex, an area known to be important for high-level visual processing, might provide these components. Monkeys were presented with a complex picture (the cue) to hold in memory during a delay period. The cue initiated activity that persisted through the delay among the neurons that were tuned to its features. The monkeys were then given 2-5 choice pictures and were required to make an eye movement to the one (the target) that matched the cue. About 90-120 milliseconds before the onset of the eye movement to the target, responses to non-targets were suppressed and the neuronal response was dominated by the target. The results suggest that inferior temporal cortex is involved in selecting the objects to which we attend and foveate.	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND	University of Cambridge	CHELAZZI, L (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1E104,BETHESDA,MD 20892, USA.		Miller, Earl K./AAE-8187-2019; Chelazzi, Leonardo/B-6084-2011; Desimone, Robert/G-1121-2018	Miller, Earl K./0000-0002-0582-6958; Chelazzi, Leonardo/0000-0001-8566-0611; Duncan, John/0000-0002-9695-2764; Desimone, Robert/0000-0002-5938-4227				BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GIMCHER PW, 1992, NATURE, V355, P542; MILLER EK, 1993, J NEUROSCI, V13, P1460; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; NEISSER U, 1963, AM J PSYCHIAT, V76, P316; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P132, DOI 10.1152/jn.1987.57.1.132; SATO T, 1988, J NEUROPHYSIOL, V60, P344, DOI 10.1152/jn.1988.60.1.344; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	13	813	834	3	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					345	347		10.1038/363345a0	http://dx.doi.org/10.1038/363345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497317				2022-12-01	WOS:A1993LD91700051
J	FORD, AM; RIDGE, SA; CABRERA, ME; MAHMOUD, H; STEEL, CM; CHAN, LC; GREAVES, M				FORD, AM; RIDGE, SA; CABRERA, ME; MAHMOUD, H; STEEL, CM; CHAN, LC; GREAVES, M			INUTERO REARRANGEMENTS IN THE TRITHORAX-RELATED ONCOGENE IN INFANT LEUKEMIAS	NATURE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CELL; TWINS; GENE; TRANSLOCATIONS; ABNORMALITIES; EXPRESSION; CHILDREN	THE majority (approximately 75%) of infant acute leukaemias have a reciprocal translocation between chromosome 11q23 and one of several partner chromosomes1. The gene at 11q23 (named MLL, ALL-1, HRX or HTRX-1; refs 2-6) has been cloned and shares homology with the Drosophila developmental gene trithorax3-5. Rearrangements of this gene (called HRX here) occur in introns and cluster in a region of approximately 10 kb; individual patients have different breakpoints3-10. Here we describe three pairs of infant twins with concordant leukaemia who each share unique (clonal) but non-constitutive HRX rearrangements in their leukaemic cells, providing evidence that the leukaemogenic event originates in utero and unequivocal support for the intra-placental 'metastasis' hypothesis for leukaemia concordance in twins11.	UNIV CHILE, HAEMATOL SECT, SANTIAGO, CHILE; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, MEMPHIS COLL MED, MEMPHIS, TN 38101 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UNIV HONG KONG, QUEEN MARY HOSP COMPOUND, DEPT PATHOL, HONG KONG, HONG KONG	Universidad de Chile; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Edinburgh; University of Hong Kong	FORD, AM (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CTR LEUKAEMIA RES FUND, 237 FULHAM RD, LONDON SW3 6JB, ENGLAND.							BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; CARTER M, 1991, LEUKEMIA, V5, P668; CHAGANTI RSK, 1979, NEW ENGL J MED, V300, P1032, DOI 10.1056/NEJM197905033001807; CHEN CS, IN PRESS BLOOD; CIMINO G, 1991, CANCER RES, V51, P6712; CLARKSON BD, 1971, LANCET, V1, P699; DEOLIVEIRA MSP, 1986, LANCET, V2, P969; DJABALI M, 1992, NAT GENET, V2, P112; DRAPER GJ, 1977, J MED GENET, V14, P81, DOI 10.1136/jmg.14.2.81; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARTLEY SE, 1981, HUM GENET, V58, P408, DOI 10.1007/BF00282824; HILTON HB, 1970, BLOOD-J HEMATOL, V35, P222, DOI 10.1182/blood.V35.2.222.222; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; Linet MS, 1985, LEUKEMIAS EPIDEMIOLO; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MILLER RW, 1971, J NATL CANCER I, V46, P203; MILLER RW, 1968, NEW ENGL J MED, V279, P122, DOI 10.1056/NEJM196807182790302; MORGAN GJ, 1992, BLOOD, V80, P2172; PRIGOGINA EL, 1979, HUM GENET, V53, P5, DOI 10.1007/BF00289443; PUI CH, 1992, LEUKEMIA LYMPHOMA, V7, P173, DOI 10.3109/10428199209053620; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; RUBIN CM, 1991, BLOOD, V78, P2982; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; Strong S.J, 1967, PLACENTA TWIN PREGNA; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDENBERGHE H, 1979, HUM GENET, V46, P173, DOI 10.1007/BF00291919; YAMAMOTO K, 1993, ONCOGENE, V8, P479; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; ZUELZER WW, 1969, SEMIN HEMATOL, V228, P228	36	343	348	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					358	360		10.1038/363358a0	http://dx.doi.org/10.1038/363358a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497319				2022-12-01	WOS:A1993LD91700056
J	KRUPA, DJ; THOMPSON, JK; THOMPSON, RF				KRUPA, DJ; THOMPSON, JK; THOMPSON, RF			LOCALIZATION OF A MEMORY TRACE IN THE MAMMALIAN BRAIN	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; RED NUCLEUS; NEURONAL RESPONSES; CEREBELLAR NUCLEI; UNCONDITIONED STIMULUS; EYELID RESPONSE; LESIONS; RABBIT; ACQUISITION; STIMULATION	The localization of sites of memory formation within the brain has proven to be a formidable task even for simple forms of learning and memory. In order to localize a particular site of memory formation within the brain, the rabbit eyeblink response was classically conditioned while regions of the cerebellum or red nucleus were temporarily inactivated by microinfusions of the gamma-aminobutyric acid agonist muscimol. Cerebellar inactivation completely blocked learning but had no effect on subsequent learning after inactivation, whereas red nucleus inactivation did not prevent learning but did block the expression of conditioned responses. The site of memory formation for this learned response thus appears to be localized within the cerebellum.			KRUPA, DJ (corresponding author), UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089, USA.				NIA NIH HHS [AG05142] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005142] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CHAPMAN PF, 1988, BRAIN RES, V442, P97, DOI 10.1016/0006-8993(88)91436-9; CHAPMAN PF, 1990, BRAIN RES, V537, P149, DOI 10.1016/0006-8993(90)90351-B; CLARK GA, 1984, BRAIN RES, V291, P125, DOI 10.1016/0006-8993(84)90658-9; CLARK RE, 1993, BEHAV NEUROSCI, V107, P264, DOI 10.1037/0735-7044.107.2.264; CLARK RE, 1992, BEHAV NEUROSCI, V106, P879, DOI 10.1037/0735-7044.106.6.879; DISTERHOFT JF, 1985, J NEUROSCI, V5, P941; DONEGAN NH, 1983, SOC NEUR ABSTR, V9, P331; ECCLES JC, 1977, BRAIN RES, V127, P327, DOI 10.1016/0006-8993(77)90550-9; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; Ito M., 1984, CEREBELLUM NEURAL CO; KEATING J G, 1991, Society for Neuroscience Abstracts, V17, P1381; LAVOND DG, IN PRESS ANN REV PSY; LEWIS JL, 1987, BEHAV NEUROSCI, V101, P151, DOI 10.1037/0735-7044.101.2.151; LYE RH, 1988, J PHYSIOL-LONDON, V403, pP58; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARTIN JH, 1988, BEHAV BRAIN RES, V28, P217, DOI 10.1016/0166-4328(88)90099-X; MATSUMOTO RR, 1989, BRAIN RES REV, V14, P203, DOI 10.1016/0165-0173(89)90001-5; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; MCCORMICK DA, 1984, J NEUROSCI, V4, P2811; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MCCORMICK DA, 1985, BRAIN RES, V359, P120, DOI 10.1016/0006-8993(85)91419-2; MCCORMICK DA, 1982, BRAIN RES, V245, P347; MINK JW, 1991, J NEUROPHYSIOL, V65, P330, DOI 10.1152/jn.1991.65.2.330; NORDHOLM AF, IN PRESS BEHAV NEURO; ROSENFIELD ME, 1985, BEHAV BRAIN RES, V17, P77, DOI 10.1016/0166-4328(85)90010-5; ROSENFIELD ME, 1983, BEHAV BRAIN RES, V10, P393, DOI 10.1016/0166-4328(83)90043-8; ROSENFIELD ME, 1983, PHYSIOL BEHAV, V34, P751; Squire L.R., 1987, MEMORY BRAIN; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; STEINMETZ JE, 1987, P NATL ACAD SCI USA, V84, P3531, DOI 10.1073/pnas.84.10.3531; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; VANNEERVEN J, 1989, ARCH ITAL BIOL, V127, P243; VONEIDA T J, 1990, Society for Neuroscience Abstracts, V16, P270; WELSH JP, 1991, J PHYSIOL-LONDON, V444, P459, DOI 10.1113/jphysiol.1991.sp018888; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022	38	353	358	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					989	991		10.1126/science.8493536	http://dx.doi.org/10.1126/science.8493536			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493536				2022-12-01	WOS:A1993LB79100045
J	KINLEN, LJ; CLARKE, K; BALKWILL, A				KINLEN, LJ; CLARKE, K; BALKWILL, A			PATERNAL PRECONCEPTIONAL RADIATION EXPOSURE IN THE NUCLEAR INDUSTRY AND LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN YOUNG-PEOPLE IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD LEUKEMIA	Objective-To determine if a relation exists between paternal exposure to relatively high levels of radiation in the Scottish nuclear industry and the risk of leukaemia and non-Hodgkin's lymphoma in subsequently conceived children. Design-Matched case-control study with three controls for each case. Setting-The whole of Scotland. Subjects-The fathers of 1024 children with leukaemia and 237 children with non-Hodgkin's lymphoma diagnosed in Scotland below the age of 25 among those born in Scotland since nuclear operations began (in 1958) and the fathers of 3783 randomly chosen controls. The fathers of 80 children with leukaemia and 16 with non-Hodgkin's lymphoma in north Cumbria were also covered since some workers at one Scottish nuclear site live over the border in that area. Details of all fathers were then matched against records of the nuclear industry. Main outcome measures-Paternal preconceptional radiation exposures, particularly relatively high levels, both lifetime and in the six and three months before conception. Results-No significant excess was observed in any subgroup and there was no significant trend: fathers of three controls but no cases were exposed to lifetime preconceptional levels of 100 mSv or greater (Fisher's exact p value 0.84). In the six months before conception, fathers of two cases and three controls received 10 mSv or more, odds ratio 2.3 (95% confidence interval 0.31 to 17.24). In the three months before conception the fathers of one case and two controls received 5 mSv or more, odds ratio 1.7 (0.10 to 30.76). The results for leukaemia and non-Hodgkin's lymphoma combined were similar. Conclusion-No significant excess of leukaemia or of leukaemia and non-Hodgkin's lymphoma was found at any radiation level in any preconceptional period.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,EPIDEMIOL,OXFORD OX2 6HE,ENGLAND.			Balkwill, Angela/0000-0002-6327-6245				BRESLOW N. E., 1980, STATISTICAL METHODS; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; DRAPER GJ, 1992, RADIOLOGICAL PROTECT, V129, P10; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KENDALL GM, 1988, NRPBR219; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1990, BRIT MED J, V300, P677, DOI 10.1136/bmj.300.6725.677-a; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1993, IN PRESS BMJ; MCLAUGHLIN JR, 1992, INFO0424 RES REP; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; 1991, ICRP60 INT COMM RAD; 1991, EGRET	18	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1153	1158		10.1136/bmj.306.6886.1153	http://dx.doi.org/10.1136/bmj.306.6886.1153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499814	Bronze, Green Published			2022-12-01	WOS:A1993LA68500017
J	Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Datta, SC; Talwar, HS; Wang, ZQ; Varani, J; Kang, S; Voorhees, JJ			Molecular basis of sun-induced premature skin ageing and retinoid antagonism	NATURE			English	Article							IV COLLAGENASE GENE; C-JUN; GLUCOCORTICOID RECEPTOR; ACID; EXPRESSION; GELATINASE; PROMOTER; BINDING; FORMS	DAMAGE to skin collagen and elastin (extracellular matrix) is the hallmark of long-term exposure to solar ultraviolet irradiation(1-3), and is believed to be responsible for the wrinkled appearance of sun-exposed skin(4,5). We report here that matrix-degrading metalloproteinase messenger RNAs, proteins and activities are induced in human skin in vivo within hours of exposure to ultraviolet-B irradiation (UVB). Induction of metalloproteinase proteins and activities occurred at UVB doses well below those that cause skin reddening. Within minutes, low-dose UVB upregulated the transcription factors AP-1 and NF-kappa B, which are known to be stimulators of metalloproteinase genes(6,7). All-trans retinoic acid, which transrepresses AP-1 (ref. 8), applied before irradiation with UVB, substantially reduced AP-1 and metalloproteinase induction, We propose that elevated metalloproteinases, resulting from activation of AP-1 and NF-kappa B by low dose solar irradiation, degrade collagen and elastin in skin, Such damage, if imperfectly repaired would result in solar scars, which through accumulation from a lifetime of repeated low-dose sunlight exposure could cause premature skin ageing (photoageing).	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT DERMATOL,KRESGE 1,R6558,ANN ARBOR,MI 48109, USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Angel P, 1992, Matrix Suppl, V1, P156; BAILLY C, 1990, J INVEST DERMATOL, V94, P47, DOI 10.1111/1523-1747.ep12873342; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EISEN AZ, 1969, J INVEST DERMATOL, V52, P442, DOI 10.1038/jid.1969.76; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; HU CL, 1978, ANAL BIOCHEM, V88, P638, DOI 10.1016/0003-2697(78)90467-0; KLIGMAN LH, 1986, PHOTODERMATOLOGY, V3, P215; Lavker RM, 1979, J INVEST DERMATOL, V73, P559; MAUCH C, 1994, ARCH DERMATOL RES, V287, P107, DOI 10.1007/BF00370728; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SATO H, 1993, ONCOGENE, V8, P395; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; WEINSTEIN GD, 1960, J INVEST DERMATOL, V35, P227, DOI 10.1038/jid.1960.109; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	30	1048	1105	8	114	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					335	339		10.1038/379335a0	http://dx.doi.org/10.1038/379335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552187	Green Submitted			2022-12-01	WOS:A1996TR32300056
J	Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG				Liston, P; Roy, N; Tamai, K; Lefebvre, C; Baird, S; ChertonHorvat, G; Farahani, R; McLean, M; Ikeda, JE; MacKenzie, A; Korneluk, RG			Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes	NATURE			English	Article								DYSREGULATION Of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers(1), or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Recently, we isolated a candidate gene, encoding neuronal apoptosis inhibitor protein (NAIP)(2), for SMA. This gene is homologous to two baculovirus inhibitor of apoptosis proteins(3,4) (Cp-IAP and Op-IAP) and is partly deleted in individuals with type I SMA, A second SMA candidate gene encoding survival motor neuron (SMN), which is contiguous with the NAIP locus on 5q13.1, was also reported(5), Here we demonstrate a NAIP-mediated inhibition of apoptosis induced by a variety of signals, and have identified three additional human complementary DNAs and a Drosophila melanogaster sequence that are also homologous to the baculovirus IAPs, The four open reading frames (ORFs) possess three baculoviral inhibition of apoptosis protein repeat (BIR) domains and a carboxy-terminal RING zinc-finger. The human iap genes have a distinct but overlapping pattern of expression in fetal and adult tissues. These proteins significantly increase the number of known apoptotic suppressors.	CHILDRENS HOSP EASTERN ONTARIO,MOLEC GENET RES LAB,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,APOPTOGEN INC,OTTAWA,ON K1H 8L1,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA,ON K1H 8M5,CANADA; MED & BIOL LABS CO,NAKA KU,NAGOYA,AICHI 460,JAPAN; TOKAI UNIV,INST MED SCI,KANAGAWA 25911,JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; Tokai University			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUJITA A, 1995, J VIROL, V69, P6180, DOI 10.1128/JVI.69.10.6180-6190.1995; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOR H, 1982, J BIOL CHEM, V257, P2419; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	15	853	924	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					349	353		10.1038/379349a0	http://dx.doi.org/10.1038/379349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552191				2022-12-01	WOS:A1996TR32300060
J	Bunsey, M; Eichenbaum, H				Bunsey, M; Eichenbaum, H			Conservation of hippocampal memory function in rats and humans	NATURE			English	Article							RHESUS-MONKEYS; ASSOCIATION; SYMMETRY; AMNESIA; LESIONS; PIGEONS	THE hippocampus is critical to declarative memory in humans(1). This kind of memory involves associations among items or events that can be accessed flexibly to guide memory expression in various and even new situations(2-4). In animals, there has been controversy about whether the hippocampus is specialized for spatial memory(5,6) or whether it mediates a general memory function(3,4), as it does in humans. To address this issue we trained normal rats and rats with hippocampal damage on non-spatial stimulus-stimulus associations, then probed the nature of their memory representations. We report here that normal rats demonstrated two forms of flexible memory expression, transitivity, the ability to judge inferentially across stimulus pairs that share a common element, and symmetry, the ability to associate paired elements presented in the reverse of training order. Rats with neurotoxic damage limited to the hippocampus demonstrated neither form of flexible expression, indicating that non-spatial declarative processing depends specifically on the hippocampus in animals as it does in humans.,			Bunsey, M (corresponding author), SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794, USA.							BUNSEY M, IN PRESS HIPPOCAMPUS; CHO YH, 1995, BEHAV BRAIN RES, V67, P91, DOI 10.1016/0166-4328(94)00109-S; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DAMATO MR, 1985, J EXP ANAL BEHAV, V44, P35, DOI 10.1901/jeab.1985.44-35; DAVIDSON TL, 1993, BEHAV NEUROSCI, V107, P227, DOI 10.1037/0735-7044.107.2.227; Dickinson A., 1980, CONT ANIMAL LEARNING; DOUGLAS RJ, 1966, NEUROPSYCHOLOGIA, V4, P197, DOI 10.1016/0028-3932(66)90028-5; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; EICHENBAUM H, 1990, J NEUROSCI, V10, P331; GAFFAN D, 1994, EXP BRAIN RES, V99, P411; HUNT ME, 1994, PSYCHOBIOLOGY, V22, P186; James W, 1918, PRINCIPLES PSYCHOL; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moscovitch Morris, 1994, P269; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Musen G., 1993, NEUROPSYCHOLOGY, V7, P119, DOI DOI 10.1037/0894-4105.7.2.119; NADEL L, 1995, HIPPOCAMPUS, V5, P232, DOI 10.1002/hipo.450050309; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; SIDMAN M, 1982, J EXP ANAL BEHAV, V37, P23, DOI 10.1901/jeab.1982.37-23; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TERRACE HS, 1993, PSYCHOL SCI, V4, P162, DOI 10.1111/j.1467-9280.1993.tb00481.x; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WEISKRANTZ L, 1975, HIPPOCAMPUS, V2, P411; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1995, HIPPOCAMPUS, V5, P235, DOI 10.1002/hipo.450050310; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	33	470	479	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					255	257		10.1038/379255a0	http://dx.doi.org/10.1038/379255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ169	8538790				2022-12-01	WOS:A1996TQ16900046
J	Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H				Mukhin, LM; Koscheev, AP; Dikov, YP; Huth, J; Wanke, H			Experimental simulations of the photodecomposition of carbonates and sulphates on Mars	NATURE			English	Article							MARTIAN ATMOSPHERE	THERE is indirect spectroscopic evidence for the presence of sulphates and carbonates on the martian surface(1-5), and such minerals are also found in SNC meteorites(6), which are thought to be of martian origin. But although carbonates are expected to be abundant in the martian regolith(7-9), attempts to detect them directly have been unsuccessful(10,11). Here we report laboratory studies of the decomposition of calcium carbonate and magnesium sulphate under ultraviolet irradiation, which mimic the conditions under which photodecomposition of surface minerals by solar ultraviolet light might occur on Mars. We find that, even for a low abundance(6) of carbonate minerals in the martian regolith, the rate of CO2 release due to photodecomposition is higher than the rate of CO2 loss from the atmosphere by solar-wind-induced sputtering processes(12-15), making this profess a potential net source of atmospheric CO2 over time. SO2 is also released from the sulphate, albeit more slowly. The rate of carbonate degradation is high enough to explain the apparent absence of these compounds at the martian surface.	INST SPACE RES,MOSCOW,RUSSIA; KARPOV INST PHYS CHEM,ACT PARTICLE ABSORPT LAB,MOSCOW 103064,RUSSIA; RUSSIAN ACAD SCI,INST ORE DEPOSIT PETROG MINERAL & GEOCHEM,MOSCOW 109017,RUSSIA; MAX PLANCK INST CHEM,ABT KOSMOCHEM,D-55122 MAINZ,GERMANY	Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; Karpov Institute of Physical Chemistry; Russian Academy of Sciences; Max Planck Society	Mukhin, LM (corresponding author), EMBASSY RUSSIAN FEDERAT,2650 WISCONSIN AVE NW,WASHINGTON,DC 20007, USA.							Banin A., 1992, MARS, P594; BELL JF, 1994, ICARUS, V111, P106, DOI 10.1006/icar.1994.1136; BIERMANN K, 1977, J GEOPHYS RES, V82, P4641; BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; BLANEY DL, 1995, J GEOPHYS RES-PLANET, V100, P14433, DOI 10.1029/95JE00224; CALVIN WM, 1994, J GEOPHYS RES-PLANET, V99, P14659, DOI 10.1029/94JE01090; CLARK BC, 1981, ICARUS, V45, P370, DOI 10.1016/0019-1035(81)90041-5; Fanale F.P., 1992, MARS, P1135; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; GREELEY R, 1982, J GEOPHYS RES, V87, P9, DOI 10.1029/JB087iB12p10009; Greeley R., 1992, MARS, P730; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; MOUNT GH, 1983, J GEOPHYS RES-OCEANS, V88, P5403, DOI 10.1029/JC088iC09p05403; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; WEBER MJ, 1986, HDB LASER SCI TECHNO, V4, P224; [No title captured]	23	38	38	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					141	143		10.1038/379141a0	http://dx.doi.org/10.1038/379141a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538763				2022-12-01	WOS:A1996TP36000050
J	Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV				Rothe, M; Pan, MG; Henzel, WJ; Ayres, TM; Goeddel, DV			The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR; ZINC-FINGER; IDENTIFICATION; SEQUENCE; CLONING; MOTIF	The 75 kDa tumor necrosis factor receptor (TNFR2) transduces extracellular signals via receptor-associated cytoplasmic proteins. Two of these signal transducers, TRAF1 and TRAF2, were isolated and characterized previously. We report here the biochemical purification and subsequent molecular cloning of two novel TNFR2-associated proteins, designated c-IAP1 and c-IAP2, that are closely related mammalian members of the inhibitor of apoptosis protein (IAP) family originally identified in baculoviruses. The viral and cellular IAPs contain N-terminal baculovirus IAP repeat (BIR) motifs and a C-terminal RING finger. The c-IAPs do not directly contact TNFR2, but rather associate with TRAF1 and TRAF2 through their N-terminal BIR motif-comprising domain. The recruitment of c-IAP1 or c-IAP2 to the TNFR2 signaling complex requires a TRAF2-TRAF1 heterocomplex.	GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech	Rothe, M (corresponding author), TULARIK INC, DEPT BIOL MOLEC, 270 E GRAND AVE, San Francisco, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAUNAGEL SC, 1992, VIROLOGY, V191, P1003, DOI 10.1016/0042-6822(92)90281-S; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PENNICA D, 1992, J BIOL CHEM, V267, P21172; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROTH E, 1995, M SCIENCE, V269, P1424; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J., 1989, MOL CLONING LAB MANU; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	43	1026	1089	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1243	1252		10.1016/0092-8674(95)90149-3	http://dx.doi.org/10.1016/0092-8674(95)90149-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548810	Bronze			2022-12-01	WOS:A1995TM76200019
J	FERMULLER, C; ALOIMONOS, Y				FERMULLER, C; ALOIMONOS, Y			DIRECT PERCEPTION OF 3-DIMENSIONAL MOTION FROM PATTERNS OF VISUAL-MOTION	SCIENCE			English	Article							OPTIC FLOW; FIELD	Measurements of retinal motion along a set of predetermined orientations on the retina of a moving system give rise to global patterns. Because the form and location of these patterns depend purely on three-dimensional (3D) motion, the effects of 3D motion and scene structure on image motion can be globally separated. The patterns are founded on easily derivable image measurements that depend only on the sign of image motion and do not require information about optical flow. The computational theory presented here explains how the self-motion of a system can be estimated by locating these patterns.	UNIV MARYLAND,CTR AUTOMAT RES,DEPT COMP SCI,COMP VIS LAB,COLLEGE PK,MD 20742; UNIV MARYLAND,INST ADV COMP STUDIES,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park			Aloimonos, Yiannis/AAI-2969-2020	Aloimonos, Yiannis/0000-0002-8152-4281				Aloimonos J., 1984, Proceedings of the Workshop on Computer Vision: Representation and Control, P72; ALOIMONOS Y, 1991, SCIENCE, V253, P1181; ALOIMONOS Y, 1993, INTEGRATION VISUAL M; ANCONA N, 1995, INT J COMPUT VISION, V14, P131, DOI 10.1007/BF01418979; BRODSKY T, 1995, CARTR780 U MAR CTR A; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; FAUGERAS OD, 1990, INT J COMPUT VISION, V4, P225, DOI 10.1007/BF00054997; FERMULLER C, 1995, INT J COMPUT VISION, V15, P7, DOI 10.1007/BF01450848; FERMULLER C, 1993, INT J COMPUT VISION, V11, P165, DOI 10.1007/BF01469227; FERMULLER C, 1993, ACTIVE PERCEPTION, P103; FERMULLER C, IN PRESS VISUAL NAVI; FERMULLER C, 1994, CARTR732 U MAR CTR A; FERMULLER C, 1995, INT J COMPUT VISION, V114, P147; Gibson J.J., 1979, ECOLOGICAL APPROACH; Horn B. K. P., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3), P2; KOENDERINK JJ, 1986, VISION RES, V26, P161, DOI 10.1016/0042-6989(86)90078-7; LONGUETHIGGINS HC, 1981, NATURE, V293, P133, DOI 10.1038/293133a0; LONGUETHIGGINS HC, 1984, P ROY SOC LOND B BIO, V208, P385; NELSON RC, 1989, IEEE T PATTERN ANAL, V11, P1102, DOI 10.1109/34.42840; POGGIO T, 1973, KYBERNETIK, V13, P223, DOI 10.1007/BF00274887; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; Reichardt W., 1961, S PRINC SENS COMM, P303; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TSAI RY, 1984, IEEE T PATTERN ANAL, V6, P13, DOI 10.1109/TPAMI.1984.4767471; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; VERRI A, 1989, IEEE T PATTERN ANAL, V11, P490, DOI 10.1109/34.24781	27	52	54	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1973	1976		10.1126/science.270.5244.1973	http://dx.doi.org/10.1126/science.270.5244.1973			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533087				2022-12-01	WOS:A1995TL42000036
J	QUELLE, DE; ZINDY, F; ASHMUN, RA; SHERR, CJ				QUELLE, DE; ZINDY, F; ASHMUN, RA; SHERR, CJ			ALTERNATIVE READING FRAMES OF THE INK4A TUMOR-SUPPRESSOR GENE ENCODE 2 UNRELATED PROTEINS CAPABLE OF INDUCING CELL-CYCLE ARREST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHASE; DNA	The INK4a (MTS1, CDKN2) gene encodes an inhibitor (p16(INK4a)) Of the cyclin D-dependent kinases CDK4 and CDK6 that blocks them from phosphorylating the retinoblastoma protein (pRB) and prevents exit from the G1 phase of the cell cycle. Deletions and mutations involving INK4a occur frequently in cancers, implying that p16(INK4a), like pRB, suppresses tumor formation. An unrelated protein (p19(ARF)) arises in major part from an alternative reading frame of the mouse INK4a gene, and its ectopic expression in the nucleus of rodent fibroblasts induces G1 and G2 phase arrest. Economical reutilization of coding sequences in this manner is practically without precedent in mammalian genomes, and the unitary inheritance of p16(INK4a) and p19(ARF) may underlie their dual requirement in cell cycle control.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES S, 1994, ONCOGENE, V9, P1633; BOLES E, 1994, MOL GEN GENET, V243, P363, DOI 10.1007/BF00280465; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; LAMB RA, 1991, TRENDS GENET, V7, P261, DOI 10.1016/0168-9525(91)90162-J; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUELLE DE, 1995, ONCOGENE, V11, P635; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STONE S, 1995, CANCER RES, V55, P2988; TAM SW, 1994, ONCOGENE, V9, P2663; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHANG SY, 1994, CANCER RES, V54, P5050	49	1252	1288	1	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 15	1995	83	6					993	1000						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521522				2022-12-01	WOS:A1995TK74500017
J	GREWAL, IS; XU, JC; FLAVELL, RA				GREWAL, IS; XU, JC; FLAVELL, RA			IMPAIRMENT OF ANTIGEN-SPECIFIC T-CELL PRIMING IN MICE LACKING CD40 LIGAND	NATURE			English	Article							HYPER-IGM SYNDROME	LACK of functional expression of CD40 ligand (CD40L) on T cells results in hyper-IgM syndrome (HIGM1), a human immunodeficiency associated with a severely impaired humoral immune response that is consistent with defects in B-cell responses(1-3). Patients also succumb to recurrent opportunistic infections such as Pneumocystis carinii and a Cryptosporidial diarrhoea(4,5), suggesting that T-cell functions are also compromised in these individuals, but so far this has not been explained. We have previously shown that mice deficient for CD40L, like HIGM1 patients, show grossly abnormal humoral responses(6). Here we report that CD40L-deficient mice are defective in antigen-specific T-cell responses, Adoptively transferred antigen-specific CD4(+) T cells lacking CD40L failed to expand upon antigen challenge of the recipients, showing that expression of CD40L on T cells is required for in vivo priming of CD4(+) T cells and therefore for the initiation of specific T-cell immune responses.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Yale University	GREWAL, IS (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.			Grewal, Iqbal S/0000-0002-4775-055X				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CONSTANT S, 1995, J IMMUNOL, V154, P4915; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; EPSTEIN MM, 1995, J EXP MED, V182, P915, DOI 10.1084/jem.182.4.915; FOY M, 1995, EUR J IMMUNOL, V25, P596; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KEAMEY ER, 1994, IMMUNITY, V1, P327; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	16	438	446	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					617	620		10.1038/378617a0	http://dx.doi.org/10.1038/378617a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524395				2022-12-01	WOS:A1995TJ22100077
J	BENDER, J; FINK, GR				BENDER, J; FINK, GR			EPIGENETIC CONTROL OF AN ENDOGENOUS GENE FAMILY IS REVEALED BY A NOVEL BLUE FLUORESCENT MUTANT OF ARABIDOPSIS	CELL			English	Article							AUXIN POLAR TRANSPORT; ASCOBOLUS-IMMERSUS; METHYLATION; THALIANA; LOCUS; MECHANISMS; EXPRESSION; NEUROSPORA; MUTATIONS; SEQUENCES	The Wassilewskija strain of Arabidopsis has four genes encoding the tryptophan enzyme phosphoribosylanthranilate isomerase (PAI) located at three unlinked sites, These four PAI genes are methylated over their regions of DNA homology, When PAI copy number is reduced by deletion of two tandemly arrayed genes (MePAI1-PAI4), a mutant with fluorescent, tryptophan-deficient phenotypes results, because the two remaining methylated PAI genes (MePAI2 and MePAI3) supply insufficient PAI activity, These two methylated genes can be inherited through meiosis, even when they are segregated away from each other in crosses to a strain with unmethylated PAI genes, However, the mutant phenotypes conferred by the methylated PAI genes are unstable, and mutant plants yield occasional revertant somatic sectors and progeny. Revertant lines display coordinately reduced methylation of both PAI2 and PAI3, implying that this hypomethylation acts in a concerted manner across the genome rather than at individual sites.	MIT, CAMBRIDGE, MA 02142 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Massachusetts Institute of Technology (MIT); Johns Hopkins University	BENDER, J (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.							ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BANKS JA, 1988, GENE DEV, V2, P1364, DOI 10.1101/gad.2.11.1364; BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; BRUTNELL TP, 1994, GENETICS, V138, P213; DEHIO C, 1994, P NATL ACAD SCI USA, V91, P5538, DOI 10.1073/pnas.91.12.5538; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ERRAMPALLI D, 1991, PLANT CELL, V3, P149, DOI 10.1105/tpc.3.2.149; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HENIKOFF S, 1994, CELL, V77, P993; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; KILBY NJ, 1992, PLANT MOL BIOL, V20, P103, DOI 10.1007/BF00029153; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI JY, 1995, PLANT CELL, V7, P447, DOI 10.1105/tpc.7.4.447; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; MARTIENSSEN R, 1994, GENETICS, V136, P1157; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; PETERSON K, 1993, ANNU REV GENET, V27, P7, DOI 10.1146/annurev.ge.27.120193.000255; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; STINARD PS, 1993, PLANT CELL, V5, P1555, DOI 10.1105/tpc.5.11.1555; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8	39	186	195	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					725	734		10.1016/0092-8674(95)90185-X	http://dx.doi.org/10.1016/0092-8674(95)90185-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521489	hybrid			2022-12-01	WOS:A1995TH94800009
J	CHEN, JW; GALL, MA; DECKERT, M; JENSEN, JS; PARVING, HH				CHEN, JW; GALL, MA; DECKERT, M; JENSEN, JS; PARVING, HH			INCREASED SERUM CONCENTRATION OF VON-WILLEBRAND-FACTOR IN NON-INSULIN-DEPENDENT DIABETIC-PATIENTS WITH AND WITHOUT DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DISEASE		STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; UNIV COPENHAGEN,RIGSHOSP,COPENHAGEN CITY HEART STUDY,DK-2200 COPENHAGEN,DENMARK	Steno Diabetes Center; Rigshospitalet; University of Copenhagen								GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; JENSEN T, 1989, BRIT MED J, V298, P27, DOI 10.1136/bmj.298.6665.27-a; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003	5	39	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1405	1406		10.1136/bmj.311.7017.1405	http://dx.doi.org/10.1136/bmj.311.7017.1405			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520276	Green Published			2022-12-01	WOS:A1995TG90200022
J	ALVIR, JMJ; LIEBERMAN, JA; SAFFERMAN, AZ; SCHWIMMER, JL; SCHAAF, JA				ALVIR, JMJ; LIEBERMAN, JA; SAFFERMAN, AZ; SCHWIMMER, JL; SCHAAF, JA			CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHLORPROMAZINE; SCHIZOPHRENIA; DRUGS	Background. Clozapine is an atypical antipsychotic agent that is more effective than standard neuroleptic drugs in the treatment of patients with refractory schizophrenia. Unlike classic neuroleptic agents, clozapine is not associated with the development of acute extrapyramidal symptoms or tardive dyskinesia. The main factor limiting its use is the risk of potentially fatal agranulocytosis, estimated to occur in 1 to 2 percent of treated patients. After clozapine was approved by the Food and Drug Administration, it became available for marketing in the United States in February 1990 only as part of a special surveillance system (the Clozaril Patient Management System, or CPMS), in which a weekly white-cell count was required for the patient to receive a supply of the drug. Methods. We evaluated the CPMS data for February 1990 through April 1991 by survival analysis to determine the incidence of agranulocytosis and the effects of potential risk factors such as age and sex. Data were available for 11,555 patients who received clozapine during the period after marketing began. Results. Agranulocytosis developed in 73 patients, resulting in death from infectious complications in 2 patients. Episodes of agranulocytosis occurred in 61 patients within three months after they began treatment. The cumulative incidence of this side effect was 0.80 percent (95 percent confidence interval, 0.61 to 0.99) at 1 year and 0.91 percent (95 percent confidence interval, 0.62 to 1.20) at 1 1/2 years. The risk of agranulocytosis increased with age and was higher among women. Conclusions. The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count. The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PSYCHIAT,BRONX,NY 10461; SANDOZ PHARMACEUT CORP,E HANOVER,NJ	Yeshiva University; Albert Einstein College of Medicine; Novartis; Sandoz	ALVIR, JMJ (corresponding author), LONG ISL JEWISH MED CTR,HILLSIDE HOSP,DEPT PSYCHIAT,75-59 263RD ST,GLEN OAKS,NY 11004, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH041960, P50MH041960] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-41960, MH-00537] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMSLER HA, 1977, ACTA PSYCHIAT SCAND, V56, P241, DOI 10.1111/j.1600-0447.1977.tb00224.x; ANDERMAN B, 1977, EUR J CLIN PHARMACOL, V11, P199, DOI 10.1007/BF00606410; BARNAS C, 1992, J CLIN PSYCHIAT, V53, P245; BASTANI B, 1989, PSYCHOPHARMACOLOGY, V99, pS122, DOI 10.1007/BF00442576; BURKI HR, 1975, PHARMAKOPSYCH NEURO, V8, P115; CHIODO LA, 1983, J NEUROSCI, V3, P1067; de la Chapelle A, 1977, Hum Genet, V37, P183; Fleming T. R., 1991, COUNTING PROCESSES S; GERSON SL, 1992, LANCET, V340, P1097, DOI 10.1016/0140-6736(92)93116-5; GERSON SL, 1991, LANCET, V338, P262, DOI 10.1016/0140-6736(91)90410-Q; GRIFFITH RW, 1975, LANCET, V2, P657; HIPPIUS H, 1958, Arztl Wochensch, V13, P501; IDANPAANHEIKKILA J, 1975, LANCET, V2, P611; IDANPAANHEIKKILA J, 1977, EUR J CLIN PHARMACOL, V11, P193, DOI 10.1007/BF00606409; JUNGI WF, 1977, SCHWEIZ MED WSCHR, V107, P1861; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1981, PSYCHOPHARMACOLOGY, V73, P184, DOI 10.1007/BF00429215; LIEBERMAN J, 1986, CLIN NEUROPHARMACOL, V9, P140; LIEBERMAN JA, 1988, J CLIN PSYCHIAT, V49, P271; LIEBERMAN JA, 1990, ARCH GEN PSYCHIAT, V47, P945; LIEBERMAN JA, 1989, PSYCHOPHARMACOL BULL, V25, P57; Lieberman Jeffrey A., 1992, Psychiatric Quarterly (New York), V63, P51, DOI 10.1007/BF01064682; LJUNGBERG T, 1978, PSYCHOPHARMACOLOGY, V56, P239, DOI 10.1007/BF00432845; PISCIOTTA AV, 1992, J LAB CLIN MED, V119, P254; PISCIOTTA AV, 1969, J AMER MED ASSOC, V208, P1862, DOI 10.1001/jama.208.10.1862; Pisciotta AV, 1990, J CLIN PSYCHIATRY MO, V8, P22; SAYERS AC, 1975, PSYCHOPHARMACOLOGIA, V41, P97, DOI 10.1007/BF00421063; Schmutz J., 1982, CHRONICLES DRUG DISC, V1, P39; WEIDE R, 1992, BRIT J HAEMATOL, V80, P557, DOI 10.1111/j.1365-2141.1992.tb04574.x; 1991, SAS STAT SOFTWARE PH; 1989, SAS STAT USERS GUIDE, V2, P1027; 1989, CLOZARIL CLOZAPINE A	32	756	777	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					162	167		10.1056/NEJM199307153290303	http://dx.doi.org/10.1056/NEJM199307153290303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL460	8515788				2022-12-01	WOS:A1993LL46000003
J	RINGDEN, O; HOROWITZ, MM; GALE, RP; BIGGS, JC; GAJEWSKI, J; RIMM, AA; SPECK, B; VEUMSTONE, JA; DEWITTE, T; BORTIN, MM				RINGDEN, O; HOROWITZ, MM; GALE, RP; BIGGS, JC; GAJEWSKI, J; RIMM, AA; SPECK, B; VEUMSTONE, JA; DEWITTE, T; BORTIN, MM			OUTCOME AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR LEUKEMIA IN OLDER ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VERSUS-HOST DISEASE; SEVERE APLASTIC-ANEMIA; RISK-FACTORS; MYELOGENOUS LEUKEMIA; RELAPSE; AGE	Objective.-To determine whether age over 40 years is associated with adverse outcome after allogeneic bone marrow transplantation for leukemia. Design.-A retrospective analysis of outcome after bone marrow transplants for leukemia reported to the International Bone Marrow Transplant Registry (IBMTR) among recipients 30 through 39 years, 40 through 44 years, 45 through 49 years, and 50 years of age and older. Setting.-Transplantations performed in 138 institutions worldwide and reported to the IBMTR. Patients.-A total of 2180 recipients of HLA-identical sibling bone marrow transplants for leukemia, divided into four cohorts based on age: 30 through 39 years (n=1282), 40 through 44 years (n=527), 45 through 49 years (n=291), and 50 years and older (n=80). Main Outcome Measures and Results.-Incidence of leukemia-free survival, graft-vs-host disease, and relapse was comparable among the four age cohorts. Patients with advanced leukemia aged 45 years or older hard a slightly higher risk of treatment-related mortality, and the 45- through 49-year-old cohort had a higher risk of interstitial pneumonia. Conclusions.-These data indicate that among leukemia patients over 30 years of age at the time of allogeneic bone marrow transplantation, increasing age into the fifth decade does not adversely affect outcome after transplants from HLA-identical siblings.	MED COLL WISCONSIN, INST HLTH POLICY, INT BONE MARROW TRANSPLANT REGISTRY, POB 26509, MILWAUKEE, WI 53226 USA; HUDDINGE HOSP, S-14186 HUDDINGE, SWEDEN; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA USA; ST VINCENTS HOSP, DARLINGHURST, NSW 2010, AUSTRALIA; KANTONSSPITAL, CH-4004 BASEL, SWITZERLAND; CATHOLIC UNIV NIJMEGEN, NIJMEGEN, NETHERLANDS	Medical College of Wisconsin; University of California System; University of California Los Angeles; St Vincents Hospital Sydney; Kantonsspital Aarau AG (KSA); University of Basel; Radboud University Nijmegen			horowitz, Mary/ABH-2173-2021; de Witte, T.J.M./L-4762-2015		NCI NIH HHS [P0L-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON K, 1990, BLOOD, V75, P2459; BAR BMAM, 1990, BRIT J HAEMATOL, V74, P53, DOI 10.1111/j.1365-2141.1990.tb02537.x; BARRETT AJ, 1989, BLOOD, V74, P862; BORTIN MM, 1981, JAMA-J AM MED ASSOC, V245, P1132, DOI 10.1001/jama.245.11.1132; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; COX DR, 1972, J R STAT SOC B, V34, P187; ELFENBEIN G, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P235; GALE RP, 1989, LANCET, V1, P1119; GALE RP, 1987, BRIT J HAEMATOL, V67, P397, DOI 10.1111/j.1365-2141.1987.tb06160.x; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; KLINGEMANN HG, 1986, BLOOD, V67, P770; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; RINGDEN O, 1987, TRANSPLANT P, V19, P2600; RINGDEN O, 1985, TRANSPLANTATION, V40, P39; STORB R, 1983, ANN INTERN MED, V98, P461, DOI 10.7326/0003-4819-98-4-461; WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168; WEINER RS, 1989, BRIT J HAEMATOL, V71, P535, DOI 10.1111/j.1365-2141.1989.tb06314.x	17	127	127	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					57	60		10.1001/jama.270.1.57	http://dx.doi.org/10.1001/jama.270.1.57			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510297				2022-12-01	WOS:A1993LK36600023
J	ERARD, F; WILD, MT; GARCIASANZ, JA; LEGROS, G				ERARD, F; WILD, MT; GARCIASANZ, JA; LEGROS, G			SWITCH OF CD8 T-CELLS TO NONCYTOLYTIC CD8-CD4- CELLS THAT MAKE T(H)2 CYTOKINES AND HELP B-CELLS	SCIENCE			English	Article							INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTES; LEISHMANIASIS; GENERATION; PROFILES; INVITRO; SUBSETS; INVIVO; CLONES	CD8+ T cells are a major defense against viral infections and intracellular parasites. Their production of interferon-gamma (IFN-gamma) and their cytolytic activity are key elements in the immune response to these pathogens. Mature mouse CD8+ T cells that were activated in the presence of interleukin-4 (IL-4) developed into a CD8-CD4- population that was not cytolytic and did not produce IFN-gamma. However, these CD8- cells produced large amounts of IL-4, IL-5, and IL-10 and helped activate resting B cells. Thus, CD8 effector functions are potentially diverse and could be exploited by infectious agents that switch off host protective cytolytic responses.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		ERARD, F (corresponding author), CIBA GEIGY AG,DIV PHARMACEUT RES,DEPT ALLERGY IMMUNOL,CH-4002 BASEL,SWITZERLAND.		Le Gros, Graham/C-6725-2011; Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; Le Gros, Graham/0000-0002-5721-0442				ABRAHAM VS, 1992, J IMMUNOL, V148, P3746; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; ERARD F, 1985, J EXP MED, V162, P1738, DOI 10.1084/jem.162.5.1738; ERARD F, 1985, J IMMUNOL, V134, P1644; GARCIASANZ JA, IN PRESS EUR J IMMUN; GEUERNE PA, 1983, J IMMUNOL, V130, P2225; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; KELSO A, 1984, J IMMUNOL, V132, P2924; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MARGOLICK JB, 1989, CLIN IMMUNOL IMMUNOP, V51, P348, DOI 10.1016/0090-1229(89)90033-0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLER I, 1991, INT IMMUNOL, V3, P587, DOI 10.1093/intimm/3.6.587; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; OWENS T, 1988, EUR J IMMUNOL, V18, P395, DOI 10.1002/eji.1830180312; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SHEARER GM, 1992, CHEM IMMUNOL, V54, P21; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TITUS RG, 1987, EUR J IMMUNOL, V17, P1429, DOI 10.1002/eji.1830171007; WHITE J, 1989, J IMMUNOL, V143, P1822; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	25	350	355	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1802	1805		10.1126/science.8511588	http://dx.doi.org/10.1126/science.8511588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511588				2022-12-01	WOS:A1993LH20500049
J	NADA, S; YAGI, T; TAKEDA, H; TOKUNAGA, T; NAKAGAWA, H; IKAWA, Y; OKADA, M; AIZAWA, S				NADA, S; YAGI, T; TAKEDA, H; TOKUNAGA, T; NAKAGAWA, H; IKAWA, Y; OKADA, M; AIZAWA, S			CONSTITUTIVE ACTIVATION OF SRC FAMILY KINASES IN MOUSE EMBRYOS THAT LACK CSK	CELL			English	Article							PROTEIN-TYROSINE KINASE; MONOCLONAL-ANTIBODIES; CARBOXY TERMINUS; PP60C-SRC; PHOSPHORYLATION; BINDING; CELLS; P60C-SRC; GENE; RNA	Csk is a novel cytoplasmic protein-tyrosine kinase that has been shown to inactivate members of the Src family of protein-tyrosine kinases in vitro. To examine the function of Csk in vivo, Csk-deficient mouse embryos were generated by gene targeting in embryonic stem cells. These embryos were developmentally arrested at the 10 to 12 somite stage and exhibited growth retardation and necrosis in the neural tissues. The kinase activity of p60c-src, p59fyn, and p53/56lyn in these embryos was greatly enhanced as an apparent consequence of enhanced specific activity. The increase in kinase activity was associated with an increase in tyrosine phosphorylation of several proteins, especially those around 85 and 120 kd. Thus, these results suggest that Csk indeed acts as an indispensable negative regulator of Src family kinases in vivo.	INST PHYS & CHEM RES,TSUKKUBA LIFE SCI CTR,GENE TECHNOL & SAFETY LAB,WAKO,SAITAMA 351,JAPAN; OSAKA UNIV,INST PROT RES,OSAKA,JAPAN	RIKEN; Osaka University	NADA, S (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,WAKO,SAITAMA 351,JAPAN.							AKEDA H, 1992, DIFFERENTIATION, V51, P121; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1989, ONCOGENE, V4, P295; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1993, ONCOGENE, V8, P117; MAEKAWA T, 1991, ONCOGENE, V6, P627; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKANO H, 1991, J NEUROCHEM, V56, P560, DOI 10.1111/j.1471-4159.1991.tb08186.x; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RUGH R, 1990, MOUSE ITS REPRODUCTI, P102; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; THEILERK, 1989, HOUSE MOUSE, P21; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	53	380	386	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1125	1135		10.1016/0092-8674(93)90642-4	http://dx.doi.org/10.1016/0092-8674(93)90642-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513497				2022-12-01	WOS:A1993LH54800009
J	BRIDGES, AJ; CONLEY, C; WANG, G; BURNS, DE; VASEY, FB				BRIDGES, AJ; CONLEY, C; WANG, G; BURNS, DE; VASEY, FB			A CLINICAL AND IMMUNOLOGICAL EVALUATION OF WOMEN WITH SILICONE BREAST IMPLANTS AND SYMPTOMS OF RHEUMATIC DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						SILICONE ELASTOMERS; IMPLANTS, ARTIFICIAL; CONNECTIVE TISSUE DISEASES; RHEUMATIC DISEASES; MAMMAPALSTY	SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; REVISED CRITERIA; SCLERODERMA; ANTIBODIES; SCLEROSIS; CLASSIFICATION; ASSOCIATION	Objective: To describe the clinical and serologic features of women with silicone breast implants who were referred for symptoms of rheumatic disease. Design: A case series. Setting: University and private rheumatology practices. Patients: A total of 156 women with silicone breast implants and rheumatic disease complaints. Controls for the serologic studies included women with silicone implants and no rheumatic symptoms (n = 12) and women with fibromyalgia without silicone implants (n = 174). Measurements: Complete physical examination and testing for immunoglobulins; complement; C-reactive protein; rheumatoid factor; and autoantibodies by indirect immunofluorescence, immunodiffusion, and Western blot. Results: Three subgroups of patients were defined based on clinical and laboratory findings: joint and muscle pain (n = 95), joint swelling (n = 32), and connective tissue disease (n = 29). Most women had normal immunologic studies. The patients with joint swelling had mild, asymmetric, rheumatoid-factor-negative synovitis that did not meet American College of Rheumatology criteria for rheumatoid arthritis. Fourteen patients had a scleroderma-like illness and anti-centromere or anti-PM-Scl antibodies by Western blot. Ten patients had a positive Western blot for BB' polypeptide, a small nuclear ribonucleoprotein (snRNP), but did not meet criteria for systemic lupus erythematosus. No autoantibodies to known disease-related polypeptides were detected on Western blot in the control groups. Conclusion: Most women with silicone implants and rheumatic complaints had normal results of serologic tests and nonspecific symptoms, suggesting no serious connective tissue disease. However, a subset of women had clinical signs and serologic tests that were unusual even for referred patients. These observations suggest, but cannot establish, that some women with silicone breast implants may develop atypical immunologic reactions.	UNIV S FLORIDA, DIV RHEUMATOL, TAMPA, FL 33612 USA; JAMES A HAILEY VET ADM HOSP, TAMPA, FL USA	State University System of Florida; University of South Florida	BRIDGES, AJ (corresponding author), UNIV WISCONSIN HOSP, H6-367 CLIN SCI CTR, 600 HIGHLAND AVE, MADISON, WI 53792 USA.							ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BARNETT AJ, 1988, J RHEUMATOL, V15, P276; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BRIDGES AJ, 1992, ANN RHEUM DIS, V51, P793, DOI 10.1136/ard.51.6.793; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOX RI, 1984, SEMIN ARTHRITIS RHEU, V14, P77, DOI 10.1016/0049-0172(84)90001-5; GIORDANO M, 1986, J RHEUMATOL, V13, P911; GULDNER HH, 1986, CLIN IMMUNOL IMMUNOP, V40, P532, DOI 10.1016/0090-1229(86)90198-4; GUTIERREZ FJ, 1990, AM J MED, V89, P390; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LEROY EC, 1988, J RHEUMATOL, V15, P202; LIFSHITZ MS, 1988, LAB MED, V19, P510, DOI 10.1093/labmed/19.8.510; MASI AT, 1980, ARTHRITIS RHEUM-US, V23, P875; MCGRATH MH, 1984, PLAST RECONSTR SURG, V74, P550, DOI 10.1097/00006534-198410000-00019; PETTERSSON I, 1986, ARTHRITIS RHEUM, V29, P986, DOI 10.1002/art.1780290807; PORTER JF, 1988, ARTHRITIS RHEUM, V31, P219, DOI 10.1002/art.1780310210; PRESS RI, 1992, LANCET, V340, P1304, DOI 10.1016/0140-6736(92)92491-W; REICHLIN M, 1984, ARTHRITIS RHEUM, V27, P1150, DOI 10.1002/art.1780271011; ROKEACH LA, 1990, J IMMUNOL, V144, P1015; SAHN EE, 1990, ARCH DERMATOL, V126, P1198, DOI 10.1001/archderm.126.9.1198; SHARP GC, 1976, NEW ENGL J MED, V295, P1149, DOI 10.1056/NEJM197611182952101; SILMAN AJ, 1991, ANN RHEUM DIS, V50, P846, DOI 10.1136/ard.50.Suppl_4.846; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STEEN VD, 1988, ARTHRITIS RHEUM, V31, P196, DOI 10.1002/art.1780310207; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TAN EM, 1980, ARTHRITIS RHEUM, V23, P617, DOI 10.1002/art.1780230602; TERBORG EJ, 1988, ARTHRITIS RHEUM, V31, P1563, DOI 10.1002/art.1780311215; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VARGA J, 1990, ARCH DERMATOL, V126, P1220, DOI 10.1001/archderm.126.9.1220; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WALSH FW, 1989, ARCH INTERN MED, V149, P1194, DOI 10.1001/archinte.149.5.1194; WEINER SR, 1986, PLAST RECONSTR SURG, V77, P185, DOI 10.1097/00006534-198602000-00001; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; 1982, DICT RHEUMATIC DISEA, P74	39	184	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					929	936		10.7326/0003-4819-118-12-199306150-00003	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489106				2022-12-01	WOS:A1993LF93700003
J	DRMANAC, R; DRMANAC, S; STREZOSKA, Z; PAUNESKU, T; LABAT, I; ZEREMSKI, M; SNODDY, J; FUNKHOUSER, WK; KOOP, B; HOOD, L; CRKVENJAKOV, R				DRMANAC, R; DRMANAC, S; STREZOSKA, Z; PAUNESKU, T; LABAT, I; ZEREMSKI, M; SNODDY, J; FUNKHOUSER, WK; KOOP, B; HOOD, L; CRKVENJAKOV, R			DNA-SEQUENCE DETERMINATION BY HYBRIDIZATION - A STRATEGY FOR EFFICIENT LARGE-SCALE SEQUENCING	SCIENCE			English	Article								The concept of sequencing by hybridization (SBH) makes use of an array of all possible n-nucleotide oligomers (n-mers) to identify n-mers present in an unknown DNA sequence. Computational approaches can then be used to assemble the complete sequence. As a validation of this concept, the sequences of three DNA fragments, 343 base pairs in length, were determined with octamer oligonucleotides. Possible applications of SBH include physical mapping (ordering) of overlapping DNA clones, sequence checking, DNA fingerprinting comparisons of normal and disease-causing genes, and the identification of DNA fragments with particular sequence motifs in complementary DNA and genomic libraries. The SBH techniques may accelerate the mapping and sequencing phases of the human genome project.	ARGONNE NATL LAB, DIV BIOL & MED RES, ARGONNE, IL 60439 USA; CALTECH, DEPT BIOL, PASADENA, CA 91125 USA; INST MOLEC GENET & GENET ENGN, YU-11000 BELGRADE, YUGOSLAVIA	United States Department of Energy (DOE); Argonne National Laboratory; California Institute of Technology			Paunesku, Tatjana/A-3488-2017; Koop, Ben F./A-8151-2008; Paunesku, Tatjana/AAF-8529-2021	Paunesku, Tatjana/0000-0001-8698-2938; Koop, Ben F./0000-0003-0045-5200; Paunesku, Tatjana/0000-0001-8698-2938				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; DRMANAC R, 1990, DNA CELL BIOL, V9, P527, DOI 10.1089/dna.1990.9.527; DRMANAC R, 1992, INT J GENOME RES, V1, P59; DRMANAC R, 1991, J BIOMOL STRUCT DYN, V8, P1085, DOI 10.1080/07391102.1991.10507867; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1992, ELECTROPHORESIS, V13, P566, DOI 10.1002/elps.11501301115; DRMANAC R, 1987, Patent No. 57087; DRMANAC R, 1991, ELECTROPHORESES SUPE, P60; DRMANAC R, 1992, GENOME MAPPING SEQUE, P318; DRMANAC R, 1990, SCI YUGOSL, V16, P97; EGGERS M, 1992, GENOME MAPPING SEQUE, P111; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; KHRAPKO KR, 1991, J DNA SEQUENCING MAP, V1, P375; KOOP BF, IN PRESS BIOTECHNIQU; LABAT I, UNPUB; LEHRACH H., 1990, GENOME ANAL, P39; LINDSAY SM, 1991, GENET ANAL-BIOMOL E, V8, P8, DOI 10.1016/1050-3862(91)90003-A; LYSOV IP, 1988, DOKL AKAD NAUK SSSR+, V303, P1508; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; PAUNESKU T, UNPUB; PEVZNER PA, 1991, J BIOMOL STRUCT DYN, V9, P399, DOI 10.1080/07391102.1991.10507920; POUSTKA A, 1986, COLD SPRING HARB SYM, V51, P131, DOI 10.1101/SQB.1986.051.01.016; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; SOUTHERN EM, 1988, Patent No. 8810400; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; WILSON RK, 1992, GENOMICS, V13, P1198, DOI 10.1016/0888-7543(92)90038-T	31	165	311	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1649	1653		10.1126/science.8503011	http://dx.doi.org/10.1126/science.8503011			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503011				2022-12-01	WOS:A1993LG17600030
J	LOHOF, AM; IP, NY; POO, MM				LOHOF, AM; IP, NY; POO, MM			POTENTIATION OF DEVELOPING NEUROMUSCULAR SYNAPSES BY THE NEUROTROPHINS NT-3 AND BDNF	NATURE			English	Article							NERVE GROWTH-FACTOR; NEURONS; EXPRESSION; NGF; RECEPTOR; CULTURE; INDUCTION; PATTERNS; INVITRO	THE neurotrophins are a family of neurotrophic factors that promote survival and differentiation of various neuronal populations1,2. Although the long-term effects of neurotrophins on neuronal survival and differentiation have been intensively studied, nothing is known about their effects on synaptic function. Here we report that acute exposure to neurotrophin-3 (NT-3)3,4 or brain-derived neurotrophic factor (BDNF)5, but not nerve growth factor (NGF)6, rapidly potentiates the spontaneous and impulse-evoked synaptic activity of developing neuromuscular synapses in culture. The effect appears to be presynaptic in origin and to be mediated by the Trk family of receptor tyrosine kinases7. These results provide evidence for the regulation of the function of developing synapses by neurotrophins.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Columbia University; Regeneron				Lohof, Ann/0000-0002-0994-7706; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BERG MM, 1992, J BIOL CHEM, V267, P13; BIXBY JL, 1984, J PHYSIOL-LONDON, V353, P143, DOI 10.1113/jphysiol.1984.sp015328; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOHN A, 1990, NATURE, V344, P39; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Lo D C, 1992, Curr Opin Neurobiol, V2, P336, DOI 10.1016/0959-4388(92)90125-5; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Tabti N., 1991, CULTURING NERVE CELL, P137; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	35	686	700	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					350	353		10.1038/363350a0	http://dx.doi.org/10.1038/363350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497318				2022-12-01	WOS:A1993LD91700053
J	RENNICK, G; SHANN, F; DECAMPO, J				RENNICK, G; SHANN, F; DECAMPO, J			CEREBRAL HERNIATION DURING BACTERIAL-MENINGITIS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							LUMBAR PUNCTURE; CHILDHOOD	Objective-To see whether the incidence of cerebral herniation is increased immediately after lumbar puncture in children with bacterial meningitis and whether any children with herniation have normal results on cranial computed tomography. Design-Retrospective review of case notes; computed tomograms were read again. Setting-Large paediatric teaching hospital. Subjects-445 children over 30 days old admitted to hospital with bacterial meningitis. Main outcome measures-Timing of herniation in relation to lumbar puncture; findings on computed tomography in children with herniation. Results-Cerebral herniation was detected in 19 (4.3%) of the 445 children (21 episodes; herniation occurred twice in two children). Herniation occurred in 14 (45%) of the 31 children who died. Nineteen episodes of herniation occurred in the 17 children who had a lumbar puncture; 12 of the episodes occurred in the first 12 hours after the lumbar puncture and seven over six other 12 hour periods (odds ratio 32.6 (95% confidence interval 8.5 to 11 7.3); p < 0.001). The results of cranial computed tomography were normal in five (36%) of the 14 episodes of herniation in which scanning was performed at about the time of herniation. Conclusions-The temporal relation between lumbar puncture and herniation strongly suggests that a lumbar puncture may cause herniation in some patients, and normal results on computed tomography do not mean that it is safe to do a lumbar puncture in a child with bacterial meningitis.	ROYAL CHILDRENS HOSP,INTENS CARE UNIT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT RADIOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne			Shann, Frank/C-9510-2011					ARMITAGE P, 1987, STATISTICAL METHODS, P479; BENJAMIN CM, 1988, BRIT MED J, V296, P20, DOI 10.1136/bmj.296.6614.20; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; FENICHEL GM, 1988, CLIN PEDIATRIC NEURO, P109; GLOVER D, 1987, PEDIATRIC INTENSIVE, P291; GOWER DJ, 1987, J NEUROL NEUROSUR PS, V50, P1071, DOI 10.1136/jnnp.50.8.1071; HARPER JR, 1985, BRIT MED J, V291, P651, DOI 10.1136/bmj.291.6496.651; HART IK, 1988, BRIT MED J, V296, P51, DOI 10.1136/bmj.296.6614.51; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; KLEIN JO, 1986, PEDIATRICS S, V78, P959; Plum F., 1980, DIAGNOSIS STUPOR COM; ROSENBERG DI, 1989, INTRACRANIAL PRESSUR, V7, P770	12	122	122	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					953	955		10.1136/bmj.306.6883.953	http://dx.doi.org/10.1136/bmj.306.6883.953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490469	Green Published, Bronze			2022-12-01	WOS:A1993KX43600013
J	Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M				Redd, SC; Kazembe, PN; Luby, SP; Nwanyanwu, O; Hightower, AW; Ziba, C; Wirima, JJ; Chitsulo, L; Franco, C; Olivar, M			Clinical algorithm for treatment of Plasmodium falciparum malaria in children	LANCET			English	Article							DIAGNOSIS; ANEMIA; INFECTIONS; THERAPY; AFRICA	Background Identification of children who need antimalarial treatment is difficult in settings where confirmatory laboratory testing is not available, as in much of sub-Saharan Africa. The current national policy in Malawi is to treat all children with fever, usually defined as the mother's report of fever in the child, for presumed malaria. To assess this policy and to find out whether a better clinical case definition could be devised, we studied acutely ill children presenting to two hospital outpatient departments in Malawi. Methods The parent or guardian of each enrolled child (n=1124) was asked a standard series of questions about the symptoms and duration of the child's illness. Each child was examined, axillary and rectal temperatures and blood haemoglobin concentrations were measured, and a giemsa-stained thick smear was examined for malaria parasites. Logistic regression procedures were used to identify clinical predictors of parasitaemia. Findings High temperature (37.7 degrees C or above), nailbed palter, enlarged spleen, and being seen at one of the clinics rather than the other were associated with an increased risk of malaria parasitaemia in univariate analyses. A revised malaria case definition of rectal temperature of 37.7 degrees C or higher, spienomegaly, or nailbed pallor was 85% sensitive in identifying parasitaemic children and 41% specific; the corresponding sensitivity and specificity for the nationally recommended definition that equates mother's history of fever with malaria were 93% and 21%. The revised case definition had 89% sensitivity in identifying parasitaemic children with concentration below g/L and 89% sensitivity in identifying children with parasite density greater than 10 000/mu L, characteristics that indicate a clear need for antimalarial treatment. Interpretation These results suggest that better clinical definitions are feasible, that splenomegaly and pallor are helpful in identifying children with malaria, and that much overtreatment of children without parasitaemia could be avoided.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA 30341; KAMUZU CENT HOSP,DEPT PAEDIAT,LILONGWE,MALAWI; MALAWI MINIST HLTH,COMMUNITY HLTH SCI UNIT,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,CHICHIRI,MALAWI	Centers for Disease Control & Prevention - USA; University of Malawi								BASSETT MT, 1991, J TROP MED HYG, V94, P65; BJORCK M, 1992, HEALTH POLICY PLANN, V7, P290, DOI 10.1093/heapol/7.3.290; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BJORKMAN A, 1991, B WORLD HEALTH ORGAN, V69, P297; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; DELFINI LF, 1973, J TROP MED HYG, V76, P111; Field J. W., 1937, Transactions of the Royal Society of Tropical Medicine and Hygiene London, V30, P569, DOI 10.1016/S0035-9203(37)90070-1; GJORUP T, 1986, AM J EPIDEMIOL, V124, P657, DOI 10.1093/oxfordjournals.aje.a114438; GREENWOOD BM, 1987, PARASITOL TODAY, V3, P206, DOI 10.1016/0169-4758(87)90061-5; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; NARDONE DA, 1990, ARCH INTERN MED, V150, P201, DOI 10.1001/archinte.150.1.201; OLIVAR M, 1991, T ROY SOC TROP MED H, V85, P729, DOI 10.1016/0035-9203(91)90432-X; PETERSEN E, 1991, J INFECT DIS, V164, P949, DOI 10.1093/infdis/164.5.949; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; SANCHEZCARRILLO CI, 1989, J CLIN EPIDEMIOL, V42, P751, DOI 10.1016/0895-4356(89)90071-1; SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; STROBACH RS, 1988, ARCH INTERN MED, V148, P831, DOI 10.1001/archinte.148.4.831; SUTRISNA B, 1991, LANCET, V338, P471, DOI 10.1016/0140-6736(91)90544-Y; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TRAORE M, 1991, EVALUATION IMPACT FO, P1; WURAPA FK, 1986, J TROP MED HYG, V89, P33; 1992, AFRO22 TECHN PAP, P1	26	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					223	227		10.1016/S0140-6736(96)90404-3	http://dx.doi.org/10.1016/S0140-6736(96)90404-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551881	Green Submitted			2022-12-01	WOS:A1996TT06900010
J	Bateman, AC				Bateman, AC			Pathogenesis of sudden ischaemic cardiac death	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; THROMBOSIS				Bateman, AC (corresponding author), QUEEN ALEXANDRA HOSP, DEPT HISTOPATHOL, PORTSMOUTH, HANTS, ENGLAND.							ALFONSO F, 1995, J AM COLL CARDIOL, V26, P135, DOI 10.1016/0735-1097(95)00186-4; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DIMAIO VJM, 1993, AM J FOREN MED PATH, V14, P273, DOI 10.1097/00000433-199312000-00001; DISCIASCIO G, 1994, AM HEART J, V128, P419, DOI 10.1016/0002-8703(94)90612-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; HENNEKENS CH, 1995, J AM COLL CARDIOL, V25, pS18; LEACH IH, 1995, EUR HEART J, V16, P1181, DOI 10.1093/oxfordjournals.eurheartj.a061073; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6	11	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	1996	347	8994					70	71		10.1016/S0140-6736(96)90204-4	http://dx.doi.org/10.1016/S0140-6736(96)90204-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538340				2022-12-01	WOS:A1996TP28100003
J	Levy, A				Levy, A			Why flush?	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							GELLER J, 1991, J AM GERIATR SOC, V39, P1208, DOI 10.1111/j.1532-5415.1991.tb03576.x; GINSBURG J, 1983, BRIT MED J, V387, P262; HARDIMAN PJ, 1995, J N AM MENOPAUSE SOC, V2, P159; Huggins C, 1941, CANCER RES, V1, P293; KARLING P, 1994, J UROLOGY, V152, P1170, DOI 10.1016/S0022-5347(17)32530-2; LABRIE F, 1995, J CLIN ENDOCR METAB, V80, P2002, DOI 10.1210/jc.80.7.2002; LOPRINZI CL, 1994, J UROLOGY, V151, P634, DOI 10.1016/S0022-5347(17)35034-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; SMITH JA, 1994, J UROLOGY, V152, P132, DOI 10.1016/S0022-5347(17)32835-5	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					73	74		10.1016/S0140-6736(96)90206-8	http://dx.doi.org/10.1016/S0140-6736(96)90206-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538342				2022-12-01	WOS:A1996TP28100005
J	Boleti, H; Karsenti, E; Vernos, I				Boleti, H; Karsenti, E; Vernos, I			Xklp2, a novel Xenopus centrosomal kinesin-like protein required for centrosome separation during mitosis	CELL			English	Article							SPINDLE FORMATION; EXTRACTS; SEQUENCES; CELLS	We describe a novel Xenopus plus end-directed kinesin-like protein (KLP), Xklp2, localized on centrosomes throughout the cell cycle and on spindle pole microtubules during metaphase. Using mitotic spindles assembled in Xenopus egg extracts and different recombinant GST-Xklp2 mutants, we show that this motor is targeted to spindle poles through its C-terminal domain. Xklp2-truncated polypeptides lacking the motor domain block centrosome separation and disrupt preassembled metaphase spindles. Antibodies directed against the tail of Xklp2 have a similar effect. These results show that Xklp2 protein is required for centrosome separation and maintenance of spindle bipolarity. This study is an example of the application of the dominant negative mutant effect on spindle assembly in Xenopus egg extracts, demonstrating the usefulness of this approach in probing the function of proteins in this system.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	Boleti, H (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Vernos, Isabelle/C-1687-2015	Vernos, Isabelle/0000-0003-1469-9214				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1994, PROTEIN PROFILE, V1; CHANDRA R, 1993, METHODS CELL BIOL; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GARD DL, 1994, DEV BIOL, V161, P131, DOI 10.1006/dbio.1994.1015; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERINGA J, 1993, PROTEINS, V17, P391, DOI 10.1002/prot.340170407; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1991, J CELL SCI S, V14, P125; Karsenti E, 1991, Semin Cell Biol, V2, P251; KISHINIO A, 1988, NATURE, V293, P566; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCINTOSJH RJ, 1994, MICROTUBULES; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN ES, 1995, P NATL ACAD SCI USA, V92, P4289; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; SELLERS JR, 1993, METHODS CELL BIOL; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SINARD JH, 1990, J CELL BIOL, V111, P2417, DOI 10.1083/jcb.111.6.2417; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1026, P146; SULLIVAN W, 1990, DEVELOPMENT, V110, P311; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361	47	131	134	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					49	59		10.1016/S0092-8674(00)80992-7	http://dx.doi.org/10.1016/S0092-8674(00)80992-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548825	Bronze			2022-12-01	WOS:A1996TQ17000008
J	Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM				Kuwayama, H; Ecke, M; Gerisch, G; VanHaastert, PJM			Protection against osmotic stress by cGMP-mediated myosin phosphorylation	SCIENCE			English	Article							HEAVY-CHAIN PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; SIGNAL-TRANSDUCTION; ATPASE ACTIVITY; CYCLIC-AMP; MUTANTS; LACKING; GENE; REPLACEMENT; DISRUPTION	Conventional myosin functions universally as a generator of motive force in eukaryotic cells. Analysis of mutants of the microorganism Dictyostelium discoideum revealed that myosin also provides resistance against high external osmolarities. An osmo-induced increase of intracellular guanosine 3',5'-monophosphate was shown to mediate phosphorylation of three threonine residues on the myosin tail, which caused a relocalization of myosin required to resist osmotic stress. This redistribution of myosin allowed cells to adopt a spherical shape and may provide physical strength to withstand extensive cell shrinkage in high osmolarities.	UNIV GRONINGEN, DEPT BIOCHEM, 9747 AG GRONINGEN, NETHERLANDS; MAX PLANCK INST BIOCHEM, D-82143 MARTINSRIED, GERMANY	University of Groningen; Max Planck Society								CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GERISCH G, 1993, SYM SOC EXP BIOL, V47, P297; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; JANSSENS PMW, 1987, MICROBIOL REV, V51, P396, DOI 10.1128/MMBR.51.4.396-418.1987; JUNGBLUTH A, 1994, J CELL SCI, V107, P117; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; KUWAYAMA H, UNPUB; LIU G, 1993, J CELL SCI, V106, P591; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MATO JM, 1977, P NATL ACAD SCI USA, V74, P2348, DOI 10.1073/pnas.74.6.2348; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; OYAMA M, UNPUB; PAGH K, 1986, J CELL BIOL, V103, P1527, DOI 10.1083/jcb.103.4.1527; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; SCHUSTER SC, UNPUB; SPUDICH JA, 1989, CELL REGUL, V1, P1; STREET HE, 1984, PHYSL FLOWERING PLAN; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	33	101	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					207	209		10.1126/science.271.5246.207	http://dx.doi.org/10.1126/science.271.5246.207			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539621	Green Submitted			2022-12-01	WOS:A1996TP36400043
J	Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX				Cocker, JH; Piatti, S; Santocanale, C; Nasmyth, K; Diffley, JFX			An essential role for the Cdc6 protein in forming the pre-replicative complexes of budding yeast	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; DIVISION; CYCLE	ORIGINS Of DNA replication in Saccharomyces cerevisiae are bound by two protein complexes during the cell cycle(1,2). Post-replicative complexes closely resemble those generated in vitro by purified origin recognition complex (ORC)(1,3-5), which is essential for DNA replication in vivo(6-11). Pre-replicative complexes (pre-RCs) are characterized by an extended region of nuclease protection overlapping the ORC footprint(1). We show here that the Cdc6 protein (Cdc6p), which is necessary for origin firing in vivo(12-16), is essential for the establishment and maintenance of pre-RCs, suggesting that it is a component of these complexes. Without Cdc6p, G1 origins closely resemble post-replicative origins, providing evidence that ORC is also a component of pre-RCs, These results suggest that pre-RCs play an essential role in initiating DNA replication and support a two-step mechanism for the assembly of functional initiation complexes.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Diffley, John/0000-0001-5184-7680; Nasmyth, Kim/0000-0001-7030-4403; Santocanale, Corrado/0000-0003-1337-5656; Piatti, Simonetta/0000-0003-1958-8919				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHEREST H, 1985, GENE, V34, P269; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351; [No title captured]	26	293	298	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					180	182		10.1038/379180a0	http://dx.doi.org/10.1038/379180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538771				2022-12-01	WOS:A1996TP36000063
J	Macready, WG; Siapas, AG; Kauffman, SA				Macready, WG; Siapas, AG; Kauffman, SA			Criticality and parallelism in combinatorial optimization	SCIENCE			English	Article							SYSTEMS; MODEL	Local search methods constitute one of the most successful approaches to solving large-scale combinatorial optimization problems. As these methods are increasingly parallelized, optimization performance initially im proves but then abruptly degrades to no better than that of random search beyond a certain point. The existence of this transition is demonstrated for a family of generalized spin-glass models and the traveling salesman problem. Finite-size scaling is used to characterize size-dependent effects near the transition, and analytical insight is obtained through a mean-field approximation.	MIT, DEPT ELECT ENGN & COMP SCI, CAMBRIDGE, MA 02139 USA; SANTA FE INST, SANTA FE, NM 87501 USA	Massachusetts Institute of Technology (MIT); The Santa Fe Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azencott R., 1992, SIMULATED ANNEALING; Binnet J. J, 1992, THEORY CRITICAL PHEN; Cheeseman P., 1991, P 12 INT JOINT C ART, P331, DOI DOI 10.5555/1631171.1631221; Creswick RJ, 1992, INTRO RENORMALIZATIO; CVIJOVIC D, 1995, SCIENCE, V267, P664, DOI 10.1126/science.267.5198.664; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; Glover F., 1990, ORSA Journal on Computing, V2, P4, DOI [10.1287/ijoc.1.3.190, 10.1287/ijoc.2.1.4]; HOGG T, 1991, IEEE T SYST MAN CYB, V21, P1325, DOI 10.1109/21.135679; KIRKPATRICK S, 1994, SCIENCE, V264, P1297, DOI 10.1126/science.264.5163.1297; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; LIN S, 1973, OPER RES, V21, P498, DOI 10.1287/opre.21.2.498; MACKEN CA, 1989, P NATL ACAD SCI USA, V86, P6191, DOI 10.1073/pnas.86.16.6191; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Reinelt G., 1994, TRAVELING SALESMAN C; SIAPAS AG, UNPUB; WEINBERGER ED, 1991, PHYS REV A, V44, P6399, DOI 10.1103/PhysRevA.44.6399	18	34	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	1996	271	5245					56	59		10.1126/science.271.5245.56	http://dx.doi.org/10.1126/science.271.5245.56			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539600				2022-12-01	WOS:A1996TP02200040
J	JOBANPUTRA, P; DAVIDON, F; GRAHAM, S; ONEILL, H; SIMMONDS, P; YAP, PL				JOBANPUTRA, P; DAVIDON, F; GRAHAM, S; ONEILL, H; SIMMONDS, P; YAP, PL			HIGH-FREQUENCY OF PARVOVIRUS B19 IN PATIENTS TESTED FOR RHEUMATOID-FACTOR	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL VICTORIA HOSP,REG VIRUS LAB,BELFAST BT12 6BN,ANTRIM,NORTH IRELAND; UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	JOBANPUTRA, P (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,RHEUMAT DIS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Jobanputra, Paresh/R-2311-2019	Jobanputra, Paresh/0000-0002-2712-667X; Simmonds, Peter/0000-0002-7964-4700				ADLER SP, 1993, J INFECT DIS, V168, P361, DOI 10.1093/infdis/168.2.361; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; ONEILL HJ, 1995, CLIN DIAGN VIROL, V3, P181, DOI 10.1016/0928-0197(94)00036-T; WHITE DG, 1985, LANCET, V1, P419; 1990, BRIT MED J, V300, P166	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1542	1542		10.1136/bmj.311.7019.1542	http://dx.doi.org/10.1136/bmj.311.7019.1542			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520398	Green Published, Green Submitted			2022-12-01	WOS:A1995TK21400026
J	CHELLURI, L; PINSKY, MR; DONAHOE, MP; GRENVIK, A				CHELLURI, L; PINSKY, MR; DONAHOE, MP; GRENVIK, A			LONG-TERM OUTCOME OF CRITICALLY ILL ELDERLY PATIENTS REQUIRING INTENSIVE-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; UPDATE 1983; AGE; RESOURCES; MORTALITY; SEVERITY; SURVIVAL; SYSTEM; UNIT	Objective.-To evaluate the long-term mortality and morbidity of critically ill elderly patients requiring intensive care. Design.-Prospective comparison of outcome of critically ill patients aged 75 years and older with patients aged 65 to 74 years. Patients.-Critically ill patients aged 65 years and older who required intensive care and who were recruited during a 3-month period. Main Outcome Measures.-Duration of hospitalization, hospital charges, procedures used in the intensive care unit, mortality in the hospital and during the follow-up period, and quality of life of survivors during the follow-up period. Results.-Ninety-seven patients were included in the study; 54 were 75 years or older and 43 were aged 65 to 74 years. No significant difference was noted between the two groups for length of stay in the hospital, hospital charges, or mortality at 1 year. Severity of illness, as assessed by Acute Physiology and Chronic Health Evaluation score at the time of intensive care unit admission, was a better predictor of survival than age. Quality of life, as assessed by activities of daily living, perceived quality of life, and Center for Epidemiologic Studies-Depression score, were not significantly different in either group at 1, 6, and 12 months after discharge from the hospital. Most patients in both groups described their quality of life as adequate and were willing to receive intensive care again, if necessary. Conclusion.-Age alone is not an adequate predictor of long-term survival and quality of life in critically ill elderly patients.	UNIV PITTSBURGH,MED CTR,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT SURG,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	CHELLURI, L (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT ANESTHESIOL CRIT CARE MED,SCAIFE HALL,ROOM 608,PITTSBURGH,PA 15213, USA.							BYRICK RJ, 1980, CRIT CARE MED, V8, P332, DOI 10.1097/00003246-198006000-00003; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CULLEN DJ, 1984, CRIT CARE MED, V12, P102, DOI 10.1097/00003246-198402000-00004; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1982, CRIT CARE MED, V10, P575; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; MARTIN L, 1987, NEW ENGL J MED, V316, P1425; MAYEROAKES SA, 1991, J AM GERIATR SOC, V39, P862, DOI 10.1111/j.1532-5415.1991.tb04452.x; MCCLISH DK, 1987, J AM GERIATR SOC, V35, P983, DOI 10.1111/j.1532-5415.1987.tb04000.x; MUNDT DJ, 1989, ARCH INTERN MED, V149, P68, DOI 10.1001/archinte.149.1.68; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; RILEY SA, 1991, INTENSIVE CRIT CARE, V10, P62; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; SLAYTER MA, 1986, ANAESTH INTENSIVE CA, V14, P381; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x	27	214	223	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3119	3123		10.1001/jama.269.24.3119	http://dx.doi.org/10.1001/jama.269.24.3119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LH145	8505814				2022-12-01	WOS:A1993LH14500025
J	HARDIE, RC; PERETZ, A; SUSSTOBY, E; ROMGLAS, A; BISHOP, SA; SELINGER, Z; MINKE, B				HARDIE, RC; PERETZ, A; SUSSTOBY, E; ROMGLAS, A; BISHOP, SA; SELINGER, Z; MINKE, B			PROTEIN-KINASE-C IS REQUIRED FOR LIGHT ADAPTATION IN DROSOPHILA PHOTORECEPTORS	NATURE			English	Article							LIMULUS PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; INOSITOL TRISPHOSPHATE; VENTRAL PHOTORECEPTORS; FLY PHOTORECEPTORS; MUTANT; PHOTOTRANSDUCTION; EXCITATION; POLYPHOSPHATE; DEACTIVATION	PROTEIN kinase C (PKC) is a key enzyme for many cellular processes1,2 but its physiological roles are poorly understood. An excellent opportunity to investigate the function of PKC has been provided by the identification of an eye-specific PKC in Drosophila3-5 and a null PKC mutant, inaC(P209) (refs 5,6). Bright conditioning lights delivered to inaC photoreceptors lead to an abnormal loss of sensitivity in whole cell recordings from dissociated ommatidia; this has been interpreted as 'hyperadaptation' and PKC's role has been suggested to be distinct from light adaptation5. A presumably related finding is that during intense light, the response of inaC declines to baseline6. Invertebrate photoreceptors use the phosphoinositide signalling cascade7-12, responding to single photons with so-called quantum bumps13 which sum to form the macroscopic response to light14-16. Light adaptation allows photoreceptors to adjust their sensitivity over the enormous range of ambient intensities14,17. Although the molecular mechanism of light adaptation remains obscure, it is a negative-feedback process12 mediated by a rise in cytosolic calcium12,18 and a decrease in bump size12,14-16. We now show that under physiological conditions light adaptation is severely reduced in inaC, suggesting that eye-specific PKC, itself activated by a rise in cytosolic calcium4,5 and diacylglycerol, is required for adaptation. Furthermore, we show that in the absence of PKC individual bumps fail to terminate normally, an effect that can account for the pleiotropic manifestations of the inaC phenotype.	HEBREW UNIV JERUSALEM,MINERVA CTR STUDIES VISUAL TRANSDUCT,DEPT PHYSIOL,IL-91010 JERUSALEM,ISRAEL; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND; HEBREW UNIV JERUSALEM,MINERVA CTR STUDIES VISUAL TRANSDUCT,DEPT BIOL CHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; University of Cambridge; Hebrew University of Jerusalem			Bishop, Sheila/AAE-8387-2020	Hardie, Roger/0000-0001-5531-3264				BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROWN JE, 1975, NATURE, V258, P252, DOI 10.1038/258252a0; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DODGE FA, 1968, SCIENCE, V160, P88, DOI 10.1126/science.160.3823.88; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HOWARD J, 1984, J EXP BIOL, V113, P471; KLEINSCHMIDT J, 1975, J GEN PHYSIOL, V66, P617, DOI 10.1085/jgp.66.5.617; LAUGHLIN SB, 1978, J COMP PHYSIOL, V128, P319, DOI 10.1007/BF00657606; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; MINKE B, 1991, J NEUROSCI, V11, P900; MINKE B, 1982, J GEN PHYSIOL, V79, P361, DOI 10.1085/jgp.79.3.361; MINKE B, 1992, PROGR RETINAL RES, V11, P99; MINKE B, 1986, PHOTOCHEM PHOTOBIOL, V32, P553; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NASI E, 1991, J GEN PHYSIOL, V97, P55, DOI 10.1085/jgp.97.1.55; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pak W.L., 1979, P67; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; PAYNE R, 1988, PHILOS T ROY SOC B, V320, P359, DOI 10.1098/rstb.1988.0082; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; Shapley R., 1984, PROG RETIN RES, V3, P263, DOI DOI 10.1016/0278-4327(84)90011-7; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STIEVE H, 1986, MOL MECHANISM PHOTOR, P199; WONG F, 1978, NATURE, V276, P76, DOI 10.1038/276076a0; Yeandle S., 1958, AM J OPHTHALMOL, V46, P82	34	131	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					634	637		10.1038/363634a0	http://dx.doi.org/10.1038/363634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510756				2022-12-01	WOS:A1993LH13900058
J	GREENBERG, AE; HINDIN, R; NICHOLAS, AG; BRYAN, EL; THOMAS, PA				GREENBERG, AE; HINDIN, R; NICHOLAS, AG; BRYAN, EL; THOMAS, PA			THE COMPLETENESS OF AIDS CASE REPORTING IN NEW-YORK-CITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVEILLANCE	Objective.-To assess the completeness of acquired immunodeficiency syndrome (AIDS) case reporting in New York City (NYC), and to determine whether the completeness of reporting differs in various populations. Design.-Retrospective record review of hospital laboratory logs, death certificates, hospital discharge records, and patient registries at private physicians' offices and hospital outpatient clinics. Setting.-Public and private hospitals, and private physicians' offices in NYC. Patients.-Adults and adolescents with AIDS or with illnesses suggestive of AIDS were identified using both population-based and nonrandom sampling techniques. These persons were matched with the NYC AIDS case registry, and the medical records of nonmatching persons were reviewed to determine whether they met the 1987 Centers for Disease Control and Prevention surveillance case definition for AIDS. Main Outcome Measures.-The completeness of reporting was calculated for the five individual projects and for the aggregate database by gender, race/ethnicity, risk, borough of residence, age, first AIDS diagnosis, and year of diagnosis. Results.-Of 7015 persons with AIDS identified in the five projects, 5912 (84%) had been previously reported (range, 77% to 89%). The completeness of reporting ranged from 81% to 87% in all major gender, race/ethnicity, risk, borough of residence, and age subgroups. In a multivariate analysis, the odds of being unreported were significantly higher among outpatients in hospital clinics, out-of-state residents, persons with diagnoses other than Pneumocystis carinii pneumonia, and persons recently diagnosed with AIDS. Conclusions.-This study indicates that the NYC AIDS surveillance system functioned effectively during the first decade of the AIDS epidemic. Completeness-of-reporting studies are an integral part of AIDS surveillance, providing data that are critical for assessing the validity of the AIDS surveillance database.	CTR DIS CONTROL & PREVENT,DIV HIV AIDS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	GREENBERG, AE (corresponding author), NEW YORK CITY DEPT HLTH,OFF AIDS SURVEILLANCE,BOX 44,125 WORTH ST,NEW YORK,NY 10013, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; CALZAVARA LM, 1990, CAN MED ASSOC J, V142, P36; CARR E, 1990, 6TH INT C AIDS SAN F; CHAMBERLAND ME, 1985, JAMA-J AM MED ASSOC, V254, P383, DOI 10.1001/jama.254.3.383; CONWAY GA, 1989, JAMA-J AM MED ASSOC, V262, P2859, DOI 10.1001/jama.262.20.2859; EVANS BG, 1991, AIDS, V5, P1261, DOI 10.1097/00002030-199110000-00018; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; GREENBERG AE, 1992, AIDS, V6, P849, DOI 10.1097/00002030-199208000-00014; GREENBERG AE, 1990, 6TH INT C AIDS SAN F; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HINDIN RH, 1989, 5 INT C AIDS MONTR; LIEB L, 1990, 6TH INT C AIDS SAN F; MODESITT SK, 1993, J ACQ IMMUN DEF SYND, V6, P91; RAUCH KJ, 1986, JAMA-J AM MED ASSOC, V256, P863, DOI 10.1001/jama.1986.03380070069013; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; THOMAS PA, 1993, AM J EPIDEMIOL, V137, P121, DOI 10.1093/oxfordjournals.aje.a116652; 1989, GAOPEMD8913  US GEN, P37; 1992, AIDS SURVEILLANCE UP; 1986, AM J EPIDEMIOL, V123, P1013; 1991, INT CLASSIFICATION D; 1987, AIDS SURVEILLANCE UP; 1987, MMWR MORB MORTAL WKL, V36, pS3; 1992, HIV AIDS SURVEILLANC	24	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2995	3001		10.1001/jama.269.23.2995	http://dx.doi.org/10.1001/jama.269.23.2995			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501841				2022-12-01	WOS:A1993LF94100028
J	SELIK, RM; CHU, SY; BUEHLER, JW				SELIK, RM; CHU, SY; BUEHLER, JW			HIV-INFECTION AS LEADING CAUSE OF DEATH AMONG YOUNG-ADULTS IN UNITED-STATES CITIES AND STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe the extent to which human immunodeficiency virus (HIV) infection has become the leading cause of death among young adults (25 to 44 years of age) in US states and cities of at least 100 000 population. Design.-Analysis of underlying causes of death using national vital statistics for 1990 by state and city. Deaths caused by HIV were defined as those with underlying cause assigned a code number of 042, 043, or 044, as established by the National Center for Health Statistics. Results.-Infection with HIV was the leading cause of death among young men in five states, causing 29% of their deaths in New York, 28% in New Jersey, 24% in California and Florida, and 16% in Massachusetts. Among young women, HIV was not the leading cause of death in any state. Among young men, HIV infection was the leading cause of death in 64 cities, with the proportion of deaths due to HIV ranging from 16% in Bridgeport, Conn, to 61% in San Francisco, Calif. Among young women, HIV infection was the leading cause of death in nine cities, with the proportion of deaths due to HIV ranging from 15% in Baltimore, Md, to 43% in Newark, NJ. Conclusion.-In many US communities, HIV infection is the leading cause of death among young men and women, causing a large proportion of deaths in this age group.			SELIK, RM (corresponding author), US PHS,CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,MAILSTOP E47,ATLANTA,GA 30333, USA.		Buehler, James/B-8419-2014					BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; MICHAELS D, 1992, JAMA-J AM MED ASSOC, V268, P3456, DOI 10.1001/jama.268.24.3456; 1989, MMWR MORB MORTAL WKL, V38, P165; 1992, MMWR MORB MORTAL WKL, V41, P121; 1993, EMPLOY EARN, V40, P174; 1992, CATALOG ELECTRONIC D; 1993, MONTHLY VITAL STA S7, V41, P1; 1992, MMWR MORB MORTAL WKL, V41, P4; 1992, MMWR MORB MORTAL WKL, V41, P708; 1992, HIV AIDS SURVEILLANC, P10; [No title captured]; 1992, MMWR MORB MORTAL WKL, V40, P6; 1992, MMWR MORB MORTAL WKL, V41, P463; 1987, MMWR MORB MORTAL  S7, V36, P1; 1991, MMWR MORB MORTAL WKL, V40, P41	18	97	97	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					2991	2994		10.1001/jama.269.23.2991	http://dx.doi.org/10.1001/jama.269.23.2991			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501840				2022-12-01	WOS:A1993LF94100027
J	BLABER, M; ZHANG, XJ; MATTHEWS, BW				BLABER, M; ZHANG, XJ; MATTHEWS, BW			STRUCTURAL BASIS OF AMINO-ACID ALPHA-HELIX PROPENSITY	SCIENCE			English	Article							T4 LYSOZYME; FORMING TENDENCIES; DIRECTED MUTATIONS; STABILITY; AREA; THERMOSTABILITY; PREDICTIONS; PROTEINS	The propensity of an amino acid to form an alpha helix in a protein was determined by multiple amino substitutions at positions 44 and 131 in T4 lysozyme. These positions are solvent-exposed sites within the alpha helices that comprise, respectively, residues 39 to 50 and 126 to 134. Except for two acidic substitutions that may be involved in salt bridges, the changes in stability at the two sites agree well. The stability values also agree with those observed for corresponding amino acid substitutions in some model peptides. Thus, helix propensity values derived from model peptides can be applicable to proteins. Among the 20 naturally occurring amino acids, proline, glycine, and alanine each have a structurally unique feature that helps to explain their low or high helix propensities. For the remaining 17 amino acids, it appears that the side chain hydrophobic surface buried against the side of the helix contributes substantially to a helix propensity.	UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon			Blaber, Michael/N-1083-2019; Blaber, Michael/E-7478-2011; Blaber, Michael/ABA-5031-2021	Blaber, Michael/0000-0002-6856-1643; 	NIGMS NIH HHS [GM 21967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, METHOD ENZYMOL, V154, P511; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1972, BIOCHEMISTRY-US, V11, P3028, DOI 10.1021/bi00766a015; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HERMANN RB, 1977, P NATL ACAD SCI USA, V74, P4144, DOI 10.1073/pnas.74.10.4144; HERMANS J, 1992, BIOCHEMISTRY-US, V31, P5646, DOI 10.1021/bi00139a031; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; NICHOLSON H, 1992, BIOPOLYMERS, V32, P1431, DOI 10.1002/bip.360321103; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; PTITSYN O B, 1972, Pure and Applied Chemistry, V31, P227, DOI 10.1351/pac197231010227; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; SHORTLE D, 1992, PROTEIN SCI, V1, P201; TANFORD C, 1980, HYDROPHOBIC EFFECT; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; [No title captured]	37	439	442	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1993	260	5114					1637	1640		10.1126/science.8503008	http://dx.doi.org/10.1126/science.8503008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8503008				2022-12-01	WOS:A1993LG17600026
J	BOYINGTON, JC; GAFFNEY, BJ; AMZEL, LM				BOYINGTON, JC; GAFFNEY, BJ; AMZEL, LM			THE 3-DIMENSIONAL STRUCTURE OF AN ARACHIDONIC-ACID 15-LIPOXYGENASE	SCIENCE			English	Article							SATIVUM SEED LIPOXYGENASE; SOYBEAN LIPOXYGENASE-1; HUMAN 5-LIPOXYGENASE; MOLECULAR-CLONING; MACROMOLECULAR CRYSTALLOGRAPHY; SUPEROXIDE-DISMUTASE; IRON ENVIRONMENT; SEQUENCE; CDNA; CRYSTALLIZATION	In mammals, the hydroperoxidation of arachidonic acid by lipoxygenases leads to the formation of leukotrienes and lipoxins, compounds that mediate inflammatory responses. Lipoxygenases are dioxygenases that contain a nonheme iron and are present in many animal cells. Soybean lipoxygenase-1 is a single-chain, 839-residue protein closely related to mammalian lipoxygenases. The structure of soybean lipoxygenase-1 solved to 2.6 angstrom resolution shows that the enzyme has two domains: a 146-residue beta barrel and a 693-residue helical bundle. The iron atom is in the center of the larger domain and is coordinated by three histidines and the COO- of the carboxyl terminus. The coordination geometry is nonregular and appears to be a distorted octahedron in which two adjacent positions are not occupied by ligands. Two cavities, in the shapes of a bent cylinder and a frustum, connect the unoccupied positions to the surface of the enzyme The iron, with two adjacent and unoccupied positions, is poised to interact with the 1 4-diene system of the substrate and with molecular oxygen during catalysis.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT CHEM,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Gaffney, Betty J/C-9666-2015	Amzel, L. Mario/0000-0002-0129-9572	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelrod B., 1981, METHODS ENZYMOLOGY, P441, DOI DOI 10.1016/0076-6879(81)71055-3; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BOYINGTON JC, 1990, J BIOL CHEM, V265, P12771; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; CHEESBROUGH TM, 1983, BIOCHEMISTRY-US, V22, P3837, DOI 10.1021/bi00285a019; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COREY EJ, 1987, J AM CHEM SOC, V109, P8108, DOI 10.1021/ja00260a039; COREY EJ, 1987, J AM CHEM SOC, V109, P8701; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; DEGROOT JJM, 1973, BIOCHIM BIOPHYS ACTA, V326, P279, DOI 10.1016/0005-2760(73)90254-3; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x; EALING PM, 1989, BIOCHEM J, V264, P929, DOI 10.1042/bj2640929; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FINNEN DC, 1991, INORG CHEM, V30, P3960, DOI 10.1021/ic00020a034; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GAFFNEY BJ, 1993, BIOPHYS J, V64, P773, DOI 10.1016/S0006-3495(93)81438-3; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P211; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVRATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70; NELSON MJ, 1990, BIOCHEMISTRY-US, V29, P6897, DOI 10.1021/bi00481a020; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; SHIBATA D, 1991, PLANT MOL BIOL, V16, P353, DOI 10.1007/BF00020569; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SLOANE DL, 1990, BIOCHEM BIOPH RES CO, V173, P507, DOI 10.1016/S0006-291X(05)80063-4; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STALLINGS WC, 1990, J MOL BIOL, V211, P685, DOI 10.1016/0022-2836(90)90067-V; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STECZKO J, 1990, J BIOL CHEM, V265, P11362; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; VANDERHEIJDT LM, 1992, EUR J BIOCHEM, V207, P793, DOI 10.1111/j.1432-1033.1992.tb17110.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITTAKER JW, 1988, J AM CHEM SOC, V110, P5329, DOI 10.1021/ja00224a017; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	51	457	464	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1482	1486		10.1126/science.8502991	http://dx.doi.org/10.1126/science.8502991			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502991				2022-12-01	WOS:A1993LF05800030
J	DESAI, DM; SAP, J; SCHLESSINGER, J; WEISS, A				DESAI, DM; SAP, J; SCHLESSINGER, J; WEISS, A			LIGAND-MEDIATED NEGATIVE REGULATION OF A CHIMERIC TRANSMEMBRANE RECEPTOR TYROSINE PHOSPHATASE	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; PHOSPHOLIPASE-C ACTIVATION; CD45 ISOFORM EXPRESSION; T-CELLS; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PROTEIN-KINASE; EGF-RECEPTOR	CD45, a transmembrane protein tyrosine phosphatase (PTPase), is required for TCR signaling. Multiple CD45 isoforms, differing in the extracellular domain, are expressed in a tissue- and activation-specific manner, suggesting an important function for this domain. We report that a chimeric protein in which the extracellular and transmembrane domains of CD45 are replaced with those of the EGF receptor (EGFR) is able to restore TCR signaling in a CD45-deficient cell. Thus, the cytoplasmic domain of CD45 is necessary and sufficient for TCR signal transduction. Moreover, EGFR ligands functionally inactivate the EGFR-CD45 chimera in a manner that is dependent on dimerization of the chimeric protein. Inactivation of EGFR-CD45 chimera function results in the loss of TCR signaling, indicating that CD45 function is continuously required for TCR-mediated proximal signaling events. These results suggest that ligand-mediated regulation of receptor-PTPases may have mechanistic similarities with receptor tyrosine kinases.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Howard Hughes Medical Institute; University of California System; University of California San Francisco; New York University	DESAI, DM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEANS JP, 1992, J IMMUNOL, V148, P1898; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDMAN SJ, 1992, J BIOL CHEM, V267, P6197; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HATHCOCK KS, 1992, J IMMUNOL, V148, P19; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING AC, 1982, J BIOL CHEM, V257, P3053; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1991, J BIOL CHEM, V266, P13828; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MARVEL J, 1989, EUR J IMMUNOL, V19, P2005, DOI 10.1002/eji.1830191106; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHRAVEN B, 1989, EUR J IMMUNOL, V19, P397, DOI 10.1002/eji.1830190226; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SHIVNAN E, 1992, EUR J IMMUNOL, V22, P1055, DOI 10.1002/eji.1830220427; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1988, FUNDAMENTAL IMMUNOLO, P359	80	261	268	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					541	554		10.1016/0092-8674(93)90141-C	http://dx.doi.org/10.1016/0092-8674(93)90141-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8490965				2022-12-01	WOS:A1993LA74300015
J	Carpenter, PB; Mueller, PR; Dunphy, WG				Carpenter, PB; Mueller, PR; Dunphy, WG			Role for a Xenopus Orc2-related protein in controlling DNA replication	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; CELL-CYCLE; INVITRO; SYSTEM; EGGS; PHOSPHORYLATION; INITIATION; MITOSIS	THE six-subunit origin recognition complex (ORC) is essential for the initiation of DNA replication at specific origins in the budding yeast Saccharomyces cerevisiae(1-9). An important issue is whether DNA replication in higher eukaryotes, in which the characteristics of replication origins are poorly defined(10), occurs by an ORC-dependent mechanism, We have identified a Xenopus laevis Orc2-related protein (XORC2) by its ability to rescue a mitotic-catastrophe mutant of the fission yeast Schizosaccharomyces pombe, We show that immunodepletion of XORC2 from Xenopus egg extracts(11-13) abolishes the replication of chromosomal DNA but not elongation synthesis on a single-stranded DNA template, Indirect immunofluorescence indicates that XORC2 binds to chromatin well before the commencement of DNA synthesis, and even under conditions that prevent the association of replication licensing factor(s) with the DNA. These findings suggest that Orc2 plays an important role at an early step of chromosomal replication in animal cells.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012					ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; ALLSHIRE RC, 1990, P NATL ACAD SCI USA, V87, P4043, DOI 10.1073/pnas.87.11.4043; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FANG F, 1993, J CELL SCI, V106, P983; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLS AD, 1989, J CELL SCI, V94, P471; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; ZUBER M, 1989, EXP CELL RES, V182, P384, DOI 10.1016/0014-4827(89)90243-7	30	180	181	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					357	360		10.1038/379357a0	http://dx.doi.org/10.1038/379357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552193				2022-12-01	WOS:A1996TR32300062
J	Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV				Takai, T; Ono, M; Hikida, M; Ohmori, H; Ravetch, JV			Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice	NATURE			English	Article							IMMUNOGLOBULIN; LYMPHOCYTES; RECEPTORS; CELLS	DESPITE its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immunoglobulin-G receptor, Fc gamma RII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production(1-6). We now report that Fc gamma RII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice, Mast cells from Fc gamma RII(-/-) are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts, Fc gamma RII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by Fc gamma RIII crosslinking, These results demonstrate that Fc gamma RII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response, Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.	MEM SLOAN KETTERING CANC CTR,DIV MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Takai, T (corresponding author), OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,TSUSHIMA NAKA,OKAYAMA 700,JAPAN.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				AMIGORENA S, 1992, SCIENCE, V243, P378; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON S, 1995, IMMUNITY, V3, P635; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PHILIPPS NE, 1984, J IMMUNOL, V132, P327; QUI WQ, 1990, SCIENCE, V248, P732; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WILSON HA, 1987, J IMMUNOL, V138, P1712	17	685	754	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					346	349		10.1038/379346a0	http://dx.doi.org/10.1038/379346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552190				2022-12-01	WOS:A1996TR32300059
J	Walworth, NC; Bernards, R				Walworth, NC; Bernards, R			rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; ATAXIA-TELANGIECTASIA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; GENE; REPAIR; CANCER; FAMILIES; MUTANTS; INSTABILITY	Exposure of eukaryotic cells to agents that generate DNA damage results in transient arrest of progression through the cell cycle. In fission yeast, the DNA damage checkpoint associated with cell cycle arrest before mitosis requires the protein kinase p56(chk1). DNA damage induced by ultraviolet light, gamma radiation, or a DNA-alkylating agent has now been shown to result in phosphorylation of p56(chk1). This phosphorylation decreased the mobility of p56(chk1) on SDS-polyacrylamide gel electrophoresis and was abolished by a mutation in the p56(chk1) catalytic domain, suggesting that it might represent autophosphorylation. Phosphorylation of p56(chk1) did not occur when other checkpoint genes were inactive. Thus, p56(chk1) appears to function downstream of several of the known Schizosaccharomyces pombe checkpoint gene products, including that encoded by rad3(+), a gene with sequence similarity to the ATM gene mutated in patients with ataxia telangiectasia. The phosphorylation of p56(chk1) provides an assayable biochemical response to activation of the DNA damage checkpoint in the G(2) phase of the cell cycle.	NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Bernards, Rene/0000-0001-8677-3423; Walworth, Nancy/0000-0001-5940-8236				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BASI G, 1993, GENE, V114, P59; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; Carr Andrew, COMMUNICATION; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KUNKEL TA, 1987, METHOD ENZYMOL, V155, P166; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCCREADY S, 1993, MOL MICROBIOL, V10, P885, DOI 10.1111/j.1365-2958.1993.tb00959.x; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1981, NATURE, V292, P448; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WALWORTH NC, UNPUB; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P662; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	39	351	358	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					353	356		10.1126/science.271.5247.353	http://dx.doi.org/10.1126/science.271.5247.353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553071	Green Submitted			2022-12-01	WOS:A1996TQ52800042
J	Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE				Eck, MJ; Pluskey, S; Trub, T; Harrison, SC; Shoelson, SE			Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2	NATURE			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; TYROSINE PHOSPHORYLATION; PROTEIN MODELS; ASSOCIATION; ACTIVATION; SUBUNIT; SYP	THE domain organization of many signalling proteins facilitates a segregation of binding, catalytic and regulatory functions(1,2). The mammalian SH2 domain protein tyrosine phosphatases (PTPs) contain tandem SH2 domains and a single carboxy-terminal catalytic domain(3). SH-PTP1 (PTP1C, HCP) and SH-PTP2 (Syp, PTP2C, PTP1D) function downstream from tyrosine kinase-linked insulin, growth factor, cytokine and antigen receptors(4-12). As well as directing subcellular localization by binding to receptors and their substrates, the two SH2 domains of these PTPs function together to regulate catalysis(7,13,14). Here we report the structure of the tandem SH2 domains of SH-PTP2 in complex with monophosphopeptides. A fixed relative orientation of the two domains, stabilized by a disulphide bond and a small hydrophobic patch within the interface, separates the peptide binding sites by similar to 40 Angstrom. The defined orientation of the SH2 domains in the structure, and data showing that peptide orientation and spacing between binding sites is critical for enzymatic activation, suggest that spatial constraints are important in this multidomain protein-protein interaction.	HARVARD UNIV,CHILDRENS HOSP,MOLEC MED LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BRUNGER AT, 1992, XPLOR VERSION 2 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	30	164	168	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					277	280		10.1038/379277a0	http://dx.doi.org/10.1038/379277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538796				2022-12-01	WOS:A1996TQ16900052
J	FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA				FitzGerald, MG; MacDonald, DJ; Krainer, M; Hoover, I; ONeil, E; Unsal, H; SilvaArrieto, S; Finkelstein, DM; BeerRomero, P; Englert, C; Sgroi, DC; Smith, BL; Younger, JW; Garber, JE; Duda, RB; Mayzel, KA; Isselbacher, KJ; Friend, SH; Haber, DA			Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL PROGRESS; FAMILIAL BREAST; LINKAGE; HISTORY; RISK	Background. Mutations in a germ-line allele of the BRCA1 gene contribute to the familial breast cancer syndrome. However, the prevalence of these mutations is unknown in women with breast cancer who do not have the features of this familial syndrome. We sought BRCA1 mutations in women who were given a diagnosis of breast cancer at an early age, because early onset is characteristic of a genetic predisposition to cancer. Methods. Clinical information and peripheral-blood mononuclear cells were obtained from 418 women from the Boston metropolitan area in whom breast cancer was diagnosed at or before the age of 40. A comprehensive BRCA1 mutational analysis, involving automated nucleotide sequencing and a protein-truncation assay, was undertaken in 30 of these women, who had breast cancer before the age of 30. In addition, the BRCA1 mutation 185delAG, which is prevalent in the Ashkenazi Jewish population, was sought with an allele-specific polymerase-chain-reaction assay in 39 Jewish women among the 418 women who had breast cancer at or before the age of 40. Results. Among 30 women with breast cancer before the age of 30, 4 (13 percent) had definite, chain-terminating mutations and 1 had a missense mutation. Two of the four Jewish women in this cohort had the 185delAG mutation, Among the 39 Jewish women with breast cancer at or before the age of 40, 8 (21 percent) carried the 185delAG mutation (95 percent confidence interval, 9 to 36 percent). Conclusions. Germ-line BRCA1 mutations can be present in young women with breast cancer who do not belong to families with multiple affected members. The specific BRCA1 mutation known as 185delAG is strongly associated with the onset of breast cancer in Jewish women before the age of 40.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED & SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; FAULKNER HOSP,BOSTON,MA 02130; CTR CANC RISK ANAL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center			Sgroi, Dennis/AAV-2487-2021	Englert, Christoph/0000-0002-5931-3189; Krainer, Michael/0000-0002-7011-4957				CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P1548; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1995, NAT GENET, V11, P113, DOI 10.1038/ng1095-113; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RIES LAG, 1994, NIH942789 PUBL; ROWELL S, 1994, AM J HUM GENET, V55, P861; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119	27	331	339	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					143	149		10.1056/NEJM199601183340302	http://dx.doi.org/10.1056/NEJM199601183340302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531968				2022-12-01	WOS:A1996TQ01700002
J	Leahy, DJ; Aukhil, I; Erickson, HP				Leahy, DJ; Aukhil, I; Erickson, HP			2.0 angstrom crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region	CELL			English	Article							3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; PLASMA FIBRONECTIN; ANOMALOUS DIFFRACTION; CELL-ADHESION; HUMAN CD4; PROTEIN; BINDING; MOLECULE; TENASCIN	We have determined the 2.0 Angstrom crystal structure of a fragment of human fibronectin encompassing the seventh through the RGD-containing tenth type III repeats (FN7-10). The structure reveals an extended rod-like molecule with a long axis of similar to 140 Angstrom and highly variable relationships between adjacent domains, An unusually small rotation between domains 9 and 10 creates a distinctive binding site, in which the RGD loop from domain 10 and the ''synergy'' region from domain 9 are on the same face of FN7-10 and thus easily accessible to a single integrin molecule. The cell-binding RGD loop is well-ordered in this structure and extends similar to 10 Angstrom away from the FN7-10 core.	UNIV N CAROLINA, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University	Leahy, DJ (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21218 USA.				NCI NIH HHS [CA47056] Funding Source: Medline; NHLBI NIH HHS [HL51202] Funding Source: Medline; NIDCR NIH HHS [DE7801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DOOLITTLE RF, 1986, URFS ORFS; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; ERICKSON HP, 1981, J CELL BIOL, V91, P673, DOI 10.1083/jcb.91.3.673; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Hynes R. O., 1990, FIBRONECTINS; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI P, 1993, J CELL SCI, V106, P389; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOSSIAKOFF AA, 1992, PROTEINS, V14, P65, DOI 10.1002/prot.340140108; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI CS, 1993, J MOL BIOL, V230, P625, DOI 10.1006/jmbi.1993.1174; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LITVINOVICH SV, 1995, J MOL BIOL, V248, P611, DOI 10.1006/jmbi.1995.0246; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCCO M, 1983, J BIOL CHEM, V258, P4545; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMADA T, 1995, J BIOL CHEM, V270, P5687, DOI 10.1074/jbc.270.11.5687	58	580	605	2	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					155	164		10.1016/S0092-8674(00)81002-8	http://dx.doi.org/10.1016/S0092-8674(00)81002-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548820	hybrid			2022-12-01	WOS:A1996TQ17000018
J	Sullivan, DJ; Gluzman, IY; Goldberg, DE				Sullivan, DJ; Gluzman, IY; Goldberg, DE			Plasmodium hemozoin formation mediated by histidine-rich proteins	SCIENCE			English	Article							FALCIPARUM INFECTED ERYTHROCYTES; MALARIA PARASITES; FERRIPROTOPORPHYRIN-IX; HEME POLYMERASE; GLYCOPROTEIN; CHLOROQUINE; IDENTIFICATION; SEQUENCE; PIGMENT; CDNA	The digestive vacuole of Plasmodium falciparum is the site of hemoglobin degradation, heme polymerization into crystalline hemozoin, and antimalarial drug accumulation. Antibodies identified histidine-rich protein II (HRP II) in purified digestive vacuoles. Recombinant or native HRP II promoted the formation of hemozoin, and chloroquine inhibited the reaction. The related HRP III also polymerized heme, and an additional HRP was identified in vacuoles. It is proposed that after secretion by the parasite into the host erythrocyte cytosol, HRPs are brought into the acidic digestive vacuole along with hemoglobin. After hemoglobin proteolysis, HRPs bind the liberated heme and mediate hemozoin formation.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31615] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BURCH MK, 1985, BIOCHEMISTRY-US, V24, P5919, DOI 10.1021/bi00342a034; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; Goldberg Daniel E., 1993, Seminars in Cell Biology, V4, P355, DOI 10.1006/scel.1993.1042; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KATAGIRI M, 1987, BIOCHEM BIOPH RES CO, V149, P1070, DOI 10.1016/0006-291X(87)90517-1; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA R, 1987, BIOCHEM BIOPH RES CO, V146, P368, DOI 10.1016/0006-291X(87)90734-0; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; Sambrook J., 1989, MOL CLONING LAB MANU; Scheibel L. W., 1988, Malaria: principles and practice of malariology. Volume 1., P219; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SHIFF CJ, 1993, T ROY SOC TROP MED H, V87, P646, DOI 10.1016/0035-9203(93)90273-S; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; STAHL HD, 1985, NUCLEIC ACIDS RES, V13, P7837, DOI 10.1093/nar/13.21.7837; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan D.J., UNPUB; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382	43	346	354	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					219	222		10.1126/science.271.5246.219	http://dx.doi.org/10.1126/science.271.5246.219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539625				2022-12-01	WOS:A1996TP36400047
J	BORJIGIN, J; WANG, MM; SNYDER, SH				BORJIGIN, J; WANG, MM; SNYDER, SH			DIURNAL-VARIATION IN MESSENGER-RNA ENCODING SEROTONIN N-ACETYLTRANSFERASE IN PINEAL-GLAND	NATURE			English	Article							MELATONIN; EXPRESSION; REPRESSOR; HAMSTER; CREM	FORMATION Of the pineal gland hormone melatonin increases markedly at night in response to light-dark environmental alterations(1-5). Melatonin is synthesized from serotonin by an initial N-acetylation followed by methylation of the 5-hydroxy moiety by hydroxyindole-O-methyltransferase(6,7). Serotonin N-acetyltransferase (NAT; EC2. 3.1.87), which catalyses the first reaction, is the rate-limiting enzyme in this process, and its activity increases dramatically with the onset of darkness. Because melatonin may play important biological roles in reproduction(1,2,8), ageing(1,2,9) and sleep(1,2,9), understanding the molecular factors that regulate NAT is of particular importance. To identify proteins that regulate light-dark variations in pineal function, we used a subtractive hybridization technique based on the polymerase chain reaction (PCR) to isolate rat pineal gland messages that are differentially expressed by day and night. Here we report the molecular cloning of NAT and dramatic diurnal variations in its transcription. Independently, Klein and associates have cloned NAT from sheep pineal glands(10).	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Borjigin, Jimo/GXA-3484-2022					AXELROD J, 1960, SCIENCE, V131, P1312, DOI 10.1126/science.131.3409.1312; Binkley S, 1988, PINEAL ENDOCRINE NON; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; COON SL, IN PRESS SCIENCE; CRAFT CM, 1984, NEUROENDOCRINOLOGY, V38, P193, DOI 10.1159/000123890; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; Hardie D. G., 1993, PROTEIN PHOSPHORYLAT; HOFFMAN R, 1966, SCIENCE, V148, P1609; KLEIN DC, 1970, SCIENCE, V168, P979, DOI 10.1126/science.168.3934.979; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; REITER RJ, 1991, TRENDS ENDOCRIN MET, V1, P13; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEINLECHNER S, 1984, P SOC EXP BIOL MED, V175, P93; TAKAHASHI JS, 1994, CURR BIOL, V4, P165, DOI 10.1016/S0960-9822(94)00040-0; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; UNDERWOOD H, 1984, GEN COMP ENDOCR, V56, P70, DOI 10.1016/0016-6480(84)90063-7; VOISIN P, 1984, J BIOL CHEM, V259, P913; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WEISSBACH H, 1960, BIOCHIM BIOPHYS ACTA, V43, P352, DOI 10.1016/0006-3002(60)90453-4; WOLFE MS, 1995, BRAIN RES, V669, P100, DOI 10.1016/0006-8993(94)01267-L; 1993, MELATONIN PINEAL GLA	24	232	239	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					783	785		10.1038/378783a0	http://dx.doi.org/10.1038/378783a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524412				2022-12-01	WOS:A1995TL41900027
J	DUCKETT, DR; MURCHIE, AIH; LILLEY, DMJ				DUCKETT, DR; MURCHIE, AIH; LILLEY, DMJ			THE GLOBAL FOLDING OF 4-WAY HELICAL JUNCTIONS IN RNA, INCLUDING THAT IN U1 SNRNA	CELL			English	Article							4-WAY DNA JUNCTION; PHENYLALANINE TRANSFER-RNA; CONFORMATION; RESOLUTION; MODEL	Helical junctions are important elements in the architecture of folded RNA molecules. The global geometry of fully base-paired four-way junctions between RNA helices has been analyzed by comparative gel electrophoresis. Junctions appear to fold by pairwise coaxial helical stacking in one of two possible stereochemically equivalent isomers based upon alternative selections of stacking partners. In the presence of 1 mM Mg2+, the two continuous helical axes are approximately at right angles to each other for all junctions studied, but the RNA junctions exhibit significant sequence-dependent differences in their structures as a function of ionic conditions. The four-way junction found in the U1 snRNA folded by coaxial helical stacking. It retained the 90 degrees crossed stacked structure under all ionic conditions tested, despite the presence of a G . A mismatch at the point of strand exchange.	UNIV DUNDEE, DEPT BIOCHEM, NUCLE ACI STRUCT RES GRP, CANC RES CAMPAIGN, DUNDEE DD1 4HN, SCOTLAND	University of Dundee								AMIRI KMA, 1994, BIOCHEMISTRY-US, V33, P13172, DOI 10.1021/bi00249a003; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BEEKWILDER MJ, 1995, J MOL BIOL, V247, P903, DOI 10.1006/jmbi.1995.0189; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CLEGG RM, 1994, BIOPHYS J, V66, P99, DOI 10.1016/S0006-3495(94)80765-9; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; DUCKETT DR, 1991, J MOL BIOL, V221, P147, DOI 10.1016/0022-2836(91)80211-C; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUCKETT DR, 1990, EMBO J, V9, P1659, DOI 10.1002/j.1460-2075.1990.tb08286.x; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GESTELAND RF, 1993, RNA WORLD; GOUGH GW, 1985, NATURE, V313, P154, DOI 10.1038/313154a0; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; KISS T, 1988, NUCLEIC ACIDS RES, V16, P2734, DOI 10.1093/nar/16.6.2734; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LEONTIS NB, 1993, J BIOMOL STRUCT DYN, V11, P215, DOI 10.1080/07391102.1993.10508722; LILLEY DMJ, 1993, Q REV BIOPHYS, V26, P131, DOI 10.1017/S0033583500004054; LILLEY DMJ, 1994, EUR J BIOCHEM, V230, P1; LIPANOV A, 1993, BIOCHEMISTRY-US, V32, P1373, DOI 10.1021/bi00056a024; Maxam A M, 1980, Methods Enzymol, V65, P499; MOLLEGAARD NE, 1994, EMBO J, V13, P1508; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; POHLER JRG, 1994, J MOL BIOL, V238, P62, DOI 10.1006/jmbi.1994.1268; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; ROSEN MA, 1993, BIOCHEMISTRY-US, V32, P6576, DOI 10.1021/bi00077a011; SEEMAN NC, 1994, ANNU REV BIOPH BIOM, V23, P53, DOI 10.1146/annurev.bb.23.060194.000413; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WELCH JB, 1993, NUCLEIC ACIDS RES, V21, P4548, DOI 10.1093/nar/21.19.4548; WELCH JB, 1995, J MOL BIOL, V251, P507, DOI 10.1006/jmbi.1995.0452	41	71	71	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					1027	1036		10.1016/0092-8674(95)90218-X	http://dx.doi.org/10.1016/0092-8674(95)90218-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521503	Bronze			2022-12-01	WOS:A1995TK74500021
J	BROWN, P				BROWN, P			EEG FINDINGS IN CREUTZFELDT-JAKOB-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BROWN, P (corresponding author), NINCDS,BETHESDA,MD 20892, USA.								0	14	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3168	3168		10.1001/jama.269.24.3168	http://dx.doi.org/10.1001/jama.269.24.3168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505822				2022-12-01	WOS:A1993LH14500038
J	CROWLEY, KS; REINHART, GD; JOHNSON, AE				CROWLEY, KS; REINHART, GD; JOHNSON, AE			THE SIGNAL SEQUENCE MOVES THROUGH A RIBOSOMAL TUNNEL INTO A NONCYTOPLASMIC AQUEOUS ENVIRONMENT AT THE ER MEMBRANE EARLY IN TRANSLOCATION	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SECRETORY PROTEIN TRANSLOCATION; RECOGNITION PARTICLE RECEPTOR; LIVER CELL FRACTIONS; ELONGATION-FACTOR-TU; TRANSFER-RNA; FLUORESCENCE LIFETIME; NASCENT POLYPEPTIDE; MICROSOMAL MEMBRANE; ESCHERICHIA-COLI	The signal sequence is in an aqueous milieu at an early stage in the translocation of a nascent secretory protein across the endoplasmic reticulum membrane. This was determined using fluorescent probes incorporated into the signal sequence of fully assembled ribosome-nascent chain-membrane complexes: the fluorescence lifetimes revealed that the probes were in an aqueous environment rather than buried in the nonpolar core of the membrane. Since these membrane-bound probes were not susceptible to collisional quenching by iodide ions, the space containing the signal sequence is sealed off from the cytoplasm by a tight ribosome-membrane junction. The nascent chain inside the ribosome is also not exposed to the cytoplasm and apparently passes through an aqueous tunnel in the ribosome.			CROWLEY, KS (corresponding author), UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019, USA.		Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [R01 GM 33216, R01 GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, R01GM033216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JAMESON DM, 1984, APPL SPECTROSC REV, V20, P55, DOI 10.1080/05704928408081716; JOHNSON AE, 1980, NUCLEIC ACIDS RES, V8, P4185, DOI 10.1093/nar/8.18.4185; JOHNSON AE, 1978, P NATL ACAD SCI USA, V75, P3075, DOI 10.1073/pnas.75.7.3075; JOHNSON AE, 1980, J MOL BIOL, V138, P273, DOI 10.1016/0022-2836(80)90287-9; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P2368, DOI 10.1021/bi00123a023; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Reinhart G D, 1991, J Fluoresc, V1, P153, DOI 10.1007/BF00865362; ROBINSON A, 1987, BIOCHEM J, V242, P767, DOI 10.1042/bj2420767; RYABOVA LA, 1988, FEBS LETT, V226, P255, DOI 10.1016/0014-5793(88)81434-0; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHORE SK, 1991, THESIS U OKLAHOMA NO; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPENCER RD, 1970, J CHEM PHYS, V52, P1654, DOI 10.1063/1.1673201; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLF DE, 1992, BIOCHEMISTRY-US, V31, P2865, DOI 10.1021/bi00126a004; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	70	239	240	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1101	1115		10.1016/0092-8674(93)90640-C	http://dx.doi.org/10.1016/0092-8674(93)90640-C			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513496				2022-12-01	WOS:A1993LH54800007
J	MARIK, PE; SIBBALD, WJ				MARIK, PE; SIBBALD, WJ			EFFECT OF STORED-BLOOD TRANSFUSION ON OXYGEN DELIVERY IN PATIENTS WITH SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; ADULT RESPIRATORY-DISTRESS; INTRAMURAL PH; GASTRIC TONOMETRY; CONSUMPTION; ENDOTOXEMIA; VALIDATION; FAILURE; SURGERY; SYSTEM	Background.-Red blood cell transfusion is commonly used to augment systemic oxygen delivery to supranormal levels in patients with sepsis. However, clinical studies have not consistently demonstrated that this therapeutic maneuver is accompanied by an increase in oxygen utilization at either the whole-body level or within individual organs. Study Objectives.-To determine the effect of red blood cell transfusion on gastrointestinal and whole-body oxygen uptake. Design.-Prospective, controlled, interventional study. Setting.-Multidisciplinary intensive care unit of a tertiary care teaching hospital. Patients.-Twenty-three critically ill patients with sepsis undergoing mechanical ventilation. Measurements and Main Results.-Systemic oxygen uptake was measured by indirect calorimetry and calculated by the Fick method. Gastric intramucosal pH as measured by tonometry was used to assess changes in splanchnic oxygen availability. Measurements were made prior to transfusion of 3 U of packed red blood cells. These were then repeated immediately following transfusion, as well as 3 and 6 hours later. There was no increase in systemic oxygen uptake measured by indirect calorimetry in any of the patients studied for up to 6 hours posttransfusion (including those patients with an elevated arterial lactate concentration). However, the calculated systemic oxygen uptake increased in parallel with the oxygen delivery in all the patients. More importantly, we found an inverse association between the change in gastric intramucosal pH and the age of the transfused blood (r=-.71; P<.001). In those patients receiving blood that had been stored for more than 15 days, the gastric intramucosal pH consistently decreased following the red blood cell transfusion. Conclusion.-We failed to demonstrate a beneficial effect of red blood cell transfusion on measured systemic oxygen uptake in patients with sepsis. Patients receiving old transfused red blood cells developed evidence of splanchnic ischemia. We postulate that the poorly deformable transfused red blood cells cause microcirculatory occlusion in some organs, which may lead to tissue ischemia in some organs.	VICTORIA HOSP, RES INST,AC BURTON VASC BIOL LAB,ROOM 482 4 NW, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, PROGRAM CRIT CARE, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT SURG, LONDON N6A 3K7, ONTARIO, CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Marik, Paul E/U-9733-2019					ALEXANDER JW, 1990, ANN SURG, V212, P496, DOI 10.1097/00000658-199010000-00012; ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; APSTEIN CS, 1985, AM J PHYSIOL, V248, pH508, DOI 10.1152/ajpheart.1985.248.4.H508; ARGWAL JB, 1970, J APPL PHYSIOL, V29, P866; BAKER CH, 1984, CIRC SHOCK, V12, P165; BARTLETT RH, 1990, J CRIT CARE, V5, P77, DOI 10.1016/0883-9441(90)90051-A; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; DOYLE MP, 1990, J APPL PHYSIOL, V69, P1270, DOI 10.1152/jappl.1990.69.4.1270; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; GANZ W, 1971, AM J CARDIOL, V27, P392, DOI 10.1016/0002-9149(71)90436-X; GREENWALT TJ, 1984, VOX SANG, V47, P261, DOI 10.1111/j.1423-0410.1984.tb01596.x; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HERSCH M, 1990, SURGERY, V107, P397; Jodal M, 1984, PHYSL INTESTINAL CIR, P83; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAM C, 1991, MICROVASC RES, V66, P501; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; LKUNDGREN O, 1973, ACTA PHYSL SCAND, V88, P551; MAETANI S, 1986, ANN SURG, V203, P275, DOI 10.1097/00000658-198603000-00010; Mollison P. L., 1987, BLOOD TRANSFUSION CL, P95; MOORE GL, 1983, DIAGN MED, V6, P33; MORISAKI H, 1992, CRIT CARE MED S1, V20, pS101; MURRAY JF, 1963, J CLIN INVEST, V42, P1150, DOI 10.1172/JCI104800; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; PARKER MM, 1990, CHEST, V97, P126, DOI 10.1378/chest.97.1.126; PEEK CC, 1981, CRIT REV CLIN LAB SC, V13, P173; RASHKIN MC, 1985, CHEST, V87, P580, DOI 10.1378/chest.87.5.580; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; SAADIA R, 1990, BRIT J SURG, V77, P487, DOI 10.1002/bjs.1800770505; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1991, CHEST, V100, pS155, DOI 10.1378/chest.100.3.155S; SIGURDSSON GH, 1992, CRIT CARE MED, V20, P458, DOI 10.1097/00003246-199204000-00005; SILVERMAN HJ, 1992, CHEST, V102, P184, DOI 10.1378/chest.102.1.184; SIMCHON S, 1987, AM J PHYSIOL, V253, pH898, DOI 10.1152/ajpheart.1987.253.4.H898; STUART J, 1990, BLOOD REV, V4, P141, DOI 10.1016/0268-960X(90)90041-P; SUGERMAN HJ, 1970, SURG GYNECOL OBSTETR, V131, P733; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WEG JG, 1991, CRIT CARE MED, V19, P650, DOI 10.1097/00003246-199105000-00011	44	571	586	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3024	3029		10.1001/jama.269.23.3024	http://dx.doi.org/10.1001/jama.269.23.3024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF941	8501845				2022-12-01	WOS:A1993LF94100032
J	EISENHANDLER, J; DRUCKER, E				EISENHANDLER, J; DRUCKER, E			OPIATE DEPENDENCY AMONG THE SUBSCRIBERS OF A NEW-YORK AREA PRIVATE INSURANCE PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IMMUNODEFICIENCY VIRUS-INFECTION; INTRAVENOUS DRUG-USERS; CITY	Objective.-To estimate the prevalence of opiate use among the subscribers of a large private insurance plan, Empire Blue Cross and Blue Shield (EBCBS). Design.-Six and a half million hospital inpatient claims for the period January 1, 1982, through June 30, 1992, were reviewed. Thirty-one thousand eight hundred ten different individuals who had a total of 55 143 hospital admissions with a primary diagnosis of opiate dependency (International Classification of Diseases, Ninth Revision, Clinical Modification 304.0 and 304.7) were identified. In the same period, 17 493 EBCBS subscribers (15 191 male and 2302 female) were identified from hospital admissions data as having acquired immunodeficiency syndrome. These data were cross-matched with the opiate dependency data to estimate the ''capture'' of opiate users in the EBCBS subscribers with acquired immunodeficiency syndrome and to model the size of the opiate using population in EBCBS. Results.-It is estimated that between 1982 and 1992 EBCBS insured approximately 141 000 opiate users, 85 000 of whom are currently insured by EBCBS. Conclusion.-There is a large population of insured opiate users who may be excluded from the estimates of the overall number of opiate users as insured opiate users are less likely to be counted via contact with government agencies. This suggests that current estimates of the number of opiate users and their social characteristics should be reconsidered.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	EISENHANDLER, J (corresponding author), EMPIRE BLUE CROSS & BLUE SHIELD,622 3RD AVE,NEW YORK,NY 10017, USA.							[Anonymous], 1992, INT CLASSIFICATION D; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BUTYNSKI W, 1990, STATE RESOURCES SERV; COHEN P, 1991, NONDEVIANT COCAINE U; COURTWRIGHT D, 1990, ADDICTS WHO SURVIVED; DESJARLAIS D, 1988, AIDS S1, V2, P565; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DRUCKER E, 1989, AM J EPIDEMIOL, V130, P133, DOI 10.1093/oxfordjournals.aje.a115304; DRUCKER E, 1986, AM J DRUG ALCOHOL AB, V12, P165, DOI 10.3109/00952998609083750; DRUCKER E, 1990, AIDS SOCIAL SCI, P45; EISENHANDLER J, 1992, APR SOC ACT SPRING M; GERSTEIN DR, 1991, TREATING DRUG PROBLE, V1; KANDEL DB, 1992, MILBANK Q, V69, P365; MANDELL J, 1989, 1ST INT C HARM RED L; MUSTO DF, 1987, AM DISEASE ORIGINS N; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; WALDORF D, 1984, PATHWAYS ADDICTION; WINICK C, 1991, MILBANK Q, V69, P437, DOI 10.2307/3350104; Zinberg N., 1984, DRUG SET SETTING BAS; 1992, NATIONAL HOUSEHOLD S; 1990, AIDS SEXUAL BEHAVIOR; 1992, AIDS SURVEILLANCE RE	22	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2890	2891		10.1001/jama.269.22.2890	http://dx.doi.org/10.1001/jama.269.22.2890			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497094				2022-12-01	WOS:A1993LE93600027
J	DRATZ, EA; FURSTENAU, JE; LAMBERT, CG; THIREAULT, DL; RARICK, H; SCHEPERS, T; PAKHLEVANIANTS, S; HAMM, HE				DRATZ, EA; FURSTENAU, JE; LAMBERT, CG; THIREAULT, DL; RARICK, H; SCHEPERS, T; PAKHLEVANIANTS, S; HAMM, HE			NMR STRUCTURE OF A RECEPTOR-BOUND G-PROTEIN PEPTIDE	NATURE			English	Article							SIGNAL TRANSDUCTION; PERTUSSIS TOXIN; ALPHA-SUBUNIT; BINDING; DETERMINANTS; MUTATION	HETEROTRIMERIC GTP-binding proteins (G proteins) regulate cellular activity by coupling to hormone or sensory receptors. Stimulated receptors catalyse the release of GDP from G protein alpha-subunits1-4 and GTP bound to the empty alpha-subunits provides signals that control effectors such as adenylyl cyclases, phosphodiesterases, phospholipases and ion channels4. Three cytoplasmic loops of the activated receptor are thought to interact with three sites on the heterotrimeric G protein to provide high-affinity interaction and catalyse G-protein activation5-8. The carboxyl terminus of the alpha-subunit is particularly important for interaction with the receptor9-14. Here we study the structure of part of the active interface between the photon receptor rhodopsin and the G protein transducin, or G(t), using nuclear magnetic resonance. An 11-amino-acid peptide from the C terminus of the alpha-subunit of G(t) (alpha(t) (340-350)) binds to rhodopsin and mimics the G protein in stabilizing its active form, metarhodopsin II. The peptide alpha(t) (340-350) binds to both excited and unexcited rhodopsin and conformational differences between the two bound forms suggest a mechanism for activation of G proteins by agonist-stimulated receptors. Insight into receptor-catalysed GDP release will have broad application because the GTP/GDP exchange and the intrinsic GTPase activity of GTP-binding proteins constitute a widespread regulatory mechanism15.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; UNIV ILLINOIS, COLL MED, DEPT OPHTHALMOL, CHICAGO, IL 60680 USA; UNIV SASSARI, IST FISIOL GEN & CHIM BIOL, I-07100 SASSARI, ITALY	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari	DRATZ, EA (corresponding author), MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA.		Hamm, Heidi E/G-2374-2014; Lambert, Christophe/AAH-4448-2021	Lambert, Christophe/0000-0003-1994-2893				AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN MF, 1982, METHOD ENZYMOL, V81, P709; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DERETIC D, 1987, J BIOL CHEM, V262, P10839; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HARGRAVE PA, 1993, BIOESSAYS, V15, P1; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HUBBARD R, 1971, P615; HWANG YW, 1992, J BIOL CHEM, V267, P22198; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1983, J BIOL CHEM, V258, P4870; OSTHEIMER GJ, 1992, J BIOL CHEM, V267, P25120; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479	33	160	163	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					276	281		10.1038/363276a0	http://dx.doi.org/10.1038/363276a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8487866				2022-12-01	WOS:A1993LC86600057
J	OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ				OBrien, WA; Hartigan, PM; Martin, D; Esinhart, J; Hill, A; Benoit, S; Rubin, M; Lahart, C; Wray, N; Finegold, SM; George, WL; Dickinson, GM; Klimas, N; Diamond, G; ZollaPazner, SB; Jensen, PC; Hawkes, C; Oster, C; Gordin, F; Labriola, AM; Spivey, P; Matthews, T; Weinhold, K; Drusano, G; Egorin, MJ			Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; CONTROLLED TRIAL; CLINICAL-TRIALS; END-POINTS; REVERSE-TRANSCRIPTASE; P24 ANTIGEN; ZIDOVUDINE; MARKER; NEOPTERIN; RESISTANCE	Background. Clinical trials of antiretroviral drugs can take years to complete because the outcomes measured are progression to the acquired immunodeficiency syndrome (AIDS) or death. Trials could be accelerated by the use of end points such as changes in CD4+ lymphocyte counts and plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and beta(2)-microglobulin, but there is uncertainty about whether these surrogate measures are valid predictors of disease progression. Methods. We analyzed data from the Veterans Affairs Cooperative Study on AIDS, which compared immediate with deferred zidovudine therapy. Patients' plasma levels of HIV-1 RNA and beta(2)-microglobulin were measured in stored plasma. Results. Among the 129 patients in the immediate-treatment group, 34 had disease that progressed to AIDS, as compared with 57 of the 141 patients in the deferred-treatment group (P=0.03). Progression to AIDS correlated strongly with base-line CD4+ lymphocyte counts (P=0.001) and plasma levels of HIV-1 RNA (P<0.001), but not with base-line levels of beta(2)-microglobulin (P=0.14). A decrease of at least 75 percent in the plasma level of HIV-1 RNA over the first six months of zidovudine therapy accounted for 59 percent of the benefit of treatment, defined as the absence of progression to AIDS (95 percent confidence interval, 13 to 112 percent). Plasma beta(2)-microglobulin levels and CD4+ lymphocyte counts explained less of the effect of treatment. A 75 percent decrease in the plasma HIV-1 RNA level plus a 10 percent increase in the CD4+ lymphocyte count could explain 79 percent of the treatment effect (95 percent confidence interval, 27 to 145 percent). Conclusions. Treatment-induced changes in the plasma HIV-1 RNA level and the CD4+ lymphocyte count, taken together, are valid predictors of the clinical progression of HIV-related disease and can be used to assess the efficacy of zidovudine and possibly other antiretroviral drugs as well. (C) 1996, Massachusetts Medical Society.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; VET AFFAIRS COOPERAT STUDIES PROGRAM, COORDINATING CTR, W HAVEN, CT USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; GLAXO INC, RES TRIANGLE PK, NC 27709 USA; VET AFFAIRS MED CTR, NEW YORK, NY USA; NYU, SCH MED, NEW YORK, NY USA; DUKE UNIV, MED CTR, DURHAM, NC USA; VET AFFAIRS MED CTR, DURHAM, NC 27705 USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; VET ADM MED CTR, MIAMI, FL 33125 USA; VET ADM MED CTR, SAN FRANCISCO, CA 94121 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC USA; VET ADM MED CTR, WASHINGTON, DC 20422 USA; DUKE UNIV, VIROL CTR, DURHAM, NC 27706 USA; UNIV MARYLAND, PHARMACOL LAB, COLLEGE PK, MD 20742 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University System of Maryland; University of Maryland College Park	OBrien, WA (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, DEPT MED, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.		Zolla-Pazner, Susan/S-1864-2019	Zolla-Pazner, Susan/0000-0002-0750-2666				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COX DR, 1979, THEORETICAL STATISTI; CUNNINGHAM AL, 1993, J ACQ IMMUN DEF SYND, V6, pS32; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; GRAHAM NMH, 1993, J ACQ IMMUN DEF SYND, V6, P1258; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; LACEY CJN, 1987, AIDS, V1, P123; LAGAKOS SW, 1993, CLIN INFECT DIS, V16, pS22, DOI 10.1093/clinids/16.Supplement_1.S22; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; Simberkoff MS, 1996, J ACQ IMMUN DEF SYND, V11, P142, DOI 10.1097/00042560-199602010-00005; SPECTOR SA, 1989, J INFECT DIS, V159, P822, DOI 10.1093/infdis/159.5.822; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1, V36, pS1	40	638	645	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					426	431		10.1056/NEJM199602153340703	http://dx.doi.org/10.1056/NEJM199602153340703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552144	Bronze			2022-12-01	WOS:A1996TU69600003
J	Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE				Dugan, JA; Bostwick, DG; Myers, RP; Qian, JQ; Bergstralh, EJ; Oesterling, JE			The definition and preoperative prediction of clinically insignificant prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLING TIME; ADENOCARCINOMA; VOLUME; CARCINOMA; ANTIGEN; PROGRESSION; PROGNOSIS	Objectives. - To define clinically insignificant prostate cancer according to cancer volume, grade, cancer doubling time, and life expectancy; and to determine how many insignificant cancers are removed by radical prostatectomy. Design and Patients. - Clinically insignificant cancer was defined as a tumor that would give rise to no more than 20 cm(3) of cancer within the prostate by the time of expected patient death (1990 life tables) and whose Gleason score was less than 4 in 40- to 49-year-olds, 5 in 50- to 59-year-olds, 6 in 60- to 69-year-olds, and 7 in 70- to 79-year-olds. Four definitions were formulated based on assumed cancer volume doubling times of 2, 3, 4, and 6 years. Using these four definitions, we reviewed 337 totally embedded prostates removed at Mayo Clinic between 1991 and 1993 for clinical stage T1c through T3 cancer to determine how many contained clinically insignificant cancer. Main Outcome Measures. - Clinically significant vs clinically insignificant prostate cancer. Results. - For cancer volume doubling time of 2, 3, 4, and 6 years, clinically insignificant cancer was identified in one (0.3%), 13 (3.9%), 25 (7.4%), and 49 (14.5%) of 337 prostatectomy specimens, respectively. Conclusions. - Clinically insignificant prostate cancer can be defined by cancer volume, grade, cancer volume doubling time, and life expectancy of the patient. According to our definitions, most men treated with radical prostatectomy have clinically significant cancer.	MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								BLACKWELL KL, 1994, J UROLOGY, V151, P1565, DOI 10.1016/S0022-5347(17)35303-X; BOSTWICK DG, 1993, UROLOGY, V41, P403, DOI 10.1016/0090-4295(93)90497-X; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CSAPO Z, 1988, J UROLOGY, V140, P1032, DOI 10.1016/S0022-5347(17)41921-5; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; DAMICO AV, 1993, CANCER-AM CANCER SOC, V72, P2638, DOI 10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; HUMPHREY PA, 1990, HUM PATHOL, V21, P799, DOI 10.1016/0046-8177(90)90048-A; IRWIN MB, 1994, UROLOGY, V44, P862, DOI 10.1016/S0090-4295(94)80171-1; KLEE GG, 1994, J UROLOGY, V151, P94, DOI 10.1016/S0022-5347(17)34879-6; KRAMER SA, 1980, J UROLOGY, V124, P223, DOI 10.1016/S0022-5347(17)55381-1; LOWE BA, 1988, J UROLOGY, V140, P1340, DOI 10.1016/S0022-5347(17)42039-8; MCNEAL JE, 1986, LANCET, V1, P60; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1992, HUM PATHOL, V23, P258, DOI 10.1016/0046-8177(92)90106-D; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q; SCHRODER FH, 1992, PROSTATE S, V4, P129; STAMEY TA, 1988, J UROLOGY, V139, P1235; STAMEY TA, 1993, CANCER, V71, P993; TERRIS MK, 1995, UROLOGY, V45, P75, DOI 10.1016/S0090-4295(95)96858-X; VILLERS AA, 1990, J UROLOGY, V143, P1183, DOI 10.1016/S0022-5347(17)40220-5; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; 1989, VITAL STATISTICS US, P22; 1981, NCI MONOGRAPH, V57; 1990, VITAL STATISTICS US, P22	28	134	136	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					288	294		10.1001/jama.275.4.288	http://dx.doi.org/10.1001/jama.275.4.288			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544268				2022-12-01	WOS:A1996TP96500024
J	Gibson, G; Hogness, DS				Gibson, G; Hogness, DS			Effect of polymorphism in the Drosophila regulatory gene Ultrabithorax on homeotic stability	SCIENCE			English	Article							BITHORAX COMPLEX; LINKAGE DISEQUILIBRIUM; MELANOGASTER; EXPRESSION; REGION; SELECTION; PRODUCTS	Development is buffered against unpredictable environmental and genetic effects. Here, a molecular genetic analysis of one type of developmental homeostasis, the establishment of thoracic segmental identity under the control of the Ultrabithorax (Ubx) gene in Drosophila melanogaster, is presented. Flies were artificially selected for differential sensitivity to the induction of bithorax phenocopies by ether vapor, The experiments demonstrated that increased sensitivity to ether correlated with a loss of expression of UBX in the third thoracic imaginal discs and that a significant proportion of the genetic variation for transcriptional stability can be attributed to polymorphism in the Ubx gene.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	Gibson, G (corresponding author), UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109, USA.							AKAM ME, 1983, NATURE, V309, P635; AQUADRO CF, 1992, GENETICS, V132, P443; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BUSTURIA A, 1989, DEVELOPMENT, V107, P575; CAIZZI R, 1990, J MOL BIOL, V212, P17, DOI 10.1016/0022-2836(90)90301-2; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.genet.21.1.285; FALCONER DS, 1981, INTRO QUANTITATIVE G, P272; GLOOR HANS. JU, 1947, REV SUISSE ZOOL, V54, P637; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HOGNESS DS, 1985, COLD SPRING HARB SYM, V50, P181, DOI 10.1101/SQB.1985.050.01.024; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAI CG, 1994, SCIENCE, V266, P1697, DOI 10.1126/science.7992053; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACKAY TFC, 1990, NATURE, V348, P64, DOI 10.1038/348064a0; MACPHERSON JN, 1990, GENETICS, V126, P121; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; ZAPATA C, 1992, EVOLUTION, V46, P1900, DOI [10.2307/2410039, 10.1111/j.1558-5646.1992.tb01177.x]; ZHIVOTOVSKY LA, 1992, THEOR POPUL BIOL, V42, P254, DOI 10.1016/0040-5809(92)90015-L	28	133	134	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					200	203		10.1126/science.271.5246.200	http://dx.doi.org/10.1126/science.271.5246.200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539619				2022-12-01	WOS:A1996TP36400041
J	MoyaSola, S; Kohler, M				MoyaSola, S; Kohler, M			A Dryopithecus skeleton and the origins of great-ape locomotion	NATURE			English	Article							PROCONSUL-NYANZAE; SIVAPITHECUS; PROPORTIONS; EVOLUTION; PAKISTAN; HOMINIDS; MIOCENE; KENYA; SIZE	THE evolution of skeletal adaptations to orthograde postures, characteristic of extant hominoids, is of great interest as it provides the key to understanding the origins of apes and humans. We report here the recent discovery of an extraordinary partial skeleton of Dryopithiecus laietanus from Can Llobateres (Spain). It provides evidence that orthograde postures and locomotion appeared at least 9.5 million years ago(1). Our results indicate that the body structure of this Miocene ape closely resembles that of extant hominoids(2,3) and differs from the pronograde pattern of Miocene proconsulids(4,5) in a set of important morphological characters. Dryopithecus also shows more traits reflecting structural adaptations for suspension than occurs in African apes. A similar positional behaviour is inferred for Simpithecus indicus, thus strengthening previous hypotheses linking both Miocene forms with Pongo(6-9).			MoyaSola, S (corresponding author), INST PALEONTOL MIQUEL CRUSAFONT,C IND 23,E-08201 SABADELL,SPAIN.			Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				AGUSTI J, IN PRESS J HUM EVOL; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; ANDREWS P, 1976, GIBBON SIAMANG, P167; Begun David R., 1994, Yearbook of Physical Anthropology, V37, P11; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; ERIKSON GE, 1963, S ZOOL SOC LOND, V10, P136; HARRISON T, 1986, J HUM EVOL, V15, P541, DOI 10.1016/S0047-2484(86)80073-2; Hurzeler J., 1968, ANN PALEONT VERT, V54, P195; Jungers W.L., 1984, P146; Jungers W.L., 1985, P345; JUNGERS WL, 1987, J HUM EVOL, V16, P445, DOI 10.1016/0047-2484(87)90072-8; JUNGERS WL, 1984, YEARB PHYS ANTHROPOL, V27, P73; Jungers WL, 1990, BODY SIZE MAMMALIAN, P107; KELLEY J, 1986, COMP PRIMATE BIOL, P316; MCHENRY HM, 1992, AM J PHYS ANTHROPOL, V87, P407, DOI 10.1002/ajpa.1330870404; NAPIER JR, 1959, FORE LIMB SKELETON A, P1; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; PILBEAM D, 1971, NATURE, V229, P408; Preuschoft H., 1990, P109; ROSE MD, 1994, J HUM EVOL, V26, P387, DOI 10.1006/jhev.1994.1025; Ruff C., 1990, P119; RUFF CB, 1989, J HUM EVOL, V18, P515, DOI 10.1016/0047-2484(89)90016-X; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SOLA SM, 1993, NATURE, V365, P543, DOI 10.1038/365543a0; SOLA SM, 1995, J HUM EVOL, V28, P101; WARD CV, 1993, AM J PHYS ANTHROPOL, V90, P77, DOI 10.1002/ajpa.1330900106; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; [No title captured]	29	144	144	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					156	159		10.1038/379156a0	http://dx.doi.org/10.1038/379156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP360	8538764				2022-12-01	WOS:A1996TP36000055
J	HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES				HUDSON, TJ; STEIN, LD; GERETY, SS; MA, JL; CASTLE, AB; SILVA, J; SLONIM, DK; BAPTISTA, R; KRUGLYAK, L; XU, SH; HU, XT; COLBERT, AME; ROSENBERG, C; REEVEDALY, MP; ROZEN, S; HUI, L; WU, XY; VESTERGAARD, C; WILSON, KM; BAE, JS; MAITRA, S; GANIATSAS, S; EVANS, CA; DEANGELIS, MM; INGALLS, KA; NAHF, RW; HORTON, LT; ANDERSON, MO; COLLYMORE, AJ; YE, WJ; KOUYOUMJIAN, V; ZEMSTEVA, IS; TAM, J; DEVINE, R; COURTNEY, DF; RENAUD, MT; NGUYEN, H; OCONNOR, TJ; FIZAMES, C; FAURE, S; GYAPAY, G; DIB, C; MORISSETTE, J; ORLIN, JB; BIRREN, BW; GOODMAN, N; WEISSENBACH, J; HAWKINS, TL; FOOTE, S; PAGE, DC; LANDER, ES			AN STS-BASED MAP OF THE HUMAN GENOME	SCIENCE			English	Article							PHYSICAL MAP; LINKAGE MAP; HUMAN DNA; CHROMOSOMES; CLONES; POLYMORPHISMS; YEAST; STRATEGY; PANEL-2; REGION	A physical map has been constructed of the human genome containing 15,086 sequence-tagged sites (STSs), with an average spacing of 199 kilobases. The project involved assembly of a radiation hybrid map of the human genome containing 6193 loci and incorporated a genetic linkage map of the human genome containing 5264 loci. This information was combined with the results of STS-content screening of 10,850 loci against a yeast artificial chromosome library to produce an integrated map, anchored by the radiation hybrid and genetic maps. The map provides radiation hybrid coverage of 99 percent and physical coverage of 94 percent of the human genome. The map also represents an early step in an international project to generate a transcript map of the human genome, with more than 3235 expressed sequences localized. The STSs in the map provide a scaffold for initiating large-scale sequencing of the human genome.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; GENETHON SA,CNRS,URA 1922,F-91000 EVRY,FRANCE; CHU LAVAL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); Laval University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HUDSON, TJ (corresponding author), WHITEHEAD MIT CTR GENOME RES,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		DeAngelis, e/J-7863-2015; Foote, Simon J/F-2802-2013; Rozen, Steven G./J-5939-2013	Foote, Simon/0000-0002-9142-2107; Fizames, Cecile/0000-0002-0551-8250; Hudson, Thomas/0000-0002-1376-4849; Rozen, Steven G./0000-0002-4288-0056; Slonim, Donna/0000-0003-3357-437X; Gerety, Sebastian/0000-0002-6126-5040; Orlin, James/0000-0002-7488-094X	NHGRI NIH HHS [HG00098, HG00017] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS MD, 1995, NATURE, V377, pS3; ALITALO T, 1995, GENOMICS, V25, P691, DOI 10.1016/0888-7543(95)80012-B; ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; BELL CJ, 1995, HUM MOL GENET, V4, P59; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1995, NATURE, V377, pS175; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; COLLINS JE, 1995, NATURE, V377, pS367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DIB C, IN PRESS NATURE; DOGGETT NA, 1995, NATURE, V377, pS335; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GEMMILL RM, 1995, NATURE, V377, pS299; Gijlswijk R. P. M. van, 1992, Molecular and Cellular Probes, V6, P223, DOI 10.1016/0890-8508(92)90020-X; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GYAPAY G, IN PRESS HUM MOL GEN; GYAPAY G, 1994, NAT GENET, V7, P247; HALDI M, 1994, GENOMICS, V24, P478, DOI 10.1006/geno.1994.1656; HESLOPHARRISON JS, 1989, HUM GENET, V84, P27, DOI 10.1007/BF00210666; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUTER K, 1995, NATURE, V377, pS321; KRUGTYAK L, 1987, P NATL ACAD SCI USA, V84, P2363; LANDER ES, 1992, GENOMICS, V14, P604; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Ott J., 1991, ANAL HUMAN GENETIC L; QUACKENBUSH J, 1995, GENOMICS, V29, P512, DOI 10.1006/geno.1995.9974; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	45	735	771	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1945	1954		10.1126/science.270.5244.1945	http://dx.doi.org/10.1126/science.270.5244.1945			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533086				2022-12-01	WOS:A1995TL42000029
J	ALDROVANDI, GM; FEUER, G; GAO, LY; JAMIESON, B; KRISTEVA, M; CHEN, ISY; ZACK, JA				ALDROVANDI, GM; FEUER, G; GAO, LY; JAMIESON, B; KRISTEVA, M; CHEN, ISY; ZACK, JA			THE SCID-HU MOUSE AS A MODEL FOR HIV-1 INFECTION	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LYMPHOCYTES	DURING normal fetal ontogeny, one of the first organs to harbour CD4-positive cells is the thymus1. This organ could therefore be one of the earliest targets infected by human immunodeficiency virus type 1 (HIV-1) in utero. HIV-1-infected cells and pathological abnormalities of the thymus have been seen in HIV-1-infected adults and children, and in some fetuses aborted from infected women2-5. Studies of HIV-1 pathogenesis have been hampered by lack of a suitable animal model system. Here we use the SCID-hu mouse6 as a model to investigate the effect of virus infection on human tissue. The mouse is homozygous for the severe combined immunodeficiency (SCID) defect7,8. The model is constructed by implanting human fetal fiver and thymus under the mouse kidney capsule. A conjoint human organ develops, which allows normal maturation of human thymocytes. After direct inoculation of HIV-1 into these implants, we observed severe depletion of human CD4-bearing cells within a few weeks of infection. This correlated with increasing virus load in the implants. Thus the SCID-hu mouse may be a useful in vivo system for the study of HIV-1-induced pathology.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT PEDIAT, DIV INFECT DIS, TORRANCE, CA 90509 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANN AJ, 1988, ONCOGENE, V3, P123; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HAYS EF, 1992, AIDS, V6, P265, DOI 10.1097/00002030-199203000-00002; JOSHI VV, 1986, ARCH PATHOL LAB MED, V110, P837; KANESHIMA H, 1991, P NATL ACAD SCI USA, V88, P4523, DOI 10.1073/pnas.88.10.4523; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; MANO H, 1991, AIDS RES HUM RETROV, V7, P83, DOI 10.1089/aid.1991.7.83; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	19	268	276	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					732	736		10.1038/363732a0	http://dx.doi.org/10.1038/363732a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515816				2022-12-01	WOS:A1993LJ33900059
J	MISHU, B; ILYAS, AA; KOSKI, CL; VRIESENDORP, F; COOK, SD; MITHEN, FA; BLASER, MJ				MISHU, B; ILYAS, AA; KOSKI, CL; VRIESENDORP, F; COOK, SD; MITHEN, FA; BLASER, MJ			SEROLOGIC EVIDENCE OF PREVIOUS CAMPYLOBACTER-JEJUNI INFECTION IN PATIENTS WITH THE GUILLAIN-BARRE-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						CAMPYLOBACTER-JEJUNI; CAMPYLOBACTER INFECTIONS; POLYRADICULONEURITIS; NEUROLOGIC MANIFESTATIONS	ENTERITIS; CHILDREN; DIARRHEA; FETUS; COLI	Objective: To determine if patients with the Guillain-Barre syndrome are likely to have had Campylobacter jejuni infection before onset of neurologic symptoms. Design: A case-control study. Setting: Several university medical centers. Patients: Case patients met clinical criteria for the Guillain-Barre syndrome between 1983 and 1990 and had a serum sample collected and frozen within 3 weeks after onset of neurologic symptoms (n = 118). Disease controls were patients with other neurologic illnesses (n = 56); healthy controls were hospital employees or healthy family members of patients (n = 47). Measurements: Serum IgA, IgG, and IgM antibodies to C. jejuni were determined by enzyme-linked immunosorbent assays. Assays were done in a blinded manner. Results: Optical density ratios greater-than-or-equal-to 2 in two or more immunoglobulin classes were seen in 43 (36%) of patients with the Guillain-Barre syndrome and in 10 (10%) of controls (odds ratio, 5.3; 95% CI, 2.4 to 12.5; P < 0.001). Increasing the optical density ratio or the number of immunoglobulin classes necessary to yield a positive result increased the strength of the association. The number of patients with the Guillain-Barre syndrome who had positive serologic responses was greatest from September to November (P = 0.02). Male patients were three times more likely to have serologic evidence of C. jejuni infection (P = 0.009); the proportion of patients with the syndrome who had a positive serologic response increased with age. Conclusions: Patients with the Guillain-Barre syndrome are more likely than controls to have serologic evidence of C. jejuni infection in the weeks before onset of neurologic symptoms. Campylobacter jejuni may play a role in the initiation of the Guillain-Barre syndrome in many patients.	UNIV MED & DENT NEW JERSEY, DEPT NEUROSCI, NEWARK, NJ 07103 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; VET AFFAIRS MED CTR, NASHVILLE, TN USA; ST LOUIS UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Saint Louis University	MISHU, B (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DIV INFECT DIS, A3310 MED CTR N, NASHVILLE, TN 37232 USA.							[Anonymous], 1978, Ann Neurol, V3, P565; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; BLASER MJ, 1981, NEW ENGL J MED, V305, P1444, DOI 10.1056/NEJM198112103052404; BLASER MJ, 1991, LANCET, V338, P308, DOI 10.1016/0140-6736(91)90447-W; BRISCOE DM, 1987, ARCH DIS CHILD, V62, P733, DOI 10.1136/adc.62.7.733; CARPO M, 1991, CLIN NEUROPATHOL, V10, P46; CONSTANT OC, 1983, J INFECTION, V6, P89, DOI 10.1016/S0163-4453(83)95881-4; FUJIMOTO S, 1990, LANCET, V335, P1350, DOI 10.1016/0140-6736(90)91234-2; FUJIMOTO S, 1992, J INFECT DIS, V165, P183, DOI 10.1093/infdis/165.1.183; GRUENEWALD R, 1991, ARCH NEUROL-CHICAGO, V48, P1080, DOI 10.1001/archneur.1991.00530220102027; HUGHES RAC, 1990, GUILLAINBARRE SYNDRO; Ismael S, 1990, Paediatr Indones, V30, P79; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; KENNEDY RH, 1978, MAYO CLIN PROC, V53, P93; KUROKI S, 1991, PEDIATR INFECT DIS J, V10, P149, DOI 10.1097/00006454-199102000-00014; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; LATOVITZKI N, 1979, NEUROLOGY, V29, P743, DOI 10.1212/WNL.29.5.743; LENEMAN F, 1966, ARCH INTERN MED, V118, P139, DOI 10.1001/archinte.118.2.139; LIOR H, 1983, CAMPYLOBACTER, V2, P72; MCCOY EC, 1975, INFECT IMMUN, V11, P517, DOI 10.1128/IAI.11.3.517-525.1975; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MOLNAR GK, 1982, BRIT MED J, V285, P652, DOI 10.1136/bmj.285.6342.652; PANDEY JP, 1986, EXP CLIN IMMUNOGENET, V3, P49; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PEI ZH, 1991, J BIOL CHEM, V266, P16363; PITKANEN T, 1983, ARCH INTERN MED, V143, P215, DOI 10.1001/archinte.143.2.215; PRYOR WM, 1984, AUST NZ J MED, V14, P687, DOI 10.1111/j.1445-5994.1984.tb05033.x; RAUTELIN H, 1983, J CLIN MICROBIOL, V17, P700, DOI 10.1128/JCM.17.4.700-701.1983; RHODES KM, 1982, BRIT MED J, V285, P173, DOI 10.1136/bmj.285.6336.173; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; ROPPER AH, 1988, ARCH NEUROL-CHICAGO, V45, P655, DOI 10.1001/archneur.1988.00520300075022; SPEED BR, 1987, MED J AUSTRALIA, V147, P13, DOI 10.5694/j.1326-5377.1987.tb133228.x; SVEDHEM A, 1980, J INFECT DIS, V142, P353, DOI 10.1093/infdis/142.3.353; Tauxe R V, 1988, MMWR CDC Surveill Summ, V37, P1; TRABELSI M, 1989, PEDIATRIE, V44, P413; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; YUKI N, 1991, NEUROLOGY, V41, P1561, DOI 10.1212/WNL.41.10.1561	37	149	152	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					947	953		10.7326/0003-4819-118-12-199306150-00006	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489109				2022-12-01	WOS:A1993LF93700006
J	LUYT, DK; BURTON, PR; SIMPSON, H				LUYT, DK; BURTON, PR; SIMPSON, H			EPIDEMIOLOGIC-STUDY OF WHEEZE, DOCTOR DIAGNOSED ASTHMA, AND COUGH IN PRESCHOOL-CHILDREN IN LEICESTERSHIRE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; NATURAL-HISTORY; RESPIRATORY SYMPTOMS; GENERAL-PRACTICE; PREVALENCE; HOSPITALIZATION; SCHOOLCHILDREN; TRENDS	Objective-To determine the cumulative prevalences of wheeze and doctor diagnosed asthma and the point prevalences of recurrent cough and wheeze in children aged 5 years and under. Design-Questionnaire survey of population based random sample of children registered on regional authority's child health index for immunisation; questionnaire completed by parents. Setting-Leicestershire. Subjects-1650 white children born in 1985-9 who were surveyed in 1990. Main outcome measures-Cumulative prevalences of wheeze and doctor diagnosed asthma and point prevalences of recurrent cough and wheeze by age and sex. Results-There were 1422 replies (86.2%; 726 for boys, 696 for girls). Overall, 11.0% (95% confidence interval 9.4% to 12.6%) of children had formally been diagnosed as having asthma, the cumulative prevalence in boys (12.7%) being somewhat higher than in girls (9.2%) (age adjusted odds ratio 1.47, p=0.03). As expected, the cumulative prevalence of asthma increased significantly with age (7.5% (13/173) in children under 1 year, 15.9% (61/383) in children of 4 years and over; p<0.001). The cumulative prevalence of wheeze overall was 15.6% (13.7% to 17.5%), being higher in boys (17.6%) than in girls (13.5%) (odds ratio 1.38, p=0.03). The overall prevalence of recurrent cough without colds was 21.8% (19.6% to 23.9%), with a non-significant excess in boys (23.1% v 20.4%). The overall prevalence of wheezing attacks during the previous 12 months was 13.0% (11.3% to 14.8%) with a non-significant excess in boys (14.5% v 11.5%). Conclusions-These findings are baseline results and emphasise the importance of studying the age group of interest rather than relying on the recall of parents of school age children.	UNIV LEICESTER, LEICESTER ROYAL INFIRM,DEPT CHILD HLTH, CLIN SCI BLDG,POB 65, LEICESTER LE2 7LX, W YORKSHIRE, ENGLAND; UNIV LEICESTER, LEICESTER ROYAL INFIRM, DEPT EPIDEMIOL & PUBL HLTH, LEICESTER LE2 7LX, W YORKSHIRE, ENGLAND	University of Leicester; University of Leicester			Burton, Paul R/H-7527-2016					ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABRAHAMSON JII, 1988, MAKING SENSE DATA; AITKIN M, 1989, STATISTICAL MODELLIN; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; ARMITAGE P, 1987, METHODS MED RES; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DAWSON B, 1969, LANCET, V1, P827; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GIBSON HB, 1969, MED J AUSTRALIA, P210; GREGG I, 1986, CLIN ALLERGY, V16, P17, DOI 10.1111/j.1365-2222.1986.tb01949.x; GREGG I, 1983, ASTHMA, P242; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HART JT, 1986, J ROY COLL GEN PRACT, V36, P78; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JONES A, 1990, RESP MED, V84, P139, DOI 10.1016/S0954-6111(08)80017-0; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; LEVY M, 1984, BRIT MED J, V289, P1115, DOI 10.1136/bmj.289.6452.1115; MARKS BE, 1983, BRIT MED J, V287, P949, DOI 10.1136/bmj.287.6397.949; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Miller R.G., 1981, SURVIVAL ANAL; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MORRISONSMITH J, 1976, BR J DIS CHEST, V70, P73; NINAN TK, 1991, THORAX, V46, pP322; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; SIBBALD B, 1986, SEMIN RESPIR MED, V7, P307, DOI 10.1055/s-2007-1012626; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; STRACHAN DP, 1985, J ROY COLL GEN PRACT, V35, P182; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; 1982, CENSUS 1981 COUNTY R	40	117	121	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1993	306	6889					1386	1390		10.1136/bmj.306.6889.1386	http://dx.doi.org/10.1136/bmj.306.6889.1386			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518607	Bronze, Green Published			2022-12-01	WOS:A1993LD82900024
J	CARR, CM; KIM, PS				CARR, CM; KIM, PS			A SPRING-LOADED MECHANISM FOR THE CONFORMATIONAL CHANGE OF INFLUENZA HEMAGGLUTININ	CELL			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; COILED-COIL; LEUCINE ZIPPER; INTRACELLULAR-TRANSPORT; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION; HEPTAD REPEAT; PROTEINS; PH	Influenza hemagglutinin (HA) undergoes a conformational change that induces viral fusion with the cellular membrane. The structure of HA in the fusogenic state is unknown. We have identified a sequence in HA that has a high propensity for forming a coiled coil. Surprisingly, this sequence corresponds to a loop region in the X-ray structure of native HA: the loop is followed by a three-stranded, coiled-coil stem. We find that a 36 residue peptide (LOOP-36), comprising the loop region and the first part of the stem, forms a three-stranded coiled coil. This coiled coll is extended and stabilized in a longer peptide, corresponding to LOOP-36 plus the residues of a preceding, short alpha helix. These findings lead to a model for the fusogenic conformation of HA: the coiled-coil stem of the native state extends, relocating the hydrophobic fusion peptide, by 100 angstrom, toward the target membrane.			CARR, CM (corresponding author), MIT,DEPT BIOL,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142, USA.				NIAID NIH HHS [AI07348] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DOMS RW, 1985, J BIOL CHEM, V260, P2973; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS C G, 1991, Peptide Research, V4, P95; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GLICK GD, 1991, J BIOL CHEM, V266, P23660; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HODGES RS, 1981, J BIOL CHEM, V256, P1217; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PEREZ LG, 1992, J VIROL, V66, P4134, DOI 10.1128/JVI.66.7.4134-4143.1992; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2; SAUTER NK, 1992, P NATL ACAD SCI USA, V89, P324, DOI 10.1073/pnas.89.1.324; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WARD CW, 1980, AUST J BIOL SCI, V33, P441; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WEIS WI, 1990, EMBO J, V9, P17, DOI 10.1002/j.1460-2075.1990.tb08075.x; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1982, NATURE, V300, P658, DOI 10.1038/300658a0; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001	65	796	837	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					823	832		10.1016/0092-8674(93)90260-W	http://dx.doi.org/10.1016/0092-8674(93)90260-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500173				2022-12-01	WOS:A1993LD83000019
J	FUTTERER, J; KISSLASZLO, Z; HOHN, T				FUTTERER, J; KISSLASZLO, Z; HOHN, T			NONLINEAR RIBOSOME MIGRATION ON CAULIFLOWER MOSAIC VIRUS-35S RNA	CELL			English	Article							MESSENGER-RNA; TRANSLATIONAL CONTROL; CHLORAMPHENICOL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC RIBOSOMES; INITIATION; SEQUENCE; REGION; EXPRESSION; LEADER	Cauliflower mosaic virus 35S RNA contains a 600 nt leader with several small open reading frames that by themselves inhibit translation of downstream coding regions. In the context of the whole leader and in certain plant cells, however, translation of downstream coding regions is allowed. This translation is dependent on the RNA 5' terminus and other elements of the leader. However, its central portion is dispensable or can be modified by insertion of an energy-rich stem-loop structure or long coding region with many internal AUG codons. We conclude that this region can be by-passed (shunted) by the scanning complex. Shunting was also observed in trans between two separate RNA molecules.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABASTADO JP, 1991, NEW BIOL, V3, P511; ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; AGOL VI, 1991, ADV VIRUS RES, V40, P103; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BAUGHMAN G, 1988, VIROLOGY, V167, P125, DOI 10.1016/0042-6822(88)90061-X; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BONNEVILLE JM, 1988, RNA GENETICS, P23; BOROVJAGIN AV, 1991, NUCLEIC ACIDS RES, V19, P4999, DOI 10.1093/nar/19.18.4999; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CHANG LJ, 1990, P NATL ACAD SCI USA, V87, P5158, DOI 10.1073/pnas.87.13.5158; CHEVRIER D, 1988, J BIOL CHEM, V263, P902; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DARLIX JL, 1982, NUCLEIC ACIDS RES, V10, P5183, DOI 10.1093/nar/10.17.5183; DONZE O, 1992, EMBO J, V11, P3747, DOI 10.1002/j.1460-2075.1992.tb05460.x; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FUTTERER J, 1988, NUCLEIC ACIDS RES, V16, P8377, DOI 10.1093/nar/16.17.8377; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; Futterer J, 1989, Virus Genes, V3, P45, DOI 10.1007/BF00301986; FUTTERER J, 1992, NUCLEIC ACIDS RES, V20, P3851, DOI 10.1093/nar/20.15.3851; FUTTERER J, 1991, EMBO J, V10, P3887, DOI 10.1002/j.1460-2075.1991.tb04958.x; FUTTERER J, 1990, NATO ASI SERIES H, V49, P349; GALILI G, 1988, J BIOL CHEM, V263, P5764; GALILIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631; GALILIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257; GIBBS MR, 1990, BIOCHEMISTRY-US, V29, P11261, DOI 10.1021/bi00503a015; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOWDA S, 1989, P NATL ACAD SCI USA, V86, P9203, DOI 10.1073/pnas.86.23.9203; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HACKETT PB, 1991, NUCLEIC ACIDS RES, V19, P6929, DOI 10.1093/nar/19.24.6929; HAY JM, 1991, NUCLEIC ACIDS RES, V19, P2615, DOI 10.1093/nar/19.10.2615; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; HULL R, 1984, PLANT MOL BIOL, V3, P121, DOI 10.1007/BF00016059; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; JEFFERSON RA, 1987, EMBO J, V6, P3901; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE S, 1989, J VIROL, V63, P1069, DOI 10.1128/JVI.63.3.1069-1075.1989; KUHN R, 1990, J VIROL, V64, P4625; LEVINE F, 1991, GENE, V108, P167, DOI 10.1016/0378-1119(91)90431-A; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Maniatis T., 1982, MOL CLONING; MASON WS, 1987, ADV VIRUS RES, V32, P35, DOI 10.1016/S0065-3527(08)60474-1; NASSAL M, 1990, CELL, V63, P1357, DOI 10.1016/0092-8674(90)90431-D; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OU JH, 1990, J VIROL, V64, P4578, DOI 10.1128/JVI.64.9.4578-4581.1990; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PUCHTA H, 1991, NUCLEIC ACIDS RES, V19, P2693, DOI 10.1093/nar/19.10.2693; SANFACON H, 1992, VIROLOGY, V190, P30, DOI 10.1016/0042-6822(92)91189-2; SANFACON H, 1990, NATURE, V346, P81, DOI 10.1038/346081a0; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; SCHOLTHOF HB, 1992, J VIROL, V66, P3131, DOI 10.1128/JVI.66.5.3131-3139.1992; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; THOMAS AAM, 1992, NEW BIOL, V4, P404; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; ZIJLSTRA C, 1992, PLANT CELL, V4, P1471, DOI 10.1105/tpc.4.12.1471; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	71	183	185	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					789	802		10.1016/0092-8674(93)90257-Q	http://dx.doi.org/10.1016/0092-8674(93)90257-Q			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500171				2022-12-01	WOS:A1993LD83000016
J	DAVIES, HA; LENNARD, L; LILLEYMAN, JS				DAVIES, HA; LENNARD, L; LILLEYMAN, JS			VARIABLE MERCAPTOPURINE METABOLISM IN CHILDREN WITH LEUKEMIA - A PROBLEM OF NONCOMPLIANCE	BRITISH MEDICAL JOURNAL			English	Article							CANCER		UNIV SHEFFIELD,CHILDRENS HOSP,DEPT PAEDIAT,PAEDIAT HAEMATOL SECT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield			Lennard, Lynne/E-1131-2011					LENNARD L, 1992, J CHROMATOGR-BIOMED, V583, P83, DOI 10.1016/0378-4347(92)80347-S; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, J CLIN ONCOL, V7, P816; SMITH SD, 1979, CANCER, V43, P169, DOI 10.1002/1097-0142(197901)43:1<169::AID-CNCR2820430125>3.0.CO;2-F; TEBBI CK, 1986, CANCER, V58, P1179, DOI 10.1002/1097-0142(19860901)58:5<1179::AID-CNCR2820580534>3.0.CO;2-E	5	58	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1239	1240		10.1136/bmj.306.6887.1239	http://dx.doi.org/10.1136/bmj.306.6887.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499854	Green Published, Bronze			2022-12-01	WOS:A1993LB80400016
J	JACOBS, I; DAVIES, AP; BRIDGES, J; STABILE, I; FAY, T; LOWER, A; GRUDZINSKAS, JG; ORAM, D				JACOBS, I; DAVIES, AP; BRIDGES, J; STABILE, I; FAY, T; LOWER, A; GRUDZINSKAS, JG; ORAM, D			PREVALENCE SCREENING FOR OVARIAN-CANCER IN POSTMENOPAUSAL WOMEN BY CA 125 MEASUREMENT AND ULTRASONOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article							SERUM CA-125 LEVELS; CARCINOMA; MARKERS; BENIGN	Objective-To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer. Design-The serum CA 125 concentration of each subject was determined and those with a concentration greater-than-or-equal-to 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire. Setting-General practice, occupational health departments, ovarian cancer screening clinic. Subjects-22 000 women volunteers who were postmenopausal and aged over 45 years. Main outcome measures-Apparent sensitivity, specificity, positive predictive value, years of cancer detected. Results-41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 1.4 years. Conclusions-This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion of cases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.	ROYAL LONDON HOSP, ACAD UNIT OBSTET & GYNAECOL, LONDON E1 1BB, ENGLAND; ROYAL LONDON HOSP, GYNAECOL ONCOL UNIT, LONDON E1 1BB, ENGLAND	Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital			Jacobs, Ian J/F-1743-2013	Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672				ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; BAST RC, 1991, CANCER-AM CANCER SOC, V68, P1758, DOI 10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO;2-#; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BAST RC, 1983, NEW ENGL J MED, V309, P169; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; CAMPBELL S, 1982, LANCET, V1, P425; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; COLE LA, 1990, GYNECOL ONCOL, V36, P391, DOI 10.1016/0090-8258(90)90149-F; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1989, HUM REPROD, V4, P1; JACOBS IJ, 1992, OBSTET GYNECOL, V80, P396; KACINSKI BM, 1990, PROG LEUC B, V10, P393; NAROD SA, 1991, LANCET, V338, P82; SCHWARTZ PE, 1987, CANCER, V60, P353, DOI 10.1002/1097-0142(19870801)60:3<353::AID-CNCR2820600312>3.0.CO;2-V; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; WARD BG, 1987, BRIT J OBSTET GYNAEC, V94, P696, DOI 10.1111/j.1471-0528.1987.tb03178.x; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; ZURAWSKI VR, 1990, GYNECOL ONCOL, V36, P299, DOI 10.1016/0090-8258(90)90130-D; 1983, CANCER STATISTICS RE, P26	21	284	316	2	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1030	1034		10.1136/bmj.306.6884.1030	http://dx.doi.org/10.1136/bmj.306.6884.1030			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490497	Bronze, Green Published			2022-12-01	WOS:A1993KY44800018
J	Leor, J; Poole, WK; Kloner, RA				Leor, J; Poole, WK; Kloner, RA			Sudden cardiac death triggered by an earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CIRCADIAN VARIATION; ISCHEMIC DEATH; STRESS; WAR; FREQUENCY; MORTALITY	Background. The earthquake that struck the Los Angeles area at 4:31 a.m. on January 17, 1994, was one of the strongest earthquakes ever recorded in a major city in North America. Once the life-threatening situation was over, the Northridge earthquake, so called because its epicenter was near Northridge, California, just north of Los Angeles, provided investigators an unusual opportunity to examine the relation between emotional stress and sudden cardiac death. Methods. We reviewed the records of the Department of Coroner of Los Angeles County for the week before the earthquake, the day of the earthquake, the six days after the earthquake, and corresponding control periods in 1991, 1992, and 1993. Results. On the day of the earthquake, there was a sharp increase in the number of sudden deaths from cardiac causes that were related to atherosclerotic cardiovascular disease, from a daily average (+/-SD) of 4.6+/-2.1 in the preceding week to 24 on the day of the earthquake (z=4.41, P<0.001). Sixteen victims of sudden death either died or had premonitory symptoms, usually chest pain, within the first hour after the initial tremor. Only three sudden deaths occurred during or immediately after unusual physical exertion. During the six days after the earthquake, the number of sudden deaths declined to below the base-line value, to an average of 2.7+/-1.2 per day. Conclusions. The Northridge earthquake was a significant trigger of sudden death due to cardiac causes, independently of physical exertion. This finding, along with the unusually low incidence of such deaths in the week after the earthquake, suggests that emotional stress may precipitate cardiac events in people who are predisposed to such events. (C) 1996, Massachusetts Medical Society.	UNIV SO CALIF,HOSP GOOD SAMARITAN,INST HEART,LOS ANGELES,CA 90017; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709	University of Southern California; Research Triangle Institute			Kloner, Robert A/B-2971-2012; Leor, Jonathan/T-8038-2019					DANENBERG HD, 1991, ISRAEL J MED SCI, V27, P627; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757, DOI 10.5694/j.1326-5377.1991.tb94029.x; Hall JF., 1994, NORTHRIDGE EARTHQUAK; KARK JD, 1995, JAMA-J AM MED ASSOC, V273, P2108; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LEOR J, 1995, J AM COLL CARDIOL, V25, pA105; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; Muller J E, 1992, Ann Epidemiol, V2, P393; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Myerburg RJ, 1992, HEART DIS TXB CARDIO, P756; NISHIYAMA Y, 1995, CIRCULATION S1, V92, P606; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RUMBOLDT Z, 1993, LANCET, V341, P965, DOI 10.1016/0140-6736(93)91260-S; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TOFLER GH, 1995, CIRCULATION, V92, P1203, DOI 10.1161/01.CIR.92.5.1203; TRICHOPOULOS D, 1983, LANCET, V1, P441; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; 1994, SCIENCE, V266, P389	26	565	577	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					413	419		10.1056/NEJM199602153340701	http://dx.doi.org/10.1056/NEJM199602153340701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552142	Bronze			2022-12-01	WOS:A1996TU69600001
J	Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R				Caron, H; vanSluis, P; deKraker, J; Bokkerink, J; Egeler, M; Laureys, G; Slater, R; Westerveld, A; Voute, PA; Versteeg, R			Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CELLULAR DNA CONTENT; NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; MYC; HETEROZYGOSITY; ONCOGENE; TUMOR	Background. Neuroblastoma is a childhood tumor derived from cells of the neural crest, with a widely variable outcome. Differences in the behavior and prognosis of the tumor suggest that neuroblastoma can be divided into several biologic subgroups. We evaluated the most frequent genetic abnormalities in neuroblastoma to determine their prognostic value. Methods. We used Southern blot analysis to study the allelic loss of chromosomes 1p, 4p, 11q, and 14q, the duplication of chromosome 17q, and the amplification of the N-myc oncogene in 89 neuroblastomas. We also determined the nuclear DNA content of the tumor cells. Results. Allelic loss of chromosome 1p, N-myc amplification, and extra copies of chromosome 17q were significantly associated with unfavorable outcomes. In a multivariate analysis, loss of chromosome Ip was the most powerful prognostic factor. It provided strong prognostic information when it was included in multivariate models containing the prognostic factors of age and stage or serum ferritin level and stage. Among the patients with stage I, II, or IVS disease, the mean (+/-SD) three-year event-free survival was 100 percent in those without allelic loss of chromosome Ip and 34 +/- 15 percent in those with such loss; the rates of three-year event-free survival among the patients with stage III and stage IV disease were 53 +/- 10 percent and 0 percent, respectively. Conclusions. The loss of chromosome 1p is a strong prognostic factor in patients with neuroblastoma, independently of age and stage. It reliably identifies patients at high risk in stages I, II, and IVS, which are otherwise clinically favorable. More intensive therapy may be considered in these patients. Patients in stages III and IV with allelic loss of chromosome 1p have a very poor outlook, whereas those without such loss are at moderate risk. (C) 1996, Massachusetts Medical Society.	UNIV AMSTERDAM, ACAD MED CTR, INST HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV NIJMEGEN, CTR PEDIAT ONCOL SE NETHERLANDS, NIJMEGEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SOPHIA KINDERZIEKENHUIS, ROTTERDAM, NETHERLANDS; STATE UNIV GHENT HOSP, INST HUMAN GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen; Erasmus University Rotterdam; Ghent University; Ghent University Hospital	Caron, H (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, EMMA KINDERZIEKENHUIS, DEPT PEDIAT ONCOL & HEMATOL, POB 22700, 1100 DE AMSTERDAM, NETHERLANDS.		laureys, genevieve/AAG-2390-2021; Versteeg, Rogier/AAQ-1765-2020; Bokkerink, J.P.M./L-4210-2015	Versteeg, Rogier/0000-0001-7172-0388				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BERTHOLD F, 1992, AM J PEDIAT HEMATOL, V14, P207; BOURHIS J, 1991, CANCER RES, V51, P33; CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CARON H, 1993, NAT GENET, V4, P431, DOI 10.1038/ng0893-431a; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHUSTER JJ, 1992, AM J CLIN ONCOL-CANC, V15, P295, DOI 10.1097/00000421-199208000-00004; SILBER JH, 1991, CANCER RES, V51, P1426; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VOUTE PA, 1992, CANCER CHILDREN CLIN	25	327	331	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					225	230		10.1056/NEJM199601253340404	http://dx.doi.org/10.1056/NEJM199601253340404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8531999	Green Published			2022-12-01	WOS:A1996TQ75500004
J	Dewji, NN; Singer, SJ				Dewji, NN; Singer, SJ			Genetic clues to Alzheimer's disease	SCIENCE			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; TYROSINE-KINASE RECEPTOR; BETA-PEPTIDE; CELL-CELL; SEVENLESS; EXPRESSION; DROSOPHILA; ADHESION; LIGAND; BRIDE		UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Dewji, NN (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; CRAS P, 1990, AM J PATHOL, V137, P241; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187	19	45	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					159	160		10.1126/science.271.5246.159	http://dx.doi.org/10.1126/science.271.5246.159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539612				2022-12-01	WOS:A1996TP36400026
J	Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA				Lock, P; Fumagalli, S; Polakis, P; McCormick, F; Courtneidge, SA			The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein	CELL			English	Article							DOMAINS; BINDING; GAP		ONYX PHARMACEUT,RICHMOND,CA 94806; SUGEN INC,REDWOOD CITY,CA 94063		Lock, P (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY.		FUMAGALLI, Stefano/C-2914-2019	Lock, Peter/0000-0003-4421-3609; , Stefano/0000-0001-5832-8680				Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OGAWA W, 1994, J BIOL CHEM, V269, P29602; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	11	74	75	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					23	24		10.1016/S0092-8674(00)80989-7	http://dx.doi.org/10.1016/S0092-8674(00)80989-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548822	Bronze			2022-12-01	WOS:A1996TQ17000005
J	Falvo, JV; Thanos, D; Maniatis, T				Falvo, JV; Thanos, D; Maniatis, T			Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y)	CELL			English	Article							NF-KAPPA-B; CRYSTAL-STRUCTURE; TATA ELEMENT; BINDING; COMPLEX; ACTIVATION; PROMOTER; AFFINITY; ADENINE; DOMAIN	In this paper, we investigate DNA bending induced by proteins required for virus induction of the human interferon-beta (IFN beta) gene. We show that NF-kappa B-DNA complexes that are functionally distinct in the context of the IFN beta enhancer are also conformationally distinct and that two sites in the enhancer contain in-phase bends that are counteracted or reversed by the binding of NF-kappa B, ATF-2/c-Jun, and HMG I(Y). Strikingly, this modulation of intrinsic enhancer architecture results in an orientation that favors predicted protein-protein interactions in a functional nucleoprotein complex, the enhanceosome. Furthermore, the subtle modulation of DNA structure by HMG I(Y) in this process distinguishes it from other architectural factors.			Falvo, JV (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20642] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI AZ, 1995, NATURE, V374, P371; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HAMM MK, 1995, BIOORG MED CHEM LETT, V5, P1621, DOI 10.1016/0960-894X(95)00266-V; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KUPRASH DV, 1995, NUCLEIC ACIDS RES, V23, P427, DOI 10.1093/nar/23.3.427; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHN DA, 1988, BIOCHEM INT, V16, P963; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MEACOCK S, 1994, J BIOL CHEM, V269, P31759; MENDOZA R, 1990, BIOCHEMISTRY-US, V29, P5035, DOI 10.1021/bi00473a006; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	63	271	273	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1101	1111		10.1016/0092-8674(95)90137-X	http://dx.doi.org/10.1016/0092-8674(95)90137-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548798	Bronze			2022-12-01	WOS:A1995TM76200007
J	Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C				Jaax, N; Jahrling, P; Geisbert, T; Geisbert, J; Steele, K; McKee, K; Nagley, D; Johnson, E; Jaax, G; Peters, C			Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory	LANCET			English	Note								Secondary transmission of Ebola virus infection in humans is known to be caused by direct contact with infected patients or body fluids. We report transmission of Ebola virus (Zaire strain) to two of three control rhesus monkeys (Macaca mulatta) that did not have direct contact with experimentally inoculated monkeys held in the same room. The two control monkeys died from Ebola virus infections at 10 and 11 days after the last experimentally inoculated monkey had died. The most likely route of infection of the control monkeys was aerosol, oral, or conjunctival exposure to virus-laden droplets secreted or excreted from the experimentally inoculated monkeys. These observations suggest approaches to the study of routes of transmission to and among humans.			Jaax, N (corresponding author), USA, MED RES INST INFECT DIS, FREDERICK, MD 21702 USA.							BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOWEN ETW, 1978, T ROY SOC TROP MED H, V72, P188, DOI 10.1016/0035-9203(78)90058-5; Breman J, 1976, EBOLA VIRUS HAEMORRH, P103; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; GEISBERT TW, 1990, J CLIN PATHOL, V43, P813, DOI 10.1136/jcp.43.10.813; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; PROPHET EB, 1992, LABORATORY METHODS H	9	133	144	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1669	1671		10.1016/S0140-6736(95)92841-3	http://dx.doi.org/10.1016/S0140-6736(95)92841-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551825				2022-12-01	WOS:A1995TL42300011
J	WOOSTER, R; BIGNELL, G; LANCASTER, J; SWIFT, S; SEAL, S; MANGION, J; COLLINS, N; GREGORY, S; GUMBS, C; MICKLEM, G; BARFOOT, R; HAMOUDI, R; PATEL, S; RICE, C; BIGGS, P; HASHIM, Y; SMITH, A; CONNOR, F; ARASON, A; GUDMUNDSSON, J; FICENEC, D; KELSELL, D; FORD, D; TONIN, P; BISHOP, DT; SPURR, NK; PONDER, BAJ; EELES, R; PETO, J; DEVILEE, P; CORNELISSE, C; LYNCH, H; NAROD, S; LENOIR, G; EGILSSON, V; BARKADOTTIR, RB; EASTON, DF; BENTLEY, DR; FUTREAL, PA; ASHWORTH, A; STRATTON, MR				WOOSTER, R; BIGNELL, G; LANCASTER, J; SWIFT, S; SEAL, S; MANGION, J; COLLINS, N; GREGORY, S; GUMBS, C; MICKLEM, G; BARFOOT, R; HAMOUDI, R; PATEL, S; RICE, C; BIGGS, P; HASHIM, Y; SMITH, A; CONNOR, F; ARASON, A; GUDMUNDSSON, J; FICENEC, D; KELSELL, D; FORD, D; TONIN, P; BISHOP, DT; SPURR, NK; PONDER, BAJ; EELES, R; PETO, J; DEVILEE, P; CORNELISSE, C; LYNCH, H; NAROD, S; LENOIR, G; EGILSSON, V; BARKADOTTIR, RB; EASTON, DF; BENTLEY, DR; FUTREAL, PA; ASHWORTH, A; STRATTON, MR			IDENTIFICATION OF THE BREAST-CANCER SUSCEPTIBILITY GENE BRCA2	NATURE			English	Article								IN Western Europe and the United States approximately 1 in 12 women develop breast cancer. A small proportion of breast cancer cases, in particular those arising at a young age, are attributable to a highly penetrant, autosomal dominant predisposition to the disease. The breast cancer susceptibility gene, BRCA2, was recently localized to chromosome 13q12-q13. Here we report the identification of a gene in which we have detected six different germline mutations in breast cancer families that are likely to be due to BRCA2. Each mutation causes serious disruption to the open reading frame of the transcriptional unit. The results indicate that this is the BRCA2 gene.	INST CANC RES,HADDOW LABS,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,HADDOW LABS,CRC CTR CELL & MOLEC BIOL,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; SANGER CTR,HINXTON CB10 1RQ,CAMBS,ENGLAND; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV GYNECOL ONCOL,DURHAM,NC 27710; UNIV HOSP ICELAND,CELL BIOL LAB,IS-121 REYKJAVIK,ICELAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,DIV HUMAN GENET,MONTREAL,PQ H3G 1A4,CANADA; IMPERIAL CANC RES FUND,GENET EPIDEMIOL LAB,LEEDS LS2 9LU,W YORKSHIRE,ENGLAND; ADDENBROOKES HOSP,CRC HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; LEIDEN UNIV,DEPT HUMAN GENET & PATHOL,2300 RA LEIDEN,NETHERLANDS; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED & PUBL HLTH,OMAHA,NE 68178; INT AGCY RES CANC,F-69372 LYON 08,FRANCE; UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,CRC GENET EPIDEMIOL GRP,CAMBRIDGE CB2 2SR,ENGLAND; WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA; WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Wellcome Trust Sanger Institute; Duke University; Duke University; Duke University; Landspitali National University Hospital; McGill University; McGill University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Leiden University; Leiden University - Excl LUMC; Creighton University; World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge; University of Toronto; University Toronto Affiliates; Womens College Hospital; Washington University (WUSTL)	WOOSTER, R (corresponding author), INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Kelsell, David P/F-8767-2011; Biggs, Patrick Jon/H-3355-2014; Narod, Steven A/AAA-6112-2022; DEVILEE, PETER/ABR-2140-2022	Biggs, Patrick Jon/0000-0002-0285-4101; Micklem, Gos/0000-0002-6883-6168; Kelsell, David/0000-0002-9910-7144; Hamoudi, Rifat/0000-0002-1402-0868; Gregory, Simon/0000-0002-7805-1743; Arason, Adalgeir/0000-0003-0480-886X; Bishop, Tim/0000-0002-8752-8785	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; EASTON DF, 1993, AM J HUM GENET, V52, P678; GAYPAY G, 1994, NAT GENET, V7, P246; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; NEHLS M, 1994, ONCOGENE, V9, P2169; SCHUTTE M, 1995, CANCER RES, V55, P4570; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	13	2614	2692	2	166	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					789	792		10.1038/378789a0	http://dx.doi.org/10.1038/378789a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524414				2022-12-01	WOS:A1995TL41900029
J	SAUER, F; HANSEN, SK; TJIAN, R				SAUER, F; HANSEN, SK; TJIAN, R			DNA-TEMPLATE AND ACTIVATOR-COACTIVATOR REQUIREMENTS FOR TRANSCRIPTIONAL SYNERGISM BY DROSOPHILA BICOID	SCIENCE			English	Article							GRADIENT MORPHOGEN; PROTEIN; CLONING; EMBRYO	The template and coactivator requirements for synergistic transcription directed by a single activator, Bicoid (BCD), bound to multiple sites have been determined. Mutagenesis studies in combination with protein binding experiments and reconstituted transcription reactions identified two independent activation domains of BCD that target different coactivator subunits (TAF(II)110 and TAF(II)60) of the basal transcription factor IID (TFIID). The presence of both coactivators is required for BCD to recruit the TATA binding protein (TBP)-TAF complex to the promoter and direct synergistic activation of transcription. Thus, contact between multiple activation domains of BCD and different targets within the TFIID complex can mediate transcriptional synergism.			SAUER, F (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JOUNG JK, 1993, P NATL ACAD SCI USA, V90, P3083, DOI 10.1073/pnas.90.7.3083; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, UNPUB; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; ZAWEL L, 1992, CURR OPIN CELL BIOL, V4	30	75	76	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1825	1828		10.1126/science.270.5243.1825	http://dx.doi.org/10.1126/science.270.5243.1825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525377				2022-12-01	WOS:A1995TK47600047
J	ZHOU, JM; LOH, YT; BRESSAN, RA; MARTIN, GB				ZHOU, JM; LOH, YT; BRESSAN, RA; MARTIN, GB			THE TOMATO GENE PTI1 ENCODES A SERINE/THREONINE KINASE THAT IS PHOSPHORYLATED BY PTO AND IS INVOLVED IN THE HYPERSENSITIVE RESPONSE	CELL			English	Article							PROTEIN-KINASE; ARABIDOPSIS-THALIANA; DISEASE RESISTANCE; PURIFICATION; ACTIVATION; CLONING	The Pto gene encodes a serine/threonine kinase that confers resistance to bacterial speck disease in tomato. Using the yeast two-hybrid system, we identified a second serine/threonine kinase, Pto-interacting 1 (Pti1), that physically interacts with Pto. Cross-phosphorylation assays revealed that Pto specifically phosphorylates Pti1 and that Pti1 does not phosphorylate Pto. Fen, another serine/threonine kinase from tomato that is closely related to Pto, was unable to phosphorylate Pti1 and was not phosphorylated by Pti1. Expression of a Pti1 transgene in tobacco plants enhanced the hypersensitive response to a P. syringae pv. tabaci strain carrying the avirulence gene avrPto. These findings indicate that Pti1 is involved in a Pto-mediated signaling pathway, probably by acting as a component downstream of Pto in a phosphorylation cascade.	PURDUE UNIV, DEPT AGRON, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT HORT, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Martin, Gregory B/F-6262-2011; Zhou, Jian-Min/A-3140-2013	Martin, Gregory B/0000-0003-0044-6830; Zhou, Jian-Min/0000-0002-9943-2975; Loh, Ying-Tsu/0000-0003-0833-4622; Bressan, Ray/0000-0002-8754-606X				BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CHOI KY, 1994, CELL, V78, P499; Cutt J. R., 1992, Genes involved in plant defense., P209; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DESPRES C, 1995, PLANT CELL, V7, P589, DOI 10.1105/tpc.7.5.589; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DWYER SC, 1995, IN PRESS BIOCH BIOPH; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Goodman R. N., 1994, HYPERSENSITIVE REACT; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Keen N. T., 1993, Biotechnology in plant disease control., P65; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MARTIN GB, 1995, IN PRESS PLANT MICRO, V1; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; REYNOLDS A, 1989, CURRENT PROTOCOLS MO; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; ROMMENS CMT, 1995, PLANT CELL, V7, P1537, DOI 10.1105/tpc.7.10.1537; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J., 1989, MOL CLONING LAB MANU; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; THILMONY RL, 1995, PLANT CELL, V7, P1529, DOI 10.1105/tpc.7.10.1529; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; YU LM, 1993, PLANT J, V3, P805, DOI 10.1111/j.1365-313X.1993.00805.x	55	319	358	4	29	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					925	935		10.1016/0092-8674(95)90208-2	http://dx.doi.org/10.1016/0092-8674(95)90208-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521516	Bronze			2022-12-01	WOS:A1995TK74500011
J	PILLANS, P				PILLANS, P			BRONCHOSPASM ASSOCIATED WITH CISAPRIDE	BRITISH MEDICAL JOURNAL			English	Letter											PILLANS, P (corresponding author), UNIV OTAGO,SCH MED,DUNEDIN,NEW ZEALAND.		Pillans, Peter/G-8719-2013					MCCALLUM RW, 1991, AM J GASTROENTEROL, V86, P135; NOLAN P, 1990, LANCET, V336, P1443, DOI 10.1016/0140-6736(90)93140-K	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520336				2022-12-01	WOS:A1995TJ04400027
J	VOSS, M; KNOTTENBELT, JD; PEDEN, MM				VOSS, M; KNOTTENBELT, JD; PEDEN, MM			PATIENTS WHO REATTEND AFTER HEAD-INJURY - A HIGH-RISK GROUP	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA	Objective-To assess risk factors for important neurosurgical effects in patients who reattend after head injury. Design-Retrospective study. Subject -606 patients who reattended a trauma unit after minor head injury. Main outcome measures-Intracranial abnormality detected on computed tomography or the need for neurosurgical intervention. Results-Five patients died: two from unrelated causes and three from raised intracranial pressure. On multiple regression analysis the only significant predictor for both abnormality on computed tomography (14.4% of reattenders) and the need for operation (5% of reattenders) was vault fracture seen on the skull radiograph (P<10(-6)); predictors for abnormal computed tomogram were a Glasgow coma scale score <15 at either first or second attendance (P<0.0001) and convulsion at second attendance (P<0.05); predictive for operation only was penetrating injury of the skull (P<10(-6)). On contingency table analysis these associations were confirmed. In addition significant associations with both abnormality on computed tomography and operation were focal neurological abnormality, weakness, or speech disturbance. Amnesia or loss of consciousness at the time of initial injury, personality change, and seizures were significantly associated only with abnormality on computed tomography. Headache, dizziness, nausea, and vomiting were common in reattenders but were found to have no independent significance. Conclusions-All patients who reattend after head injury should undergo computed tomography as at least 14% of scans can be expected to yield positive results. Where this facility is not available patients with predictors for operation should be urgently referred for neurosurgical opinion. Other patients can be readmitted and need referral only if symptoms persist despite symptomatic treatment or there is neurological deterioration while under observation. These patients are a high risk group and should be treated seriously.	GROOTE SCHUUR HOSP,TRAUMA UNIT,CAPE TOWN,SOUTH AFRICA; S AFRICAN MRC,CAPE TOWN,SOUTH AFRICA	University of Cape Town; South African Medical Research Council				Mary, Margaret/0000-0003-0872-9851				DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; GUSTAFFSON T, 1985, EPISTAT STATISTICAL; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JONES RK, 1974, SURG NEUROL, V2, P101; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; 1990, SAS USERS GUIDE STAT; 1984, BRIT MED J, V288, P983	11	37	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1395	1398		10.1136/bmj.311.7017.1395	http://dx.doi.org/10.1136/bmj.311.7017.1395			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520273	Green Published			2022-12-01	WOS:A1995TG90200017
J	LEHN, JM				LEHN, JM			SUPRAMOLECULAR CHEMISTRY	SCIENCE			English	Article							MOLECULAR DEVICES; PERSPECTIVES; ORGANIZATION; RECOGNITION; COMPLEXES; LECTURE		UNIV STRASBOURG 1, F-67070 STRASBOURG, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	LEHN, JM (corresponding author), COLL FRANCE, F-75231 PARIS 05, FRANCE.							AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; Balzani V., 1991, SUPRAMOLECULAR PHOTO; BERNSTEIN J, IN PRESS STRUCTURE C; COLLET A, 1987, TETRAHEDRON, V43, P5725, DOI 10.1016/S0040-4020(01)87780-2; CONSTABLE EC, 1992, TETRAHEDRON, V48, P10013, DOI 10.1016/S0040-4020(01)89035-9; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; Desiraju G.R., 1989, CRYSTAL ENG DESIGN O; Die- derich F., 1991, CYCLOPHANES; DIETRICHBUCHECKER C, 1990, TETRAHEDRON, V46, P503, DOI 10.1016/S0040-4020(01)85433-8; FAGAN PJ, 1992, SCI AM, V267, P48, DOI 10.1038/scientificamerican0792-48; Gokel G. W., 1991, CROWN ETHERS CRYPTAN; GUTSCHE CD, 1987, CALIXARENES, V43, P5725; KUNITAKE T, 1992, ANGEW CHEM INT EDIT, V31, P709, DOI 10.1002/anie.199207091; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LEHN JM, 1978, PURE APPL CHEM, V50, P871, DOI 10.1351/pac197850090871; LEHN JM, 1985, SCIENCE, V227, P849, DOI 10.1126/science.227.4689.849; Lehn JM., 1973, STRUCT BONDING BERLI, V16, P1, DOI DOI 10.1017/BFB0004364; LINDSEY JS, 1991, NEW J CHEM, V15, P153; ORGEL LF, 1992, NATURE, V358, P2032; OVCHINNIKOV YA, 1974, MEMBRANE ACTIVE COMP; PEDERSEN CJ, 1988, ANGEW CHEM INT EDIT, V27, P1021, DOI 10.1002/anie.198810211; PHILP D, 1991, SYNLETT, P445; Rebek Julius Jr., 1992, Journal of Molecular Recognition, V5, P83, DOI 10.1002/jmr.300050302; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; SEEL C, 1992, ANGEW CHEM INT EDIT, V31, P528, DOI 10.1002/anie.199205281; SEEL C, 1993, TOP CURR CHEM, V165; TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381; VONKIEDROWSKI G, 1992, NACHR CHEM TECH LAB, V40, P578; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	30	625	637	8	316	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1762	1763		10.1126/science.8511582	http://dx.doi.org/10.1126/science.8511582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511582				2022-12-01	WOS:A1993LH20500034
J	FIGDOR, MC; STERN, CD				FIGDOR, MC; STERN, CD			SEGMENTAL ORGANIZATION OF EMBRYONIC DIENCEPHALON	NATURE			English	Article							CHICK-EMBRYO; NEURONAL DEVELOPMENT; NERVOUS-SYSTEM; SOMITE CELLS; EXPRESSION; MOUSE; FOREBRAIN; PATTERN; DROSOPHILA; HINDBRAIN	THE diencephalon is a complex integration centre and intricate relay station of the vertebrate brain1-3. Its development involves the generation of great cellular diversity and neuronal specificity. We report here that it becomes organized in steps, through a stereotyped sequence of neuromeric subdivisions. Diencephalic neuromeres define four cellular domains (D1-D4) that can be followed throughout development, each unit contributing to a well defined part of the adult structural pattern. We propose that the segmental identity of each diencephalic unit is specified by a unique combination of genes4-13, maintained by polyclonal cell lineage restrictions. A comparison of vertebrate and arthropod development suggests that the basic principles that control anterior axial patterning and set up neuronal specificity in the embryonic central nervous system are highly conserved in evolution.	UNIV OXFORD,DEPT HUMAN ANAT,S PARKS RD,OXFORD OX1 3QX,ENGLAND; INST HISTOL & EMBRYOL,A-1090 VIENNA,AUSTRIA	University of Oxford			Stern, Claudio D/C-6265-2008; Stern, Claudio/AAZ-7381-2021	Stern, Claudio D/0000-0002-9907-889X; Stern, Claudio/0000-0002-9907-889X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN J, 1988, J COMP NEUROL, V275, P346, DOI 10.1002/cne.902750304; [Anonymous], 1966, STUDIES DIENCEPHALON; Ariens Kappers C. N., 1960, COMP ANATOMY NERVOUS; BATE CM, 1981, J EMBRYOL EXP MORPH, V61, P317; BERGQUIST H, 1964, PROGR BRAIN RES, V5, P223; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; COOPER NGF, 1986, J COMP NEUROL, V249, P157, DOI 10.1002/cne.902490204; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; KEYSER AJM, 1972, ACTA ANAT        S59, V83, P1; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; Kuhlenbeck, 1973, CENTRAL NERVOUS SYST; LAWRENCE PA, 1990, NATURE, V344, P382, DOI 10.1038/344382a0; LAYER PG, 1990, DEVELOPMENT, V109, P613; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGREW LL, 1992, DEVELOPMENT, V115, P463; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; RENDAHL H, 1924, ACTA ZOOLOGICA, V5, P119; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Sarnat H. B., 1981, EVOLUTION NERVOUS SY, V2nd; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STERN CD, 1986, J EMBRYOL EXP MORPH, V91, P209; STERN CD, 1987, DEVELOPMENT, V99, P261; STERN CD, 1988, DEVELOPMENT, V104, P231; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VAAGE S, 1969, SEGMENTATION PRIMITI; VONKUPFFER K, 1906, HDB VERGLEICHENDEN E, V2; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	37	368	370	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					630	634		10.1038/363630a0	http://dx.doi.org/10.1038/363630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510755				2022-12-01	WOS:A1993LH13900057
J	CLEMETSON, DBA; MOSS, GB; WILLERFORD, DM; HENSEL, M; EMONYI, W; HOLMES, KK; PLUMMER, F; NDINYAACHOLA, J; ROBERTS, PL; HILLIER, S; KREISS, JK				CLEMETSON, DBA; MOSS, GB; WILLERFORD, DM; HENSEL, M; EMONYI, W; HOLMES, KK; PLUMMER, F; NDINYAACHOLA, J; ROBERTS, PL; HILLIER, S; KREISS, JK			DETECTION OF HIV DNA IN CERVICAL AND VAGINAL SECRETIONS - PREVALENCE AND CORRELATES AMONG WOMEN IN NAIROBI, KENYA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; HETEROSEXUAL TRANSMISSION; INFECTION; RISK; FEMALE; TYPE-1; ASSOCIATION; ECTOPY; SEMEN	Objective.-Factors that influence heterosexual transmission of the human immunodeficiency virus (HIV), including sexually transmitted diseases, contraceptive practices, sexual practices, HIV-related immunosuppression, and presence of cervical ectopy and the penile foreskin, have been identified through cross-sectional and prospective cohort epidemiologic studies. To more directly characterize factors that influence infectivity, we conducted a study of HIV shedding from the genital tract in women. Design.-Ninety-seven HIV-seropositive women attending a sexually transmitted disease clinic in Nairobi, Kenya, completed a questionnaire and underwent a physical examination and an evaluation for sexually transmitted diseases. Cervical and vaginal secretions were obtained for HIV DNA detection using polymerase chain reaction amplification. Results.-Human immunodeficiency virus DNA was detected by polymerase chain reaction in 28 (33%) of 84 cervical samples and 13 (17%) of 77 vaginal samples. The prevalence of H IV was higher in specimens from the endocervix than from the vaginal wall (P=.002), and there was no correlation between presence of virus at the two sites. After adjusting for age, cervical HIV shedding was independently associated with oral contraceptive pill use (odds ratio [OR], 11.6; 95% confidence interval [CI], 1.7 to 77.6), cervical mucopus (OR, 6.2; 95% CI, 0.9 to 41.4; P=.05), cervical ectopy (OR, 5.0; 95% CI, 1.5 to 16.9), and pregnancy (OR, 4.5; 95% CI, 1.2 to 16.3). Conclusions.-Human immunodeficiency virus was detected in one third of cervical samples and one sixth of vaginal samples. The presence of HIV DNA in cervical secretions was significantly associated with oral contraceptive pill use, cervical ectopy, and pregnancy. There was a marginally significant association with cervical mucopus. The identification of factors that increase the infectivity of women suggests potential strategies for reducing heterosexual transmission of HIV.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; UNIV NAIROBI, DEPT MED MICROBIOL, NAIROBI, KENYA; UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG R3T 2N2, MANITOBA, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Nairobi; University of Manitoba			, Holmes/K-6215-2019					ANDERSON D, 1990, 6TH INT C AIDS SAN F; ANDERSON DJ, 1990, CONRAD W S, P167, DOI 10.1017/CBO9780511666582.008; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; [Anonymous], 1992, BMJ, V304, P809; CAMERON DW, 1989, LANCET, V2, P403; DAVEY DA, 1986, DEWHURSTS TXB OBSTET, P126; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOLDACRE MJ, 1978, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6115.748; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; KRONE WJA, 1990, J ACQ IMMUN DEF SYND, V3, P517; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; LOUV WC, 1989, AM J OBSTET GYNECOL, V160, P396, DOI 10.1016/0002-9378(89)90456-0; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PIOT P, 1990, SCAND J INFECT DIS, P89; PLOURDE PJ, 1991, 1ST HAEM DUCR S INT; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POLITCH J, 1991, 7TH INT C AIDS FLOR; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; SCHUURS AHWM, 1990, J STEROID BIOCHEM, V35, P157, DOI 10.1016/0022-4731(90)90270-3; SINGER A, 1976, CERVIX, P105; STYRT B, 1991, REV INFECT DIS, V13, P1139; VOGT MW, 1987, ANN INTERN MED, V106, P380, DOI 10.7326/0003-4819-106-3-380; VOGT MW, 1986, LANCET, V1, P525; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WOFSY CB, 1986, LANCET, V1, P527; 1992, CURRENT FUTURE DIMEN	33	224	231	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2860	2864		10.1001/jama.269.22.2860	http://dx.doi.org/10.1001/jama.269.22.2860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497089				2022-12-01	WOS:A1993LE93600021
J	CONNOLLY, AM; SALMON, RL; LERVY, B; WILLIAMS, DH				CONNOLLY, AM; SALMON, RL; LERVY, B; WILLIAMS, DH			WHAT ARE THE COMPLICATIONS OF INFLUENZA AND CAN THEY BE PREVENTED - EXPERIENCE FROM THE 1989 EPIDEMIC OF H3N2 INFLUENZA-A IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-In an epidemic: to measure the incidence and risk of complications of influenza; to determine the effect of pre-existing disease on complications; to estimate vaccine uptake and efficacy. Design-Case-control study. Setting-Primary care: two group practices. Subjects-342 of the 395 cases of clinically diagnosed influenza reported to the general practice surveillance of infectious diseases scheme of the Public Health Laboratory Service during the 1989 epidemic, and 342 age and sex matched controls. Interventions-Examination of records. Main outcome measures-Documented recognised complications; hospital admission; previous vaccination. Results-Of 15 recognised complications, bronchitis was the commonest (rate 190.1/1000 cases) and significantly commoner in cases (summary odds ratio 9.7) after adjusting for higher consultation rates (mean 6.1 per annum v 4.2 among controls; p<0.0001). No deaths were recorded. The risk of bronchitis complicating influenza was higher in patients with pre-existing illnesses regarded as an indication for vaccination (odds ratio 3.3; p<0.0001). Observed vaccination efficacy in those with pre-existing illnesses and in elderly subjects was high (63% and 77% respectively) but uptake was low (4.5% and 6.1% respectively). Conclusions-Bronchitis complicates about one fifth of all cases of influenza presenting to general practitioners. Patients with pre-existing illnesses regarded as an indication for vaccination are particularly at risk. Vaccine uptake is extremely low, precluding an unequivocal demonstration of a protective effect.	PHLS,CTR COMMUNICABLE DIS SURVEILLANCE,WELSH UNIT,CARDIFF CF4 3QX,WALES; LLYS MEDDYG,THE SURGERY,SWANSEA SA6 6HU,WALES; EGLWYSBACH SURG,PONTYPRIDD CF37 2AA,M GLAM,WALES									Ashley J., 1991, Population Trends, P16; CAMPOSHILHO BSN, 1988, MULTLR MICROCOMPUTER; CATE TR, 1987, AM J MED, V82, P15, DOI 10.1016/0002-9343(87)90555-9; DAN BB, 1987, JAMA-J AM MED ASSOC, V257, P1094, DOI 10.1001/jama.257.8.1094; DEAN AD, 1990, EPI INFOR VERSION 5; FLEMING DM, 1990, BRIT J GEN PRACT, V40, P495; FLEMING DM, 1988, J ROY COLL GEN PRACT, V38, P159; GARDNER MJ, 1989, STATISTICS CONFIDENC; GRIST N, 1989, PRACTITIONER, V233, P56; HALL CB, 1986, PRACTICAL APPROACH I; MILLER DL, 1969, J HYG-CAMB, V67, P559, DOI 10.1017/S0022172400042005; NAGINGTON J, 1983, OXFORD TXB MED, V1; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; Palmer S R, 1991, CDR (Lond Engl Rev), V1, pR25; PALMER SR, 1990, MMWR-MORBID MORTAL W, V39, P913; SCHAFFNER W, 1987, AM J MED, V82, P61, DOI 10.1016/0002-9343(87)90566-3; SHANN F, 1990, LANCET, V335, P898, DOI 10.1016/0140-6736(90)90489-R; STUARTHA.CH, 1966, BRIT MED J, V1, P217, DOI 10.1136/bmj.1.5481.217; STUARTHA.CH, 1966, BRIT MED J, V1, P149, DOI 10.1136/bmj.1.5480.149; 1990, CMO909 CHIEF MED OFF	20	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1452	1454		10.1136/bmj.306.6890.1452	http://dx.doi.org/10.1136/bmj.306.6890.1452			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518643	Green Published, Bronze			2022-12-01	WOS:A1993LE93500020
J	PARSONS, WL; GODWIN, M; ROBBINS, C; BUTLER, R				PARSONS, WL; GODWIN, M; ROBBINS, C; BUTLER, R			PREVALENCE OF CERVICAL PATHOGENS IN WOMEN WITH AND WITHOUT INFLAMMATORY CHANGES ON SMEAR TESTING	BRITISH MEDICAL JOURNAL			English	Article							CHLAMYDIA-TRACHOMATIS INFECTION	Objective-To assess correlation between nonspecific cervicitis, inflammation, or exudate on cervical smears tests and confirmed presence of known cervical pathogens. Design-Investigation of women attending a family practice clinic for smear test by microbiological screening for Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum Trichomonas vaginalis, Candida species, group B streptococcus, Gardnerella vaginalis, and Neisseria gonorrhoeae. Setting-Family practice teaching clinic in a university hospital. Patients-411 women presenting for a smear test. Main outcome measures-Prevalence of genital infections associated with presence or absence of inflammatory changes on cervical smear. Results-Of the 132 women with inflammatory changes on cervical smear, 64 (48%) had positive cultures. Of the 248 without inflammatory changes, 117 (47%) had positive cultures. Subgroup analysis on individual organisms also showed no significant difference between the two groups. Conclusion-Reports of inflammatory changes on cervical smear testing are a poor indicator of infection.			PARSONS, WL (corresponding author), MEM UNIV NEWFOUNDLAND,HLTH SCI CTR,FAMILY PRACTICE UNIT,ST JOHNS A1B 3V6,NEWFOUNDLAND,CANADA.							ADDISS DG, 1987, FAM PLANN PERSPECT, V19, P252, DOI 10.2307/2135105; Bertolino J G, 1992, Fam Med, V24, P447; BOWIE WR, 1981, CAN MED ASSOC J, V124, P1477; DORMAN SA, 1983, AM J CLIN PATHOL, V79, P421, DOI 10.1093/ajcp/79.4.421; EMBIL JA, 1985, CAN MED ASSOC J, V138, P34; GEERLING S, 1985, ACTA CYTOL, V29, P671; KELLY BA, 1990, BRIT J GEN PRACT, V40, P238; KIVIAT NB, 1985, JAMA-J AM MED ASSOC, V253, P989, DOI 10.1001/jama.253.7.989; Koss L.G., 1992, DIAGNOSTIC CYTOLOGY; MASSE R, 1991, CAN MED ASSOC J, V145, P953; SHAFER MA, 1985, AM J OBSTET GYNECOL, V151, P765, DOI 10.1016/0002-9378(85)90516-2; SMITH JR, 1991, BRIT MED J, V302, P82, DOI 10.1136/bmj.302.6768.82; SMITH TF, 1977, HEALTH LAB SCI, V14, P30; WEISMEIER E, 1987, J REPRODUCT MED, V32, P251; WILSON JD, 1990, BRIT MED J, V300, P638, DOI 10.1136/bmj.300.6725.638	15	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1173	1174		10.1136/bmj.306.6886.1173	http://dx.doi.org/10.1136/bmj.306.6886.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8499824	Bronze, Green Published			2022-12-01	WOS:A1993LA68500028
J	Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF				Considine, RV; Sinha, MK; Heiman, ML; Kriauciunas, A; Stephens, TW; Nyce, MR; Ohannesian, JP; Marco, CC; McKee, LJ; Bauer, TL; Caro, JF			Serum immunoreactive leptin concentrations in normal-weight and obese humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Leptin, the product of the ob gene, is a hormone secreted by adipocytes, Animals with mutations in the ob gene are obese and lose weight when given leptin, but little is known about the physiologic actions of leptin in humans. Methods. Using a newly developed radioimmunoassay, we measured serum concentrations of leptin in 136 normal-weight subjects and 139 obese subjects (body-mass index, greater than or equal to 27.3 for men and greater than or equal to 27.8 for women; the body-mass index was defined as the weight in kilograms divided by the square of the height in meters). The measurements were repeated in seven obese subjects after weight loss and during maintenance of the lower weight. The ob messenger RNA (mRNA) content of adipocytes was determined in 27 normal-weight and 27 obese subjects. Results. The mean (+/-SD) serum leptin concentrations were 31.3+/-24.1 ng per milliliter in the obese subjects and 7.5+/-9.3 ng per milliliter in the normal-weight subjects (P < 0.001). There was a strong positive correlation between serum leptin concentrations and the percentage of body fat (r = 0.85, P < 0.001). The ob mRNA content of adipocytes was about twice as high in the obese subjects as in the normal-weight subjects (P = 0.005) and was correlated with the percentage of body fat (r = 0.68, P < 0.001) in the 54 subjects in whom it was measured. In the seven obese subjects studied after weight loss, both serum leptin concentrations and ob mRNA content of adipocytes declined, but these measures increased again during the maintenance of the lower weight. Conclusions. Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production. (C) 1996, Massachusetts Medical Society.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT CLIN PHARMACOL,BIOSTAT SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT SURG,PHILADELPHIA,PA 19107; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Jefferson University; Jefferson University; Jefferson University; Eli Lilly	Considine, RV (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV ENDOCRINOL & METAB,1025 WALNUT ST,813 COLL BLDG,PHILADELPHIA,PA 19107, USA.		sheng, jian/E-9474-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045592] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK45592] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; JEBB SA, 1993, INT J OBESITY, V17, P611; KOLACZYNSKI JW, 1994, INT J OBESITY, V18, P161; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NIH Technology Assessment Conference Panel, 1992, ANN INTERN MED, V116, P942; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	20	5070	5238	3	282	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					292	295		10.1056/NEJM199602013340503	http://dx.doi.org/10.1056/NEJM199602013340503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV695	8532024				2022-12-01	WOS:A1996TV69500003
J	Ryan, CJ; Kaye, M				Ryan, CJ; Kaye, M			Euthanasia in Australia - The Northern Territory rights of the terminally ill act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV SYDNEY,SYDNEY,NSW 2000,AUSTRALIA	University of Sydney	Ryan, CJ (corresponding author), WESTMEAD HOSP,SYDNEY,NSW 2145,AUSTRALIA.		Ryan, Christopher/B-4095-2010	Kaye, Miranda/0000-0003-4484-1904; Ryan, Christopher/0000-0003-2158-9427				BATTIN MP, 1994, LEAST WORST DEATH, P123; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; GLOVER J, 1988, CAUSING DEATH SAVING, P188; Griffiths John, 1994, Med Law Int, V1, P137; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; OGILVIE AD, 1994, BRIT MED J, V309, P492, DOI 10.1136/bmj.309.6953.492; Ryan CJ, 1995, AUST NZ J PSYCHIAT, V29, P580, DOI 10.3109/00048679509064970; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1995, NO TERRITORY RIGHTS	11	46	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					326	328		10.1056/NEJM199602013340512	http://dx.doi.org/10.1056/NEJM199602013340512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532033				2022-12-01	WOS:A1996TV69500012
J	Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R				Thadhani, R; Pascual, M; Nickeleit, V; TolkoffRubin, N; Colvin, R			Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease	LANCET			English	Article							PROTEINURIA	Background Primary and secondary forms of focal segmental glomerulosclerosis (FSGS) are common causes of glomerular proteinuria. Secondary forms of FSGS seem to be the result of adaptive changes that follow a reduction in renal mass. We saw an elderly patient with severe bilateral renal vascular disease (RVD) who had FSGS on percutaneous biopsy. To find out whether elderly patients with atherosclerotic RVD are predisposed to the development of FSGS, we reviewed all cases of FSGS at our institution between 1990 and 1995. Methods We identified 59 cases of biopsy-proven FSGS and examined clinical, histological, and radiographic records. Findings Of the 59 patients, 24 were older than 50 years; eight of these had RVD. No patient under the age of 50 had RVD. Seven of the eight patients with RVD and FSGS had substantial proteinuria at presentation. All had typical glomerular lesions with focal segmental tuft collapse and synechiae; other glomeruli were hypertrophic. All patients showed further decline in renal function on follow-up. Interpretation The association of FSGS and RVD may represent an under-recognised aetiology of significant proteinuria in elderly patients.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital				Pascual, Manuel A./0000-0001-7747-1693				ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; DAGATI V, 1994, KIDNEY INT, V46, P1223, DOI 10.1038/ki.1994.388; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; FREEDMAN BI, 1995, AM J KIDNEY DIS, V25, P207, DOI 10.1016/0272-6386(95)90001-2; GEPHARDT GN, 1984, CLEVELAND CLIN Q, V51, P371, DOI 10.3949/ccjm.51.2.371; HARVEY JM, 1992, LANCET, V340, P1435, DOI 10.1016/0140-6736(92)92624-O; KUMAR A, 1980, ARCH INTERN MED, V140, P1631, DOI 10.1001/archinte.140.12.1631; MCLACHLAN M, 1981, BRIT J RADIOL, V54, P488, DOI 10.1259/0007-1285-54-642-488; PICKERING TG, 1993, DISEASES KIDNEY, P1451; RENNKE HG, 1989, AM J KIDNEY DIS, V13, P443, DOI 10.1016/S0272-6386(89)80001-0	10	61	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					231	233		10.1016/S0140-6736(96)90406-7	http://dx.doi.org/10.1016/S0140-6736(96)90406-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551883				2022-12-01	WOS:A1996TT06900012
J	Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT				Dempsey, PW; Allison, MED; Akkaraju, S; Goodnow, CC; Fearon, DT			C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity	SCIENCE			English	Article							RAPID PURIFICATION; MOUSE COMPLEMENT; LYMPHOCYTES-B; RECEPTOR; SYSTEM; ANTIBODY; PROTEINS; INVIVO; SELF	An optimal immune response should differentiate between harmful and innocuous antigens. Primitive systems of innate immunity, such as the complement system, may play a role in this distinction. When activated, the C3 component of complement attaches to potential antigens on microorganisms. To determine whether this alters acquired immune recognition, mice were immunized with a recombinant model antigen, hen egg lysozyme (HEL), fused to murine C3d. HEL bearing two and three copies of C3d was 1000- and 10,000-fold more immunogenic, respectively, than HEL alone. Thus, C3d is a molecular adjuvant of innate immunity that profoundly influences an acquired immune response.	UNIV CAMBRIDGE,SCH MED,DEPT MED,WELLCOME TRUST IMMUNOL UNIT,CAMBRIDGE CB2 2SP,ENGLAND; STANFORD UNIV,SCH MED,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of Cambridge; Stanford University; Howard Hughes Medical Institute; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155; Allison, Michael/0000-0003-3677-3294	NIAID NIH HHS [AI07247, AI19512] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.iy.13.040195.001015; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KROP I, IN PRESS EUR J IMMUN; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; TAYLOR ME, 1991, BIOCHEM J, V274, P575, DOI 10.1042/bj2740575; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; WENG WK, 1994, J BIOL CHEM, V269, P32514	21	943	1042	4	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					348	350		10.1126/science.271.5247.348	http://dx.doi.org/10.1126/science.271.5247.348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553069				2022-12-01	WOS:A1996TQ52800040
J	Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE				Hahn, SA; Schutte, M; Hoque, ATMS; Moskaluk, CA; daCosta, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH; Kern, SE			DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1	SCIENCE			English	Article							CANCER; CARCINOMAS; PANCREAS	About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel of pancreatic carcinomas were analyzed for convergent sites of homboygous deletion. Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway. Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,GRAD PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741	NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CONE D, 1993, NATURE, V366, P698; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRANCKE U, 1994, CYTOGENET CELL GENET, V66, P196, DOI 10.1159/000133697; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HAHN S, UNPUB; HAHN SA, 1995, CANCER RES, V55, P4670; HAHN SA, IN PRESS CANCER RES; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HURSH DA, 1993, DEVELOPMENT, V117, P1211; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1985, CANCER RES, V45, P1437; Leach Francis, COMMUNICATION; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; REDSTON MS, 1994, CANCER RES, V54, P3025; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SILVERMAN GA, 1993, PCR METH APPL, V3, P141; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	27	2054	2165	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					350	353		10.1126/science.271.5247.350	http://dx.doi.org/10.1126/science.271.5247.350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553070				2022-12-01	WOS:A1996TQ52800041
J	Slotnick, RN; Abuhamad, AZ				Slotnick, RN; Abuhamad, AZ			Prognostic implications of fetal echogenic bowel	LANCET			English	Article							DENSITOMETRY; DISEASE	Background An increased frequency of hyperechogenic bowel on ultrasound has been reported in fetuses with cystic fibrosis (CF) and trisomy-21. However, the diagnostic application of this observation has been hampered by the absence of a means of measuring echogenicity. Methods We devised an ultrasonic grading system in which echogenicity was quantified by linear gain reduction and comparison with fetal iliac crest. From 7400 second-trimester ultrasound referrals, 145 patients were identified as having a fetus with abnormally echogenic bowel. They were offered genetic counselling, parental and (if appropriate) CF carrier testing, and amniocentesis for karyotype and CF status if parents were informative. Follow-up was to 4 months of age. Findings Of 40 fetuses with mild increase in bowel sonodensity (grade 1), none had CF or aneuploidy. Of 81 patients identified with a moderate increase (grade 2), 2 had trisomy 21 and 2 had CF. And of 24 pregnancies with a pronounced increase (grade 3), 5 had CF and 6 had trisomy-21. Interpretation Parental CF carrier testing and amniocentesis to identify aneuploidy or fetal CF status has a high positive ascertainment rate in fetuses with echogenic bowel grades 2 and 3.			Slotnick, RN (corresponding author), EASTERN VIRGINIA MED SCH,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,NORFOLK,VA 23507, USA.							BEAUDET AL, 1990, NEW ENGL J MED, V323, P70; BLICKSTEIN I, 1994, J ULTRAS MED, V13, P675, DOI 10.7863/jum.1994.13.9.675; BLICKSTEIN I, 1993, J ULTRAS MED, V12, P567; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASPI B, 1992, GYNECOL OBSTET INVES, V33, P26, DOI 10.1159/000294842; CASPI B, 1988, PRENATAL DIAG, V8, P379, DOI 10.1002/pd.1970080508; CHALUBINSKI K, 1992, PRENATAL DIAG, V12, P631, DOI 10.1002/pd.1970120802; DICKE JM, 1992, OBSTET GYNECOL, V80, P778; FOROUZAN I, 1992, OBSTET GYNECOL, V80, P535; NYBERG DA, 1990, OBSTET GYNECOL, V76, P370; NYBERG DA, 1993, RADIOLOGY, V188, P527, DOI 10.1148/radiology.188.2.8327709; PLATT JF, 1988, AM J ROENTGENOL, V151, P317, DOI 10.2214/ajr.151.2.317; SCIOSCIA AL, 1992, AM J OBSTET GYNECOL, V167, P889, DOI 10.1016/S0002-9378(12)80007-X; WEINER CP, 1993, AM J OBSTET GYNECOL, V68, P6	14	93	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					85	87		10.1016/S0140-6736(96)90210-X	http://dx.doi.org/10.1016/S0140-6736(96)90210-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538346				2022-12-01	WOS:A1996TP28100009
J	Enomoto, N; Sakuma, I; Asahina, Y; Kurosaki, M; Murakami, T; Yamamoto, C; Ogura, Y; Izumi, N; Marumo, F; Sato, C				Enomoto, N; Sakuma, I; Asahina, Y; Kurosaki, M; Murakami, T; Yamamoto, C; Ogura, Y; Izumi, N; Marumo, F; Sato, C			Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; NON-A; MOLECULAR-CLONING; GENOME; RNA; GENOTYPES; THERAPY; PRIMERS; SERUM	Background. A region associated with sensitivity to interferon has been identified in the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) genotype Ib. The region spans amino acid residues 2209 to 2248 (NS5A2209-2248) Of HCV-J, a strain of HCV-lb whose complete genomic sequence has been identified. We examined whether the NS5A2209-2248 sequence present before therapy could be used as a predictor of the response to interferon therapy in patients with chronic HCV-lb infection. Methods. We retrospectively analyzed 84 patients with chronic HCV-lb infection who had received interferon alfa (total dose, 516 million to 880 million units) for six months. Pretreatment serum samples were analyzed. The amino acid sequence of NS5A2209-2248 was determined by direct sequencing of the HCV genome amplified by the polymerase chain reaction (PCR) and was compared with the established sequence for HCV-J. Results. A complete response, as evidenced by the absence of HCV RNA in serum on nested reverse-transcription PCR for six months after therapy, did not occur in any of the 30 patients whose NS5A2209-2248 sequences were identical to that of HCV-J (wild type). Five of 38 patients (13 percent) with 1 to 3 changes in NS5A2209-2248 (intermediate type) had complete responses, as did all 16 patients with 4 to II amino acid substitutions (mutant type), indicating that the mutant type was significantly associated with a complete response (P<0.001). Although baseline serum HCV RNA levels, as measured by a branched-chain DNA assay, were lower in patients with the mutant type of NS5A2209-2248 than in those with the other types (P<0.001), multivariate analyses revealed that the number of amino acid substitutions in NS5A2209-2248 was the only variable associated with an independent effect on the outcome of interferon therapy (odds ratio, 5.3; 95 percent confidence interval, 1.6 to 18; P=0.007). Conclusions. In patients with chronic HCV-lb infection, there is a substantial correlation between responses to interferon and mutations in the NS5A gene.	TOKYO MED & DENT UNIV,FAC MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC MED,DIV HLTH SCI,TOKYO 113,JAPAN; MUSASHIMO RED CROSS HOSP,DEPT INTERNAL MED,TOKYO,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)			Yang, Chen/G-1379-2010					CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DAVIS GL, 1990, J HEPATOL, V11, pS72, DOI 10.1016/0168-8278(90)90168-Q; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; ENOMOTO N, 1994, J GEN VIROL, V75, P1361, DOI 10.1099/0022-1317-75-6-1361; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HINO K, 1994, J MED VIROL, V42, P299, DOI 10.1002/jmv.1890420318; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MITA E, 1994, DIGEST DIS SCI, V39, P977, DOI 10.1007/BF02087547; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; SAKAMOTO N, 1994, J HEPATOL, V20, P593, DOI 10.1016/S0168-8278(05)80345-9; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1016/0270-9139(95)90121-3; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TAKADA N, 1992, J HEPATOL, V14, P435; TANAKA T, 1992, VIRUS RES, V23, P39; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; VANDERPOEL CL, 1994, LANCET, V344, P1475, DOI 10.1016/S0140-6736(94)90293-3; VANDOORN LJ, 1994, J MED VIROL, V43, P345, DOI 10.1002/jmv.1890430406; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	34	885	921	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					77	81		10.1056/NEJM199601113340203	http://dx.doi.org/10.1056/NEJM199601113340203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531962				2022-12-01	WOS:A1996TP36300003
J	Zinner, E				Zinner, E			Stardust in the laboratory	SCIENCE			English	Editorial Material							INTERSTELLAR GRAINS; METEORITES; GRAPHITE		WASHINGTON UNIV,DEPT PHYS,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT EARTH & PLANETARY SCI,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)	Zinner, E (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130, USA.							ALEXANDER CMO, 1993, GEOCHIM COSMOCHIM AC, V57, P2869, DOI 10.1016/0016-7037(93)90395-D; AMARI S, 1990, NATURE, V345, P238, DOI 10.1038/345238a0; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; BERNATOWICZ T, UNPUB; BOOTHROYD AI, 1994, ASTROPHYS J, V430, pL77, DOI 10.1086/187442; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CAMERON AGW, 1957, 1CRL41 AT EN CAN REP; EBISUZAKI T, 1989, ASTROPHYS J, V344, pL65, DOI 10.1086/185532; GALLINO R, 1994, ASTROPHYS J, V430, P858, DOI 10.1086/174457; HOPPE P, 1994, ASTROPHYS J, V430, P870, DOI 10.1086/174458; HUSS GR, 1994, ASTROPHYS J, V430, pL81, DOI 10.1086/187443; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; NITTLER L, 1995, NUCLEI COSMOS, V3, P585; NITTLER LR, 1994, NATURE, V370, P443, DOI 10.1038/370443a0; NITTLER LR, 1995, ASTROPHYS J, V453, pL25, DOI 10.1086/309743; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; SRINIVASAN G, 1994, ASTROPHYS J, V431, pL67, DOI 10.1086/187474; WASSERBURG GJ, 1995, ASTROPHYS J, V440, pL101, DOI 10.1086/187771; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; ZINNER E, 1995, LUNAR PLANET SCI, V26, P1561; ZINNER E, 1995, NUCLEI COSMOS, V3, P567	24	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					41	42		10.1126/science.271.5245.41	http://dx.doi.org/10.1126/science.271.5245.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539598				2022-12-01	WOS:A1996TP02200034
J	Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J				Hunt, JF; Weaver, AJ; Landry, SJ; Gierasch, L; Deisenhofer, J			The crystal structure of the GroES co-chaperonin at 2.8 angstrom resolution	NATURE			English	Article							PROTEIN STRUCTURES; SURFACE; COOPERATIVITY; HYDROLYSIS; INTERFACES; BINDING; CYCLE	The GroES heptamer forms a dome, approximately 75 Angstrom in diameter and 30 Angstrom high, with an 8 Angstrom orifice in the centre of its roof. The 'mobile loop' segment, previously identified as a GroEL binding determinant, is disordered in the crystal structure in six subunits; the single well-ordered copy extends from the bottom outer rim of the GroES dome, suggesting that the cavity within the dome is continuous with the polypeptide binding chamber of GroEL in the chaperonin complex.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hunt, JF (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.		Landry, Samuel/AAK-5778-2020; Gierasch, Lila M/D-1494-2009	Landry, Samuel/0000-0002-4082-0543; 				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1994, CURR BIOL, V2, P1125; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LORIMER GH, 1994, STRUCTURE, V2, P1125, DOI 10.1016/S0969-2126(94)00114-6; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MERNITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Seale JW, 1995, J BIOL CHEM, V270, P30268, DOI 10.1074/jbc.270.51.30268; STEIGERMANN W, 1991, INT UNION CRYSTALLOG, V5, P115; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	53	388	394	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					37	45		10.1038/379037a0	http://dx.doi.org/10.1038/379037a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538739				2022-12-01	WOS:A1996TN21600047
J	BUSCIGLIO, J; YANKNER, BA				BUSCIGLIO, J; YANKNER, BA			APOPTOSIS AND INCREASED GENERATION OF REACTIVE OXYGEN SPECIES IN DOWNS-SYNDROME NEURONS IN-VITRO	NATURE			English	Article							ALZHEIMER-DISEASE; CEREBRAL-CORTEX; HUMAN-FETUS; CELLS; GOLGI; DEATH; BRAIN	DOWN'S syndrome (DS) or trisomy 21 is the most common genetic cause of mental retardation(1). Development of the DS brain is associated with decreased neuronal number and abnormal neuronal differentiation(2-7), and adults with DS develop Alzheimer's disease(8,9). The cause of the neurodegenerative process in DS is unknown. Here we report that cortical neurons from fetal DS and age-matched normal brain differentiate normally in culture, but DS neurons subsequently degenerate and undergo apoptosis whereas normal neurons remain viable. Degeneration of DS neurons is prevented by treatment with free-radical scavengers or catalase. Furthermore, DS neurons exhibit a three- to fourfold increase in intracellular reactive oxygen species and elevated levels of lipid peroxidation that precede neuronal death. These results suggest that DS neurons have a defect in the metabolism of reactive oxygen species that causes neuronal apoptosis. This defect may contribute to mental retardation early in life and predispose to Alzheimer's disease in adults.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital								BASS DA, 1983, J IMMUNOL, V130, P1910; BECKER L, 1991, PROG CLIN BIOL RES, V373, P133; BROOKSBANK BWL, 1984, DEV BRAIN RES, V16, P37, DOI 10.1016/0165-3806(84)90060-9; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; COLON EJ, 1972, NEUROPADIATRIE, V3, P362, DOI 10.1055/s-0028-1091775; COYLE JT, 1986, BRAIN RES BULL, V16, P773, DOI 10.1016/0361-9230(86)90074-2; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; LAI F, 1989, ARCH NEUROL-CHICAGO, V46, P849, DOI 10.1001/archneur.1989.00520440031017; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; MARINPAD.M, 1972, BRAIN RES, V44, P625, DOI 10.1016/0006-8993(72)90324-1; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; PETIT TL, 1984, EXP NEUROL, V83, P13, DOI 10.1016/0014-4886(84)90041-4; ROSS MH, 1984, NEUROLOGY, V34, P909, DOI 10.1212/WNL.34.7.909; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; TAKASHIMA S, 1981, BRAIN RES, V225, P1, DOI 10.1016/0006-8993(81)90314-0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; [No title captured]	26	610	623	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					776	779		10.1038/378776a0	http://dx.doi.org/10.1038/378776a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524410				2022-12-01	WOS:A1995TL41900025
J	WAGNER, J; LERNER, RA; BARBAS, CF				WAGNER, J; LERNER, RA; BARBAS, CF			EFFICIENT ALDOLASE CATALYTIC ANTIBODIES THAT USE THE ENAMINE MECHANISM OF NATURAL ENZYMES	SCIENCE			English	Article							LEWIS ACID; DEOXYRIBOSE-5-PHOSPHATE ALDOLASE; ACYCLIC STEREOSELECTION; CHIRAL ALDEHYDES; CONDENSATION; ADDITIONS	Antibodies that catalyze the aldol reaction, a basic carbon-carbon bond-forming reaction, have been generated. The mechanism for antibody catalysis of this reaction mimics that used by natural class I aldolase enzymes. Immunization with a reactive compound covalently trapped a Lys residue in the binding pocket of the antibody by formation of a stable vinylogous amide. The reaction mechanism for the formation of the covalent antibody-hapten complex was recruited to catalyze the aldol reaction. The antibodies use the epsilon-amino group of Lys to form an enamine with ketone substrates and use this enamine as a nascent carbon nucleophile to attack the second substrate, an aldehyde, to form a new carbon-carbon bond. The antibodies control the diastereofacial selectivity of the reaction in both Cram-Felkin and anti-Cram-Felkin directions.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCI NIH HHS [CA27489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACH T, 1994, ANGEW CHEM INT EDIT, V33, P417, DOI 10.1002/anie.199404171; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1990, J AM CHEM SOC, V112, P2013, DOI 10.1021/ja00161a064; Bednarski M. D., 1991, COMPREHENSIVE ORGANI, V2, P455; CARREIRA EM, 1995, J AM CHEM SOC, V117, P3649, DOI 10.1021/ja00117a049; CHEN LR, 1992, J AM CHEM SOC, V114, P741, DOI 10.1021/ja00028a050; CHEREST M, 1968, TETRAHEDRON LETT, P2199; CRAM DJ, 1952, J AM CHEM SOC, V74, P5828, DOI 10.1021/ja01143a007; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; EVANS DA, 1988, SCIENCE, V240, P420, DOI 10.1126/science.3358127; EVANS DA, 1982, TOP STEREOCHEM, V13, P1, DOI DOI 10.1002/9780470147221.CHL; FURUTA K, 1991, J AM CHEM SOC, V113, P1041, DOI 10.1021/ja00003a047; GIJSEN HJM, 1995, J AM CHEM SOC, V117, P2947, DOI 10.1021/ja00115a038; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; Heathcock C. H., 1990, ALDRICHIM ACTA, V23, P99; HEATHCOCK CH, 1983, J AM CHEM SOC, V105, P1667, DOI 10.1021/ja00344a050; HEATHCOCK CH, 1981, SCIENCE, V214, P395, DOI 10.1126/science.214.4519.395; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JEFREY T, 1984, J CHEM SOC CHEM COMM, P1287; KOBAYASHI S, 1993, TETRAHEDRON, V49, P1761, DOI 10.1016/S0040-4020(01)80533-0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LODGE EP, 1987, J AM CHEM SOC, V109, P3353, DOI 10.1021/ja00245a027; MASAMUNE S, 1985, ANGEW CHEM INT EDIT, V24, P1, DOI 10.1002/anie.198500013; MORIYASU M, 1986, J CHEM SOC PERK T 2, P515, DOI 10.1039/p29860000515; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PATERSON I, 1992, PURE APPL CHEM, V64, P1821, DOI 10.1351/pac199264121821; PRETSCH E, 1989, TABLES SPECTRAL DATA, pU20; REYMOND JL, 1995, TETRAHEDRON LETT, V36, P2575, DOI 10.1016/0040-4039(95)00343-B; RUTTER WJ, 1964, FED PROC, V23, P1248; TAGAKI W, 1968, BIOCHEMISTRY-US, V7, P905, DOI 10.1021/bi00843a004; Trost B. M., 1993, COMPREHENSIVE ORGANI, V2, p[133, 181], DOI DOI 10.1016/B978-0-08-052349-1.00027-5; WIRSCHING P, IN PRESS SCIENCE; WONG CH, 1995, J AM CHEM SOC, V117, P3333, DOI 10.1021/ja00117a003; WONG CH, 1994, ENZYMES SYNTHETIC OR; ZIMMERMAN HE, 1957, J AM CHEM SOC, V79, P1920, DOI 10.1021/ja01565a041; [No title captured]	39	393	405	0	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1797	1800		10.1126/science.270.5243.1797	http://dx.doi.org/10.1126/science.270.5243.1797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	TK476	8525368				2022-12-01	WOS:A1995TK47600038
J	WU, CY; KEIVENS, VM; OTOOLE, TE; MCDONALD, JA; GINSBERG, MH				WU, CY; KEIVENS, VM; OTOOLE, TE; MCDONALD, JA; GINSBERG, MH			INTEGRIN ACTIVATION AND CYTOSKELETAL INTERACTION ARE ESSENTIAL FOR THE ASSEMBLY OF A FIBRONECTIN MATRIX	CELL			English	Article							STIMULATED HUMAN-PLATELETS; IIB-IIIA COMPLEX; MONOCLONAL-ANTIBODIES; PLASMA FIBRONECTIN; CYTOPLASMIC DOMAIN; CELL-ADHESION; GPIIB-IIIA; EXTRACELLULAR-MATRIX; FIBRINOGEN RECEPTOR; AFFINITY MODULATION	Fibronectin (Fn) matrices are vital to vertebrate development and wound healing and modulate tumorigenesis. We used a recombinant Fn-binding integrin, alpha(IIb)beta(3), to define rules for integrin-initiated Fn matrix formation. We report the following. First, multiple Fn-binding integrins can support matrix assembly; their activation state controls fibrillogenesis. Second, Fn binding to cells expressing an activated integrin is necessary but not sufficient for matrix assembly. Additional ''postoccupancy'' events involving the integrin beta, but not the alpha subunit, cytoplasmic domain are needed. Third, these postoccupancy events require an intact actin cytoskeleton. We propose a model for integrin involvement in Fn fibrillogenesis that reconciles previous paradoxes and suggests novel approaches to the therapeutic control of Fn matrix assembly.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	WU, CY (corresponding author), MAYO CLIN, DEPT BIOCHEM & MOLEC BIOL, 13400 E SHEA BLVD, SCOTTSDALE, AZ 85259 USA.		O'Toole, Timothy/I-4172-2013					AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; AOTA S, 1994, J BIOL CHEM, V269, P24756; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BOUCAUT J-C, 1990, International Journal of Developmental Biology, V34, P139; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CLARK RAF, 1985, PLASMA FIBRONECTIN S, P197; CRITCHLEY DR, 1979, NATURE, V280, P498, DOI 10.1038/280498a0; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes R O, 1978, Ann N Y Acad Sci, V312, P317, DOI 10.1111/j.1749-6632.1978.tb16811.x; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KESKIOJA J, 1976, FEBS LETT, V71, P325, DOI 10.1016/0014-5793(76)80962-3; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WENNERBERG K, 1995, IN PRESS J CELL BIOL; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WOODS VL, 1984, BLOOD, V63, P368; WU CY, 1995, J CELL SCI, V108, P2511; WU CY, 1993, J BIOL CHEM, V268, P21883; YANG JT, 1993, DEVELOPMENT, V119, P1093; YIANNE J, 1993, J CELL BIOL, V122, P223; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	72	303	310	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					715	724		10.1016/0092-8674(95)90184-1	http://dx.doi.org/10.1016/0092-8674(95)90184-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521488	Bronze			2022-12-01	WOS:A1995TH94800008
J	TSUJII, M; DUBOIS, RN				TSUJII, M; DUBOIS, RN			ALTERATIONS IN CELLULAR ADHESION AND APOPTOSIS IN EPITHELIAL-CELLS OVEREXPRESSING PROSTAGLANDIN-ENDOPEROXIDE-SYNTHASE-2	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; FAMILIAL ADENOMATOUS POLYPOSIS; E-CADHERIN EXPRESSION; COLON CARCINOGENESIS; RECTAL ADENOMAS; SODIUM-BUTYRATE; REDUCED RISK; ASPIRIN USE; CANCER; SULINDAC	Prostaglandin endoperoxide synthase 2, also referred to as cyclooxygenase 2 (COX-2), is a key enzyme in the conversion of arachidonic acid to prostaglandins and other eicosanoids. Rat intestinal epithelial (RIE) cells were permanently transfected with a COX-2 expression vector oriented in the sense (RIE-S) or antisense (RIE-AS) direction. The RIE-S cells expressed elevated COX-2 protein levels and demonstrated increased adhesion to extracellular matrix (ECM) proteins. E-cadherin was undetectable in RIE-S cells, but was elevated in parental RIE (RIE-P) and RIE-AS cells. RIE-S cells were resistant to butyrate-induced apoptosis, had elevated BCL2 protein expression, and reduced transforming growth factor beta 2 receptor levels. The phenotypic changes involving both increased adhesion to ECM and inhibition of apoptosis were reversed by sulindac sulfide (a COX inhibitor). These studies demonstrate that overexpression of COX-2 leads to phenotypic changes in intestinal epithelial cells that could enhance their tumorigenic potential.	VANDERBILT UNIV,MED CTR,VET AFFAIRS MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	TSUJII, M (corresponding author), VANDERBILT UNIV,MED CTR,VET AFFAIRS MED CTR,DEPT MED,NASHVILLE,TN 37232, USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R37DK047297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47297-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BRONSTEIN JC, 1993, PROSTAGLANDINS, V46, P387, DOI 10.1016/0090-6980(93)90075-I; CARROLL KM, 1988, AM J PHYSIOL, V254, pG355, DOI 10.1152/ajpgi.1988.254.3.G355; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1047, DOI 10.1152/ajpgi.1992.262.6.G1047; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FU JY, 1990, J BIOL CHEM, V265, P16737; GENG Y, 1995, J IMMUNOL, V155, P796; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAGUE A, 1994, ONCOGENE, V9, P3367; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HODIN RA, 1994, AM J PHYSIOL, V266, pG83, DOI 10.1152/ajpgi.1994.266.1.G83; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KARGMAN SL, 1995, CANCER RES, V55, P2556; KLEIN T, 1994, BIOCHEM PHARMACOL, V48, P1605, DOI 10.1016/0006-2952(94)90205-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MARNETT LJ, 1992, CANCER RES, V52, P5575; MAYER B, 1993, CANCER RES, V53, P1690; MEADE EA, 1993, J BIOL CHEM, V268, P6610; OKA H, 1993, CANCER RES, V53, P1696; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1992, CARCINOGENESIS, V13, P1019, DOI 10.1093/carcin/13.6.1019; REDDY BS, 1987, CANCER RES, V47, P5340; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WINDE G, 1993, INT J COLORECTAL DIS, V8, P13, DOI 10.1007/BF00341270	54	2030	2154	0	63	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					493	501		10.1016/0092-8674(95)90127-2	http://dx.doi.org/10.1016/0092-8674(95)90127-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521479	Bronze			2022-12-01	WOS:A1995TC97700019
J	HE, ZG; BRINTON, BT; GREENBLATT, J; HASSELL, JA; INGLES, CJ				HE, ZG; BRINTON, BT; GREENBLATT, J; HASSELL, JA; INGLES, CJ			THE TRANSACTIVATOR PROTEIN-VP16 AND PROTEIN-GAL4 BIND REPLICATION FACTOR-A	CELL			English	Article							DNA-POLYMERASE-ALPHA; HERPES-SIMPLEX VIRUS; TRANSCRIPTIONAL ACTIVATION DOMAIN; ORIGIN AUXILIARY SEQUENCES; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; T-ANTIGEN; EUKARYOTIC TRANSCRIPTION; INVITRO REPLICATION; ESCHERICHIA-COLI	Many transcription factors can activate the initiation of DNA replication. We have used affinity chromatography to show that the acidic activation domains of the transcription factors VP16, GAL4, and p53 each bind selectively to human and yeast replication factor A (RPA). The binding is direct and to the largest subunit of the trimeric RPA complex, RPA-1. Mutations in VP16 that reduce the ability of GAL4-VP16 to activate polyomavirus DNA replication also compromise the binding of VP16 to RPA. We suggest that transcription factors may interact with RPA either to stabilize single-stranded DNA at a replication origin or to recruit DNA polymerase alpha to the replication initiation complex.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5S 1A1,ONTARIO,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON L8S 4K1,ONTARIO,CANADA	University of Toronto; McMaster University	HE, ZG (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA.							AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOSHER J, 1990, New Biologist, V2, P1083; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; Coulombe Benoit, 1992, Gene Expression, V2, P99; COUSENS DJ, 1989, EMBO J, V8, P237; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; GUTIERREZ C, 1990, MOL CELL BIOL, V10, P1719, DOI 10.1128/MCB.10.4.1719; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOANG AT, 1992, MOL CELL BIOL, V12, P3087, DOI 10.1128/MCB.12.7.3087; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MELANDY T, 1993, J BIOL CHEM, V268, P3389; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOOS M, 1988, J BIOL CHEM, V263, P6005; MULLER WJ, 1988, MOL CELL BIOL, V8, P5000, DOI 10.1128/MCB.8.11.5000; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHULTZ MC, 1992, GENE DEV, V6, P1332, DOI 10.1101/gad.6.7.1332; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SETO YS, 1993, P NATL ACAD SCI USA, V90, P2865; SKELLY S, 1987, P NATL ACAD SCI USA, V84, P8365, DOI 10.1073/pnas.84.23.8365; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOPTA M, 1985, J BIOL CHEM, V260, P353; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UMBRICHT CB, 1983, J BIOL CHEM, V268, P6131; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VERRIJZER CP, 1992, NUCLEIC ACIDS RES, V20, P6369, DOI 10.1093/nar/20.23.6369; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	89	209	209	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1223	1232		10.1016/0092-8674(93)90650-F	http://dx.doi.org/10.1016/0092-8674(93)90650-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513504				2022-12-01	WOS:A1993LH54800017
J	GERSTEIN, RM; LIEBER, MR				GERSTEIN, RM; LIEBER, MR			EXTENT TO WHICH HOMOLOGY CAN CONSTRAIN CODING EXON JUNCTIONAL DIVERSITY IN V(D)J RECOMBINATION	NATURE			English	Article							STREPTOCOCCUS-PNEUMONIAE; GENE REARRANGEMENT; JOINING SIGNALS; IMMUNE-SYSTEM; ANTIBODIES; PHOSPHORYLCHOLINE; PHOSPHOCHOLINE; CELL; INSERTION; SEQUENCES	AMONG site-directed DNA recombination systems, V(D)J recombination is noteworthy in that identical reactants yield different recombination products at the junction of joined segments. This variation is the basis for diversity at the base of antigen receptor binding pockets and corresponds to V-(D)-J DNA junctions. An abundance of certain junctions has been noted1-5. It has been proposed that these junctions are favoured because they occur where short regions of homology in participating coding ends might align preferentially1. Here we use a system that is entirely free from cellular selection to show that the diversity of coding joints can be severely restricted when the coding ends participating in the reaction have short regions of homology. This constraint on diversity is diminished but not eliminated by terminal deoxynucleotidyl transferase, a mechanistic feature that has implications for the establishment of the immune repertoire.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University				Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; CLAFLIN JL, 1988, J IMMUNOL, V141, P4012; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1988, J IMMUNOL, V141, P1267; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; GEARHART PJ, 1981, NATURE, V291, P29, DOI 10.1038/291029a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HERZENBERG LA, 1989, CELL, V59, P953, DOI 10.1016/0092-8674(89)90748-4; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LAL RB, 1987, J IMMUNOL, V138, P3454; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, IN PRESS MOL CELL BI; POLLOK BA, 1984, NATURE, V311, P376, DOI 10.1038/311376a0; POTTER M, 1971, ANN NY ACAD SCI, V190, P306, DOI 10.1111/j.1749-6632.1971.tb13543.x; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	29	97	98	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 17	1993	363	6430					625	627		10.1038/363625a0	http://dx.doi.org/10.1038/363625a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510753				2022-12-01	WOS:A1993LH13900055
J	MANSER, E; LEUNG, T; SALIHUDDIN, H; TAN, L; LIM, L				MANSER, E; LEUNG, T; SALIHUDDIN, H; TAN, L; LIM, L			A NONRECEPTOR TYROSINE KINASE THAT INHIBITS THE GTPASE ACTIVITY OF P21(CDC42)	NATURE			English	Article							MOLECULAR-CLONING; PROTEIN; GENE; PRODUCT; YEAST; BCR; RAS	THE Ras-related Rho subfamily of GTP-binding proteins (p21s), which includes Rho, Rac and Cdc42Hs, is implicated in different aspects of cytoskeletal organization1,2. These proteins behave like Ras (p21ras) in that their active GTP-bound form is inactivated by intrinsic hydrolysis of the nucleotide gamma-phosphate, which can be stimulated by GTPase-activating proteins (GAPs). We have previously shown that there is a diversity of GAPs that recognize this subfamily3, including n-chimaerin, which is enriched in the hippocampus4; we also detected proteins that bind these p21 proteins and seem to inhibit GTP hydrolysis. We now report the characterization of a hippocampal complementary DNA encoding a tyrosine kinase that specifically binds Cdc42Hs in its GTP-bound form. This binding is mediated by a unique sequence of 47 amino acids C-terminal to an SH3 domain and inhibits both the intrinsic and GAP-stimulated GTPase activity of Cdc42Hs. Our findings indicate that there may be a regulatory mechanism that sustains the GTP-bound active form of Cdc42Hs and which is directly linked to a tyrosine phosphorylation pathway.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	MANSER, E (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1990, J BIOL CHEM, V265, P590; LEE KL, 1989, ARCH BIOCHEM BIOPHYS, V269, P106, DOI 10.1016/0003-9861(89)90091-X; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442	22	282	290	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					364	367		10.1038/363364a0	http://dx.doi.org/10.1038/363364a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497321				2022-12-01	WOS:A1993LD91700058
J	SMAS, CM; SUL, HS				SMAS, CM; SUL, HS			PREF-1, A PROTEIN CONTAINING EGF-LIKE REPEATS, INHIBITS ADIPOCYTE DIFFERENTIATION	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; ENHANCER BINDING-PROTEIN; INDUCED GENE-EXPRESSION; ADIPOSE CELL LINE; 3T3-L1 PREADIPOCYTES; DROSOPHILA-NOTCH; MESSENGER-RNAS; NUCLEOTIDE-SEQUENCE; BLOOD-COAGULATION; FACTOR-ALPHA	With the aim of identifying novel regulators of adipocyte differentiation, we have cloned and characterized preadipocyte factor 1 (pref-1), a novel member of the epidermal growth factor (EGF)-like family of proteins. Pref-1 is synthesized as a transmembrane protein with six tandem EGF-like repeats. In preadipocytes, multiple discrete forms of pref-1 protein of 45-60 kd are present, owing in part to N-linked glycosylation. While pref-1 mRNA is abundant in preadipocytes, its expression is completely abolished during differentiation of 3T3-L1 preadipocytes to adipocytes. Moreover, constitutive expression of pref-1 in preadipocytes, which in effect blocks its down-regulation, drastically inhibits adipose differentiation. This indicates that pref-1 functions asa negative regulator of adipocyte differentiation, possibly in a manner analogous to EGF-like proteins that govern cell fate decisions in invertebrates.			SMAS, CM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA.		Han, Zaiqi/AAI-2233-2019					ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; CALVO JC, 1991, CAMPJ, V266, P11237; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DANI C, 1989, J BIOL CHEM, V264, P10119; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DJIAN P, 1988, GENE DEV, V2, P1251, DOI 10.1101/gad.2.10.1251; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Maniatis T, 1989, MOL CLONING; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; NIES DE, 1991, J BIOL CHEM, V266, P2818; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SIDHU RS, 1979, J BIOL CHEM, V254, P1111; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WENZ HM, 1992, P NATL ACAD SCI USA, V89, P1065, DOI 10.1073/pnas.89.3.1065; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WISE LS, 1984, J BIOL CHEM, V259, P4827; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	75	551	576	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					725	734		10.1016/0092-8674(93)90252-L	http://dx.doi.org/10.1016/0092-8674(93)90252-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500166				2022-12-01	WOS:A1993LD83000011
J	BROCKLEHURST, JC				BROCKLEHURST, JC			URINARY-INCONTINENCE IN THE COMMUNITY - ANALYSIS OF A MORI POLL	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; WOMEN; HOME	Objectives-To investigate the prevalence of urinary incontinence among people living at home, their responses to it, and its emotional and social effects. Design-Random sample of 4007 adults interviewed in their own homes. Setting-Random sample of 178 constituency sampling points throughout Great Britain. Subjects-1883 men, 2124 women aged 30 and over. Main outcome measures-Responses to questionnaire. Results-6.6% (125) men and 14.0% (297) women had been incontinent of urine at some time-2.8% (52) men and 7.5% (159) women in the previous two months and 61% (124) of these for more than four years. 52% (108) had consulted their general practitioner at the onset of incontinence and a further 31% (65) later. Doctors commonly took a urine sample (163, 54%), referred the patient to a specialist (127, 42%), and prescribed tablets (109, 36%); only 22% (66) carried out an abdominal, rectal, or vaginal examination. Patients were not embarrassed in seeing their doctor and most thought they were treated sympathetically. 60% (265) of all those affected were concerned or worried about their incontinence, and in almost half incontinence limited their daily social activities. Conclusion-More people with incontinence seem to be consulting their doctors about it than has been found in previous studies, but the procedures carried out by general practitioners still seem to be suboptimal. Urinary incontinence has a profound effect on the day to day lives of most of those who suffer from it.			BROCKLEHURST, JC (corresponding author), PRISM INT,BRITISH ASSOC CONTINENCE CARE,PINEWOOD STUDIOS,IVER HEATH SL0 0NH,BUCKS,ENGLAND.							BATES P, 1979, J UROLOGY, V121, P551, DOI 10.1016/S0022-5347(17)56874-3; BRIGGS M, 1992, BRIT MED J, V304, P255, DOI 10.1136/bmj.304.6821.255; BROCKLEHURST J C, 1972, Age and Ageing, V1, P41, DOI 10.1093/ageing/1.1.41; JOLLEYS JV, 1988, BRIT MED J, V296, P1300, DOI 10.1136/bmj.296.6632.1300; MCGROTHER CW, 1987, AGE AGEING, V16, P105, DOI 10.1093/ageing/16.2.105; NEMIR A, 1954, AM J OBSTET GYNECOL, V68, P1166; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243; VETTER NJ, 1981, LANCET, V2, P1275; WELLS T, 1984, UROLOGY ELDERLY, P119; WOLLIN LH, 1969, J UROLOGY, V101, P545; WYMAN JF, 1987, OBSTET GYNECOL, V70, P378	13	215	218	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					832	834		10.1136/bmj.306.6881.832	http://dx.doi.org/10.1136/bmj.306.6881.832			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490377	Bronze, Green Published			2022-12-01	WOS:A1993KV34800023
J	Godecke, I; Bonhoeffer, T				Godecke, I; Bonhoeffer, T			Development of identical orientation maps for two eyes without common visual experience	NATURE			English	Article							CROSS-CORRELATION; STRIATE CORTEX; ORGANIZATION; SELECTIVITY; POTENTIALS; DOMAINS; AREA-18; CELLS	IN the mammalian visual cortex, many neurons are driven binocularly and response properties such as orientation preference or spatial frequency tuning are virtually identical for the two eyes(1). A precise match of orientation is essential in order to detect disparity and is therefore a prerequisite for stereoscopic vision. It is not clear whether this match is accomplished by activity-dependent mechanisms together wit the common visual experience normally received by the eyes(2,3), or whether the visual system relies on other, perhaps even innate, cues to achieve this task(4-7). Here we test whether visual experience is responsible for the match in a reverse-suturing experiment in which kittens were raised so that both eyes were never able to see at the same time. A comparison of the layout of the two maps formed under these conditions showed them to be virtually identical. Considering that the two eyes never had common visual experience, this indicates that correlated visual input is not required for the alignment of orientation preference maps.	MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BONHOEFFER T, 1995, CHALLENGES PERSPECTI, P117; BRAASTAD BO, 1985, J NEUROPHYSIOL, V53, P1158, DOI 10.1152/jn.1985.53.5.1158; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CROOK JM, 1992, J NEUROSCI, V12, P1816; FERSTER D, 1986, J NEUROSCI, V6, P1284; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306	25	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					251	254		10.1038/379251a0	http://dx.doi.org/10.1038/379251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538789				2022-12-01	WOS:A1996TQ16900045
J	Last, EC				Last, EC			For Corrie	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1996	124	2					271	272		10.7326/0003-4819-124-2-199601150-00016	http://dx.doi.org/10.7326/0003-4819-124-2-199601150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ016	8534008				2022-12-01	WOS:A1996TQ01600016
J	GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB				GlucksmannKuis, MA; Dai, X; Markiewicz, P; RothmanDenes, LB			E-coli SSB activates N4 virion RNA polymerase promoters by stabilizing a DNA hairpin required for promoter recognition	CELL			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; PURIFICATION; REPLICATION; INITIATION	Bacteriophage N4 virion RNA polymerase transcription of double-stranded promoter-containing DNAs requires supercoiled template and E. coli single-stranded DNA-binding protein (EcoSSB); other single-stranded DNA-binding proteins cannot substitute. The DNA determinants of virion RNA polymerase binding at the promoter comprise a small template-strand hairpin. The requirement for EcoSSB is surprising, since single-stranded DNA-binding proteins destabilize hairpin structures. DNA footprinting of EcoSSB on wild-type and mutant promoters indicates that EcoSSB stabilizes the template-strand hairpin owing to the hairpin-loop sequences. Other single-stranded DNA-binding proteins destabilize the promoter hairpin, explaining the specificity of EcoSSB activation. We conclude that EcoSSB activates transcription by providing the appropriate DNA structure for polymerase binding. The existence of small hairpins stable to single-stranded protein binding suggests a novel mechanism that provides structural determinants for specific recognition in single-stranded DNA transactions by an otherwise nonspecific DNA-binding protein.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago	GlucksmannKuis, MA (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007099, R01AI012575] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI12575, 5T32 AI 07099] Funding Source: Medline; NIGMS NIH HHS [GM08369] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1995, NATURE, V374, P371; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BENZ EW, 1983, MECHANISTIC STUDIES, P279; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P130; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P320; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIRAO I, 1994, NUCLEIC ACIDS RES, V22, P576, DOI 10.1093/nar/22.4.576; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KIM YT, 1992, J BIOL CHEM, V267, P15022; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.bi.63.070194.002523; LONBERG N, 1981, J MOL BIOL, V145, P122; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; Maxam A M, 1980, Methods Enzymol, V65, P499; POOM R, 1977, BIOCHEMISTRY-US, V16, P486; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SUN W, 1994, J BIOL CHEM, V268, P8026; VOLOGODSKII A, 1992, TOPOLOGY PHYSICS CIR, P105; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	32	57	59	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					147	154		10.1016/S0092-8674(00)81001-6	http://dx.doi.org/10.1016/S0092-8674(00)81001-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548819	Bronze			2022-12-01	WOS:A1996TQ17000017
J	Koelle, MR; Horvitz, HR				Koelle, MR; Horvitz, HR			EGL-10 regulates G protein signaling in the C-elegans nervous system and shares a conserved domain with many mammalian proteins	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; MOTOR NEURONS; A-FACTOR; MUTANTS; RECEPTOR; TRANSDUCIN; PHOSDUCIN	The frequencies of certain periodic behaviors of the nematode C. elegans are regulated in a dose-dependent manner by the activity of the gene egl-10. These behaviors are modulated oppositely by the activity of the G protein alpha subunit gene goa-1, suggesting that egl-10 may regulate a G protein signaling pathway in a dose-dependent fashion. egl-10 encodes a protein similar to Sst2p, a negative regulator of G protein signaling in yeast. EGL-10 protein is localized in neural processes, where it may function in neurotransmitter signaling. Two previously known and 13 newly identified mammalian genes have similarity to egl-10 and SST2, and we propose that members of this family regulate many G protein signaling pathways.			Koelle, MR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BAILEY CH, 1994, ADV SEC MESS PHOSPH, V29, P529; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; BRENNER S, 1974, GENETICS, V77, P71; Catty D., 1988, ANTIBODIES PRACTICAL; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CROLL NA, 1975, J ZOOL, V176, P159, DOI 10.1111/j.1469-7998.1975.tb03191.x; DESAI C, 1989, GENETICS, V121, P703; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; Hille B., 1992, IONIC CHANNELS EXCIT; HONG JX, 1993, J IMMUNOL, V150, P3895; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KURJAN J, 1993, ANNU REV GENET, V27, P147; LEE BN, 1994, MOL MICROBIOL, V14, P323, DOI 10.1111/j.1365-2958.1994.tb01293.x; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sambrook J., 1989, MOL CLONING LAB MANU; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; THOMAS JH, 1990, GENETICS, V124, P855; TRENT C, 1983, GENETICS, V104, P619; Trent C, 1983, THESIS MIT; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB, 1988, NEMATODE CAENORHABDI	47	489	507	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					115	125		10.1016/S0092-8674(00)80998-8	http://dx.doi.org/10.1016/S0092-8674(00)80998-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548815	Bronze			2022-12-01	WOS:A1996TQ17000014
J	Shore, MF; Beigel, A				Shore, MF; Beigel, A			The challenges posed by managed behavioral health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV ARIZONA, TUCSON, AZ 85721 USA	University of Arizona	Shore, MF (corresponding author), JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA.							HOLMES OW, 1861, CURRENTS COUNTER CUR, P7; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; MANDERSCHEID RW, 1990, DHHS ADM901708 PUBL, P14; SABIN JE, 1991, HOSP COMMUNITY PSYCH, V42, P605; SMITH ML, 1977, AM PSYCHOL, V32, P752, DOI 10.1037/0003-066X.32.9.752	5	33	33	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					116	118		10.1056/NEJM199601113340211	http://dx.doi.org/10.1056/NEJM199601113340211			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP363	8531945				2022-12-01	WOS:A1996TP36300011
J	Gohdes, D; RithNajarian, S; Acton, K; Shields, R				Gohdes, D; RithNajarian, S; Acton, K; Shields, R			Improving diabetes care in the primary health setting - The Indian Health Service experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			AMERICAN-INDIANS; COMPLICATIONS; PREVALENCE; MELLITUS; TRIAL	Purpose: To identify key systems issues from the Indian Health Service (IHS) experience that must be addressed to improve metabolic control among patients with noninsulin-dependent diabetes mellitus (NIDDM) who were followed in primary care settings. Data Sources: Records of diabetic patients seen in IHS facilities in specific geographic regions from 1987 to 1994. Study Selection: A representative-sample of charts from each facility was reviewed yearly to measure key variables. The sampling frame was the number of diabetic patients currently active on the registry and the sample size calculated to measure a 10% change in selected practices at each facility. Extraction: Regional diabetes coordinators reviewed charts or trained local providers to sample and extract data in a standard format. Results: Regional data were examined to show trends in the performance of immunizations and foot examinations and in other variables such as hypertension and metabolic control. The percentage of diabetic patients who received a single dose of pneumococcal vaccine improved from 24% in 1987 to 1988 to 57% in 1994 (P < 0.01 for trend) among diabetic patients in Minnesota, Wisconsin, and Michigan. Rates of yearly comprehensive foot examination increased from 36% to 58% (P < 0.01 for trend) over the same period. In Montana and Wyoming, the percentage of diabetic patients with uncontrolled hypertension (defined as the mean of three systolic blood pressure measurements of greater than or equal to 140 mm Hg or diastolic pressure measurements greater than or equal to 90 mm Hg, or both, during the previous year) decreased from 36% in 1992 to 25% in 1993 after the regional diabetes coordinator emphasized hypertension control. In 1994, when less emphasis was placed on hypertension, 33% of the diabetic patients had uncontrolled hypertension. Estimates of metabolic control from records of diabetic patients in Washington, Oregon, and Idaho in 1994 showed that 29% of patients had excellent metabolic control (a hemoglobin A(1c) [HbA(1c)] level less than or equal to 7.5% or mean blood glucose level less than or equal to 9.2 mmol/L) within the past year; only 9% experienced poor control (a HbA(1c) level > 12% or mean blood glucose level > 18.9 mmol/L). Conclusions: The IHS experience shows that standard, ongoing monitoring of key variables allows facilities to improve diabetes care. Simple, reliable methods of defining metabolic control combined with a feedback system in the primary care setting are needed to improve metabolic control in patients with NIDDM.	BEMIDJI AREA INDIAN HLTH SERV, BEMIDJI, MN 56601 USA; TRIBAL HLTH & HUMAN SERV, BILLINGS AREA DIABET PROGRAM, ST IGNATIUS, MT 59865 USA; PORTLAND AREA DIABET PROGRAM, BELLINGHAM, WA 98225 USA		Gohdes, D (corresponding author), INDIAN HLTH SERV, DIABET PROGRAM, 5300 HOMESTEAD RD NE, ALBUQUERQUE, NM 87110 USA.							ACTON K, 1993, DIABETES CARE, V16, P372, DOI 10.2337/diacare.16.1.372; BIRKE JA, 1986, LEPROSY REV, V57, P261; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; DUMAS J, 1994, DIABETES CARE, V17, P1227, DOI 10.2337/diacare.17.10.1227; FIELD M, 1992, I MED GUIDELINES CLI; GOHDES D, 1995, NEW ENGL J MED, V332, P269; GOHDES DM, 1986, DIABETES CARE, V9, P609, DOI 10.2337/diacare.9.6.609; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; LITTLE RR, 1992, CLIN CHEM, V38, P2472; LITTLE RR, 1991, CLIN CHEM, V37, P1725; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MAYFIELD JA, 1994, DIABETES CARE, V17, P918, DOI 10.2337/diacare.17.8.918; NAGAFUCHI S, 1993, DIABETES CARE, V16, P1408, DOI 10.2337/diacare.16.10.1408; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; NATHAN DM, 1994, DIABETES CARE, V17, P1228, DOI 10.2337/diacare.17.10.1228; RITHNAJARIAN SJ, 1992, DIABETES CARE, V15, P1386, DOI 10.2337/diacare.15.10.1386; SANTIAGO JV, 1993, DIABETES, V42, P1549, DOI 10.2337/diab.42.11.1549; SANTIAGO JV, 1994, DIABETES CARE, V17, P1229, DOI 10.2337/diacare.17.10.1229; SCHRAER C, 1995, DIABETES, V44, pA121; SCHRAER CD, 1993, DIABETES CARE, V16, P257, DOI 10.2337/diacare.16.1.257; 1989, MMWR-MORBID MORTAL W, V38, P73; 1994, NIH943530 US DEP HLT; 1994, GUIDE ADULT IMMUNIZA, P107; 1994, TRENDS INDIAN HLTH 1	27	23	23	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				149	152		10.7326/0003-4819-124-1_Part_2-199601011-00013	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554208				2022-12-01	WOS:A1996TL94400013
J	Quickel, KE				Quickel, KE			Diabetes in a managed care system	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			SERVICE; OUTCOMES; SETTINGS; PROGRAM; FEE	Health care expenditures account for over 14% of the gross domestic product in the United States. Managed care has evolved to control these costs. Because diabetes accounts for nearly 15% of health care expenditures, the strategies used by managed care organizations are expected to have a particular effect on diabetes. Managed care organizations have two primary goals: to control costs and to provide care of sufficient quality to attract and satisfy enrollees. Managed care organizations have designed strategies to meet these goals. Four primary managed care strategies and their effects on diabetes care are discussed: 1) payment incentives rewarding desired provider practice patterns; 2) designation of providers who possess desirable practice behaviors; 3) coverage policies that control the services paid for; and 4) traditional insurance strategies that determine who is eligible for insurance and what premiums are to be paid. The few direct studies of the effects of each strategy on the care of diabetic persons are discussed. The conclusion is that although managed care organizations have the potential to provide excellent care for diabetic persons, little evidence exists that they have improved either the quality or the cost-effectiveness of diabetes care. Recommendations to guide the development of cost-effective care for diabetic persons are presented.			Quickel, KE (corresponding author), JOSLIN DIABET CTR, 1 JOSLIN PL, BOSTON, MA 02215 USA.							CARTLAND JDC, 1992, PEDIATRICS, V89, P183; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; GEFFNER DL, 1992, DIABETES CARE, V15, P44, DOI 10.2337/diacare.15.1.S44; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KERTESZ L, 1995, MODERN HEALTHCA 0417, P17; LANGWELL K, 1992, CBO STAFF MEMORANDUM; LEVETAN CS, 1995, AM J MED, V99, P22, DOI 10.1016/S0002-9343(99)80100-4; LYTTLE C, 1989, ANN INTERN MED, V111, P604, DOI 10.7326/0003-4819-111-7-604; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MUHLHAUSER I, 1983, DIABETOLOGIA, V25, P470; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; PRASHKER MJ, 1991, ANN INTERN MED, V115, P715, DOI 10.7326/0003-4819-115-9-715; REDHEAD J, 1993, DIABETIC MED, V10, P672, DOI 10.1111/j.1464-5491.1993.tb00143.x; RETCHIN SM, 1991, ARCH INTERN MED, V151, P2244, DOI 10.1001/archinte.151.11.2244; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINNOCK P, 1986, J INSURANCE MED, V18, P24; SLEE VN, 1991, HLTH CARE TERMS; STARFIELD B, 1994, DIABETES CARE, V17, P12; STARR B, 1995, BUSINESS HLTH MAG SC, V13, P56; TAYLOR AK, 1987, DIABETES CARE, V10, P87, DOI 10.2337/diacare.10.1.87; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; VAUGHAN NJA, 1994, DIABETIC MED, V11, P418; WEINBERGER M, 1988, MED CARE, V26, P77, DOI 10.1097/00005650-198801000-00008; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; 1987, 3RD PARTY REIMBURSEM, V6, P1; 1992, CBO STUDY PROJECTION; 1994, DIABETES CARE S1, V2, P1555; 1993, DIRECT INDIRECT COST	34	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				160	163		10.7326/0003-4819-124-1_Part_2-199601011-00016	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554211				2022-12-01	WOS:A1996TL94400016
J	MORITZ, M; BRAUNFELD, MB; SEDAT, JW; ALBERTS, B; AGARD, DA				MORITZ, M; BRAUNFELD, MB; SEDAT, JW; ALBERTS, B; AGARD, DA			MICROTUBULE NUCLEATION BY GAMMA-TUBULIN-CONTAINING RINGS IN THE CENTROSOME	NATURE			English	Article								THE microtubule cytoskeleton of animal cells does not assemble spontaneously, but instead requires the centrosome. This organelle consists of a pair of centrioles surrounded by a complex collection of proteins known as the pericentriolar material (PCM)(1). The PCM is required for microtubule nucleation(2). The minus, or slow-growing, ends of microtubules are embedded in the PCM and the plus, or fast-growing, ends project outwards into the cytoplasm during interphase, or into the spindle apparatus during mitosis. gamma-Tubulin is the only component of the PCM that is so far implicated in microtubule nucleation(3-6). Here we use immune-electron microscopic tomography to show that gamma-tubulin is localized in ring structures in the PCM of purified centrosomes without microtubules. When these centrosomes are used to nucleate microtubule growth, gamma-tubulin is localized at the minus ends of the microtubules. We conclude that microtubule-nucleating sites within the PCM are ring-shaped templates that contain multiple copies of gamma-tubulin.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	MORITZ, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,513 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.			Moritz, Michelle/0000-0003-3811-5623				EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FELIX MA, 1994, J CELL BIOL, V24, P19; FUNG JC, IN PRESS J STRUCT BI; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Koster A. J., 1993, MICROSC SOC AM B, V23, P176; KOSTER AJ, 1992, ULTRAMICROSCOPY, V46, P207, DOI 10.1016/0304-3991(92)90016-D; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TILNEY LG, 1973, J CELL BIOL, V59, P267, DOI 10.1083/jcb.59.2.267; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	13	430	436	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					638	640		10.1038/378638a0	http://dx.doi.org/10.1038/378638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524401				2022-12-01	WOS:A1995TJ22100084
J	FARLEY, MM; HARVEY, RC; STULL, T; SMITH, JD; SCHUCHAT, A; WENGER, JD; STEPHENS, DS				FARLEY, MM; HARVEY, RC; STULL, T; SMITH, JD; SCHUCHAT, A; WENGER, JD; STEPHENS, DS			A POPULATION-BASED ASSESSMENT OF INVASIVE DISEASE DUE TO GROUP-B STREPTOCOCCUS IN NONPREGNANT ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METROPOLITAN ATLANTA; III POLYSACCHARIDE; CONJUGATE VACCINE; INFECTION; BACTEREMIA; MENINGITIS; INFANTS; WOMEN	Background. Group B streptococci (Streptococcus agalactiae) are a major cause of meningitis and septicemia in neonates and pregnant women, but the importance of group B streptococcal disease in nonpregnant adults has not been clearly defined. Methods. We conducted a prospective surveillance of the pathogens responsible for meningitis for a period of 24 months in 35 hospitals and a referral laboratory in metropolitan Atlanta. We reviewed the clinical and laboratory records of all the nonpregnant adults identified as having invasive group B streptococcal disease during this period. Results. During 1989 and 1990 there were 424 patients with invasive group B streptococcal disease (annual incidence, 9.2 cases per 1 00,000 population). Of these patients, 46 percent were 1 month of age or younger, 6 percent were older than 1 month but younger than 18 years of age, and 48 percent were 18 or older. Men and nonpregnant women accounted for 68 percent (n = 140) of all cases among adults (annual incidence, 4.4 per 100,000). Clinical and laboratory records were available for 137. In the nonpregnant adult patients (age, 18 to 99 years), the most common clinical diagnoses were skin, soft-tissue, or bone infection (in 36 percent); bacteremia with no identified source (30 percent); urosepsis (14 percent); pneumonia (9 percent); and peritonitis (7 percent). Risk factors included older age (greater-than-or-equal-to 60 years), the presence of diabetes meilitus, the presence of malignant neoplasms, and infection with the human immunodeficiency virus. The mortality rate in nonpregnant adults was 21 percent, accounting for 67 percent of all deaths related to group B streptococcal infection during the surveillance period. Conclusions. Invasive group B streptococcal infection is a major problem not only in pregnant women and neonates but also in nonpregnant adults, especially those who are elderly and those who have chronic diseases.	GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA	Emory University; Centers for Disease Control & Prevention - USA	FARLEY, MM (corresponding author), VET AFFAIRS MED CTR,1670 CLAIRMONT RD,DECATUR,GA 30033, USA.		Stephens, David S/A-8788-2012					BAKER CJ, 1981, PEDIATRICS, V68, P544; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAKER CJ, 1990, INFECT DIS, P742; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; EYKYN SJ, 1991, LANCET, V338, P446, DOI 10.1016/0140-6736(91)91069-7; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LERNER PI, 1975, J INFECT DIS, V131, pS9, DOI 10.1093/infdis/131.Supplement.S9; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; OPAL SM, 1988, ARCH INTERN MED, V148, P641, DOI 10.1001/archinte.148.3.641; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; VERGHESE A, 1986, REV INFECT DIS, V8, P912; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; ZANGWILLKM, 1992, MMWR MORB MORTAL WKL, V41, P25; 1992, DIABETES SURVEILLANC, P60; 1985, NEW VACCINE DEV ESTA, V2, P423; 1990, NCI FACT BOOK 1990, P46	25	387	398	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1807	1811		10.1056/NEJM199306243282503	http://dx.doi.org/10.1056/NEJM199306243282503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	8502269				2022-12-01	WOS:A1993LH21000003
J	GERMAIN, RN; RINKER, AG				GERMAIN, RN; RINKER, AG			PEPTIDE BINDING INHIBITS PROTEIN AGGREGATION OF INVARIANT-CHAIN FREE CLASS-II DIMERS AND PROMOTES SURFACE EXPRESSION OF OCCUPIED MOLECULES	NATURE			English	Article							HLA-DR MOLECULES; HISTOCOMPATIBILITY ANTIGENS; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODIES; CELL LINE; IA; ASSOCIATION; RECOGNITION; GENE; H-2	EFFICIENT egress of major histocompatibility complex (MHC) class I molecules from the endoplasmic reticulum (ER) depends on peptide binding1-7. For MHC class II molecules, invariant chain (Ii) promotes ER exit of newly assembled, peptide-free dimers8-14. This raises the question of whether a mechanism exists elsewhere in the cell that dictates selective expression of peptide-associated class II molecules. We report here that dissociation of MHC class II-Ii complexes at low pH and physiological temperature leads to inclusion of empty class II in protein aggregates, and that this aggregation is specifically prevented by peptide binding. Combined with data showing that antigen exposure increases cell surface class II expression on living cells by a post-translational mechanism12, these results provide evidence for peptide-dependent intracellular editing of class II dimers, which limits surface expression of empty molecules unsuitable for antigen-specific T-cell activation.			GERMAIN, RN (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CLAESSONWELSH L, 1985, J IMMUNOL, V135, P3551; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	37	162	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					725	728		10.1038/363725a0	http://dx.doi.org/10.1038/363725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515815				2022-12-01	WOS:A1993LJ33900057
J	CANO, RJ; POINAR, HN; PIENIAZEK, NJ; ACRA, A; POINAR, GO				CANO, RJ; POINAR, HN; PIENIAZEK, NJ; ACRA, A; POINAR, GO			AMPLIFICATION AND SEQUENCING OF DNA FROM A 120-135-MILLION-YEAR-OLD WEEVIL	NATURE			English	Article							EXTRACTION	DNA has been successfully isolated from both fossilized plant1 and animal tissues2-6. The oldest material, dated as 25-40 million years old (Tertiary), was obtained from amber-entombed been4,5 and termites6. Tissues from both these insects yielded DNA of good quality, which could be amplified by the polymerase chain reaction (PCR) and subsequently sequenced, including the genes encoding 18S ribosomal RNA5,6 and 16S rRNA6. We report here the extraction of DNA from a 120-135-million-year-old weevil (Nemonychidae, Coleoptera) found in Lebanese amber, PCR amplification of segments of the 18S rRNA gene and the internal transcribed spacer, and the corresponding nucleotide sequences of their 315- and 226-base-pair fragments, respectively. These sequences were used for preliminary phylogenetic analysis of the nemonychidae, sequence with three extant coleopterans: Lecontellus pinicola (Nemonychidae), Hypera brunneipennis (Curculionidae) and the mealworm Tenebrio molitor (Tenebrionidae), and two extant dipterans: the fruitfly Drosophila melanogaster (Drosophilidae) and mosquito Aedes albopictus (Culicidae) for the purpose of ascertaining the origin of the extracted and amplified DNA. The results revealed that the PCR-amplified material is that of the extinct nemonychid weevil. This represents the oldest fossil DNA ever extracted and sequenced, extending by 80 million years the age of any previously reported DNA4-6.	CTR DIS CONTROL,PARASIT DIS BRANCH,ATLANTA,GA 30333; AMER UNIV BEIRUT,DEPT ENVIRONM HLTH,BEIRUT,LEBANON; UNIV CALIF BERKELEY,DEPT ENTOMOL SCI,BERKELEY,CA 94720	Centers for Disease Control & Prevention - USA; American University of Beirut; University of California System; University of California Berkeley	CANO, RJ (corresponding author), CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,DEPT BIOL SCI,SAN LUIS OBISPO,CA 93407, USA.							Arnoldi L.V., 1977, Trudy Paleontologicheskogo Instituta, V161, P142; BANDEL K, 1981, JB GEOL PALEONT MK, V1, P19; CANO R J, 1992, Medical Science Research, V20, P619; CANO RJ, 1992, MED SCI RES, V20, P649; Crowson R.A., 1981, BIOL COLEOPTERA; CROWSON RA, 1985, ENTOMOL GEN, V11, P57; CROWSON RA, 1974, 10 ATT C NAZ IT ENT, P1; DAMS E, 1988, NUCLEIC ACIDS RES, V16, pR87, DOI 10.1093/nar/16.suppl.r87; DESALLE R, 1992, SCIENCE, V257, P1860; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HEDGES SB, 1992, MOL BIOL EVOL, V9, P366; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; JUNG JM, 1991, INT J LEGAL MED, V104, P145, DOI 10.1007/BF01369719; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kuschel G., 1983, GeoJournal, V7, P499; KUSCHEL G, IN PRESS ENT SCAND; Poinar Jr GO, 1992, LIFE AMBER; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schlee D., 1970, NEUES JB GEOL PAL, V1, P40; SCHLEE W, 1978, BERNESTEIN, P1; SWOFFORD D, 1991, ILLINOIS NAT HIST SU; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WHALLEY P, 1981, INSECTS LEBANESE AMB; White TJ., 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1	27	190	207	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					536	538		10.1038/363536a0	http://dx.doi.org/10.1038/363536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505978				2022-12-01	WOS:A1993LF93900047
J	CONWAY, GA; EPSTEIN, MR; HAYMAN, CR; MILLER, CA; WENDELL, DA; GWINN, M; KARON, JM; PETERSEN, LR				CONWAY, GA; EPSTEIN, MR; HAYMAN, CR; MILLER, CA; WENDELL, DA; GWINN, M; KARON, JM; PETERSEN, LR			TRENDS IN HIV PREVALENCE AMONG DISADVANTAGED YOUTH - SURVEY RESULTS FROM A NATIONAL JOB-TRAINING PROGRAM, 1988 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							IMMUNODEFICIENCY-VIRUS INFECTION; ADOLESCENTS; WOMEN; AIDS; POOR	Objective.-To describe trends in the prevalence of human immunodeficiency virus (HIV) among socially and educationally disadvantaged US youth. Design.-Analysis of demographic and geographic trends of HIV infection among Job Corps students from January 1988 through December 1992. Setting.-The Job Corps is a national training program for disadvantaged and out-of-school youth. Population Screened.-Youths aged 16 to 21 years who entered the Job Corps residential training centers during the survey period. Main Outcome Measure.-Trends in prevalence of HIV infection among Job Corps students stratified by sex, age, race, and region of the country. Results.-Of the 269 956 Job Corps students screened, 812 (0.3%) tested positive for the antibody to HIV type 1. Seroprevalence of HIV for young men decreased from 3.6 per 1000 in 1988 to 2.2 per 1000 in 1992 (chi2 test for trend, P<.001). Seroprevalence for young women increased from 2.1 per 1000 in 1988 to 4.2 per 1000 in 1990 (P=.001), with seroprevalence remaining stable from 1990 through 1992. The decreasing trends in HIV prevalence among men and increasing trends among women were primarily due to changes in seroprevalence in African-American students. Conclusions.-The overall prevalence of HIV infection of three per 1000 is high, given the youth of Job Corps students. The significant rise in HIV rates among female Job Corps students provides evidence of the increasing risk of infection for socioeconomically disadvantaged young women. Reasons for the declining trend in HIV prevalence among male Job Corps students are not clear, Efforts to prevent the spread of HIV infection among adolescents must focus on the group that is hardest to reach-out-of-school and impoverished youth.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,TECH INFORMAT ACT,1600 CLIFTON RD,ATLANTA,GA 30333; US DEPT LABOR,EMPLOYMENT & TRAINING ADM,OFF JOB CORPS,WASHINGTON,DC 20210	Centers for Disease Control & Prevention - USA; United States Department of Labor								BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; DANGELO LJ, 1991, PEDIATRICS, V88, P982; FIFE D, 1992, AIDS, V5, P1111; GAYLE HD, 1991, PEDIATRIC AIDS CHALL, P38; KRUEGER LE, 1990, AIDS, V4, P811, DOI 10.1097/00002030-199008000-00015; SHAYNE VT, 1991, WOMEN HEALTH, V17, P21, DOI 10.1300/J013v17n01_02; STLOUIS ME, 1991, JAMA-J AM MED ASSOC, V266, P2387, DOI 10.1001/jama.266.17.2387; WENDELL D, 1991, AJDC, V146, P76; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1993, HIV AIDS SURVEILLANC, P1; 1992, PREVALENCE HIV 1 ANT; 1990, JOB CORPS BRIEF PROG; 1993, 9231 US DEP LAB JOB; 1992, IMPROVING MINORITY H, P43	14	38	38	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2887	2889		10.1001/jama.269.22.2887	http://dx.doi.org/10.1001/jama.269.22.2887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497093				2022-12-01	WOS:A1993LE93600026
J	GROENINK, M; FOUCHIER, RAM; BROERSEN, S; BAKER, CH; KOOT, M; VANTWOUT, AB; HUISMAN, HG; MIEDEMA, F; TERSMETTE, M; SCHUITEMAKER, H				GROENINK, M; FOUCHIER, RAM; BROERSEN, S; BAKER, CH; KOOT, M; VANTWOUT, AB; HUISMAN, HG; MIEDEMA, F; TERSMETTE, M; SCHUITEMAKER, H			RELATION OF PHENOTYPE EVOLUTION OF HIV-1 TO ENVELOPE V2 CONFIGURATION	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120; GLYCOPROTEIN; REGIONS; TROPISM; PANEL	Biological variability of human immunodeficiency virus type-1 (HIV-1) is involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS). Syncytium-inducing (SI) HIV-1 variants emerge in 50 percent of infected individuals during infection, preceding accelerated CD4+ T cell loss and rapid progression to AIDS. The V1 to V2 and V3 region of the viral envelope glycoprotein gp120 contained the major determinants of SI capacity. The configuration of a hypervariable locus in the V2 domain appeared to be predictive for non-SI to SI phenotype conversion. Early prediction of HIV-1 phenotype evolution may be useful for clinical monitoring and treatment of asymptomatic infection.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS	University of Amsterdam	GROENINK, M (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.		Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869				ANDEWEG AC, IN PRESS J VIROL; ASJO B, 1986, LANCET, V2, P660; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; GROENINK M, 1992, J VIROL, V66, P6175, DOI 10.1128/JVI.66.10.6175-6180.1992; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; GROENINK M, UNPUB; HO DD, 1991, P NATL ACAD SCI USA, V88, P8949, DOI 10.1073/pnas.88.20.8949; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOOT M, IN PRESS J INFECT DI; MYERS G, 1990, HUMAN RETROVIRUSES A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, VIROLOGY, V171, P149, DOI 10.1016/0042-6822(89)90521-7; TERSMETTE M, 1989, LANCET, V1, P983; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992	24	207	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1513	1516		10.1126/science.8502996	http://dx.doi.org/10.1126/science.8502996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502996				2022-12-01	WOS:A1993LF05800039
J	YOUNGNER, SJ; ARNOLD, RM				YOUNGNER, SJ; ARNOLD, RM			ETHICAL, PSYCHOSOCIAL, AND PUBLIC-POLICY IMPLICATIONS OF PROCURING ORGANS FROM NON-HEART-BEATING CADAVER DONORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICING INTUBATION; NEWLY DEAD; PROCUREMENT		UNIV HOSP CLEVELAND, CLIN ETH PROGRAM, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR BIOMED ETH, CLEVELAND, OH 44106 USA; UNIV PITTSBURGH, CTR MED ETH, DEPT MED, DIV GEN INTERNAL MED, PITTSBURGH, PA 15260 USA	University Hospitals of Cleveland; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	YOUNGNER, SJ (corresponding author), UNIV HOSP CLEVELAND, DEPT MED, DIV GEN INTERNAL MED, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA.							ANAISE D, 1990, TRANSPLANTATION, V49, P290, DOI 10.1097/00007890-199002000-00013; [Anonymous], 1968, JAMA, V205, P337; ATKINS J, 1986, ANN EMERG MED, V15, P178; Burdick James F., 1993, Kennedy Institute of Ethics Journal, V3, P199; CALLENDER CO, 1991, NEW ENGL J MED, V325, P442, DOI 10.1056/NEJM199108083250631; CAPLAN AL, 1989, CLIN TRANSPLANT, V3, P170; CAPLAN AL, 1992, TRANSPLANT P, V24, P722; CAPLAN AL, 1992, SURG GEN WORKSH INCR, P199; Caplan Arthur L., 1993, Kennedy Institute of Ethics Journal, V3, P251; Childress James F., 1993, Kennedy Institute of Ethics Journal, V3, P203; Cole David, 1993, Kennedy Institute of Ethics Journal, V3, P145; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P113; Devita Michael A., 1993, Kennedy Institute of Ethics Journal, V3, P131; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; Fox Renee C., 1993, Kennedy Institute of Ethics Journal, V3, P231; Frader Joel, 1993, Kennedy Institute of Ethics Journal, V3, P189; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; GRENVIK A, 1992, OPUSC MED, V37, P33; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; KOOSTRA G, 1991, TRANSPL P, V23, P910; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Lynn Joanne, 1993, Kennedy Institute of Ethics Journal, V3, P167; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MEISEL A, 1986, CRIT CARE MED, V14, P239, DOI 10.1097/00003246-198603000-00016; NATHAN H, 1992, OCT C ETH PSYCH PUBL; NATHAN HM, 1991, TRANSPLANTATION, V51, P142, DOI 10.1097/00007890-199101000-00022; NOVELLO A, 1992, SURGEON GENERALS WOR; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; PROTTAS JM, 1991, J HEALTH POLIT POLIC, V16, P121, DOI 10.1215/03616878-16-1-121; PROTTAS JM, 1986, ATTITUDES INCENTIVES; ROBBINS RA, 1990, DEATH STUD, V14, P219, DOI 10.1080/07481189008252363; Robertson John A., 1993, Kennedy Institute of Ethics Journal, V3, P241; ROSENTAL R, 1991, TRANSPLANT P, V23, P2588; RUERS TJM, 1986, TRANSPLANT P, V18, P408; Shaw Byers W. Jr., 1993, Kennedy Institute of Ethics Journal, V3, P179; SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919; SPITAL A, 1986, ARCH INTERN MED, V146, P1993, DOI 10.1001/archinte.146.10.1993; Starzl TE., 1992, PUZZLE PEOPLE MEMOIR, V1st ed; STRYKER J, 1989, NEW ENGL J MED, V320, P396; Tomlinson T, 1993, Kennedy Inst Ethics J, V3, P157; Weisbard Alan J., 1993, Kennedy Institute of Ethics Journal, V3, P217; YOUNGNER SJ, 1990, TRANSPLANT P, V22, P1014; YOUNGNER SJ, 1992, ARCH NEUROL-CHICAGO, V49, P570, DOI 10.1001/archneur.1992.00530290162028; 1981, DEFINING DEATH; 1992, UNOS UPDATE      JUN, P15; 1988, HASTINGS CENT REP S, V18, P5; 1992, U PITTSBURGH MED CTR; 1983, DECIDING FORGO LIFE; 1990, SOLVING ORGAN SHORTA	50	93	96	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2769	2774		10.1001/jama.269.21.2769	http://dx.doi.org/10.1001/jama.269.21.2769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492404				2022-12-01	WOS:A1993LD67100028
J	JARRETT, P; SHARP, C; MCLELLAND, J				JARRETT, P; SHARP, C; MCLELLAND, J			PROTECTION OF CHILDREN BY THEIR MOTHERS AGAINST SUNBURN	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; EXPOSURE		SUNDERLAND ROYAL INFIRM,DEPT DERMATOL,SUNDERLAND SR2 7JE,ENGLAND	Sunderland Royal Hospital								GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; HOLMAN CD, 1984, JNCI-J NATL CANCER I, V73, P75; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199	5	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1448	1448		10.1136/bmj.306.6890.1448	http://dx.doi.org/10.1136/bmj.306.6890.1448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8518641	Green Published, Bronze			2022-12-01	WOS:A1993LE93500018
J	HOWCROFT, TK; STREBEL, K; MARTIN, MA; SINGER, DS				HOWCROFT, TK; STREBEL, K; MARTIN, MA; SINGER, DS			REPRESSION OF MHC CLASS-I GENE PROMOTER ACTIVITY BY 2-EXON TAT OF HIV	SCIENCE			English	Article							NF-KAPPA-B; EXPRESSION; RECOGNITION; MODULATION; INFECTION; PROTEINS; PRODUCT; DENSITY; H-2KB	Major histocompatibility complex (MHC) class I molecules are the major receptors for viral peptides and serve as targets for specific cytotoxic T lymphocytes. Human immunodeficiency virus-type 1 (HIV-1) specifically decreased activity of an MHC class I gene promoter up to 12-fold. Repression was effected by the HIV-1 Tat protein derived from a spliced viral transcript (two-exon Tat). These studies define an activity for two-exon Tat distinct from that of one-exon Tat and suggest a mechanism whereby HIV-1-infected cells might be able to avoid immune surveillance, allowing the virus to persist in the infected host.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B-17,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FLORES RV, 1984, J IMMUNOL, V132, P2767; GODING LR, 1990, CRC CRIT REV IMMUNOL, V10, P53; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HOWCROFT TK, UNPUB; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045	23	203	205	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1320	1322		10.1126/science.8493575	http://dx.doi.org/10.1126/science.8493575			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493575	Green Submitted			2022-12-01	WOS:A1993LE02500042
J	STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C				STERN, MC; JAGGER, C; CLARKE, M; ANDERSON, J; MCGROTHER, C; BATTOCK, T; MCDONALD, C			RESIDENTIAL CARE FOR ELDERLY PEOPLE - A DECADE OF CHANGE	BRITISH MEDICAL JOURNAL			English	Article							HOMES	Objective-To determine the changes between 1979 and 1990 in demography and dependency levels in elderly people in residential care. Design-Censuses of those aged 65 years and over in any type of residential care at midnight on 11 December 1979 and 27 November 1990. Setting-Leicestershire District Health Authority (population 865 133, 1991 census), coterminous with county and social services boundaries. Main outcome measures-Age, sex, length of stay, and dependency levels (measured by activities of daily living). Results-In 1990 (1979), 6079 (4678) elderly people were enumerated in 241 (133) establishments, a 30% increase in the numbers of elderly people in residential care and an 82% increase in the number of establishments between 1979 and 1990. Dependency levels rose between 1979 and 1990 in all but the geriatric sector, the greatest increases being found in private residential homes where the largest percentage increase in the number of residents had occurred. Conclusions-Dependency levels in residential care have risen substantially, particularly in the private sector, even beyond levels expected from the greater numbers of elderly people. With the impending move to community care, dependency levels are likely to rise further, and more appropriate staff training and medical input to homes will become necessary.	UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,POB 65,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND; DEPT HLTH,LONDON SW1A 2NS,ENGLAND; UNIV LEICESTER,DEPT PSYCHIAT,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND; UNIV LEICESTER,DEPT MED ELDERLY,LEICESTER LE1 7RH,ENGLAND; LEICESTERSHIRE CTY COUNCIL,DEPT SOCIAL SERV,SERV OLDER PEOPLE,LEICESTER,ENGLAND	University of Leicester; University of Leicester; University of Leicester; University of Leicester				Jagger, Carol/0000-0002-6377-9926				BAKER RJ, 1985, GLIM 3 77 USER REFER; CAMPBELL H, 1990, AGE AGEING, V19, P318, DOI 10.1093/ageing/19.5.318; Clarke M, 1979, HLTH TRENDS, V11, P17; DAY P, 1987, BRIT MED J, V294, P384, DOI 10.1136/bmj.294.6568.384; Donaldson L J, 1983, Health Trends, V15, P58; DONALDSON LJ, 1983, PUBLIC HEALTH, V97, P257, DOI 10.1016/S0033-3506(83)80101-2; GODBER C, 1984, BRIT MED J, V288, P1473, DOI 10.1136/bmj.288.6429.1473; GOSNEY M, 1991, HLTH TRENDS, V22, P153; Griffiths R., 1988, COMMUNITY CARE AGEND; GRUNDY E, 1982, BRIT MED J, V284, P799, DOI 10.1136/bmj.284.6318.799; GRUNDY E, 1987, BRIT MED J, V294, P626, DOI 10.1136/bmj.294.6572.626; JAGGER C, 1991, INT J EPIDEMIOL, V20, P234, DOI 10.1093/ije/20.1.234; LAING, 1988, CARE ELDERLY PEOPLE; LOWY S, 1988, BMJ, V296, P541; STOTT D J, 1990, Health Bulletin (Edinburgh), V48, P17; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; WILKIN D, 1978, BRIT MED J, V2, P1274, DOI 10.1136/bmj.2.6147.1274; 1975, BETTER SERVICES MENT; 1991, NATIONAL POPULAT PP2; 1989, CARING PEOPLE COMMUN; 1988, POSITIVE CHOICE; 1990, MORTALITY STATIS DHI	22	36	36	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					827	830		10.1136/bmj.306.6881.827	http://dx.doi.org/10.1136/bmj.306.6881.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490375	Bronze, Green Published			2022-12-01	WOS:A1993KV34800021
J	Li, TG; Janda, KD; Lerner, RA				Li, TG; Janda, KD; Lerner, RA			Cationic cyclopropanation by antibody catalysis	NATURE			English	Article							BIOSYNTHESIS; SQUALENE	REACTIONS involving highly reactive carbocations play a central role in many important chemical processes, such as cyclization reactions(1,2). However, the potential for controlling the pathways of such reactions to obtain energetically disfavoured (but desirable) products has been hard to realize because of the difficulties inherent in controlling the conformation and chemical environment of the carbocation intermediates. Antibody catalysts, with their high specificity and binding energies, can provide the degree of conformational and chemical control necessary for directing such reactions(3,4). Here we show how antibody catalysis can guide cationic cyclization reactions selectively to form products (in high yield) that would otherwise be highly disfavoured. Most notable is the formation of a strained bicyclic compound containing a rare cyclopropane group. To explain our results, we propose a common reaction scheme in which the key step is the formation of a highly reactive protonated cyclopropane intermediate; subtle structural modifications to the substrate (the compound on which the catalytic antibody acts) lead to dramatic differences in the structure of the final product.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P6174, DOI 10.1021/ja00487a037; BAYLESS JH, 1967, J AM CHEM SOC, V89, P147, DOI 10.1021/ja00977a029; BEATON JM, 1955, J CHEM SOC, P3992, DOI 10.1039/jr9550003992; BROWN HC, 1982, PURE APPL CHEM, V54, P1783, DOI 10.1351/pac198254101783; COLLINS CJ, 1969, CHEM REV, V69, P543, DOI 10.1021/cr60260a004; DJERASSI C, 1990, NEW J CHEM, V14, P713; FLEMING I, 1976, J CHEM SOC CHEM COMM, P182, DOI 10.1039/c39760000182; GUILFORD WJ, 1982, J AM CHEM SOC, V104, P3506, DOI 10.1021/ja00376a045; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JOHNSON WS, 1968, ACCOUNTS CHEM RES, V1, P1, DOI 10.1021/ar50001a001; Lee C. C., 1970, PROGR PHYS ORG CHEM, V7, P129; LEWINSOHN E, 1993, ARCH BIOCHEM BIOPHYS, V94, P2189; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; LI TY, 1995, J AM CHEM SOC, V117, P3308, DOI 10.1021/ja00116a050; LOGRASSO PV, 1993, ARCH BIOCHEM BIOPHYS, V307, P193, DOI 10.1006/abbi.1993.1578; MARCH J, 1985, ADV ORG CHEM, P673; OLAH GA, 1995, ANGEW CHEM INT EDIT, V34, P1393, DOI 10.1002/anie.199513931; OLAH GA, 1970, CARBONIUM IONS; RUZICKA L, 1947, HELV CHIM ACTA, V30, P140, DOI 10.1002/hlca.19470300117; SAUNDERS M, 1973, ACCOUNTS CHEM RES, V6, P53, DOI 10.1021/ar50062a003; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SILVER MS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a079; SKELL PS, 1960, J AM CHEM SOC, V82, P2971, DOI 10.1021/ja01496a078	25	41	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 25	1996	379	6563					326	327						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552185				2022-12-01	WOS:A1996TR32300052
J	Guadagno, TM; Newport, JW				Guadagno, TM; Newport, JW			Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity	CELL			English	Article							CYCLIN-DEPENDENT KINASE-2; HUMAN CELL-CYCLE; PROTEIN-KINASE; DNA-REPLICATION; CATALYTIC SUBUNIT; CDC25 PROTEIN; S-PHASE; XENOPUS; PHOSPHORYLATION; YEAST	In higher eukaryotes, Cdk2 kinase plays an essential role in regulating the G1-S transition. Here, we use cycling Xenopus egg extracts to examine the requirement of Cdk2 kinase on progression into mitosis. Interestingly, when Cdk2 kinase activity is inhibited by the Cdk-specific inhibitor, p21(Clp1), a block to mitosis occurs, and inactive Cdc2-cyclin B accumulates. This block occurs in the absence of nuclei and is not due to direct inhibition of Cdc2 by Cip. Importantly, this block to mitosis is reversible by restoring Cdk2-cyclin E kinase activity to a Cip-treated cycling extract. Moreover, immunodepletion of Cdk2 from interphase extracts prevents activation of Cdc2 upon the addition of exogenous cyclin B. Thus, our data show that Cdk2 kinase is a positive regulator of Cdc2-cyclin B complexes and establish a link between Cdk2 kinase and cell cycle progression into mitosis.			Guadagno, TM (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, R01GM033523] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07721-03] Funding Source: Medline; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1995, MOL BIOL CELL, V6, P3877; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEICHMAN KA, 1994, CELL, V79, P556; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUNTER T, 1994, CELL, V79, P673; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1	57	197	200	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					73	82		10.1016/S0092-8674(00)80994-0	http://dx.doi.org/10.1016/S0092-8674(00)80994-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548828	Bronze			2022-12-01	WOS:A1996TQ17000010
J	Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT				Burling, FT; Weis, WI; Flaherty, KM; Brunger, AT			Direct observation of protein solvation and discrete disorder with experimental crystallographic phases	SCIENCE			English	Article							MANNOSE-BINDING PROTEIN; MOLECULAR-DYNAMICS SIMULATION; ANOMALOUS SCATTERING FACTORS; ATOMIC FLUCTUATIONS; CRYSTAL-STRUCTURES; WATER-STRUCTURE; REFINEMENT; ANHARMONICITY; ANISOTROPY; DOMAIN	A complete and accurate set of experimental crystallographic phases to a resolution of 1.8 angstroms was obtained for a 230-residue dimeric fragment of rat mannose-binding protein A with the use of multiwavelength anomalous dispersion (MAD) phasing. An accurate image of the crystal structure could thus be obtained without resort to phases calculated from a model. Partially reduced disulfide bonds, local disorder, and differences in the mobility of chemically equivalent molecules are apparent in the experimental electron density map. A solvation layer is visible that includes well-ordered sites of hydration around polar and charged protein atoms, as well as diffuse, partially disordered solvent shells around exposed hydrophobic groups. Because the experimental phases and the resulting electron density map are free from the influence of a model, they provide a stringent test of theoretical models of macromolecular solvation, motion, and conformational heterogeneity.	STANFORD UNIV,DEPT BIOL STRUCT,STANFORD,CA 94305; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Stanford University; Howard Hughes Medical Institute; Yale University; Yale University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Brunger, Axel/0000-0001-5121-2036	NIGMS NIH HHS [GM50565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BADGER J, 1991, P NATL ACAD SCI USA, V88, P622, DOI 10.1073/pnas.88.2.622; BADGER J, 1995, NAT STRUCT BIOL, V2, P77, DOI 10.1038/nsb0195-77; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, UNPUB; BURLING FT, 1994, ISRAEL J CHEM, V34, P165; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Drenth J, 1994, PRINCIPLES PROTEIN X; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENDRICKSON WA, UNPUB; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; ICHIYE T, 1987, PROTEINS, V2, P236, DOI 10.1002/prot.340020308; ICHIYE T, 1988, BIOCHEMISTRY-US, V27, P3487, DOI 10.1021/bi00409a054; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLE J, 1980, INT J QUANTUM CHEM, V7, P356; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KOMEIJI Y, 1993, PROTEINS, V16, P268, DOI 10.1002/prot.340160305; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; KURIYAN J, 1986, J MOL BIOL, V190, P227, DOI 10.1016/0022-2836(86)90295-0; LEVITT M, 1988, P NATL ACAD SCI USA, V85, P7557, DOI 10.1073/pnas.85.20.7557; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LOUNNAS V, 1994, BIOPHYS J, V66, P601, DOI 10.1016/S0006-3495(94)80835-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NALL BT, 1991, CONFORMATIONS FORCES; OTWINOWSKI Z, 1993, JAN P CCP4 STUD WEEK; OTWINOWSKI Z, 1991, JAN P CCP4 STUD WEEK; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REES DC, 1983, ACTA CRYSTALLOGR A, V39, P94, DOI 10.1107/S0108767383000173; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; STEINBACH PJ, 1993, P NATL ACAD SCI USA, V90, P9135, DOI 10.1073/pnas.90.19.9135; TEETER MM, 1984, P NATL ACAD SCI-BIOL, V81, P6014, DOI 10.1073/pnas.81.19.6014; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P6, DOI 10.1107/S0108767387099987; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEIS WI, UNPUB; Westhof E., 1993, WATER BIOL MACROMOLE; 1994, CCP4 SUITE PROGRAMS	55	221	223	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					72	77		10.1126/science.271.5245.72	http://dx.doi.org/10.1126/science.271.5245.72			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539602				2022-12-01	WOS:A1996TP02200046
J	Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S				Chen, C; Kano, M; Abeliovich, A; Chen, L; Bao, SW; Kim, JJ; Hashimoto, K; Thompson, RF; Tonegawa, S			Impaired motor coordination correlates with persistent multiple climbing fiber innervation in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CEREBELLAR PURKINJE-CELLS; INFERIOR OLIVARY NEURONS; VESTIBULO-OCULAR REFLEX; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; GLUTAMATE SENSITIVITY; INVITRO	It is generally believed that a smooth execution of a compound movement, or motor coordination, requires learning of component movements as well as experience-based refinement of the motor program as a whole. PKC gamma mutant mice display impaired motor coordination but intact eyeblink conditioning, a form of component movement learning. Cerebellar long-term depression, a putative cellular mechanism for component motor learning, is also unimpaired. Thus, PKC gamma mutant mice are defective in refinement of the motor program. In the accompanying paper, we demonstrate that innervation of multiple climbing fibers onto Purkinje cells persists in adulthood in these mutant mice. We propose that this defective elimination of surplus climbing fibers underlies motor discoordination.	MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Jichi Medical University; University of Southern California	Chen, C (corresponding author), MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Kano, Masanobu/0000-0002-0725-3292; Hashimoto, Kouichi/0000-0002-3884-8213; Kim, Jeansok/0000-0001-7964-106X; Chen, Lu/0000-0002-8097-2699	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925] Funding Source: Medline; OMHHE CDC HHS [1F32MN10521-01] Funding Source: Medline; ACF HHS [NIA AF05142] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OMHHE CDC HHS; ACF HHS		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; CHEN C, 1995, IN PRESS LTP CURRE 3; CHEN C, 1995, LEARN MEMORY, V2, P18; CHEN S, 1993, NEUROSCIENCE, V56, P177, DOI 10.1016/0306-4522(93)90572-W; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DAUM I, 1993, BEHAV NEUROSCI, V107, P748, DOI 10.1037/0735-7044.107.5.748; Dow R. S., 1958, PHYSL PATHOLOGY CERE; DUFOSSE M, 1978, BRAIN RES, V150, P611, DOI 10.1016/0006-8993(78)90825-9; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Fetz E E, 1993, Curr Opin Neurobiol, V3, P932, DOI 10.1016/0959-4388(93)90165-U; GELLMAN R, 1985, J NEUROPHYSIOL, V54, P40, DOI 10.1152/jn.1985.54.1.40; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HUANG FL, 1988, J NEUROSCI, V8, P4734; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Ito M., 1984, CEREBELLUM NEURAL CO; ITO M, 1994, CELLULAR MOL MECHANI, P25; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KOSE A, 1988, J NEUROSCI, V8, P4262; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1985, BRAIN RES, V326, P179, DOI 10.1016/0006-8993(85)91400-3; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LISBERGER SG, 1992, NATURE, V360, P159, DOI 10.1038/360159a0; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; Llinas R, 1993, Curr Opin Neurobiol, V3, P958, DOI 10.1016/0959-4388(93)90168-X; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MERCHENTHALER I, 1993, J COMP NEUROL, V336, P378, DOI 10.1002/cne.903360306; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NAGAO S, 1989, EXP BRAIN RES, V77, P531; SAITO N, 1988, J NEUROSCI, V8, P369; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P8383; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; THOMPSON RF, 1993, SYNAPTIC PLASTICITY, P230; WATANABE E, 1984, BRAIN RES, V297, P169, DOI 10.1016/0006-8993(84)90555-9; WELSH JP, 1995, NATURE, V374, P453, DOI 10.1038/374453a0; YEO CH, 1984, BEHAV BRAIN RES, V13, P261, DOI 10.1016/0166-4328(84)90168-2	61	276	281	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1233	1242		10.1016/0092-8674(95)90148-5	http://dx.doi.org/10.1016/0092-8674(95)90148-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548809	Bronze			2022-12-01	WOS:A1995TM76200018
J	Strick, R; Laemmli, UK				Strick, R; Laemmli, UK			SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein	CELL			English	Article							TOPOISOMERASE-II SITES; ATTACHMENT SITES; HISTONE H-1; BINDING; CHROMATIN; EXTRACTS; SCAFFOLD; REGIONS; LOOP; CONDENSATION	SARs are candidate DNA elements for defining the bases of chromatin loops and possibly for serving as cis elements of chromosome dynamics. SARs contain numerous A tracts, whose altered DNA structure is recognized by cooperatively interacting proteins such as topoisomerase II. We constructed multi-AT hook (MATH) proteins and demonstrate that they specifically bind the clustered A tracts of SARs in chromatin and chromosomes. They are also potent inhibitors of chromosome assembly in mitotic Xenopus extracts, demonstrating the importance of SARs in this process. Titration of SARs with MATH20 (20 hooks) blocks shape determination of chromatids but not chromatin condensation per se. SARs are also required for shape maintenance of chromosomes. If MATH20 is added after formation of chromatids, they collapse and are reshaped by an active, mitotic process into spherical chromatid balls.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Strick, R (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GOTO T, 1982, J BIOL CHEM, V257, P5866; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1984, J CELL BIOL, V98, P122; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Sambrook J., 1989, MOL CLONING LAB MANU; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	41	131	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1137	1148		10.1016/0092-8674(95)90140-X	http://dx.doi.org/10.1016/0092-8674(95)90140-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548801	Bronze			2022-12-01	WOS:A1995TM76200010
J	Heathcote, JA				Heathcote, JA			Why do old men have big ears?	BRITISH MEDICAL JOURNAL			English	Article											Heathcote, JA (corresponding author), S VIEW LODGE,BROMLEY BR1 3DR,KENT,ENGLAND.								0	39	40	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1668	1668		10.1136/bmj.311.7021.1668	http://dx.doi.org/10.1136/bmj.311.7021.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541753	Green Published			2022-12-01	WOS:A1995TL94200012
J	Williams, TM; Kim; Williams, G				Williams, TM; Kim; Williams, G			Excessive impertinence or a missed diagnosis?	BRITISH MEDICAL JOURNAL			English	Note											Williams, TM (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MED,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							CAVALIERO G, 1986, B POTTERS J; de la Tourette Gilles, 1885, ARCH NEUROL-CHICAGO, V9, P158; PEARCE JMS, 1994, J ROY SOC MED, V87, P396; Potter B., 1903, TALE SQUIRREL NUTKIN; POTTER B, 1905, TALE MRS TIGGY WINKL; ROBERTSON MM, 1988, BRIT J PSYCHIAT, V152, P383, DOI 10.1192/bjp.152.3.383; SACKS O, 1992, BRIT MED J, V305, P1515, DOI 10.1136/bmj.305.6868.1515; SIMKIN B, 1992, BRIT MED J, V305, P1563, DOI 10.1136/bmj.305.6868.1563; TAYLOR J, 1987, ARTIST WORLD	9	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1700	1701		10.1136/bmj.311.7021.1700	http://dx.doi.org/10.1136/bmj.311.7021.1700			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541765	Green Published			2022-12-01	WOS:A1995TL94200026
J	COLLINGE, J; PALMER, MS; SIDLE, KCL; HILL, AF; GOWLAND, I; MEADS, J; ASANTE, E; BRADLEY, R; DOEY, LJ; LANTOS, PL				COLLINGE, J; PALMER, MS; SIDLE, KCL; HILL, AF; GOWLAND, I; MEADS, J; ASANTE, E; BRADLEY, R; DOEY, LJ; LANTOS, PL			UNALTERED SUSCEPTIBILITY TO BSE IN TRANSGENIC MICE EXPRESSING HUMAN PRION PROTEIN	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB DISEASE; SCRAPIE; PRP; TRANSMISSION; GENE	PRION diseases are transmissible neurodegenerative conditions of humans and animals. Prions consist principally of a post-translationally modified form of prion protein (PrP), PrPSc, which is partly protease resistant(1). Transmission of prion diseases between species is limited by a 'species barrier'(2) determined in part by the degree of sequence homology between host PrP and inoculated PrPSc (ref.3) and by prion strain type(4). The epidemic of bovine spongiform encephalopathy (BSE) in the United Kingdom and other countries has led to concerns that transmission to humans may occur by dietary exposure. BSE appears to be caused by a single strain, distinct from those of natural or experimental scrapie(4), which is also seen in the nerv prion diseases of cats and ruminants that have presumably arisen from dietary BSE exposure(4). Here we show that transgenic mice expressing human PrP in addition to mouse PrP can generate human PrPSc and 'human' prions. These mice therefore provide a model to study experimentally the species barrier limiting BSE transmission to humans. Incubation periods to BSE in transgenic mice are not shortened by expression of human PrP, and only mouse PrPSc is produced in response to such challenge.	ST MARYS HOSP,DEPT NEUROL,LONDON W2 1NY,ENGLAND; MAFF,CENT VET LAB,WEYBRIDGE KT15 3NB,SURREY,ENGLAND; INST PSYCHIAT,DEPT NEUROPATHOL,LONDON SE5 8AF,ENGLAND	Imperial College London; University of London; King's College London	COLLINGE, J (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Hill, Andrew F./AAH-2854-2020; Hill, Andrew F/B-4527-2009; Hill, Andrew/GZL-4124-2022	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew/0000-0001-5581-2354; Asante, Emmanuel A/0000-0003-3771-4843	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BARLOW RM, 1990, VET REC, V126, P111; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1994, NEUROLOGY, V44, P291, DOI 10.1212/WNL.44.2.291; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1994, 1993 P CONS BSE SCI, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTOS PL, 1992, NEUROSCI LETT, V147, P67, DOI 10.1016/0304-3940(92)90776-4; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; TAYLOR DM, 1994, ARCH VIROL, V139, P313, DOI 10.1007/BF01310794; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Wells GAH, 1991, BRAIN PATHOL, V1, P69, DOI 10.1111/j.1750-3639.1991.tb00642.x; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197	30	184	193	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					779	783		10.1038/378779a0	http://dx.doi.org/10.1038/378779a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524411				2022-12-01	WOS:A1995TL41900026
J	MAHMOUDI, A; ISEMAN, MD				MAHMOUDI, A; ISEMAN, MD			PITFALLS IN THE CARE OF PATIENTS WITH TUBERCULOSIS - COMMON ERRORS AND THEIR ASSOCIATION WITH THE ACQUISITION OF DRUG-RESISTANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RADIOMETRIC METHOD; INFECTION; SUSCEPTIBILITY; DISEASE	Objective.-To determine, among a group of patients with multidrug-resistant pulmonary tuberculosis, whether there had been management practices that deviated from established guidelines, and whether these decisions were associated with the acquisition of multidrug resistance and adverse medical sequelae. Design.-Case series. Setting.-Referral center. Patients.-All patients with pulmonary tuberculosis admitted to the National Jewish Center for Immunology and Respiratory Medicine in 1989 through 1990. Interventions.-The records of all patients referred to this institution for the treatment of tuberculosis in 1989 through 1990 were reviewed to ascertain the nature of management decisions that might have been associated with the acquisition of drug resistance. Main Outcome Measures.-Standards of practice as defined by the American Thoracic Society, the Centers for Disease Control and Prevention, and the American College of Chest Physicians were compared with these management decisions to determine whether ''errors'' had been made, resulting in treatment failure and the development of acquired drug resistance. Results.-Among the 35 study patients, errors were detected in the management decisions in 28; there was an average of 3.93 errors per patient. The most common errors were the addition of a single drug to a failing regimen, failure to identify preexisting or acquired drug resistance, initiation of an inadequate primary regimen, failure to identify and address noncompliance, and inappropriate isoniazid preventive therapy. The multidrug resistance acquired through the errors resulted in prolonged hospitalizations, treatment with more toxic drugs, and high-risk resectional surgery. The costs for this ''salvage therapy'' were extraordinary, averaging $180 000 per patient. Conclusions.-Aggressive professional education, tighter control on the provisions of care for tuberculosis patients, and the committing of additional resources to tuberculosis control programs are vital in improving the care of tuberculosis patients and limiting the development of acquired drug resistance.	NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,ROOM J201,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007085] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07085] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDINGTON WW, 1979, CHEST, V76, pS741; [Anonymous], 1991, Am Rev Respir Dis, V143, P707; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BYRD RB, 1977, ANN INTERN MED, V86, P799, DOI 10.7326/0003-4819-86-6-799; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GOODMAN PC, 1990, J THORAC IMAG, V5, P38, DOI 10.1097/00005382-199004000-00007; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; HEIFETS L, 1988, AM REV RESPIR DIS, V137, P1217, DOI 10.1164/ajrccm/137.5.1217; Heifets L B, 1986, Semin Respir Infect, V1, P242; HEIFETS LB, 1985, J CLIN MICROBIOL, V21, P200, DOI 10.1128/JCM.21.2.200-204.1985; ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MANALO F, 1990, AM REV RESPIR DIS, V142, P1301, DOI 10.1164/ajrccm/142.6_Pt_1.1301; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; MCDERMOT.W, 1970, AM REV RESPIR DIS, V102, P857; MITCHISON DA, 1950, THORAX, V5, P144, DOI 10.1136/thx.5.2.144; MURRAY CJL, 1990, LANCET, V335, P1043, DOI 10.1016/0140-6736(90)91114-P; MURRAY JF, 1989, AM REV RESPIR DIS, V140, P1788, DOI 10.1164/ajrccm/140.6.1788; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; REICHMAN LB, 1989, ANN INTERN MED, V111, P197, DOI 10.7326/0003-4819-111-3-197; ROBERTS GD, 1983, J CLIN MICROBIOL, V18, P689, DOI 10.1128/JCM.18.3.689-696.1983; SATHE SS, 1989, CLIN CHEST MED, V10, P445; SBARBARO JA, 1979, CHEST, V76, pS750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; Slutkin G, 1988, Bull Int Union Tuberc Lung Dis, V63, P21; Styblo K, 1988, Bull Int Union Tuberc Lung Dis, V63, P25; WATSON JM, 1990, BMJ-BRIT MED J, V300, P63, DOI 10.1136/bmj.300.6717.63; 1986, AM REV RESPIR DIS, V134, P335; 1985, CHEST S, V87, pS115; 1990, LANCET, V335, P1249; 1992, MMWR MORB MORTAL WKL, V41, P507; 1989, MMWR MORB MORTAL S3, V38, P1; 1990, AM REV RESPIR DIS, V142, P725; 1990, MMWR MORB MORTAL REP, V39, P718; 1981, AM REV RESPIR DIS, V123, P343; 1983, AM REV RESPIR DIS, V128, P336; 1991, MMWR MORB MORTAL REP, V40, P585; [No title captured]; 1990, MMWR MORB MORTAL WKL, V39, P3	49	231	241	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					65	68		10.1001/jama.270.1.65	http://dx.doi.org/10.1001/jama.270.1.65			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510299				2022-12-01	WOS:A1993LK36600025
J	WU, L; RUSSELL, P				WU, L; RUSSELL, P			NIM1 KINASE PROMOTES MITOSIS BY INACTIVATING WEE1 TYROSINE KINASE	NATURE			English	Article							FISSION YEAST; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; ACTIVATES P34CDC2; MITOTIC INDUCER; CDC25 PROTEIN; PHOSPHORYLATION; PHOSPHATASE; CELLS; GENE	IN most species, including the fission yeast Schizosaccharomyces pombe, the Cdc2/cyclin B mitosis-inducing kinase is maintained in an inhibited state during interphase as a result of phosphorylation of a tyrosine residue in the ATP-binding region of Cdc2 (refs 1-3). This site is phosphorylated by Wee1 kinase4-9 and dephosphorylated by Cdc25 phosphatase10-15. In fission yeast an additional element of the G2/M control Nim1/Cdr1 kinase, has been identified which functions as a potent mitotic inducer16,17. These studies suggested that Nim1 acts by inhibiting Wee1, perhaps by direct phosphorylation. Consistent with this model, we report here that Wee1 is hyperphosphorylated in cells that overproduce Nim1. Likewise, Weel phosphorylation is reduced in nim1- cells. Highly purified Nim1 kinase phosphorylates Wee1 in vitro, resulting in strong inhibition of Weel kinase. These observations show that Nim1 promotes the onset of mitosis by inhibiting Wee1.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								COHEN P, 1988, METHOD ENZYMOL, V159, P390; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	26	137	138	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1993	363	6431					738	741		10.1038/363738a0	http://dx.doi.org/10.1038/363738a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515818				2022-12-01	WOS:A1993LJ33900061
J	COX, JS; SHAMU, CE; WALTER, P				COX, JS; SHAMU, CE; WALTER, P			TRANSCRIPTIONAL INDUCTION OF GENES ENCODING ENDOPLASMIC-RETICULUM RESIDENT PROTEINS REQUIRES A TRANSMEMBRANE PROTEIN-KINASE	CELL			English	Article							GLUCOSE-REGULATED PROTEINS; CHAIN BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; HEMAGGLUTININ-NEURAMINIDASE; DISULFIDE ISOMERASE; ESCHERICHIA-COLI; SHUTTLE VECTORS; S-CEREVISIAE; YEAST	The transcription of genes encoding soluble proteins that reside in the endoplasmic reticulum (ER) is induced when unfolded proteins accumulate in the ER. Thus, an intracellular signal transduction pathway must exist that mediates communication between the ER lumen and the nucleus. We have identified a gene in S. cerevisiae, IRE1, that is required for this pathway: ire1- mutants cannot activate transcription of KAR2 and PDI1, which encode the ER resident proteins BiP and protein disulfide isomerase. Moreover, IRE1 is essential for cell viability under stress conditions that cause unfolded proteins to accumulate in the ER. IRE1 encodes a transmembrane serine/threonine kinase that we propose transmits the unfolded protein signal across the ER or inner nuclear membrane. IRE1 is also required for inositol prototrophy, suggesting that the induction of ER resident proteins is coupled to the biogenesis of new ER membrane.			COX, JS (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Favaloro J, 1980, Methods Enzymol, V65, P718; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J., 1989, MOL CLONING LAB MANU; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1	57	908	948	2	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1197	1206		10.1016/0092-8674(93)90648-A	http://dx.doi.org/10.1016/0092-8674(93)90648-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513503				2022-12-01	WOS:A1993LH54800015
J	MCMICHAEL, A				MCMICHAEL, A			NATURAL-SELECTION AT WORK ON THE SURFACE OF VIRUS-INFECTED CELLS	SCIENCE			English	Article							CLASS-II REGION; CYTOTOXIC T-CELLS; MHC; PEPTIDES; ANTIGENS; MOLECULES; TRANSPORTERS; SPECIFICITY; RECOGNITION; HLA-B27				MCMICHAEL, A (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROWN MG, 1991, NATURE, V353, P365; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; LJUNGGREN HG, 1990, NATURE, V346, P4476; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	30	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1771	1772		10.1126/science.8511585	http://dx.doi.org/10.1126/science.8511585			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511585				2022-12-01	WOS:A1993LH20500039
J	REICHARD, P				REICHARD, P			FROM RNA TO DNA, WHY SO MANY RIBONUCLEOTIDE REDUCTASES	SCIENCE			English	Article							ESCHERICHIA-COLI; TRIPHOSPHATE REDUCTASE; MECHANISM; COFACTOR; PROTEIN; ENZYME; WORLD	It is generally accepted that DNA appeared after RNA during the chemical evolution of life. To synthesize DNA, deoxyribonucleotides are required as building blocks. At present, these are formed from the corresponding ribonucleotides through the enzymatic action of ribonucleotide reductases. Three classes of enzymes are present in various organisms. There is little sequence similarity among the three classes of reductases. However, enzymic mechanisms and the allosteric behavior of the enzymes from various organisms are strongly conserved, suggesting that the enzymes might have evolved from a common ancestor, with the class III anaerobic Escherichia coli reductase as its closest relative.			REICHARD, P (corresponding author), KAROLINSKA INST, DEPT BIOCHEM 1, S-10401 STOCKHOLM 60, SWEDEN.							ABELES RH, 1967, J BIOL CHEM, V242, P3589; ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHLEY GW, 1985, PHARMACOL THERAPEUT, V30, P301, DOI 10.1016/0163-7258(85)90054-3; BARLOW T, 1983, P NATL ACAD SCI-BIOL, V80, P1492, DOI 10.1073/pnas.80.6.1492; BECK WS, 1967, J BIOL CHEM, V242, P3148; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BLAKLEY RL, 1964, BIOCHEM BIOPH RES CO, V16, P391, DOI 10.1016/0006-291X(64)90363-8; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; COWLES JR, 1968, ARCH BIOCHEM BIOPHYS, V127, P770, DOI 10.1016/0003-9861(68)90288-9; DURHAM LJ, 1967, EUR J BIOCHEM, V1, P92, DOI 10.1111/j.1432-1033.1967.tb00048.x; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ELIASSON R, UNPUB; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAMMARSTEN E, 1950, J BIOL CHEM, V183, P105; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; ISAACS SY, 1992, BIOCHEM BIOPH RES CO, V84, P1101; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; REICHARD P, 1987, BIOCHEMISTRY-US, V26, P3245, DOI 10.1021/bi00386a001; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1951, J BIOL CHEM, V188, P839; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE J, COMMUNICATION; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; THELANDER L, 1974, J BIOL CHEM, V249, P4858; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	50	506	522	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1993	260	5115					1773	1777		10.1126/science.8511586	http://dx.doi.org/10.1126/science.8511586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511586				2022-12-01	WOS:A1993LH20500040
J	BARRON, SA; ROGOVSKI, Z; HEMLI, Y				BARRON, SA; ROGOVSKI, Z; HEMLI, Y			VAGAL CARDIOVASCULAR REFLEXES IN YOUNG PERSONS WITH SYNCOPE	ANNALS OF INTERNAL MEDICINE			English	Article						SYNCOPE; EMOTIONS; HEART RATE; AUTONOMIC NERVOUS SYSTEM; VAGUS NERVE	UNKNOWN ORIGIN; ISOPROTERENOL; MANAGEMENT; HEART	Objective: To study the neurocardiologic reflexes in young persons who have fainted under conditions of emotional stress. Design: Case-control study. Setting: Clinical neurophysiology laboratory in Haifa, Israel. Patients: Sixty persons (41 women and 19 men), 15 to 17 years old, who were referred for study because of syncope related to an emotionally distressing event. Forty aged-matched, healthy volunteers drawn from the same population served as controls. Measurements: Resting electrocardiogram, inspiratory-expiratory difference in heart rate during deep breathing, heart rate response to the Valsalva maneuver, and blood pressure during motionless standing for 5 minutes. Results: Although individual results were within widely accepted limits of normal, patients with syncope as a group had higher vagal autonomic tone than did controls. This manifested as a slower heart rate at rest (mean, 67.8 beats/min compared with 73.2 beats/min; P = 0.005), a higher inspiratory-expiratory difference in heart rate (mean, 44.1 beats/min compared with 37.9 beats/min; P = 0.001), and a higher Valsalva ratio (1.91 compared with 1.72; P < 0.0001). No significant difference was found in the PR and QT(c) (QT interval corrected for rate) intervals of the electrocardiogram or in the blood pressure response to standing. Conclusion: Many young persons who faint under conditions of emotional distress do so because a relatively high vagal tone predisposes them to the cardioinhibitory component of the syncope. Age-related physiologic reduction in vagal cardiac responses may explain the lower incidence of this type of syncope with increasing age.	RAMBAM MED CTR, HAIFA, ISRAEL	Rambam Health Care Campus; Technion Israel Institute of Technology	BARRON, SA (corresponding author), TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, CLIN NEUROPHYSIOL LAB, EFRON ST, POB 9649, IL-31096 HAIFA, ISRAEL.							ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; ARNOLD RW, 1991, MAYO CLIN PROC, V66, P797, DOI 10.1016/S0025-6196(12)61197-5; BALDWA VS, 1977, BRIT HEART J, V39, P641; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; JOHNSON RH, 1984, NEUROCARDIOLOGY INTE, P3; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; LEVIN AB, 1966, AM J CARDIOL, V18, P90, DOI 10.1016/0002-9149(66)90200-1; LINZER M, 1991, AM J MED, V90, P1, DOI 10.1016/0002-9343(91)90498-M; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MUSTONEN J, 1989, CLIN PHYSIOL, V9, P249, DOI 10.1111/j.1475-097X.1989.tb00977.x; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; WEISSLER AM, 1986, HEART, P507; WIELING W, 1982, DIABETOLOGIA, V22, P163, DOI 10.1007/BF00283745	17	19	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					943	946		10.7326/0003-4819-118-12-199306150-00005	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8489108				2022-12-01	WOS:A1993LF93700005
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			ACCIDENTAL DURAL PUNCTURE IN OBSTETRIC PATIENTS AND LONG-TERM SYMPTOMS	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS; ANESTHESIA; MANAGEMENT; BLOCK	Objective-To examine the association between accidental dural puncture and long term headache and related symptoms. Design-Postal questionnaire survey to elucidate new symptoms occurring after childbirth, and linking of these to data in obstetric and anaesthetic case notes. Women were surveyed between 13 months and nine years after delivery. Setting-Birmingham Maternity Hospital. Subjects-4700 women who had delivered their most recent baby under epidural anaesthesia, 74 of whom had suffered an accidental dural puncture. Main outcome measures-Frequencies of new headache or migraine or neck ache starting within three months after childbirth and lasting over six weeks. Results-Among the 74 women who had had an accidental dural puncture there were 17 (23%) who reported one or more of the above symptoms. By comparison, among those who had had an epidural anaesthetic but no recorded puncture, only 329 (7.1%) reported these symptoms. The duration of the headache or migraine or neck ache in the dural tap group ranged from nine weeks to over eight years. Ten of these women reported still unresolved symptoms. Conclusions-Conclusions on causality were tentative. Most women would remember a dural tap, and this might influence their reporting of subsequent symptoms attributable to the event. In addition, detailed characterisation of the symptoms was not available. Nevertheless, the findings provide a clear indication of the need for further study of the possible long term sequelae of accidental dural puncture.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				ABOULEISH E, 1978, ANESTHESIOLOGY, V49, P291, DOI 10.1097/00000542-197810000-00016; Bromage PR, 1978, EPIDURAL ANALGESIA, V1st; BROWNRIDGE P, 1982, ANAESTH INTENS CARE, V10, P298, DOI 10.1177/0310057X8201000401; BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CAST W, 1974, JAMA-J AM MED ASSOC, V227, P786; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P1277, DOI 10.1093/bja/44.12.1277; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; KALAS DB, 1972, ANESTH ANAL CURR RES, V51, P192; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1992, BRIT MED J, V304, P1279, DOI 10.1136/bmj.304.6837.1279; MACARTHUR C, 1991, HLTH CHILDBIRTH; OKELL RW, 1987, ANAESTHESIA, V42, P1110, DOI 10.1111/j.1365-2044.1987.tb05181.x; ONG B, 1987, CAN J ANAESTH, V34, P294, DOI 10.1007/BF03015169; REYNOLDS F, 1989, BRIT MED J, V299, P751, DOI 10.1136/bmj.299.6702.751; SCOTT DB, 1990, BRIT J ANAESTH, V64, P537, DOI 10.1093/bja/64.5.537; STRIDE PC, 1993, ANAESTHESIA, V48, P247, DOI 10.1111/j.1365-2044.1993.tb06913.x; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005	17	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 3	1993	306	6882					883	885		10.1136/bmj.306.6882.883	http://dx.doi.org/10.1136/bmj.306.6882.883			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490410	Bronze, Green Published			2022-12-01	WOS:A1993KW38700016
J	Weeks, KM; Cech, TR				Weeks, KM; Cech, TR			Assembly of a ribonucleoprotein catalyst by tertiary structure capture	SCIENCE			English	Article							16-S RIBOSOMAL-RNA; PRE-MESSENGER RNA; GROUP-I INTRON; ESCHERICHIA-COLI; CBP2 PROTEIN; YEAST; INVITRO; BINDING; SUBSTRATE; SEQUENCE	CBP2 is an RNA tertiary structure binding protein required for efficient splicing of a yeast mitochondrial group I intron. CBP2 must wait for folding of the two RNA domains that make up the catalytic core before it can bind. In a subsequent step, association of the 5' domain of the RNA is stabilized by additional interactions with the protein. Thus, CBP2 functions primarily to capture otherwise transient RNA tertiary structures. This simple one-RNA, one-protein system has revealed how the kinetic pathway of RNA folding can direct the assembly of a specific ribonucleoprotein complex. There are parallels to steps in the formation of a much more complex ribonucleoprotein, the 30S ribosomal subunit,			Weeks, KM (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							ALBERTY RA, 1957, J PHYS CHEM-US, V62, P154; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CAREY J, 1993, BIOCHEMISTRY-US, V2, P2610; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; GESTELAND RF, 1993, RNA WORLD; GU XG, 1992, BIOCHEMISTRY-US, V31, P10295, DOI 10.1021/bi00157a017; HELD WA, 1974, J BIOL CHEM, V249, P3103; HELD WA, 1973, BIOCHEMISTRY-US, V12, P3273, DOI 10.1021/bi00741a020; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; LI Y, 1995, BIOCHEMISTRY-US, V34, P14394, DOI 10.1021/bi00044a016; LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041; MANDIYAN V, 1989, J MOL BIOL, V210, P323, DOI 10.1016/0022-2836(89)90334-3; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOMURA M, 1969, COLD SPRING HARB SYM, V34, P49, DOI 10.1101/SQB.1969.034.01.009; PARTONO S, 1988, MOL CELL BIOL, V8, P2562, DOI 10.1128/MCB.8.6.2562; PINGOUD A, 1973, FEBS LETT, V30, P1, DOI 10.1016/0014-5793(73)80605-2; POWERS T, 1993, J MOL BIOL, V232, P362, DOI 10.1006/jmbi.1993.1396; POWERS T, 1995, RNA, V1, P194; SALDANHA RJ, 1995, BIOCHEMISTRY-US, V34, P1275, DOI 10.1021/bi00004a022; SIEBER G, 1978, BIOCHEMISTRY-US, V17, P3505, DOI 10.1021/bi00610a013; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WEEKS KM, 1995, BIOCHEMISTRY-US, V34, P7728, DOI 10.1021/bi00023a020; WEEKS KM, UNPUB; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	36	105	109	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 19	1996	271	5247					345	348		10.1126/science.271.5247.345	http://dx.doi.org/10.1126/science.271.5247.345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553068				2022-12-01	WOS:A1996TQ52800039
J	Mannuzzu, LM; Moronne, MM; Isacoff, EY				Mannuzzu, LM; Moronne, MM; Isacoff, EY			Direct physical measure of conformational rearrangement underlying potassium channel gating	SCIENCE			English	Article							SHAKER K+ CHANNELS; SODIUM-CHANNEL; S4 REGION; INACTIVATION; DROSOPHILA; CURRENTS; CHARGE; GENE	In response to membrane depolarization, voltage-gated ion channels undergo a structural rearrangement that moves charges or dipoles in the membrane electric field and opens the channel-conducting pathway. By combination of site-specific fluorescent labeling of the Shaker potassium channel protein with voltage clamping, this gating conformational change was measured in real time. During channel activation, a stretch of at least seven amino acids of the putative transmembrane segment S4 moved from a buried position into the extracellular environment. This movement correlated with the displacement of the gating charge, providing physical evidence in support of the hypothesis that S4 is the voltage sensor of voltage-gated ion channels.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory			isacoff, ehud/AAP-1459-2020	Isacoff, Ehud Y./0000-0003-4775-9359				Aggarwal Sanjay K., 1995, Biophysical Journal, V68, pA138; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.bi.55.070186.004513; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MCCORMACK K, 1994, NEURON, V12, P301, DOI 10.1016/0896-6273(94)90273-9; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	30	500	515	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					213	216		10.1126/science.271.5246.213	http://dx.doi.org/10.1126/science.271.5246.213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539623				2022-12-01	WOS:A1996TP36400045
J	Edmondstone, WM				Edmondstone, WM			Cardiac chest pain: Does body language help the diagnosis?	BRITISH MEDICAL JOURNAL			English	Article											Edmondstone, WM (corresponding author), ROYAL NAVAL HOSP,GOSPORT PO12 2AA,HANTS,ENGLAND.							BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1	1	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1660	1661		10.1136/bmj.311.7021.1660	http://dx.doi.org/10.1136/bmj.311.7021.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541748	Green Published			2022-12-01	WOS:A1995TL94200007
J	CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D				CUKIERMAN, E; HUBER, I; ROTMAN, M; CASSEL, D			THE ARF1 GTPASE-ACTIVATING PROTEIN - ZINC-FINGER MOTIF AND GOLGI-COMPLEX LOCALIZATION	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; BINDING-PROTEIN; GUANINE-NUCLEOTIDE; PHOSPHOLIPASE-D; BREFELDIN-A; MEMBRANES; COATOMER; EXCHANGE; COP	Hydrolysis of guanosine triphosphate (GTP) by the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor-1 (ARF1) depends on a GTPase-activating protein (GAP). A complementary DNA encoding the ARF1 GAP was cloned from rat liver and predicts a protein with a zinc finger motif near the amino terminus. The GAP function required an intact zinc finger and additional amino-terminal residues. The ARF1 GAP was localized to the Golgi complex and was redistributed into a cytosolic pattern when cells were treated with brefeldin A, a drug that prevents ARF1-dependent association of coat proteins with the Golgi. Thus, the GAP is likely to be recruited to the Golgi by an ARF1-dependent mechanism.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Cukierman, Edna/A-3951-2013; cukierman, edna/AAU-8932-2020	cukierman, edna/0000-0002-1452-9576				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, UNPUB; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; IRELAND LS, 1995, EMBO J, V13, P3812; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARTICK S, 1991, NUCLEIC ACIDS RES, V19, P4008; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POON P, UNPUB; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	22	264	268	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1999	2002		10.1126/science.270.5244.1999	http://dx.doi.org/10.1126/science.270.5244.1999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533093				2022-12-01	WOS:A1995TL42000044
J	FORMAN, BM; TONTONOZ, P; CHEN, J; BRUN, RP; SPIEGELMAN, BM; EVANS, RM				FORMAN, BM; TONTONOZ, P; CHEN, J; BRUN, RP; SPIEGELMAN, BM; EVANS, RM			15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA	CELL			English	Article							NECROSIS-FACTOR-ALPHA; HORMONE RECEPTOR SUPERFAMILY; 9-CIS RETINOIC ACID; ANTIDIABETIC AGENTS; ACTIVATED RECEPTOR; INSULIN RESISTANCE; GROWTH-INHIBITION; FATTY-ACIDS; X RECEPTOR; CELLS	Regulation of adipose cell mass is a critical homeostatic process in higher vertebrates. The conversion of fibroblasts into cells of the adipose lineage is induced by expression of the orphan nuclear receptor PPAR gamma. This suggests that an endogenous PPAR gamma ligand mar be an important regulator of adipogenesis. By assaying arachidonate metabolites for their capacity to activate PPAR response elements, we have identified 15-deoxy-Delta(12,14)-prostaglandin J(2) as both a PPAR gamma ligand and an inducer of adipogenesis. Similarly, the thiazolidinedione class of antidiabetic drugs also bind to PPAR gamma and act as potent regulators of adipocyte development. Thus, adipogenic prostanoids and antidiabetic thiazolidinediones initiate key transcriptional events through a common nuclear receptor signaling pathway. These findings suggest a pivotal role for PPAR gamma and its endogenous ligand in adipocyte development and glucose homeostasis and as a target for intervention in metabolic disorders.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NIDDK NIH HHS [DK-31405, DK09090] Funding Source: Medline; NIGMS NIH HHS [T32 GM07753, T32 GM007753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031405, R37DK031405, F32DK009090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CANTELLO BCC, 1994, J MED CHEM, V37, P3977, DOI 10.1021/jm00049a017; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FOXWORTHY PS, 1988, BIOCHEM J, V252, P409, DOI 10.1042/bj2520409; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRUNDY SM, 1990, DM-DIS MON, V36, P641; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARRIS PKW, 1994, MOL PHARMACOL, V45, P439; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOFMANN CA, 1992, DIABETES CARE, V15, P1075, DOI 10.2337/diacare.15.8.1075; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P659; MAHMUD I, 1984, PROSTA LEUKOTR MED, V16, P131, DOI 10.1016/0262-1746(84)90066-0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSHALL WS, 1987, J MED CHEM, V30, P682, DOI 10.1021/jm00387a018; MCCALL JL, 1992, BRIT J SURG, V79, P1361, DOI 10.1002/bjs.1800791240; MCKINNEY B, 1967, STAIN TECHNOL, V42, P245, DOI 10.3109/10520296709115018; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1995, ADV PROSTAG THROMB L, V23, P17; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SOHDA T, 1990, ARZNEIMITTEL-FORSCH, V40-1, P37; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	66	2636	2711	2	86	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					803	812		10.1016/0092-8674(95)90193-0	http://dx.doi.org/10.1016/0092-8674(95)90193-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521497	Bronze			2022-12-01	WOS:A1995TH94800017
J	MORHAM, SG; LANGENBACH, R; LOFTIN, CD; TIANO, HF; VOULOUMANOS, N; JENNETTE, JC; MAHLER, JF; KLUCKMAN, KD; LEDFORD, A; LEE, CA; SMITHIES, O				MORHAM, SG; LANGENBACH, R; LOFTIN, CD; TIANO, HF; VOULOUMANOS, N; JENNETTE, JC; MAHLER, JF; KLUCKMAN, KD; LEDFORD, A; LEE, CA; SMITHIES, O			PROSTAGLANDIN-SYNTHASE-2 GENE DISRUPTION CAUSES SEVERE RENAL PATHOLOGY IN THE MOUSE	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; ENDOPEROXIDE SYNTHASE; G/H SYNTHASE; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; MESSENGER-RNA; CDNA CLONING; EXPRESSION; INHIBITION	The prostaglandin endoperoxide H synthase isoform 2, cyclooxygenase 2 (COX-2), is induced at high levels in migratory and other responding cells by proinflammatory stimuli. COX-2 is generally considered to be a mediator of inflammation. Its isoform, COX-1, is constitutively expressed in most tissues and is thought to mediate ''housekeeping'' functions. These two enzymes are therapeutic targets of the widely used nonsteroidal anti-inflammatory drugs (NSAIDs). To investigate further the different physiologic roles of these isoforms, we have used homologous recombination to disrupt the mouse gene encoding COX-2 (PtgsS). Mice lacking COX-2 have normal inflammatory responses to treatments with tetradecanoyl phorbol acetate or with arachidonic acid. However, the; develop severe nephropathy and are susceptible to peritonitis.	NIEHS,EXPTL CARCINOGENESIS & MUTAGENESIS LAB,RES TRIANGLE PK,NC 27709; NIEHS,EXPTL PATHOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	MORHAM, SG (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599, USA.			Jennette, John Charles/0000-0002-8081-6565	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49227] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CELSI G, 1986, PEDIATR RES, V20, P347, DOI 10.1203/00006450-198604000-00018; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CROMLISH WA, 1994, ARCH BIOCHEM BIOPHYS, V314, P193, DOI 10.1006/abbi.1994.1429; DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER R, 1972, NATURE-NEW BIOL, V238, P104, DOI 10.1038/newbio238104a0; FLOWER RJ, 1972, NATURE, V240, P410, DOI 10.1038/240410a0; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; GILBERT T, 1991, PEDIATR RES, V30, P450, DOI 10.1203/00006450-199111000-00011; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HOOPER M, 1987, NATURE, V336, P348; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; KESTER M, 1994, J BIOL CHEM, V269, P22574; KIM HS, 1988, NUCLEIC ACIDS RES, V162, P8887; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANGENBACH R, 1995, CELL, V83; LEE SH, 1992, J BIOL CHEM, V267, P25934; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MCGRAW M, 1984, INT J PED NEPHROL, V5, P67; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Meade T. W., 1992, P321; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OPAS EE, 1985, J INVEST DERMATOL, V84, P253, DOI 10.1111/1523-1747.ep12265320; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROME LH, 1976, PROSTAGLANDINS, V11, P23, DOI 10.1016/0090-6980(76)90169-6; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P6168; SIMMONS DL, 1992, PROSTAGLANDINS LEUKO, P67; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; THUN MJ, 1993, CANCER RES, V53, P1322; THUN MJ, 1991, NEW ENGL J MED, V25, P1593; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568	60	948	963	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					473	482		10.1016/0092-8674(95)90125-6	http://dx.doi.org/10.1016/0092-8674(95)90125-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521477	Bronze			2022-12-01	WOS:A1995TC97700017
J	ZANGWILL, KM; HAMILTON, DH; PERKINS, BA; REGNERY, RL; PLIKAYTIS, BD; HADLER, JL; CARTTER, ML; WENGER, JD				ZANGWILL, KM; HAMILTON, DH; PERKINS, BA; REGNERY, RL; PLIKAYTIS, BD; HADLER, JL; CARTTER, ML; WENGER, JD			CAT-SCRATCH DISEASE IN CONNECTICUT - EPIDEMIOLOGY, RISK-FACTORS, AND EVALUATION OF A NEW DIAGNOSTIC-TEST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AGENT	Background. Although cat scratch disease is commonly diagnosed in patients who have unexplained regional lymphadenopathy after encounters with cats, its epidemiology and the risk factors for disease are not clearly defined, and there is no generally accepted diagnostic test Methods. We conducted a physician survey to identify cases of cat scratch disease occurring over a 13-month period in cat owners in Connecticut. We interviewed both the patients (or their parents) and controls matched for age who owned cats. Serum from the patients was tested for antibodies to Rochalimaea henselae with a new, indirect fluorescent-antibody test. Results. We identified 60 patients with cat scratch disease and 56 age-matched, cat-owning control subjects. Patients were more likely than controls to have at least one pet kitten 12 months old or younger (odds ratio, 15), to have been scratched or kitten by a kitten (odds ratio, 27), and to have had at least one kitten with fleas (odds ratio, 29). A conditional logistic-regression analysis found that in kitten-owning households, patients were more likely than controls to have been scratched or bitten by a cat or kitten (odds ratio, 12.4; 95 percent confidence interval, 1.0 to 150). Of 45 patients, 38 had serum samples with titers of 1:64 or higher for antibody to R. henselae, as compared with 4 of 112 samples from controls (P<0.001). The positive predictive value of the serologic test was 91 percent. Of 48 serum samples from patients' cats, 39 were positive for antibodies to R. henselae, as compared with positive samples from 11 of 29 control cats (P<0.001). Conclusions. Cat scratch disease is strongly associated with owning a kitten, and fleas may be involved in its transmission. The serologic test for rochalimaea may be useful diagnostically, and our results suggest an etiologic role for this genus.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,HARTFORD,CT; CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD SERV,HARTFORD,CT; CONNECTICUT DEPT HLTH SERV,BUR HLTH PROMOT,EPIDEMIOL SECT,HARTFORD,CT; CTR DIS CONTROL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	ZANGWILL, KM (corresponding author), CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.							BOYD GL, 1961, J PEDIATR-US, V59, P313, DOI 10.1016/S0022-3476(61)80282-5; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; DANIELS WB, 1954, JAMA-J AM MED ASSOC, V154, P1247, DOI 10.1001/jama.1954.02940490011003; DEBRE R., 1950, BuL Mem. Soc. Med. Hop., V66, P76; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; GERBER MA, 1985, LANCET, V1, P1236; GROVES R, 1988, TELEPHONE SURVEY MET; Harwood RF., 1979, ENTOMOLOGY HUMAN ANI; JACKSON LA, IN PRESS AM J PUBLIC; KALTER SS, 1969, NATURE, V224, P190, DOI 10.1038/224190a0; KWOCHKA KW, 1987, VET CLIN N AM-SMALL, V17, P1235, DOI 10.1016/S0195-5616(87)50001-8; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MARGILETH AM, 1968, PEDIATRICS, V42, P803; MARGILETH AM, 1987, VET CLIN N AM-SMALL, V17, P91, DOI 10.1016/S0195-5616(87)50607-6; MARGILETH AM, 1971, CLIN P CHILDRENS HOS, V27, P213; MARGILETH AM, 1990, CONT PEDIATR, V7, P25; Moriarty R A, 1987, Infect Dis Clin North Am, V1, P575; PERKINS BA, 1992, NEW ENGL J MED, V327, P1599, DOI 10.1056/NEJM199211263272215; REGNERY R, 1992, LANCET, V340, P557, DOI 10.1016/0140-6736(92)91760-6; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SHINALL EA, 1990, PEDIATR DERMATOL, V7, P11, DOI 10.1111/j.1525-1470.1990.tb01066.x; Shinall EA, 1990, PEDIAT DERMATOL, V7, P165; SPAULDING WB, 1960, AM J MED, V28, P504, DOI 10.1016/0002-9343(60)90144-3; TROUTMAN CM, 1988, J AM VET MED ASSOC, V193, P1217; TURNER W, 1960, J BACTERIOL, V80, P430, DOI 10.1128/JB.80.4.430-435.1960; Warwick W J, 1967, Prog Med Virol, V9, P256; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZITELLI BJ, 1990, CONT PEDIATR, V7, P90; 1988, SAS USERS GUIDE VERS	31	411	422	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					8	13		10.1056/NEJM199307013290102	http://dx.doi.org/10.1056/NEJM199307013290102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8505963				2022-12-01	WOS:A1993LJ33800002
J	DEBONDT, HL; ROSENBLATT, J; JANCARIK, J; JONES, HD; MORGAN, DO; KIM, SH				DEBONDT, HL; ROSENBLATT, J; JANCARIK, J; JONES, HD; MORGAN, DO; KIM, SH			CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2	NATURE			English	Article							P34CDC2 PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REGULATORY PHOSPHORYLATION; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MUTANT ALLELES; GENE CDC28; IDENTIFICATION	Cyclin-dependent kinase 2 (CDK2) is a member of a highly conserved family of protein kinases that regulate the eukaryotic cell cycle. The crystal structures of the human CDK2 apoenzyme and its Mg2+ ATP complex have been determined to 2.4angstrom resolution. The structure is bi-lobate, like that of the cyclic AMP-dependent protein kinase, but contains a unique helix-loop segment that interferes with ATP and protein substrate binding and probably plays a key part in the regulation of all cyclin-dependent kinases.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco			Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868; Morgan, David/0000-0001-8753-4416				ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; AYSCOUGH K, 1992, MOL GEN GENET, V232, P344, DOI 10.1007/BF00266236; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FUREY W, 1992, PHASES MANUAL; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P286; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETSKO GA, 1985, METHOD ENZYMOL, V114, P147; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHENG J, 1993, ACTA CRYSTALLOG RD, V49, P363; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	50	829	853	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1993	363	6430					595	602		10.1038/363595a0	http://dx.doi.org/10.1038/363595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH139	8510751				2022-12-01	WOS:A1993LH13900045
J	JORDAN, G; MOLLON, JD				JORDAN, G; MOLLON, JD			THE NAGEL ANOMALOSCOPE AND SEASONAL-VARIATION OF COLOR-VISION	NATURE			English	Article								IN 1948 the German physicist, Manfred Richter, reported that colour vision has a seasonal variation1,2. For four colour-normal subjects, he found a sinusoidal variation in the proportion of red and green required to match a monochromatic yellow, the equation known as the 'Rayleigh match'3. In summer, subjects required more red in their mixture. The measurements were made with the Nagel anomaloscope, an instrument introduced in 1907(4,5) and which today, essentially unchanged, remains the definitive clinical instrument for classifying the many phenotypic variations in colour vision. The variation that Richter recorded in the red-green ratio was large (three Nagel units), and it now takes on fresh interest because it is comparable in size to the difference in Nagel settings later reported between normal observers of different genetic type6,7. We have been able to replicate Richter's result, but report here that it is almost certainly instrumental: the Nagel anomaloscope proves to be very sensitive to ambient temperature.			JORDAN, G (corresponding author), UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, DOWNING ST, CAMBRIDGE CB2 3EB, ENGLAND.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X; Jordan, Gabriele/0000-0002-3994-6675				HAHN H, 1948, PFLUG ARCH GES PHYS, V250, P357, DOI 10.1007/BF00369741; HEINSIUS E, 1973, FARBSINNSTORUNGEN IH; JORDAN G, 1992, POLYM NORMAL COLOUR; KNOWLES A, 1980, VISION RES, V20, P475, DOI 10.1016/0042-6989(80)90122-4; KOLLNER H, 1915, ARCH AUGENHEILKD, V78, P302; Merton TR, 1927, P R SOC LOND A-CONTA, V113, P704, DOI 10.1098/rspa.1927.0018; MORELAND JD, 1974, COLOUR VISION DEFICI, V2, P14; NAGEL W, 1909, HDB PHYSL METHODIK; NAGEL WA, 1907, Z AUGENHEILKD, V18, P201; POKORNY J., 1979, CONGENITAL ACQUIRED; Rayleigh L., 1881, NATURE, V25, P64, DOI [10.1038/025064a0, DOI 10.1038/025064A0]; RICHTER M, 1951, Klin Monbl Augenheilkd Augenarztl Fortbild, V119, P561; RICHTER M, 1948, Z WISS PHOTOGR PHOTO, V43, P209; Waaler G. H. M., 1967, AVHANDL DET NORSKE V, V9, P1; WAALER GHM, 1967, NATURE, V215, P406, DOI 10.1038/215406a0; WINDERICKX J, 1992, NAT GENET, V1, P251, DOI 10.1038/ng0792-251	16	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					546	549		10.1038/363546a0	http://dx.doi.org/10.1038/363546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505982				2022-12-01	WOS:A1993LF93900051
J	SARY, G; VOGELS, R; ORBAN, GA				SARY, G; VOGELS, R; ORBAN, GA			CUE-INVARIANT SHAPE SELECTIVITY OF MACAQUE INFERIOR TEMPORAL NEURONS	SCIENCE			English	Article							INFEROTEMPORAL CORTEX; CORTICAL CONNECTIONS; MONKEY; DISCRIMINATION; CONTRAST; SULCUS	The perception of shape is independent of the size and position of the shape and also of the visual cue that defines it. The same shape can be recognized whether defined by a difference in luminance, by motion, or by texture. Experiments showed that the shape selectivity of individual cells in the macaque inferior temporal cortex did not vary with the size and position of a shape and also did not vary with the visual cue used to define the shape. This cue invariance was true for static luminance and texture cues as well as for relative motion cues-that is, for cues that are processed in ventral and dorsal visual pathways. The properties of these inferior temporal cells meet the demands of cue-invariant shape coding.	CATHOLIC UNIV LEUVEN,FAC GENEESKUNDE,NEURO & PSYCHOFYSIOL LAB,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM	KU Leuven				Orban, Guy/0000-0002-8179-9584				ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; BAIZER JS, 1991, J NEUROSCI, V11, P168; BRITTEN KH, 1992, EXP BRAIN RES, V88, P292, DOI 10.1007/BF02259104; DEAN P, 1976, PSYCHOL BULL, V83, P41, DOI 10.1037/0033-2909.83.1.41; DESIMONE R, 1984, J NEUROSCI, V4, P2051; DESIMONE R, 1980, BRAIN RES, V184, P41, DOI 10.1016/0006-8993(80)90586-7; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; LOGOTHETIS NK, 1990, INVEST OPHTH VIS SCI, V31, P444; MARCAR V L, 1991, Society for Neuroscience Abstracts, V17, P525; Marcar V. L., 1992, Society for Neuroscience Abstracts, V18, P1275; MARCAR VL, 1992, EUR J NEUROSCI, V4, P1228, DOI 10.1111/j.1460-9568.1992.tb00148.x; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; OLAVARRIA JF, 1992, J NEUROPHYSIOL, V68, P164, DOI 10.1152/jn.1992.68.1.164; REGAN D, 1991, PERCEPTION, V20, P315, DOI 10.1068/p200315; ROLLS ET, 1986, EXP BRAIN RES, V65, P38; SATO T, 1980, EXP BRAIN RES, V38, P313; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204	23	247	249	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 14	1993	260	5110					995	997		10.1126/science.8493538	http://dx.doi.org/10.1126/science.8493538			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	8493538	Green Accepted			2022-12-01	WOS:A1993LB79100047
J	SMITH, AP; THOMAS, M; BROCKMAN, P; KENT, J; NICHOLSON, KG				SMITH, AP; THOMAS, M; BROCKMAN, P; KENT, J; NICHOLSON, KG			EFFECT OF INFLUENZA B-VIRUS INFECTION ON HUMAN-PERFORMANCE	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 7RH,ENGLAND	University of Leicester	SMITH, AP (corresponding author), UNIV WALES COLL CARDIFF,SCH PSYCHOL,HLTH PSYCHOL RES UNIT,CARDIFF CF1 3YG,WALES.		Smith, Andrew P/B-2192-2010	Smith, Andrew/0000-0001-8805-8028; Thomas, Marie/0000-0003-2360-255X				CARPENTER JA, 1959, J COMP PHYSIOL PSYCH, V52, P491, DOI 10.1037/h0048652; GLUE P, 1991, Journal of Psychopharmacology, V5, P377, DOI [10.1177/026988119200600306, 10.1177/026988119100500432]; Smith A.P., 1992, HDB HUMAN PERFORMANC, V2, P197; SMITH AP, 1990, PHILOS T ROY SOC B, V327, P519, DOI 10.1098/rstb.1990.0095; SMITH AP, 1985, CONT ERGONOMICS 1985, P33	5	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					760	761		10.1136/bmj.306.6880.760	http://dx.doi.org/10.1136/bmj.306.6880.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490339	Bronze, Green Published			2022-12-01	WOS:A1993KU17300023
J	Leatherwood, J; LopezGirona, A; Russell, P				Leatherwood, J; LopezGirona, A; Russell, P			Interaction of Cdc2 and Cdc18 with a fission yeast ORC2-like protein	NATURE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; CELL-CYCLE; MITOSIS; GENE; SYSTEM	IN fission yeast, Cdc2 kinase has both positive and negative roles in regulating DNA replication, being first necessary for the transition from G(1) to S phase and later required to prevent the re-initiation of DNA replication during G(2)(1-3). We report here that Cdc2 interacts with Orp2, a protein similar to the Orc2 replication factor subunit of Saccharomyces cerevisiae origin recognition complex (ORC). ORC binds chromosomal origins and is essential for chromosomal replication initiation(4-6). Fission yeast Orp2 is required for DNA replication and interacts with the rate-limiting replication activator Cdc18. Cells lacking Orp2 undergo aberrant mitosis, indicating that Orp2 is involved in generating a checkpoint signal, These findings suggest that ORC functions are conserved among eukaryotes and provide evidence that Cdc2 controls DNA replication initiation by acting directly at chromosomal origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MAUNDRELL K, 1985, NUCLEIC ACIDS RES, V13, P3711, DOI 10.1093/nar/13.10.3711; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ZHOU C, 1989, J BIOL CHEM, V264, P9022	28	109	114	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					360	363		10.1038/379360a0	http://dx.doi.org/10.1038/379360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552194				2022-12-01	WOS:A1996TR32300063
J	Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB				Sondek, J; Bohm, A; Lambright, DG; Hamm, HE; Sigler, PB			Crystal structure of a G(A) protein beta gamma dimer at 2.1 angstrom resolution	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SUBUNIT; PHEROMONE	MANY signalling cascades use seven-helical transmembrane receptors coupled to heterotrimeric G proteins (G(alpha beta gamma)) to convert extracellular signals into intracellular responses(1). Upon nucleotide exchange catalysed by activated receptors, heterotrimers dissociate into GTP-bound G(alpha) subunits and G(beta gamma) dimers, either of which can modulate many downstream effectors(2,3). Here we use multiwavelength anomalous diffraction data to solve the crystal structure of the beta gamma dimer of the G protein transducin. The beta-subunit is primarily a seven-bladed beta-propeller that is partially encircled by an extended gamma-subunit. The beta-propeller, which contains seven structurally similar WD repeats, defines the stereochemistry of the WD repeat and the probable architecture of all WD-repeat-containing domains. The structure details interactions between G protein beta- and gamma-subunits and highlights regions implicated in effector modulation for the conserved family of G protein beta gamma dimers.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Sondek, John/0000-0002-1127-8310				BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAMISTEN A, 1993, P NATL ACAD SCI USA, V90, P7706; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; GRISHIN AV, 1994, GENETICS, V138, P1081; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERVOOM L, 1992, FEBS LETT, V30, P131; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223	32	687	704	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					369	374		10.1038/379369a0	http://dx.doi.org/10.1038/379369a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552196				2022-12-01	WOS:A1996TR32300065
J	MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E				MacLean, JD; Arthur, JR; Ward, BJ; Gyorkos, TW; Curtis, MA; Kokoskin, E			Common-source outbreak of acute infection due to the North American liver fluke Metorchis conjunctus	LANCET			English	Article								Background We investigated an outbreak of acute clinical illness among 19 people who ate raw fish (sashimi) prepared from the white sucker, Catostomus commersoni, caught in a river north of Montreal, Canada. Methods We collected epidemiological, clinical, laboratory, and serological data on 19 individuals who ate the sashimi and six who did not. Because of the suggestive clinical picture, we set out to recover helminth parasites from uneaten fish. Findings The illness consisted of persistent upper abdominal pain, low grade fever, high blood eosinophil concentrations, and raised liver enzymes. After 10 days, opisthorchiid-like eggs were found in stools. Symptoms persisted for 3 days to 4 weeks without treatment, but responded rapidly to praziquantel therapy. Necropsy of golden hamsters infected with metacercariae from uneaten fish revealed adult flukes identified as Metorchis conjunctus. Interpretation We describe an acute illness caused by the North American liver fluke M conjunctus. This is a new human disease and is the first report of a common-source outbreak of an acute illness caused by liver flukes of the family Opisthorchiidae.	FISHERIES & OCEANS CANADA, MAURICE LAMONTAGNE INST, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA; MCGILL UNIV, INST PARASITOL, MONTREAL, PQ, CANADA	Fisheries & Oceans Canada; McGill University; McGill University	MacLean, JD (corresponding author), MCGILL UNIV, MONTREAL GEN HOSP, CTR TROP DIS, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							ALLEN J. A., 1934, CANADIAN JOUR RES, V10, P404; BABERO BERT B., 1952, PROC HELMINTHOL SOC WASHINGTON, V19, P15; BRASSARD P, 1985, CAN J PUBLIC HEALTH, V76, P322; BRONSHTEIN AM, 1985, MED PARAZITOL MOSK, V5, P31; Burch J. B, 1982, FRESHWATER SNAILS MO; CAMERON T W M, 1945, Can J Comp Med Vet Sci, V9, P302; Cameron Thomas W. M., 1944, CANADIAN JOUR RES SECT D ZOOL SCI, V22, P6; CAMERON THOMAS W. M., 1940, CANADIAN JOUR RES SECT D ZOOL SCI, V18, P325; CARTWRIGHT GE, 1949, AM J MED, V6, P259, DOI 10.1016/0002-9343(49)90021-2; CLARKE A.H., 1981, FRESHWATER MOLLUSCS; Cobbold T. S., 1860, P LINNEAN SOC LONDON, V17, P1; DITRICH O, 1992, FOLIA PARASIT, V39, P123; EVANS WS, 1963, THESIS U MANITOBA WI; FREEMAN AE, 1937, T AM MICROSC SOC, V57, P113; HARKEMA R, 1964, J PARASITOL, V50, P60, DOI 10.2307/3276029; HASWELLELKINS MR, 1992, J GASTROEN HEPATOL, V7, P538, DOI 10.1111/j.1440-1746.1992.tb01035.x; KOENIGSTEIN RP, 1949, T ROY SOC TROP MED H, V42, P503, DOI 10.1016/0035-9203(49)90057-7; Lee DS, 1980, ATLAS N AM FRESHWATE, DOI DOI 10.5962/BHL.TITLE.141711; MEL'NIKOV V I, 1979, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V48, P12; Mongeau N, 1961, Can Vet J, V2, P33; Rim H.-J., 1986, Korean Journal of Parasitology, V24, P1; Scott W.B., 1973, B FISH RES BOARD CAN, V184, DOI DOI 10.1002/IROH.19760610109; SKRJABIN K.I., 1950, TREMATODES ANIMALS M, V4; SMITH JW, 1975, INT J PARASITOL, V5, P133, DOI 10.1016/0020-7519(75)90019-3; WATSON TG, 1979, CAN J PUBLIC HEALTH, V70, P179; WATSON TG, 1979, THESIS MCGILL U MONT; WOBESER G, 1983, J WILDLIFE DIS, V19, P353; XU Z, 1979, CHIN MED J, V93, P423; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; 1995, WHO TECH REP SER, P849	30	32	38	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					154	158		10.1016/S0140-6736(96)90342-6	http://dx.doi.org/10.1016/S0140-6736(96)90342-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544550				2022-12-01	WOS:A1996TQ24400011
J	Ertem, G; Ferris, JP				Ertem, G; Ferris, JP			Synthesis of RNA oligomers on heterogeneous templates	NATURE			English	Article							5'-PHOSPHORIMIDAZOLIDE; RIBONUCLEOTIDES; MONTMORILLONITE; RIBOZYME; REPLICATION; ADENOSINE; MINERALS; CATALYST; MODEL; LIFE	THE concept of an RNA world(1,2) in the chemical origin of life is appealing, as nucleic acids are capable of both information storage and acting as templates that catalyse the synthesis of complementary molecules(3). Template-directed synthesis has been demonstrated for homogeneous oligonucleotides that, like natural nucleic acids, have 3',5' linkages between the nucleotide monomers(4-7). But it seems likely that prebiotic routes to RNA-like molecules would have produced heterogeneous molecules,vith various kinds of phosphodiester linkages and both linear and cyclic nucleotide chains. Here we show that such heterogeneity need be no obstacle to the templating of complementary molecules. Specifically, we show that heterogeneous oligocytidylates, formed by the montmorillonite clay-catalysed condensation of actuated monomers, can serve as templates for the synthesis of oligoguanylates. Furthermore, we show that oligocytidylates that are exclusively 2',5'-linked can also direct synthesis of oligoguanylates. Such heterogeneous templating reactions could have increased the diversity of the pool of protonucleic acids from which life ultimately emerged.			Ertem, G (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ATKINS RF, 1993, RNA WORLD; DOUDNA JA, 1993, BIOCHEMISTRY-US, V32, P2111, DOI 10.1021/bi00059a032; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; FERRIS JP, 1992, ORIGINS LIFE EVOL B, V22, P369, DOI 10.1007/BF01809373; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P229, DOI 10.1007/BF01581901; FERRIS JP, 1993, ORIGINS LIFE EVOL B, V23, P307, DOI 10.1007/BF01582081; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GRZESKOWIAK K, 1986, J MOL EVOL, V23, P287, DOI 10.1007/BF02100635; HOHN T, 1967, BIOCHIM BIOPHYS ACTA, V138, P466, DOI 10.1016/0005-2787(67)90543-6; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JUNG KE, 1994, J AM CHEM SOC, V116, P6059, DOI 10.1021/ja00093a001; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P1685, DOI 10.1093/nar/20.7.1685; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; LOHRMANN R, 1980, SCIENCE, V208, P1464, DOI 10.1126/science.6247762; LOHRMANN R, 1982, J MOL EVOL, V18, P185, DOI 10.1007/BF01733045; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; PRABAHAR KJ, 1994, J AM CHEM SOC, V116, P10914, DOI 10.1021/ja00103a006; SAWAI H, 1976, J AM CHEM SOC, V98, P7037, DOI 10.1021/ja00438a050; SAWAI H, 1992, J CHEM SOC PERK T 1, P505, DOI 10.1039/p19920000505; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; STRIBLING R, 1991, J CHROMATOGR, V538, P474, DOI 10.1016/S0021-9673(01)88872-5	28	127	143	0	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					238	240		10.1038/379238a0	http://dx.doi.org/10.1038/379238a0			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538788				2022-12-01	WOS:A1996TQ16900040
J	Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA				Italiano, JE; Roberts, TM; Stewart, M; Fontana, CA			Reconstitution in vitro of the motile apparatus from the amoeboid sperm of Ascaris shows that filament assembly and bundling move membranes	CELL			English	Article							HEAVY-CHAIN GENE; AMEBOID SPERM; PROTEIN MSP; DICTYOSTELIUM-DISCOIDEUM; CELL LOCOMOTION; ACTIN; NEMATODE; SUUM; CYTOSKELETON; PONTICULIN	We have developed an in vitro motility system from Ascaris sperm, unique amoeboid cells that use filament arrays composed of major sperm protein (MSP) instead of an actin-based apparatus for locomotion. Addition of ATP to sperm extracts induces formation of fibers similar to 2 mu m in diameter. These fibers display the key features of the MSP cytoskeleton in vivo. Each fiber consists of a meshwork of MSP filaments and has at one end a vesicle derived from the plasma membrane at the leading edge of the cell. Fiber growth is due to filament assembly at the vesicle; thus, fiber elongation results in vesicle translocation, This in vitro system demonstrates directly that localized polymerization and bundling of filaments can move membranes acid provides a powerful assay for evaluating the molecular mechanism of amoeboid cell motility.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	Italiano, JE (corresponding author), FLORIDA STATE UNIV,DEPT BIOL SCI,B-157,TALLAHASSEE,FL 32306, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029994, R37GM029994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHIA CP, 1993, J CELL BIOL, V120, P909, DOI 10.1083/jcb.120.4.909; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1991, ANN REV PHYSL, V53, P584; COSSART P, 1994, MOL MICROBIOL, V13, P395, DOI 10.1111/j.1365-2958.1994.tb00434.x; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HITT AL, 1994, J CELL BIOL, V126, P1433, DOI 10.1083/jcb.126.6.1433; Inoue S, 1986, VIDEO MICROSCOPY; KING KL, 1994, J CELL SCI, V107, P2941; KING KL, 1994, CELL MOTIL CYTOSKEL, V27, P193, DOI 10.1002/cm.970270302; KING KL, 1992, J CELL SCI, V101, P847; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; ROBERTS TM, 1995, CURR OPIN CELL BIOL, V7, P13, DOI 10.1016/0955-0674(95)80039-5; ROBERTS TM, 1991, CELL MOTIL CYTOSKEL, V20, P228, DOI 10.1002/cm.970200306; ROYAL D, 1995, CELL MOTIL CYTOSKEL, V31, P241, DOI 10.1002/cm.970310307; SEPSENWOL S, 1986, J PARASITOL, V72, P962, DOI 10.2307/3281855; SEPSENWOL S, 1989, J CELL BIOL, V108, P55, DOI 10.1083/jcb.108.1.55; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; SOUTHWICK FS, 1994, BIOESSAYS, V16, P885, DOI 10.1002/bies.950161206; STEWART M, 1993, J MOL BIOL, V232, P298, DOI 10.1006/jmbi.1993.1383; STEWART M, 1994, J MOL BIOL, V242, P60; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	43	96	98	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					105	114		10.1016/S0092-8674(00)80997-6	http://dx.doi.org/10.1016/S0092-8674(00)80997-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548814	Bronze			2022-12-01	WOS:A1996TQ17000013
J	ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK				ONeill, EM; Kaffman, A; Jolly, ER; OShea, EK			Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; YEAST; PHOSPHORYLATION; SEQUENCES; PROMOTER	PHO4, a transcription factor required for induction of the PHO5 gene in response to phosphate starvation, is phosphorylated by the PHO80-PHO85 cyclin-CDK (cyclin-dependent kinase) complex when yeast are grown in phosphate-rich medium. PHO4 was shown to be concentrated in the nucleus when yeast were starved for phosphate and was predominantly cytoplasmic when yeast were grown in phosphate-rich medium. The sites of phosphorylation on PHO4 were identified, and phosphorylation was shown to be required for full repression of PHO5 transcription when yeast were grown in high phosphate. Thus, phosphorylation of PHO4 by PHO80-PHO85 turns off PHO5 transcription by regulating the nuclear localization of PHO4.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Jolly, Emmitt R/I-6646-2012	Jolly, Emmitt R/0000-0002-7141-2307				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FISHER F, 1991, ONCOGENE, V6, P1099; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONEILL EM, UNPUB; OSHEA EK, UNPUB; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	20	274	279	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					209	212		10.1126/science.271.5246.209	http://dx.doi.org/10.1126/science.271.5246.209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539622				2022-12-01	WOS:A1996TP36400044
J	Hiss, RG				Hiss, RG			Barriers to care in non-insulin-dependent diabetes mellitus - The Michigan experience	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat				Objective: To determine the barriers to optimal care at the community level for patients with non-insulin-dependent diabetes mellitus (NIDDM). Design: Comprehensive evaluation of the clinical, psychosocial, and educational status of community-based patients with NIDDM, with subsequent review by local diabetes advisory councils of this status and the care those patients have received. The frequency with which patients visited their physician for diabetes management, received patient education, received diet counseling, and were examined by an ophthalmologist-four services universally recognized to be components of optimal diabetes care-was determined for all patients. Setting: Eight Michigan communities, four large and four small. Patients: From 1988 to 1994, 1056 patients with NIDDM (defined by stimulated C-peptide criteria) were studied. Results: The frequency with which all patients with NIDDM visited their community primary care physician in 1994 was 3.7 times per year (4.6 times for patients taking insulin and 3.2 times for those not taking insulin). Thirty-three percent of all patients with NIDDM (48% of those taking insulin and 24% of those not taking insulin) had received all three other essential services, whereas 15% (6% taking insulin and 20% not taking insulin) had never received any of these services. Factors contributing to this level of care and barriers preventing more intensive management of community-based patients with NIDDM were identified by the diabetes advisory councils as they analyzed data from their own communities. The councils determined that the main barriers to optimal care of community-based patients with NIDDM are that 1) NIDDM is not considered or managed as a serious problem by most physicians and their patients; 2) the genetic basis for and refractory nature of obesity are not generally appreciated; and 3) as a complex, multisystemic chronic illness, diabetes fits poorly in a health care delivery system designed to deal with acute and episodic illnesses. Conclusion: Most community-based patients with NIDDM are not aggressively managed because of attitudinal, educational, and systemic factors that act as barriers to optimal health care delivery.			Hiss, RG (corresponding author), UNIV MICHIGAN, SCH MED, CTR DIABET RES & TRAINING, G1103 TOWSLEY CTR, BOX 0201, ANN ARBOR, MI 48109 USA.				NIADDK NIH HHS [P60-AM-20572] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, DIABETES CARE, V17, P519; [Anonymous], 1994, Diabetes Care, V17, P616; DCCT Res Grp, 1986, DIABETES, V35, P530; HISS RG, 1994, DIABETES CARE, V17, P1124, DOI 10.2337/diacare.17.10.1124; HISS RG, 1992, DIABETES COMMUNITIES, V2; HORTON ES, 1990, DIABETES MELLITUS TH, P457; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; Logsdon D N, 1984, J Ambul Care Manage, V7, P46; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MARX J, 1994, SCIENCE, V266, P1477, DOI 10.1126/science.7985012; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1989, GUIDE CLIN PREVENTIV, pR19; 1995, DIABETES CARE S1, V18, P1	13	76	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				146	148		10.7326/0003-4819-124-1_Part_2-199601011-00012	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554207				2022-12-01	WOS:A1996TL94400012
J	SMITH, PJS				SMITH, PJS			NONINVASIVE ION PROBES - TOOLS FOR MEASURING TRANSMEMBRANE ION FLUX	NATURE			English	Article											SMITH, PJS (corresponding author), MARINE BIOL LAB,WOODS HOLE,MA 02543, USA.			Smith, Peter/0000-0003-4400-6853				Ammann D., 1986, ION SELECTIVE MICROE; DEMAREST JR, IN PRESS BIOL B, V189; JAFFE LF, 1976, J CELL BIOL, V33, P614; KEEFE D, IN PRESS BIOL B, V189; KOCHIAN LV, 1992, PLANTA, V188, P601, DOI 10.1007/BF00197055; KUHTREIBER WM, 1990, J CELL BIOL, V110, P1565, DOI 10.1083/jcb.110.5.1565; LAND SC, IN PRESS BIOL B, V189; MARCUS DC, 1994, BIOPHYS J, V66, P1939, DOI 10.1016/S0006-3495(94)80987-7; NUCCITELLI R, 1990, NONINVASIVE TECHNIQU; SCHEFFEY C, 1988, REV SCI INSTRUM, V59, P787, DOI 10.1063/1.1139830; SMITH PJS, 1994, METHOD CELL BIOL, V40, P115; SMITH PJS, IN PRESS, V189; YAMOAH E, 1994, BIOL BULL, V187, P270, DOI 10.1086/BBLv187n2p270	13	47	56	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					645	646		10.1038/378645a0	http://dx.doi.org/10.1038/378645a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524403				2022-12-01	WOS:A1995TJ22100089
J	SCHWACHA, A; KLECKNER, N				SCHWACHA, A; KLECKNER, N			IDENTIFICATION OF DOUBLE HOLLIDAY JUNCTIONS AS INTERMEDIATES IN MEIOTIC RECOMBINATION	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX-FORMATION; ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ENDONUCLEASE-VII; HETERODUPLEX DNA; REPAIR MODEL; YEAST; MEIOSIS	During meiosis, branched DNA molecules containing information from both parental chromosomes occur in vivo at loci where meiosis-specific double-stranded breaks occur. We demonstrate here that these joint molecules are recombination intermediates: they contain single strands that have undergone exchange of information. Moreover, these joint molecules are resolved into both parental and recombinant duplexes when treated in vitro with Holliday junction-resolving endonucleases RuvC or T4 endo VII. Taken together with previous observations, these results strongly suggest that joint molecules are double Holliday junctions.			SCHWACHA, A (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BYERS B, 1994, CURR BIOL, V4, P448, DOI 10.1016/S0960-9822(00)00100-7; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; FAN QQ, 1995, MOL CELL BIOL, V15, P1679; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; GAME JC, 1989, GENETICS, V123, P695; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HABER JE, 1995, MICROB GENE TECH, V6, P204; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEENEY S, 1995, IN PRESS P NATL ACAD, V92; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; MALONE RE, 1980, CURR GENET, V1, P241, DOI 10.1007/BF00390950; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1990, GENETICS, V125, P753; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PORTER SE, 1993, GENETICS, V134, P5; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; SOBELL HM, 1974, MOL MECHANISMS GENET, P433; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1987, GENETICS, V116, P501; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	55	389	395	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					783	791		10.1016/0092-8674(95)90191-4	http://dx.doi.org/10.1016/0092-8674(95)90191-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521495	Bronze			2022-12-01	WOS:A1995TH94800015
J	VASSYLYEV, DG; KASHIWAGI, T; MIKAMI, Y; ARIYOSHI, M; IWAI, S; OHTSUKA, E; MORIKAWA, K				VASSYLYEV, DG; KASHIWAGI, T; MIKAMI, Y; ARIYOSHI, M; IWAI, S; OHTSUKA, E; MORIKAWA, K			ATOMIC MODEL OF A PYRIMIDINE DIMER EXCISION-REPAIR ENZYME COMPLEXED WITH A DNA SUBSTRATE - STRUCTURAL BASIS FOR DAMAGED DNA RECOGNITION	CELL			English	Article							T4 ENDONUCLEASE-V; SITE-DIRECTED MUTAGENESIS; SYN THYMINE DIMER; CRYSTAL-STRUCTURE; CIS-SYN; DUPLEX D(GCGTTGCG).D(CGCAACGC); T4-ENDONUCLEASE-V; GLYCOSYLASE; PHOTODIMER; ACID	T4 endonuclease V is a DNA repair enzyme from bacteriophage T4 that catalyzes the first reaction step of the pyrimidine dimer-specific base excision repair pathway. The crystal structure of this enzyme complexed with a duplex DNA substrate, containing a thymine dimer, has been determined at 2.75 Angstrom resolution, The atomic structure of the complex reveals the unique conformation of the DNA duplex, which exhibits a sharp kink with a 60 degrees inclination at the central thymine dimer, The adenine base complementary to the 5' side of the thymine dimer is completely flipped out of the DNA duplex and trapped in a cavity on the protein surface. These structural features allow an understanding of the catalytic mechanism and implicate a general mechanism of how other repair enzymes recognize damaged DNA duplexes.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	VASSYLYEV, DG (corresponding author), PROT ENGN RES INST,6-2-3 FURUDEAI,SUITA,OSAKA 565,JAPAN.		Vassylyev, Dmitry/A-9005-2008	Ariyoshi, Mariko/0000-0002-1361-2642				BABCOCK MS, 1993, BIOMOL STRUCT DYN, V2, P597; BAKER D, 1993, ACTA CRYSTALLOGR D, V49, P429, DOI 10.1107/S0907444993004032; BRUNGER AT, 1993, XPLOR VERSION 31; CAMERMAN N, 1970, J AM CHEM SOC, V92, P2523, DOI 10.1021/ja00711a050; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HORI N, 1992, J BIOL CHEM, V267, P15591; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; INAOKA T, 1989, J BIOL CHEM, V264, P2609; IWAI S, 1994, BIOCHEMISTRY-US, V33, P5581, DOI 10.1021/bi00184a029; IWAI S, 1995, BIOCHEMISTRY-US, V34, P4601, DOI 10.1021/bi00014a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAO JY, 1993, J BIOL CHEM, V268, P17787; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHAM KA, 1994, BIOCHEMISTRY-US, V33, P9024, DOI 10.1021/bi00196a021; LATHAM KA, 1995, J BACTERIOL, V177, P5166, DOI 10.1128/jb.177.17.5166-5168.1995; LATHAM KA, 1994, DNA DAMAGE, P181; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; MACMILLAN S, 1981, J VIROL, V40, P211; MANOHARAN M, 1988, J AM CHEM SOC, V11, P2690; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1993, CURR OPIN STRUC BIOL, V3, P17, DOI 10.1016/0959-440X(93)90196-R; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; MORIKAWA K, 1994, DNA DAMAGE, P198; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SARVA R, 1995, NATURE, V373, P487; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	51	245	246	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					773	782		10.1016/0092-8674(95)90190-6	http://dx.doi.org/10.1016/0092-8674(95)90190-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521494	Bronze			2022-12-01	WOS:A1995TH94800014
J	VANASPEREN, IA; DEROVER, CM; SCHIJVEN, JF; OETOMO, SB; SCHELLEKENS, JFP; VANLEEUWEN, NJ; COLLE, C; HAVELAAR, AH; KROMHOUT, D; SPRENGER, MWJ				VANASPEREN, IA; DEROVER, CM; SCHIJVEN, JF; OETOMO, SB; SCHELLEKENS, JFP; VANLEEUWEN, NJ; COLLE, C; HAVELAAR, AH; KROMHOUT, D; SPRENGER, MWJ			RISK OF OTITIS-EXTERNA AFTER SWIMMING IN RECREATIONAL FRESH-WATER LAKES CONTAINING PSEUDOMONAS-AERUGINOSA	BRITISH MEDICAL JOURNAL			English	Article							MORBIDITY; POLLUTION; QUALITY; BEACHES	Objective-To determine whether an outbreak of otitis externa was due to bathing in recreational fresh water lakes and to establish whether the outbreak was caused by Pseudomonas aeruginosa in the water. Design-Matched case-control study. Setting-The Achterhoek area, the Netherlands. Subjects-98 cases with otitis externa and 149 controls matched for age, sex, and place of residence. Main outcome measures-Odds ratios for type of swimming water and frequency of swimming; presence of P aeruginosa in ear swabs and fresh water lakes. Results-Otitis externa was strongly associated with swimming in recreational fresh water lakes in the previous two weeks (odds ratio 15.5 (95% confidence interval) 4.9 to 49.2) compared with non-swimming). The risk increased with the number of days of swimming, and subjects with recurrent ear disease had a greatly increased risk. The lakes met the Dutch bathing water standards and those set by the European Commission for faecal pollution in the summer of 1994, but P aeruginosa was isolated from all of them, as well as from the ear swabs of 78 (83%) of the cases and 3 (4%) of the controls. Conclusions-Even when current bathing water standards are met, swimming can be associated with a substantial risk of otitis externa because of exposure to P aeruginosa. People with recurrent ear disease should take special care when swimming in waters containing P aeruginosa.			VANASPEREN, IA (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Havelaar, Arie H./P-8495-2014; Kromhout, Daan/A-8566-2014	Havelaar, Arie H./0000-0002-6456-5460; Schijven, Jack/0000-0002-9327-1584				BALARAJAN R, 1991, BRIT MED J, V303, P1444, DOI 10.1136/bmj.303.6815.1444; BROEN A, 1994, CONCEPE STANDARD OTI; CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CALDERON R, 1982, ARCH ENVIRON HEALTH, V37, P83; CHEUNG WHS, 1990, EPIDEMIOL INFECT, V105, P139, DOI 10.1017/S0950268800047737; CORBETT SJ, 1993, AM J PUBLIC HEALTH, V83, P1701, DOI 10.2105/AJPH.83.12.1701; Dufour A.P., 1984, EPA600184004; El Sharkawi F, 1982, B HIGH I PUB HLTH AL, V12, P337; FATTAL B, 1987, CHEMOSPHERE, V16, P565, DOI 10.1016/0045-6535(87)90268-2; Foulon G, 1983, REV FR SCI EAUX, V2, P127; HAVELAAR AH, 1985, CAN J MICROBIOL, V31, P686, DOI 10.1139/m85-130; HAVELAAR AH, 1984, H2O, V17, P367; KAY D, 1994, LANCET, V344, P905, DOI 10.1016/S0140-6736(94)92267-5; Lanyi B., 1978, METHOD MICROBIOL, V10, P93; LIGHTFOOT N, 1989, THESIS U TORONTO TOR; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; SENTURIA BH, 1980, DISEASES EXTERNAL CA; SEYFRIED P L, 1985, American Journal of Public Health, V75, P1068, DOI 10.2105/AJPH.75.9.1068; SEYFRIED PL, 1985, AM J PUBLIC HEALTH, V75, P1071, DOI 10.2105/AJPH.75.9.1071; SEYFRIED PL, 1984, CAN J PUBLIC HEALTH, V75, P83; SINGER DE, 1952, ANN OTO RHINOL LARYN, V61, P317, DOI 10.1177/000348945206100201; SPRINGER GL, 1985, ARCH ENVIRON HEALTH, V40, P202, DOI 10.1080/00039896.1985.10545918; STEVENSON AH, 1953, AM J PUBLIC HEALTH, V43, P529; 1994, COM94940006SYN COMM; 1985, EGRET EPIDEMIOLOGICA; 1989, STATISTICAL ANAL SYS; 1994, BILT, V91, P2	27	67	73	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1407	1410		10.1136/bmj.311.7017.1407	http://dx.doi.org/10.1136/bmj.311.7017.1407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520277	Green Published			2022-12-01	WOS:A1995TG90200024
J	SCHIEPPATI, A; MOSCONI, L; PERNA, A; MECCA, G; BERTANI, T; GARATTINI, S; REMUZZI, G				SCHIEPPATI, A; MOSCONI, L; PERNA, A; MECCA, G; BERTANI, T; GARATTINI, S; REMUZZI, G			PROGNOSIS OF UNTREATED PATIENTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM PROGNOSIS; CONTROLLED TRIAL; NEPHROTIC SYNDROME; NATURAL-HISTORY; RENAL-FUNCTION; ACUTE-LEUKEMIA; GLOMERULONEPHRITIS; CHLORAMBUCIL; THERAPY; METHYLPREDNISOLONE	Background. Defining the most appropriate treatment for patients with idiopathic membranous nephropathy is a matter of controversy. The course of the disorder is often benign, and the immunosuppressive regimens used in some patients have uncertain benefits and substantial risks. We studied the natural history of idiopathic membranous nephropathy in patients who received only symptomatic therapy. Methods. We prospectively studied 100 consecutive patients (68 men and 32 women; mean [+/-SD] age, 51+/-17 years) with biopsy-proved idiopathic membranous nephropathy. The patients received diuretic or antihypertensive drugs as needed, but no glucocorticoid or immunosuppressive drugs. We examined the patients and measured their urinary protein excretion and serum creatinine concentrations every 6 months for a mean of 52 months. Results. Twenty-four (65 percent) of the 37 patients followed for at least five years had complete or partial remission of proteinuria; in 6 others (16 percent), end-stage renal disease developed, and they required dialysis. As calculated by the Kaplan-Meier method, the estimated probability (+/- the standard error of the estimate) of retaining adequate kidney function was 88+/-5 percent after five years and 73+/-7 percent after eight years. The prognosis was poorer in men and in patients over 50 years of age, but not in patients with the nephrotic syndrome, hypertension, or hypercholesterolemia. Conclusions. Most untreated patients with idiopathic membranous nephropathy maintain renal function for prolonged periods and are likely to have spontaneous remission. These results do not support the use of glucocorticoids and immunosuppressive drugs in patients with idiopathic membranous nephropathy.	MARIO NEGRI INST PHARMACOL RES,BERGAMO,ITALY; OSPED RIUNITI BERGAMO,DIV NEPHROL & DIALYSIS,I-24100 BERGAMO,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo			Perna, Annalisa/AAC-1323-2020; Garattini, Silvio/AAA-6390-2020; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Garattini, Silvio/0000-0003-0647-9297; Remuzzi, Giuseppe/0000-0002-6194-3446				BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; CAMERON JS, 1990, PEDIATR NEPHROL, V4, P193, DOI 10.1007/BF00858840; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COX DR, 1972, J R STAT SOC B, V34, P187; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; GARATTINI S, 1987, NEPHRON, V45, P1, DOI 10.1159/000184062; GLASSOCK RJ, 1991, SEMIN NEPHROL, V11, P138; GRUNWALD HW, 1979, ARCH INTERN MED, V139, P461, DOI 10.1001/archinte.139.4.461; HONKANEN E, 1986, CLIN NEPHROL, V25, P122; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIDA H, 1986, CLIN NEPHROL, V25, P64; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; LAGRUE G, 1975, KIDNEY INT, V8, P274; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MATHIESON PW, 1988, LANCET, V2, P869; MURPHY BF, 1992, CLIN NEPHROL, V37, P229; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PASSERINI P, 1992, G ITAL NEFROL S2, V9, P23; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; SHEARMAN JD, 1988, CLIN NEPHROL, V30, P320; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WASS V, 1981, NEPHRON, V27, P58, DOI 10.1159/000182025; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247; WILLIAMS PS, 1989, NEPHROL DIAL TRANSPL, V4, P181, DOI 10.1093/oxfordjournals.ndt.a091853; 1971, BMJ, V2, P239; 1976, CAN MED ASSOC J, V115, P1209	32	320	342	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1993	329	2					85	89		10.1056/NEJM199307083290203	http://dx.doi.org/10.1056/NEJM199307083290203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL196	8510707				2022-12-01	WOS:A1993LL19600003
J	VIJN, I; DASNEVES, L; VANKAMMEN, A; FRANSSEN, H; BISSELING, T				VIJN, I; DASNEVES, L; VANKAMMEN, A; FRANSSEN, H; BISSELING, T			NOD FACTORS AND NODULATION IN PLANTS	SCIENCE			English	Article											VIJN, I (corresponding author), AGR UNIV WAGENINGEN,DEPT MOLEC BIOL,DREIJENLAAN 3,6703 HA WAGENINGEN,NETHERLANDS.		Bisseling, Ton/A-2421-2013	Neves, Lucinda/0000-0002-2817-354X				DAVIS EO, 1988, MOL GEN GENET, V212, P531, DOI 10.1007/BF00330860; DEJONG A, IN PRESS PLANT CELL; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; FIRMIN J, COMMUNICATION; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; HORVATH B, IN PRESS PLANT J; Libbenga K.R., 1974, BIOL NITROGEN FIXATI, P430; LIE TA, 1971, PLANT SOIL, P117, DOI 10.1007/BF02661845; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; NICOLAOU KC, 1992, J AM CHEM SOC, V114, P8701, DOI 10.1021/ja00048a054; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; SMIT G, 1993, NEW HORIZONS NITROGE, P371; SPAINK HP, 1992, PLANT MOL BIOL, V20, P977, DOI 10.1007/BF00027167; YANG WC, 1993, PLANT J, V3, P573, DOI 10.1046/j.1365-313X.1993.03040573.x	14	80	81	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1764	1765		10.1126/science.8511583	http://dx.doi.org/10.1126/science.8511583			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8511583				2022-12-01	WOS:A1993LH20500035
J	REGEVIK, NK				REGEVIK, NK			MY HEROES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2910	2910		10.1001/jama.269.22.2910	http://dx.doi.org/10.1001/jama.269.22.2910			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497097				2022-12-01	WOS:A1993LE93600031
J	ROY, MJ; DAMATO, JJ; BURKE, DS				ROY, MJ; DAMATO, JJ; BURKE, DS			ABSENCE OF TRUE SEROREVERSION OF HIV-1 ANTIBODY IN SEROREACTIVE INDIVIDUALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; INFECTION; COHORT	Objectives.-First, to determine whether there is evidence for loss of human immunodeficiency virus type 1 (HIV-1) antibody in seroreactive individuals. Second, if true seroreversion occurs, to determine its incidence relative to errors in the testing process. Design.- A retrospective cohort study reviewing the results of 5 446 161 HIV-1 antibody tests performed on 2 580 974 individuals (the US Army HIV Data System) from 1985 through 1992. For all patients with one or more seroreactive sample followed by one or more nonreactive sample, we examined available records and retested the samples. Participants.-Serum samples had been obtained from active-duty and retired military personnel, their dependents, and applicants to the military. Results.-Of 4911 individuals reported to be seroreactive for HIV-1 by two independent samples, only six were potential seroreverters. Review of the six cases revealed that five actually were HIV-seroreactive patients who had samples from nonreactive individuals mistakenly attributed to them, while the sixth had a testing error proven by retesting the discrepant specimen. Errors in the testing process were identified (n=23) or suspected (n=3) in another 26 individuals who had not had independent confirmation of reactivity by a second sample. The cumulative error rate was 12.4 per 1 million patients tested. An additional group of 31 uninfected infants appeared to serorevert due to loss of antibody acquired from their HIV-1-infected mothers. Conclusions.-Review of this database demonstrates no evidence for true seroreversion of HIV-1 antibody status. We conclude that if seroreversion occurs at all, it is exceedingly rare. In fact, most (if not all) cases of apparent seroreversion represent errors of attribution or testing.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; WALTER REED ARMY INST RES,DIV RETROVIROL,WASHINGTON,DC 20307	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	ROY, MJ (corresponding author), WALTER REED ARMY MED CTR,DEPT MED,WASHINGTON,DC 20307, USA.			/0000-0002-5704-8094				BURGER H, 1985, ANN INTERN MED, V103, P545, DOI 10.7326/0003-4819-103-4-545; DAMATO J, 1988, LAB MED, V19, P577, DOI 10.1093/labmed/19.9.577; DAMATO JJ, 1991, LAB MED, V22, P107, DOI 10.1093/labmed/22.2.107; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; HOLMBERG SD, 1988, ANN INTERN MED, V109, P679, DOI 10.7326/0003-4819-109-8-679_2; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961; 1991, LANCET, V338, P253	10	31	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2876	2879		10.1001/jama.269.22.2876	http://dx.doi.org/10.1001/jama.269.22.2876			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8497091				2022-12-01	WOS:A1993LE93600024
J	HOLBROOK, TL; BARRETTCONNOR, E				HOLBROOK, TL; BARRETTCONNOR, E			A PROSPECTIVE-STUDY OF ALCOHOL-CONSUMPTION AND BONE-MINERAL DENSITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; OSTEOPOROSIS; FRACTURES; DISEASE; MEN; INDICATORS; COMMUNITY; FEMUR; WOMEN	Objectives-To study the effects of alcohol consumption on bone mineral density in a defined population. Design-Prospective study of bone mineral density, measured during 1988-91, in a cohort who had given baseline data on alcohol intake in the previous week and in the previous 24 hours and other factors affecting bone mineral density during 1973-5. Setting-Rancho Bernardo, California. Subjects-182 men and 267 women aged 45 and over at baseline, half having been randomly selected and half having been chosen for hyperlipidaemia, who gave baseline information on alcohol intake in one week. Of these subjects, 142 men and 220 women gave information on alcohol intake in 24 hours. Main outcome measures-Bone mineral density of the radial shaft, ultradistal wrist, femoral neck, and lumbar spine. Results-Men and women were considered separately, and the tertiles of alcohol consumption were used to delineate low, medium, and high values of alcohol intake. With increasing alcohol intake in one week, bone mineral density (adjusted for age, body mass index, smoking, taking exercise, and oestrogen replacement therapy in women) increased significantly in the femoral neck of men (p<0.01) and the spine of women (p<0.01). With increasing alcohol intake in 24 hours, adjusted bone mineral density increased significantly in the radial shaft (p<0.05) and spine (p<0.001) of women. Similar, but not significant, patterns were seen at the other bone sites. Conclusions-Social drinking is associated with higher bone mineral density in men and women.			HOLBROOK, TL (corresponding author), UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, LA JOLLA, CA 92093 USA.				NIA NIH HHS [AG 07181] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGUS RM, 1988, BONE MINER, V4, P265; BARRETTCONNOR E, 1982, AM J EPIDEMIOL, V115, P888, DOI 10.1093/oxfordjournals.aje.a113376; BJORNEBOE GEA, 1988, ALCOHOL CLIN EXP RES, V12, P229, DOI 10.1111/j.1530-0277.1988.tb00185.x; COOPER C, 1987, BMJ-BRIT MED J, V295, P13, DOI 10.1136/bmj.295.6589.13; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; GAVALER JS, 1991, ALCOHOL ALCOHOLISM, P327; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HALL ML, 1990, BRIT J RADIOL, V63, P266, DOI 10.1259/0007-1285-63-748-266; Hansen M A, 1991, Osteoporos Int, V1, P95; HARDING A, 1988, ORTHOPEDICS, V11, P279; HENRY RJ, 1960, AM J CLIN PATHOL, V34, P381; ISRAEL Y, 1980, ALCOHOL CLIN EXP RES, V4, P420, DOI 10.1111/j.1530-0277.1980.tb04842.x; JOHNELL O, 1984, INT ORTHOP, V7, P229; JOHNELL O, 1985, SCAND J SOC MED, V13, P95; JOHNSON RD, 1984, BRIT MED J, V288, P365, DOI 10.1136/bmj.288.6414.365; JONES BR, 1982, AM J CLIN NUTR, V35, P135, DOI 10.1093/ajcn/35.1.135; KRISTENSSON H, 1980, ACTA ORTHOP SCAND, V51, P205, DOI 10.3109/17453678008990787; LAITINEN K, 1990, ALCOHOL CLIN EXP RES, V14, P551, DOI 10.1111/j.1530-0277.1990.tb01198.x; LAITINEN K, 1991, CALCIFIED TISSUE INT, V49, pS70, DOI 10.1007/BF02555094; LAITINEN K, IN PRESS CALCIF TISS; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; RICO H, 1990, ALCOHOL ALCOHOLISM, V25, P345; SAVILLE PD, 1965, J BONE JOINT SURG AM, VA 47, P492, DOI 10.2106/00004623-196547030-00005; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924	25	196	200	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	1993	306	6891					1506	1509		10.1136/bmj.306.6891.1506	http://dx.doi.org/10.1136/bmj.306.6891.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518677	Green Published, Bronze			2022-12-01	WOS:A1993LF94000023
J	WOYCHIK, RP; WASSOM, JS; KINGSBURY, D				WOYCHIK, RP; WASSOM, JS; KINGSBURY, D			TBASE - A COMPUTERIZED DATABASE FOR TRANSGENIC ANIMALS AND TARGETED MUTATIONS	NATURE			English	Article									JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Johns Hopkins University	WOYCHIK, RP (corresponding author), OAK RIDGE NATL LAB,OAK RIDGE,TN 37831, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; LYON MF, 1989, GENETIC VARIANTS STR, P2; MALTAIS LJ, GBASE GENOMIC DATABA; 1992, ILAR NEWS, V34, P45	5	21	21	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					375	376		10.1038/363375a0	http://dx.doi.org/10.1038/363375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497324				2022-12-01	WOS:A1993LD91700061
J	COFFMAN, CR; SKOGLUND, P; HARRIS, WA; KINTNER, CR				COFFMAN, CR; SKOGLUND, P; HARRIS, WA; KINTNER, CR			EXPRESSION OF AN EXTRACELLULAR DELETION OF XOTCH DIVERTS CELL FATE IN XENOPUS-EMBRYOS	CELL			English	Article							DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; EARLY NEUROGENESIS; LATERAL INHIBITION; NEURAL INDUCTION; NOTCH LOCUS; ACTIVIN-A; N-CAM; RNA; MESODERM	Xotch is a Xenopus homolog of Notch, a receptor involved in cell fate decisions in Drosophila. Using an extracellular deletion construct, XotchDELTAE, we show that Xotch has a similar role in Xenopus embryos. Broad expression causes the loss of dorsal structures and the expansion and disorganization of the brain. Single blastomere injections of XotchDELTAE induce autonomous neural and mesodermal hypertrophy, even in the absence of cell division. XotchDELTAE inhibits the early expression of epidermal and neural crest markers yet enhances and extends the response of animal caps to mesodermal and neural induction. Our data suggest a mechanism for the function of Notch homologs in which they delay differentiation and leave undetermined cells competent to respond to later inductive signals.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Diego; Salk Institute	COFFMAN, CR (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.							ALBERS B, 1987, DEV GROWTH DIFFER, V29, P535; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLMAN A, 1986, J EMBRYOL EXP MORPH, V97, P197; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HOPWOOD ND, 1991, DEVELOPMENT, P95; Horstadius S., 1950, NEURAL CREST; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JONES EA, 1986, CELL, V44, P345, DOI 10.1016/0092-8674(86)90769-5; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KINTNER C, 1988, NEURON, V1, P545, DOI 10.1016/0896-6273(88)90104-3; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Le Douarin N.M., 1982, NEURAL CREST; LEHMANN R, 1981, ROUX ARCH DEV BIOL, V190, P226, DOI 10.1007/BF00848307; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MARKOPOULOU K, 1989, J NEUROGENET, V6, P11, DOI 10.3109/01677068909107097; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SAHA MS, 1989, CELL DIFFER DEV, V28, P153, DOI 10.1016/0922-3371(89)90001-4; SAKAGUCHI DS, 1989, DEV BIOL, V134, P158, DOI 10.1016/0012-1606(89)90086-9; Sambrook J., 1989, MOL CLONING LAB MANU; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; XU T, 1992, DEVELOPMENT, V115, P913	68	343	358	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					659	671		10.1016/0092-8674(93)90247-N	http://dx.doi.org/10.1016/0092-8674(93)90247-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500162				2022-12-01	WOS:A1993LD83000006
J	HENSHAW, RC; COOPER, K; ELREFAEY, H; SMITH, NC; TEMPLETON, AA				HENSHAW, RC; COOPER, K; ELREFAEY, H; SMITH, NC; TEMPLETON, AA			MEDICAL-MANAGEMENT OF MISCARRIAGE - NONSURGICAL UTERINE EVACUATION OF INCOMPLETE AND INEVITALE SPONTANEOUS-ABORTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article											HENSHAW, RC (corresponding author), ABERDEEN MATERN HOSP, DEPT OBSTET & GYNAECOL, ABERDEEN AB2 9ZD, SCOTLAND.			cooper, kevin/0000-0003-1486-0071				BYGDEMAN M, 1989, ACTA OBSTET GYN SCAN, P13; FRIEDMAN T, 1989, J ROY COLL GEN PRACT, V39, P456; Hertig AT, 1944, NEW ENGL J MED, V230, P797; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; 1990, LANCET, V336, P1480	5	71	72	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					894	895		10.1136/bmj.306.6882.894	http://dx.doi.org/10.1136/bmj.306.6882.894			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490413	Bronze, Green Published			2022-12-01	WOS:A1993KW38700019
J	Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A				Brandner, S; Isenmann, S; Raeber, A; Fischer, M; Sailer, A; Kobayashi, Y; Marino, S; Weissmann, C; Aguzzi, A			Normal host prion protein necessary for scrapie-induced neurotoxicity	NATURE			English	Article							CELL-SURFACE; PRP	ACCUMULATION of the prion protein PrPSc, a pathological and protease-resistant isoform of the normal host protein PrPC, is a feature of prion disease such as scrapie(1,2). It is still unknown whether scrapie pathology comes about by neurotoxicity of PrPSc, acute depletion of PrPC, or some other mechanism. Here we investigate this question by grafting neural tissue overexpressing PrPC into the brain of PrP-deficient mice which are scrapie-resistant and do not propagate infectivity(3-5). After intracerebral inoculation with scrapie prions, the grafts accumulated high levels of PrPSc and infectivity and developed the severe histopathological changes characteristic of scrapie. Moreover, substantial amounts of graft-derived PrPSc migrated into the host brain. Even 16 months after inoculation no pathological changes were seen in PrP-deficient tissue, not even in the immediate vicinity of the grafts. Therefore, in addition to being resistant to scrapie infection, brain tissue devoid of PrPC is not damaged by exogenous PrPSc.	UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOLEC BIOL,DEPT 1,ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich			Isenmann, Stefan/AAJ-3788-2020; Aguzzi, Adriano/A-3351-2008; Brandner, Sebastian/J-4562-2014; Sailer, Andreas/M-9913-2016	Brandner, Sebastian/0000-0002-9821-0342; Sailer, Andreas/0000-0002-9015-7946; Aguzzi, Adriano/0000-0002-0344-6708; Marino, Silvia/0000-0002-9612-2883				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; FISCHER M, IN PRESS EMBO J; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; ISENMANN S, IN PRESS NEUROPATHOL; JEFFREY M, 1994, BRAIN RES, V656, P329, DOI 10.1016/0006-8993(94)91477-X; JEFFREY M, 1994, NEUROSCI LETT, V174, P39, DOI 10.1016/0304-3940(94)90113-9; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUISINER SBA, 1994, REV MICROBIOL, V48, P655; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9	23	641	659	0	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					339	343		10.1038/379339a0	http://dx.doi.org/10.1038/379339a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552188				2022-12-01	WOS:A1996TR32300057
J	Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M				Norris, MD; Bordow, SB; Marshall, GM; Haber, PS; Cohn, SL; Haber, M			Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; N-MYC ONCOGENE; POLYMERASE CHAIN-REACTION; NEURO-BLASTOMA; MDR1; AMPLIFICATION; TUMORS; CHILDHOOD; CANCER; CELLS	Background. Overexpression of the gene for the multidrug-resistance-associated protein (MRP) has been linked with resistance to chemotherapeutic agents (multidrug resistance) in vitro. The expression of MRP by neuroblastoma cells correlates with N-myc oncogene amplification, a well-established prognostic indicator in patients with neuroblastoma. Methods. To relate MRP gene expression to established prognostic markers and the clinical outcome of neuroblastoma, we analyzed MRP expression in specimens of primary tumors from 60 patients with neuroblastoma. Results. Levels of MRP gene expression were significantly higher in tumors with N-myc amplification than in tumors without such amplification (P<0.001). High levels of MRP expression were strongly associated with reductions in both survival and event-free survival (P<0.001) in the overall study population and in subgroups of patients without N-myc amplification and patients with localized disease. For the overall study population, the five-year cumulative survival rates in the groups with high and low levels of MRP expression were 57 percent (95 percent confidence interval, 37 to 78 percent) and 94 percent (95 percent confidence interval, 86 to 100 percent), respectively. In contrast, expression of the MDR1 multidrug-resistance gene was not predictive of survival or event-free survival. After adjustment by multivariate analysis for the effects of N-myc amplification and other prognostic indicators, high levels of MRP expression retained significant prognostic value for poor survival (relative hazard, 14.9; P=0.01) and poor event-free survival (relative hazard, 9.7; P=0.004), whereas N-myc amplification had no prognostic value. Conclusions. High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome. The findings suggest that expression of this multidrug-resistance gene accounts for the association between N-myc amplification and reduced survival. (C) 1996, Massachusetts Medical Society.	UNIV NEW S WALES,CHILDRENS LEUKAEMIA & CANC RES CTR,SYDNEY,NSW,AUSTRALIA; PRINCE WALES CHILDRENS HOSP,DEPT GASTROENTEROL,SYDNEY,NSW,AUSTRALIA; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614	University of New South Wales Sydney; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago			Cohn, Susan/AAB-6010-2021	Norris, Murray/0000-0002-0632-4589; Cohn, Susan/0000-0001-5749-7650; Haber, Michelle/0000-0003-2036-8817				Benard J, 1994, Prog Clin Biol Res, V385, P111; BERNARD JL, 1987, J CLIN ONCOL, V5, P1952, DOI 10.1200/JCO.1987.5.12.1952; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BORDOW SB, 1994, CANCER RES, V54, P5036; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; BOWMAN LC, 1990, MED PEDIATR ONCOL, V18, P364; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 1993, PRINCIPLES PRACTICE, P739; CASTLEBERRY RP, 1991, J CLIN ONCOL, V9, P789, DOI 10.1200/JCO.1991.9.5.789; CASTLEBERRY RP, 1994, J CLIN ONCOL, V12, P1616, DOI 10.1200/JCO.1994.12.8.1616; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORRIAS MV, 1990, ANTICANCER RES, V10, P897; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FAVROT M, 1991, BRIT J CANCER, V64, P233, DOI 10.1038/bjc.1991.282; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V206, P119, DOI 10.1006/bbrc.1995.1017; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; GILBERT J, 1993, MOL CELL PROBE, V7, P227, DOI 10.1006/mcpr.1993.1033; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; GRANT CE, 1994, CANCER RES, V54, P357; Haber M, 1994, Prog Clin Biol Res, V385, P245; HOLZMAYER TA, 1992, J NATL CANCER I, V84, P1486, DOI 10.1093/jnci/84.19.1486; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOSHI VV, 1993, CANCER-AM CANCER SOC, V71, P3173, DOI 10.1002/1097-0142(19930515)71:10<3173::AID-CNCR2820711045>3.0.CO;2-P; KRUH GD, 1994, CANCER RES, V54, P1649; LEIER I, 1994, J BIOL CHEM, V269, P27807; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARSHALL GM, 1995, ONCOGENE, V11, P485; MCCOWAGE GB, 1995, J CLIN ONCOL, V13, P2789, DOI 10.1200/JCO.1995.13.11.2789; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; NITSCHKE R, 1988, J CLIN ONCOL, V6, P1271, DOI 10.1200/JCO.1988.6.8.1271; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLOVAK ML, 1993, CANCER RES, V53, P3221; STROTHER D, 1995, J PEDIAT HEMATOL ONC, V17, P254, DOI 10.1097/00043426-199508000-00007; TELFORD DJ, 1992, J PAEDIATR CHILD H, V28, P58, DOI 10.1111/j.1440-1754.1992.tb02619.x; TEW KD, 1994, CANCER RES, V54, P4313; VERSANTVOORT CHM, 1994, BIOCHEM PHARMACOL, V48, P1129, DOI 10.1016/0006-2952(94)90149-X; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHU QC, 1994, CANCER RES, V54, P4488	51	271	281	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	1996	334	4					231	238		10.1056/NEJM199601253340405	http://dx.doi.org/10.1056/NEJM199601253340405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ755	8532000				2022-12-01	WOS:A1996TQ75500005
J	Reichman, LB				Reichman, LB			How to ensure the continued resurgence of tuberculosis	LANCET			English	Editorial Material							NEW-YORK-CITY		UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07107	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), UNIV MED & DENT NEW JERSEY,NATL TB CTR,DEPT MED,GB1,65 BERGEN ST,NEWARK,NJ 07107, USA.							BINYA T, 1992, CHINESE J ANTIBIOTIC, V7, P313; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Comstock GW, 1993, TUBERCULOSIS COMPREH, P23; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P299; HORTON R, 1995, LANCET, V346, P790, DOI 10.1016/S0140-6736(95)91616-4; MOULDING T, 1995, ANN INTERN MED, V122, P951, DOI 10.7326/0003-4819-122-12-199506150-00010; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIDZON R, 1995, AM J RESP CRIT CARE, V151, pA665; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; WARING JJ, 1956, JAMA-J AM MED ASSOC, V161, P1368, DOI 10.1001/jama.1956.02970140024007; 1995, MMWR-MORBID MORTAL W, V44, P387; 1993, OTR H574 US C OFF TE, P91; 1961, DHEW PHS ML784 PUBL; 1995, MMWR-MORBID MORTAL W, V44, P835; 1995, WHO TUBERCULOSIS PRO; 1995, GAOHEHS9511 US GEN A; 1993, WORLD HEALTH FORUM, V14, P438	21	33	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					175	177		10.1016/S0140-6736(96)90348-7	http://dx.doi.org/10.1016/S0140-6736(96)90348-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544556				2022-12-01	WOS:A1996TQ24400017
J	Volberding, PA				Volberding, PA			HIV quantification: Clinical applications	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION				Volberding, PA (corresponding author), SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110, USA.							BAGNARELLI P, 1991, J MED VIROL, V34, P89, DOI 10.1002/jmv.1890340204; CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; ERON J, 1995, 2ND NAT C HUM RETR R; HAVLIR D, 1995, J INFECT DIS, V172, P1379, DOI 10.1093/infdis/172.5.1379; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; JURRIAANS S, 1995, AIDS RES HUM RETROV, V11, P473, DOI 10.1089/aid.1995.11.473; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1; MELLORS JW, 1995, ANN INTERN MED, V122, P537; OBRIEN W, 1995, 10TH P INT C AIDS IN; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PAXTON W, 1995, 2ND NAT C HUM RETR R; REVETS H, 1995, FEB P MOL APPR LAB D; VERHOFSTEDE C, 1994, AIDS, V8, P1421, DOI 10.1097/00002030-199410000-00008; YERLY S, 1995, AIDS, V9, P159, DOI 10.1097/00002030-199509020-00007	16	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 13	1996	347	8994					71	73		10.1016/S0140-6736(96)90205-6	http://dx.doi.org/10.1016/S0140-6736(96)90205-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP281	8538341				2022-12-01	WOS:A1996TP28100004
J	Stratmann, R; Lehner, CF				Stratmann, R; Lehner, CF			Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase anaphase transition	CELL			English	Article							DNA TOPOISOMERASE-II; CYCLIN-A; MELANOGASTER; CHROMOSOME; GENE; MUTATIONS; SEQUENCE; EMBRYOS; PROGRESSION; SEGREGATION	Mutations in the Drosophila genes pimples and three rows result in a defect of sister chromatid separation during mitosis. As a consequence, cytokinesis is also defective. However, cell cycle progression including the mitotic degradation of cyclins A and B is not blocked by the failure of sister chromatid separation, and as a result, metaphase chromosomes with twice the normal number of chromosome arms still connected in the centromeric region are observed in the following mitosis. pimples encodes a novel protein that is rapidly degraded in mitosis. Our observations suggest that Pimples and Three rows act during mitosis to release the cohesion between sister centromeres.			Stratmann, R (corresponding author), MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,SPEMANNSTR 37-39,D-72076 TUBINGEN,GERMANY.							ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARMENA M, 1993, J CELL SCI, V105, P41; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DANDREA RJ, 1993, MOL BIOL CELL, V4, P1161, DOI 10.1091/mbc.4.11.1161; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOE VE, 1989, DEVELOPMENT, V107, P1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GHOSH S, 1992, EXP CELL RES, V200, P215, DOI 10.1016/S0014-4827(05)80091-6; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUACCI V, 1993, S QYANT BIOL, V58, P677; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HOLLOWAY SL, 1995, CURR OPIN GENET DEV, V5, P243, DOI 10.1016/0959-437X(95)80015-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IMIGER S, 1995, CELL, V81, P269; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MATSUMOTO K, 1994, CHROMOSOMA, V103, P338, DOI 10.1007/BF00417881; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cb.01.110185.001445; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PHILP AV, 1993, J CELL SCI, V106, P87; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; STEM B, 1993, DEVELOPMENT, V117, P219; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	59	116	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					25	35		10.1016/S0092-8674(00)80990-3	http://dx.doi.org/10.1016/S0092-8674(00)80990-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548823	Bronze			2022-12-01	WOS:A1996TQ17000006
J	Tirrell, DA				Tirrell, DA			Putting a new spin on spider silk	SCIENCE			English	Editorial Material											Tirrell, DA (corresponding author), UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003, USA.							Byrom D., 1991, BIOMATERIALS; FOURNIER MJ, 1995, MOL BIOL BIOTECHNOLO, P714; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018	8	42	55	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					39	40		10.1126/science.271.5245.39	http://dx.doi.org/10.1126/science.271.5245.39			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539596				2022-12-01	WOS:A1996TP02200032
J	Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S				Kano, M; Hashimoto, K; Chen, C; Abeliovich, A; Aiba, A; Kurihara, H; Watanabe, M; Inoue, Y; Tonegawa, S			Impaired synapse elimination during cerebellar development in PKC gamma mutant mice	CELL			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; LONG-TERM DEPRESSION; PURKINJE-CELLS; CLIMBING FIBERS; RAT-BRAIN; MULTIPLE INNERVATION; POSTNATAL-DEVELOPMENT; EXPRESSION; LOCALIZATION	PKC gamma is highly expressed in Purkinje cells (PCs) but not in other types of neurons in the cerebellum. The expression of PKC gamma changes markedly during cerebellar development, being very low at birth and reaching a peak around the third postnatal week. This temporal pattern of PKC gamma expression coincides with the developmental transition from multiple to single climbing fiber innervation onto each PC. In adult mutant mice deficient in PKC gamma, we found that 41% of PCs are still innervated by multiple climbing fibers, while other aspects of the cerebellum including the morphology and excitatory synaptic transmission of PCs appear normal. Thus, elimination of multiple climbing fiber innervation appears to be specifically impaired in the mutant cerebellum. We suggest that the developmental role of PKC gamma may be to act as a downstream element in the signal cascade necessary for the elimination of surplus climbing fiber synapses.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 606,JAPAN	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Hokkaido University	Kano, M (corresponding author), JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		WATANABE, Masahiko/A-4055-2012; Watanabe, Masahiko/S-3614-2019	WATANABE, Masahiko/0000-0001-5037-7138; Watanabe, Masahiko/0000-0001-5037-7138; Hashimoto, Kouichi/0000-0002-3884-8213; Aiba, Atsu/0000-0002-8192-0778; Kano, Masanobu/0000-0002-0725-3292	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ASE K, 1988, J NEUROSCI, V8, P3850; BRANDT SJ, 1987, CELL, V49, P57, DOI 10.1016/0092-8674(87)90755-0; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1979, J PHYSIOL-LONDON, V290, P97, DOI 10.1113/jphysiol.1979.sp012762; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARCIASEGURA LM, 1984, BRAIN RES, V296, P75, DOI 10.1016/0006-8993(84)90512-2; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HEMART N, 1995, EUR J NEUROSCI, V7, P45, DOI 10.1111/j.1460-9568.1995.tb01019.x; HERMS J, 1993, NEUROREPORT, V4, P899, DOI 10.1097/00001756-199307000-00015; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1990, DEV BRAIN RES, V52, P121, DOI 10.1016/0165-3806(90)90227-P; HUANG FL, 1988, J NEUROSCI, V8, P4734; HUANG FL, 1987, J BIOL CHEM, V262, P15714; Ito M., 1984, CEREBELLUM NEURAL CO; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; KITANO T, 1987, J NEUROSCI, V7, P1520; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KOSE A, 1988, J NEUROSCI, V8, P4262; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1992, J NEUROSCI, V12, P3601; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARANI E, 1979, ACTA MORPHOL NEER SC, V17, P33; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLEARY JL, 1971, J COMP NEUROL, V142, P377, DOI 10.1002/cne.901420307; Palay S.L., 1974, CEREBELLAR CORTEX CY; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAITO N, 1988, J NEUROSCI, V8, P369; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; WATANABE M, 1994, J COMP NEUROL, V343, P513, DOI 10.1002/cne.903430402; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	52	284	286	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1223	1231		10.1016/0092-8674(95)90147-7	http://dx.doi.org/10.1016/0092-8674(95)90147-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548808	Bronze			2022-12-01	WOS:A1995TM76200017
J	Zhou, QY; Palmiter, RD				Zhou, QY; Palmiter, RD			Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic	CELL			English	Article							BASAL GANGLIA; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; RAT NEOSTRIATUM; NEONATAL RATS; FOOD REWARD; NEURONS; LESIONS; NEUROTRANSMITTERS; RECEPTOR	Mice unable to synthesize dopamine (DA) specifically in dopaminergic neurons were created by inactivating the tyrosine hydroxylase (TH) gene then by restoring TH function in noradrenergic cells. These DA-deficient (DA(-/-)) mice were born at expected frequency but became hypoactive and stopped feeding a few weeks after birth. Midbrain dopaminergic neurons, their projections, and most characteristics of their target neurons in the striatum appeared normal. Within a few minutes of being injected with L-dihydroxyphenylalanine (L-DOPA), the product of TH, the DA(-/-) mice became more active and consumed more food than control mice. With continued administration of L-DOPA, nearly normal growth was achieved. These studies indicate that DA is essential for movement and feeding, but is not required for the development of neural circuits that control these behaviors.			Zhou, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R01HD009172] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-09172] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANAND BK, 1951, YALE J BIOL MED, V24, P123; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ARNT J, 1987, DOPAMINE RECEPTORS, P199; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BAYER SA, 1984, INT J DEV NEUROSCI, V2, P163, DOI 10.1016/0736-5748(84)90008-X; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; BUNNEY BS, 1976, BRAIN RES, V117, P423, DOI 10.1016/0006-8993(76)90751-4; CARLSSON A, 1959, PHARMACOL REV, V11, P490; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; Cooper SJ, 1993, D1 D2 DOPAMINE RECEP, P203; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DOURISH CT, 1993, BIOL PSYCHIAT, V7, P487; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FIBIGER HC, 1973, BRAIN RES, V55, P135, DOI 10.1016/0006-8993(73)90493-9; FIBIGER HC, 1988, ANN NY ACAD SCI, V537, P206, DOI 10.1111/j.1749-6632.1988.tb42107.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GROSSMAN SP, 1978, SCIENCE, V202, P537, DOI 10.1126/science.705344; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; HEMMINGS HC, 1986, PROG BRAIN RES, V69, P149; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7; HERNANDEZ L, 1966, PHARMACOL REV, V18, P925; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JICHA GA, 1991, J NEUROSCI, V11, P3822; JOSEPH MH, 1990, J NEUROSCI METH, V34, P143, DOI 10.1016/0165-0270(90)90052-H; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.neuro.11.1.81; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1992, J NEUROSCI, V12, P4281; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LUDECKE B, 1995, HUM GENET, V95, P123; LYTLE LD, 1978, SCIENCE, V200, P1175; MARROCCO RT, 1994, CURR OPIN NEUROBIOL, V4, P166, DOI 10.1016/0959-4388(94)90067-1; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORGANE PJ, 1961, AM J PHYSIOL, V201, P420, DOI 10.1152/ajplegacy.1961.201.3.420; NYGAARD TG, 1995, CURR OPIN NEUROL, V8, P310, DOI 10.1097/00019052-199508000-00011; ONN SP, 1990, BRAIN RES, V518, P274, DOI 10.1016/0006-8993(90)90980-P; PARKER SW, 1967, EXP NEUROL, V17, P313, DOI 10.1016/0014-4886(67)90109-4; PHILLIPS AG, 1975, NATURE, V258, P750, DOI 10.1038/258750a0; PHILLIPSON OT, 1979, J COMP NEUROL, V187, P117, DOI 10.1002/cne.901870108; RODRIGUES PD, 1990, P NATL ACAD SCI USA, V87, P9693, DOI 10.1073/pnas.87.24.9693; ROGERS DC, 1990, EXP BRAIN RES, V80, P172; ROLLS ET, 1981, HDB HYPOTHALAMUS, V3, P439; SALAMONE JD, 1990, NEUROSCIENCE, V39, P17, DOI 10.1016/0306-4522(90)90218-S; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SCHWARZ SS, 1987, EXP BRAIN RES, V65, P449; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SKUTELLA T, 1994, NEUROSCI LETT, V167, P55, DOI 10.1016/0304-3940(94)91026-X; SMITH GP, 1988, ANN NY ACAD SCI, V537, P254, DOI 10.1111/j.1749-6632.1988.tb42111.x; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P95; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WADDINGTON JL, 1993, D1 D2 DOPAMINE RECEP, P51; WELF DW, 1995, ANNU REV NEUROSCI, V18, P463; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WINN P, 1984, NEUROSCIENCE, V12, P225, DOI 10.1016/0306-4522(84)90149-0; WISE RA, 1992, SYNAPSE, V10, P247, DOI 10.1002/syn.890100307; WISE RA, 1978, SCIENCE, V201, P262, DOI 10.1126/science.566469; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C; WRIGHT AK, 1980, APPETITE, V1, P43, DOI 10.1016/S0195-6663(80)80007-9; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1; ZIGMOND MJ, 1972, SCIENCE, V177, P1211	77	574	584	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1197	1209		10.1016/0092-8674(95)90145-0	http://dx.doi.org/10.1016/0092-8674(95)90145-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548806	Bronze			2022-12-01	WOS:A1995TM76200015
J	Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A				Lehmuskallio, E; Lindholm, H; Koskenvuo, K; Sarna, S; Friberg, O; Viljanen, A			Frostbite of the face and ears: Epidemiological study of risk factors in Finnish conscripts	BRITISH MEDICAL JOURNAL			English	Article							MILITARY OPERATIONS; COLD	Objective-To determine the incidence of and the risk factors for local cold injuries of the face and ears in peacetime military service. Design-Prospective, controlled epidemiological study using a questionnaire. Setting-Finnish defence forces, 1976-89. Subjects-913 young male conscripts with local frostbite of the head that needed medical attention and 2478 uninjured control conscripts. Main outcome measures-Type of activity, clothing, and other risk factors at the time of cold injury. Odds ratios were used to calculate risk. Controls were handled as one group. Results-The mean annual incidence of frostbite was 1 . 8 per 1000 conscripts. Frostbite of the ear was most common (533 conscripts (58%)), followed by frostbite of the nose (197 (22%)) and of the cheeks and other regions of the face (183 (20%)). Most conscripts (803 (88%)) had mild or superficial frostbite. Risk factors included not wearing a hat with earflaps (odds ratio 18 . 5 for frostbite of the ear); not wearing a scarf(odds ratio 2 . 1 and 3 . 8 for frostbite of the ear and cheeks respectively); using protective ointments (odds ratio 3 . 3, 4 . 5, and 5 . 6 for frostbite of the cheeks, ear, and nose respectively); being extremely sensitive to cold and having hands and feet that sweat profusely (odds ratio 3 . 5 for frostbite of the nose); and being transported in the open or in open vehicles under windy conditions (odds ratio 2 . 2 for frostbite of the cheek). Conclusions-Wearing warm clothing, including a scarf and a hat with earflaps, helps to prevent frostbite. Each person's sensitivity to cold may also be important. The routine use of protective ointments should not be recommended.	FINNISH DEF FORCES,INST MIL MED,SF-00300 HELSINKI,FINLAND; FINNISH DEF STAFF,MED SECT,SF-00101 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00014 HELSINKI,FINLAND	University of Helsinki	Lehmuskallio, E (corresponding author), SANTAHAMINA MIL HLTH CTR,POB 6,SF-00861 HELSINKI,FINLAND.			Sarna, Seppo/0000-0003-3458-1627				DICK HJ, 1989, MED CORPS INT, V4, P41; FRITZ RL, 1989, CLIN SPORT MED, V8, P111; HAMLET MP, 1987, MIL MED, V152, P393; HANSON HE, 1969, MIL MED, V134, P1307; KOSKENVUO K, 1977, ANN MED MILITARIS FE, V52, P9; KOSKENVUO K, 1976, ANN MED MILITARIS FE, V51, P59; LEHMUSKALLIO E, 1993, 3RD P C EUR AC DERM, P10; LINDHOLM H, 1993, A19931 SCI COMM NAT; Siple Paul A., 1945, PROC AMER PHIL SOC, V89, P177; STEINMAN AM, 1987, MIL MED, V152, P389; TERVAHAUTA R, 1993, FIELD SURGERY MED, P461; VAUGHN PB, 1980, MIL MED, V145, P305; WILSON O, 1970, J APPL PHYSIOL, V29, P658, DOI 10.1152/jappl.1970.29.5.658	13	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1661	1663		10.1136/bmj.311.7021.1661	http://dx.doi.org/10.1136/bmj.311.7021.1661			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541749	Green Published			2022-12-01	WOS:A1995TL94200008
J	ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC				ZWIEBEL, LJ; SACCONE, G; ZACHAROPOULOU, A; BESANSKY, NJ; FAVIA, G; COLLINS, FH; LOUIS, C; KAFATOS, FC			THE WHITE GENE OF CERATITIS-CAPITATA - A PHENOTYPIC MARKER FOR GERMLINE TRANSFORMATION	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; DNA; INTEGRATION; CLONING	Reliable germline transformation is required for molecular studies and ultimately for genetic control of economically important insects, such as the Mediterranean fruit fly (medfly) Ceratitis capitata. A prerequisite for the establishment and maintenance of transformant lines is selectable or phenotypically dominant markers. To this end, a complementary DNA clone derived from the medfly white gene was isolated, which showed substantial similarity to white genes in Drosophila melanogaster and other Diptera. It is correlated with a spontaneous mutation causing white eyes in the medfly and can be used to restore partial eye color in transgenic Drosophila carrying a null mutation in the endogenous white gene.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; FORTH,INST MOLEC BIOL & BIOTECHNOL,CRETE,GREECE; UNIV NAPLES FEDERICO II,DIPARTIMENTO GENET BIOL GEN & MOLEC,NAPLES,ITALY; UNIV PATRAS,DEPT BIOL,PATRAI,GREECE; CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA 30341	European Molecular Biology Laboratory (EMBL); Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Naples Federico II; University of Patras; Centers for Disease Control & Prevention - USA			Louis, Christos/F-2527-2012; saccone, giuseppe/F-8627-2013	saccone, giuseppe/0000-0002-9835-3693; Favia, Guido/0000-0002-4420-8482; Zwiebel, Laurence/0000-0001-6686-7289				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Besansky NJ, 1995, INSECT MOL BIOL, V4, P217, DOI 10.1111/j.1365-2583.1995.tb00027.x; BEVERLY S, 1984, J MOL EVOL, V12, P1; BROGNA S, UNPUB; CHRISTENSON LD, 1960, ANNU REV ENTOMOL, V5, P171, DOI 10.1146/annurev.en.05.010160.001131; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; ELIZUR A, 1990, J MOL EVOL, V30, P347, DOI 10.1007/BF02101889; FIMIANI P, 1989, FRUIT FLIES THEIR A, V3, P39; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Malacrida A., 1986, ATTI ASSOC GENET IT, V31, P121; MCGRANE V, 1988, AM J TROP MED HYG, V39, P502, DOI 10.4269/ajtmh.1988.39.502; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; OBROCHTA DA, 1994, MOL GEN GENET, V244, P9, DOI 10.1007/BF00280181; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saul S.H., 1986, Agricultural Zoology Reviews, V1, P73; SAVAKIS C, COMMUNICATION; TEARLE RG, 1989, GENETICS, V122, P595; WALKER JE, 1992, EMBO J, V1, P945; ZACHAROPOULOU A, 1992, CHROMOSOMA, V101, P448, DOI 10.1007/BF00582839; ZACHAROPOULOU A, 1990, GENOME, V33, P184, DOI 10.1139/g90-030; ZACHAROPOULOU A, UNPUB; ZIEGLER I, 1965, Z NATURFORSCH PT B, VB 20, P318, DOI 10.1515/znb-1965-0410	31	78	82	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2005	2008		10.1126/science.270.5244.2005	http://dx.doi.org/10.1126/science.270.5244.2005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533095				2022-12-01	WOS:A1995TL42000046
J	FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB				FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB			STRUCTURE OF THE HIGH-AFFINITY COMPLEX OF INOSITOL TRISPHOSPHATE WITH A PHOSPHOLIPASE-C PLECKSTRIN HOMOLOGY DOMAIN	CELL			English	Article							BINDING; C-DELTA-1; PROTEINS; VESICLES	The X-ray crystal structure of the high affinity complex between the pleckstrin homology (PH) domain from rat phospholipase C-delta(1) (PLC-delta(1)) and inositol-(1,4,5)-trisphosphate (Ins(1,4,5)P-3) has been refined to 1.9 Angstrom resolution. The domain fold is similar to others of known structure. Ins(1,4,5)P-3 binds on the positively charged face of the electrostatically polarized domain, interacting predominantly with the beta 1/beta 2 and beta 3/beta 4 loops. The 4- and B-phosphate groups of Ins(1,4,5)P-3 interact much more extensively than the l-phosphate. Two amino acids in the PLC-delta(1) PH domain that contact lns(1,4,5)P-3 have counterparts in the Bruton's tyrosine kinase (Btk) PH domain, where mutational changes cause inherited agammaglobulinemia, suggesting a mechanism for loss of function in Btk mutants. Using electrostatics and varying levels of head-group specificity, PH domains may localize and orient signaling proteins, providing a general membrane targeting and regulatory function.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; New York University				Lemmon, Mark/0000-0002-3379-5319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324, R01GM015225, R37GM015225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22324, GM15225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMMON MA, 1995, P NATL ACAD SCI USA, V62, P10472; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P55; OTWINOWSKI Z, 1991, ML PHARE; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SARASTE M, 1995, CURR OPIN STRUC BIOL, V8, P403; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHENG J, 1996, IN PRESS J MOL BIOL	42	517	522	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					1037	1046		10.1016/0092-8674(95)90219-8	http://dx.doi.org/10.1016/0092-8674(95)90219-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521504	hybrid			2022-12-01	WOS:A1995TK74500022
J	TSUKIYAMA, T; DANIEL, C; TAMKUN, J; WU, C				TSUKIYAMA, T; DANIEL, C; TAMKUN, J; WU, C			ISWI, A MEMBER OF THE SW12/SNF2 ATPASE FAMILY, ENCODES THE 140-KDA SUBUNIT OF THE NUCLEOSOME REMODELING FACTOR	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; DROSOPHILA; CHROMATIN; PROTEIN; ANTENNAPEDIA; EXPRESSION	The generation of an accessible heat shock promoter in chromatin in vitro requires the concerted action of the GAGA transcription factor and NURF, an ATP-dependent nucleosome remodeling factor. NURF is composed of four subunits and is biochemically distinct from the SW12/SNF2 multiprotein complex, a transcriptional activator that also appears to alter nucleosome structure. We have obtained protein microsequence and immunological evidence identifying the 140 kDa subunit of NURF as ISWI, previously of unknown function but highly related to SW12/SNF2 only in the ATPase domain. The ISWI protein is localized to the cell nucleus and is expressed throughout Drosophila development at levels as high as 100,000 molecules/cell. The convergence of biochemical and genetic studies on ISWI and SW12/SNF2 underscores these ATPases and their close relatives as key components of independent systems for chromatin remodeling.	NCI,BIOCHEM LAB,BETHESDA,MD 20892; UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049883] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KHAVARI PA, 1993, NATURE, V336, P170; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PATTATUCCI AM, 1991, GENETICS, V129, P443; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; REUTER R, 1990, DEVELOPMENT, V109, P289; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1	44	310	315	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					1021	1026		10.1016/0092-8674(95)90217-1	http://dx.doi.org/10.1016/0092-8674(95)90217-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521502	Bronze			2022-12-01	WOS:A1995TK74500020
J	FRANCESCHI, S; DALMASO, L; LAVECCHIA, C				FRANCESCHI, S; DALMASO, L; LAVECCHIA, C			TRENDS IN INCIDENCE OF AIDS-ASSOCIATED WITH TRANSFUSION OF BLOOD AND BLOOD PRODUCTS IN EUROPE AND THE UNITED-STATES, 1985-93	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PERIOD	Objective--To quantify patterns and trends in incidence of AIDS associated with transfusion of blood and its products in 14 European countries and the United States. Design--Data were derived ti om the World Health Organisation's European non-aggregate AIDS dataset and, for the United States, from the Centers for Disease Control AIDS public information dataset. Rates were standardised by using the world standard populations and adjusted for reporting delays in each country. Subjects--Cases of AIDS in patients with haemophilia and recipients of transfusions. Results--Overall, between 1985 and 1993 almost 6000 cases of AIDS associated with transfusions were registered in the 14 European countries considered and over 8000 in the United States between 1985 and 1992. Most European countries had annual age adjusted rates lower than 0.5 per million children aged 12 or less and between 1 and 2 per million adults. The United States had rates around 1 per million children and 5 per million adults in the most recent period. For children, the highest rates were generally reached in 1985-7, whereas in adults the highest rates were in the late 1980s. France had the highest overall incidence of AIDS related to transfusion in Europe (3.3 per million). Romania had a major epidemic in children (over 30 cases per million children in 1988-90). Incidence rates of AIDS associated with transfusion were still increasing in some southern European countries in the early 1990s. Conclusions--Apart from in France and Romania it is clear that rates of bloodborne AIDS in European countries are lower than those registered in the United States.	IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	FRANCESCHI, S (corresponding author), CTR RIFERIMENTO ONCOL,SERV EPIDEMIOL,12,I-33081 AVIANO,ITALY.		dal maso, luigino/J-3616-2018; franceschi, silvia/M-2452-2014	dal maso, luigino/0000-0001-6163-200X; franceschi, silvia/0000-0003-4181-8071; La Vecchia, Carlo/0000-0003-1441-897X				ANDERSON C, 1991, NATURE, V353, P197; Bader J M, 1992, Lancet, V340, P360, DOI 10.1016/0140-6736(92)91419-9; BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; DALMASO L, 1995, SOZ PRAVENTIV MED, V40, P239, DOI 10.1007/BF01354479; DOLL R, 1982, SCI PUBLICATION 42, V4, P58; FRANCESCHI S, 1994, AIDS, V8, P1173, DOI 10.1097/00002030-199408000-00022; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; MEDLEY GF, 1987, NATURE, V328, P719, DOI 10.1038/328719a0; NESS PM, 1994, ARCH PATHOL LAB MED, V118, P337; PATRASCU IV, 1993, AIDS RES HUM RETROV, V9, P99, DOI 10.1089/aid.1993.9.99; ROSENBERG PS, 1990, J ACQ IMMUN DEF SYND, V3, P49; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SELIK RM, 1994, AM J EPIDEMIOL, V140, P105, DOI 10.1093/oxfordjournals.aje.a117221; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; 1985, MMWR-MORBID MORTAL W, V34, P373; 1986, WKLY EPIDEMIOL RES, V61, P69; 1993, AIDS SURVEILLANCE EU; 1982, MMWR-MORBID MORTAL W, V31, P652; 1987, MMWR-MORBID MORTAL W, V36, pS3; 1988, WKLY EPIDEMIOL REC, V63, P1	21	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1534	1536		10.1136/bmj.311.7019.1534	http://dx.doi.org/10.1136/bmj.311.7019.1534			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520395	Green Published			2022-12-01	WOS:A1995TK21400022
J	STURDY, P; NAISH, J; PEREIRA, F; GRIFFITHS, C; DOLAN, S; TOON, P; CHAMBERS, M				STURDY, P; NAISH, J; PEREIRA, F; GRIFFITHS, C; DOLAN, S; TOON, P; CHAMBERS, M			CHARACTERISTICS OF GENERAL PRACTICES THAT PRESCRIBE APPROPRIATELY FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,MED COLL ST BARTHOLOMEWS & LONDON HOSP,LONDON E1 4NS,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP MED COLL,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND; ST MARYS HOSP,SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,LONDON W2 1PG,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; CAMPBELL M, 1995, BRIT MED J, V310, P1069, DOI 10.1136/bmj.310.6986.1069b; NAISH J, 1995, BRIT MED J, V310, P97, DOI 10.1136/bmj.310.6972.97	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 9	1995	311	7019					1547	1548		10.1136/bmj.311.7019.1547	http://dx.doi.org/10.1136/bmj.311.7019.1547			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK214	8520400	Green Published			2022-12-01	WOS:A1995TK21400028
J	UNGEWICKELL, E; UNGEWICKELL, H; HOLSTEIN, SEH; LINDNER, R; PRASAD, K; BAROUCH, W; MARTIN, B; GREENE, LE; EISENBERG, E				UNGEWICKELL, E; UNGEWICKELL, H; HOLSTEIN, SEH; LINDNER, R; PRASAD, K; BAROUCH, W; MARTIN, B; GREENE, LE; EISENBERG, E			ROLE OF AUXILIN IN UNCOATING CLATHRIN-COATED VESICLES	NATURE			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; BOVINE BRAIN; ATPASE; BINDING; DISSOCIATION; HYDROLYSIS; HOMOLOGS; BASKETS; DOMAIN	CLATHRIN-coated vesicles transport selected integral membrane proteins from the cell surface and the a trans-Golgi network to the endosomal system(1,2). Before fusing with their target the vesicles must be stripped of their coats, This process is effected by the chaperone protein hsp70c together with a 100K cofactor(3) which we here identify as the coat protein auxilin. Auxilin binds with high affinity to assembled clathrin lattices and, in the presence of ATP, recruits hsp70c. Dissociation of the lattice does not depend as previously supposed on clathrin light chains or on the aminoterminal domain of the heavy chain4,5. The presence of a J-domain at its carboxy terminus now defines auxilin as a member of the DnaJ protein family. In conjunction with hsp70, DnaJ proteins catalyse protein folding, protein transport across membranes and the selective disruption of protein-protein interactions(6-8). We show that deletion of the J-domain of auxilin results in the loss of cofactor activity.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	UNGEWICKELL, E (corresponding author), WASHINGTON UNIV,SCH MED,CTR IMMUNOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Lindner, Robert/AAO-9538-2020	Lindner, Robert/0000-0002-6421-5778				AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CRY DM, 1994, TRENDS BIOCHEM SCI, V19, P176; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN JL, 1988, REV CELL BIOL, V1, P1; Hartl F U, 1991, Semin Immunol, V3, P5; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LINDNER R, 1992, J BIOL CHEM, V267, P16567; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1982, P NATL ACAD SCI-BIOL, V79, P91, DOI 10.1073/pnas.79.1.91; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; SCHMID SL, 1985, J BIOL CHEM, V26, P10057; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; WALL D, 1994, J BIOL CHEM, V269, P5446; WINKLER FK, 1983, EMBO J, V2, P1363	30	388	395	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					632	635		10.1038/378632a0	http://dx.doi.org/10.1038/378632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524399				2022-12-01	WOS:A1995TJ22100082
J	REISER, L; MODRUSAN, Z; MARGOSSIAN, L; SAMACH, A; OHAD, N; HAUGHN, GW; FISCHER, RL				REISER, L; MODRUSAN, Z; MARGOSSIAN, L; SAMACH, A; OHAD, N; HAUGHN, GW; FISCHER, RL			THE BELL1 GENE ENCODES A HOMEODOMAIN PROTEIN INVOLVED IN PATTERN-FORMATION IN THE ARABIDOPSIS OVULE PRIMORDIUM	CELL			English	Article							MAIZE HOMEOBOX GENE; FLOWER DEVELOPMENT; EMBRYO SAC; WILD-TYPE; EXPRESSION; KNOTTED-1; THALIANA; PLANTS; CELLS; FATES	Ovule development in Arabidopsis involves the formation of three morphologically defined proximal-distal pattern elements. Integuments arise from the central pattern element. Analysis of Bell1 (Bel1) mutant ovules indicated that BEL1 was required for integument development, Cloning of the BEL1 locus reveals that it encodes a homeodomain transcription factor. Prior to integument initiation, BEL1 RNA localizes to the central domain, providing molecular evidence for a central pattern element. Therefore, proximal-distal patterning of the ovule involves the regulated expression of the BEL1 gene that controls integument morphogenesis. A model for BEL1 function is evaluated with regard to new data showing the expression pattern of the floral homeotic gene AGAMOUS (AG) early in wild-type and Bel1 ovule development.	UNIV BRITISH COLUMBIA,DEPT BOT,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia	REISER, L (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720, USA.			Ohad, Nir/0000-0002-7094-2939; Reiser, Leonore/0000-0003-0073-0858				[Anonymous], 1960, [No title captured], DOI DOI 10.1097/00010694-196008000-00031; BARTON MK, 1993, DEVELOPMENT, V119, P823; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COLUMBO L, 1995, IN PRESS PLANT CELL, V7; COMAI L, 1992, PLANT PHYSIOL, V98, P53, DOI 10.1104/pp.98.1.53; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRIIS EM, 1990, ADV BOT RES, V17, P99, DOI 10.1016/S0065-2296(08)60133-0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLDBERG RB, 1994, SCIENCE, V466, P605; HERR JM, 1995, AM J BOT, V82, P547, DOI 10.2307/2445703; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; JACKSON D, 1994, DEVELOPMENT, V120, P405; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; KATAVIC V, 1994, MOL GEN GENET, V245, P363, DOI 10.1007/BF00290117; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; LUPPUNER V, 1994, J BIOL CHEM, V269, P7863; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MANSFIELD SG, 1991, CAN J BOT, V69, P447, DOI 10.1139/b91-062; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MODRUSAN Z, 1994, PLANT CELL, V6, P333, DOI 10.1105/tpc.6.3.333; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; RAY A, 1994, P NATL ACAD SCI USA, V91, P5761, DOI 10.1073/pnas.91.13.5761; REISER L, 1993, PLANT CELL, V5, P1291, DOI 10.1105/tpc.5.10.1291; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; ROBINSONBEERS K, 1992, PLANT CELL, V4, P1237, DOI 10.1105/tpc.4.10.1237; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHNEEBERGER RG, 1995, GENE DEV, V9, P2292, DOI 10.1101/gad.9.18.2292; SCHNEITZ K, 1995, PLANT J, V7, P731, DOI 10.1046/j.1365-313X.1995.07050731.x; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; Slack J, 1983, EGG EMBRYO; SMITH LG, 1992, DEVELOPMENT, V116, P21; Stebbins G.L., 1974, FLOWERING PLANTS EVO; Takhtadzhian A., 1991, EVOLUTIONARY TRENDS; VOLLBRECHT E, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P111; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	50	197	229	3	40	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					735	742		10.1016/0092-8674(95)90186-8	http://dx.doi.org/10.1016/0092-8674(95)90186-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521490	Bronze			2022-12-01	WOS:A1995TH94800010
J	STENMARK, H; VITALE, G; ULLRICH, O; ZERIAL, M				STENMARK, H; VITALE, G; ULLRICH, O; ZERIAL, M			RABAPTIN-5 IS A DIRECT EFFECTOR OF THE SMALL GTPASE RAB5 IN ENDOCYTIC MEMBRANE-FUSION	CELL			English	Article							BINDING PROTEIN; YEAST; TRANSPORT; DOMAIN; CELLS; EXPRESSION; ANTIBODIES; VESICLES; PATHWAY; INVITRO	We have identified a novel 100 kDa coiled-coil protein, rabaptin-5, that specifically interacts with the GTP form of the small GTPase Rab5, a potent regulator of endocytic transport. It is mainly cytosolic, but a fraction colocalizes with Rab5 to early endosomes. Expression of a GTPase-deficient Rab5 mutant enhances the binding of rabaptin-5 to enlarged endosomes. Over-expression of rabaptin-5 alone is sufficient to promote expansion of early endosomes. Rab5 recruits rabaptin-5 to purified early endosomes in a GTP-dependent manner, demonstrating functional similarities with other members of the Ras superfamily. Immunodepletion of rabaptin-5 from cytosol strongly inhibits Rab5-dependent early endosome fusion. Rabaptin-5 is thus a Rab effector required for membrane docking and fusion.	NORWEGIAN RADIUM HOSP,DEPT BIOCHEM,N-0310 OSLO,NORWAY	University of Oslo	STENMARK, H (corresponding author), EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY.		Stenmark, Harald/B-8868-2008					ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bartel PL, 1993, CELLULAR INTERACTION, P153; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; DIAZ R, 1988, J BIOL CHEM, V263, P6093; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRUENBERG J, 1988, CELL FREE ANAL MEMBR, P317; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HORIUCHI H, 1995, J BIOL CHEM, V271, P11257; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI GP, 1994, J BIOL CHEM, V269, P14631; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MU FT, 1995, J BIOL CHEM, V270, P13505; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OIKKONEN VM, 1993, J CELL SCI, V106, P1249; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	58	399	413	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					423	432		10.1016/0092-8674(95)90120-5	http://dx.doi.org/10.1016/0092-8674(95)90120-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521472	Bronze			2022-12-01	WOS:A1995TC97700012
J	VERHEIJ, C; BAKKER, CE; DEGRAAFF, E; KEULEMANS, J; WILLEMSEN, R; VERKERK, AJMH; GALJAARD, H; REUSER, AJJ; HOOGEVEEN, AT; OOSTRA, BA				VERHEIJ, C; BAKKER, CE; DEGRAAFF, E; KEULEMANS, J; WILLEMSEN, R; VERKERK, AJMH; GALJAARD, H; REUSER, AJJ; HOOGEVEEN, AT; OOSTRA, BA			CHARACTERIZATION AND LOCALIZATION OF THE FMR-1 GENE-PRODUCT ASSOCIATED WITH FRAGILE-X SYNDROME	NATURE			English	Article							EXPRESSION; PURIFICATION; CELLS	THE fragile X syndrome is the most frequent form of inherited mental retardation after Down's syndrome, having an incidence of one in 1,250 males1,2. The fragile X syndrome results from amplification of the CGG repeat found in the FMR-1 gene3-6. This CGG repeat shows length variation in normal individuals and is increased significantly in both carriers and patients3-6; it is located 250 base pairs distal to a CpG island6 which is hypermethylated in fragile X patients4-7. The methylation probably results in downregulation of FMR-1 gene expression8. No information can be deduced about the function of the FMR-1 protein from its predicted sequence. Here we investigate the nature and function of the protein encoded by the FMR-1 gene using polyclonal antibodies raised against the predicted amino-acid sequences. Four different protein products, possibly resulting from alternative splicing, have been identified by immunoblotting in lymphoblastoid cell lines of healthy individuals. All these proteins were missing in cell lines from patients not expressing FMR-1 messenger RNA. The intracellular localization of the FMR-1 gene products was investigated by transient expression in COS-1 cells and found to be cytoplasmic. Localization was also predominantly cytoplasmic in the epithelium of the oesophagus, but in some cells was obviously nuclear.	ERASMUS UNIV ROTTERDAM,MGC DEPT CLIN GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			de Graaff, Esther/D-3287-2011	Verkerk, Annemieke JMH/0000-0002-7523-3656				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OBERLE I, 1991, SCIENCE, V252, P1179; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDONGEN JM, 1984, HISTOCHEM J, V16, P941, DOI 10.1007/BF01003850; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	17	292	299	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					722	724		10.1038/363722a0	http://dx.doi.org/10.1038/363722a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515814	Green Published			2022-12-01	WOS:A1993LJ33900056
J	BRISKIN, MJ; MCEVOY, LM; BUTCHER, EC				BRISKIN, MJ; MCEVOY, LM; BUTCHER, EC			MADCAM-1 HAS HOMOLOGY TO IMMUNOGLOBULIN AND MUCIN-LIKE ADHESION RECEPTORS AND TO IGA1	NATURE			English	Article							VASCULAR ADDRESSIN; ENDOTHELIAL-CELLS; LYMPH-NODE; BINDING; GENE; LYMPHOCYTES; SUPERFAMILY; RECOGNITION; ANTIBODIES; MOLECULE	TISSUE-SPECIFIC homing of lymphocytes is regulated by interactions with the endothelium of specialized venules, such as the high endothelial venules (HEV) in lymph nodes and mucosal lymphoid tissues1-3. The mucosal vascular addressin, a 58-66K glycoprotein adhesion receptor for lymphocytes, is selectively expressed on HEV of mucosal lymphoid organ and on lamina propria venules and helps direct lymphocyte traffic to these mucosal tissues4,5. We now report the isolation of a complementary DNA that, on transfection into COS cells, encodes immunoreactive addressin that specifically binds the mucosal HEV-binding T-cell lymphoma TK1. The predicted amino-acid sequence defines the mucosal addressin as a novel immunoglobulin family member, MAdCAM-1, with two amino-terminal domains that display strong homology to previously described vascular adhesion receptors for leukocytes, ICAM-1 (ref. 6) and VCAM-1 (ref. 7). The membrane proximal domain is homologous to the third domain (Calpha2) of another mucosa-associated immunoglobulin family member, IgA1 (refs 8, 9). In addition to the immunoglobulin domains, there is a serine/threonine-rich region which may serve as a backbone to present carbohydrate ligands to lymphocytes. MAdCAM-1 is thus a complex multidomain receptor displaying several structural motifs that may participate in lymphocyte homing interactions.	STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOLEC BIOL & MED, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BRISKIN, MJ (corresponding author), STANFORD UNIV, DEPT PATHOL, IMMUNOL & VASC BIOL LAB, STANFORD, CA 94305 USA.							BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V133, P2961; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; HOLTZMANN B, 1989, CELL, V56, P37; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAWAMURA S, 1989, NUCLEIC ACIDS RES, V17, P6732, DOI 10.1093/nar/17.16.6732; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1990, MOL CLONING; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIMONETMARTIN MT, 1986, CR SOC BIOL, V180, P229; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	28	366	392	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1993	363	6428					461	464		10.1038/363461a0	http://dx.doi.org/10.1038/363461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502297				2022-12-01	WOS:A1993LE93800062
J	FRANK, S; LAUTERBUR, PC				FRANK, S; LAUTERBUR, PC			VOLTAGE-SENSITIVE MAGNETIC GELS AS MAGNETIC-RESONANCE MONITORING AGENTS	NATURE			English	Article							PHASE-TRANSITION; ELECTRIC-FIELD; SYSTEMS	MANY polymer gels undergo a volume phase transition in electric fields1-5. We report here the synthesis of a Polyelectrolyte gel that incorporates magnetic particles of iron oxide into the polymer network; these particles couple the gel volume transition to the NMR relaxation times of the surrounding water. We find that the water proton relaxation rates (T2(-1)) in aqueous suspensions of particles of the magnetic gel increase significantly in an electric field. Such changes can also be induced by the hyperpolarization of red blood cells in the suspension, presumably as a result of the electric fields at the cell membrane surfaces. These gels may play a part in magnetic resonance imaging analogous to that of voltage-sensitive dyes in optical imaging6-9.	UNIV ILLINOIS,BIOMED MAGNET RESONANCE LAB,1307 W PK ST,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								COHEN L, 1988, NATURE, V331, P112, DOI 10.1038/331112a0; CORTI M, 1991, PHYS REV A, V43, P6887, DOI 10.1103/PhysRevA.43.6887; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; HIROSE Y, 1987, MACROMOLECULES, V20, P1342, DOI 10.1021/ma00172a029; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; KAJIWARA K, 1992, NATURE, V355, P208, DOI 10.1038/355208a0; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KISHI R, 1989, J CHEM SOC FARAD T 1, V85, P655, DOI 10.1039/f19898500655; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MATSUO ES, 1988, J CHEM PHYS, V89, P1695, DOI 10.1063/1.455115; MULLER RN, 1991, MAGNET RESON MED, V22, P178, DOI 10.1002/mrm.1910220203; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; OHGUSHI M, 1978, J MAGN RESON, V29, P599, DOI 10.1016/0022-2364(78)90018-5; OSADA Y, 1987, ADV POLYM SCI, V82, P1; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; RINK TJ, 1982, RED CELL MEMBRANES M, P321; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Shaw D. J., 1969, ELECTROPHORESIS; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA J, 1992, ACS SYM SER, V480, P1; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; 1977, Patent No. 4064080	23	67	70	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					334	336		10.1038/363334a0	http://dx.doi.org/10.1038/363334a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497316				2022-12-01	WOS:A1993LD91700047
J	WALWORTH, N; DAVEY, S; BEACH, D				WALWORTH, N; DAVEY, S; BEACH, D			FISSION YEAST CHK1-PROTEIN KINASE LINKS THE RAD CHECKPOINT PATHWAY TO CDC2	NATURE			English	Article							TYROSINE PHOSPHATASE; GENE	THE dependence of cell-cycle progression on the integrity of the genome has been described as checkpoint control1,2. A number of mutants of the fission yeast Schizosaccharomyces pombe, selected for their sensitivity to DNA damage caused by radiation (rad mutants) or to the DNA synthesis inhibitor hydroxyurea (hus mutants) have been classified as checkpoint mutants because they fail to arrest the cell cycle in response to DNA damage or incompletely replicated DNA3-6. Coupling of the checkpoint pathways that monitor DNA repair and replication to control of the cell cycle is essential. In a search for components that interact with the cell-cycle regulatory kinase p34cdc2, we have identified a novel fission yeast protein kinase homologue which is involved in cell-cycle arrest when DNA damage has occurred or when unligated DNA is present. We have called the gene encoding this protein chk1 for checkpoint kinase. Multiple copies of chk1 partially rescue the ultraviolet sensitivity of rad1-1, a mutant deficient in checkpoint control3-5. Identification of a gene involved in checkpoint control as a rescue of a cdc2 mutant links the rad1-dependent DNA-damage-sensing pathway and p34cdc2 activity.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute								ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; COTTAREL G, IN PRESS GENE; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2	19	412	435	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1993	363	6427					368	371		10.1038/363368a0	http://dx.doi.org/10.1038/363368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497322				2022-12-01	WOS:A1993LD91700059
J	RUSSELL, R; GROVES, P; TAUB, N; ODOWD, J; REYNOLDS, F				RUSSELL, R; GROVES, P; TAUB, N; ODOWD, J; REYNOLDS, F			ASSESSING LONG-TERM BACKACHE AFTER CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate the factors associated with long term backache after childbirth, to assess all women reporting new onset long term backache, and to investigate any relation with pain relief in labour. Design-Data collected from obstetric records and postal questionnaires or telephone interviews on morbidity after childbirth from all women delivering their first baby between March 1990 and February 1991, followed by analysis of data collected from outpatient consultations. Setting-St Thomas's Hospital, London. Subjects-Questionnaires were sent to 1615 women who had delivered their first baby in the defined period; 1015 either replied by post or were contacted by telephone. Results-299 women (29.5% of responders) reported backache lasting more than six months and of these 156 (15.4%) said they had had no back problems previously. Those women who had received epidural analgesia in labour were significantly more likely to report new onset backache (17.8%; 95% confidence interval 14.8% to 20.8%) than those who did not (11.7%; 8.6% to 14.8%). Younger women, unmarried women, and those reporting other antenatal symptoms were significantly more likely to report new long term backache. The 156 women reporting new backache were asked to attend an outpatient clinic and 36 (23%) did so. The majority had a postural backache which was not severe. Psychological factors were present in 14 women. Conclusions-Though new long term backache is reported more commonly after epidural analgesia in labour, it tends to be postural and not severe. There were no differences in the nature of the backache between those who had or had not received epidural analgesia in labour.	ST THOMAS HOSP,DEPT ORTHOPAED SURG,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	RUSSELL, R (corresponding author), ST THOMAS HOSP,DEPT ANAESTHET,LONDON SE1 7EH,ENGLAND.			Russell, Robin/0000-0001-7294-6629				DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P1013; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1992, BRIT MED J, V304, P1279, DOI 10.1136/bmj.304.6837.1279; MAIN CJ, 1983, J PSYCHOSOM RES, V27, P503, DOI 10.1016/0022-3999(83)90040-5; Ransford AO., 1976, SPINE, V1, P127, DOI DOI 10.1097/00007632-197606000-00007; WADDELL G, 1987, LUMBAR SPINE BACK PA, P419; WHITEHEAD CR, 1986, DEWHURSTS TXB OBSTET	7	70	73	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1299	1303		10.1136/bmj.306.6888.1299	http://dx.doi.org/10.1136/bmj.306.6888.1299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518569	Green Published, Bronze			2022-12-01	WOS:A1993LC72200019
J	JOHNSON, AG				JOHNSON, AG			FOR DEBATE - GALL-STONES - THE REAL ISSUES	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, AG (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SURG UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							JORGENSEN T, 1989, HEPATOLOGY, V9, P856, DOI 10.1002/hep.1840090611; SCOTT EA, 1992, ANN ROY COLL SURG, V74, P97	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1114	1115		10.1136/bmj.306.6885.1114	http://dx.doi.org/10.1136/bmj.306.6885.1114			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ565	8495160	Bronze, Green Published			2022-12-01	WOS:A1993KZ56500028
J	Ifudu, O; Feldman, J; Friedman, EA				Ifudu, O; Feldman, J; Friedman, EA			The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; AMBULATORY PERITONEAL-DIALYSIS; ANEMIA; FAILURE; UREMIA	Background. Anemia (characterized by a hematocrit of 30 percent or lower) persists in 40 to 60 percent of patients treated for end-stage renal disease with maintenance hemodialysis, despite concomitant erythropoietin (epoetin) therapy. We tested the hypothesis that inadequate dialysis is a key reason for the insufficient response to erythropoietin in patients with end-stage renal disease who are receiving hemodialysis. Methods. We prospectively studied 135 randomly selected patients undergoing hemodialysis who had been receiving intravenous erythropoietin for at least four months. The adequacy of dialysis was assessed by measuring the percent reduction in the blood urea nitrogen concentration and the serum albumin concentration. The hematocrit was measured weekly for four weeks, transferrin saturation was measured, and coexisting illnesses were documented. To determine the effect of an increased level of dialysis on the hematocrit, the thrice-weekly schedule of dialysis was increased to raise the mean urea-reduction value from 60.7 to 72.0 percent for six weeks in 20 consecutive patients whose base-line urea-reduction value was less than 65 percent. The change in the hematocrit in these patients was compared with that observed in the next 20 patients who had an equivalent base-line urea-reduction value but whose level of dialysis was not altered. Results. The mean (+/-SD) hematocrit of the entire group was 29.2+/-4 percent, and the mean thrice-weekly dose of erythropoietin was 59+/-29 U per kilogram of body weight. The mean serum albumin concentration was 3.8+/-0.4 g per deciliter, the mean urea-reduction value was 62+/-4.8 percent, and the mean transferrin saturation was 20+/-9 percent. Multiple regression analysis revealed direct correlations between the hematocrit and the serum albumin concentration (P=0.009) and between the hematocrit and the urea-reduction value (P=0.012) after adjustment for other factors. A logistic-regression analysis indicated that an 11 percent increase in the urea-reduction value doubled the odds that a patient would have a hematocrit above 30 percent. After six weeks of increased intensity of dialysis in 20 patients with base-line urea-reduction values of less than 65 percent, the mean (+/-SE) hematocrit rose from 28.4+/-0.78 percent to 32.3+/-0.71 percent (P=0.002); there was no significant change in a control group of 20 patients with equivalent base-line urea-reduction values in whom the dialysis level was not altered (28.2+/-0.84 percent to 26.3+/-0.85 percent; P=0.175). Conclusions. In patients with end-stage renal disease, inadequate hemodialysis is associated with a suboptimal response to erythropoietin therapy, Increasing the intensity of dialysis in patients with anemia who are receiving inadequate dialysis results in a significant increase in the hematocrit. (C) 1996, Massachusetts Medical Society.	SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,RENAL DIS DIV,450 CLARKSON AVE,BOX 52,BROOKLYN,NY 11203, USA.							BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; CARO J, 1979, J LAB CLIN MED, V93, P449; ESCHBACH JW, 1992, KIDNEY INT, V42, P407, DOI 10.1038/ki.1992.302; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCHBACH JW, 1970, ARCH INTERN MED, V126, P812, DOI 10.1001/archinte.126.5.812; ESSERS U, 1974, P EUR DIAL TRANS, V11, P389; GOODNOUGH LT, 1994, CLIN NEPHROL, V41, P303; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; IFUDU O, 1994, JAMA-J AM MED ASSOC, V271, P29, DOI 10.1001/jama.271.1.29; IFUDU O, 1995, ASAIO J, V41, pM426, DOI 10.1097/00002480-199507000-00045; IFUDU O, 1994, CLIN RES, V42, pA263; INGELFINGER JA, 1994, BIOSTATISTICS CLIN M, P166; KOCH KM, 1974, NEPHRON, V12, P405, DOI 10.1159/000180353; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; LUNDIN AP, 1989, SEMIN NEPHROL, V9, P22; MARKSON J L, 1956, Scott Med J, V1, P320; MCGONIGLE RJS, 1984, KIDNEY INT, V25, P430, DOI 10.1038/ki.1984.35; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; ORTEGA JA, 1977, AM J HEMATOL, V2, P299, DOI 10.1002/ajh.2830020312; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; POWE NR, 1993, KIDNEY INT, V43, P1125, DOI 10.1038/ki.1993.158; RADTKE HW, 1981, J CLIN INVEST, V67, P1623, DOI 10.1172/JCI110197; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WALLNER SF, 1981, J LAB CLIN MED, V97, P170; ZAPPACOSTA AR, 1982, AM J MED, V72, P53, DOI 10.1016/0002-9343(82)90577-0; 1992, 1992 SE KIDN COUNC A; 1994, ANN INTERN MED, V121, P62	30	230	237	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	1996	334	7					420	425		10.1056/NEJM199602153340702	http://dx.doi.org/10.1056/NEJM199602153340702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU696	8552143				2022-12-01	WOS:A1996TU69600002
J	Poland, GA				Poland, GA			Acellular pertussis vaccines: New vaccines for an old disease	LANCET			English	Editorial Material											Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,200 1ST ST SW,ROCHESTER,MN 55905, USA.							DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; EDWARDS KM, 1995, PEDIATRICS, V96, P548; EDWARDS KM, 1993, J INFECT DIS, V168, P15, DOI 10.1093/infdis/168.1.15; Folkers G, 1995, NIAID AIDS Agenda, P14; GRECO D, 1995, 35TH ANN ICAAC M, V11, pLB22; PLOTKIN SL, 1994, VACCINES, P1; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					209	210		10.1016/S0140-6736(96)90398-0	http://dx.doi.org/10.1016/S0140-6736(96)90398-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551875				2022-12-01	WOS:A1996TT06900004
J	Koretz, RL				Koretz, RL			Polyp surveillance in patients with limited life expectancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Koretz, RL (corresponding author), OLIVE VIEW UCLA MED CTR,DIV GASTROENTEROL,14445 OLIVE VIEW DR,SYLMAR,CA 91342, USA.							DAY DW, 1984, SCAND J GASTROENTE S, V104, P99; KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011; MINAMOTO T, 1994, GASTROENTEROLOGY, V106, P1436, DOI 10.1016/0016-5085(94)90395-6; SPRATT JS, 1958, ANN SURG, V148, P682, DOI 10.1097/00000658-195810000-00014	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					327	327		10.1001/jama.275.4.327	http://dx.doi.org/10.1001/jama.275.4.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544278				2022-12-01	WOS:A1996TP96500035
J	Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS				Kessler, E; Takahara, K; Biniaminov, L; Brusel, M; Greenspan, DS			Bone morphogenetic protein-1: The type I procollagen C-proteinase	SCIENCE			English	Article							POLYACRYLAMIDE GELS; MOUSE FIBROBLASTS; PURIFICATION; QUANTITIES; CLEAVAGE; SEQUENCE; PATTERN; DOMAIN; EMBRYO; BMP-1	Bone morphogenetic proteins (BMPs) are bone-derived factors capable of inducing ectopic bone formation. Unlike other BMPs, BMP-1 is not like transforming growth factor-beta (TGF-beta), but it is the prototype of a family of putative proteases implicated in pattern formation during development in diverse organisms. Although some members of this group, such as Drosophila tolloid (TLD), are postulated to activate TGF-beta-like proteins, actual substrates are unknown, Procollagen C-proteinase (PCP) cleaves the COOH-propeptides of procollagens I, II, and III to yield the major fibrous components of vertebrate extracellular matrix. Here it is shown that BMP-1 and PCP are identical. This demonstration of enzymatic activity for a BMP-1/TLD-like protein links an enzyme involved in matrix deposition to genes involved in pattern formation.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Kessler, E (corresponding author), TEL AVIV UNIV, SACKLER FAC MED, CHAIM SHEBA MED CTR, MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST, IL-52621 TEL HASHOMER, ISRAEL.			Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [GM46846] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FINELLI L, 1995, GENETICS, V141, P271; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KESSLER E, 1978, ANAL BIOCHEM, V86, P463, DOI 10.1016/0003-2697(78)90770-4; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KESSLER EM, UNPUB; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ST, 1990, J BIOL CHEM, V265, P21992; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	433	456	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					360	362		10.1126/science.271.5247.360	http://dx.doi.org/10.1126/science.271.5247.360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553073				2022-12-01	WOS:A1996TQ52800044
J	Iglehart, JK				Iglehart, JK			Health policy report - Managed care and mental health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ARONS BS, 1994, HEALTH AFFAIR, V13, P192, DOI 10.1377/hlthaff.13.1.192; AUERBACH S, 1995, WASHINGTON POST 1020, pB1; BATTAGLIOLA M, 1994, BUSINESS HLTH    JUN, P53; CALLAHAN JJ, 1995, HEALTH AFFAIR, V14, P173, DOI 10.1377/hlthaff.14.3.173; CHRISTIANSON JB, 1995, HEALTH AFFAIR, V14, P160, DOI 10.1377/hlthaff.14.3.160; CHRISTIANSON JB, 1994, HOSP COMMUNITY PSYCH, V45, P898; England M J, 1993, New Dir Ment Health Serv, P5; ESSOCK SM, 1995, HEALTH AFFAIR, V14, P34, DOI 10.1377/hlthaff.14.3.34; FELDMAN S, 1992, MANAGED MENTAL HLTH; FRANK RG, 1995, HEALTH AFFAIR, V14, P50, DOI 10.1377/hlthaff.14.3.50; FRANK RG, 1995, HEALTH AFFAIR, V14, P102, DOI 10.1377/hlthaff.14.3.102; FRANK RG, 1995, MILBANK Q, V73, P19; GOTTLIEB M, 1995, NY TIMES        1004, pA1; HYMOWITZ C, 1995, WALL STREET J   1221, pA1; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; KOYANAGI C, 1995, HEALTH AFFAIR, V14, P124, DOI 10.1377/hlthaff.14.3.124; MECHANIC D, 1995, MILBANK Q, V73, P19, DOI 10.2307/3350312; Meyer R E, 1993, Acad Psychiatry, V17, P149, DOI 10.1007/BF03341518; MEYER RE, 1995, HEALTH AFFAIR, V14, P65, DOI 10.1377/hlthaff.14.3.65; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NORQUIST G, 1991, ARCH GEN PSYCHIAT, V48, P475; OSS M, 1995, OPEN MINDS       MAR, P12; PANZARINO P, 1995, BEHAVIORAL  HEAL MAY, P49; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; SABIN JE, 1994, HASTINGS CENT REP, V24, P5, DOI 10.2307/3563458; STRUMWASSER I, 1991, MED CARE, V29, pAS77; 1995, MEDICAID MANAGED CAR; 1995, MANAGING MANAGED CAR; 1995, 1995 LEAD C WASH	31	94	94	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					131	135		10.1056/NEJM199601113340221	http://dx.doi.org/10.1056/NEJM199601113340221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP363	8531959				2022-12-01	WOS:A1996TP36300031
J	Schmitt, HJ; vonKonig, CHW; Neiss, A; Bogaerts, H; Bock, HL; SchulteWissermann, H; Gahr, M; Schult, R; Folkens, JU; Rauh, W; Clemens, R				Schmitt, HJ; vonKonig, CHW; Neiss, A; Bogaerts, H; Bock, HL; SchulteWissermann, H; Gahr, M; Schult, R; Folkens, JU; Rauh, W; Clemens, R			Efficacy of acellular pertussis vaccine in early childhood after household exposure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against ''typical'' pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design.-Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting.-Six areas in Germany with a high incidence of pertussis, Subjects.-Four hundred fifty-three households with index cases comprising 360 evaluable contacts eligible for analysis of vaccine efficacy. Main Outcome Measure.-Vaccine efficacy from attack rates of pertussis in household contacts classified by vaccination status. Results.-Of the 173 nonvaccinated household contacts, 96 developed typical pertussis, compared with seven of 112 contacts vaccinated with acellular pertussis vaccine. Vaccine efficacy was consequently calculated to be 88.7% (95% confidence interval, 76.6% to 94.6%). Protection did not wane until at least the time recommended for booster vaccination. None of the analyzed potential confounding factors-age, socioeconomic status, erythromycin treatment, household composition, center effect, and selection bias-influenced study results in favor of the vaccine. Conclusions.-Under conditions of intense household exposure, primary vaccination with acellular vaccine protected against pertussis until at least the time recommended for booster vaccination, The vaccine can be expected to be equally or more effective in settings with lower infectious pressure.	UNIV MAINZ,CHILDRENS HOSP,W-6500 MAINZ,GERMANY; MUNICIPAL HOSP KREFELD,INST HYG & LAB MED,KREFELD,GERMANY; MUNICIPAL HOSP KREFELD,CHILDRENS HOSP,KREFELD,GERMANY; TECH UNIV MUNICH,INST MED STAT & EPIDEMIOL,W-8000 MUNICH,GERMANY; SMITHKLINE BEECHAM BIOL,RIXENSART,BELGIUM; UNIV GOTTINGEN,CHILDRENS HOSP,W-3400 GOTTINGEN,GERMANY; PEDIATRICIANS FLENSBURG,FLENSBURG,GERMANY; CHILDRENS HOSP OFFENBURG,OFFENBURG,GERMANY; MUTTERHAUS BORROMAERINNEN,CHILDRENS HOSP,TRIER,GERMANY	Johannes Gutenberg University of Mainz; Technical University of Munich; GlaxoSmithKline; University of Gottingen				Clemens, Ralf/0000-0003-4685-4207				[Anonymous], 1988, LANCET, Vi, P955; AOYAMA T, 1985, J PEDIATR, V107, P80; BROOME CV, 1981, J PEDIATR-US, V98, P362, DOI 10.1016/S0022-3476(81)80696-8; BURSTYN DG, 1983, INFECT IMMUN, V41, P1150, DOI 10.1128/IAI.41.3.1150-1156.1983; DECKER MD, 1995, PEDIATRICS, V96, P557; EDWARDS KM, 1995, PEDIATRICS, V96, P548; FINE PEM, 1987, REV INFECT DIS, V9, P866; KIMURA M, 1988, Acta Paediatrica Japonica, V30, P143; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P446, DOI 10.1001/jama.274.6.446; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; MULLER AS, 1984, WHO EPIGAG84WP11 DOC; ONEILL RT, 1988, STAT MED, V7, P1279, DOI 10.1002/sim.4780071208; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Pocock SJ., 1983, CLIN TRIALS PRACTICA; SCHMITZ M, 1994, MONATSSCHR KINDERH, V142, P41; SPRAUER MA, 1992, AM J DIS CHILD, V146, P177, DOI 10.1001/archpedi.1992.02160140043018; STORSAETER J, 1992, AM J DIS CHILD, V146, P167, DOI 10.1001/archpedi.1992.02160140033016; STORSAETER J, 1992, VACCINE, V10, P142, DOI 10.1016/0264-410X(92)90002-2; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; 1991, 1991 WHO M CAS DEF P, P4	22	221	229	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					37	41		10.1001/jama.275.1.37	http://dx.doi.org/10.1001/jama.275.1.37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531284				2022-12-01	WOS:A1996TM23800019
J	Krek, W; Xu, GF; Livingston, DM				Krek, W; Xu, GF; Livingston, DM			Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint	CELL			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; COMPLEX-FORMATION; GENE-PRODUCT; PROTEIN; IDENTIFICATION; EXPRESSION; TRANSACTIVATION; REPLICATION; COMPONENT	Commitment of mammalian cells to enter S phase enables the transcription factor E2F-1 to activate certain genes whose products mediate cell cycle advance. In S phase, E2F-1 forms stable complexes with cyclin A-kinase, which in turn eliminates E2F-1 DNA binding function. Here, we show that suppression of E2F-1 DNA-binding activity by cyclin A-kinase is linked to orderly S phase progression. Disruption of this linkage resulted in S phase delay/arrest followed by regrowth or apoptosis, depending upon whether the DNA-bound E2F-1 could transactivate. Hence, the unscheduled presence of E2F-1 on specific DNA sequences during S phase can activate a specific S phase checkpoint, thereby linking transcription, DNA replication, and cell cycle control.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SELLERS WR, 1995, IN PRESS P NATL ACAD; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	43	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1149	1158		10.1016/0092-8674(95)90141-8	http://dx.doi.org/10.1016/0092-8674(95)90141-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548802	Bronze			2022-12-01	WOS:A1995TM76200011
J	Wilson, ME				Wilson, ME			Infectious diseases: An ecological perspective	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL-CHANGES		HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	Wilson, ME (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							[Anonymous], 1993, MANAGING GLOBAL GENE; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; Chivian E., 1993, CRITICAL CONDITION H; Crosby A.W, 1989, AM FORGOTTEN PANDEMI; Crosby Alfred W., 1972, COLUMBIAN EXCHANGE B; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELTON CS, 1972, ECOLOGY INVASIONS AN; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; GRIST NR, 1993, LANCET, V339, P1363; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; HOMERDIXON TF, 1991, INT SECURITY, V16, P76, DOI 10.2307/2539061; KOHN MA, 1995, J INFECT DIS, V172, P246, DOI 10.1093/infdis/172.1.246; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECT MICR; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCCARTHY SA, 1994, APPL ENVIRON MICROB, V60, P2597, DOI 10.1128/AEM.60.7.2597-2601.1994; McMichael AJ, 1993, PLANETARY OVERLOAD G; McNeill W.H., 1976, PLAGUES PEOPLES; MOORE PS, 1989, LANCET, V2, P260; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; RAEBURN P, 1995, LAST HARVEST GENETIC; REEVES WC, 1995, J MED ENTOMOL, V31, P323; ROOT TL, 1995, SCIENCE, V269, P334, DOI 10.1126/science.269.5222.334; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Snow J., 1849, MODE COMMUNICATION C; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; TESH RB, 1994, DISEASE EVOLUTION GL; TICKELL C, 1993, PARASITOLOGY, V106, pS5, DOI 10.1017/S0031182000086078; Toole M. J., 1994, MED GLOBAL SURVIVAL, V1, P200; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; Weiner J., 1994, BEAK FINCH STORY EVO; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201; WILSON ME, 1995, EPIDEMIOLOGY, V6, P458, DOI 10.1097/00001648-199507000-00027; WILSON ME, 1994, DISEASE EVOLUTION GL; WINKELSTEIN W, 1995, AM J EPIDEMIOL, V142, pS3, DOI 10.1093/aje/142.Supplement_9.S3; 1995, WHO1995 WORLD HLTH R; 1991, MMWR-MORBID MORTAL W, V40, P838; 1993, 1993 WORLD DEV REP; 1995, MMWR-MORBID MORTAL W, V44, P468; 1995, MMWR-MORBID MORTAL W, V44, P243; IN PRESS POLICY MAKE; 1995, MMWR-MORBID MORTAL W, V44, P237; 1995, LANCET, V345, P339; 1995, MMWR-MORBID MORTAL W, V44, P475	48	66	70	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1681	1684		10.1136/bmj.311.7021.1681	http://dx.doi.org/10.1136/bmj.311.7021.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541756	Green Published			2022-12-01	WOS:A1995TL94200016
J	BEZPROZVANNY, I; SCHELLER, RH; TSIEN, RW				BEZPROZVANNY, I; SCHELLER, RH; TSIEN, RW			FUNCTIONAL IMPACT OF SYNTAXIN ON GATING OF N-TYPE AND Q-TYPE CALCIUM CHANNELS	NATURE			English	Article							EXPRESSION; SUBUNIT; DOCKING; BRAIN; CDNA	RAPID and reliable synaptic transmission depends upon the close proximity of voltage-gated calcium channels and neurotransmitter-containing vesicles in the presynaptic terminal(1). Although it is clear that a local Ca2+ rise conveys the crucial signal from Ca2+ channels to the exocytotic mechanism(2), little is known about whether communication ever proceeds in the opposite direction, from the release machinery to Ca2+ channels(3,4). To look for such signalling, we examined the interaction of various types of voltage-gated Ca2+ channels with syntaxin, a presynaptic membrane protein of relative molecular mass 35,000 (refs 5-7) which may play a key part in synaptic vesicle docking and fusions and which interacts strongly with N-type Ca2+ channels(5,6,9-12). Here we report that co-expression of syntaxin 1A with N-type channels in Xenopus oocytes sharply decreases the availability of these channels. This is due to the stabilization of channel inactivation rather than to a simple block or lack of channel expression, because it is overcome by strong hyperpolarization. Deletion of syntaxin's carboxy-terminal transmembrane domain abolishes its functional effect on Ca2+ channels. Syntaxin produced a similar effect on Q-type Ca2+ channels encoded by alpha(1A) (refs 13-15) but not on L-type Ca2+-channels. Thus, the syntaxin effect is specific for Ca2+ channel types that participate in fast transmitter release in the mammalian central nervous system (ref. 16 and therein). We hypothesize that, in addition to acting as a vesicle-docking site, syntaxin may influence presynaptic Ca2+ channels, opposing Ca2+ entry where it is not advantageous, but allowing it at release sites where synaptic vesicles have become docked and/or ready for fusion.	STANFORD UNIV, MED CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, BECKMAN CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA	Stanford University; Howard Hughes Medical Institute; Stanford University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Katz B., 1969, RELEASE NEURAL TRANS; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SMIMOVA T, 1995, NEUROSCIENCE, V68, P125; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WHEELER DB, 1994, SCIENCE, V266, P830, DOI 10.1126/science.266.5186.830; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	30	363	372	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	1995	378	6557					623	626		10.1038/378623a0	http://dx.doi.org/10.1038/378623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524397				2022-12-01	WOS:A1995TJ22100079
J	EVANS, MR				EVANS, MR			IS TUBERCULOSIS TAKEN SERIOUSLY IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							BCG VACCINATION; ENGLAND; WALES; SCHOOLCHILDREN; IMMUNIZATION; POLICY; AUDIT	Tuberculosis has been the subject of much concern in recent years. Notifications have increased, inadequacies in surveillance revealed, and policies for BCG immunisation and screening of immigrants questioned. Until recently the disease was given low priority in the United Kingdom. There is no overall strategic framework for tackling tuberculosis, and fears have been expressed about the future of local tuberculosis control programmes in the new market economy of the NHS. An action plan for tuberculosis within the context of a national programme is urgently required. Only then will a major impact on the incidence of the disease be seen.			EVANS, MR (corresponding author), S GLAMORGAN HLTH AUTHOR,DEPT PUBL HLTH,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				AHMED S, 1992, J PUBLIC HEALTH MED, V14, P389, DOI 10.1093/oxfordjournals.pubmed.a042778; [Anonymous], 1994, TUBER LUNG DIS, V75, P179; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; BROWN JS, 1995, BRIT MED J, V310, P974, DOI 10.1136/bmj.310.6985.974; Citron KM, 1995, OUT SHADOW DETECTING; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DAVIES PDO, 1993, BRIT MED J, V307, P59, DOI 10.1136/bmj.307.6895.59-b; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; DIPERRI G, 1989, LANCET, V2, P1502; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; HARDIE RM, 1993, BRIT MED J, V307, P1539, DOI 10.1136/bmj.307.6918.1539; HAYWARD AC, 1995, COMM DIS RESP CDR RE, V5, P29; HICKMAN M, 1992, BRIT MED J, V304, P1567, DOI 10.1136/bmj.304.6841.1567-c; HUSSAIN SF, 1992, BRIT MED J, V304, P1213, DOI 10.1136/bmj.304.6836.1213; ISEMAN MD, 1995, NEW ENGL J MED, V332, P1094, DOI 10.1056/NEJM199504203321611; JOSEPH CA, 1992, BRIT MED J, V305, P495, DOI 10.1136/bmj.305.6852.495; KENT RJ, 1994, BRIT MED J, V309, P639, DOI 10.1136/bmj.309.6955.639; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; ORMEROD LP, 1994, THORAX, V49, P1085, DOI 10.1136/thx.49.11.1085; ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; SELBY CD, 1993, RESPIR MED, V83, P353; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; STOKER N, 1994, BRIT MED J, V309, P1178, DOI 10.1136/bmj.309.6963.1178; SUTHERLAND I, 1989, J EPIDEMIOL COMMUN H, V43, P15, DOI 10.1136/jech.43.1.15; SUTHERLAND I, 1987, TUBERCLE, V68, P81, DOI 10.1016/0041-3879(87)90023-7; WATBURTON ARE, 1993, COMM DIS REP CDR REV, V3, P175; 1990, MMWR-MORBID MORTAL W, V39, P1; 1989, MMWR S5, V38, P1; 1989, MMWR-MORBID MORTAL W, V38, P313; 1994, THORAX, V49, P1193; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, LOCAL STRATEGIES HLT; 1992, HLTH NATION; 1992, IMMUNISATION INFECTI; 1994, REGISTRAR GENERAL MB; 1985, BRIT MED J, V291, P658; 1993, COMM DIS REP CDR WKL, V3, P1; 1990, MMWR-MORBID MORTAL W, V39, P8; 1990, THORAX, V45, P403; 1992, THORAX, V47, P770; 1980, BRIT MED J, V281, P895; 1992, BRIT MED J, V304, P1231; 1993, MMWR-MORBID MORTAL W, V42, P1; 1989, MMWR-MORBID MORTAL W, V38, P236; 1992, MMWR-MORBID MORTAL W, V41, P1	47	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1483	1485		10.1136/bmj.311.7018.1483	http://dx.doi.org/10.1136/bmj.311.7018.1483			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520341	Green Published			2022-12-01	WOS:A1995TJ04400031
J	ZHONG, T; ARNDT, KT				ZHONG, T; ARNDT, KT			THE YEAST SIS1-PROTEIN, A DNAJ HOMOLOG, IS REQUIRED FOR THE INITIATION OF TRANSLATION	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; 2 GENES; MUTANTS; REPLICATION; RNA; BACTERIOPHAGE; BIOSYNTHESIS; BINDING	The S. cerevisiae SIS1 gene is essential and encodes a heat shock protein with similarity to the bacterial DnaJ protein. At the nonpermissive temperature, temperature-sensitive sis1 strains rapidly accumulate 80S ribosomes and have decreased amounts of polysomes. Certain alterations in 60S ribosomal subunits can suppress the temperature-sensitive phenotype of sis1 strains and prevent the accumulation of 80S ribosomes and the loss of polysomes normally seen under conditions of reduced SIS1 function. Analysis of sucrose gradients for SIS1 protein shows that a large fraction of SIS1 is associated with 40S ribosomal subunits and the smaller polysomes. These and other results indicate that SIS1 is required for the normal initiation of translation. Because DnaJ has been shown to mediate the dissociation of several protein complexes, the requirement of SIS1 in the initiation of translation might be for mediating the dissociation of a specific protein complex of the translation machinery.	SUNY,GRAD PROGRAM GENET,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; SUNY Maritime College	ZHONG, T (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				NIGMS NIH HHS [GM45179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO SG, 1990, NUCLEIC ACIDS RES, V18, P1447, DOI 10.1093/nar/18.6.1447; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; ITIKAWA H, 1986, J BIOCHEM, V99, P1719, DOI 10.1093/oxfordjournals.jbchem.a135648; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MUNROE D, 1990, RIBOSOME, P299; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OHKI M, 1987, J BACTERIOL, V169, P1917, DOI 10.1128/jb.169.5.1917-1922.1987; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SHERMAN F, 1989, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V167, P1377, DOI 10.1016/0006-291X(90)90675-D; WADA M, 1982, JPN J GENET, V57, P407, DOI 10.1266/jjg.57.407; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; Woolford J. L., 1991, MOL CELLULAR BIOL YE, P587; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	38	134	141	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1175	1186		10.1016/0092-8674(93)90646-8	http://dx.doi.org/10.1016/0092-8674(93)90646-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513501				2022-12-01	WOS:A1993LH54800013
J	SEMPOS, CT; CLEEMAN, JI; CARROLL, MD; JOHNSON, CL; BACHORIK, PS; GORDON, DJ; BURT, VL; BRIEFEL, RR; BROWN, CD; LIPPEL, K; RIFKIND, BM				SEMPOS, CT; CLEEMAN, JI; CARROLL, MD; JOHNSON, CL; BACHORIK, PS; GORDON, DJ; BURT, VL; BRIEFEL, RR; BROWN, CD; LIPPEL, K; RIFKIND, BM			PREVALENCE OF HIGH BLOOD CHOLESTEROL AMONG UNITED-STATES ADULTS - AN UPDATE BASED ON GUIDELINES FROM THE 2ND REPORT OF THE NATIONAL-CHOLESTEROL-EDUCATION-PROGRAM ADULT TREATMENT PANEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To estimate the current levels and trends in the proportion of US adults with high blood cholesterol based on guidelines from the second report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP II). Design.-Nationally representative cross-sectional surveys. Setting/Participants.-Data for 7775 participants 20 years of age and older from phase 1 of the third National Health and Nutrition Examination Survey (NHANES III) (data collected from 1988 through 1991) and for 9797 participants 20 through 74 years of age from NHANES II (data collected from 1976 through 1980) were used. Results.-From the data collection period in NHANES II (1976 through 1980) to the period in NHANES III (1988 through 1991), the proportion of adults with high blood cholesterol levels (greater-than-or-equal-to 240 mg/dL [6.21 mmol/L]) fell from 26% to 20%, while the proportion with desirable levels (<200 mg/dL [5.17 mmol/L]) rose f rom 44% to 49%. Currently, using the ATP II guidelines and NHANES III data, 40% of all adults 20 years of age and older would require fasting lipoprotein analysis; and 29% of all adults would be candidates for dietary therapy (as compared with 36%, using NHANES II data). Based on 1990 population data, it is estimated that approximately 52 million Americans 20 years of age and older would be candidates for dietary therapy. Assuming that dietary intervention would reduce low-density lipoprotein (LDL) cholesterol levels by 10%, as many as 7% of all adult Americans (approximately 12.7 million) might be candidates for cholesterol-lowering drugs. This estimate reflects approximately 4 million adults with established coronary heart disease, of whom half are aged 65 years and older, and up to 8.7 million adults without established coronary heart disease, of whom up to 3.1 million are aged 65 years and older. Conclusions.-Substantial progress has been made in reducing the prevalence of high blood cholesterol; yet a large proportion of all adults, approximately 29%, require dietary intervention for high blood cholesterol.	NHLBI,NATL CHOLESTEROL EDUC PROGRAM,BLDG 31,ROOM 4A-05,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD; JOHNS HOPKINS UNIV,CTR CHILDRENS MED & SURG,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Johns Hopkins University								CLEEMAN JI, 1989, CLIN LAB MED, V9, P7, DOI 10.1016/S0272-2712(18)30638-3; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FEINLEIB M, IN PRESS CAN J CARDI; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROLICH ED, 1988, HYPERTENSION, V11, pA210; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIFKIND BM, 1983, ATHEROSCLEROSIS, V4; Rose G.A., 1982, CARDIOVASCULAR SURVE; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; 1988, ARCH INTERN MED, V148, P36; 1961, HLTH PEOPLE 200 NATI; 1985, VITAL HLTH STAT 1, V19; 1993, JAMA-J AM MED ASSOC, V269, P3015; 1991, NATIONAL HLTH NUTRIT; 1976, EXAMINATION STAFF PR; [No title captured]	18	306	314	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1993	269	23					3009	3014		10.1001/jama.269.23.3009	http://dx.doi.org/10.1001/jama.269.23.3009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LF941	8501843				2022-12-01	WOS:A1993LF94100030
J	GRIFFIN, DK; WILTON, LJ; HANDYSIDE, AH; ATKINSON, GHG; WINSTON, RML; DELHANTY, JDA				GRIFFIN, DK; WILTON, LJ; HANDYSIDE, AH; ATKINSON, GHG; WINSTON, RML; DELHANTY, JDA			DIAGNOSIS OF SEX IN PREIMPLANTATION EMBRYOS BY FLUORESCENT INSITU HYBRIDIZATION	BRITISH MEDICAL JOURNAL			English	Article							DNA AMPLIFICATION		UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,LONDON NW1 2HE,ENGLAND; ZOOL SOC LONDON,INST ZOOL,LONDON NW1 4RY,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0NN,ENGLAND	University of London; University College London; Zoological Society of London; Imperial College London								GRIFFIN DK, 1992, HUM GENET, V89, P18, DOI 10.1007/BF00207035; Handyside A.H., 1993, PREIMPLANTATION DIAG, P239; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0	4	48	50	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1382	1382		10.1136/bmj.306.6889.1382	http://dx.doi.org/10.1136/bmj.306.6889.1382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518605	Bronze, Green Published			2022-12-01	WOS:A1993LD82900022
J	Brock, DJH				Brock, DJH			Prenatal screening for cystic fibrosis: 5 years' experience reviewed	LANCET			English	Article							CARRIERS; CARE	Background Although several programmes of prenatal screening for cystic fibrosis have been completed and reported, there are still uncertainties about rates of take up and also about the action of parents identified as having a one-in-four risk of an affected child. I report 5 years' experience with the two-step and couple models of prenatal screening of cystic fibrosis. Methods Screening has been available at two antenatal clinics in Edinburgh, UK, since January, 1992, first on a research basis and then routinely. 25 000 couples have been screened. Findings Take-up rates for the two-step and couple models of delivery are very similar at about 70%. Take-up rates did not change when screening moved from a research to a routine service. Of 22 high-risk couples identified entirely through screening, 20 (91%) opted for prenatal diagnosis. Four couples returned for second and two for third monitored pregnancies. In all eight cases where affected fetuses were identified, pregnancy was terminated. Interpretation These data remove one of the few remaining obstacles to a general implementation of prenatal screening for cystic fibrosis.			Brock, DJH (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BOWMAN JE, 1991, AM J HUM GENET, V48, P433; BROCK D, 1990, AM J HUM GENET, V47, P164; DOHERTY RA, 1994, LANCET, V343, P172, DOI 10.1016/S0140-6736(94)90961-X; KABACK MM, 1977, TAY SACHS DISEASE SC, P13; LIVINGSTONE J, 1993, CLIN GENET, V43, P57, DOI 10.1111/j.1399-0004.1993.tb04427.x; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MENNIE ME, 1993, J MED GENET, V30, P543, DOI 10.1136/jmg.30.7.543; MODELL B, 1984, CLIN APPROACH THALAS, P354; Morris J K, 1995, J Med Screen, V2, P22; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1988, BRIT MED J, V297, P1599	16	55	55	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 20	1996	347	8995					148	150		10.1016/S0140-6736(96)90340-2	http://dx.doi.org/10.1016/S0140-6736(96)90340-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544548				2022-12-01	WOS:A1996TQ24400009
J	Gabriel, K; Schneider, J; McClain, WH				Gabriel, K; Schneider, J; McClain, WH			Functional evidence for indirect recognition of G center dot U in tRNA(Ala) by alanyl-tRNA synthetase	SCIENCE			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; IDENTITY; SPECIFICITY; DETERMINES; END	The structural features of the G . U wobble pair in Escherichia coli alanine transfer RNA (tRNA(Ala)) that are associated with aminoacylation by alanyl-tRNA synthetase (AlaRS) were investigated in vivo for wild-type tRNA(Ala) and mutant tRNAs with G . U substitutions. tRNA(Ala) with G . U, C . A, or G . A gave similar amounts of charged tRNA(Ala) and supported viability of E. coli lacking chromosomal tRNA(Ala) genes. tRNA(Ala) With G . C was inactive. Recognition of G . U by AlaRS thus requires more than the functional groups on G . U in a regular helix and may involve detection of a helical distortion.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042123] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42123] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLAIN FHT, 1995, NUCLEIC ACIDS RES, V23, P341, DOI 10.1093/nar/23.3.341; BLUM P, 1989, J BACTERIOL, V171, P538, DOI 10.1128/jb.171.1.538-546.1989; BRUN YV, 1990, J MOL BIOL, V214, P825, DOI 10.1016/0022-2836(90)90339-N; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; GABRIEL K, UNPUB; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	21	106	106	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 12	1996	271	5246					195	197		10.1126/science.271.5246.195	http://dx.doi.org/10.1126/science.271.5246.195			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539617				2022-12-01	WOS:A1996TP36400039
J	Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME				Zitnan, D; Kingan, TG; Hermesman, JL; Adams, ME			Identification of ecdysis-triggering hormone from an epitracheal endocrine system	SCIENCE			English	Article							MANDUCA-SEXTA; ECLOSION HORMONE; MOTOR PATTERN; CARDIOACTIVE PEPTIDE; NEURAL ORGANIZATION; TOBACCO HORNWORM; NERVOUS-SYSTEM; METAMORPHOSIS; ANTIBODIES; DROSOPHILA	Developing insects repeatedly shed their cuticle by means of a stereotyped behavior called ecdysis, thought to be initiated by the brain peptide eclosion hormone. Here an ecdysis-triggering hormone, Mas-ETH, is described from the tobacco hornworm Manduca sexta. Mas-ETH contains 26 amino acids and is produced by a segmentally distributed endocrine system of epitracheal glands (EGs). The EGs undergo a marked reduction in volume, appearance, and immunohistochemical staining during ecdysis, at which time Mas-ETH is found in the hemolymph. Injection of EGs extract or synthetic Mas-ETH into pharate larvae, pupae,or adults initiates preecdysis within 2 to 10 minutes, followed by ecdysis. Sensitivity to injected Mas-ETH appears much earlier before ecdysis and occurs with shorter latency than that reported for eclosion hormone. The isolated central nervous system responds to Mas-ETH, but not to eclosion hormone, with patterned motor bursting corresponding to in vivo preecdysis and ecdysis. Mas-ETH may be an immediate blood-borne trigger for ecdysis through a direct action on the nervous system.	UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,AGR EXPT STN,RIVERSIDE,CA 92521; USDA ARS,INSECT NEUROBIOL & HORMONE LAB,BELTSVILLE,MD 20705; UNIV MARYLAND,DEPT BIOL SCI,BALTIMORE,MD 21228	University of California System; University of California Riverside; University of California System; University of California Riverside; United States Department of Agriculture (USDA); University System of Maryland; University of Maryland Baltimore			Adams, Michael/ABF-6728-2020	Adams, Michael/0000-0003-0519-6113				AKAI H, 1992, Cytologia (Tokyo), V57, P195; COPENHAVER PF, 1982, J INSECT PHYSIOL, V28, P695, DOI 10.1016/0022-1910(82)90148-2; CURTIS AT, 1984, J INSECT PHYSIOL, V30, P597, DOI 10.1016/0022-1910(84)90043-X; EWER J, 1994, J NEUROSCI, V14, P7704; HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; Keilin D., 1944, PARASITOLOGY, V36, P1, DOI 10.1017/S0031182000011975; MASINOVSKY B, 1988, J COMP NEUROL, V273, P500, DOI 10.1002/cne.902730406; MILES CI, 1991, J COMP PHYSIOL A, V168, P179, DOI 10.1007/BF00218410; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; REYNOLDS SE, 1979, J EXP BIOL, V78, P77; Truman J.W., 1985, P381; TRUMAN JW, 1992, PROG BRAIN RES, V92, P361, DOI 10.1016/S0079-6123(08)61189-9; TRUMAN JW, 1978, J EXP BIOL, V74, P151; TRUMAN JW, 1980, J EXP BIOL, V88, P327; TRUMAN JW, 1994, INSECT NEUROCHEMISTRY AND NEUROPHYSIOLOGY 1993, P39; TRUMAN JW, 1983, NEURAL CONTROL RHYTH, V37, P223; WEEKS JC, 1984, J COMP PHYSIOL, V155, P407, DOI 10.1007/BF00610594; WEEKS JC, 1984, J COMP PHYSIOL, V155, P423, DOI 10.1007/BF00610595; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063; ZITNAN D, 1989, THESIS SLOVAK ACADEM; ZITNAN D, 1995, J COMP NEUROL, V355, P1; ZITNAN D, UNPUB	23	188	195	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 5	1996	271	5245					88	91						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP022	8539606				2022-12-01	WOS:A1996TP02200050
J	Hargarten, SW; Karlson, TA; OBrien, M; Hancock, J; Quebbeman, E				Hargarten, SW; Karlson, TA; OBrien, M; Hancock, J; Quebbeman, E			Characteristics of firearms involved in fatalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To document the types of firearms associated with firearm fatalities, and to determine the availability of information on firearm characteristics in existing data sources. Design.-Review of police, medical examiner, and crime laboratory records for all firearm homicides and review of medical examiner records for all suicides and unintentional and undetermined firearm fatalities. Setting.-City of Milwaukee, Wis, from 1990 through 1994. Population.-A total of 175 firearm suicides and 524 firearm homicides. Main Outcome Measures.-Source of data, circumstances and means of death; host demographic characteristics; firearm make, model, caliber, barrel length, and serial number. Results.-Handguns accounted for 468 (89%) of 524 firearm homicides and 124 (71%) of 175 firearm suicides. Handguns of .25 caliber accounted for 14% (n=63) of 438 firearm homicides and 12% (n=15) of all firearm suicides in which caliber was known. The Raven MP-25 was the single most commonly identified firearm and accounted for 10% (n=15) of 153 handgun homicide cases and 7% (n=7) of the 76 suicide cases in which the manufacturer of the firearm was identified. From all data sources combined, information on firearm type was available in 681 (97%) of 699 cases, caliber/gauge in 636 cases (91%), manufacturer/model in 309 cases (44%), and serial number in 276 cases (40%). Conclusions.-Inexpensive, short-barreled .25-caliber handguns were the most common weapon type associated with firearm homicides and suicides in Milwaukee during 1990 through 1994. Product-specific Information is a crucial part of planning appropriate injury countermeasures for firearms. in combination, police, crime laboratory, and medical examiner data can supply this information with modest changes in data collection procedures.	MED COLL WISCONSIN,DEPT GEN SURG,MILWAUKEE,WI 53226; UNIV WISCONSIN,CTR HLTH SYST RES & ANAL,MADISON,WI; WISCONSIN DEPT JUSTICE,OFF CONSUMER PROTECT,MADISON,WI	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Hargarten, SW (corresponding author), MED COLL WISCONSIN,DEPT EMERGENCY MED,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							BAKER S, 1992, INJURY FACT BOOK, P9; FREEDMAN A, 1992, WALL STREET J   0218, pA1; HARGARTEN S, 1994, WIS MED J        OCT, P521; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; Wintemute G., 1994, RING FIRE HANDGUN MA; Zane D F, 1991, Tex Med, V87, P63; 1992, FATAL ACCIDENT REPOR; 1983, ATF FORM 4590; 1994, 1994 BUYERS GUIDE SH, V38, P153; 1994, 1994 GUYERS GUIDE SH, V38, P145; 1994, MMWR-MORBID MORTAL W, V43, P3; 1994, 1994 BUYERS GUIDE SH, V38, P148; 1985, INJURY AM, P191; 1994, US DOT HS808169 US D	16	65	66	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	1996	275	1					42	45		10.1001/jama.275.1.42	http://dx.doi.org/10.1001/jama.275.1.42			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM238	8531285				2022-12-01	WOS:A1996TM23800020
J	Molkentin, JD; Black, BL; Martin, JF; Olson, EN				Molkentin, JD; Black, BL; Martin, JF; Olson, EN			Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins	CELL			English	Article							HELIX-LOOP-HELIX; ENHANCER-BINDING-FACTOR; TRANSCRIPTION FACTORS; BASIC REGION; MYOD FAMILY; FACTOR-II; OLIGOMERIZATION; MYOBLASTS; COMPLEXES; PRODUCTS	Members of the myocyte enhancer factor-2 (MEF2) family of MADS domain transcription factors cannot induce myogenesis in transfected fibroblasts, but when coexpressed with the myogenic basic-helix-loop-helix (bHLH) proteins MyoD or myogenin they dramatically increase the extent of myogenic conversion above that seen with either myogenic bHLH factor alone. This cooperativity required direct interactions between the DNA-binding domains of MEF2 and the myogenic bHLH factors, but only one of the factors needed a transactivation domain, and only one of the factors needed to be bound to DNA. These interactions allow either factor to activate transcription through the other's binding site and reveal a novel mechanism for indirect activation of gene expression via protein-protein interactions between the DNA-binding domains of heterologous classes of transcription factors.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Black, Brian/0000-0002-6664-8913; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	56	682	704	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 29	1995	83	7					1125	1136		10.1016/0092-8674(95)90139-6	http://dx.doi.org/10.1016/0092-8674(95)90139-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548800	Bronze			2022-12-01	WOS:A1995TM76200009
J	FIELDS, BA; OBER, B; MALCHIODI, EL; LEBEDEVA, MI; BRADEN, BC; YSERN, X; KIM, JK; SHAO, XG; WARD, ES; MARIUZZA, RA				FIELDS, BA; OBER, B; MALCHIODI, EL; LEBEDEVA, MI; BRADEN, BC; YSERN, X; KIM, JK; SHAO, XG; WARD, ES; MARIUZZA, RA			CRYSTAL-STRUCTURE OF THE V-ALPHA DOMAIN OF A T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; VARIABLE PORTIONS; ENCEPHALOMYELITIS; RECOGNITION; ACTIVATION; CLONES; REI	The crystal structure of the V-alpha domain of a T cell antigen receptor (TCR) was determined at a resolution of 2.2 angstroms. This structure represents an immunoglobulin topology set different from those previously described. A switch in a polypeptide strand from one beta sheet to the other enables a pair of V-alpha homodimers to pack together to form a tetramer, such that the homodimers are parallel to each other and all hypervariable loops face in one direction. On the basis of the observed mode of V-alpha association, a model of an (alpha beta)(2) TCR tetramer can be positioned relative to the major histocompatibility complex class II (alpha beta)(2) tetramer with the third hypervariable loop of V-alpha over the amino-terminal portion of the antigenic peptide and the corresponding loop of V-beta over its carboxyl-terminal residues. TCR dimerization that is mediated by the alpha chain may contribute to the coupling of antigen recognition to signal transduction during T cell activation.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; UNIV TEXAS, SW MED CTR, CTR CANC IMMUNOBIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Food & Drug Administration (FDA)				Malchiodi, Emilio/0000-0001-7501-3330; Ward, E. Sally/0000-0003-3232-7238; Fields, Barry/0000-0003-0628-1328	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031592] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31592] Funding Source: Medline; NIGMS NIH HHS [GM52801] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; FIELDS BA, 1994, J MOL BIOL, V239, P339, DOI 10.1006/jmbi.1994.1373; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; GOODMAN S, 1995, J IMMUNOL, V155, P1210; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KAPPLER J, 1983, CELL, V34, P727, DOI 10.1016/0092-8674(83)90529-9; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; STEINMAN L, 1991, ADV IMMUNOL, V49, P357; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	35	180	181	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	1995	270	5243					1821	1824		10.1126/science.270.5243.1821	http://dx.doi.org/10.1126/science.270.5243.1821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525376				2022-12-01	WOS:A1995TK47600046
J	HELLWALD, KH; PALUKAITIS, P				HELLWALD, KH; PALUKAITIS, P			VIRAL-RNA AS A POTENTIAL TARGET FOR 2 INDEPENDENT MECHANISMS OF REPLICASE-MEDIATED RESISTANCE AGAINST CUCUMBER MOSAIC-VIRUS	CELL			English	Article							NUCLEOTIDE-SEQUENCE; X INFECTION; PLANTS; PROTEIN; INVITRO; GENE; COMPLEMENTARY; TRANSCRIPTS; EXPRESSION; POLYMERASE	Transgenic tobacco showing replicase-mediated resistance against cucumber mosaic virus (CMV) can be infected by the strain K-CMV. By use of chimeric constructs between full-length cDNA clones of RNA2 of strains Fny-CMV and K-CMV, the existence of two independent mechanisms of replicase-mediated resistance against viral replication and movement of Fny-CMV was demonstrated in these plants. The data indicate that viral RNA may serve as the target for both mechanisms of resistance. A positive correlation was observed between the amount of K-CMV RNA2 sequence present in the chimeric constructs and the ability to overcome the inhibition of replication, whereas a sequence domain was delimited in K-CMV RNAS responsible for the ability of this strain to break resistance against virus movement.	CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853	Cornell University								AHLQUIST P, 1981, CELL, V23, P183, DOI 10.1016/0092-8674(81)90283-X; ANDERSON JM, 1992, P NATL ACAD SCI USA, V89, P8759, DOI 10.1073/pnas.89.18.8759; AUDY P, 1994, MOL PLANT MICROBE IN, V7, P15, DOI 10.1094/MPMI-7-0015; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BOCCARD F, 1992, GENE, V114, P223, DOI 10.1016/0378-1119(92)90578-D; BRAUN CJ, 1992, PLANT CELL, V4, P735, DOI 10.1105/tpc.4.6.735; BREDERODE FT, 1995, VIROLOGY, V207, P467, DOI 10.1006/viro.1995.1106; CAMERON FH, 1991, NUCLEIC ACIDS RES, V19, P469, DOI 10.1093/nar/19.3.469; CARR JP, 1994, VIROLOGY, V199, P439, DOI 10.1006/viro.1994.1142; CARR JP, 1993, SEMIN VIROL, V4, P339, DOI 10.1006/smvy.1993.1032; COOPER B, 1995, VIROLOGY, V206, P307, DOI 10.1016/S0042-6822(95)80046-8; COUTTS RHA, 1977, PLANT SCI LETT, V9, P45, DOI 10.1016/0304-4211(77)90009-8; DING SW, 1994, VIROLOGY, V198, P593, DOI 10.1006/viro.1994.1071; DING SW, 1995, J GEN VIROL, V76, P459, DOI 10.1099/0022-1317-76-2-459; DONSON J, 1993, MOL PLANT MICROBE IN, V6, P635, DOI 10.1094/MPMI-6-635; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; GALON A, 1994, VIROLOGY, V205, P280, DOI 10.1006/viro.1994.1644; GOLEMBOSKI DB, 1990, P NATL ACAD SCI USA, V87, P6311, DOI 10.1073/pnas.87.16.6311; HAYES RJ, 1990, J GEN VIROL, V71, P2503, DOI 10.1099/0022-1317-71-11-2503; HELLWALD KH, 1994, J GEN VIROL, V75, P2121, DOI 10.1099/0022-1317-75-8-2121; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOSHI RL, 1983, EMBO J, V2, P1123, DOI 10.1002/j.1460-2075.1983.tb01556.x; KAPLAN IB, 1995, VIROLOGY, V209, P188, DOI 10.1006/viro.1995.1242; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LONGSTAFF M, 1993, EMBO J, V12, P379, DOI 10.1002/j.1460-2075.1993.tb05669.x; MACFARLANE SA, 1992, P NATL ACAD SCI USA, V89, P5829, DOI 10.1073/pnas.89.13.5829; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; PALUKAITIS P, 1992, ADV VIRUS RES, V41, P281, DOI 10.1016/B978-0-12-394314-9.00013-0; PALUKAITIS P, 1994, METH MOL G, V4, P237; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; POWELLABEL P, 1986, SCIENCE, V232, P738, DOI DOI 10.1126/SCIENCE.3457472; QUADT R, 1991, FEBS LETT, V279, P273, DOI 10.1016/0014-5793(91)80166-Z; REZAIAN MA, 1985, EUR J BIOCHEM, V150, P331, DOI 10.1111/j.1432-1033.1985.tb09025.x; RIZZO TM, 1990, MOL GEN GENET, V222, P249, DOI 10.1007/BF00633825; RIZZO TM, 1988, J GEN VIROL, V69, P1777, DOI 10.1099/0022-1317-69-8-1777; RUBINO L, 1993, MOL PLANT MICROBE IN, V6, P729, DOI 10.1094/MPMI-6-729; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; SUZUKI M, 1991, VIROLOGY, V183, P106, DOI 10.1016/0042-6822(91)90123-S; TRAYNOR P, 1991, J VIROL, V65, P2807, DOI 10.1128/JVI.65.6.2807-2815.1991; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; ZAITLIN M, 1994, VIROLOGY, V201, P200, DOI 10.1006/viro.1994.1286; ZHANG L, 1994, J GEN VIROL, V75, P3185, DOI 10.1099/0022-1317-75-11-3185	43	44	50	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					937	946		10.1016/0092-8674(95)90209-0	http://dx.doi.org/10.1016/0092-8674(95)90209-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521517	hybrid			2022-12-01	WOS:A1995TK74500012
J	THERRIEN, M; CHANG, HC; SOLOMON, NM; KARIM, FD; WASSERMAN, DA; RUBIN, GM				THERRIEN, M; CHANG, HC; SOLOMON, NM; KARIM, FD; WASSERMAN, DA; RUBIN, GM			KSR, A NOVEL PROTEIN-KINASE REQUIRED FOR RAS SIGNAL-TRANSDUCTION	CELL			English	Article							TYROSINE KINASE; DROSOPHILA; EXPRESSION; ACTIVATION; PATTERN; CELLS	We have identified and characterized two genes in Drosophila whose products are required for activated RAS to signal with normal efficiency, but do not appear to effect signaling by activated RAF, One encodes the beta subunit of type I geranylgeranyl transferase, a prenylation enzyme essential for targeting RAS to the plasma membrane, The other encodes a protein kinase that we have named kinase suppressor of ras (ksr). By genetic criteria, we show that KSR functions in multiple receptor tyrosine kinase pathways. We have isolated mammalian homologs of KSR that, together with the Drosophila gene, define a novel class of kinases. Our results suggest that KSR is a general and evolutionarily conserved component of the RAS signaling pathway that acts between RAS and RAF.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	THERRIEN, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDI G, 1995, PROTEIN KINASE 1; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUBBARD SR, 1991, SCIENCE, V254, P1776; KARPEN GH, 1992, GENETICS, V132, P737; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XU T, 1993, DEVELOPMENT, V117, P1223	44	328	342	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					879	888		10.1016/0092-8674(95)90204-X	http://dx.doi.org/10.1016/0092-8674(95)90204-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521512	Bronze			2022-12-01	WOS:A1995TK74500007
J	PERNEGER, TV; SUDRE, P; LUNDGREN, JD; HIRSCHEL, B				PERNEGER, TV; SUDRE, P; LUNDGREN, JD; HIRSCHEL, B			DOES THE ONSET OF TUBERCULOSIS IN AIDS PREDICT SHORTER SURVIVAL - RESULTS OF A COHORT STUDY IN 17 EUROPEAN COUNTRIES OVER 13 YEARS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Objective-To assess the impact of tuberculosis on mortality in patients with AIDS. Design-Community based cohort study. Setting-52 centres in 17 countries (AIDS in Europe study). Subjects-5249 patients who were alive and free of tuberculosis one month after the diagnosis of AIDS, enrolled between 1979 and 1989, and followed up until 1992. Main outcome measures-Onset of clinically active tuberculosis or death, or both. Results-During a mean follow up period of 15 months 201 (4%) patients developed tuberculosis and 3889 (74%) died. Patients who developed tuberculosis survived significantly longer (median 22 months) than those who did not (median 16 months). This apparent survival advantage was due to patients who survived longer having more opportunity to develop tuberculosis (or any other disease). In models that took into account the time at which tuberculosis was diagnosed, the onset of tuberculosis was associated with a significant increase in mortality (adjusted relative hazard of death 1 . 34; 95% confidence interval 1 . 12 to 1 . 60). Conclusions-The onset of tuberculosis in patients with AIDS predicts a substantial increase in mortality. Whether this increased mortality is directly attributable to the tuberculosis remains uncertain. If the association is causal preventive chemotherapy and aggressive treatment of tuberculosis could improve survival in AIDS.	UNIV HOSP GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND; UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK	University of Geneva; University of Copenhagen	PERNEGER, TV (corresponding author), UNIV GENEVA, INST SOCIAL & PREVENT MED, CMU CASE POSTALE, CH-1211 GENEVA 4, SWITZERLAND.		Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; Collett, 2014, MODELLING SURVIVAL D; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; HORSBURGH CR, 1993, AIDS, V7, pS109, DOI 10.1097/00002030-199301001-00014; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; 1987, MMWR-MORBID M      S, V36, P3	15	57	58	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 2	1995	311	7018					1468	1471		10.1136/bmj.311.7018.1468	http://dx.doi.org/10.1136/bmj.311.7018.1468			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520334	Green Published, Green Submitted			2022-12-01	WOS:A1995TJ04400023
J	GRIFF, IC; REED, RR				GRIFF, IC; REED, RR			THE GENETIC-BASIS FOR SPECIFIC ANOSMIA TO ISOVALERIC ACID IN THE MOUSE	CELL			English	Article							RECOMBINANT-INBRED STRAINS; ODORANT-BINDING PROTEIN; HUMAN COLOR-VISION; OLFACTORY EPITHELIUM; RECEPTOR EXPRESSION; MOLECULAR-GENETICS; CONGENIC STRAINS; LIGAND-BINDING; MICE; SENSITIVITY	The detection and discrimination of odorants in mammals is thought to be mediated by a family of 100-1000 seven transmembrane domain receptor proteins, although none of these putative olfactory receptors have been shown to bind individual odorants with high affinity. We have used a genetic approach to identify the genomic regions responsible for the differential ability of two inbred mouse strains to detect a single odorant, isovaleric acid. Results obtained with a behavioral assay were consistent with a limited number of genes conf erring the ability to detect isovaleric acid. One genetic location mapped to a 0.3 cM region between D4MIT37 and D4MIT156 on mouse chromosome 4. A second locus mapped to the distal end of mouse chromosome 6. The most likely cause of the behavior difference between the two strains of mice is the loss of the receptor protein or proteins responsible for recognizing isovaleric acid. High resolution genetic mapping provides a novel approach to the identification of genes critical for the detection of particular odorants.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University	GRIFF, IC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.							ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; Amoore J. E., 1991, SMELL TASTE HLTH DIS, P655; AMOORE JE, 1967, NATURE, V214, P1095, DOI 10.1038/2141095a0; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BELKNAP JK, 1992, BEHAV GENET, V22, P81, DOI 10.1007/BF01066794; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAPELESS CG, 1992, BEHAV GENET, V22, P655, DOI 10.1007/BF01066636; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DEAR TN, 1991, EMBO J, V10, P2813, DOI 10.1002/j.1460-2075.1991.tb07830.x; Defranco Anthony L., 1993, P505; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GROSSISSEROFF R, 1992, NEUROSCI LETT, V141, P115, DOI 10.1016/0304-3940(92)90347-A; HUBERT HB, 1980, SCIENCE, V208, P607, DOI 10.1126/science.7189296; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KISHIMOTO J, 1994, MOL BRAIN RES, V23, P33, DOI 10.1016/0169-328X(94)90208-9; KOSHIMOTO H, 1994, NEUROSCI LETT, V169, P73, DOI 10.1016/0304-3940(94)90359-X; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUSH IE, 1988, GENET RES, V52, P207, DOI 10.1017/S0016672300027671; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PATTERSON PM, 1948, J HERED, V39, P295, DOI 10.1093/oxfordjournals.jhered.a105774; PEVSNER J, 1990, J BIOL CHEM, V265, P6118; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; POURTIER L, 1990, BEHAV GENET, V20, P499, DOI 10.1007/BF01067716; PRICE S, 1977, NEUROSCI LETT, V4, P49, DOI 10.1016/0304-3940(77)90123-9; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STROTMANN J, 1994, CELL TISSUE RES, V276, P429; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; WANG HW, 1993, SCIENCE, V260, P998, DOI 10.1126/science.8493539; WHISSELL.D, 1973, NATURE, V245, P157, DOI 10.1038/245157b0; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; WYSOCKI CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4899, DOI 10.1073/pnas.81.15.4899; WYSOCKI CJ, 1991, CHEM SENSES, V3, P331	53	53	57	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					407	414		10.1016/0092-8674(95)90118-3	http://dx.doi.org/10.1016/0092-8674(95)90118-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521470	Bronze			2022-12-01	WOS:A1995TC97700010
J	MICHAEL, WM; CHOI, MY; DREYFUSS, G				MICHAEL, WM; CHOI, MY; DREYFUSS, G			A NUCLEAR EXPORT SIGNAL IN HNRNP A1 - A SIGNAL-MEDIATED, TEMPERATURE-DEPENDENT NUCLEAR-PROTEIN EXPORT PATHWAY	CELL			English	Article							RNA-BINDING-PROTEINS; LOCATION SIGNALS; 2 STEPS; LARGE-T; TRANSLOCATION; NUCLEOPLASMIN; SEQUENCE; COMPLEX; IMPORT; PORE	Pre-mRNAs are associated with hnRNPs, and these proteins play important roles in the biogenesis of mRNAs, The hnRNP Al is one of the most abundant hnRNPs, and although localized primarily in the nucleoplasm, shuttles continuously between the nucleus and the cytoplasm, A 38 amino acid domain within Al, termed M9, which bears no resemblance to classical nuclear localization signal (NLS) sequences, localizes Al to the nucleus, Here we show that M9 is also a nuclear export signal; placing M9 on a protein that is otherwise restricted to the nucleus, the nucleoplasmin core domain (NPc), efficiently exports it to the cytoplasm in a temperature-dependent manner. In contrast, classical NLSs cannot promote the export of NPc. These findings demonstrate that there is a signal-dependent, temperature-sensitive nuclear export pathway and strengthen the suggestion that Al and other shuttling hnRNPs function as carriers for RNA during export to the cytoplasm.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	MICHAEL, WM (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013; McDermott, Michael Francis/GZM-5330-2022	Dreyfuss, Gideon/0000-0001-8129-8774; 				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CULLEN BR, 1991, J VIROL, V65, P1053, DOI 10.1128/JVI.65.3.1053-1056.1991; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MEHLIN H, 1995, J CELL BIOL, V129, P1205, DOI 10.1083/jcb.129.5.1205; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1988, CELL, V64, P615; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZAPP ML, 1995, CURR OPIN GENET DEV, V5, P229, DOI 10.1016/0959-437X(95)80013-1	49	469	478	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					415	422						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521471				2022-12-01	WOS:A1995TC97700011
J	MOORE, J				MOORE, J			AIDS - STRIKING THE HAPPY MEDIA	NATURE			English	Editorial Material											MOORE, J (corresponding author), AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016, USA.							BROWN P, 1993, NEW SCI         0515; CHOW M, 1993, NATURE, V361, P650; GLUCKMAN JC, 1993, SCIENCE, V259, P1809, DOI 10.1126/science.8456306; 1993, LANCET, V341, P889	4	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					391	392		10.1038/363391a0	http://dx.doi.org/10.1038/363391a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8502291				2022-12-01	WOS:A1993LE93800024
J	BOURNE, TH; CAMPBELL, S; REYNOLDS, KM; WHITEHEAD, MI; HAMPSON, J; ROYSTON, P; CRAYFORD, TJB; COLLINS, WP				BOURNE, TH; CAMPBELL, S; REYNOLDS, KM; WHITEHEAD, MI; HAMPSON, J; ROYSTON, P; CRAYFORD, TJB; COLLINS, WP			SCREENING FOR EARLY FAMILIAL OVARIAN-CANCER WITH TRANSVAGINAL ULTRASONOGRAPHY AND COLOR BLOOD-FLOW IMAGING	BRITISH MEDICAL JOURNAL			English	Article							SONOGRAPHY; ULTRASOUND; MASSES; TUMORS; WOMEN	Objective-To assess the value of transvaginal ultrasonography with colour blood flow imaging in detecting early ovarian cancer in women with a family history of the disease. Design-Study of self referred symptomless women with a close relative who had developed the disease. Each woman was screened to detect persistent lesions and defined changes in ovarian volume. Morphological score and pulsatility index were recorded. Setting-Ovarian screening clinic. Subjects-1601 self referred women. Interventions-Women with a positive screening result were recommended to have further investigations. Main outcome measures-Findings at surgery and histology of abnormal ovaries. Morphological score greater-than-or-equal-to 5 and pulsatility index < 1.0 at last scan. Results-Women were aged 17 to 79 (mean 47) years; 959 (60%) were premenopausal, 469 (29%) were naturally postmenopausal, and 173 (11%) had had a hysterectomy. 157 women had a pedigree suggestive of the site specific ovarian cancer syndrome and 288 of multiple site cancers. 61 women had a positive screening result (3.8%, 95% confidence interval 2.9 to 4.9%), six of whom had primary ovarian cancer detected at surgery (five stage Ia, one stage III). Use of a high morphological score or a low pulsatility index increased the odds of finding ovarian cancer from 1:9 to about 2:5 (1:1 in the highest risk groups). Five interval cancers were reported (three ovarian and two peritoneal). Eight of the 11 cancers developed in women with pedigrees suggestive of inherited cancer. Conclusions-Transvaginal ultrasonography with colour flow imaging can effectively detect early ovarian cancer in women with a family history of the disease. The screening interval should be less than two years.	KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED PHYS,LONDON W12 0NN,ENGLAND	University of London; King's College London; Imperial College London			Bourne, Tom/I-6478-2012	Bourne, Tom/0000-0003-1421-6059				BHAN V, 1989, BRIT J OBSTET GYNAEC, V96, P1384, DOI 10.1111/j.1471-0528.1989.tb06299.x; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1991, GYNECOL ONCOL, V40, P253; BOURNE TH, 1992, BRIT J HOSP MED, V48, P454; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CAMPBELL S, 1990, BRIT J OBSTET GYNAEC, V97, P304, DOI 10.1111/j.1471-0528.1990.tb01806.x; CAMPBELL S, 1992, OVARIAN CANCER, V2, P237; COLLINS WP, 1992, OVARIAN CANCER, V2, P225; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; HATA K, 1991, INT J GYNECOL OBSTET, V36, P301, DOI 10.1016/0020-7292(91)90484-M; HOULSTON R, 1992, GYNECOL ONCOL, V47, P247, DOI 10.1016/0090-8258(92)90114-X; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; KAWAI M, 1992, OBSTET GYNECOL, V79, P163; KURJAK A, 1991, J ULTRAS MED, V10, P295; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; PETTERSSON F, 1991, INT J GYNECOL OBSTET, V36, P238; ROTTEM S, 1990, J CLIN ULTRASOUND, V18, P359, DOI 10.1002/jcu.1870180422; SASSONE AM, 1991, OBSTET GYNECOL, V78, P70; Serov S., 1973, INT HISTOLOGICAL CLA, V9; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4; WEINER Z, 1992, OBSTET GYNECOL, V79, P159; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501	26	172	176	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1993	306	6884					1025	1029		10.1136/bmj.306.6884.1025	http://dx.doi.org/10.1136/bmj.306.6884.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8490496	Bronze, Green Published			2022-12-01	WOS:A1993KY44800017
J	Davis, CE				Davis, CE			Fresh vs preserved stool specimens for detection of parasites	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Davis, CE (corresponding author), UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103, USA.							BRONSDON MA, 1984, J CLIN MICROBIOL, V19, P952, DOI 10.1128/JCM.19.6.952-953.1984; DAVIS CE, 1994, HARRISONS PRINCIPLES, P872; Garcia Lynne S., 1995, P1145; SMITH JW, 1979, AM J CLIN PATHOL, V72, P371; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	327						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544277				2022-12-01	WOS:A1996TP96500034
J	Nightingale, SL				Nightingale, SL			First protease inhibitor approved for treatment of HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-01	WOS:A1996TP96500005
J	Naktinis, V; Turner, J; ODonnell, M				Naktinis, V; Turner, J; ODonnell, M			Molecular switch in a replication machine defined by an internal competition for protein rings	CELL			English	Article							POLYMERASE-III HOLOENZYME; CELL NUCLEAR ANTIGEN; PRIMER-TEMPLATE JUNCTION; ACCESSORY PROTEINS; ESCHERICHIA-COLI; FACTOR-C; DNA; COMPLEX; BACTERIOPHAGE-T4; SUBUNIT	Replication machines use ring-shaped clamps that encircle DNA to tether the polymerase to the chromosome. The clamp is assembled on DNA by a clamp loader. This report shows that the polymerase and clamp loader coordinate their actions with the clamp by competing for it through overlapping binding sites. The competition is modulated by DNA. In the absence of DNA, the clamp associates with the clamp loader. But after the clamp is placed on DNA, the polymerase develops a tight grip on the clamp and out-competes the clamp loader. After replication of the template, the polymerase looses affinity for the clamp. Now the clamp loader regains access to the clamp and removes it from DNA thus recycling it for future use.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute	Naktinis, V (corresponding author), CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021, USA.							BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; JUE RA, 1985, BIOCHEMISTRY-US, V24, P162, DOI 10.1021/bi00322a023; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SH, 1991, J BIOL CHEM, V266, P594; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MUNN MM, 1991, J BIOL CHEM, V266, P20034; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TURNER J, 1994, METHOD ENZYMOL, V262, P442; XIAO H, 1993, J BIOL CHEM, V268, P11773; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZHONG M, 1995, P NATL ACAD SCI USA, V92, P2111, DOI 10.1073/pnas.92.6.2111	41	128	131	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					137	145		10.1016/S0092-8674(00)81000-4	http://dx.doi.org/10.1016/S0092-8674(00)81000-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548818	Bronze			2022-12-01	WOS:A1996TQ17000016
J	Bennett, DA; Beckett, LA; Murray, AM; Shannon, KM; Goetz, CG; Pilgrim, DM; Evans, DA				Bennett, DA; Beckett, LA; Murray, AM; Shannon, KM; Goetz, CG; Pilgrim, DM; Evans, DA			Prevalence of Parkinsonian signs and associated mortality in a community population of older people	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARADIGM-BASED DIAGNOSIS; ALZHEIMERS-DISEASE; HETEROGENEOUS POPULATION; COGNITIVE FUNCTION; GAIT DISORDERS; DEATH; INDIVIDUALS; DEMENTIA; SYSTEM; RATES	Background. Older people frequently have signs of parkinsonism, but information about the prevalence of parkinsonism and mortality among those with the condition in the community is limited. Methods. A stratified random sample of 467 residents of East Boston, Massachusetts, 65 years of age or older, were given structured neurologic examinations. Using uniform, specified combinations of parkinsonian signs, we estimated the prevalence of four categories of signs - bradykinesia, gait disturbance, rigidity, and tremor - and of parkinsonism, defined as the presence of two or more categories. We did not study Parkinson's disease because it could not be distinguished from other conditions that carl cause parkinsonism. Proportional-hazards models were used to compare the risk of death among people with and those without parkinsonism. Results. One hundred fifty-nine persons had parkinsonism, 301 did not, and 7 could not be classified. The overall prevalence estimates were 14.9 percent for people 65 to 74 years of age, 29.5 percent for those 75 to 84, and 52.4 percent for those 85 and older. With a mean follow-up period of 9.2 years, 124 persons with parkinsonism (78 percent) and 146 persons without it (49 percent) died. Adjusted for age and sex, the overall risk of death among people with parkinsonism was 2.0 (95 percent confidence interval, 1.6 to 2.6) times that among people without it. Among people with parkinsonism, the presence of gait disturbance was associated with an increased risk of death. Conclusions. Parkinsonism is very common among people over the age of 65, and its prevalence increases markedly with age, Parkinsonism is associated with a twofold increase in the risk of death, which is strongly related to the presence of a gait disturbance.	RUSH UNIV,DEPT NEUROL SCI,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA	Rush University; Rush University	Bennett, DA (corresponding author), RUSH UNIV,RUSH INST AGING,1645 W JACKSON BLVD,SUITE 675,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [N01AG002107, U01AG006789, N01AG012106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-1-2106, AG06789, N01-AG-0-2107] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; BARBEAU A, 1973, J AM GERIATR SOC, V21, P145, DOI 10.1111/j.1532-5415.1973.tb00865.x; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; BENSHLOMO Y, 1995, J NEUROL NEUROSUR PS, V58, P293, DOI 10.1136/jnnp.58.3.293; BONIFATI V, 1993, ACTA NEUROL SCAND, V87, P9; CALNE DB, 1991, ANN NEUROL, V30, P206, DOI 10.1002/ana.410300213; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; CORNONIHUNTLEY J, 1986, DHHS NIH862443 PUBL; COX DR, 1972, J R STAT SOC B, V34, P187; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; EBMEIER KP, 1990, SCOT MED J, V35, P173, DOI 10.1177/003693309003500605; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1991, AM J EPIDEMIOL, V134, P403, DOI 10.1093/oxfordjournals.aje.a116102; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; GIBB WRG, 1988, POSTGRAD MED J, V64, P345, DOI 10.1136/pgmj.64.751.345; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JOHNSON RA, 1982, APPLIED MULTIVARIATE; JONES MK, 1990, ANTHONYS 1991 INPATI; Katzman R., 1992, PRINCIPLES GERIATRIC, P18; KAYE JA, 1994, ARCH NEUROL-CHICAGO, V51, P1205, DOI 10.1001/archneur.1994.00540240049015; KOKMEN E, 1977, J GERONTOL, V32, P411, DOI 10.1093/geronj/32.4.411; KOLLER WC, 1992, NEUROLOGY, V42, P6; KURTZKE JF, 1990, NEUROLOGY, V40, P42, DOI 10.1212/WNL.40.1.42; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARTINEZMARTIN P, 1988, PARKINSONS DIS MOVEM, P235; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORGANTE L, 1992, NEUROLOGY, V42, P1901; NEWMAN RP, 1985, NEUROLOGY, V35, P571, DOI 10.1212/WNL.35.4.571; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; ODENHEIMER G, 1994, ARCH NEUROL-CHICAGO, V51, P573, DOI 10.1001/archneur.1994.00540180051013; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POTVIN AR, 1980, J AM GERIATR SOC, V28, P1; QUINN NP, 1986, BRIT MED J, V293, P379, DOI 10.1136/bmj.293.6543.379; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; RAJPUT AH, 1991, NEUROLOGY, V41, P1298, DOI 10.1212/WNL.41.8.1298; RAJPUT AH, 1992, CAN J NEUROL SCI, V19, P103, DOI 10.1017/S0317167100041457; RICHARDS M, 1993, ANN NEUROL, V33, P267, DOI 10.1002/ana.410330307; SAWLE GV, 1994, ARCH NEUROL-CHICAGO, V51, P237, DOI 10.1001/archneur.1994.00540150027011; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; Skinner C, 1989, ANAL COMPLEX SURVEYS; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; WEBSTER DD, 1968, MOD TREAT, V5, P257	44	497	504	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	1996	334	2					71	76		10.1056/NEJM199601113340202	http://dx.doi.org/10.1056/NEJM199601113340202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP363	8531961				2022-12-01	WOS:A1996TP36300002
J	Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM				Copeland, JWR; Nasiadka, A; Dietrich, BH; Krause, HM			Patterning of the Drosophila embryo by a homeodomain-deleted Ftz polypeptide	NATURE			English	Article							FUSHI-TARAZU; DNA-BINDING; GENE; EXPRESSION; PROTEIN; SEGMENTATION; DOMAIN; ESTABLISHMENT; MAINTENANCE; ACTIVATION	HOMEODOMAIN proteins regulate diverse developmental processes in a wide range of organisms, yet bind in vitro to DNA sequences that are remarkably similar(1). This has raised the fundamental question of how target gene specificity is achieved in vivo. The Drosophila fushi tarazu protein (Ftz) contains a homeodomain(2) and is required for the formation of alternate segments(3). We have shown previously that a homeodomain-deleted Ftz polypeptide (Ftz Delta HD), incapable of binding DNA in vitro, could regulate endogenous ftz gene expression(4). Here we test Ftz Delta HD activities in a ftz mutant background and find that, surprisingly, Ftz Delta HD can directly regulate ftz-dependent segmentation, suggesting that it can control target gene expression through interactions with other proteins. A likely candidate is the pair-rule protein Paired (Prd). Ftz Delta HD bound directly to Prd in vitro and required Prd to repress wingless in vivo. These results emphasize the pivotal importance of protein-protein interactions in homeodomain protein function.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; DEPT MED & MOLEC GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto				Krause, Henry/0000-0002-6182-7074				ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; BAUMGARTNER S, 1991, MECH DEVELOP, V33, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X	22	79	79	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					162	165		10.1038/379162a0	http://dx.doi.org/10.1038/379162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538765				2022-12-01	WOS:A1996TP36000057
J	CROSS, DAE; ALESSI, DR; COHEN, P; ANDJELKOVICH, M; HEMMINGS, BA				CROSS, DAE; ALESSI, DR; COHEN, P; ANDJELKOVICH, M; HEMMINGS, BA			INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULAR-CLONING; PHOSPHORYLATION; IDENTIFICATION; SUBFAMILY	GLYCOGEN synthase kinase-3 (GSK3)(1) is implicated in the regulation of several physiological processes, including the control of glycogen(2) and protein(3) synthesis by insulin, modulation of the transcription factors AP-1 and CREB(4-6), the specification of cell fate in Drosophila(7) and dorsoventral patterning in Xenopus embryos(8). GSK3 is inhibited by serine phosphorylation in response to insulin or growth factors and in vitro by either MAP kinase-activated protein (MAPKAP) kinase-1 (also known as p90(rsk)) or p70 ribosomal S6 kinase (p70(S6k))(12,13). Here we show, however, that agents which prevent the activation of both MAPKAP kinase-1 and p70(S6k) by insulin in vivo do not block the phosphorylation and inhibition of GSK3. Another insulin-stimulated protein kinase inactivates GSK3 under these conditions, and Ne demonstrate that it is the product of the proto-oncogene protein kinase B (PKB, also known as Akt/RAC). Like the inhibition of GSK3 (refs 10, 14), the activation of PKB is prevented by inhibitors of phosphatidylinositol (PT) 3-kinase.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research	CROSS, DAE (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT LAB,DUNDEE DD1 4HN,SCOTLAND.			Alessi, Dario/0000-0002-2140-9185				AHMED NN, 1995, MOL CELL BIOL, V15, P2304; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DALTO Y, 1994, BIOCHEM J, V303, P27; DEGROOT RP, 1993, ONCOGENE, V8, P841; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOODE N, 1992, J BIOL CHEM, V267, P16878; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015	29	4194	4326	2	216	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1995	378	6559					785	789		10.1038/378785a0	http://dx.doi.org/10.1038/378785a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL419	8524413				2022-12-01	WOS:A1995TL41900028
J	NISHITANI, H; NURSE, P				NISHITANI, H; NURSE, P			P65(CDC18) PLAYS A MAJOR ROLE CONTROLLING THE INITIATION OF DNA-REPLICATION IN FISSION YEAST	CELL			English	Article							CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; S-PHASE; MITOSIS; GENE; P34CDC2; RECOGNITION; ORIGINS; COMPLEX	A key problem in the cell cycle is understanding what brings about the initiation of DNA replication and how this is linked with global cell cycle controls. The fission yeast gene cdc18 is required for DNA replication and is transcriptionally activated by the cdc10/res1/res2 control acting at START in late G1. We show here that overexpressing cdc18 is able to bring about repeated rounds of DNA synthesis in the absence of mitosis and of continuing protein synthesis. The level of the cdc18-encoded protein p65(cdc18) is periodic in the cell cycle, peaking at the G1 to S phase transition, and p65(cdc18) is located in the nucleus when cdc18 is overexpressed. We propose that p65(cdc18) acts af the initiation of DNA replication and plays a major role in controlling the onset of S phase.			NISHITANI, H (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Nishitani, Hideo/0000-0001-5907-9380				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; SAZER S, 1990, J CELL SCI, V97, P509; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	37	236	241	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					397	405		10.1016/0092-8674(95)90117-5	http://dx.doi.org/10.1016/0092-8674(95)90117-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521469	Bronze			2022-12-01	WOS:A1995TC97700009
J	ROSEMOND, RL				ROSEMOND, RL			CARDIOVERSION DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ROSEMOND, RL (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37240, USA.							DESILVA RA, 1980, AM HEART J, V100, P881, DOI 10.1016/0002-8703(80)90071-X; SANCHEZDIAZ CJ, 1957, ARCH I CARDIOL MEX, V57, P387; UELAND K, 1981, Clinical Obstetrics and Gynecology, V24, P809, DOI 10.1097/00003081-198109000-00008	3	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3167	3167						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505820				2022-12-01	WOS:A1993LH14500037
J	JONES, PH; WATT, FM				JONES, PH; WATT, FM			SEPARATION OF HUMAN EPIDERMAL STEM-CELLS FROM TRANSIT AMPLIFYING CELLS ON THE BASIS OF DIFFERENCES IN INTEGRIN FUNCTION AND EXPRESSION	CELL			English	Article							TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; MONOCLONAL-ANTIBODIES; INVOLUCRIN SYNTHESIS; STRATUM CORNEUM; BURN WOUNDS; FIBRONECTIN; ADHESION; CULTURE; INVITRO	The epidermis is believed to contain two types of proliferating cells: stem cells and cells with a lower capacity for self-renewal and higher probability of undergoing terminal differentiation (transit amplifying cells). We report that keratinocytes with characteristics of stem cells can be isolated from cultured human epidermis on the basis of high surface expression of beta1 integrins and rapid adhesion to extracellular matrix (ECM) proteins. Among keratinocytes there was a log linear relationship between the relative level of beta1 integrins on the cell surface and proliferative capacity; furthermore, the cells with the highest colony-forming efficiency adhered most rapidly to type IV collagen, fibronectin, or keratinocyte ECM. Proliferating keratinocytes that adhered more slowly had characteristics of transit amplifying cells: after one to five rounds of division, all of their daughters underwent terminal differentiation. Since stem cells can be isolated to greater than 90% purity on the basis of their adhesive properties, it will now be possible to investigate the mechanisms that regulate the fate of their progeny.			JONES, PH (corresponding author), IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Watt, Fiona/AHB-0226-2022; Jones, Philip/D-2464-2009	Watt, Fiona/0000-0001-9151-5154; Jones, Philip/0000-0002-5904-795X				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ANDREWS RG, 1990, J EXP MED, V172, P355, DOI 10.1084/jem.172.1.355; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; CHRISTOPHERS E, 1971, J INVEST DERMATOL, V56, P165, DOI 10.1111/1523-1747.ep12260765; COMPTON CC, 1989, LAB INVEST, V60, P600; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; CURRY JL, 1967, DEV BIOL, V15, P395, DOI 10.1016/0012-1606(67)90034-6; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GREEN H, 1988, NEWS PHYSIOL SCI, V3, P53; HALL PA, 1989, DEVELOPMENT, V106, P619; HARLOW E, 1988, ANTIBODIES LABORATOR; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; HUME WJ, 1976, J CELL SCI, V22, P149; IVERSEN O H, 1968, Cell and Tissue Kinetics, V1, P351, DOI 10.1111/j.1365-2184.1968.tb00964.x; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KAY HEM, 1965, LANCET, V2, P418; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; Lane E B, 1990, Semin Cancer Biol, V1, P165; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; LENOIR MC, 1988, DEV BIOL, V130, P610, DOI 10.1016/0012-1606(88)90356-9; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORHENN VB, 1983, J INVEST DERMATOL, V81, pS127, DOI 10.1111/1523-1747.ep12540890; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PLOEMACHER RE, 1989, EXP HEMATOL, V17, P263; Potten C S, 1981, Int Rev Cytol, V69, P271; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1973, INT J RADIAT BIOL, V24, P537, DOI 10.1080/09553007314551441; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1991, CURR OPIN IMMUNOL, V3, P171, DOI 10.1016/0952-7915(91)90046-4; TENCHINI ML, 1993, IN PRESS CELL ADHESI; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1992, BIOCHEM SOC T, V20, P285, DOI 10.1042/bst0200285; WATT FM, 1993, IN PRESS KERATINOCYT; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WITHERS HR, 1967, RADIAT RES, V32, P227, DOI 10.2307/3572220	59	941	1026	1	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					713	724		10.1016/0092-8674(93)90251-K	http://dx.doi.org/10.1016/0092-8674(93)90251-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500165				2022-12-01	WOS:A1993LD83000010
J	SERAPHIN, B; KANDELSLEWIS, S				SERAPHIN, B; KANDELSLEWIS, S			3' SPLICE SITE RECOGNITION IN SACCHAROMYCES-CEREVISIAE DOES NOT REQUIRE BASE-PAIRING WITH U1 SNRNA	CELL			English	Article							PRE-MESSENGER-RNA; 5' CLEAVAGE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SACCHAROMYCES-CEREVISIAE; MAMMALIAN INTRONS; YEAST; SELECTION; SEQUENCES; INVITRO; PRECURSORS	The conserved nucleotides 9 and 10 of U1 small nuclear RNA (snRNA) have been proposed to base pair with either 5' exon or 3' splice site sequences. In S. pombe, U1 snRNA pairing with the conserved 3' splice site is required for the first step of splicing and viability. In contrast, we show that S. cerevisiae Ul mutants at positions 9 and 10 are fully functional. Splicing of several genes is normal in these strains, ruling out an essential base pairing between U1 snRNA and 3' splice sites. U1 snRNA positions 9 and 10 are shown to be involved in 5' splice site selection through their interaction with exon sequences. Our results demonstrate that some snRNA-pre-mRNA interactions are not evolutionarily conserved and that 3' splice site recognition occurs by different mechanisms in various organisms.			SERAPHIN, B (corresponding author), EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY.			Seraphin, Bertrand/0000-0002-5168-1921				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; IGEL AH, 1988, NATURE, V334, P450, DOI 10.1038/334450a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEBER S, 1988, NUCLEIC ACIDS RES, V16, P471, DOI 10.1093/nar/16.2.471; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521; ZHUANG Y, 1990, GENE, V90, P263, DOI 10.1016/0378-1119(90)90189-X; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	63	46	46	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					803	812		10.1016/0092-8674(93)90258-R	http://dx.doi.org/10.1016/0092-8674(93)90258-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500172				2022-12-01	WOS:A1993LD83000017
J	SMITH, T				SMITH, T			INFLUENCE OF SOCIOECONOMIC-FACTORS ON ATTAINING TARGETS FOR REDUCING TEENAGE PREGNANCIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the rate of pregnancy and outcome in teenagers in areas of different socioeconomic conditions, and to assess the implication for achievement of government and local targets in reducing unwanted pregnancies in teenagers. Design-Records of pregnancies were obtained from hospital discharge files and rates of live and still births and abortions calculated for each postcode sector. Postcodes were grouped by categories of deprivation and by local government district. Setting-Tayside, Scotland. Subjects-Teenage girls admitted to National Health Service hospitals for delivery or abortion in 1980-90. Main outcome measures-Conception in girls aged under 16 by area of residence and relative proportion leading to live births or terminations. Rate of different outcomes in girls under the age of 20 by area of residence. Results-The pregnancy rate in girls aged under 16 was three times as high, and in all girls under 20 six times as high in the most deprived areas as in the most affluent areas. The proportion of teenage pregnancies ending in abortions was higher in the affluent areas, where two out of three ended in abortion compared with one out of four in the deprived areas. Conclusions-Although there was a higher pregnancy rate in teenagers in more deprived areas, the proportion ending in abortion was greater in more affluent areas, possibly due to social and parental pressure. The wide geographical variation in patterns of teenage pregnancy indicates the need for a small area rather than a regional approach to setting targets and devising measures of achieving them.			SMITH, T (corresponding author), TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND.							Carstairs V., 1991, DEPRIVATION HLTH SCO; SMITH T, 1992, J PUBLIC HEALTH MED, V14, P402, DOI 10.1093/oxfordjournals.pubmed.a042781; WILSON SH, 1992, J PUBLIC HEALTH MED, V14, P17; 1992, SCOTLANDS HLTH CHALL; 1992, HLTH NATION STRATEGY; 1991, 136 GEN REG OFF SCOT; 1992, BRIT STATISTICS 1990, P19; 1991, SCOTTISH HLTH STATIS	8	73	74	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1232	1235		10.1136/bmj.306.6887.1232	http://dx.doi.org/10.1136/bmj.306.6887.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LB804	8499852	Bronze, Green Published			2022-12-01	WOS:A1993LB80400014
J	CHEN, ZM; KEECH, A; COLLINS, R; SLAVIN, B; CHEN, JS; CAMPBELL, TC; PETO, R				CHEN, ZM; KEECH, A; COLLINS, R; SLAVIN, B; CHEN, JS; CAMPBELL, TC; PETO, R			PROLONGED INFECTION WITH HEPATITIS-B VIRUS AND ASSOCIATION BETWEEN LOW BLOOD CHOLESTEROL CONCENTRATION AND LIVER-CANCER	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; VERTICAL TRANSMISSION; SURFACE-ANTIGEN; HEART-DISEASE; MORTALITY; RISK; MEN; POPULATION; TAIWAN; DEATH	Objective-To determine whether prolonged infection with hepatitis B virus is associated with a lower blood cholesterol concentration. Design-Cross sectional study. Setting-81 villages in rural China with a high prevalence of chronic infection with hepatitis B virus. Subjects-1556 apparently healthy men aged 35-64 years, randomly selected. Main outcome measures-Hepatitis B virus carrier state; plasma concentrations of cholesterol, apolipoprotein B, and apolipoprotein A I. Results-238 (15%) of the men were positive for hepatitis B surface antigen, indicating that they were chronic carriers. Plasma concentration of cholesterol was 4.2% (0.11 mmol/l) lower among carriers (that is, positive for hepatitis B surface antigen) than among non-carriers (95% confidence inverval 0.6% to 8.0% (0.01 to 0.21 mmol/l), p < 0.05), and apolipoprotein B concentration was 7.0% (0.036 g/l) lower (2.8% to 11.2% (0.014 to 0.058 g/l), p<0.001). In contrast, no association was observed between plasma concentrations of cholesterol or apolipoprotein and hepatitis B that had been eradicated (that is, patient positive for hepatitis B core antibody but negative for hepatitis B surface antigen). Conclusions-Chronic hepatitis B virus infection, which usually starts in early childhood in China, seems to lead not only to a greatly increased risk of death from liver disease but also to a somewhat lower cholesterol concentration in adulthood. This common cause produces an inverse association between cholesterol concentration and risk of death from liver cancer or from other chronic liver diseases.	UNIV OXFORD, RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,MRC, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT ENDOCRINOL & CHEM PATHOL, LONDON, ENGLAND; CHINESE ACAD PREVENT MED, INST NUTR & FOOD HYG, BEIJING, PEOPLES R CHINA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Radcliffe Infirmary; University of Oxford; University of London; King's College London; Chinese Center for Disease Control & Prevention; National Institute for Nutrition & Health, Chinese Center for Disease Control & Prevention; Cornell University	CHEN, ZM (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, IMPERIAL CANC RES FUND, OXFORD OX2 6HE, ENGLAND.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				[Anonymous], 1982, JAMA-J AM MED ASSOC, V248, P2853; BEAGLEHOLE R, 1980, BMJ-BRIT MED J, V280, P285, DOI 10.1136/bmj.280.6210.285; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1981, LANCET, V2, P1129; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cox DR, 1974, THEORETICAL STATISTI; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FEELY J, 1992, BRIT MED J, V304, P545, DOI 10.1136/bmj.304.6826.545; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JIANG YT, 1982, VIRAL HEPATITIS, P121; JUNYAO L, 1981, INT J EPIDEMIOL, V10, P127, DOI 10.1093/ije/10.2.127; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; LUMB PJ, IN PRESS J CLIN PATH; MA XK, 1984, CHINA PEOPLES LIBERA, V9, P1; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MEADE TW, 1987, THROMB RES, V45, P709, DOI 10.1016/0049-3848(87)90336-7; MOUNT JN, 1988, J CLIN PATHOL, V41, P471, DOI 10.1136/jcp.41.4.471; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; ROSE G, 1974, LANCET, V1, P181, DOI 10.1016/S0140-6736(74)92492-1; ROSE G, 1980, LANCET, V1, P523; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; UEYAMA Y, 1990, LANCET, V336, P707, DOI 10.1016/0140-6736(90)92204-U; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; [No title captured]	35	43	46	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	1993	306	6882					890	894		10.1136/bmj.306.6882.890	http://dx.doi.org/10.1136/bmj.306.6882.890			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW387	8490412	Green Published, Bronze			2022-12-01	WOS:A1993KW38700018
J	KELLETT, J				KELLETT, J			FOR DEBATE - LONG-TERM CARE ON THE NHS - A VANISHING PROSPECT	BRITISH MEDICAL JOURNAL			English	Article											KELLETT, J (corresponding author), ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.							JOLLY DJ, 1992, PSYCHIATRIC B, V16, P567; 1992, HOSPITAL HLTH SERVIC; 1992, DIRECTORY INDEPENDEN	3	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					846	848		10.1136/bmj.306.6881.846	http://dx.doi.org/10.1136/bmj.306.6881.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8490381	Green Published, Bronze			2022-12-01	WOS:A1993KV34800028
J	Evens, RG				Evens, RG			Appropriateness of routine chest radiography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Evens, RG (corresponding author), WASHINGTON UNIV,DEPT RADIOL,ST LOUIS,MO 63130, USA.							FENGOLD AO, 1975, PUBLIC HLTH REP, V90, P544; RUCKER L, 1983, JAMA-J AM MED ASSOC, V250, P3209, DOI 10.1001/jama.250.23.3209; SAGEL SS, 1974, NEW ENGL J MED, V291, P1001, DOI 10.1056/NEJM197411072911904; 1993, ACR STANDARD ADULT C; 1983, HHS FDA838204 US DEP	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					326	326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544276				2022-12-01	WOS:A1996TP96500033
J	Bickmore, WA; Oghene, K				Bickmore, WA; Oghene, K			Visualizing the spatial relationships between defined DNA sequences and the axial region of extracted metaphase chromosomes	CELL			English	Article							SCAFFOLD ATTACHMENT; NUCLEAR SCAFFOLD; REPLICATION; KINETOCHORE; LOOP; ORGANIZATION; GENOME; GENES; SITES; SIZE	Using fluorescence in situ hybridization to extracted metaphase chromosomes, we present visual evidence that specific human DNA sequences occupy distinctive positions with respect to the axial region of chromosomes and that the DNA is organized into loops emanating from this region. In a stretch of unique DNA on chromosome 11, large loops of DNA can be traced and one specific region associated with the axial region of the chromosome. Within rDNA, nontranscribed spacer sequences are more closely apposed to the chromosome axis than are rRNA genes. Heterochromatic and euchromatic DNAs appear to be organized into loops of similar size. We could not detect loops at centromeres; most alphoid DNA appears to remain close to the axial region.			Bickmore, WA (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Bickmore, Wendy A/C-7314-2013	Bickmore, Wendy A/0000-0001-6660-7735				AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BLUMENTHAL AB, 1979, J CELL BIOL, V81, P255, DOI 10.1083/jcb.81.1.255; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; CALLAN HG, 1982, PROC R SOC SER B-BIO, V214, P417, DOI 10.1098/rspb.1982.0020; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1993, J CELL BIOL, V120, P1083, DOI 10.1083/jcb.120.5.1083; COOKE H, 1976, NATURE, V262, P182, DOI 10.1038/262182a0; CREMISI F, 1988, CHROMOSOMA, V97, P204, DOI 10.1007/BF00292962; DIJKWEL PA, 1988, BIOESSAYS, V9, P147; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; GASSER SM, 1989, INT REV CYTOL, V119, P57; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JEPPESEN P, 1985, J CELL SCI, V73, P245; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOENS PB, 1990, CHROMOSOMA, V100, P8, DOI 10.1007/BF00337598; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RAZIN SV, 1993, COLD SPRING HARB SYM, V58, P25, DOI 10.1101/SQB.1993.058.01.006; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SATYAPRAKASH KL, 1980, CHROMOSOMA, V81, P1, DOI 10.1007/BF00292418; TRASK BJ, 1991, AM J HUM GENET, V48, P1; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YOON Y, 1995, MOL CELL BIOL, V15, P2482	37	63	65	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	1996	84	1					95	104		10.1016/S0092-8674(00)80996-4	http://dx.doi.org/10.1016/S0092-8674(00)80996-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548831	Bronze			2022-12-01	WOS:A1996TQ17000012
J	Trachtenberg, JT; Thompson, WJ				Trachtenberg, JT; Thompson, WJ			Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor	NATURE			English	Article							NERVOUS-SYSTEM; MOTOR UNITS; MUSCLE; IDENTIFICATION; BIRTH; DEATH	DENERVATED adult mammalian muscle fibres are reinnervated by regenerating axons and, in the case of partially denervated muscles, by sprouts extended from remaining, intact axons(1,3). Recent experiments suggest that Schwann cells (SCs) regulate these events, inducing and guiding axonal outgrowth through the processes they extend(4,5). In contrast to adults, reinnervation of denervated neonatal muscles is deficient and axonal sprouting is absent(6-9). In light of the proposed roles for SCs in these processes, we examined whether SCs in neonatal muscles exhibit altered responses to denervation. We report here that neonatal denervation leads to the rapid, apoptotic death of SCs at rat neuromuscular junctions. Injection of glial growth factor, a member of the neuregulin family of trophic factors present in developing sensory and motor neurons(10), prevents this apoptosis in vivo. These results provide further evidence for the importance of SCs in regulating nerve grow,vth and suggest that axon-Schwann cell trophic interactions play a role in the normal development of the neuromuscular system.			Trachtenberg, JT (corresponding author), UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712, USA.							ASTROW SH, 1994, J NEUROBIOL, V25, P937, DOI 10.1002/neu.480250804; BETZ WJ, 1980, J PHYSIOL-LONDON, V303, P265, DOI 10.1113/jphysiol.1980.sp013284; BROWN MC, 1981, A REV NEUROSCI, V4, P57; DENNIS MJ, 1980, DEV BIOL, V74, P173, DOI 10.1016/0012-1606(80)90059-7; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCARDLE JJ, 1977, J PHYSIOL-LONDON, V271, P567, DOI 10.1113/jphysiol.1977.sp012015; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SON YJ, 1995, NEURON, V14, P125, DOI 10.1016/0896-6273(95)90246-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; THOMPSON W, 1977, NEUROSCIENCE, V2, P523, DOI 10.1016/0306-4522(77)90049-5; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7	18	250	254	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 11	1996	379	6561					174	177		10.1038/379174a0	http://dx.doi.org/10.1038/379174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP360	8538769				2022-12-01	WOS:A1996TP36000061
J	Zabin, LS; Emerson, MR; Ringers, PA; Sedivy, V				Zabin, LS; Emerson, MR; Ringers, PA; Sedivy, V			Adolescents with negative pregnancy test results - An accessible at-risk group	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABORTION; CHILDBEARING	Objective.-To estimate nationally what percentage of young women receive negative pregnancy test results before becoming pregnant, to explore their fertility and test histories, and to estimate the potential for intervention at the time of a negative test result. Design.-A cross-sectional study in which young women presenting to clinics for pregnancy tests were asked to complete a self-administered questionnaire before test results were known that explored prior pregnancy tests, pregnancies, sexual and contraceptive histories, and childbearing attitudes. Setting.-Fifty-two clinics including hospital, health department, Planned Parenthood, and independent facilities. Participants.-A total of 2926 patients aged 17 years or younger requesting pregnancy tests at presentation. Results.-Among young women who had ever conceived, 34.2% had a prior negative pregnancy test result and 24.4% had a prior negative test result at a clinic. Almost three of five of the adolescent girls, including both those who had and those who had not-conceived, received a negative test result at a clinic before they ever became pregnant. By the age of 14 years, the probability of a negative test result was substantially greater than the chance of a positive test. Many presented for tests even though they were quite certain that they were not pregnant. Conclusions.-Adolescent girls with a negative pregnancy test result may be an appropriate target group for intervention. One fourth of adolescent girls who have a negative pregnancy test may be identified by the health care system on that occasion in time to prevent early childbearing.			Zabin, LS (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT POPULAT DYNAM,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							BERGER DK, 1991, ADOLESCENCE, V26, P951; Chiang C., 1968, INTRO STOCHASTIC PRO; EVANS JR, 1976, FAM PLANN PERSPECT, V8, P192, DOI 10.2307/2134210; Hardy J. B., 1991, ADOLESCENT PREGNANCY; HATCHER RA, 1992, CONTRACEPTIVE TECHNO; HAYES CD, 1987, RISKING FUTURE ADOLE, P1; MARCY SA, 1983, RES NURS HEALTH, V6, P175, DOI 10.1002/nur.4770060405; MOSHER WD, 1988, FAM PLANN PERSPECT, V20, P33, DOI 10.2307/2135595; MOSHER WD, 1990, 184 NAT CTR HLTH STA; Schorr LB, 1988, OUR REACH BREAKING C; Zabin L S, 1993, J Res Adolesc, V3, P67, DOI 10.1207/s15327795jra0301_4; ZABIN LS, 1989, FAM PLANN PERSPECT, V21, P248, DOI 10.2307/2135377; ZABIN LS, 1990, J ADOLESCENT HEALTH, V11, P107, DOI 10.1016/0197-0070(90)90018-W; ZABIN LS, 1981, FAM PLANN PERSPECT, V13, P205, DOI 10.2307/2134551; ZABIN LS, 1994, FAM PLANN PERSPECT, V26, P212, DOI 10.2307/2135941; ZABIN LS, 1987, EVALUATION PREGNANCY	16	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 10	1996	275	2					113	117		10.1001/jama.275.2.113	http://dx.doi.org/10.1001/jama.275.2.113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TN280	8531305				2022-12-01	WOS:A1996TN28000026
J	YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K				YAMAGUCHI, K; SHIRAKABE, T; SHIBUYA, H; IRIE, K; OISHI, I; UENO, N; TANIGUCHI, T; NISHIDA, E; MATSUMOTO, K			IDENTIFICATION OF A MEMBER OF THE MAPKKK FAMILY AS A POTENTIAL MEDIATOR OF TGF-BETA SIGNAL-TRANSDUCTION	SCIENCE			English	Article							GROWTH-FACTOR-BETA; KINASE; GENE; EXPRESSION; CELLS; RAF	The mitogen-activated protein kinase (MAPK) pathway is a conserved beta eukaryotic signaling module that converts receptor signals into various outputs. MAPK is activated through phosphorylation by MAPK kinase (MAPKK), which is first activated by MAPKK kinase (MAPKKK). A genetic selection based on a MAPK pathway in yeast was used to identify a mouse protein kinase (TAK1) distinct from other members of the MAPKKK family. TAK1 was shown to participate in regulation of transcription by transforming growth factor-beta (TGF-beta). Furthermore, kinase activity of TAK1 was stimulated in response to TGF-beta and bone morphogenetic protein. These results suggest that TAK1 functions as a mediator in the signaling pathway of TGF-beta superfamily members.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Hokkaido University; Nagoya University; Kyoto University; Osaka University			Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349; Ueno, Naoto/0000-0002-8375-2317				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRAI R, COMMUNICATION; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; IRIE K, UNPUB; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SHIBUYA H, UNPUB; Shibuya K., UNPUB; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	28	1156	1199	2	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					2008	2011		10.1126/science.270.5244.2008	http://dx.doi.org/10.1126/science.270.5244.2008			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533096				2022-12-01	WOS:A1995TL42000047
J	BARTSCH, D; GHIRARDI, M; SKEHEL, PA; KARL, KA; HERDER, SP; CHEN, M; BAILEY, CH; KANDEL, ER				BARTSCH, D; GHIRARDI, M; SKEHEL, PA; KARL, KA; HERDER, SP; CHEN, M; BAILEY, CH; KANDEL, ER			APLYSIA CREB2 REPRESSES LONG-TERM FACILITATION - RELIEF OF REPRESSION CONVERTS TRANSIENT FACILITATION INTO LONG-TERM FUNCTIONAL AND STRUCTURAL-CHANGE	CELL			English	Article							DNA-BINDING PROTEINS; GILL-WITHDRAWAL REFLEX; GLUTATHIONE-S-TRANSFERASE; LEUCINE ZIPPER PROTEINS; CAMP RESPONSE ELEMENT; SENSORY NEURONS; TRANSCRIPTION FACTOR; BEHAVIORAL SENSITIZATION; SYNAPTIC FACILITATION; FUSION PROTEINS	The switch from short- to long-term facilitation induced by behavioral sensitization in Aplysia involves CREB-like proteins, as well as the immediate-early gene ApC/EBP. Using the bZIP domain of ApC/EBP in a two-hybrid system, we have cloned ApCREB2, a transcription factor constitutively expressed in sensory neurons that resembles human CREB2 and mouse ATF4. ApCREB2 represses ApCREB-1-mediated transcription in F9 cells. Injection of anti-ApCREB2 antibodies into Aplysia sensory neurons causes a single pulse of serotonin (5-HT), which induces only short-term facilitation lasting minutes, to evoke facilitation lasting more than 1 day. This facilitation has the properties of long-term facilitation: it requires transcription and translation, induces the growth of new synaptic connections, and occludes further facilitation by five pulses of 5-HT.	COLUMBIA UNIV COLL PHYS & SURG,COLL PHYSICIANS & SURGEONS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	BARTSCH, D (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.		ghirardi, mirella/AEQ-0420-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1979, J NEUROCYTOL, V8, P415, DOI 10.1007/BF01214801; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BROWN E, 1995, J HIST BEHAV SCI, V11, P342; BROWN R, 1977, COGNITION, V5, P73, DOI 10.1016/0010-0277(77)90018-X; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW T J, 1971, International Journal of Neuroscience, V2, P79, DOI 10.3109/00207457109146995; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conway M. A., 1995, FLASHBULB MEMORIES; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEXNER JB, 1963, SCIENCE, V141, P57, DOI 10.1126/science.141.3575.57; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1988, ANTIBODIES; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; Luria A.R, 1968, MIND MNEMONIST LITTL; MA J, 1987, CELL, V57, P113; MCGAUGH JL, 1993, BEHAV BRAIN RES, V58, P81, DOI 10.1016/0166-4328(93)90092-5; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Neisser U., 1982, MEMORY OBSERVED REME, P43; NORBY PL, 1992, NUCLEIC ACIDS RES, V20, P6317, DOI 10.1093/nar/20.23.6317; PETERSEN RC, 1992, NEUROLOGY, V42, P396, DOI 10.1212/WNL.42.2.396; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PINSKER H, 1970, SCIENCE, V167, P1740, DOI 10.1126/science.167.3926.1740; PINSKER HM, 1973, SCIENCE, V182, P1039, DOI 10.1126/science.182.4116.1039; RAYPORT SG, 1986, J NEUROSCI, V6, P759; Sambrook J., 1989, MOL CLONING; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SKEHEL PA, 1994, GENE, V145, P231, DOI 10.1016/0378-1119(94)90011-6; Stratton GM, 1917, PSYCHOL REV, V24, P244, DOI 10.1037/h0070091; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	64	451	472	0	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					979	992		10.1016/0092-8674(95)90213-9	http://dx.doi.org/10.1016/0092-8674(95)90213-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521521	Bronze			2022-12-01	WOS:A1995TK74500016
J	CUCKLE, HS; RICHARDSON, GA; SHELDON, TA; QUIRKE, P				CUCKLE, HS; RICHARDSON, GA; SHELDON, TA; QUIRKE, P			COST-EFFECTIVENESS OF ANTENATAL SCREENING FOR CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; IDENTIFICATION; GENE; MUTATIONS; APPRAISAL	Objective-To estimate the cost effectiveness of different antenatal screening programmes for cystic fibrosis. Setting-Antenatal clinics and general practices in the United Kingdom. Design-Four components of the screening process were identified: information giving, DNA testing, genetic counselling, and prenatal diagnosis. The component costs were derived from the literature and from a pilot screening study in Yorkshire. The cost of a given screening programme was then obtained by summing the components according to the specific screening strategy adopted (sequential and couple), the proportion of carriers detected by the DNA test, and the uptake of screening. Baseline assumptions were made about the proportion with missing information on carrier status from previous pregnancies (20%), the proportion changing partners between pregnancies (20%), and the uptake of prenatal diagnosis (100%). Sensitivity analysis was performed by varying these assumptions. Main outcome measure-Cost per affected pregnancy detected. Results-Under the baseline assumptions sequential screening costs between pound 40000 and pound 90000 per affected pregnancy detected, depending on the carrier detection rate and uptake. Couple screening was more expensive, ranging from pound 46000 to pound 104000. From the sensitivity analysis a 10% change in the assumed proportion with missing information from a previous pregnancy alters the cost by pound 4000; a 10%, change in the proportion with new partners has a similar effect but only for couple screening; and cost will change directly in proportion to the uptake of prenatal diagnosis. Conclusions-While economic analysis cannot determine screening policy, the paper provides the NHS with the information on cost effectiveness needed to inform decisions on the introduction of a screening service for cystic fibrosis.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV LEEDS,CTR CANC RES,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of York - UK; University of York - UK; University of Leeds	CUCKLE, HS (corresponding author), UNIV LEEDS,RES SCH MED,CTR REPROD GROWTH & DEV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Quirke, Philip/AAI-1362-2019; Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913; Quirke, Philip/0000-0002-3597-5444				ASCH DA, 1993, AM J OBSTET GYNECOL, V168, P1; CHEADLE J, 1992, J MED GENET, V29, P642, DOI 10.1136/jmg.29.9.642; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; GARBER AM, 1991, MED CARE, V29, P473, DOI 10.1097/00005650-199105000-00007; GINSBERG G, 1994, HEALTH ECON, V3, P5, DOI 10.1002/hec.4730030104; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LIEU TA, 1994, OBSTET GYNECOL, V84, P903; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MIEDZYBRODZKA Z, 1995, J MED GENET, V32, P282, DOI 10.1136/jmg.32.4.282; MIEDZYBRODZKA ZH, 1994, J MED GENET, V31, P545, DOI 10.1136/jmg.31.7.545; MIEDZYBRODZKA ZH, 1995, BRIT MED J, V310, P353, DOI 10.1136/bmj.310.6976.353; MIEDZYBRODZKA ZH, 1993, J MED GENET, V30, P316, DOI 10.1136/jmg.30.4.316; MOONEY G, 1993, SOC SCI MED, V37, P873, DOI 10.1016/0277-9536(93)90140-Y; Piggott M, 1994, J Med Screen, V1, P45; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHACKLEY P, 1993, J PUBLIC HEALTH MED, V15, P175; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SUPER M, 1994, BRIT MED J, V308, P1462, DOI 10.1136/bmj.308.6942.1462; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; 1988, BRIT MED J, V297, P1599; 1995, NATIONAL POPULAT PP2, V19	27	46	47	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1460	1463		10.1136/bmj.311.7018.1460	http://dx.doi.org/10.1136/bmj.311.7018.1460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ044	8520332	Green Published			2022-12-01	WOS:A1995TJ04400020
J	REXACH, M; BLOBEL, G				REXACH, M; BLOBEL, G			PROTEIN IMPORT INTO NUCLEI - ASSOCIATION AND DISSOCIATION REACTIONS INVOLVING TRANSPORT SUBSTRATE, TRANSPORT FACTORS, AND NUCLEOPORINS	CELL			English	Article							PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; BINDING; TRANSLOCATION; LOCATION; RAN/TC4	The molecular dynamics of nuclear protein import were examined in a solution binding assay by testing for interactions between a protein containing a nuclear localization signal (NLS), the transport factors karyopherin alpha, karyopherin beta, and Ran, and FXFG or GLFG repeat regions of nucleoporins. We found that karyopherins alpha and beta cooperate to bind FXFG but not GLFG repeat regions. Binding of the NLS protein to karyopherin alpha was enhanced by karyopherin beta. Two novel reactions were discovered. First, incubation of a karyopherin heterodimer-NLS protein complex with an FXFG repeat region stimulated the dissociation of the NLS protein from the karyopherin heterodimer. Second, incubation of the karyopherin heterodimer with RanGTP (or with a Ran mutant that cannot hydrolyze GTP) led to the dissociation of karyopherin alpha from beta and to an association of Ran with karyopherin beta; RanGDP had no effect. We propose that movement of NLS proteins across the nuclear pore complex is a stochastic process that operates via repeated association-dissociation reactions.	HOWARD HUGHES MED RES INST, CELL BIOL LAB, NEW YORK, NY 10021 USA		REXACH, M (corresponding author), ROCKEFELLER UNIV, CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	38	670	675	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 1	1995	83	5					683	692		10.1016/0092-8674(95)90181-7	http://dx.doi.org/10.1016/0092-8674(95)90181-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521485	Bronze			2022-12-01	WOS:A1995TH94800005
J	ISAACS, AJ; BRITTON, AR; MCPHERSON, K				ISAACS, AJ; BRITTON, AR; MCPHERSON, K			UTILIZATION OF HORMONE REPLACEMENT THERAPY BY WOMEN DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; HEART-DISEASE; HRT	Objectives-To ascertain the prevalence and duration of use of hormone replacement therapy by menopausal women doctors. Design-Postal questionnaire. Setting-General practices in the United Kingdom. Subjects-Randomised stratified sample of women doctors who obtained full registration between 1952 and 1976, taken from the current principal list of the Medical Register. Main outcome measures- Prevalence and duration of use of hormone replacement therapy; menopausal status. Results-Overall, 45.7% (436/954) of women doctors aged between 45 and 65 years had ever used hormone replacement therapy. When the results from women still menstruating regularly were excluded, 55.2% (428) were ever users and 41.2% (319) current users. The cumulative probability of remaining on hormone replacement therapy was 0.707 at five years and 0.576 at 10 years. Conclusions-Women doctors have a higher prevalence of use of hormone replacement therapy than has been reported for other women in the United Kingdom, and most users seem to be taking hormone replacement therapy for more than five years. The results may become generalisable to the wider population as information on the potential benefits of hormone replacement therapy is disseminated.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUNKER JP, 1974, NEW ENGL J MED, V290, P1051, DOI 10.1056/NEJM197405092901905; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; COOPE J, 1991, LANCET, V337, P1162; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; DEAN AD, 1990, EPI INFO; DOLL R, 1980, BRIT MED J, V1, P967; DUGOWSON CE, 1987, WESTERN J MED, V146, P494; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FERGUSON KJ, 1989, ARCH INTERN MED, V49, P132; HAHN RG, 1989, AM J OBSTET GYNECOL, V161, P1854, DOI 10.1016/S0002-9378(89)80006-7; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JANNAUSCH ML, 1992, MATURITAS, V14, P161, DOI 10.1016/0378-5122(92)90111-G; MCPHERSON K, 1994, CORONARY HEART DISEA, P141; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; RAVNIKAR VA, 1987, AM J OBSTET GYNECOL, V156, P1332, DOI 10.1016/0002-9378(87)90173-6; ROSENBERG L, 1993, AM J PUBLIC HEALTH, V3, P1670; ROSS RK, 1989, LANCET, V1, P505; SINCLAIR HK, 1993, BRIT J GEN PRACT, V43, P365; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317	26	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 25	1995	311	7017					1399	1401		10.1136/bmj.311.7017.1399	http://dx.doi.org/10.1136/bmj.311.7017.1399			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG902	8520274	Green Published			2022-12-01	WOS:A1995TG90200020
J	NEDIVI, E; HEVRONI, D; NAOT, D; ISRAELI, D; CITRI, Y				NEDIVI, E; HEVRONI, D; NAOT, D; ISRAELI, D; CITRI, Y			NUMEROUS CANDIDATE PLASTICITY-RELATED GENES REVEALED BY DIFFERENTIAL CDNA CLONING	NATURE			English	Article							MOLECULAR-CLONING; STRESS PROTEINS; EXPRESSION; CELLS; ACID; PROENKEPHALIN; MECHANISMS; EXTRACTION; SEQUENCE; SEIZURE	PLASTICITY is a property of the nervous system that allows it to modify its response to an altered input. This capacity for change suggests that there are molecular mechanisms in neurons that can couple stimuli to long-term alterations in phenotype1-3. Neuronal excitation elicits rapid transcriptional activation of several immediate-early genes4, for example c-fos, c-jun and zif268. Many immediate-early genes encode transcription factors that control expression of downstream genes whose products are believed to bring about long-term plastic changes3,4. Here we use a highly sensitive differential complementary DNA cloning procedure to identify genes that may participate in long-term plasticity. We cloned 52 cDNAs of genes induced by the glutamate analogue kainate in the hippocampus dentate gyrus. The number of these candidate plasticity-related genes (CPGs) is estimated to be 500-1,000. One of the cloned CPGs (16C8), encoding a protease inhibitor, is induced by a stimulus producing long-term potentiation and during dentate gyrus development; a second, cpg1, is dependent on activation of the NMDA (N-methyl-D-aspartate) receptor for induction and encodes a new small, dentate-gyrus-specific protein. Seventeen of the cloned CPGs encode known proteins, including six suggesting that strong neuronal activation leads to de novo synthesis of vesicular and other synaptic components.			NEDIVI, E (corresponding author), WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL.		Nedivi, Elly/ABC-9923-2021	Naot, Dorit/0000-0001-9498-2639; Israeli, David/0000-0003-2762-2195; /0000-0002-1710-0767				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ALTIN JG, 1993, NEUROTROPHIC FACTORS, P129; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GALL C, 1988, J NEUROSCI, V8, P1852; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBB DO, 1949, ORG BEHAVIOR; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; MCNAMARA JO, 1988, TRENDS NEUROSCI, V11, P33, DOI 10.1016/0166-2236(88)90047-1; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORRIS BJ, 1988, P NATL ACAD SCI USA, V85, P3226, DOI 10.1073/pnas.85.9.3226; NAIM AC, 1992, CURR OPIN NEUROBIOL, V2, P296; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; Sambrook J., 1989, MOL CLONING LAB MANU; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; UHL GR, 1986, IN SITU HYBRIDIZATIO; [No title captured]	38	428	455	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					718	722		10.1038/363718a0	http://dx.doi.org/10.1038/363718a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515813				2022-12-01	WOS:A1993LJ33900055
J	NOVELLO, AC; PETERSON, HB; ARROWSMITHLOWE, JT; KELAGHAN, J; PERLMAN, JA				NOVELLO, AC; PETERSON, HB; ARROWSMITHLOWE, JT; KELAGHAN, J; PERLMAN, JA			CONDOM USE FOR PREVENTION OF SEXUAL TRANSMISSION OF HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US OFF SURGEON GEN,WASHINGTON,DC									FDA BROCHURE CONDOMS	1	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2840	2840		10.1001/jama.269.22.2840	http://dx.doi.org/10.1001/jama.269.22.2840			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LE936	8497081				2022-12-01	WOS:A1993LE93600005
J	DEDIOS, AC; PEARSON, JG; OLDFIELD, E				DEDIOS, AC; PEARSON, JG; OLDFIELD, E			SECONDARY AND TERTIARY STRUCTURAL EFFECTS ON PROTEIN NMR CHEMICAL-SHIFTS - AN ABINITIO APPROACH	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; STAPHYLOCOCCAL NUCLEASE; C-13; MOLECULES; MODEL; CONFORMATION; SHIELDINGS; INHIBITOR; PROGRAM; DISTAL	Recent theoretical developments permit the prediction of H-1, C-13, N-15, and F-19 nuclear magnetic resonance chemical shifts in proteins and offer new ways of analyzing secondary and tertiary structure as well as for probing protein electrostatics. For C-13, phi,psi torsion angles dominate shielding for Calpha and Cbeta, but the addition of hydrogen bonding and electrostatics gives even better accord with experiment. For N-15H, side chain (chi1) torsion angles are also important, as are nearest neighbor sequence effects, whereas for H-1N, hydrogen bonding is particularly significant. For F-19, weak or long-range electrostatic fields dominate F-19 shielding nonequivalencies. The ability to predict chemical shifts in proteins from known or test structures opens new avenues to structure refinement or determination, especially for condensed systems.	UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			de Dios, Angel C/H-4034-2011		NHLBI NIH HHS [HL-19481] Funding Source: Medline; NIGMS NIH HHS [GM-14545, GM-40426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040426, F32GM014545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLERHAN.A, 1973, BIOCHEMISTRY-US, V12, P1335, DOI 10.1021/bi00731a013; ANDO I, 1984, MACROMOLECULES, V17, P457, DOI 10.1021/ma00133a036; AUGSPURGER J, 1992, J MAGN RESON, V100, P342, DOI 10.1016/0022-2364(92)90267-B; AUGSPURGER JD, 1991, J AM CHEM SOC, V113, P2447, DOI 10.1021/ja00007a015; AUGSPURGER JD, 1991, J PHYS CHEM-US, V95, P9230, DOI 10.1021/j100176a037; BATCHELOR JG, 1975, J AM CHEM SOC, V97, P3410, DOI 10.1021/ja00845a022; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUCKINGHAM AD, 1960, CAN J CHEM, V38, P300, DOI 10.1139/v60-040; BUCKINGHAM AD, 1960, MOL PHYS, V3, P219, DOI 10.1080/00268976000100261; CHESNUT DB, 1989, J COMPUT CHEM, V10, P648, DOI 10.1002/jcc.540100507; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CUMMINS PL, 1987, MOL PHYS, V61, P795, DOI 10.1080/00268978700101481; DEDIOS A, UNPUB; DEDIOS AC, 1993, CHEM PHYS LETT, V205, P108, DOI 10.1016/0009-2614(93)85175-N; DITCHFIELD R, 1972, J CHEM PHYS, V56, P5688, DOI 10.1063/1.1677088; DYKSTRA CE, IN PRESS CALCULATION; GLUSHKA J, 1989, J AM CHEM SOC, V111, P7716, DOI 10.1021/ja00202a009; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P9029, DOI 10.1073/pnas.89.19.9029; HANSEN AE, 1985, J CHEM PHYS, V82, P5035, DOI 10.1063/1.448625; JAMAN AI, 1991, CHEM PHYS, V154, P281, DOI 10.1016/0301-0104(91)80078-V; LE C, UNPUB; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; London F, 1937, J PHYS-PARIS, V8, P397, DOI 10.1051/jphysrad:01937008010039700; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MCDONALD CC, 1967, J AM CHEM SOC, V89, P6332, DOI 10.1021/ja01000a061; Mowbray S L, 1990, Receptor, V1, P41; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; OLDFIELD E, UNPUBN; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PEARSON JG, IN PRESS J AM CHEM S; Salem L., 1966, MOL ORBITAL THEORY C; SCHINDLER M, 1983, J AM CHEM SOC, V105, P1360, DOI 10.1021/ja00343a049; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; TORCHIA DA, 1989, BIOCHEMISTRY-US, V28, P5509, DOI 10.1021/bi00439a028; TOSSELL JA, 1991, J MAGN RESON, V94, P301, DOI 10.1016/0022-2364(91)90108-6; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG JF, 1992, BIOCHEMISTRY-US, V31, P921, DOI 10.1021/bi00118a039; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WILLIAMSON MP, 1992, J BIOMOL NMR, V2, P83, DOI 10.1007/BF02192802; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005	45	430	433	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1491	1496		10.1126/science.8502992	http://dx.doi.org/10.1126/science.8502992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502992				2022-12-01	WOS:A1993LF05800033
J	POPE, AM				POPE, AM			INDOOR ALLERGENS - ASSESSING AND CONTROLLING ADVERSE HEALTH-EFFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POPE, AM (corresponding author), INST MED,COMM HLTH EFFECTS INDOOR ALLERGENS,ROOM FO-3034,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1993	269	21					2721	2721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD671	8492388				2022-12-01	WOS:A1993LD67100006
J	COLONNA, M; BROOKS, EG; FALCO, M; FERRARA, GB; STROMINGER, JL				COLONNA, M; BROOKS, EG; FALCO, M; FERRARA, GB; STROMINGER, JL			GENERATION OF ALLOSPECIFIC NATURAL-KILLER-CELLS BY STIMULATION ACROSS A POLYMORPHISM OF HLA-C	SCIENCE			English	Article							PARENTAL LYMPHOCYTES; EXPRESSION; NK; RECOGNITION; RESISTANCE; MOLECULES; ANTIGENS; GENE	The cytotoxicity of human natural killer (NK) cells is modulated by the major histocompatibility complex human leukocyte antigen (HLA)-C molecules on the surface of the target cell. Alloreactive NK cells specific for the NK-1 alloantigen could be reproducibly generated from individuals that were homozygous for HLA-C with asparagine at residue 77 and lysine at residue 80 [HLA-C(Asn77, Lys80] by stimulation with target cells that were homozygous for HLA-C(Ser77, Asn80); the reciprocal stimulation yielded NK cells specific for the NK-2 alloantigen. However, neither homozygous target cell stimulated the generation of alloreactive NK cells from heterozygous individuals. Thus, these data reveal an unanticipated difference between human NK alloreactivity defined by this system and murine ''hybrid resistance.''	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; CTR RIC AVIS,BERGAMO,ITALY; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University	COLONNA, M (corresponding author), IST NAZL RIC CANC,IMMUNOGENET LAB,I-16132 GENOA,ITALY.		Falco, Michela/K-1574-2016	Falco, Michela/0000-0002-0317-9830; Colonna, Marco/0000-0001-5222-4987	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001064] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline; NIAID NIH HHS [KO8 AI01064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHADWICK BS, 1992, J IMMUNOL, V148, P2307; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CICCONE E, 1988, J EXP MED, V168, P2403, DOI 10.1084/jem.168.6.2403; CICCONE E, 1991, P NATL ACAD SCI USA, V88, P5477; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HERCEND T, 1985, J CLIN INVEST, V75, P932, DOI 10.1172/JCI111794; ISHIKAWA H, 1982, J IMMUNOL, V129, P1181; KAUFMAN DS, 1992, P NATL ACAD SCI USA, V89, P8337, DOI 10.1073/pnas.89.17.8337; KNOBLOCH C, 1988, TRANSPLANTATION, V45, P175, DOI 10.1097/00007890-198801000-00037; LANIER LL, 1986, J IMMUNOL, V136, P4480; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; SENTMAN CL, 1988, NAT IMMUN CELL GROW, V7, P95; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1992, J IMMUNOL, V149, P1185; SUZUKI N, 1990, J EXP MED, V172, P457, DOI 10.1084/jem.172.2.457; TAKIGUCHI M, 1989, J IMMUNOL, V143, P1372; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZEMMOUR J, 1992, J EXP MED, V176, P937, DOI 10.1084/jem.176.4.937	23	222	236	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1121	1124		10.1126/science.8493555	http://dx.doi.org/10.1126/science.8493555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8493555				2022-12-01	WOS:A1993LC94200028
J	HANDYSIDES, S				HANDYSIDES, S			HELPING PEOPLE WITH DEMENTIA FEEL AT HOME	BRITISH MEDICAL JOURNAL			English	Article																		BURLEY R, 1992, EVERY HOUSE YOULL EV; MANSER M, 1991, PSYCHIATRY ELDERLY, P550; MARSHALL M, 1992, RECENT ADV PSYCHOGER, V2, P201; MURPHY E, 1991, ASYLUMS COMMUNITY CA, P6; NETTEN A, 1989, INT J GERIATR PSYCH, V4, P143, DOI 10.1002/gps.930040305; CR16 ROYAL COLL PSYC; 1976, POPULATION ESTIM PP1; 1991, NATIONAL POPULAT PP2	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 24	1993	306	6885					1115	1117		10.1136/bmj.306.6885.1115	http://dx.doi.org/10.1136/bmj.306.6885.1115			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KZ565	8495161	Bronze, Green Published			2022-12-01	WOS:A1993KZ56500029
J	GLOVER, GR; ROHDE, J; FARMER, RDT				GLOVER, GR; ROHDE, J; FARMER, RDT			IS THE MONEY FOLLOWING THE CLIENTS WITH LEARNING-DISABILITIES	BRITISH MEDICAL JOURNAL			English	Article								For the past decade patients with learning disabilities living in long stay mental handicap hospitals have been resettled in the community. Local authorities have also taken on the care of new patients who would once have been long stay residents. The imperfect data that are available suggest that in England about half the residents in mental handicap hospitals in 1981 are now the responsibility of local authorities; the figures for Wales and Northern Ireland are 38% and 33%. Data on revenue suggest that the savings to the health service are much less -perhaps 9% in Northern Ireland and 3.6% in England, although there have also been capital gains through the sale of hospitals. Existing methods of transferring money from health to local authorities-joint finance and ''dowries'' for individual patients -do not seem adequately to have compensated local authorities. Moreover, as patients still to be transferred are more severely disabled local authorities will require larger sums-about 26 000 Pounds per patient per year plus 39 200 Pounds in capital. If the government chooses not to transfer these resources from health authorities it will be switching funds away from learning disabled people to other care groups.			GLOVER, GR (corresponding author), CHARING CROSS & WESTMINTER MED SCH,ACAD DEPT PUBL HLTH & EPIDEMIOL,LONDON SW1P 2AR,ENGLAND.							FARMER RDT, 1990, BMJ, V601, P646; Fryers Tom, 1984, EPIDEMIOLOGY SEVERE; KENNY DJ, 1986, HLTH SERVICES MENTAL; Knapp M., 1992, CARE COMMUNITY CHALL; 1971, BETTER SERVICES MENT; 1990, COMMUNITY CARE SERVI; 1992, COMMUNITY CARE MANAG	7	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 10	1993	306	6883					987	990		10.1136/bmj.306.6883.987	http://dx.doi.org/10.1136/bmj.306.6883.987			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX436	8490482	Bronze, Green Published			2022-12-01	WOS:A1993KX43600027
J	Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW				Lee, MA; Nelson, HD; Tilden, VP; Ganzini, L; Schmidt, TA; Tolle, SW			Legalizing assisted suicide - Views of physicians in Oregon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; LIFE; DEPRESSION; ATTITUDES; AID	Background. Since the Oregon Death with Dignity Act was passed in November 1994, physicians in Oregon have faced the prospect of legalized physician-assisted suicide. We studied the attitudes and current practices of Oregon physicians in relation to assisted suicide. Methods. From March to June 1995, we conducted a cross-sectional mailed survey of all physicians who might be eligible to prescribe a lethal dose of medication if the Oregon law is upheld, Physicians were asked to complete and return a confidential 56-item questionnaire. Results. Of the 3944 eligible physicians who received the questionnaire, 2761 (70 percent) responded. Sixty percent of the respondents thought physician-assisted suicide should be legal in some cases, and nearly half (46 percent) might be willing to prescribe a lethal dose of medication if it were legal to do so; 31 percent of the respondents would be unwilling to do so on moral grounds. Twenty-one percent of the respondents have previously received requests for assisted suicide, and 7 percent have complied. Half the respondents were not sure what to prescribe for this purpose, and 83 percent cited financial pressure as a possible reason for such requests. The respondents also expressed concern about complications of suicide attempts and doubts about their ability to predict survival at six months accurately. Conclusions. Oregon physicians have a more favorable attitude toward legalized physician-assisted suicide, are more willing to participate, and are currently participating in greater numbers than other surveyed groups of physicians in the United States. A sizable minority of physicians in Oregon objects to legalization and participation on moral grounds. Regardless of their attitudes, physicians had a number of reservations about the practical applications of the act. (C) 1996, Massachusetts Medical Society.	OREGON HLTH SCI UNIV,SCH MED,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT PSYCHIAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH MED,DEPT EMERGENCY MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,SCH NURSING,RES OFF,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,CTR BIOMED INFORMAT COMMUN,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lee, MA (corresponding author), OREGON HLTH SCI UNIV,CTR ETH HLTH CARE L101,PORTLAND,OR 97201, USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CARALIS PV, 1992, CRIT CARE MED, V20, P683, DOI 10.1097/00003246-199205000-00023; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CROSBY C, 1992, INTERNIST, V31, P10; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EMANUEL EJ, 1994, ANN INTERN MED, V121, P793, DOI 10.7326/0003-4819-121-10-199411150-00010; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GATES V, 1995, OREGON HLTH PLAN REP, P71; HEILIG S, 1989, SF MED, V61, P24; KEISLING P, 1995, OREGON BLUE BOOK, P296; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KOENIG HG, 1988, ARCH INTERN MED, V148, P1929, DOI 10.1001/archinte.148.9.1929; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; MEIER D, 1993, SURVEY END LIFE PRAC; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; TENO JM, 1994, J AM GERIATR SOC, V42, P1202, DOI 10.1111/j.1532-5415.1994.tb06990.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1995, ACAD MED, V70, P583; 1995, J AM GERIATR SOC, V42, P579; 1994, POISITON STATEMENT A; 1994, OREGON VOTERS PAMPHL; 1991, INITATIVE 119 WSMA M	29	208	208	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	1996	334	5					310	315		10.1056/NEJM199602013340507	http://dx.doi.org/10.1056/NEJM199602013340507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV695	8532028				2022-12-01	WOS:A1996TV69500007
J	Collier, J				Collier, J			Medicines mismatch	LANCET			English	Editorial Material							DRUG				Collier, J (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CLIN PHARMACOL,CRANMER TERRACE,LONDON,ENGLAND.							CHANDRA S, 1995, OCT NAT MED DRUG POL; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; KRISHNASWAMY K, 1985, EUR J CLIN PHARMACOL, V29, P363, DOI 10.1007/BF00544095; PHADKE A, 1995, STUDY SUPPLY USE PHA, P152	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					212	212		10.1016/S0140-6736(96)90400-6	http://dx.doi.org/10.1016/S0140-6736(96)90400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TT069	8551877				2022-12-01	WOS:A1996TT06900006
J	McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P				McPherson, PS; Garcia, EP; Slepnev, VI; David, C; Zhang, XM; Grabs, D; Sossin, WS; Bauerfeind, R; Nemoto, Y; DeCamilli, P			A presynaptic inositol-5-phosphatase	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; YEAST GOLGI; IDENTIFICATION; MUTATIONS	SYNAPTOJANIN is a nerve terminal protein of relative molecular mass 145,000 which appears to participate with dynamin in synaptic vesicle recycling(1,2). The central region of synaptojanin defines it as a member of the inositol-5-phosphatase family, which includes the product of the gene that is defective in the oculocerebrorenal syndrome of Lowe(3-7). Synaptojanin has 5-phosphatase activity and its amino-terminal domain is homologous with the yeast protein Sac1 (Rsd1), which is genetically implicated in phospholipid metabolism and in the function of the actin cytoskeleton(8-10). The carboxy terminus, which is of different lengths in adult and developing neurons owing to the alternative use of two termination sites, is proline-rich, consistent,vith the reported interaction of synaptojanin with the SH3 domains of Grb2 (refs 1, 2), Synaptojanin is the only other major brain protein besides dynamin that binds the SH3 domain of amphiphysin, a presynaptic protein with a putative function in endocytosis(11-14). Our results suggest a link between phosphoinositide metabolism and synaptic vesicle recycling.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	Yale University; Howard Hughes Medical Institute; Yale University; McGill University								ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DAVID C, IN PRESS P NATN ACAD; GAIDAROV IO, 1995, MOL BIOL CELL, V6, P407; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	30	482	491	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 25	1996	379	6563					353	357		10.1038/379353a0	http://dx.doi.org/10.1038/379353a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TR323	8552192				2022-12-01	WOS:A1996TR32300061
J	Nightingale, SL				Nightingale, SL			Guidance on industry dissemination of textbooks and reprints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					273	273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544255				2022-12-01	WOS:A1996TP96500006
J	Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP				Furukawa, K; Barger, SW; Blalock, EM; Mattson, MP			Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein	NATURE			English	Article							POTASSIUM CHANNEL; ALZHEIMERS-DISEASE; RAT; MODULATION; GENE	THE Alzheimer's beta-amyloid precursor protein (beta-APP) is widely expressed in neural cells, and in neurons secreted forms of beta-APP (sAPPs) are released from membrane-spanning holo-beta APP in an activity-dependent manner(1,2). Secreted APPs can modulate neurite outgrowth, synaptogenesis, synaptic plasticity and cell survival(3,9); a signal transduction mechanism of sAPPs may involve modulation of intracellular calcium levels ([Ca2+](i))(4,10). Here we use whole-cell perforated patch and single-channel patch-clamp analysis of hippocampal neurons to demonstrate that sAPPs suppress action potentials and hyperpolarize neurons by activating high-conductance, charybdotoxin-sensitive K+ channels. Activation of K+ channels by sAPPs was mimicked by a cyclic GMP analogue and sodium nitroprusside and blocked by an antagonist of cGMP-dependent kinase and a phosphatase inhibitor, suggesting that the effect is mediated by cGMP and protein dephosphorylation. Calcium imaging studies indicate that activation of K+ channels mediates the ability of sAPPs to decrease [Ca-2](i). Modulation of neuronal excitability may be a major mechanism by which beta-APP regulates developmental and synaptic plasticity in the nervous system.	UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT PHARMACOL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky			Mattson, Mark P/F-6038-2012	Barger, Steven/0000-0001-6049-6480				AKON DL, 1991, BRAIN RES REV, V16, P193; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BARGER SW, 1995, BIOCHEM J, V311, P45, DOI 10.1042/bj3110045; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CRITZ SD, 1992, J NEUROPHYSIOL, V68, P1079, DOI 10.1152/jn.1992.68.4.1079; EGAN TM, 1993, J NEUROPHYSIOL, V69, P1433, DOI 10.1152/jn.1993.69.5.1433; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; Firestein Stuart, 1994, Seminars in Cell Biology, V5, P39, DOI 10.1006/scel.1994.1006; HAYDON PG, 1995, TRENDS NEUROSCI, V18, P196, DOI 10.1016/0166-2236(95)93901-9; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; Sperelakis N, 1994, Adv Pharmacol, V26, P217, DOI 10.1016/S1054-3589(08)60056-3; WAKAMORI M, 1993, J PHYSIOL-LONDON, V463, P585, DOI 10.1113/jphysiol.1993.sp019612; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0	29	289	294	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					74	78		10.1038/379074a0	http://dx.doi.org/10.1038/379074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538744				2022-12-01	WOS:A1996TN21600058
J	Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI				Tartaglia, LA; Dembski, M; Weng, X; Deng, NH; Culpepper, J; Devos, R; Richards, GJ; Campfield, LA; Clark, FT; Deeds, J; Muir, C; Sanker, S; Moriarty, A; Moore, KJ; Smutko, JS; Mays, GG; Woolf, EA; Monroe, CA; Tepper, RI			Identification and expression cloning of a leptin receptor, OB-R	CELL			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA-INHIBITORY FACTOR; SIGNAL TRANSDUCER; MOLECULAR-CLONING; GP130; EFFICIENT; OBESITY; DOMAINS; MICE	The ob gene product, leptin, is an important circulating signal for the regulation of body weight. To identify high affinity leptin-binding sites, we generated a series of leptin-alkaline phosphatase (AP) fusion proteins as well as [I-125]leptin. After a binding survey of cell lines and tissues, we identified leptin-binding sites in the mouse choroid plexus. A cDNA expression library was prepared from mouse choroid plexus and screened with a leptin-AP fusion protein to identify a leptin receptor (OB-R). OB-R is a single membrane-spanning receptor most related to the gp130 signal-transducing component of the IL-6 receptor, the G-CSF receptor, and the LIF receptor. OB-R mRNA is expressed not only in choroid plexus, but also in several other tissues, including hypothalamus. Genetic mapping of the gene encoding OB-R shows that it is within the 5.1 cM interval of mouse chromosome 4 that contains the db locus.	ROCHE RES GENT, B-9000 GHENT, BELGIUM; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding	Tartaglia, LA (corresponding author), MILLENNIUM PHARMACEUT INC, 640 MEM DR, CAMBRIDGE, MA 02139 USA.		sheng, jian/E-9474-2012					BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEBONS AF, 1977, FED PROC, V36, P143; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SAITO M, 1992, J IMMUNOL, V148, P4066; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	2931	3137	1	147	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1263	1271		10.1016/0092-8674(95)90151-5	http://dx.doi.org/10.1016/0092-8674(95)90151-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548812	Bronze			2022-12-01	WOS:A1995TM76200021
J	Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M				Qizilbash, N; Lewington, S; Duffy, S; Peto, R; Smith, T; Spiegelhalter, D; Iso, H; Shimamoto, T; Komachi, Y; Iida, M; Doyle, J; Strogatz, D; Ebrahim, S; Wannamethee, G; Whincup, P; Burke, V; Cullen, K; Knuiman, M; Welborn, T; Bainton, D; Baker, I; Elwood, P; Sweetnam, P; Yarnell, J; Keil, J; Sutherland, S; Hames, C; Tyroler, H; DAgostino, R; Kannel, W; Wolf, P; Aromaa, A; Knekt, P; Maatela, J; Reunanen, A; Puska, P; Sarti, C; Tamminen, M; Tuomilehto, J; Vartiainen, E; Bengtsson, C; Bjorkelund, C; Lissner, L; Kodama, K; Shimizu, Y; Kagan, A; Popper, J; Reed, D; Yano, K; Goldbourt, U; Medalie, J; Yaari, S; Criqui, M; Davis, C; Blackburn, H; Jacobs, D; Leupker, R; Harris, T; Madans, J; Ofstedal, M; Bjartveit, K; Stensvold, I; Tverdal, A; Garrow, K; Meade, T; Ruddock, V; Haheim, L; Hjermann, I; Holme, I; Leren, P; Cambien, F; Ducimetiere, P; Richard, J; Assmann, G; BarrettConnor, E; Langer, R; Gillis, C; Hart, C; Hawthorne, V; Hole, D; Isles, C; Lever, A; Smith, GD; Aravanis, C; Blackburn, H; Buzina, R; Dontas, A; Fidanza, F; Giampaoli, S; Karvonen, M; Keys, A; Kromhout, D; Lanti, M; Menotti, A; Mohacek, I; Nedeljkovic, S; Nissinen, A; Punsar, S; Seccareccia, F; Toshima, H; Chen, Z; Collins, R; Li, W; Lu, J; Date, C; Nakayama, T; Tanaka, H; Yokoyama, T; Yoshiike, N; Brown, C; TunstallPedoe, H; Higgins, M; Keller, J; Carstensen, J; Tornberg, S; Marmot, M; Shipley, M			Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; CEREBRAL INFARCTION; CIVIL-SERVANTS; BRITISH MEN; FOLLOW-UP; MORTALITY; POPULATION	Individual studies of stroke have not clearly answered two questions: on the relation, if any, between total blood cholesterol and stroke; and on how the strength of the relation between diastolic blood pressure and stroke varies with age. The associations of blood cholesterol and diastolic blood pressure with subsequent stroke rates were investigated by review of 45 prospective observational cohorts involving 450 000 individuals with 5-30 years of follow-up (mean 16 years, total 7 . 3 million person-years of observation), during which 13 397 participants were recorded as having had a stroke. Most of these were fatal strokes in studies that recorded only mortality and not incidence, but about one-quarter were from studies that recorded both fatal and non-fatal strokes. After standardisation for age, there was no association between blood cholesterol and stroke except, perhaps, in those under 45 years of age when screened. This lack of association was not influenced by adjustment for sex, diastolic blood pressure, history of coronary heart disease, or ethnicity (Asian or non-Asian). However, because the types of the strokes were not centrally available, the lack of any overall relation might conceal a positive association with ischaemic stroke together with a negative association with haemorrhagic stroke. When the highest and the lowest of the six blood pressure categories were compared, the difference in usual diastolic blood pressure was 27 mm Hg (102 vs 75 mm Hg), and there was a fivefold difference in stroke risk. This fivefold difference was seen both in those with a preexisting history of coronary heart disease and in those without it. The proportional difference stroke risk, was more extreme in middle in old age. Among those aged <45, 45-64, and 65+ when screened, the differences in the relative risks of stroke (between the highest diastolic blood pressure category and a combination of the lowest two categories) were tenfold, fivefold, and twofold, respectively. However, because the absolute stroke risks are greater in old age, the absolute differences in the annual stroke rates showed an opposite pattern, being 2, 5, and 8 per thousand, respectively. This suggests that the effects of therapeutic blood pressure reductions should be assessed separately in middle age and in old age.	GOTHENBURG WOMEN, GOTHENBURG, SWEDEN; HONOLULU HEART PROGRAM, HONOLULU, HI USA		Qizilbash, N (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN GERATOL, OXFORD OX2 6HE, ENGLAND.		Marmot, M G/Y-3920-2019; Kromhout, Daan/A-8566-2014; Knuiman, Matthew W/I-5549-2013; Davey Smith, George/A-7407-2013	Marmot, M G/0000-0002-2431-6419; Davey Smith, George/0000-0002-1407-8314; Carstensen, John/0000-0003-2256-8089; Seccareccia, Fulvia/0000-0003-4135-2806	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BAINTON D, 1992, BRIT HEART J, V68, P60; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOLTONSMITH C, 1993, BRIT J NUTR, V69, P315, DOI 10.1079/BJN19930036; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX CS, 1992, VITAL HLTH STAT, P27; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GILKS WR, 1993, J R STAT SOC B, V55, P39; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; Keil J E, 1992, Ann Epidemiol, V2, P93; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; KNUIMAN MW, 1994, AUST J PUBLIC HEALTH, V18, P129; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LIN CH, 1984, STROKE, V15, P653, DOI 10.1161/01.STR.15.4.653; LINDENSTROM E, 1994, BMJ-BRIT MED J, V309, P11, DOI 10.1136/bmj.309.6946.11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEATON JD, 1995, HYPERTENSION PATHOPH, V1, P127; PEDERSEN TR, 1994, LANCET, V344, P1383; PSATY BM, 1990, J CLIN EPIDEMIOL, V43, P961, DOI 10.1016/0895-4356(90)90079-5; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; REID DD, 1974, LANCET, V1, P469; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; Speizer, 1976, NATURAL HIST CHRONIC, P218; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TANAKA H, 1985, STROKE, V16, P773, DOI 10.1161/01.STR.16.5.773; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; TUOMILEHTO J, 1991, STROKE, V22, P7, DOI 10.1161/01.STR.22.1.7; Wolf P A, 1983, Neurol Clin, V1, P317; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460	53	706	729	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	1995	346	8991-2					1647	1653						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551820				2022-12-01	WOS:A1995TL42300006
J	SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y				SEO, S; OKAMOTO, N; SETO, H; ISHIZUKA, K; SANO, H; OHASHI, Y			TOBACCO MAP KINASE - A POSSIBLE MEDIATOR IN WOUND SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							PATHOGENESIS-RELATED PROTEINS; INHIBITOR-INDUCING FACTOR; JASMONIC ACID; GENE-EXPRESSION; ACQUIRED-RESISTANCE; VIRUS-INFECTION; SALICYLIC-ACID; PHOSPHORYLATION; PLANTS; INDUCTION	A complementary DNA encoding a mitogen-activated protein (MAP) kinase homolog has been isolated from tobacco plants. Transcripts of the corresponding gene were not observed in healthy tobacco leaves but began to accumulate 1 minute after mechanical wounding. In tobacco plants transformed with the cloned complementary DNA, trans inactivation of the endogenous homologous gene occurred, and both production of wound-induced jasmonic acid and accumulation of wound-inducible gene transcripts were inhibited. In contrast, the levels of salicylic acid and transcripts for pathogen-inducible, acidic pathogenesis-related proteins were increased upon wounding. These results indicate that this MAP kinase is part of the initial response of higher plants to mechanical wounding.	NATL INST AGROBIOL RESOURCES,DEPT MOLEC BIOL,TSUKUBA,IBARAKI 305,JAPAN; NARA INST SCI & TECHNOL,IKOMA,NARA 63001,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; TOAGOUSEI CORP LTD,TSUKUBA INST,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan; Nara Institute of Science & Technology; RIKEN; RIKEN; University of Tsukuba				Seo, Shigemi/0000-0003-4940-288X				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; EYAL Y, 1992, PLANT MOL BIOL, V19, P589, DOI 10.1007/BF00026785; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FARMER EE, 1989, P NATL ACAD SCI USA, V86, P1539, DOI 10.1073/pnas.86.5.1539; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAHLBROCK K, 1995, P NATL ACAD SCI USA, V92, P4150, DOI 10.1073/pnas.92.10.4150; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINTHORST HJM, 1990, P NATL ACAD SCI USA, V87, P8756, DOI 10.1073/pnas.87.22.8756; MACKINTOSH C, 1994, PLANT J, V5, P137, DOI 10.1046/j.1365-313X.1994.5010137.x; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MALAMY J, 1992, PLANT J, V2, P642; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATSUOKA M, 1987, PLANT PHYSIOL, V85, P942, DOI 10.1104/pp.85.4.942; MATZKE M, 1993, ANNU REV PLANT PHYS, V44, P53, DOI 10.1146/annurev.pp.44.060193.000413; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; NAGY F, 1988, PLANT MOL BIOL MANUA; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NOJIRI H, 1992, PLANT CELL PHYSIOL, V33, P1225; OHSHIMA M, 1990, PLANT CELL, V2, P95, DOI 10.1105/tpc.2.2.95; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sambrook J., 1989, MOL CLONING LAB MANU; SANO H, 1995, P NATL ACAD SCI USA, V92, P4138, DOI 10.1073/pnas.92.10.4138; SANO H, 1994, P NATL ACAD SCI USA, V91, P10556, DOI 10.1073/pnas.91.22.10556; SANO H, 1994, P NATL ACAD SCI USA, V91, P2582, DOI 10.1073/pnas.91.7.2582; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; URANO T, 1994, MOL GEN GENET, V244, P331; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; XU Y, 1994, PLANT CELL, V6, P1077, DOI 10.1105/tpc.6.8.1077	58	433	464	2	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 22	1995	270	5244					1988	1992		10.1126/science.270.5244.1988	http://dx.doi.org/10.1126/science.270.5244.1988			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TL420	8533090				2022-12-01	WOS:A1995TL42000041
J	MANIAK, M; RAUCHENBERGER, R; ALBRECHT, R; MURPHY, J; GERISCH, G				MANIAK, M; RAUCHENBERGER, R; ALBRECHT, R; MURPHY, J; GERISCH, G			CORONIN INVOLVED IN PHAGOCYTOSIS - DYNAMICS OF PARTICLE-INDUCED RELOCALIZATION VISUALIZED BY A GREEN FLUORESCENT PROTEIN TAG	CELL			English	Article							ACTIN-BINDING-PROTEIN; DICTYOSTELIUM-DISCOIDEUM; ALPHA-ACTININ; MONOCLONAL-ANTIBODIES; MYOSIN-I; CELLS; MUTANTS; LACKING; GENE; EXPRESSION	Coronin is a protein involved in cell locomotion and cytokinesis of Dictyostelium discoideum. Here we show that coronin is strongly enriched in phagocytic cups formed in response to particle attachment. A fusion of coronin with green fluorescent protein (GFP) accumulates in the cups within less than 1 min upon attachment of a particle and is gradually released from the phagosome within 1 min after engulfment is completed, Phagocytic cup formation competes with leading edge formation and can be interrupted at any stage, When the cup regresses, coronin dissociates from the site of accumulation, TRITC-labeled yeast cells have been used to assay phagocytosis quantitatively in wild-type and coronin-null cells, In the mutant, the rate of uptake is reduced to about one third, which shows that coronin contributes to the efficiency of phagocytosis to about the same extent as it improves the speed of cell locomotion.			MANIAK, M (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.			Maniak, Markus/0000-0001-6442-5372				ASHWORTH JM, 1970, BIOCHEM J, V119, P175, DOI 10.1042/bj1190175; BOF M, 1992, J CELL SCI, V101, P139; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1986, J CELL SCI, V86, P69; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FURUKAWA R, 1994, CELL MOTIL CYTOSKEL, V29, P46, DOI 10.1002/cm.970290105; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gerisch G., 1960, Roux Archiv fuer Entwicklungsmechanik Organismen, V152, P632; GERISCH G, 1964, ENCY CINEMATOGRAPHIC, P237; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HANAICHI T, 1986, J ELECTRON MICROSC, V35, P304; HANAKAM F, 1995, J BIOL CHEM, V270, P596, DOI 10.1074/jbc.270.2.596; HARWOOD AJ, 1990, NUCLEIC ACIDS RES, V18, P4292, DOI 10.1093/nar/18.14.4292; Hed J, 1986, Methods Enzymol, V132, P198; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HUMBEL BM, 1992, SCANNING MICROSCOPY, V6, P817; JAY PY, 1992, NATURE, V356, P438, DOI 10.1038/356438a0; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; PETERSON MD, 1994, J EUKARYOT MICROBIOL, V41, P852; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHLEICHER M, 1988, J CELL SCI, V90, P59; Segall JE, 1989, CURR OPIN CELL BIOL, V1, P44, DOI 10.1016/S0955-0674(89)80035-3; STEMPAK JG, 1964, J CELL BIOL, V22, P697, DOI 10.1083/jcb.22.3.697; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; VOSSKUHLER C, 1993, J EUKARYOT MICROBIOL, V40, P556; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	42	313	320	0	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					915	924		10.1016/0092-8674(95)90207-4	http://dx.doi.org/10.1016/0092-8674(95)90207-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521515	Bronze			2022-12-01	WOS:A1995TK74500010
J	SUNDARAM, M; HAN, M				SUNDARAM, M; HAN, M			THE C-ELEGANS KSR-1 GENE ENCODES A NOVEL RAF-RELATED KINASE INVOLVED IN RAS-MEDIATED SIGNAL-TRANSDUCTION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VULVAL CELL LINEAGES; PROTEIN; INDUCTION; LET-60; IDENTIFICATION; MUTANTS; FATES; PHOSPHORYLATION; EXPRESSION	Vulval induction in C. elegans is controlled by a highly conserved signaling pathway similar to the RTK-Ras-MAPK cascade in mammals. By screening for suppressors of the Multivulva phenotype caused by an activated let-60 ras allele, we isolated mutations in a gene, ksr-1, that acts as a positive modifier of vulval induction and is required for at least two other let-60 ras-mediated processes. Although ksr-1 mutations do not perturb vulval induction in an otherwise wild-type background, they have very strong effects on vulval induction in genetic backgrounds where Ras pathway activity is constitutively activated or compromised, suggesting that ksr-1 activity is required for maximal stimulation of vulval fates by the Ras pathway. Genetic epistasis analysis suggests that ksr-1 acts downstream of or in parallel to let-60 ras. We cloned ksr-1 and have shown that it encodes a novel putative protein kinase related to the Raf family of Ser/Thr kinases.			SUNDARAM, M (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.			Sundaram, Meera/0000-0002-2940-8750	NIGMS NIH HHS [R01 GM47869] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047869] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BEITEL G, 1996, IN PRESS GENES DEV; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; COX GN, 1980, GENETICS, V95, P317; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HODGKIN J, 1979, GENETICS, V91, P67; HOSONO R, 1982, J EXP ZOOL, V224, P135, DOI 10.1002/jez.1402240203; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENEELY PM, 1984, GENETICS, V106, P29; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742	72	241	262	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					889	901		10.1016/0092-8674(95)90205-8	http://dx.doi.org/10.1016/0092-8674(95)90205-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521513	Bronze			2022-12-01	WOS:A1995TK74500008
J	VANESSEN, D; KIKUTANI, H; GRAY, D				VANESSEN, D; KIKUTANI, H; GRAY, D			CD40 LIGAND-TRANSDUCED CO-STIMULATION OF T-CELLS IN THE DEVELOPMENT OF HELPER FUNCTION	NATURE			English	Article							X-LINKED IMMUNODEFICIENCY; HYPER-IGM; B-CELLS; MONOCLONAL-ANTIBODIES; DEFECTIVE EXPRESSION; B7/BB1; SIGNAL	MICE that lack either CD40(1,2) (expressed on B cells) or CD40 ligand(3,4) (expressed on activated T cells) are able neither to make IgG, IgA or IgE antibody responses, nor to generate germinal centres (the sites of formation of memory B cells), It has been assumed that these lesions were the result of an absence of signals to B cells through CD40. Here we show that the failure to signal T cells through CD40 ligand is an important contributory cause. Administration of soluble CD40 in vivo to CD40 knockout mice, restoring the missing signal through CD40 ligand, initiates germinal centre formation, Furthermore, T cells primed in the absence of CD40 (in CD40 knockout mice) are unable to help normal B cells to class switch or to form germinal centres (GC). These results indicate that cc-stimulation of T cells through CD40 ligand causes their differentiation into cells that help B cells to make mature antibody responses and to generate memory populations.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,DIV IMMUNOL,OSAKA 565,JAPAN	Imperial College London; Osaka University			Kikutani, Hitoshi/C-9525-2009; Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934; van Essen, Dominic/0000-0002-7225-1138				ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BUHLMANN JE, 1995, IMMUNITY, V2, P645; CATIGLI E, 1994, P NATL ACAD SCI USA, V9, P12135; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; Gray D, 1994, Semin Immunol, V6, P303, DOI 10.1006/smim.1994.1039; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; GRAY D, 1986, EUR J IMMUNOL, V16, P641, DOI 10.1002/eji.1830160609; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOSCO MH, 1992, J IMMUNOL, V148, P2331; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	369	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					620	623		10.1038/378620a0	http://dx.doi.org/10.1038/378620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524396				2022-12-01	WOS:A1995TJ22100078
J	ETEMADMOGHADAM, B; GUO, S; KEMPHUES, KJ				ETEMADMOGHADAM, B; GUO, S; KEMPHUES, KJ			ASYMMETRICALLY DISTRIBUTED PAR-3 PROTEIN CONTRIBUTES TO CELL POLARITY AND SPINDLE ALIGNMENT IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CYTOPLASMIC LOCALIZATION; SPLICED LEADER; GENE; EMBRYOGENESIS; MICROFILAMENTS; SEGREGATION; MUTATIONS; YEAST; ESTABLISHMENT	The par-3 gene is required for establishing polarity in early C. elegans embryos. Embryos from par-3 homozygous mothers show defects in segregation of cytoplasmic determinants and in positioning of the early cleavage spindles. We report here that the PAR-3 protein is asymmetrically distributed at the periphery of the zygote and asymmetrically dividing blastomeres of the germline lineage. The PAR-3 distribution is roughly the reciprocal of PAR-1, another protein required-for establishing embryonic polarity in C. elegans. Analysis of the distribution of PAR-3 and PAR-1 in other par mutants reveals that par-2 activity is required for proper localization of PAR-3 and that PAR-3 is required for proper localization of PAR-1. In addition, the distribution of the PAR-3 protein correlates with differences in cleavage spindle orientation and suggests a mechanism by which PAR-3 contributes to control of cleavage pattern.			ETEMADMOGHADAM, B (corresponding author), CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27689] Funding Source: Medline; NIGMS NIH HHS [GM07617] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENG NN, 1995, GENETICS, V139, P549; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; GOODNER B, 1993, PLANT CELL, V5, P1471; GUETHHALLONET C, 1992, TRENDS GENET, V8, P274, DOI 10.1016/0168-9525(92)90253-Z; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HOLY J, 1991, J CELL SCI, V98, P423; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KEMPHUES KJ, 1989, FRONTIERS MOL BIOL G; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MAINS PE, 1990, GENETICS, V126, P593; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORTON DG, 1992, GENETICS, V130, P771; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; Nigon V., 1960, B BIOL FR BELG, V94, P132; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIESS JR, 1994, CURR OPIN GENET DEV, V4, P563, DOI 10.1016/0959-437X(94)90073-C; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; ROSE LS, 1995, DEV BIOL, V168, P479, DOI 10.1006/dbio.1995.1096; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Schierenberg E., 1992, Seminars in Developmental Biology, V3, P25; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WADDLE JA, 1994, DEVELOPMENT, V120, P2317; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1	49	327	341	0	28	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					743	752		10.1016/0092-8674(95)90187-6	http://dx.doi.org/10.1016/0092-8674(95)90187-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521491	hybrid			2022-12-01	WOS:A1995TH94800011
J	POLYAKOV, A; SEVERINOVA, E; DARST, SA				POLYAKOV, A; SEVERINOVA, E; DARST, SA			3-DIMENSIONAL STRUCTURE OF ESCHERICHIA-COLI CORE RNA-POLYMERASE - PROMOTER-BINDING AND ELONGATION CONFORMATIONS OF THE ENZYME	CELL			English	Article							LAC UV5 PROMOTER; OPEN COMPLEX-FORMATION; LAMBDA-PR PROMOTER; RIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; DUPLEX DNA	The structure of E, coli core RNA polymerase (RNAP) has been determined to similar to 23 Angstrom resolution by three-dimensional reconstruction from electron micrographs of flattened helical crystals. The structure reveals extensive conformational changes when compared with the previously determined E. coli RNAP holoenzyme structure, but resembles the yeast RNAPII structure, While each of these structures contains a thumb-like projection surrounding a channel 25 Angstrom in diameter, the E. coli RNAP holoenzyme thumb defines a deep but open groove on the molecule, whereas the thumb of E. coli core and yeast RNAPII form part of a ring that surrounds the channel. This may define promoter-binding and elongation conformations of RNAP, as E. coli holoenzyme recognizes promoter sites on double-stranded DNA, while both E. coli core and yeast RNAPII are elongating forms of the polymerase and ate incapable of promoter recognition.			POLYAKOV, A (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALYAR SE, 1994, J BIOL CHEM, V269, P13179; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BONNER G, 1994, J BIOL CHEM, V269, P25129; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAMBERLIN MJ, 1993, HARVEY LECT, V88, P1; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)90823-O; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hessler D, 1992, Neuroimage, V1, P55, DOI 10.1016/1053-8119(92)90007-A; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KENSLER RW, 1982, J MUSCLE RES CELL M, V3, P349, DOI 10.1007/BF00713042; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg RD, 1991, CURR OPIN STRUC BIOL, V1, P642, DOI 10.1016/S0959-440X(05)80090-9; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NEFF NF, 1980, BIOCHEMISTRY-US, V19, P3005, DOI 10.1021/bi00554a027; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PARK CS, 1982, J BIOL CHEM, V257, P6950; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROSENBERG S, 1982, J MOL BIOL, V155, P31, DOI 10.1016/0022-2836(82)90490-9; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WELLINGTON SR, 1991, BIOCHEM BIOPH RES CO, V179, P1107, DOI 10.1016/0006-291X(91)91934-5; WU FYH, 1976, BIOCHEMISTRY-US, V15, P3254, DOI 10.1021/bi00660a014; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	77	157	159	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					365	373		10.1016/0092-8674(95)90114-0	http://dx.doi.org/10.1016/0092-8674(95)90114-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521466	Bronze			2022-12-01	WOS:A1995TC97700006
J	VERSCHUEREN, KHG; SELJEE, F; ROZEBOOM, HJ; KALK, KH; DIJKSTRA, BW				VERSCHUEREN, KHG; SELJEE, F; ROZEBOOM, HJ; KALK, KH; DIJKSTRA, BW			CRYSTALLOGRAPHIC ANALYSIS OF THE CATALYTIC MECHANISM OF HALOALKANE DEHALOGENASE	NATURE			English	Article							XANTHOBACTER-AUTOTROPHICUS GJ10; ALPHA-HELIX DIPOLE; X-RAY-DIFFRACTION; HALOGENATED ALKANES; ENZYME INTERMEDIATE; SERINE PROTEINASE; CRYSTAL; ACETYLCHOLINESTERASE; PURIFICATION; DEGRADATION	Crystal structures of haloalkane dehalogenase were determined in the presence of the substrate 1,2-dichloroethane. At pH 5 and 4-degrees-C, substrate is bound in the active site without being converted; warming to room temperature causes the substrate's carbon-chlorine bond to be broken, producing a chloride ion with concomitant alkylation of the active-site residue Asp124. At pH 6 and room temperature the alkylated enzyme is hydrolysed by a water molecule activated by the His289-Asp260 pair in the active site. These results show that catalysis by the dehalogenase proceeds by a two-step mechanism involving an ester intermediate covalently bound at Asp124.	UNIV GRONINGEN,BIOSON RES INST,NIJENBORGH 4,9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,BIOPHYS CHEM LAB,9747 AG GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477				DOUGLAS KT, 1976, J AM CHEM SOC, V98, P8231, DOI 10.1021/ja00441a057; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FROEDE HC, 1984, J BIOL CHEM, V259, P1010; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; HAMILTON WC, 1965, ACTA CRYSTALLOGR, V18, P129, DOI 10.1107/S0365110X65000233; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JANSSEN DB, 1988, EUR J BIOCHEM, V171, P67, DOI 10.1111/j.1432-1033.1988.tb13759.x; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEUNING S, 1985, J BACTERIOL, V163, P635, DOI 10.1128/JB.163.2.635-639.1985; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROZEBOOM HJ, 1988, J MOL BIOL, V200, P611, DOI 10.1016/0022-2836(88)90548-7; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VERSCHUEREN KHG, IN PRESS J MOL BIOL	27	412	417	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					693	698		10.1038/363693a0	http://dx.doi.org/10.1038/363693a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515812	Green Submitted			2022-12-01	WOS:A1993LJ33900047
J	VANHAM, SM; VANALPHEN, L; MOOI, FR; VANPUTTEN, JPM				VANHAM, SM; VANALPHEN, L; MOOI, FR; VANPUTTEN, JPM			PHASE VARIATION OF HAEMOPHILUS-INFLUENZAE FIMBRIAE - TRANSCRIPTIONAL CONTROL OF 2 DIVERGENT GENES THROUGH A VARIABLE COMBINED PROMOTER REGION	CELL			English	Article							NONTYPABLE HAEMOPHILUS-INFLUENZAE; OROPHARYNGEAL EPITHELIAL-CELLS; HEMOPHILUS-INFLUENZAE; ESCHERICHIA-COLI; PILIN GENE; RNA-POLYMERASE; MESSENGER-RNA; FRAMESHIFT MUTATION; ANTIGENIC VARIATION; HUMAN-ERYTHROCYTES	The expression of H. influenzae fimbriae is subject to reversible phase variation between three expression levels. This phenomenon is controlled at the transcriptional level of two divergently orientated genes, hifA and hifB, encoding the major fimbrial subunit and the fimbrial chaperone, respectively. The hifA and hifB promoter regions were found to be clustered through an almost complete divergent overlap with a variable DNA backbone of repetitive TA units. Variation in the number of units changes the normally strictly constrained spacing between the -35 and -10 sequences and controls the bidirectional transcription initiation, thus forming a novel mechanism directing multiple gene transcription.	UNIV AMSTERDAM,DEPT MED MICROBIOL,1105 AZ AMSTERDAM,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS	University of Amsterdam; Netherlands National Institute for Public Health & the Environment	VANHAM, SM (corresponding author), MAX PLANCK INST BIOL,INFEKT BIOL ABT,SPEMANNSTR 34,W-7400 TUBINGEN,GERMANY.			van Putten, Jos/0000-0002-4126-8172				ARMES LG, 1990, J PROTEIN CHEM, V9, P45, DOI 10.1007/BF01024983; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; BAKKER D, 1991, MOL MICROBIOL, V5, P875, DOI 10.1111/j.1365-2958.1991.tb00761.x; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRINTON CC, 1989, PEDIATR INFECT DIS J, V8, pS54; COLEMAN T, 1991, INFECT IMMUN, V59, P1716, DOI 10.1128/IAI.59.5.1716-1722.1991; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; EISENSTEIN BI, 1981, SCIENCE, V214, P337, DOI 10.1126/science.6116279; FARLEY MM, 1990, J INFECT DIS, V161, P274, DOI 10.1093/infdis/161.2.274; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILSDORF JR, 1990, INFECT IMMUN, V58, P1065, DOI 10.1128/IAI.58.4.1065-1072.1990; GUERINA NG, 1982, J INFECT DIS, V146, P564, DOI 10.1093/infdis/146.4.564; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KAR S, 1990, INFECT IMMUN, V58, P903, DOI 10.1128/IAI.58.4.903-908.1990; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LANGERMANN S, 1990, MOL MICROBIOL, V4, P221, DOI 10.1111/j.1365-2958.1990.tb00589.x; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MANDECKI W, 1982, NUCLEIC ACIDS RES, V10, P903, DOI 10.1093/nar/10.3.903; MASON EO, 1985, INFECT IMMUN, V49, P98, DOI 10.1128/IAI.49.1.98-103.1985; MEYER TF, 1990, ANNU REV MICROBIOL, V44, P451; MOOI FR, 1983, J BACTERIOL, V154, P41, DOI 10.1128/JB.154.1.41-49.1983; NIEUWKOOP AJ, 1984, J BACTERIOL, V159, P934, DOI 10.1128/JB.159.3.934-939.1984; PETERSEN C, 1992, MOL MICROBIOL, V6, P277, DOI 10.1111/j.1365-2958.1992.tb01469.x; PETERSEN C, 1991, J BACTERIOL, V173, P2167, DOI 10.1128/JB.173.7.2167-2172.1991; PETERSON ML, 1985, J MOL BIOL, V185, P525, DOI 10.1016/0022-2836(85)90069-5; PICHICHERO ME, 1982, LANCET, V2, P960; READ RC, 1991, J INFECT DIS, V163, P549, DOI 10.1093/infdis/163.3.549; REZNIKOFF WS, 1986, RNA POLYM REGULATION, P105; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SMITH HO, 1981, ANNU REV BIOCHEM, V50, P41, DOI 10.1146/annurev.bi.50.070181.000353; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; STREISINGER G, 1985, GENETICS, V109, P633; TRAVERS AA, 1983, CELL, V35, P265, DOI 10.1016/0092-8674(83)90229-5; TURK DC, 1985, J MED MICROBIOL, V18, P1; VANALPHEN L, 1991, INFECT IMMUN, V59, P4473, DOI 10.1128/IAI.59.12.4473-4477.1991; VANALPHEN L, 1986, FEMS MICROBIOL LETT, V37, P69, DOI 10.1016/0378-1097(86)90218-1; VANALPHEN L, 1983, J INFECT DIS, V148, P75, DOI 10.1093/infdis/148.1.75; VANALPHEN L, 1988, INFECT IMMUN, V56, P1800, DOI 10.1128/IAI.56.7.1800-1806.1988; VANHAM SM, 1989, EMBO J, V8, P3535, DOI 10.1002/j.1460-2075.1989.tb08519.x; WEBER A, 1991, INFECT IMMUN, V59, P4724, DOI 10.1128/IAI.59.12.4724-4728.1991; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; WILLEMS R, 1990, EMBO J, V9, P2803, DOI 10.1002/j.1460-2075.1990.tb07468.x; YOGEV D, 1991, EMBO J, V10, P4069, DOI 10.1002/j.1460-2075.1991.tb04983.x	54	144	146	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1187	1196		10.1016/0092-8674(93)90647-9	http://dx.doi.org/10.1016/0092-8674(93)90647-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513502				2022-12-01	WOS:A1993LH54800014
J	DETOLEDO, GA; FERNANDEZCHACON, R; FERNANDEZ, JM				DETOLEDO, GA; FERNANDEZCHACON, R; FERNANDEZ, JM			RELEASE OF SECRETORY PRODUCTS DURING TRANSIENT VESICLE FUSION	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; MOUSE MAST-CELLS; CAPACITANCE MEASUREMENTS; CHROMAFFIN CELLS; EXOCYTOSIS; GRANULES; VOLTAMMETRY; INVITRO; MATRIX; PORE	PATCH-CLAMP experiments have shown that fusion of secretory granules with the plasma membrane does not always occur as an all-or-none event, but can develop slowly in a fluctuating manner or can be transient1-5. These observations suggested that release could be detected during such incomplete fusion events. To test this hypothesis we have combined patch-clamp measurements of the activity of single exocytotic fusion pores in beige mouse mast cells with the electrochemical detection of serotonin released during the exocytotic events. We report here that on fusion pore opening there is a small release of serotonin which is directly proportional to the pore conductance. We also show that a significant release occurs during transient fusion events. These results demonstrate, to our knowledge for the first time, release of a neurotransmitter from a secretory vesicle that did not undergo complete fusion.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic	DETOLEDO, GA (corresponding author), UNIV SEVILLA,FAC MED,DEPT FISIOL MED & BIOFIS,AVDA SANCHEZ PIZJUAN 4,E-41009 SEVILLE,SPAIN.		Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015; Alvarez de Toledo, Guillermo/I-2888-2015	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Fernandez-Chacon, Rafael/0000-0002-9845-9885				ALMERS W, 1989, SECRETION ITS CONTRO, P269; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; DETOLEDO GA, 1988, CELL PHYSL BLOOD, P333; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERNANDEZ-CHACO R, 1992, Biophysical Journal, V61, pA226; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heuser JE, 1977, HDB PHYSL, VI, P261; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LUDOWYKE RI, 1986, BIOCHEMISTRY-US, V25, P6287, DOI 10.1021/bi00368a068; MILLAR J, 1990, J ELECTROANAL CHEM, V282, P33, DOI 10.1016/0022-0728(91)85088-7; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RABENSTEIN DL, 1987, BIOCHEMISTRY-US, V26, P6923, DOI 10.1021/bi00396a010; TATHAM PER, 1991, PFLUG ARCH EUR J PHY, V419, P409, DOI 10.1007/BF00371124; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	21	491	491	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					554	558		10.1038/363554a0	http://dx.doi.org/10.1038/363554a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8505984				2022-12-01	WOS:A1993LF93900054
J	WOODWARD, MN; GRIFFITHS, DM				WOODWARD, MN; GRIFFITHS, DM			USE OF DIPSTICKS FOR ROUTINE ANALYSIS OF URINE FROM CHILDREN WITH ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTION		SOUTHAMPTON GEN HOSP,WESSEX REG CTR PAEDIAT SURG,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; LEJEUNE B, 1991, J CLIN PATHOL, V44, P1029, DOI 10.1136/jcp.44.12.1029; SHAW KN, 1991, J PEDIATR-US, V118, P733, DOI 10.1016/S0022-3476(05)80035-6; STEVENS M, 1989, MED LAB SCI, V46, P194; WIGGELINKHUIZEN J, 1988, S AFR MED J, V74, P224	5	25	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1512	1512		10.1136/bmj.306.6891.1512	http://dx.doi.org/10.1136/bmj.306.6891.1512			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8518679	Green Published, Bronze			2022-12-01	WOS:A1993LF94000025
J	RUOHOLABAKER, H; GRELL, E; CHOU, TB; BAKER, D; JAN, LY; JAN, YN				RUOHOLABAKER, H; GRELL, E; CHOU, TB; BAKER, D; JAN, LY; JAN, YN			SPATIALLY LOCALIZED RHOMBOID IS REQUIRED FOR ESTABLISHMENT OF THE DORSAL-VENTRAL AXIS IN DROSOPHILA OOGENESIS	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; PATTERN-FORMATION; DORSOVENTRAL PATTERN; CELL FATE; TRANSMEMBRANE PROTEIN; EMBRYONIC POLARITY; NEUROGENIC GENES; SERINE PROTEASE; NERVOUS-SYSTEM	The establishment of dorsal-ventral asymmetry of the Drosophila embryo requires a group of genes that act maternally. None of the previously identified dorsal-ventral axis genes are known to produce asymmetrically localized gene products during oogenesis. We show that rhomboid (rho), a novel member of this group, encodes a protein that is localized on the apical surface of the dorsal-anterior follicle cells surrounding the oocyte. Loss of rho function causes ventralization of the eggshell and the embryo, whereas ectopic expression leads to dorsalization of both structures. Thus, spatially restricted rho is necessary and sufficient for dorsal-ventral axis formation. We propose, based on these observations and double mutant experiments, that the spatially restricted rho protein leads to selective activation of the epidermal growth factor receptor in the dorsal follicle cells and subsequently the specification of the dorsal follicle cells.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	RUOHOLABAKER, H (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012; Chou, Tze-Bin/S-1188-2017	Baker, David/0000-0001-7896-6217; Chou, Tze-Bin/0000-0003-2453-0164; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P140; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CLIFFORD RJ, 1989, GENETICS, V123, P771; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FREEMAN M, 1992, DEVELOPMENT, V116, P335; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; King RC., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; PROST E, 1988, GENE DEV, V2, P891, DOI 10.1101/gad.2.7.891; RAY RP, 1991, DEVELOPMENT, V113, P35; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHUPBACH T, 1991, CELL CELL INTERACTIO, P1163; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRADLING A, 1992, DROSOPHILA DEV, P1; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; Wieschaus E., 1986, P199; WIESCHAUS E, 1979, CELL LINEAGE STEM CE, P291; ZAK NB, 1990, DEVELOPMENT, V109, P865	58	137	138	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					953	965		10.1016/0092-8674(93)90273-S	http://dx.doi.org/10.1016/0092-8674(93)90273-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500182	Bronze			2022-12-01	WOS:A1993LF06100011
J	WANG, CY; PETRYNIAK, B; THOMPSON, CB; KAELIN, WG; LEIDEN, JM				WANG, CY; PETRYNIAK, B; THOMPSON, CB; KAELIN, WG; LEIDEN, JM			REGULATION OF THE ETS-RELATED TRANSCRIPTION FACTOR ELF-1 BY BINDING TO THE RETINOBLASTOMA PROTEIN	SCIENCE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; LONG TERMINAL REPEAT; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; DNA-BINDING; LEUKEMIA-VIRUS; FACTOR E2F; SEQUENCE	The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NIAID NIH HHS [R01 AI29673-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029673] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HORWITZ JM, 1989, SCIENCE, V243, P937; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Wang C.-W., UNPUB; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	52	206	212	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1330	1335		10.1126/science.8493578	http://dx.doi.org/10.1126/science.8493578			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493578				2022-12-01	WOS:A1993LE02500045
J	HARPER, PS				HARPER, PS			RESEARCH SAMPLES FROM FAMILIES WITH GENETIC-DISEASES - A PROPOSED CODE OF CONDUCT	BRITISH MEDICAL JOURNAL			English	Article							HUNTINGTONS-DISEASE; DIAGNOSIS	Research on samples from families with genetic disease underlies many of the major advances that are occurring in medical genetics. But ethical and practical problems may arise when samples from relatives who are healthy but at risk are included in such studies. In particular, new molecular tests for specific gene mutations may result in the detection of a genetic defect in relatives who had neither expected this possibility nor given specific consent to such testing. Family members at risk should not be included in such studies unless strictly necessary, and in such cases specific consent should be obtained and information should be given about the implications of an abnormal result of a test. This is particularly important when stored samples from previous studies without such implications are being reused and is also relevant to the genetic testing of samples taken primarily for epidemiological studies of disorders when only a small proportion of cases is thought to be genetic in origin. There is a need for guidelines to protect both subjects and investigators in a field which is spreading rapidly and involving many clinical and laboratory research workers previously unfamiliar with genetic testing.			HARPER, PS (corresponding author), UNIV WALES COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							[Anonymous], 1989, REV GUIDANCE RES USE; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; FIRTH MA, 1983, BRIT MED J, V286, P700, DOI 10.1136/bmj.286.6366.700; HARPER PS, 1992, J ROY COLL PHYS LOND, V26, P184; MORRIS MJ, 1989, LANCET, V2, P601; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YATES JRW, 1989, J MED GENET, V26, P245, DOI 10.1136/jmg.26.4.245; 1992, RESPONSIBILITY INVES; 1984, COMMITTEE INQUIRY HU; 1992, BIBLIO ETHICAL LEGAL; 1991, ETHICAL ISSUES CLIN; 1992, COMMITTEE ETHICS GEN	14	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1993	306	6889					1391	1394		10.1136/bmj.306.6889.1391	http://dx.doi.org/10.1136/bmj.306.6889.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD829	8518608	Bronze, Green Published			2022-12-01	WOS:A1993LD82900025
J	MORTONJONES, TJ; PRINGLE, MAL				MORTONJONES, TJ; PRINGLE, MAL			PRESCRIBING COSTS IN DISPENSING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine differences in prescribing between dispensing and non-dispensing practices. Setting-The 108 practices covered by Lincolnshire Family Health Services Authority. Design-Analysis of prescribing data for 1990-1 from PD2 reports from the Prescription Pricing Authority in relation to data on practice characteristics obtained from Lincolnshire Family Health Services Authority; and aggregated level 3 prescribing and cost information (PACT data) for 10 selected drugs from the Prescription Pricing Authority to examine amounts prescribed. Main outcome measures-Prescribing cost per patient, items per patient, and cost per item in dispensing and non-dispensing practices. Results-Dispensing practices had higher prescribing costs per patient than non-dispensing practices. This difference held for non-dispensing patients within dispensing practices. Structural features failed to explain the differences in prescribing cost, except for the higher numbers of elderly patients in dispensing practices (which explained 13% of the difference) and the number of partners (5%). The main determinant of the difference was the lower use of generic drugs in dispensing practices (84%). Dispensing patients were prescribed lower quantities of drugs on average for each item. Conclusions-Dispensing practices could reduce their prescribing expenditure to that of non-dispensing practices by increasing their prescribing of generic drugs. The shorter prescribing intervals for dispensing patients may be due to dispensing fees being related to the number of prescribed items.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; DYER C, 1988, BRIT MED J, V296, P735; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GEDDES GL, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1990, ANAL PRESCRIBING GEN; JENNINGS SJ, 1988, BRIT MED J, V296, P936, DOI 10.1136/bmj.296.6626.936-h; MORTONJONES AJ, 1992, BRIT MED J, V305, P478, DOI 10.1136/bmj.305.6851.478-a; MORTONJONES AJ, IN PRESS BMJ; ROBERTS D, 1992, BRIT MED J, V305, P187, DOI 10.1136/bmj.305.6846.187-c; 1991, 1990 1991 PRESCR PRI, P8; 1991, HLTH SERVICES INDICA	12	37	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1993	306	6887					1244	1246		10.1136/bmj.306.6887.1244	http://dx.doi.org/10.1136/bmj.306.6887.1244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	8499855	Bronze, Green Published			2022-12-01	WOS:A1993LB80400019
J	Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ				Sanchez, Y; Desany, BA; Jones, WJ; Liu, QH; Wang, B; Elledge, SJ			Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; GENE; IDENTIFICATION; THREONINE; TYROSINE; PROTEINS; FAMILIES; ENCODES	Mutants of the Saccharomyces cerevisiae ataxia telangiectasia mutated (ATM) homolog MEC1/SAD3/ESR1 were identified that could live only if the RAD53/SAD1 checkpoint kinase was overproduced. MEC1 and a structurally related gene, TEL1, have overlapping functions in response to DNA damage and replication blocks that in mutants can be provided by overproduction of RAD53. Both MEC1 and TEL1 were found to control phosphorylation of Rad53p in response to DNA damage. These results indicate that RAD53 is a signal transducer in the DNA damage and replication checkpoint pathways and functions downstream of two members of the ATM lipid kinase family. Because several members of this pathway are conserved among eukaryotes, it is likely that a RAD53-related kinase will function downstream of the human ATM gene product and play an important role in the mammalian response to DNA damage.	BAYLOR COLL MED, HOWARD HUGHES MED INST, DEPT MOLEC & HUMAN GENET, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07696] Funding Source: Medline; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Allen JB, 1994, GENE DEV, V8, P2416; BENTLEY N, COMMUNICATION; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DESANY B, UNPUB; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GIETZ RD, 1994, MOL GENETICS YEAST P, pCH8; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MOORE CW, 1978, MUTAT RES, V51, P165, DOI 10.1016/S0027-5107(78)80016-5; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASIM A, 1977, CAN J GENET CYTOL, V19, P323, DOI 10.1139/g77-035; NASR F, 1994, CR ACAD SCI III-VIE, V317, P607; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; STACK JH, 1994, J BIOL CHEM, V269, P31552; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	36	538	549	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	1996	271	5247					357	360		10.1126/science.271.5247.357	http://dx.doi.org/10.1126/science.271.5247.357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ528	8553072				2022-12-01	WOS:A1996TQ52800043
J	Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE				Celermajer, DS; Adams, MR; Clarkson, P; Robinson, J; McCredie, R; Donald, A; Deanfield, JE			Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; RISK; ATHEROSCLEROSIS; CHILDREN; CHOLESTEROL; LIPOPROTEIN; RABBITS; SMOKERS; INVIVO	Background. Passive smoking has been linked to an increased risk of dying from atherosclerotic heart disease. Since endothelial dysfunction is an early feature of atherogenesis and occurs in young adults who actively smoke cigarettes, we hypothesized that passive smoking might also be associated with endothelial damage in healthy young-adult nonsmokers. Methods. We studied 78 healthy subjects (39 male and 39 female) 15 to 30 years of age (mean +/-SD, 22+/-4): 26 control subjects who had never smoked or had regular exposure to environmental tobacco smoke, 26 who had never smoked but had been exposed to environmental tobacco smoke for at least one hour dally for three or more years, and 26 active smokers. Using ultrasonography, we measured the brachial-artery diameter under base-line conditions, during reactive hyperemia (with flow increase causing endothelium-dependent dilatation), and after sublingual administration of nitroglycerin (an endothelium-independent dilater). Results. Flow-mediated dilatation was observed in all control subjects (8.2+/-3.1 percent; range, 2.1 to 16.7) but was significantly impaired in the passive smokers (3.1+/-2.7 percent; range, 0 to 9; P<0.001 for the comparison with the controls) and in the active smokers (4.4+/-3.1 percent; range, 0 to 10; P<0.001 for the comparison with the controls; P=0.48 for the comparison with the passive smokers). In the passive smokers, there was an inverse relation between the intensity of exposure to tobacco smoke and flow-mediated dilatation (r=-0.67, P<0.001). In contrast, dilatation induced by nitroglycerin was similar in all groups. Conclusions. Passive smoking is associated with dose-related impairment of endothelium-dependent dilatation in healthy young adults, suggesting early arterial damage.	HEART RES INST, SYDNEY, NSW, AUSTRALIA; HOSP SICK CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND	University of Sydney; Heart Research Institute; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Celermajer, DS (corresponding author), ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA.		Deanfield, John E/C-5178-2008	Robinson, Jacqui/0000-0001-6671-5437; Deanfield, John/0000-0001-8806-6052				ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BROWN RE, 1993, CIRCULATION, V88, P260; BURGHUBER OC, 1986, CHEST, V90, P34, DOI 10.1378/chest.90.1.34; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHAUVEAU M, 1985, CARDIOVASC RES, V19, P700, DOI 10.1093/cvr/19.11.700; COLLEY JRT, 1974, LANCET, V2, P1031; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; DAVIS JW, 1990, J VASC MED BIOL, V2, P289; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FELDMAN J, 1991, PEDIATRICS, V88, P259; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HOGG RV, 1978, INTRO MATH STATISTIC; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; JENDRYCZKO A, 1993, NEOPLASMA, V40, P199; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LIEBERMAN EH, 1994, CIRCULATION, V90, P138; MOORE S, 1973, LAB INVEST, V29, P478; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RAIJ L, 1994, CIRCULATION, V90, P575; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; SORENSEN KE, 1995, BRIT HEART J, V74, P247; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; SUN YP, 1994, CIRCULATION, V90, P459; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; TEIRSTEIN PS, 1993, J AM COLL CARDIOL, V21, P590, DOI 10.1016/0735-1097(93)90089-J; WELLS AJ, 1988, ENVIRON INT, V14, P249; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I; 1983, DHHS PHS8450204 PUBL	40	754	785	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					150	154		10.1056/NEJM199601183340303	http://dx.doi.org/10.1056/NEJM199601183340303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531969				2022-12-01	WOS:A1996TQ01700003
J	Scragg, RKR; Mitchell, EA; Stewart, AW; Ford, RPK; Taylor, BJ; Hassall, IB; Williams, SM; Thompson, JMD				Scragg, RKR; Mitchell, EA; Stewart, AW; Ford, RPK; Taylor, BJ; Hassall, IB; Williams, SM; Thompson, JMD			Infant room-sharing and prone sleep position in sudden infant death syndrome	LANCET			English	Article							HONG-KONG	Background There is evidence that the risk of sudden infant death syndrome is lower among ethnic groups in which parents generally share a room with the infant for sleeping. We investigated whether the presence of other family members in the infant's sleeping room affects the risk of the sudden infant death syndrome. Methods The case-control study covered a region with 78% of all births in New Zealand during 1987-90. Home interviews were completed with parents of 393 (81.0% of total) babies who died from the sudden infant death syndrome aged 28 days to 1 year and 1592 (88.4% of total) controls, selected from all hospital births in the study region. Findings The relative risk of sudden infant death for sharing the room with one or more adults compared with not sharing was 0.19 (95% Cl 0.08-0.45) for sharing at night during the last 2 weeks and 0.27 (0.17-0.41) for sharing in the last sleep, after control for other confounders. Sharing the room with one or more children did not affect the relative risk (1.25 [0.86-1.82] for sharing during last 2 weeks; 1.29 [0.85-1.94] for sharing in last sleep). There was a significant interaction (p=0.033) between not sharing the room with an adult and prone sleep position in the last sleep. Compared with infants sharing the room with an adult and not prone, the multivariate relative risk was 16.99 (10.43-27.69) for infants not sharing with an adult and prone, 3.28 (2.06-5.23) for infants sharing the room and prone, and 2.60 (1.58-4.30) for infants not sharing the room and not prone. The interaction between adult room-sharing and prone sleep position suggests that both exposures may affect the risk of sudden infant death syndrome through a common mechanism. Interpretation We recommend that infants sleep in the same bedroom as their parents at night to reduce the risk of sudden infant death syndrome.	UNIV AUCKLAND, DEPT PAEDIAT, AUCKLAND, NEW ZEALAND; UNIV OTAGO, DEPT PAEDIAT & CHILD HLTH, DUNEDIN, NEW ZEALAND; UNIV OTAGO, DEPT PREVENT & SOCIAL MED, DUNEDIN, NEW ZEALAND; HEALTHLINK S, COMMUNITY PAEDIAT UNIT, CHRISTCHURCH, NEW ZEALAND; INDEPENDENT CHILDRENS ADVOCATE, AUCKLAND, NEW ZEALAND	University of Auckland; University of Otago; University of Otago	Scragg, RKR (corresponding author), UNIV AUCKLAND, DEPT COMMUNITY HLTH, PRIVATE BAG 92019, AUCKLAND, NEW ZEALAND.		Taylor, Barry j/G-1410-2010; Williams, Sheila/L-4028-2019	Scragg, Robert/0000-0003-0013-2620; Taylor, Barry/0000-0002-6450-8677				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BEGG NC, 1970, NZ CHILD HIS FAMILY, P98; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DAVIES DP, 1985, LANCET, V2, P1346; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; Farooqi S, 1993, Paediatr Perinat Epidemiol, V7, P245; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KING FT, 1931, FEEDING CARE BABY, P64; Leach P., 1980, BABY CHILD, P93; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MALCOLM G, 1994, J PAEDIATR CHILD H, V30, P45, DOI 10.1111/j.1440-1754.1994.tb00565.x; McKenna J J, 1986, Med Anthropol, V10, P9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; Mitchell E. A., 1995, P266; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; Spock B, 1985, BABY CHILD CARE, P219; WILLIAMS SM, IN PRESS PAEDIATR PE	25	67	68	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					7	12		10.1016/S0140-6736(96)91554-8	http://dx.doi.org/10.1016/S0140-6736(96)91554-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531589	Bronze			2022-12-01	WOS:A1996TN76200009
J	Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ				Graeber, TG; Osmanian, C; Jacks, T; Housman, DE; Koch, CJ; Lowe, SW; Giaccia, AJ			Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours	NATURE			English	Article							CANCER; BCL-2; P53	APOPTOSIS is a genetically encoded programme of cell death that can be activated under physiological conditions(1,2) and may be an important safeguard against tumour development(3-6). Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours(7,8). Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as less of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; UNIV PENN,PHILADELPHIA,PA 19104; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Stanford University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Pennsylvania; Cold Spring Harbor Laboratory				Graeber, Thomas/0000-0001-8574-9181				BAKER SJ, 1990, CANCER RES, V50, P7717; BARDEESY N, 1995, CANCER RES, V55, P215; BECLI A, 1995, CANCER RES, V55, P1811; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOCKEL M, 1993, GYNECOL ONCOL, V51, P141, DOI 10.1006/gyno.1993.1262; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LORD EM, 1993, CANCER RES, V53, P5721; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, IN PRESS CURR OPIN O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SIRICROPE FA, 1995, CANCER RES, V55, P237; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaupel P., 1995, TUMOR OXYGENATION, P219; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	30	2051	2110	1	116	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					88	91		10.1038/379088a0	http://dx.doi.org/10.1038/379088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538748				2022-12-01	WOS:A1996TN21600062
J	Harris, MI				Harris, MI			Medical care for patients with diabetes - Epidemiologic aspects	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			UNITED-STATES; BLOOD-GLUCOSE; COMPLICATIONS TRIAL; MELLITUS; ADULTS; INTERVENTIONS; RELIABILITY; INFORMATION; PHYSICIANS; BEHAVIORS	Objective: To describe the epidemiologic characteristics of physician care and self-care for adults with diabetes in the U.S. population. Design and Subjects: Data are drawn from the 1989 National Health Interview Survey, in which a personal household interview was administered to a representative sample of U.S. adults aged 18 years or older. The response rate was 96% (n = 84 572). All subjects identified as having diabetes previously diagnosed by a physician were asked a series of questions about their diabetes. Response rate for this representative sample of U.S. diabetic patients was 95% (n = 2405). Measurements: Self-reported information was obtained about various aspects of diabetes care, including care by physicians and self-care practices of the diabetic persons. Sociodemographic and clinical factors that may influence diabetes care were also determined. Results: More than 90% of diabetic adults had one physician for the usual care of their diabetes, but 32% made fewer than four visits to this physician each year. Most physician visits by diabetic patients were not made to diabetes specialists, and the visit rate to other health care professionals such as ophthalmologists, podiatrists, and nutritionists was low. About half of insulin-treated diabetic subjects used multiple daily insulin injections; and 40% of patients with insulin-dependent diabetes mellitus, 26% of those with non-insulin-dependent diabetes mellitus (NIDDM) who were taking insulin, and 5% of those with NIDDM who were not taking insulin monitored their blood glucose level daily. Diabetes patient education classes had been attended by 35% of diabetic adults. Conclusions: These and other data indicate that medical care for diabetic patients and their self-care practices may not be optimal for prevention of diabetes complications. The Diabetes Control and Complications Trial showed that achieving and maintaining near-normal glycemia, with a concomitant 50% to 70% reduction in diabetes complications, may require close monitoring and ongoing support from a health care team, ample financial resources, and advanced patient knowledge and motivation. Providing this level of diabetes management to all diabetic persons may require major changes in the health care system and in patient self-care practices.			Harris, MI (corresponding author), NIDDKD, NATCHER BLDG, ROOM 5AN24, 45 CTR DR, MSC 6600, BETHESDA, MD 20892 USA.							ADAMS PF, 1990, VITAL HLTH STAT, V176, P1; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; BRANSOME ED, 1992, DIABETES CARE, V15, P1; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BROWN SA, 1990, PATIENT EDUC COUNS, V16, P189, DOI 10.1016/0738-3991(90)90070-2; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Cochran WG, 1977, SAMPLING TECHNIQUES, P319; COONROD BA, 1994, DIABETES CARE, V17, P852, DOI 10.2337/diacare.17.8.852; COWIE CC, 1995, NIH951468 US DEP HLT, P541; DUDL RJ, 1982, DIABETES CARE, V5, P649, DOI 10.2337/diacare.5.6.649; EASTMAN RC, 1993, J CLIN ENDOCR METAB, V77, P1105, DOI 10.1210/jc.77.5.1105; EASTMAN RC, 1993, DIABETES CARE, V16, P1095, DOI 10.2337/diacare.16.8.1095; GONDERFREDERICK LA, 1988, DIABETES CARE, V11, P579, DOI 10.2337/diacare.11.7.579; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GUTHRIE RA, 1991, AM FAM PHYSICIAN, V43, P570; HARRIS MI, 1994, DIABETES CARE, V17, P585, DOI 10.2337/diacare.17.6.585; HARRIS MI, 1994, DIABETES CARE, V17, P761, DOI 10.2337/diacare.17.7.761; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; HARRIS MI, 1994, DIABETES CARE, V17, P1337, DOI 10.2337/diacare.17.11.1337; HARRIS MI, 1990, DIABETES CARE, V13, P419, DOI 10.2337/diacare.13.4.419; HELIOVAARA M, 1993, J CLIN EPIDEMIOL, V46, P181, DOI 10.1016/0895-4356(93)90056-7; Janes GR, 1995, NIH PUBLICATION, P541; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813, DOI 10.1093/oxfordjournals.aje.a117078; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; LASKER RD, 1993, NEW ENGL J MED, V329, P1035, DOI 10.1056/NEJM199309303291410; MIDTHJELL K, 1992, J EPIDEMIOL COMMUN H, V46, P537, DOI 10.1136/jech.46.5.537; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PEYROT M, 1988, DIABETES S1, V37, pA53; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; SHAH BV, 1984, SESUDAAN STANDARD ER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEBERT C, 1993, DIABETES CARE, V16, P759, DOI 10.2337/diacare.16.5.759; SONGER TJ, 1992, DIABETES CARE, V15, P15, DOI 10.2337/diacare.15.1.S15; TUTTLEMAN M, 1993, DIABETES CARE, V16, P765, DOI 10.2337/diacare.16.5.765; 1993, DIABETES CARE, V16, P113; 1995, DIABETES CARE S1, V18, P1	39	82	84	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				117	122		10.7326/0003-4819-124-1_Part_2-199601011-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554202				2022-12-01	WOS:A1996TL94400007
J	Hay, BA; Wassarman, DA; Rubin, GM				Hay, BA; Wassarman, DA; Rubin, GM			Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ZINC-FINGER; GENE; EYE; EXPRESSION; ROUGH; DIVERSITY; P35-GENE; MOTIF	Apoptotic cell death is a mechanism by which organisms eliminate superfluous or harmful cells. Expression of the cell death regulatory protein REAPER (RPR) in the developing Drosophila eye results in a small eye owing to excess cell death. We show that mutations in thread (th) are dominant enhancers of RPR-induced cell death and that th encodes a protein homologous to baculovirus inhibitors of apoptosis (IAPs), which we call Drosophila IAP1 (DIAP1). Overexpression of DIAP1 or a related protein, DIAP2, in the eye suppresses normally occurring cell death as well as death due to overexpression of rpr or head in volution defective. IAP death-preventing activity localizes to the N-terminal baculovirus IAP repeats, a motif found in both viral and cellular proteins associated with death prevention.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	Hay, BA (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; ELLIS MC, 1993, DEVELOPMENT, V119, P855; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GOMBART AF, 1989, J GEN VIROL, V70, P1815, DOI 10.1099/0022-1317-70-7-1815; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOLFF T, 1991, DEVELOPMENT, V113, P825; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	53	616	635	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1253	1262		10.1016/0092-8674(95)90150-7	http://dx.doi.org/10.1016/0092-8674(95)90150-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548811	Bronze			2022-12-01	WOS:A1995TM76200020
J	Fazel, M				Fazel, M			Now show me your tongue: A taste of medicine in China	LANCET			English	Editorial Material											Fazel, M (corresponding author), LINCOLN COLL,OXFORD OX1 3DR,ENGLAND.			Fazel, Mina/0000-0001-9342-2365				WILSON A, 1991, BRIT J GEN PRACT, V41, P119	1	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1687	1688		10.1016/S0140-6736(95)92847-2	http://dx.doi.org/10.1016/S0140-6736(95)92847-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551831				2022-12-01	WOS:A1995TL42300017
J	Groves, KE				Groves, KE			How I'd like to be treated if I was terminally ill	BRITISH MEDICAL JOURNAL			English	Article											Groves, KE (corresponding author), QUEENSCOURT HOSPICE,SOUTHPORT PR8 6RE,MERSEYSIDE,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 23	1995	311	7021					1690	1691		10.1136/bmj.311.7021.1690	http://dx.doi.org/10.1136/bmj.311.7021.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL942	8541760	Green Published			2022-12-01	WOS:A1995TL94200020
J	KUJALA, UM; TAIMELA, S; ANTTIPOIKA, I; ORAVA, S; TUOMINEN, R; MYLLYNEN, P				KUJALA, UM; TAIMELA, S; ANTTIPOIKA, I; ORAVA, S; TUOMINEN, R; MYLLYNEN, P			ACUTE INJURIES IN SOCCER, ICE HOCKEY, VOLLEYBALL, BASKETBALL, JUDO, AND KARATE - ANALYSIS OF NATIONAL REGISTRY DATA	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL-ACTIVITY; SPORTS; RATES	Objective-To determine the acute injury profile in each of six sports and compare the injury rates between the sports. Design-Analysis of national sports injury insurance registry data. Setting-Finland during 1987-98. Subjects-621 691 person years of exposure among participants in soccer, ice hockey, volleyball, basketball, judo, or karate. Main outcome measures-Acute sports injuries requiring medical treatment and reported to the insurance company on structured forms by the patients and their doctors. Results-54186 sports injuries were recorded. Injury rates were low in athletes aged under IS, while 20-24 year olds had the highest rates. Differences in injury rates between the sports were minor in this adult age group. Overall injury rates were higher in sports entailing more frequent and powerful body contact. Each sport had a specific injury profile. Fractures and dental injuries were most common in ice hockey and karate and least frequent in volleyball. Knee injuries were the most common cause of permanent disability. Conclusions-Based on the defined injury profiles in the different sports it is recommended that sports specific preventive measures should be employed to decrease the number of violent contacts between athletes, including improved game rules supported by careful refereeing. To prevent dental injuries the wearing of mouth guards should be encouraged, especially in ice hockey, karate, and basketball.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT ORTHOPAED & TRAUMATOL,SF-00260 HELSINKI,FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	KUJALA, UM (corresponding author), UNIV HELSINKI,INST BIOMED,SPORTS & EXERCISE MED UNIT,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,SF-00250 HELSINKI,FINLAND.		Kujala, Urho/AAP-2547-2020	Kujala, Urho/0000-0002-9262-1992; Taimela, Simo/0000-0001-6755-2983				BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; BAXTERJONES A, 1993, ARCH DIS CHILD, V68, P130, DOI 10.1136/adc.68.1.130; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; DELOES M, 1990, INT J SPORTS MED, V11, P66, DOI 10.1055/s-2007-1024765; DELOES M, 1988, INT J SPORTS MED, V9, P461, DOI 10.1055/s-2007-1025052; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; EKSTRAND J, 1983, INT J SPORTS MED, V4, P124, DOI 10.1055/s-2008-1026025; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; HAYES D, 1978, CAN J APPL SPORT SCI, V3, P61; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Johnson R J, 1982, Clin Sports Med, V1, P181; KUJALA UM, 1994, BRIT MED J, V308, P231, DOI 10.1136/bmj.308.6923.231; KUJALA UM, 1988, SPORTS MED, V6, P197, DOI 10.2165/00007256-198806040-00002; KUJALA UM, 1995, INT J SPORTS MED, V16, P122, DOI 10.1055/s-2007-972977; MCLATCHIE GR, 1980, J TRAUMA, V20, P956, DOI 10.1097/00005373-198011000-00009; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SAMA S, 1993, MED SCI SPORTS EXERC, V25, P237; SANDELIN J, 1987, INT J SPORTS MED, V8, P61; SIM FH, 1987, AM J SPORTS MED, V15, P86; TATOR CH, 1991, CAN J SURG, V34, P63; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; WALTER SD, 1985, SPORTS MED, V2, P47, DOI 10.2165/00007256-198502010-00005; WATSON AWS, 1993, AM J SPORT MED, V21, P137, DOI 10.1177/036354659302100123; 1985, SPORTS INJURIES 1976	26	206	215	3	55	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 2	1995	311	7018					1465	1468		10.1136/bmj.311.7018.1465	http://dx.doi.org/10.1136/bmj.311.7018.1465			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ044	8520333	Green Published			2022-12-01	WOS:A1995TJ04400022
J	MCBLANE, JF; VANGENT, DC; RAMSDEN, DA; ROMEO, C; CUOMO, CA; GELLERT, M; OETTINGER, MA				MCBLANE, JF; VANGENT, DC; RAMSDEN, DA; ROMEO, C; CUOMO, CA; GELLERT, M; OETTINGER, MA			CLEAVAGE AT A V(D)J RECOMBINATION SIGNAL REQUIRES ONLY RAG1 AND RAG2 PROTEINS AND OCCURS IN 2 STEPS	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; BROKEN DNA-MOLECULES; MOUSE THYMOCYTES; STRAND TRANSFER; MECHANISM; REARRANGEMENT; EXPRESSION; GENES; MICE	Formation of double-strand breaks at recombination signal sequences is an early step in V(D)J recombination. Here we show that purified RAG1 and RAGS proteins are sufficient to carry out this reaction. The cleavage reaction can be divided into two distinct steps. First, a nick is introduced at the 5' end of the signal sequence, The other strand is then broken, resulting in a hairpin structure at the coding end and a blunt, 5'-phosphorylated signal end. The hairpin is made as a direct consequence of the cleavage mechanism. Nicking and hairpin formation each require the presence of a signal sequence and both RAG proteins.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	MCBLANE, JF (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Cuomo, Christina/L-2222-2019	Cuomo, Christina/0000-0002-5778-960X; Ramsden, Dale/0000-0003-1575-4748	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COEN ES, 1986, CELL, V47, P285, DOI 10.1016/0092-8674(86)90451-4; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GELLERT M, 1992, ANNU REV GENET, V22, P425; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KALLENBACH S, 1992, RES IMMUNOL, V143, P873, DOI 10.1016/0923-2494(92)80110-7; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDEN DA, 1995, IN PRESS GENES DEV, V9; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	32	560	570	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 3	1995	83	3					387	395		10.1016/0092-8674(95)90116-7	http://dx.doi.org/10.1016/0092-8674(95)90116-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521468	Bronze, Green Submitted			2022-12-01	WOS:A1995TC97700008
J	SOWERS, M; CORTON, G; SHAPIRO, B; JANNAUSCH, ML; CRUTCHFIELD, M; SMITH, ML; RANDOLPH, JF; HOLLIS, B				SOWERS, M; CORTON, G; SHAPIRO, B; JANNAUSCH, ML; CRUTCHFIELD, M; SMITH, ML; RANDOLPH, JF; HOLLIS, B			CHANGES IN BONE-DENSITY WITH LACTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM PARATHYROID-HORMONE; MINERAL HOMEOSTASIS; WOMEN; PREGNANCY; CALCIUM; MASS; 1,25-DIHYDROXYVITAMIN-D; CALCITONIN; 25-HYDROXYVITAMIN-D; PERFORMANCE	Objective.-To test the a priori hypotheses that significant bone loss occurs in lactation of greater than 5 months' duration and that bone mass returns to baseline levels when breast-feeding ceases. Design.-Prospective cohort study design of 12 months' duration. Setting.-General community setting with recruitment occurring at birthing education classes. Participants.-Volunteer sample of 98 healthy women of white (n=95) and Asian (n=3) origin, aged 20 to 40 years, and 0 to 1 parity prior to parturition, grouped according to lactation duration: 0 through 1, 2 through 5, and 6 or more months. Main Outcome Measures.-Bone mineral density (BMD) of the proximal femur was measured by dual-energy x-ray densitometry at 2 weeks (baseline), 2 months, 4 months, 6 months, and 12 months following parturition, and BMD of the lumbar spine was measured at baseline, 6 months, and 12 months after parturition. Results.-Women with lactation duration of 6 months or longer had mean BMD losses of 5.1% and 4.8% at the lumbar spine and femoral neck, respectively, comparing baseline values with those at 6 months post partum. Women who breast-fed 0 through 1 month lost no BMD at either bone site. Bone loss in women who breast-fed 6 months or longer was not explained by differences in age, diet, body size, or physical activity. Among women who breast-fed 6 months or longer, there was evidence of return to baseline levels of the lumbar spine at 12 months after parturition. The BMD of the lumbar spine of those women who continued to breast-feed more than 9 months had increased but was still significantly lower than baseline. Conclusion.-Extended lactation (greater-than-or-equal-to 70% of energy intake is provided for greater-than-or-equal-to 6 months) is associated with bone loss; however, there is evidence of return to baseline BMD measurement at 12 months after parturition.	MED COLL S CAROLINA,DEPT NEONATOL,CHARLESTON,SC; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT FAMILY PRACTICE,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT OBSTET & GYNECOL,ANN ARBOR,MI 48109	Medical University of South Carolina; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	SOWERS, M (corresponding author), UNIV MICHIGAN,DEPT EPIDEMIOL,109 OBSERV ST,ANN ARBOR,MI 48109, USA.			Randolph, John/0000-0003-4901-7711	NIAMS NIH HHS [R29-AR39651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039651] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALDERMAN BW, 1986, AM J EPIDEMIOL, V124, P262, DOI 10.1093/oxfordjournals.aje.a114384; ALOIA JF, 1983, ARCH INTERN MED, V143, P1700, DOI 10.1001/archinte.143.9.1700; ATKINSON P J, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P555; BAIRD DT, 1979, J CLIN ENDOCR METAB, V49, P500, DOI 10.1210/jcem-49-4-500; BATSAKIS JG, 1982, DIAGN MED        MAY, P25; BENZIE D., 1956, Journal of Agricultural Science, V48, P175, DOI 10.1017/S0021859600030458; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BROMMAGE R, 1985, AM J PHYSIOL, V248, pE182, DOI 10.1152/ajpendo.1985.248.2.E182; BUTTE NF, 1984, AM J CLIN NUTR, V39, P296, DOI 10.1093/ajcn/39.2.296; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CHAN GM, 1982, AM J OBSTET GYNECOL, V144, P438, DOI 10.1016/0002-9378(82)90250-2; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUNNINGHAM AS, 1983, J PEDIATR-US, V103, P338, DOI 10.1016/S0022-3476(83)80392-8; DADA OA, 1982, CLIN CHIM ACTA, V123, P293; DAVIS OK, 1988, J CLIN ENDOCR METAB, V67, P850, DOI 10.1210/jcem-67-4-850; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; ELLINGER BM, 1952, BR J NUTR, V5, P235; FRISANCHO AR, 1971, INVEST RADIOL, V6, P119, DOI 10.1097/00004424-197103000-00006; GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6; GOLDSMITH NF, 1982, J BONE JOINT SURG AM, V101, P718; GRAY GE, 1980, J AM DIET ASSOC, V77, P534; GREER FR, 1984, AM J CLIN NUTR, V40, P562, DOI 10.1093/ajcn/40.3.562; GREER FR, 1982, AM J CLIN NUTR, V36, P431, DOI 10.1093/ajcn/36.3.431; GRIZZLE JE, 1969, BIOMETRICS, V25, P357, DOI 10.2307/2528795; HAGAMAN JR, 1990, J BONE MINER RES, V5, P123, DOI 10.1002/jbmr.5650050205; HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588; HILLMAN L, 1981, AM J OBSTET GYNECOL, V139, P471, DOI 10.1016/0002-9378(81)90327-6; JOHNSTON CC, 1981, RECENT ADV PATHOGENE, P285; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384; KHOSLA S, 1990, MAYO CLIN PROC, V65, P1408, DOI 10.1016/S0025-6196(12)62164-8; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KRUKOWSKI M, 1987, BONE, V8, P251, DOI 10.1016/8756-3282(87)90173-6; KUMAR R, 1980, NEW ENGL J MED, V302, P1143, DOI 10.1056/NEJM198005153022010; KUSHNER RF, 1986, AM J CLIN NUTR, V44, P417, DOI 10.1093/ajcn/44.3.417; LAMKE B, 1977, ACTA OBSTET GYN SCAN, V56, P217, DOI 10.3109/00016347709162123; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MILLER MA, 1989, BONE, V10, P279, DOI 10.1016/8756-3282(89)90065-3; MILLER SC, 1986, BONE, V7, P283, DOI 10.1016/8756-3282(86)90209-7; MILLER SC, 1982, CALCIFIED TISSUE INT, V34, P245, DOI 10.1007/BF02411245; PRICE PA, 1980, J CLIN INVEST, V66, P878, DOI 10.1172/JCI109954; Rosner B, 1982, FUNDAMENTALS BIOSTAT; ROWLAND GN, 1972, CALC TISS RES, V9, P179, DOI 10.1007/BF02061956; RYAN AS, 1991, PEDIATRICS, V88, P719; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SCHLECHTE JA, 1983, J CLIN ENDOCR METAB, V56, P1120, DOI 10.1210/jcem-56-6-1120; SHAABAN MM, 1987, J STEROID BIOCHEM, V21, P1043; SOWERS M, 1991, OBSTET GYNECOL, V77, P841; SOWERS MF, 1985, PREV MED, V14, P585, DOI 10.1016/0091-7435(85)90079-9; SPENCER GR, 1979, AM J PATHOL, V95, P277; Termine J.D., 1990, PRIMER METABOLIC BON, P16; WARDLAW GM, 1986, AM J CLIN NUTR, V44, P283, DOI 10.1093/ajcn/44.2.283; ZARATE A, 1987, J STEROID BIOCHEM, V27, P1023, DOI 10.1016/0022-4731(87)90185-3	54	286	288	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	1993	269	24					3130	3135		10.1001/jama.269.24.3130	http://dx.doi.org/10.1001/jama.269.24.3130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH145	8505816				2022-12-01	WOS:A1993LH14500027
J	DOHENY, KF; SORGER, PK; HYMAN, AA; TUGENDREICH, S; SPENCER, F; HIETER, P				DOHENY, KF; SORGER, PK; HYMAN, AA; TUGENDREICH, S; SPENCER, F; HIETER, P			IDENTIFICATION OF ESSENTIAL COMPONENTS OF THE SACCHAROMYCES-CEREVISIAE KINETOCHORE	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; YEAST SACCHAROMYCES-CEREVISIAE; CENTROMERE DNA; MUTANTS; PROTEIN; SEGREGATION; MOVEMENT; SEQUENCE; COMPLEX; MINICHROMOSOMES	We have designed and utilized two in vivo assays of kinetochore integrity in S. cerevisiae. One assay detects relaxation of a transcription block formed at centromeres; the other detects an increase in the mitotic stability of a dicentric test chromosome. ctf13-30 and ctf14-42 were identified as putative kinetochore mutants by both assays. CTF14 is identical to NDC10/CBF2, a recently identified essential gene that encodes a 110 kd kinetochore component. CTF13 is an essential gene that encodes a predicted 478 amino acid protein with no homology to known proteins. ctf13 mutants missegregate chromosomes at permissive temperature and transiently arrest at nonpermissive temperature as large-budded cells with a G2 DNA content and a short spindle. Antibodies recognizing epitope-tagged CTF13 protein decrease the electrophoretic mobility of a CEN DNA-protein complex formed in vitro. Together, the genetic and biochemical data indicate that CTF13 is an essential kinetochore protein.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	DOHENY, KF (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838	NCI NIH HHS [5T32CA09139, CA16519] Funding Source: Medline; NIGMS NIH HHS [P32GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009139, P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BLOOM KS, 1984, J CELL BIOL, V99, P1559, DOI 10.1083/jcb.99.5.1559; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARBON J, 1990, New Biologist, V2, P10; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CELLINI A, 1986, MOL CELL BIOL, V6, P1571, DOI 10.1128/MCB.6.5.1571; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COTTAREL G, 1989, MOL CELL BIOL, V9, P3342, DOI 10.1128/MCB.9.8.3342; DENSMORE L, 1991, MOL CELL BIOL, V11, P154, DOI 10.1128/MCB.11.1.154; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; GERRING S, 1990, METHOD ENZYMOL, V194, P57; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GOH PY, 1993, IN PRESS J CELL BIOL; HABER JE, 1984, GENETICS, V106, P207; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; JIANG W, 1993, IN PRESS J CELL BIOL; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAINE GT, 1984, GENETICS, V106, P365; MANN C, 1983, P NATL ACAD SCI-BIOL, V80, P228, DOI 10.1073/pnas.80.1.228; MCCLEOD M, 1986, MOL CELL BIOL, V6, P3357; MEEKSWAGNER D, 1986, CELL, V44, P53, DOI 10.1016/0092-8674(86)90484-8; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; PALMER RE, 1989, J CELL BIOL, V109, P3355, DOI 10.1083/jcb.109.6.3355; PERIER F, 1992, GENETICS, V132, P39; PETERSON JB, 1976, J CELL SCI, V22, P219; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; ROSE MD, 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SHERO JH, 1991, METHOD ENZYMOL, V194, P749; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; SPENCER F, 1990, GENETICS, V124, P237; SPENCER F, 1988, CANCER CELL, V6, P441; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841; [No title captured]	69	190	193	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					761	774		10.1016/0092-8674(93)90255-O	http://dx.doi.org/10.1016/0092-8674(93)90255-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500169	Green Published, Bronze			2022-12-01	WOS:A1993LD83000014
J	LIAN, JP; FERRONOVICK, S				LIAN, JP; FERRONOVICK, S			BOS1P, AN INTEGRAL MEMBRANE-PROTEIN OF THE ENDOPLASMIC-RETICULUM TO GOLGI TRANSPORT VESICLES, IS REQUIRED FOR THEIR FUSION COMPETENCE	CELL			English	Article							YEAST SECRETORY PATHWAY; BINDING YPT1 PROTEIN; ESCHERICHIA-COLI; COMPLEX; ER; RECONSTITUTION; IDENTIFICATION; MUTANTS	BOS1 encodes an integral endoplasmic reticulum (ER) membrane protein and genetically interacts with three other yeast genes (BET1, SEC22, and YPT1) whose products are required for membrane traffic between the ER and the Golgi apparatus. Using an assay that reconstitutes transport at this stage of the pathway, we find that anti-Bos1p antibody blocks protein export after vesicles bud from the ER but prior to fusion with the Golgi. Additionally, the depletion of Bos1p from the ER leads to the formation of transport-incompetent vesicles. Carrier vesicles, immunoisolated with anti-Bos1p antibody, are approximately 50 nm in size. These vesicles contain Bos1p, Sec22p, and Ypt1p, but not Bet1p. The functional interactions of Bos1p with Ypt1p and Sec22p may be necessary for the fusion competence of the ER to Golgi transport vesicles.			LIAN, JP (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.				NCI NIH HHS [CA 46128] Funding Source: Medline; NIGMS NIH HHS [1 RO1 GM45431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GROESCH ME, 1992, METHOD ENZYMOL, V219, P137; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, BIOESSAYS, V12, P485, DOI 10.1002/bies.950121006; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	33	137	139	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					735	745		10.1016/0092-8674(93)90253-M	http://dx.doi.org/10.1016/0092-8674(93)90253-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500167				2022-12-01	WOS:A1993LD83000012
J	YAMADA, T; PFAFF, SL; EDLUND, T; JESSELL, TM				YAMADA, T; PFAFF, SL; EDLUND, T; JESSELL, TM			CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - MOTOR-NEURON INDUCTION BY DIFFUSIBLE FACTORS FROM NOTOCHORD AND FLOOR PLATE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; CHICK-EMBRYO; SPINAL-CORD; MONOCLONAL-ANTIBODIES; CREST CELLS; EXPRESSION; MOUSE; DIFFERENTIATION; MOTONEURONS; GUIDANCE	The identity of cell types generated along the dorsoventral axis of the neural tube depends on inductive signals that derive from both mesodermal and neural cells. To define the nature of these signals, we have analyzed the differentiation of cells in neural plate explants. Motor neurons and neural crest cells differentiate in vitro from appropriate regions of the neural plate, indicating that the specification of cell fate along the dorsoventral axis of the neural tube begins at the neural plate stage. Motor neuron differentiation can be induced by a diffusible factor that derives initially from the notochord and later from floor plate cells. By contrast, floor plate induction requires contact with the notochord. Thus, the identity and patterning of neural cell types appear to involve distinct contact-mediated and diffusible signals from the notochord and floor plate.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University	YAMADA, T (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.							ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BERND P, 1985, DEV BIOL, V112, P145, DOI 10.1016/0012-1606(85)90128-9; BERNHARDT RR, 1992, J COMP NEUROL, V326, P263, DOI 10.1002/cne.903260208; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DELANNET M, 1992, DEVELOPMENT, V116, P275; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSELL TM, 1992, HARVEY LECT, V86, P87; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1990, J NEUROSCI, V10, P2451; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MAXWELL GD, 1988, NEURON, V1, P557, DOI 10.1016/0896-6273(88)90105-5; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; SECHRIST J, 1991, NEURON, V7, P947, DOI 10.1016/0896-6273(91)90340-6; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STOCKER KM, 1991, DEVELOPMENT, V111, P635; TANAKA H, 1989, DEV BIOL, V132, P419, DOI 10.1016/0012-1606(89)90238-8; TANAKA H, 1990, DEVELOPMENT, V110, P565; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TOUSSAINT JL, 1992, GENOMICS, V12, P412, DOI 10.1016/0888-7543(92)90395-9; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	49	442	452	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					673	686		10.1016/0092-8674(93)90248-O	http://dx.doi.org/10.1016/0092-8674(93)90248-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500163				2022-12-01	WOS:A1993LD83000007
J	Berkelman, RL; Pinner, RW; Hughes, JM				Berkelman, RL; Pinner, RW; Hughes, JM			Addressing emerging microbial threats in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Berkelman, RL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,1600 CLIFTON RD NE,MAILSTOP C12,ATLANTA,GA 30333, USA.							BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Cassel GH, 1994, ASM NEWS, V60, P251; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; DOWDLE WR, 1993, ANNU REV PUBL HEALTH, V14, P649; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; GAYNES RP, 1991, AM J MED, V91, P1165; KAPLAN JE, 1995, CLIN INFECT DIS   S1, V21, P12; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEDERBERG J, 1993, ASM NEWS, V59, P162; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Morse Stephen S., 1993, EMERGING VIRUSES; STACHE RD, 1995, EMERGING INFECT DIS, V1, P1; 1995, MMWR-MORBID MORTAL W, V44, P1; 1995, EMERGING INFECT J, V1, P105; 1995, REPORT NSTC COMMITTE; 1994, MMWR-MORBID MORTAL W, V43, P740; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V43, P421; 1991, ADDRESSING EMERGING; 1995, MMWR-MORBID MORTAL W, V44, P121; 1994, CAN COMMUN DIS REP, V20, P1; 1995, MMWR-MORBID MORTAL W, V44, P535	24	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 24	1996	275	4					315	317		10.1001/jama.275.4.315	http://dx.doi.org/10.1001/jama.275.4.315			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP965	8544273				2022-12-01	WOS:A1996TP96500029
J	Sorrell, VL; Davis, MJ; Bove, AA				Sorrell, VL; Davis, MJ; Bove, AA			Origins of coronary artery ectasia	LANCET			English	Editorial Material									UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; TEMPLE UNIV HOSP & MED SCH, PHILADELPHIA, PA 19140 USA	University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sorrell, VL (corresponding author), E CAROLINA UNIV, SCH MED, 4S-22 BRODY, GREENVILLE, NC 27834 USA.							CARMICHAEL P, 1963, ARCH ENVIRON HEALTH, V7, P424, DOI 10.1080/00039896.1963.10663561; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P113; England JF., 1981, MED J AUSTRALIA, V68, P260; ENGLAND JF, 1981, MED J AUSTRALIA, V2, P140; HARTNELL GG, 1985, BRIT HEART J, V54, P392; LANGE RL, 1972, CIRCULATION, V46, P666, DOI 10.1161/01.CIR.46.4.666; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658	10	37	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	1996	347	8995					136	137		10.1016/S0140-6736(96)90335-9	http://dx.doi.org/10.1016/S0140-6736(96)90335-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ244	8544543				2022-12-01	WOS:A1996TQ24400004
J	Akopian, AN; Sivilotti, L; Wood, JN				Akopian, AN; Sivilotti, L; Wood, JN			A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons	NATURE			English	Article							ROOT GANGLION NEURONS; NERVOUS-SYSTEM; RAT; CURRENTS; CELLS	DORSAL root ganglion sensory neurons associated with C-fibres, many of which are activated by tissue-damage, express an unusual voltage-gated sodium channel that is resistant to tetrodotoxin(1-9). We report here that we have identified a 1,957 aminoacid sodium channel in these cells that shows 65% identity with the rat cardiac tetrodotoxin-insensitive sodium channel(10), and is not expressed in other peripheral and central neurons, glia or non-neuronal tissues. In situ hybridization shows that the channel is expressed only by small-diameter sensory neurons in neonatal and adult dorsal root and trigeminal ganglia. The channel is resistant to tetrodotoxin when expressed in Xenopus oocytes. The electrophysiological and pharmacological properties of the expressed channel are similar to those described for the small-diameter sensory neuron tetrodotoxin-resistant sodium channels. As some noxious input into the spinal cord is resistant to tetrodotoxin(8,11,12), block of expression or function of such a C-fibre-restricted sodium channel may have a selective analgesic effect.	UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London			Sivilotti, Lucia/D-8919-2011	Sivilotti, Lucia/0000-0003-2510-8424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; BECKH S, 1990, FEBS LETT, V262, P317, DOI 10.1016/0014-5793(90)80218-8; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; CARRIER GO, 1992, PFLUG ARCH EUR J PHY, V421, P7, DOI 10.1007/BF00374726; CHABAL C, 1989, PAIN, V38, P333, DOI 10.1016/0304-3959(89)90220-0; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cohen S A, 1993, Int Rev Cytol, V137C, P55; DELBIANCO E, 1994, NEUROSCI LETT, V170, P163, DOI 10.1016/0304-3940(94)90264-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; JEFTINIJA S, 1994, BRAIN RES, V665, P69, DOI 10.1016/0006-8993(94)91153-3; JEFTINIJA S, 1994, BRAIN RES, V639, P125, DOI 10.1016/0006-8993(94)91772-8; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; Mandel G, 1993, Curr Opin Neurobiol, V3, P278, DOI 10.1016/0959-4388(93)90118-I; MATSUDA Y, 1978, BRAIN RES, V154, P69, DOI 10.1016/0006-8993(78)91052-1; MATZNER O, 1994, J NEUROPHYSIOL, V72, P349, DOI 10.1152/jn.1994.72.1.349; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; NOWYCKY M, 1993, SENSORY NEURONS, P97; OH YS, 1994, NEUROSCI LETT, V176, P119, DOI 10.1016/0304-3940(94)90885-0; RAJ PP, 1988, NEURAL BLOCKADE CLIN, P899; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROY ML, 1992, J NEUROSCI, V12, P2104; SATIN J, 1992, SCIENCE, V256, P1205; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301	30	842	889	2	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 18	1996	379	6562					257	262		10.1038/379257a0	http://dx.doi.org/10.1038/379257a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ169	8538791				2022-12-01	WOS:A1996TQ16900047
J	Thompson, WG				Thompson, WG			Things that go red in the urine; And others that don't	LANCET			English	Editorial Material											Thompson, WG (corresponding author), UNIV OTTAWA, DIV GASTROENTEROL, OTTAWA CIVIC HOSP, OTTAWA, ON, CANADA.							EASTWOOD MA, 1995, QJM-INT J MED, V88, P711; JARNEROT G, 1995, GASTROENTEROLOGY, V109, P449, DOI 10.1016/0016-5085(95)90332-1; RILEY SA, 1990, Q J MED, V75, P551; STROCCHI A, 1991, GUT, V32, P1498, DOI 10.1136/gut.32.12.1498; THOMPSON WG, 1989, GUT REACTIONS; WATSON WC, 1963, BMJ-BRIT MED J, P971, DOI 10.1136/bmj.2.5363.971	6	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 6	1996	347	8993					5	6						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TN762	8531553				2022-12-01	WOS:A1996TN76200006
J	Laakso, M				Laakso, M			Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus - The Finnish studies	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Regenstrief Conference on Risks and Benefits of Intensive Management in Non-Insulin-dependent Diabetes Mellitus	DEC 11-13, 1994	WASHINGTON, D.C.	Regemstroef Omst, NIH, NIDDKD, Ctr Dis Control & Prevent, Div Diabetes Translat			GLUCOSE	Purpose: To review population-based studies that investigated the association and nature of association between glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus (NIDDM). Data Sources: Study 1 included 133 newly diagnosed patients with NIDDM from eastern Finland, who were 45 to 64 years of age at baseline. These patients were followed up to 10 years for cardiovascular mortality. Study 2 included 229 newly or previously diagnosed patients with NIDDM from eastern Finland, aged 65 to 74 years at baseline. These patients were followed up to 3.5 years for coronary heart disease mortality and all coronary heart disease events (mortality or nonfatal myocardial infarction). Study Selection: Prospective, population-based studies that included indicators of glycemic control and the evaluation of coronary heart disease and cardiovascular risk. Results: Study 1 : 10-year cardiovascular mortality was significantly and linearly associated with glycemic control (fasting blood glucose and glycated hemoglobin A(1) levels) independently of the mode of treatment. A high fasting blood glucose level significantly predicted cardiovascular mortality in multiple logistic regression analysis independently of other risk factors. Study 2: Glycated hemoglobin A(1c) was the most important single risk factor associated with coronary heart disease death or all coronary heart disease events. In multiple logistic regression analysis, glycated hemoglobin A(1c) was significantly associated with coronary heart disease death after adjustment for other cardiovascular risk factors. Conclusions: Two prospective, population-based studies from Finland give evidence for the linear association of glycemic control with the risk for coronary heart disease in middle-aged and elderly patients with NIDDM.			Laakso, M (corresponding author), KUOPIO UNIV, DEPT MED, SF-70210 KUOPIO, FINLAND.							BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LYONS TJ, 1992, DIABETES, V41, P67, DOI 10.2337/diab.41.2.S67; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TURNER RC, 1985, DIABETES, V34, P793; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; 1985, TECHNICAL REPORT SER, V727; 1990, MONICA MANUAL	12	124	129	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	2				127	130		10.7326/0003-4819-124-1_Part_2-199601011-00009	http://dx.doi.org/10.7326/0003-4819-124-1_Part_2-199601011-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TL944	8554204				2022-12-01	WOS:A1996TL94400009
J	Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W				Economou, A; Pogliano, JA; Beckwith, J; Oliver, DB; Wickner, W			SecA membrane cycling at SecYEG is driven by distinct ATP binding and hydrolysis events and is regulated by SecD and SecF	CELL			English	Article							COLI PLASMA-MEMBRANE; PROTON MOTIVE FORCE; PRECURSOR PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; TRIGGER FACTOR; PREPROTEIN TRANSLOCASE; PRESECRETORY PROTEINS; SECRETORY PROTEINS	The SecA subunit of E. coli preprotein translocase promotes protein secretion during cycles of membrane insertion and deinsertion at SecYEG. This process is regulated both by nucleotide binding and hydrolysis and by the SecD and SecF proteins. In the presence of associated preprotein, the energy of ATP binding at nucleotide-binding domain 1 (NBD1) drives membrane insertion of a 30 kDa domain of SecA, while deinsertion of SecA requires the hydrolysis of this ATP. SecD and SecF stabilize the inserted state of SecA. ATP binding at NBD2, though needed for preprotein translocation, is not needed for SecA insertion or deinsertion.	UNIV CRETE, DEPT BIOL, GR-71110 IRAKLION, GREECE; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	University of Crete; Harvard University; Harvard Medical School; Wesleyan University	Economou, A (corresponding author), DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P4205, DOI 10.1002/j.1460-2075.1990.tb07645.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRUNDERSON KL, 1995, CELL, V82, P231; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RENSING SA, 1994, MOL PHYLOGENET EVOL, V3, P187, DOI 10.1006/mpev.1994.1021; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; TANI K, 1989, J BIOL CHEM, V264, P18582; UEGUCHI C, 1990, J BACTERIOL, V172, P5643, DOI 10.1128/jb.172.10.5643-5649.1990; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.biochem.60.1.101; YAMADA H, 1989, J BIOL CHEM, V264, P18577	56	271	274	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 29	1995	83	7					1171	1181		10.1016/0092-8674(95)90143-4	http://dx.doi.org/10.1016/0092-8674(95)90143-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TM762	8548804	hybrid			2022-12-01	WOS:A1995TM76200013
J	Cairns, JA				Cairns, JA			Medical management of unstable angina	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIALS; ACUTE CORONARY SYNDROMES; ARTERY DISEASE; HEART-DISEASE; DOUBLE-BLIND; ASPIRIN; NIFEDIPINE; DILTIAZEM; PATHOGENESIS				Cairns, JA (corresponding author), MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA.		Cairns, John/AAI-8744-2021					ANDREFOUET X, 1983, EUR HEART J, V4, P691, DOI 10.1093/oxfordjournals.eurheartj.a061380; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; FANG ZY, 1991, AM J CARDIOL, V68, pC42; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GERSTENBLITH G, 1982, NEW ENGL J MED, V306, P885, DOI 10.1056/NEJM198204153061501; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P121; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LUBSEN J, 1987, AM J CARDIOL, V60, pA18; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1990, LANCET, V336, P827; 1994, CIRCULATION, V89, P1545	18	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 23	1995	346	8991-2					1644	1645		10.1016/S0140-6736(95)92834-0	http://dx.doi.org/10.1016/S0140-6736(95)92834-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL423	8551818				2022-12-01	WOS:A1995TL42300004
J	BETTS, L; JOSEY, JA; VEAL, JM; JORDAN, SR				BETTS, L; JOSEY, JA; VEAL, JM; JORDAN, SR			A NUCLEIC-ACID TRIPLE-HELIX FORMED BY A PEPTIDE NUCLEIC-ACID DNA COMPLEX	SCIENCE			English	Article							THYMINE-SUBSTITUTED POLYAMIDE; STRAND-DISPLACEMENT; BINDING; PNA	The crystal structure of a nucleic acid triplex reveals a helix, designated P-form, that differs from previously reported nucleic acid structures. The triplex consists of one polypurine DNA strand complexed to a polypyrimidine hairpin peptide nucleic acid (PNA) and was successfully designed to promote Watson-Crick and Hoogsteen base pairing. The P-form helix is underwound, with a base tilt similar to B-form DNA. The bases are displaced from the helix axis even more than in A-form DNA. Hydrogen bonds between the DNA backbone and the Hoogsteen PNA backbone explain the observation that polypyrimidine PNA sequences form highly stable 2:1 PNA-DNA complexes. This structure expands the number of known stable helical forms that nucleic acids can adopt.			BETTS, L (corresponding author), GLAXO WELLCOME,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.							ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BABCOCK MS, 1993, J BIOMOL STRUCT DYN, V11, P597, DOI 10.1080/07391102.1993.10508018; BROWN SC, 1994, SCIENCE, V265, P777, DOI 10.1126/science.7519361; BRUNGER AT, 1987, X PLOR MANUAL VERSIO; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRIFFITH MC, 1995, J AM CHEM SOC, V117, P831, DOI 10.1021/ja00107a033; HUNTER WN, 1989, BIOCHEMISTRY-US, V28, P2444, DOI 10.1021/bi00432a015; JONES AT, 1994, MANUAL VERSION 5 9 1; JOSEY JA, UNPUB; KIM SK, 1992, J AM CHEM SOC, V115, P6477; MACAYA R, 1992, J MOL BIOL, V225, P755, DOI 10.1016/0022-2836(92)90399-5; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1995, J MOL RECOGNIT, V7, P165; OTWINOWSKI Z, 1993, JAN P CCP4 STUD WEEK; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; RADHAKRISHNAN I, 1994, STRUCTURE, V2, P17, DOI 10.1016/S0969-2126(00)00005-8; Saenger W., 1984, PRINCIPLES NUCL ACID, P132; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063; VANMEERVELT L, 1995, NATURE, V374, P742, DOI 10.1038/374742a0; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; 1994, QUANTA 4 0	27	272	293	2	46	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1838	1841		10.1126/science.270.5243.1838	http://dx.doi.org/10.1126/science.270.5243.1838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525381				2022-12-01	WOS:A1995TK47600051
J	HUANG, HF; ZHU, LM; REID, BR; DROBNY, GP; HOPKINS, PB				HUANG, HF; ZHU, LM; REID, BR; DROBNY, GP; HOPKINS, PB			SOLUTION STRUCTURE OF A CISPLATIN-INDUCED DNA INTERSTRAND CROSS-LINK	SCIENCE			English	Article							DOUBLE HELICAL DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); DUPLEX	The widely used antitumor drug cis-diamminedichloroplatinum(II) (cisplatin or cis-DDP) reacts with DNA, cross-linking two purine residues through the N7 atoms, which reside in the major groove in B-form DNA. The solution structure of the short duplex [d(CATAGCTATG)](2) cross-linked at the GC:GC site was determined by nuclear magnetic resonance (NMR). The deoxyguanosine-bridging cis-diammineplatinum(II) lies in the minor groove, and the complementary deoxycytidines are extrahelical. The double helix is locally reversed to a left-handed form, and the helix is unwound and bent toward the minor groove. These findings were independently confirmed by results from a phase-sensitive gel electrophoresis bending assay. The NMR structure differs markedly from previously proposed models but accounts for the chemical reactivity, the unwinding, and the bending of cis-DDP interstrand cross-linked DNA and may be important in the formation and repair of these cross-links in chromatin.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45804, GM32681] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNHAM KJ, 1995, INORG CHEM, V34, P2826, DOI 10.1021/ic00115a008; CHOU SH, 1994, J MOL BIOL, V244, P259, DOI 10.1006/jmbi.1994.1727; CRIPPEN GM, 1981, DISTANCE GEOMETRY CO; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HOPKINS PB, 1991, TETRAHEDRON, V47, P2475, DOI 10.1016/S0040-4020(01)81782-8; HUANG HF, 1995, BIOORGAN MED CHEM, V3, P659, DOI 10.1016/0968-0896(95)00059-P; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYET D, 1993, NUCLEIC ACIDS RES, V21, P5846, DOI 10.1093/nar/21.25.5846; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; Pratt WB, 1994, ANTI-CANCER DRUG, P133; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; RINK SM, 1995, BIOCHEMISTRY-US, V34, P1439, DOI 10.1021/bi00004a039; ROBERTS JJ, 1987, PHARMACOL THERAPEUT, V34, P215, DOI 10.1016/0163-7258(87)90012-X; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SIP M, 1992, BIOCHEMISTRY-US, V31, P2508, DOI 10.1021/bi00124a010; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TOMSON AJ, 1974, RECENT RES CANCER, V48, P38; WANG AHJ, 1978, NATURE, V276, P471, DOI 10.1038/276471a0; WANG AHJ, 1981, SCIENCE, V211, P171, DOI 10.1126/science.7444458; YANG DZ, 1995, NAT STRUCT BIOL, V2, P577, DOI 10.1038/nsb0795-577; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; ZHU LM, 1995, J MAGN RESON SER B, V106, P227, DOI 10.1006/jmrb.1995.1038; ZHU LM, 1995, J MOL BIOL, V254, P623, DOI 10.1006/jmbi.1995.0643; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	32	289	294	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1842	1845		10.1126/science.270.5243.1842	http://dx.doi.org/10.1126/science.270.5243.1842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525382				2022-12-01	WOS:A1995TK47600052
J	YOSHIMOTO, T; BENDELAC, A; WATSON, C; HULI, J; PAUL, WE				YOSHIMOTO, T; BENDELAC, A; WATSON, C; HULI, J; PAUL, WE			ROLE OF NK1.1(+) T-CELLS IN A T(H)2 RESPONSE AND IN IMMUNOGLOBULIN-E PRODUCTION	SCIENCE			English	Article							MURINE IMMUNE-SYSTEM; POLYCLONAL ACTIVATION; LYMPHOKINE SECRETION; INTERLEUKIN-4; ANTIBODY; CD4+; CD1; GENERATION; INVIVO; FAMILY	Immune responses dominated by interleukin-4 (IL-4)-producing T helper type 2 (T(H)2) cells or by interferon gamma (IFN-gamma)-producing T helper type 1 (T(H)1) cells express distinctive protection against infection with different pathogens. Interleukin-4 promotes the differentiation of naive CD4(+) T cells into IL-4 producers and suppresses their development into IFN-gamma producers. CD1-specific splenic CD4(+)NK1.1(+) T cells, a numerically minor population, produced IL-4 promptly on in vivo stimulation. This T cell population was essential for the induction of IL-4-producing cells and for switching to immunoglobulin E, an IL-4-dependent event, in response to injection of antibodies to immunoglobulin D.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Princeton University			Yoshimoto, Tomohiro/E-2224-2014					ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; GOROFF DK, 1991, J IMMUNOL, V146, P18; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; SCHMITT D, 1986, IMMUNOL LETT, V12, P231, DOI 10.1016/0165-2478(86)90009-X; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SMALL TN, 1987, J IMMUNOL, V138, P2864; SWAIN SL, 1990, J IMMUNOL, V145, P3796; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	27	451	467	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 15	1995	270	5243					1845	1847		10.1126/science.270.5243.1845	http://dx.doi.org/10.1126/science.270.5243.1845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK476	8525383				2022-12-01	WOS:A1995TK47600053
J	CUDMORE, S; COSSART, P; GRIFFITHS, G; WAY, M				CUDMORE, S; COSSART, P; GRIFFITHS, G; WAY, M			ACTIN-BASED MOTILITY OF VACCINIA VIRUS	NATURE			English	Article							LISTERIA-MONOCYTOGENES; RELEASE; GENE; PROTEIN; SPREAD; N1-ISONICOTINOYL-N2-3-METHYL-4-CHLOROBENZOYLHYDRAZINE; POLYMERIZATION; DISSEMINATION; CYTOSKELETON; SEQUENCE	THE role of the cytoskeleton during viral infection is poorly understood, Here we show, using a combination of mutant and drug studies, that the intracellular enveloped form of vaccinia virus is capable of inducing the formation of actin tails that are strikingly similar to those seen in Listeria, Shigella and Rickettsia infections, Analysis using,video microscopy reveals that single viral particles are propelled in vivo on the tip of actin tails, at a speed of 2.8 mu m min(-1). On contact with the cell surface, virus particles extend outwards on actin projections at a similar rate, to contact and infect neighbouring cells, Given the similarities between the motility of vaccinia virus and bacterial pathogens, we suggest that intracellular pathogens have developed a common mechanism to exploit the actin cytoskeleton as a means to facilitate their direct spread between cells.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69117 HEIDELBERG, GERMANY; INST PASTEUR, UNITE INTERACT BACTERIES CELLULES, F-75724 PARIS 15, FRANCE	European Molecular Biology Laboratory (EMBL); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Cudmore, Sally/N-7736-2014	Way, Michael/0000-0001-7207-2722; Cudmore, Sally/0000-0002-3131-7428				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BLASCO R, 1991, J VIROL, V65, P4598, DOI 10.1128/JVI.65.9.4598-4608.1991; BLASCO R, 1992, J VIROL, V66, P4170, DOI 10.1128/JVI.66.7.4170-4179.1992; COSSART P, 1995, CURR OPIN CELL BIOL, V7, P94, DOI 10.1016/0955-0674(95)80050-6; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOUIN E, 1995, INFECT IMMUN, V63, P2729, DOI 10.1128/IAI.63.7.2729-2737.1995; HEINZEN RA, 1993, INFECT IMMUN, V61, P1926, DOI 10.1128/IAI.61.5.1926-1935.1993; HERZOG M, 1994, CELL BIOL LABORATORY; HILLER G, 1982, J VIROL, V44, P647, DOI 10.1128/JVI.44.2.647-657.1982; HILLER G, 1979, VIROLOGY, V98, P142, DOI 10.1016/0042-6822(79)90533-6; HILLER G, 1981, J VIROL, V39, P903, DOI 10.1128/JVI.39.3.903-913.1981; HILLER G, 1981, EXP CELL RES, V132, P81, DOI 10.1016/0014-4827(81)90085-9; KATO N, 1969, J EXP MED, V129, P795, DOI 10.1084/jem.129.4.795; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KREMPIEN U, 1981, VIROLOGY, V113, P556, DOI 10.1016/0042-6822(81)90183-5; MARCHAND JB, 1995, J CELL BIOL, V130, P1; MORGAN C, 1976, VIROLOGY, V73, P43, DOI 10.1016/0042-6822(76)90059-3; PAYNE LG, 1982, ARCH VIROL, V74, P11, DOI 10.1007/BF01320778; PAYNE LG, 1979, J VIROL, V32, P614, DOI 10.1128/JVI.32.2.614-622.1979; PAYNE LG, 1980, J GEN VIROL, V50, P89, DOI 10.1099/0022-1317-50-1-89; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHMUTZ C, 1991, J VIROL, V65, P3435, DOI 10.1128/JVI.65.7.3435-3442.1991; STOKES GV, 1976, J VIROL, V18, P636, DOI 10.1128/JVI.18.2.636-643.1976; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; [No title captured]	30	362	372	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					636	638		10.1038/378636a0	http://dx.doi.org/10.1038/378636a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524400				2022-12-01	WOS:A1995TJ22100083
J	POSTE, G				POSTE, G			THE CASE FOR GENOMIC PATENTING	NATURE			English	Note											POSTE, G (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1995, NATURE S, V377; [Anonymous], 1995, HUMAN TISSUE ETHICAL; [Anonymous], 1995, INTELLECTUAL PROPERT; [Anonymous], 1992, INTELLECTUAL PROPERT; Bernstein T, 1994, RADON RENTAL HOUSING; BUTLER D, 1994, NATURE, V370, P4; COHEN J, 1995, SCIENCE, V268, P1715, DOI 10.1126/science.7792594; SCOTTRAM N, 1993, NATURE, V364, P666, DOI 10.1038/364666a0; SMITH GK, 1994, AM INTELLECT PROP LA, V22, P28; WARSHOFSKY F, 1994, PATENT WARS; WILLIAMSON AR, 1994, NATURE, V372, P40; 1991, BIOTECHNOLOGY GLOBAL, P203; 1995, NATURE, V374, P750; 1995, NATURE, V374, P391; 1993, REALISING OUR POTENT; 1995, HUGO STATEMENT PATEN; 1994, PATENTING HUMAN GENE; 1995, FED REGISTER, V60, P12771; [No title captured]; 1994, NATURE, V371, P270; 1995, EPLC9 PHARM LAW REP; 1995, HUMAN GENETICS SCI I, V1; 1994, GENETIC SCREENING ET	23	22	22	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 7	1995	378	6557					534	536		10.1038/378534a0	http://dx.doi.org/10.1038/378534a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ221	8524376				2022-12-01	WOS:A1995TJ22100022
J	GRELL, M; DOUNI, E; WAJANT, H; LOHDEN, M; CLAUSS, M; MAXEINER, B; GEORGOPOULOS, S; LESSLAUER, W; KOLLIAS, G; PFIZENMAIER, K; SCHEURICH, P				GRELL, M; DOUNI, E; WAJANT, H; LOHDEN, M; CLAUSS, M; MAXEINER, B; GEORGOPOULOS, S; LESSLAUER, W; KOLLIAS, G; PFIZENMAIER, K; SCHEURICH, P			THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR	CELL			English	Article							FACTOR TNF RECEPTOR; HUMAN-ENDOTHELIAL-CELLS; FACTOR-ALPHA; MONOCLONAL-ANTIBODIES; IDENTIFICATION; RESPONSES; MICE; SIGNAL; 55-KDA	The 60 kDa tumor necrosis factor receptor (TNFR(60)) is regarded as the major signal transducer of TNF-induced cellular responses, whereas the signal capacity and role of the 80 kDa TNFR (TNFR(80)) remain largely undefined, We show here that the transmembrane form of TNF is superior to soluble TNF in activating TNFR(80) in various systems such as T cell activation, thymocyte proliferation, and granulocyte/macrophage colony-stimulating factor production, Intriguingly, activation of TNFR(80) by membrane TNF can lead to qualitatively different TNF responses such as rendering resistant tumor cells sensitive to TNF-mediated cytotoxicity. This study demonstrates that the diversity of TNF effects can be controlled through the differential sensitivity of TNFR(80) for the two forms of TNF and suggests an important physiological role for TNFR(80) in local inflammatory responses.	HELLEN INST PASTEUR,MOLEC GENET LAB,GR-11521 ATHENS,GREECE; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4002 BASEL,SWITZERLAND; MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCKHOFF INST,D-61231 BAD NAUHEIM,GERMANY	Roche Holding; Max Planck Society	GRELL, M (corresponding author), UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY.		Wajant, Harald/A-3020-2017; Kollias, George/A-7079-2012	Wajant, Harald/0000-0002-2005-3949; Kollias, George/0000-0003-1867-3150; Clauss, Matthias/0000-0001-5180-3899; DOUNI, ELENI/0000-0003-0004-5121				ADOLF RA, 1994, EPIDERMAL GROWTH FAC, P63; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1994, J IMMUNOL, V153, P1963; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOPEZCEPERO M, 1994, J IMMUNOL, V152, P3333; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MENEGAZZI R, 1994, BLOOD, V84, P287; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PROBERT L, 1993, J IMMUNOL, V151, P1894; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SCHEURICH P, 1992, TUMOR NECROSIS FACTO, V4, P52; SCHMID E, 1995, J INTERF CYTOK RES, V15, P819, DOI 10.1089/jir.1995.15.819; SCHMIDT EF, 1995, BLOOD, V86, P123; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015	43	1098	1151	4	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					793	802		10.1016/0092-8674(95)90192-2	http://dx.doi.org/10.1016/0092-8674(95)90192-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521496	Bronze			2022-12-01	WOS:A1995TH94800016
J	KLIEWER, SA; LENHARD, JM; WILLSON, TM; PATEL, I; MORRIS, DC; LEHMANN, JM				KLIEWER, SA; LENHARD, JM; WILLSON, TM; PATEL, I; MORRIS, DC; LEHMANN, JM			A PROSTAGLANDIN J(2) METABOLITE BINDS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AND PROMOTES ADIPOCYTE DIFFERENTIATION	CELL			English	Article							9-CIS RETINOIC ACID; ARACHIDONIC-ACID; D SYNTHETASE; FATTY-ACIDS; X RECEPTOR; RAT; MECHANISMS; TISSUES; 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2; BIOSYNTHESIS	Prostaglandins (PGs) of the J(2) series form in vivo and exert effects on a variety of biological processes. While most PGs mediate their effects through G protein-coupled receptors, the mechanism of action for the J(2) series of PGs remains unclear. Here, we report that PGJ(2) and its derivatives are efficacious activators of peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and PPAR gamma, respectively), orphan nuclear receptors implicated in lipid homeostasis and adipocyte differentiation. The PGJ(2) metabolite 15-deoxy-Delta(12,14)-PGJ(2) binds directly to PPAR gamma and promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes. These data provide strong evidence that a fatty acid metabolite can function as an adipogenic agent through direct interactions with PPAR gamma and, furthermore, suggest a novel mechanism of action for PGs of the J(2) series.	GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT BIOL MOLEC,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT MOLEC PHARMACOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	KLIEWER, SA (corresponding author), GLAXO INC,RES INST,DEPT CELL BIOL,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.		feinstein, doug/M-9414-2019					AXELROD L, 1981, DIABETES, V30, P163, DOI 10.2337/diabetes.30.2.163; BANNER CD, 1993, J LIPID RES, V34, P1583; BRAISSANT O, IN PRESS ENDOCRINOLO; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHIABRANDO C, 1984, BIOCHIM BIOPHYS ACTA, V794, P292, DOI 10.1016/0005-2760(84)90158-9; CHRIST EJ, 1970, BIOCHIM BIOPHYS ACTA, V218, P296, DOI 10.1016/0005-2760(70)90148-7; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GAO G, 1990, J BIOL CHEM, V265, P2431; GASKINS HR, 1989, J NUTR, V119, P458, DOI 10.1093/jn/119.3.458; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Greene M. E., 1995, Gene Expression, V4, P281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KOJIMA A, 1980, PROSTAGLANDINS, V20, P171, DOI 10.1016/0090-6980(80)90016-7; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; NOWAK J, 1979, ACTA PHYSIOL SCAND, V106, P307, DOI 10.1111/j.1748-1716.1979.tb06403.x; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; URADE Y, 1989, J IMMUNOL, V143, P2982	38	1812	1862	0	34	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 1	1995	83	5					813	819		10.1016/0092-8674(95)90194-9	http://dx.doi.org/10.1016/0092-8674(95)90194-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TH948	8521498	Bronze			2022-12-01	WOS:A1995TH94800018
J	KUNKEL, MT; PERALTA, EG				KUNKEL, MT; PERALTA, EG			IDENTIFICATION OF DOMAINS CONFERRING G-PROTEIN REGULATION ON INWARD RECTIFIER POTASSIUM CHANNELS	CELL			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; K+-CHANNEL; CLONING	Cardiac m2 muscarinic acetylcholine receptors reduce heart rate by coupling to heterotrimeric (alpha beta gamma) guanine nucleotide-binding (G) proteins that activate I-KaCh, an inward rectifier K+ channel (IRK), Activation of the GIRK subunit of I-KaCh requires G(beta gamma) subunits; however, the structural basis of channel regulation is unknown. To determine which sequences confer G(beta gamma) regulation upon IRKs, we generated chimeric proteins composed of GIRK and RB-IRK2, a related, G protein-insensitive channel, Importantly, a chimeric channel containing the hydrophobic pore region of RB-IRK2 joined to the amino and carboxyl termini of GIRK exhibited voltage- and receptor-dependent activation in Xenopus oocytes, Furthermore, carboxy-terminal sequences specific to this chimera and GIRK bound G(beta gamma) subunits in vitro. Thus, G(beta gamma), may regulate IRKs by interacting with sequences adjacent to the putative channel pore.			KUNKEL, MT (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.							BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	24	132	132	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 3	1995	83	3					443	449		10.1016/0092-8674(95)90122-1	http://dx.doi.org/10.1016/0092-8674(95)90122-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TC977	8521474	Bronze			2022-12-01	WOS:A1995TC97700014
J	JURKOVICH, GJ; RIVARA, FP; GURNEY, JG; FLIGNER, C; RIES, R; MUELLER, BA; COPASS, M				JURKOVICH, GJ; RIVARA, FP; GURNEY, JG; FLIGNER, C; RIES, R; MUELLER, BA; COPASS, M			THE EFFECT OF ACUTE ALCOHOL-INTOXICATION AND CHRONIC ALCOHOL-ABUSE ON OUTCOME FROM TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURY SEVERITY SCORE; TUMOR NECROSIS FACTOR; SCREENING-TEST; CONSUMPTION; MICHIGAN; ETHANOL; POPULATION; EMERGENCY; ACCIDENTS; CARE	Objective.-To determine the effect of acute alcohol intoxication and chronic alcohol abuse on morbidity and mortality from trauma. Design.-Prospective cohort study. Patients.-Blunt or penetrating trauma patients at least 18 years of age admitted to one trauma center or dying at the injury scene. Main Outcome Measures.-Mortality, complications (infection, pneumonia, respiratory failure, or multiple organ failure), and length of hospital stay. Results.-Acute intoxication had no effect on risk of dying-at the injury scene, within the first 24 hours of hospitalization, after the first 24 hours, or overall. Acute intoxication also did not increase the risk of complications and was associated with shorter lengths of stay. Patients with both biochemical and behavioral evidence of chronic alcohol abuse had a twofold increased risk of complications, particularly pneumonia and any infection, compared with those with no evidence of chronic alcohol-abuse. Conclusions.-Chronic, but not acute, alcohol abuse adversely affects outcome from trauma. Attention to the problem of chronic alcohol abuse in trauma patients is necessary, and screening trauma patients for chronic alcohol abuse appears to be warranted.	UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PSYCHIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIAAA NIH HHS [R01-AA07116] Funding Source: Medline; PHS HHS [R40/CCR-002570] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007116] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baker S, 1992, INJURY FACTBOOK; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DESIDERIO MA, 1986, J TRAUMA, V26, P467, DOI 10.1097/00005373-198605000-00011; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; DSOUZA NB, 1989, ALCOHOL CLIN EXP RES, V13, P295, DOI 10.1111/j.1530-0277.1989.tb00329.x; ELMER O, 1981, LANCET, V2, P639; Fleming M. F, 1989, J SUBST ABUSE, V1, P173, DOI [10.1016/S0899-3289(88)80020-8, DOI 10.1016/S0899-3289(88)80020-8]; Garriott J C, 1983, Clin Lab Med, V3, P385; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GERSHMAN H, 1991, Journal of Emergency Medicine, V9, P307, DOI 10.1016/0736-4679(91)90371-L; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JERRELLS TR, 1991, DRUGS ABUSE IMMUNITY; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; KRANZLER HR, 1990, ALCOHOL CLIN EXP RES, V14, P119, DOI 10.1111/j.1530-0277.1990.tb00457.x; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; LIEDTKE AJ, 1975, AM J CARDIOL, V35, P243, DOI 10.1016/0002-9149(75)90008-9; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MARTIN CS, 1990, ALCOHOL CLIN EXP RES, V14, P853, DOI 10.1111/j.1530-0277.1990.tb01827.x; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; NELSON S, 1989, J INFECT DIS, V160, P422, DOI 10.1093/infdis/160.3.422; NELSON S, 1991, ADV EXP MED BIOL, V288, P245; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; PERRINE MW, 1988, SURGEON GENERALS WOR, P35; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; POLLOCK DA, 1989, J TRAUMA, V29, P827; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; ROBERTS PJ, 1987, IMMUNOLOGY, V62, P581; ROSALKI SB, 1974, CLIN CHEM, V20, P1384; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH FE, 1976, J CHRON DIS, V29, P35, DOI 10.1016/0021-9681(76)90066-7; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; STERNBACH G L, 1990, Emergency Medicine Clinics of North America, V8, P793; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WAGNER F, 1992, J STUD ALCOHOL, V53, P277, DOI 10.15288/jsa.1992.53.277; WALLER JA, 1988, J TRAUMA, V28, P1632, DOI 10.1097/00005373-198812000-00003; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1988, MMWR MORB MORTAL WKL, V37, P753; 1989, ALCOHOL TRAUMA; 1988, ICDMAP DETERMING INJ; 1985, INJURY AM CONTINUING	53	222	223	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					51	56		10.1001/jama.270.1.51	http://dx.doi.org/10.1001/jama.270.1.51			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8510296				2022-12-01	WOS:A1993LK36600022
J	PARKER, LL; WALTER, SA; YOUNG, PG; PIWNICAWORMS, H				PARKER, LL; WALTER, SA; YOUNG, PG; PIWNICAWORMS, H			PHOSPHORYLATION AND INACTIVATION OF THE MITOTIC INHIBITOR WEE1 BY THE NIM1/CDR1 KINASE	NATURE			English	Article							TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; DEPHOSPHORYLATION; INDUCER; FISSION	THE G2-M phase transition in eukaryotes is regulated by the synergistic and opposing activities of a cascade of distinct protein kinases and phosphatases. This cascade converges on Cdc2, a serine/threonine protein kinase required for entry into mitosis (reviewed in ref. 1). In the fission yeast Schizosacckaromyces pombe, inactivation of the Cdc2/cyclin B complex is achieved by phosphorylation of tyrosine 15 by Wee1 (refs 2, 3). The action of the Wee1 kinase is opposed by the action of the Cdc25 phosphatase, which dephosphorylates Cdc2 on tyrosine 15, thereby activating the Cdc2/cyclin B complex4-9. Much less is known about the regulatory signals upstream of cdc25 and wee1. Genetics indicate that the mitotic inducer nim1/cdr1 acts upstream of wee1, possibly as a negative regulator of wee1 (refs 10, 11). To characterize the nim1/cdr1 protein (Nim1), we have overproduced it in both bacterial and baculoviral expression systems. We report that Nim1 possesses intrinsic serine-kinase, threonine-kinase and tyrosine-kinase activities. Co-expression of the Nim1 and Wee1 kinases in insect cells results in the phosphorylation of Wee1 and therefore a shift in its electrophoretic mobility on SDS-polyacrylamide gels. When Weel is phosphorylated, its ability to phosphorylate Cdc2 on tyrosine 15 is inhibited; treatment with phosphatase restores this kinase activity. Furthermore, purified bacterially produced Nim1 kinase directly phosphorylates and inactivates Weel in vitro. These results show that nim1/cdr1 functions as a positive regulator of mitosis by directly phosphorylating and inactivating the mitotic inhibitor Wee1.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Harvard University; Harvard Medical School; Queens University - Canada	PARKER, LL (corresponding author), BETH ISRAEL HOSP,BLDG D2,ROOM 143,200 LONGWOOD AVE,BOSTON,MA 02215, USA.		Piwnica-Worms, Helen/C-5214-2012					FEILOTTER H, 1991, GENETICS, V127, P309; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0	14	135	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					736	738		10.1038/363736a0	http://dx.doi.org/10.1038/363736a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8515817				2022-12-01	WOS:A1993LJ33900060
J	STAMNES, MA; ROTHMAN, JE				STAMNES, MA; ROTHMAN, JE			THE BINDING OF AP-1 CLATHRIN ADAPTER PARTICLES TO GOLGI MEMBRANES REQUIRES ADP-RIBOSYLATION FACTOR, A SMALL GTP-BINDING PROTEIN	CELL			English	Article							COATED VESICLES; BREFELDIN-A; BETA-COP; APPARATUS; EXPRESSION; TRANSPORT; HOMOLOGY; COFACTOR; COMPLEX; CELLS	The small GTP-binding protein, ADP-ribosylation factor (ARF), has previously been shown to mediate the binding to Golgi membranes of the coatomer of non-clathrin-coated (COP-coated) vesicles. We now report that ARF is also required for the binding of the AP-1 adaptor protein of clathrin-coated vesicles to Golgi membranes. The binding of coat proteins from both clathrin- and COP-coated vesicles requires an additional Golgi membrane-associated factor. These results suggest that a mechanistic similarity underlies diverse types of vesicle coats.			STAMNES, MA (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, ROCKEFELLER RES LAB, NEW YORK, NY 10021 USA.			Stamnes, Mark/0000-0002-5869-7985				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BREW K, 1975, J BIOL CHEM, V250, P1434; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, IN PRESS NATURE; PALMER DJ, 1993, IN PRESS J BIOL CHEM; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	38	367	376	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					999	1005		10.1016/0092-8674(93)90277-W	http://dx.doi.org/10.1016/0092-8674(93)90277-W			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500185	Bronze			2022-12-01	WOS:A1993LF06100015
J	MEYN, MS				MEYN, MS			HIGH SPONTANEOUS INTRACHROMOSOMAL RECOMBINATION RATES IN ATAXIA-TELANGIECTASIA	SCIENCE			English	Article							MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; RECEPTOR GENES; DNA-REPAIR; G2 PHASE; FIBROBLASTS; RADIOSENSITIVITY; HYPERSENSITIVITY; HETEROZYGOTES	Ataxia-telangiectasia (A-T) is an inherited human disease associated with neurologic degeneration, immune dysfunction, and high cancer risk. It has been proposed that the underlying abnormality in A-T is a defect in genetic recombination that interferes with immune gene rearrangements and the repair of DNA damage. Recombination was studied in A-T and control human fibroblast lines by means of two recombination vectors. Unexpectedly, spontaneous intrachromosomal recombination rates were 30 to 200 times higher in A-T fibroblast lines than in normal cells, whereas extrachromosomal recombination frequencies were near normal. Increased recombination is thus a component of genetic instability in A-T and may contribute to the cancer risk seen in A-T patients.	YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06510 USA	Yale University	MEYN, MS (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.				NIGMS NIH HHS [GM38588] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038588] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BHATTACHARYYA NP, 1989, MUTAT RES, V211, P205, DOI 10.1016/0027-5107(89)90003-1; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; COHEN MM, 1989, ADV HUM GENET, V18, P43; COX R, 1984, BRIT J CANCER, V49, P67; DASGUPTA UB, 1980, MOL GEN GENET, V178, P617, DOI 10.1007/BF00337869; EJIMA Y, 1990, INT J RADIAT BIOL, V58, P989, DOI 10.1080/09553009014552301; GATTI RA, 1991, CLIN IMMUNOL IMMUNOP, V61, pS10, DOI 10.1016/S0090-1229(05)80032-7; GREEN MHL, 1987, J CELL SCI, P127; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; HERZING LBK, UNPUB; HILGERS G, 1987, CARCINOGENESIS, V8, P315, DOI 10.1093/carcin/8.2.315; HILGERS G, 1989, MUTAGENESIS, V4, P271, DOI 10.1093/mutage/4.4.271; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOBAYASHI Y, 1991, J IMMUNOL, V147, P3201; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; Luria SE, 1943, GENETICS, V28, P491; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MIRZAYANS R, 1991, CARCINOGENESIS, V12, P19, DOI 10.1093/carcin/12.1.19; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PATERSON MC, 1979, ANNU REV GENET, V13, P291, DOI 10.1146/annurev.ge.13.120179.001451; PETERSON RDA, 1989, IMMUNOL TODAY, V10, P313, DOI 10.1016/0167-5699(89)90087-X; PIPPARD EC, 1988, CANCER RES, V48, P2929; ROSIN MP, 1989, HUM GENET, V83, P133, DOI 10.1007/BF00286705; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sedgwick RP, 1991, HDB CLIN NEUROLOGY, P347; SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378; SMITH PJ, 1985, INT J RADIAT BIOL, V47, P701, DOI 10.1080/09553008514550941; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; THACKER J, 1989, MUTAT RES, V220, P187, DOI 10.1016/0165-1110(89)90024-9; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; ZIV Y, 1989, CANCER RES, V49, P2495	45	219	222	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1327	1330		10.1126/science.8493577	http://dx.doi.org/10.1126/science.8493577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8493577				2022-12-01	WOS:A1993LE02500044
J	KINLEN, LJ; OBRIEN, F; CLARKE, K; BALKWILL, A; MATTHEWS, F				KINLEN, LJ; OBRIEN, F; CLARKE, K; BALKWILL, A; MATTHEWS, F			RURAL-POPULATION MIXING AND CHILDHOOD LEUKEMIA - EFFECTS OF THE NORTH-SEA-OIL INDUSTRY IN SCOTLAND, INCLUDING THE AREA NEAR DOUNREAY NUCLEAR SITE	BRITISH MEDICAL JOURNAL			English	Article							INFECTIOUS-DISEASES; LEUKEMIA; CHILDREN; VIRUS	Objective-To determine if any excess of childhood leukaemia and non-Hodgkin's lymphoma was associated with certain striking examples of population mixing in rural Scotland produced by the North Sea oil industry. Design-Details were traced for over 30 000 workers involved in the construction of the large oil terminals in the Shetland and Orkney islands in northern Scotland or employed offshore. Home addresses of the 17 160 Scottish residents were postcoded, integrated with census data, and then classified as urban or rural. Rural postcode sectors, ranked by proportion of oil workers, were grouped into three categories with similar numbers of children but contrasting densities of oil workers. The incidence of leukaemia and non-Hodgkin's lymphoma was examined in these rural (and also in urban) categories in the periods 1974-8, 1979-83 and 1984-8. Setting-Scotland. Subjects-Young people below age 25. Results-A significant excess of leukaemia and non-Hodgkin's lymphoma was found in 1979-83 in the group of rural home areas with the largest proportion of oil workers, following closely on large increases in the workforce. The area near the Dounreay nuclear installation, where an excess of leukaemia is already well known, was within the rural high oil category. Conclusion-The findings support the infection hypothesis that population mixing can increase the incidence of childhood leukaemia in rural areas. They also suggest that the recent excess in the Dounreay-Thurso area is due to population mixing linked to the oil industry, promoted by certain unusual local demographic factors.	INST CANC RES,DIV EPIDEMIOL,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.		Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388; Balkwill, Angela/0000-0002-6327-6245				ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; ALEXANDER FE, 1992, BRIT J CANCER, V65, P589, DOI 10.1038/bjc.1992.119; ALVAREZ A, 1986, OFFSHORE N SEA JOURN; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BLACK RJ, 1992, BRIT MED J, V304, P1401, DOI 10.1136/bmj.304.6839.1401; BOLIN SR, 1985, AM J VET RES, V46, P573; BRESLOW NE, 1987, IARC SCI PUBL, V82, P95; CARR BJ, 1982, P I MECH ENG, V196, P239; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; GRANT CK, 1980, CANCER RES, V40, P823; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MACGREGOR JD, 1981, BRIT MED J, V282, P434, DOI 10.1136/bmj.282.6262.434; MACGREGOR JD, 1980, 8021 COMM DIS SCOTL; Miles A, 1983, TOPLEY WILSONS PRINC, V1, P413; ONIONS DE, 1987, CANCER SURV, V6, P161; Topley WWC, 1942, PROC R SOC SER B-BIO, V130, P337, DOI 10.1098/rspb.1942.0005; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, 2ND COMM MED ASP RAD; 1981, SULLOM VOE SCENE	25	84	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					743	748		10.1136/bmj.306.6880.743	http://dx.doi.org/10.1136/bmj.306.6880.743			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8490337	Green Published, Bronze			2022-12-01	WOS:A1993KU17300019
J	Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M				Southall, DP; Ellis, J; McMaster, P; McMaster, H; Willock, A; Plunkett, M			Medical evacuation from Mostar	LANCET			English	Article											Southall, DP (corresponding author), KEELE UNIV,N STAFFS HOSP,ACAD DEPT PAEDIAT,STOKE ON TRENT ST4 6QG,STAFFS,ENGLAND.							[Anonymous], 1991, CONVENTION RIGHTS CH; MORLEY D, 1986, MY NAME IS TODAY; Ressler Everett M., 1992, EVACUATION CHILDREN; SOUTHALL D, IN PRESS PROGRAMME I; 1994, INTRO IOM SPECIAL ME	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 27	1996	347	8996					244	245		10.1016/S0140-6736(96)90411-0	http://dx.doi.org/10.1016/S0140-6736(96)90411-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TT069	8551888				2022-12-01	WOS:A1996TT06900017
J	Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA				Langston, AA; Malone, KE; Thompson, JD; Daling, JR; Ostrander, EA			BRCA1 mutations in a population-based sample of young women with breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL BREAST; OVARIAN-CANCER; LINKAGE ANALYSIS	Background. Inherited mutations in the BRCA1 gene are associated with a high risk of breast and ovarian cancer in some families, However, little is known about the contribution of BRCA1 mutations to breast cancer in the general population, We analyzed DNA samples from women enrolled in a population-based study of early-onset breast cancer to assess the spectrum and frequency of germ-line BRCA1 mutations in young women with breast cancer. Methods. We studied 80 women in whom breast cancer was diagnosed before the age of 35, and who were not selected on the basis of family history. Genomic DNA was studied for BRCA1 mutations by analysis involving singlestrand conformation polymorphisms and with allele-specific assays, Alterations were defined by DNA sequencing. Results. Germ-line BRCA1 mutations were identified in 6 of the 80 women, Four additional rare sequence variants of unknown functional importance were also identified, Two of the mutations and three of the rare sequence variants were found among the 39 women who reported no family history of breast or ovarian cancer. None of the mutations and only one of the rare variants was identified in a reference population of 73 unrelated subjects. Conclusions. Alterations in BRCA1 were identified in approximately 10 percent of this cohort of young women with breast cancer, The risk of harboring a mutation was not limited to women with family histories of breast or ovarian cancer, These results represent a minimal estimate of the frequency of BRCA1 mutations in this population. Comprehensive methods of identifying BRCA1 mutations and understanding their importance will be needed before testing of women in the general population can be undertaken.	FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Ostrander, Elaine/0000-0001-6075-9738	DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA041416, R01CA063705] Funding Source: NIH RePORTER; NCI NIH HHS [N01 CN 05230, R01 CA41416, R01 CA63705] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEDMAN LS, 1995, THESIS U CALIFORNIA; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sambrook J., 1989, MOL CLONING LAB MANU; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1995, CANCER FACTS FIGURES, P10	32	277	280	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	1996	334	3					137	142		10.1056/NEJM199601183340301	http://dx.doi.org/10.1056/NEJM199601183340301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TQ017	8531967				2022-12-01	WOS:A1996TQ01700001
J	Boismenu, R; Rhein, M; Fischer, WH; Havran, WL				Boismenu, R; Rhein, M; Fischer, WH; Havran, WL			A role for CD81 in early T cell development	SCIENCE			English	Article							RECEPTOR-BETA-CHAIN; TAPA-1; TCR; RESTORATION; CD3-EPSILON; ANTIBODY; PROTEINS; IMMATURE; SURFACE; THYMUS	Early stages of T cell development are thought to include a series of coordinated interactions between thymocytes and other cells of the thymus. A monoclonal antibody specific for mouse CD81 was identified that blocked the appearance of alpha beta but nor gamma delta T cells in fetal organ cultures initiated with day 14.5 thymus lobes. In reaggregation cultures with CD81-transfected fibroblasts, CD4(-)CD8(-) thymocytes differentiated into CD4(+)CD8(+) T cells, Thus, interactions between immature thymocytes and stromal cells expressing CD81 are required and may be sufficient to induce early events associated with T cell development.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Salk Institute					NIAID NIH HHS [AI32751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032751, R29AI032751, R21AI032751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1982, J IMMUNOL, V129, P2293; Alschul S F, 1990, J Mol Biol, V215, P403; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; BOISMENU R, UNPUB; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Jenkinson E J, 1990, Semin Immunol, V2, P51; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISLELOW P, 1995, ADV IMMUNOL, V58, P87; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVELT CN, 1993, J EXP MED, V177, P707, DOI 10.1084/jem.177.3.707; LEVY S, 1991, J BIOL CHEM, V266, P14597; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	26	92	94	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 12	1996	271	5246					198	200		10.1126/science.271.5246.198	http://dx.doi.org/10.1126/science.271.5246.198			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TP364	8539618				2022-12-01	WOS:A1996TP36400040
J	Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR				Crossley, PH; Minowada, G; MacArthur, CA; Martin, GR			Roles for FGF8 in the induction, initiation, and maintenance of chick limb development	CELL			English	Article							BUD; OUTGROWTH; GROWTH; EMBRYO; MOUSE	We provide evidence that FGF8 serves as an endogenous inducer of chick limb formation and that its expression in the intermediate mesoderm at the appropriate time and place to trigger forelimb development is directly linked to the mechanism of embryonic kidney differentiation. One function of the limb inducer is to initiate Fgf8 gene expression in the ectoderm overlying the prospective limb-forming territories. FGF8 secreted by the ectoderm then appears to initiate limb bud formation by promoting outgrowth of and Sonic hedgehog expression in the underlying lateral plate mesoderm. FGF8 also maintains mesoderm outgrowth and Sonic hedgehog expression in the established limb bud. Our data thus point to FGF8 as a key regulator of limb development that not only induces and initiates the formation of a limb bud, but also sustains its subsequent development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	University of California System; University of California San Francisco; Washington University (WUSTL)	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURNS RK, 1955, ANAL DEV, P462; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GEDUSPAN JS, 1992, DEV BIOL, V151, P212; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KIENY M, 1971, Annales d'Embryologie et de Morphogenese, V4, P281; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; MUCHMORE WB, 1957, J EXP ZOOL, V134, P293, DOI 10.1002/jez.1401340205; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PINOT M, 1970, Journal of Embryology and Experimental Morphology, V23, P109; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; STEPHENS TD, 1981, J EMBRYOL EXP MORPH, V61, P191; STRECKER TR, 1983, TERATOLOGY, V27, P159, DOI 10.1002/tera.1420270204; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZWILLING E, 1956, COLD SPRING HARB SYM, V21, P349, DOI 10.1101/SQB.1956.021.01.028	38	509	523	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					127	136		10.1016/S0092-8674(00)80999-X	http://dx.doi.org/10.1016/S0092-8674(00)80999-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548816	Bronze			2022-12-01	WOS:A1996TQ17000015
J	Walczak, CE; Mitchison, TJ; Desai, A				Walczak, CE; Mitchison, TJ; Desai, A			XKCM1: A Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly	CELL			English	Article							CELL-FREE-EXTRACTS; EGG EXTRACTS; CYTOPLASMIC DYNEIN; TOPOISOMERASE-II; KINETOCHORES; INSTABILITY; ORGANIZATION; MICROSCOPY; ANAPHASE; MITOSIS	We isolated a cDNA clone encoding a kinesin-related protein, which we named XKCM1. Antibodies to XKCM1 stain mitotic centromeres and spindle poles. Immunodepletion and antibody addition experiments in an in vitro spindle assembly assay show that XKCM1 is required for both establishment and maintenance of mitotic spindles, The structures that form in the absence of XKCM1 contain abnormally long microtubules. This long microtubule defect can be rescued by the addition of purified XKCM1 protein. Analysis of microtubule dynamics in a clarified mitotic extract reveals that loss of XKCM1 function causes a 4-fold suppression in the catastrophe frequency, XKCM1 thus exhibits a novel activity for a kinesin-related protein by promoting microtubule depolymerization during mitotic spindle assembly.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Walczak, CE (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565, R37GM039565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39565-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1995, MOL BIOL CELL, P16319; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SALMON ED, 1984, J CELL BIOL, V99, P2165, DOI 10.1083/jcb.99.6.2165; Sambrook J., 1989, MOL CLONING LAB MANU; SAWIN KE, 1992, J CELL SCI, V101, P303; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	44	447	469	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 12	1996	84	1					37	47		10.1016/S0092-8674(00)80991-5	http://dx.doi.org/10.1016/S0092-8674(00)80991-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TQ170	8548824	Bronze			2022-12-01	WOS:A1996TQ17000007
J	Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM				Barton, K; Muthusamy, N; Chanyangam, M; Fischer, C; Clendenin, C; Leiden, JM			Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB	NATURE			English	Article							CYCLIC-AMP; T-CELLS; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; NUCLEAR FACTOR; BINDING; PHOSPHORYLATION; PROTEIN; GENE; FOS	THE basic/leucine zipper (bZip) transcription factor, CREB, binds to the CRE element (TGANNTCA)(1-5). The transcriptional activity of CREB requires phosphorylation of the protein on a serine residue at position 119 (ref. 6). CREs are present in a number of T-cell genes(7,8) but the precise role of CREB in T-cell differentiation and function was unknown. Here we show that resting thymocytes contain predominantly unphosphorylated (inactive) CREB, which is rapidly activated by phosphorylation on Ser 119 following thymocyte activation. T-cell development is normal in transgenic mice that express a dominant-negative form of CREB (CREB(A119), with alanine at position 119) under the control of the T-cell-specific CD2 promoter/enhancer. In contrast, thymocytes and T cells from these animals display a profound proliferative defect characterized by markedly decreased interleukin-2 production, G1 cell-cycle arrest and subsequent apoptotic death in response to a number of different activation signals. This proliferative defect is associated with the markedly reduced induction of c-jun, c-fos, Fra-2 and FosB following activation of the CREB(A119), transgenic thymocytes. We propose that T-cell activation leads to the phosphorylation and activation of CREB, which in turn is required for normal induction of the transcription factor AP1 and subsequent interleukin-2 production and cell-cycle progression.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALAME K, 1988, ADV IMMUNOL, V43, P235; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; OTIR R, 1991, GENE EXPRESSION, V1, P55; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; VALLEJO MJ, 1994, NEUROENDOCRINOLOGY, V6, P587; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578	29	209	213	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	1996	379	6560					81	85		10.1038/379081a0	http://dx.doi.org/10.1038/379081a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538746				2022-12-01	WOS:A1996TN21600060
J	Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL				Takeuchi, Y; Porter, CD; Strahan, KM; Preece, AF; Gustafsson, K; Cosset, FL; Weiss, RA; Collins, MKL			Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase	NATURE			English	Article							COMPLEMENT PATHWAY ACTIVATION; RNA TUMOR-VIRUSES; HUMAN-ANTIBODIES; LYSIS; INACTIVATION; ONCORNAVIRUSES; GLYCOPROTEINS; SPECIFICITY; RECEPTOR; ANTIGEN	MAMMALIAN C-type retroviruses are inactivated by human serum(1,2), following triggering of the classical complement cascade(3). This may have inhibited transmission to humans of C-type oncoviruses from other mammals(1). Indeed, the retroviruses human immunodeficiency virus and human T-cell leukaemia virus are resistant of human C1q, the first component of the classical pathway, by retroviral envelope proteins has been described(6). However, retroviruses produced from human cells are resistant to inactivation by human complement(7,8) and human serum is known to contain antibodies directed against carbohydrates on retroviral envelopes(9-11). Gal(alpha 1-3)Gal terminal carbohydrates are expressed by most mammals but are absent in humans, which lack a functional (alpha 1-3)galactosyltransferase gene (12,13). Here, we demonstrate that anti-Gal(alpha 1-3)Gal antibodies in human serum inactivate retroviruses produced from animal cells. Expression of porcine (alpha 1-3)galactosyltransferase(14,16) in human cells renders the cells and the retroviruses they produce sensitive to human serum.	UNIV LONDON,INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Takeuchi, Y (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Cosset, François-Loïc/M-5862-2019	Cosset, François-Loïc/0000-0001-8842-3726				ALMEIDA IC, 1993, J CLIN LAB ANAL, V7, P307, DOI 10.1002/jcla.1860070603; BANAPOUR B, 1986, VIROLOGY, V152, P268, DOI 10.1016/0042-6822(86)90392-2; BARBACID M, 1979, P NATL ACAD SCI USA, V77, P1617; BARTHOLOMEW RM, 1978, J EXP MED, V147, P844, DOI 10.1084/jem.147.3.844; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; COOPER NR, 1976, J EXP MED, V144, P970, DOI 10.1084/jem.144.4.970; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; COSSET FL, IN PRESS J VIROL; FABRE JW, 1995, NAT MED, V1, P403, DOI 10.1038/nm0595-403; GALILI U, 1993, BLOOD, V82, P2485, DOI 10.1182/blood.V82.8.2485.bloodjournal8282485; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GUSTAFSSON K, 1994, IMMUNOL REV, V141, P59, DOI 10.1111/j.1600-065X.1994.tb00872.x; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HIRSCH RL, 1981, J IMMUNOL, V127, P1740; HOSHINO H, 1984, NATURE, V310, P324, DOI 10.1038/310324a0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LOWER J, 1981, VIROLOGY, V109, P409, DOI 10.1016/0042-6822(81)90511-0; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MCKENZIE IF, 1968, LANCET, V2, P386; ORLOL R, 1993, TRANSPLANTATION, V56, P1433; REPIK PM, 1994, J GEN VIROL, V75, P1177, DOI 10.1099/0022-1317-75-5-1177; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SNYDER HW, 1980, P NATL ACAD SCI-BIOL, V77, P1622, DOI 10.1073/pnas.77.3.1622; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; WELSH RM, 1976, VIROLOGY, V74, P432, DOI 10.1016/0042-6822(76)90349-4; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; WELSH RM, 1977, J IMMUNOL, V118, P348	30	237	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 4	1996	379	6560					85	88		10.1038/379085a0	http://dx.doi.org/10.1038/379085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TN216	8538747				2022-12-01	WOS:A1996TN21600061
J	KORNFELD, K; HOM, DB; HORVITZ, HR				KORNFELD, K; HOM, DB; HORVITZ, HR			THE KSR-1 GENE ENCODES A NOVEL PROTEIN-KINASE INVOLVED IN RAS-MEDIATED SIGNALING IN C-ELEGANS	CELL			English	Article							VULVAL CELL LINEAGES; CAENORHABDITIS-ELEGANS; MAP KINASE; LET-60; NEMATODE; PATHWAY; FATES; INDUCTION; ONCOGENE; DOMAINS	By screening for mutations that suppress the vulval defects caused by a constitutively active let gb ras gene, we identified six loss-of-function alleles of ksr-1, a novel C. elegans gene. Our genetic analysis showed ksr-1 positively mediates Ras signaling and functions downstream of or in parallel to let-60. In the absence of ksr-1 function, normal Ras signaling is impaired only slightly, suggesting ksr-1 may act to modulate, or in a branch that diverges from, the main signaling pathway. The predicted KSR-1 protein has a protein kinase domain and is most similar to a recently identified Drosophila protein involved in Ras signaling. We propose that the function of ksr-1 is evolutionarily conserved.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								Ausubel FM., 2006, ENZYMATIC MANIPULATI; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNER S, 1974, GENETICS, V77, P71; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARK SG, 1992, COLD SPRING HARB SYM, V57, P363, DOI 10.1101/SQB.1992.057.01.041; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FERGUSON EL, 1985, THESIS MIT CAMBRIDGE; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742	52	233	249	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 15	1995	83	6					903	913		10.1016/0092-8674(95)90206-6	http://dx.doi.org/10.1016/0092-8674(95)90206-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521514	Bronze			2022-12-01	WOS:A1995TK74500009
J	SNYDER, PM; PRICE, MP; MCDONALD, FJ; ADAMS, CM; VOLK, KA; ZEIHER, BG; STOKES, JB; WELSH, MJ				SNYDER, PM; PRICE, MP; MCDONALD, FJ; ADAMS, CM; VOLK, KA; ZEIHER, BG; STOKES, JB; WELSH, MJ			MECHANISM BY WHICH LIDDLES SYNDROME MUTATIONS INCREASE ACTIVITY OF A HUMAN EPITHELIAL NA+ CHANNEL	CELL			English	Article							INTERNALIZATION SIGNAL; CAENORHABDITIS-ELEGANS; PROTEIN	Liddle's syndrome is an inherited form of hypertension caused by mutations that truncate the C-terminus of human epithelial Na+ channel (hENaC) subunits, Expression of truncated beta and gamma hENaC subunits increased Na+ current, However, truncation did not alter single-channel conductance or open state probability, suggesting there were more channels in the plasma membrane. Moreover, truncation of the C-terminus of the beta subunit increased apical cell-surface expression of hENaC in a renal epithelium, We identified a conserved motif in the C-terminus of all three subunits that, when mutated, reproduced the effect of Liddle's truncations. Further, both truncation of the C-terminus and mutation of the conserved C-terminal motif increased surface expression of chimeric proteins containing the C-terminus of beta hENaC, Thus, by deleting a conserved motif, Liddle's mutations increase the number of Na+ channels in the apical membrane, which increases renal Na+ absorption and creates a predisposition to hypertension.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa	SNYDER, PM (corresponding author), UNIV IOWA, HOWARD HUGHES MED INST, COLL MED, IOWA CITY, IA 52242 USA.			Welsh, Michael/0000-0002-1646-6206; Adams, Christopher/0000-0002-5795-7212	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07344] Funding Source: Medline; NIDDK NIH HHS [DK-25231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BOLEROVELEZ M, 1994, NEW ENGL J MED, V330, P178; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GORDON RD, 1995, NAT GENET, V11, P6, DOI 10.1038/ng0995-6; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; MCDONALD FJ, 1995, BIOCHEM J, V312, P491, DOI 10.1042/bj3120491; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; VOLK KA, 1995, IN PRESS J CLIN INVE; WILDE A, 1994, J BIOL CHEM, V269, P7131; YOKOYAMA WM, 1992, CURRENT PROTOCOLS IM	36	365	370	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 15	1995	83	6					969	978		10.1016/0092-8674(95)90212-0	http://dx.doi.org/10.1016/0092-8674(95)90212-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TK745	8521520	Bronze			2022-12-01	WOS:A1995TK74500015
J	GU, H; ZOU, YR; RAJEWSKY, K				GU, H; ZOU, YR; RAJEWSKY, K			INDEPENDENT CONTROL OF IMMUNOGLOBULIN SWITCH RECOMBINATION AT INDIVIDUAL SWITCH REGIONS EVIDENCED THROUGH CRE-IOXP-MEDIATED GENE TARGETING	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; EMBRYONIC STEM-CELLS; HEAVY-CHAIN GENES; B-CELLS; CIRCULAR DNA; LYMPHOID-CELLS; IGH LOCI; SEQUENCE; MOUSE; EXPRESSION	We have employed a method based on the Cre-IoxP recombination system of bacteriophage Pl to generate a mouse strain in which the J(H) segments and the intron enhancer in the IgH locus are deleted. By analysis of immunoglobulin isotype switch recombination in heterozygous mutant B cells activated by lipopolysaccharide plus interleukin-4, we show that, on the mutant chromosome, switch recombination at the mu gene switch region is strongly suppressed, whereas the switch region of the gamma1 gene is efficiently rearranged. These data demonstrate an independent control of switch recombination at individual switch regions and suggest that, in the process of switch recombination, the alignment of the recombining strands occurs independently of and probably after the introduction of double-strand breaks into the switch regions involved.			GU, H (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, W-5000 COLOGNE 41, GERMANY.							AKIRA S, 1984, EMBO J, V3, P677, DOI 10.1002/j.1460-2075.1984.tb01866.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CORY S, 1980, NATURE, V285, P450, DOI 10.1038/285450a0; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; Honjo T., 1989, Immunoglobulin genes., P123; HONJO T, 1978, P NATL ACAD SCI USA, V75, P2140, DOI 10.1073/pnas.75.5.2140; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HUMMEL M, 1987, J IMMUNOL, V138, P3539; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; RABBITTS TH, 1980, NATURE, V283, P351, DOI 10.1038/283351a0; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Sambrook J., 1989, MOL CLONING LAB MANU; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAUER B, 1990, New Biologist, V2, P441; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZER J, 1984, CURR TOP MICROBIOL, V113, P109; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SZUREK P, 1985, J IMMUNOL, V135, P620; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; WINTER E, 1987, EMBO J, V6, P1663, DOI 10.1002/j.1460-2075.1987.tb02415.x; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x	56	795	884	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1155	1164		10.1016/0092-8674(93)90644-6	http://dx.doi.org/10.1016/0092-8674(93)90644-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8513499				2022-12-01	WOS:A1993LH54800011
J	BLISKA, JB; GALAN, JE; FALKOW, S				BLISKA, JB; GALAN, JE; FALKOW, S			SIGNAL-TRANSDUCTION IN THE MAMMALIAN-CELL DURING BACTERIAL ATTACHMENT AND ENTRY	CELL			English	Review							ENTEROPATHOGENIC ESCHERICHIA-COLI; PSEUDOTUBERCULOSIS INVASIN PROTEIN; TISSUE-CULTURE CELLS; MONOCYTE COMPLEMENT RECEPTORS; OUTER-MEMBRANE PROTEIN; YERSINIA-PSEUDOTUBERCULOSIS; EPITHELIAL-CELLS; VIRULENCE PLASMID; HEP-2 CELLS; SALMONELLA-TYPHIMURIUM		STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; NIH, NATL INST ALLERGY & INFECT DIS, ROCKY MT LAB, HAMILTON, MT 59840 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BLISKA, JB (corresponding author), SUNY, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030492, R37AI030492, R29AI030492, R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30492, AI26-195] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; ATKINSON M, 1992, J BACTERIOL, V174, P4356, DOI 10.1128/JB.174.13.4356-4360.1992; BALDWIN TJ, 1990, INFECT IMMUN, V58, P761, DOI 10.1128/IAI.58.3.761-765.1990; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BLISKA JB, 1992, INFECT IMMUN, V60, P2475; BOLIN I, 1982, INFECT IMMUN, V37, P506; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BUKHOLM G, 1984, ACTA PATH MICRO IM B, V92, P145; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHIANG TM, 1989, J BIOL CHEM, V264, P2957; CLEMENS JC, 1991, MOL MICROBIOL, V5, P2617, DOI 10.1111/j.1365-2958.1991.tb01970.x; CORNELIS G, 1987, REV INFECT DIS, V9, P64; CORNELIS GR, 1989, MOL MICROBIOL, V3, P1455, DOI 10.1111/j.1365-2958.1989.tb00129.x; DIRITA VJ, 1989, ANNU REV GENET, V23, P455; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; DONNENBERG MS, 1989, J INFECT DIS, V160, P452, DOI 10.1093/infdis/160.3.452; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; DOWLING JN, 1992, MICROBIOL REV, V56, P32, DOI 10.1128/MMBR.56.1.32-60.1992; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; ELWELL LP, 1980, ANNU REV MICROBIOL, V34, P465, DOI 10.1146/annurev.mi.34.100180.002341; EMODY L, 1989, J BACTERIOL, V171, P6674; ENNIS E, 1993, J EXP MED, V177, P207, DOI 10.1084/jem.177.1.207; ERNST RK, 1990, INFECT IMMUN, V58, P2014, DOI 10.1128/IAI.58.6.2014-2016.1990; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cellbio.8.1.333; FALKOW S, 1987, REV INFECT DIS, V9, pS450; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Fujimura Yoshinori, 1992, Journal of Clinical Electron Microscopy, V25, P35; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOGUEN JD, 1986, INFECT IMMUN, V51, P788, DOI 10.1128/IAI.51.3.788-794.1986; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GULIG PA, 1993, IN PRESS MOL MICROBI; HANSKI C, 1989, INFECT IMMUN, V57, P673, DOI 10.1128/IAI.57.3.673-678.1989; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V40, P37, DOI 10.1016/0378-1097(87)90512-X; HEESEMANN J, 1985, J CLIN MICROBIOL, V22, P168, DOI 10.1128/JCM.22.2.168-175.1985; HOEPELMAN AIM, 1992, INFECT IMMUN, V60, P1729, DOI 10.1128/IAI.60.5.1729-1733.1992; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INMAN LR, 1983, J CLIN INVEST, V71, P1, DOI 10.1172/JCI110737; ISBERG RR, 1988, INFECT IMMUN, V56, P2133, DOI 10.1128/IAI.56.8.2133-2138.1988; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1990, MOL BIOL MED, V7, P73; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISBERG RR, 1989, INFECT IMMUN, V57, P1998, DOI 10.1128/IAI.57.7.1998-2005.1989; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; JERSE AE, 1991, INFECT IMMUN, V59, P3869, DOI 10.1128/IAI.59.11.3869-3875.1991; JOHNSON RJ, 1992, J LEUKOCYTE BIOL, V52, P3, DOI 10.1002/jlb.52.1.3; JONES BD, 1992, INFECT IMMUN, V60, P2475, DOI 10.1128/IAI.60.6.2475-2480.1992; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAPPERUD G, 1987, INFECT IMMUN, V55, P2247, DOI 10.1128/IAI.55.9.2247-2254.1987; KELLYWINTENBERG K, 1990, J BACTERIOL, V172, P5135, DOI 10.1128/jb.172.9.5135-5139.1990; KIHLSTROM E, 1977, ACTA PATH MICRO IM B, V85, P322; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEUNG KY, 1989, J BACTERIOL, V171, P4623, DOI 10.1128/jb.171.9.4623-4632.1989; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; LIAN CJ, 1987, J MED MICROBIOL, V24, P219, DOI 10.1099/00222615-24-3-219; LIAN CJ, 1987, INFECT IMMUN, V55, P1176, DOI 10.1128/IAI.55.5.1176-1183.1987; LINDLER LE, 1993, IN PRESS MOL MICROBI, V8; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; LONDON E, 1992, MOL MICROBIOL, V6, P3277, DOI 10.1111/j.1365-2958.1992.tb02195.x; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MADSHUS IH, 1992, CURR TOP MICROBIOL, V175, P1; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MANJARREZHERNANDEZ HA, 1992, LANCET, V339, P521, DOI 10.1016/0140-6736(92)90340-9; MANJARREZHERNANDEZ HA, 1991, FEBS LETT, V292, P121, DOI 10.1016/0014-5793(91)80848-W; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MILLER VL, 1990, J BACTERIOL, V172, P1062, DOI 10.1128/jb.172.2.1062-1069.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, CURR TOP MICROBIOL, V138, P15; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOON HW, 1983, INFECT IMMUN, V41, P1340, DOI 10.1128/IAI.41.3.1340-1351.1983; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAYNE NR, 1987, J EXP MED, V166, P1377, DOI 10.1084/jem.166.5.1377; PEPE J, 1993, IN PRESS P NATL ACAD; PIERSON DE, 1990, INFECT IMMUN, V58, P1059, DOI 10.1128/IAI.58.4.1059-1064.1990; POLLACK C, 1986, NATURE, V322, P834, DOI 10.1038/322834a0; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; PORTNOY DA, 1985, CURR TOP MICROBIOL, V118, P29; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; REISNER BS, 1992, INFECT IMMUN, V60, P5242, DOI 10.1128/IAI.60.12.5242-5252.1992; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROSENSHINE I, 1993, BIOESSAYS, V15, P17, DOI 10.1002/bies.950150104; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; ROSQVIST R, 1986, MICROB PATHOGENESIS, V1, P229, DOI 10.1016/0882-4010(86)90047-1; ROSQVIST R, 1988, NATURE, V334, P522, DOI 10.1038/334522a0; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHULZEKOOPS H, 1992, INFECT IMMUN, V60, P2153, DOI 10.1128/IAI.60.6.2153-2159.1992; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIMONET M, 1990, INFECT IMMUN, V58, P841, DOI 10.1128/IAI.58.3.841-845.1990; SIMONET M, 1992, INFECT IMMUN, V60, P366, DOI 10.1128/IAI.60.2.366-373.1992; SIMONET M, 1992, INFECT IMMUN, V60, P4414, DOI 10.1128/IAI.60.10.4414-4417.1992; SJOLANDER A, 1988, EUR J CELL BIOL, V134, P473; SKURNIK M, 1989, MOL MICROBIOL, V3, P517, DOI 10.1111/j.1365-2958.1989.tb00198.x; SLOMIANY BL, 1992, BIOCHEM BIOPH RES CO, V186, P1496, DOI 10.1016/S0006-291X(05)81575-X; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; STRALEY SC, 1991, MICROB PATHOGENESIS, V10, P87, DOI 10.1016/0882-4010(91)90069-M; STRALEY SC, 1993, IN PRESS INFECT IMMU; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TERTTI R, 1992, INFECT IMMUN, V60, P3021, DOI 10.1128/IAI.60.7.3021-3024.1992; TESH VL, 1992, MICROB PATHOGENESIS, V12, P245, DOI 10.1016/0882-4010(92)90043-N; TRANVANNHIEU T, 1991, J BIOL CHEM, V266, P24367; WALKER RI, 1990, ANNU REV MED, V41, P393; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	157	301	308	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					903	920		10.1016/0092-8674(93)90270-Z	http://dx.doi.org/10.1016/0092-8674(93)90270-Z			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8500180	Bronze			2022-12-01	WOS:A1993LF06100008
J	HARADA, T; KAGAMIYAMA, H; HATAKEYAMA, K				HARADA, T; KAGAMIYAMA, H; HATAKEYAMA, K			FEEDBACK-REGULATION MECHANISMS FOR THE CONTROL OF GTP CYCLOHYDROLASE-I ACTIVITY	SCIENCE			English	Article							6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; PHENYLALANINE-HYDROXYLASE; INTERFERON-GAMMA; ADRENAL-MEDULLA; NITRIC-OXIDE; RAT STRIATUM; TETRAHYDROBIOPTERIN; BIOPTERIN; COFACTOR; BIOSYNTHESIS	Guanosine triphosphate (GTP) cyclohydrolase I, the rate-limiting enzyme in the biosynthesis of tetrahydrobiopterin (BH4), is subject to feedback inhibition by BH4, a cofactor for phenylalanine hydroxylase. Inhibition was found to depend specifically on BH4 and the presence of another protein (p35). The inhibition occurred through BH4-dependent complex formation between p35 protein and GTP cyclohydrolase I. Furthermore, the inhibition was specifically reversed by phenylalanine, and, in conjunction with p35, phenylalanine reduced the cooperativity of GTP cyclohydrolase I. These findings also provide a molecular basis for high plasma BH4 concentrations observed in patients with hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency.	OSAKA MED COLL, DEPT BIOCHEM, TAKATSUKI, OSAKA 569, JAPAN	Osaka Medical College								ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BECK B, 1983, ACTA PAEDIATR SCAND, V72, P449, DOI 10.1111/j.1651-2227.1983.tb09745.x; BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; COTE LJ, 1975, J NEUROBIOL, V6, P233, DOI 10.1002/neu.480060209; DHONDT JL, 1983, EUR J PEDIATR, V141, P92, DOI 10.1007/BF00496797; GREENGARD O, 1976, BIOCHEM J, V154, P619, DOI 10.1042/bj1540619; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATAKEYAMA K, 1992, J BIOL CHEM, V267, P20734; KAUFMAN S, 1985, BIOCHEM SOC T, V13, P433, DOI 10.1042/bst0130433; KAUFMAN S, 1967, ANNU REV BIOCHEM, V36, P171, DOI 10.1146/annurev.bi.36.070167.001131; KAUFMAN S, 1978, NEW ENGL J MED, V299, P673, DOI 10.1056/NEJM197809282991301; KAUFMAN S, 1982, PEDIATRICS, V70, P376; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KETTLER R, 1974, NATURE, V249, P476, DOI 10.1038/249476a0; KOSHIMURA K, 1990, J NEUROCHEM, V54, P1391, DOI 10.1111/j.1471-4159.1990.tb01974.x; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCINNES RR, 1984, J CLIN INVEST, V73, P458, DOI 10.1172/JCI111232; MILSTIEN S, 1975, J BIOL CHEM, V250, P4777; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.bi.54.070185.003501; NIEDERWIESER A, 1982, EUR J PEDIATR, V138, P110, DOI 10.1007/BF00441135; NIEDERWIESER A, 1987, EUR J PEDIATR, V146, P228, DOI 10.1007/BF00716465; PARNIAK MA, 1989, BIOCHEM CELL BIOL, V67, P293, DOI 10.1139/o89-044; SCHOTT K, 1992, EXP CELL RES, V200, P105, DOI 10.1016/S0014-4827(05)80077-1; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1987, METHOD ENZYMOL, V142, P17; Stadtman E.R., 1970, ENZYMES, V1, P397; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WOLF WA, 1991, J NEUROCHEM, V57, P1191, DOI 10.1111/j.1471-4159.1991.tb08279.x; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; [No title captured]	39	143	146	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1993	260	5113					1507	1510		10.1126/science.8502995	http://dx.doi.org/10.1126/science.8502995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8502995				2022-12-01	WOS:A1993LF05800037
J	SERIZAWA, H; CONAWAY, JW; CONAWAY, RC				SERIZAWA, H; CONAWAY, JW; CONAWAY, RC			PHOSPHORYLATION OF C-TERMINAL DOMAIN OF RNA POLYMERASE-II IS NOT REQUIRED IN BASAL TRANSCRIPTION	NATURE			English	Article							PREINITIATION COMPLEX; BETA-GAMMA; INITIATION; PURIFICATION; PROMOTER; KINASE; ALPHA; FORM	PHOSPHORYLATION of the heptapeptide repeats in the C-terminal domain (CTD) of the largest subunit of RNA polymerase II has been widely proposed as an essential step in transcription initiation1-8 on the basis of findings indicating (1) that the CTDs of RNA polymerase II molecules actively engaged in transcription are highly phosphorylated4,9,10; (2) that polymerase molecules containing non-phosphorylated CTDs preferentially enter the preinitiation complex3,11,12 where they are subsequently phosphorylated3,13; and (3) that essential initiation factors b from yeast14-16, delta from rat17,18, and BTF2(TFIIH) from human cells19-21 have closely associated CTD-kinase activities. Here we take advantage of a highly purified enzyme system which supports both CTD phosphorylation and basal transcription to test this hypothesis directly. Using the isoquinoline sulphonamide derivative H-8, which is a potent inhibitor of CTD kinase, we show that basal transcription occurs in the absence of CTD phosphorylation.			SERIZAWA, H (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.			Conaway, Joan/0000-0002-2786-0663				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	29	157	159	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					371	374		10.1038/363371a0	http://dx.doi.org/10.1038/363371a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8497323				2022-12-01	WOS:A1993LD91700060
J	MAKAROV, VL; LEJNINE, S; BEDOYAN, J; LANGMORE, JP				MAKAROV, VL; LEJNINE, S; BEDOYAN, J; LANGMORE, JP			NUCLEOSOMAL ORGANIZATION OF TELOMERE-SPECIFIC CHROMATIN IN RAT	CELL			English	Article							OXYTRICHA MACRONUCLEAR DNA; RIBOSOMAL-RNA GENES; SACCHAROMYCES-CEREVISIAE; PROTEIN INTERACTIONS; INTERPHASE NUCLEI; BINDING PROTEIN; SEQUENCE; TETRAHYMENA; LOCATION; TERMINI	Rat liver interphase chromosomes have telomeres 20-100 kb in length. Micrococcal nuclease digestion of nuclei cleaves telomeres with a uniform 157 bp periodicity, producing soluble particles that sediment in sucrose gradients exactly like oligonucleosomes. The monomeric telomere particles comigrate with nucleosome core particles on nucleoprotein and DNA gels but do not bind H1. DNAase I cleaves telomere nucleoprotein into a series of bands spaced by about 10.4 bp and with the same intensity distribution as bands from bulk nucleosomes. Removal of H1 from chromatin alters the sedimentation properties of telomeres in parallel with bulk chromatin. Thus, telomeres of mammals are constructed of closely spaced nucleosomes, in contrast with the telomeres of lower eukaryotes, which show no evidence of nucleosomal structure.	UNIV MICHIGAN, GRAD PROGRAM CELLULAR & MOLEC BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL SCI, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MAKAROV, VL (corresponding author), UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM44403, 5T32GM07315] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUDARF ML, 1986, J BIOL CHEM, V261, P363; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; DANNA JA, 1989, BIOCHEMISTRY-US, V28, P2895, DOI 10.1021/bi00433a022; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; EDWARDS CA, 1984, J MOL BIOL, V180, P73, DOI 10.1016/0022-2836(84)90431-5; FINCH JT, 1975, P NATL ACAD SCI USA, V72, P3320, DOI 10.1073/pnas.72.9.3320; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRUENBAUM Y, 1984, J CELL SCI, P223; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; LIU A, 1991, GENE DEV, V5, P4959; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Maniatis T., 1982, MOL CLONING; MAREKOV LN, 1981, ANAL BIOCHEM, V115, P93, DOI 10.1016/0003-2697(81)90529-7; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NOLL H, 1989, METHOD ENZYMOL, V170, P55; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; OMORI A, 1980, NUCLEIC ACIDS RES, V8, P5363, DOI 10.1093/nar/8.22.5363; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; OSIPOVA TN, 1986, MOL BIOL+, V20, P63; PENNINGS S, 1992, NUCLEIC ACIDS RES, V20, P6667, DOI 10.1093/nar/20.24.6667; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; RAWLINS DJ, 1991, CHROMOSOMA, V100, P424, DOI 10.1007/BF00364552; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; van Holde K.E., 1989, CHROMATIN; VANDEKKEN H, 1989, J CELL SCI, V94, P299; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; VINCENZ C, 1991, NUCLEIC ACIDS RES, V19, P1325, DOI 10.1093/nar/19.6.1325; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7279, DOI 10.1021/bi00346a039; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	71	155	164	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					775	787		10.1016/0092-8674(93)90256-P	http://dx.doi.org/10.1016/0092-8674(93)90256-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500170	Green Published			2022-12-01	WOS:A1993LD83000015
J	TAKEDA, J; MIYATA, T; KAWAGOE, K; IIDA, Y; ENDO, Y; FUJITA, T; TAKAHASHI, M; KITANI, T; KINOSHITA, T				TAKEDA, J; MIYATA, T; KAWAGOE, K; IIDA, Y; ENDO, Y; FUJITA, T; TAKAHASHI, M; KITANI, T; KINOSHITA, T			DEFICIENCY OF THE GPI ANCHOR CAUSED BY A SOMATIC MUTATION OF THE PIG-A GENE IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	CELL			English	Article							CELL-ADHESION MOLECULE; DECAY-ACCELERATING FACTOR; INSITU HYBRIDIZATION; MEMBRANE ATTACHMENT; PROTEIN-ANCHOR; N-CAM; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; GLYCOPROTEIN; SURFACE	Paroxysmal nocturnal hemoglobinuria is an acquired hematopoietic disease characterized by abnormal blood cell populations in which the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor is deficient. Deficiency of surface expressions of GPI-anchored complement inhibitors leads to complement-mediated hemolysis. Here we report that PIG-A, which participates in the early step of GPI anchor biosynthesis, is the gene responsible for paroxysmal nocturnal hemoglobinuria. Affected granulocytes and B lymphocytes had the same somatic mutation of PIG-A, indicating their clonal origin from a multipotential hematopoietic stem cell. We localized PIG-A to the X chromosome, which accounts for expression of the recessive phenotype of the somatic mutation and the fact that the same one of the multiple biosynthetic steps is affected in all patients so far characterized.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT INTERNAL MED,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,BRANCH HOSP,SCH MED,DEPT INTERNAL MED,NAGOYA 461,JAPAN; FUKUSHIMA MED COLL,DEPT BIOCHEM,FUKUSHIMA 96012,JAPAN	Osaka University; Nagoya University; Fukushima Medical University	TAKEDA, J (corresponding author), OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN.		Kinoshita, Taroh/C-7353-2009; Miyata, Toshio/A-4872-2010					BESSLER M, 1992, BLOOD, V80, P844; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; INOUE N, 1993, IN PRESS J BIOL CHEM, V268; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; JOSTEN KM, 1991, BLOOD, V78, P3162; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAHONEY JF, 1992, BLOOD, V79, P1400; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NICHOLSONWELLER A, 1985, NEW ENGL J MED, V312, P1091, DOI 10.1056/NEJM198504253121704; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSSE WF, 1989, BLOOD REV, V3, P192, DOI 10.1016/0268-960X(89)90016-7; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUBERT J, 1990, BLOOD, V76, P1181; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SYMINGTON BE, 1990, J BIOL CHEM, V265, P14069; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1992, INT IMMUNOL, V4, P1263, DOI 10.1093/intimm/4.11.1263; UEDA E, 1989, J IMMUNOL, V143, P1274; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; [No title captured]	52	803	820	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					703	711		10.1016/0092-8674(93)90250-T	http://dx.doi.org/10.1016/0092-8674(93)90250-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8500164				2022-12-01	WOS:A1993LD83000009
J	ADES, AE; DAVISON, CF; HOLLAND, FJ; GIBB, DM; HUDSON, CN; NICHOLL, A; GOLDBERG, D; PECKHAM, CS				ADES, AE; DAVISON, CF; HOLLAND, FJ; GIBB, DM; HUDSON, CN; NICHOLL, A; GOLDBERG, D; PECKHAM, CS			VERTICALLY TRANSMITTED HIV-INFECTION IN THE BRITISH-ISLES	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; AIDS	Objective-To describe the epidemiology of vertically acquired HIV infection in the British Isles, the level of underreporting, the vertical transmission rate, and clinical spectrum of paediatric AIDS. Design--Confidential, linked registers based on reporting from obstetricians and paediatricians; anonymous unlinked neonatal HIV serosurveys. Setting-British Isles. Subjects-Children born to mothers with HIV infection. Main outcome measures-Trends in HIV infection and vertical transmission rate. Results-In Scotland and the Irish Republic, where most maternal HIV infection is related to drug misuse, the annual number of reports of children born to infected mothers has fallen since 1989. In England and Wales nearly half of maternal infections have been acquired overseas, and the number of children born to these women, and to women who became infected in Britain, is increasing. In south east England the proportion of live births to women whose infection was identified before delivery was only 17% (50/287), compared with 68% (26/38) in Scotland. The vertical transmission rate was 13.7% (23/168), and 23% of infected children developed AIDS in the first year of life. 41% (38/92) of children born to infected mothers who were ascertained after delivery were breast fed, compared with 5% (12/236) of those ascertained before delivery. Conclusions-The incidence of vertically transmitted HIV infection is increasing in England and Wales. More extensive antenatal testing would enable infected women to be counselled against breast feeding, which could prevent a substantial proportion of vertical transmission in some areas, and would increase opportunities for early diagnosis and treatment of infected children.	ST BARTHOLOMEWS HOSP,DEPT OBSTET & GYNAECOL,LONDON EC1A 7BE,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,CTR AIDS,LONDON NW9 5EQ,ENGLAND; RUCHILL HOSP,COMMUNICABLE DIS SCOTLAND UNIT,GLASGOW G20 9NB,SCOTLAND	University of London; Queen Mary University London; Public Health England	ADES, AE (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,DIV PUBL HLTH,LONDON WC1N 1EH,ENGLAND.			Gibb, Diana/0000-0002-9738-5490				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; ADES AE, 1992, AIDS, P1031; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; DAVISON CF, 1989, LANCET, V2, P1442; DAVISON CF, 1993, AIDS CARE, V5, P135, DOI 10.1080/09540129308258593; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HALL SM, 1990, ARCH DIS CHILD, V65, P807, DOI 10.1136/adc.65.7.807; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; JONES DS, 1992, PEDIATRICS, V89, P123; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; Lynn R, 1992, Commun Dis Rep CDR Rev, V2, pR145; ROUZIOUX C, 1992, 8TH INT C AIDS AMST; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SEKAR CC, 1949, J AM STAT ASSOC, V44, P101, DOI 10.2307/2280353; TAPPIN DM, 1991, LANCET, V337, P1565; THOMAS P, 1992, PEDIATR INFECT DIS J, V11, P34, DOI 10.1097/00006454-199201000-00009; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; 1993, 9305 COMM DIS UN COM; 1993, COMMUNICABLE DISEASE, V3, P20; 1992, AIDS SCOTLAND, V7, P1; 1991, LANCET, V337, P253; 1992, NATIONAL STUDY HIV P; 1987, MMWR, V15, P225	26	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1296	1299		10.1136/bmj.306.6888.1296	http://dx.doi.org/10.1136/bmj.306.6888.1296			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	8518568	Green Published			2022-12-01	WOS:A1993LC72200018
